{"51cec2e534fbc6a2a3779074ba95ad5228989a01": [["INTRODUCTIONCoronavirus disease-2019 (COVID-19) is a highly transmissible disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).", [["COVID-19", "CHEMICAL", 38, 46], ["transmissible disease", "DISEASE", 60, 81], ["acute respiratory syndrome coronavirus", "DISEASE", 99, 137], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 92, 139], ["SARS-CoV-2", "ORGANISM", 141, 151], ["INTRODUCTIONCoronavirus disease-2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 92, 137], ["SARS-CoV-2", "SPECIES", 141, 151], ["INTRODUCTIONCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["a highly transmissible disease", "PROBLEM", 51, 81], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 92, 137], ["CoV", "TEST", 146, 149], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["respiratory syndrome coronavirus", "OBSERVATION", 105, 137]]], ["The majority of COVID-19 patients have only mild symptoms and do not need hospitalization [48, 179] .", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["COVID", "TEST", 16, 21], ["mild symptoms", "PROBLEM", 44, 57], ["mild", "OBSERVATION_MODIFIER", 44, 48], ["symptoms", "OBSERVATION", 49, 57]]], ["Compared to the outbreaks of severe acute respiratory syndrome (SARS; 2002 ; 774 deaths/8096 cases, case fatality rate (CFR) 9.6%) and Middle East respiratory syndrome (MERS; 2012-ongoing; 858 deaths/2494 cases, CFR 34.4%), the CFR of COVID-19 is relatively low (333,401 deaths/5,103,006 cases, CFR 6.5%) (recorded on May 23, 2020), but SARS-CoV-2 infection has caused the worst death toll worldwide [179] .", [["acute respiratory syndrome", "DISEASE", 36, 62], ["SARS", "DISEASE", 64, 68], ["deaths", "DISEASE", 81, 87], ["Middle East respiratory syndrome", "DISEASE", 135, 167], ["deaths", "DISEASE", 193, 199], ["deaths", "DISEASE", 271, 277], ["SARS", "DISEASE", 337, 341], ["infection", "DISEASE", 348, 357], ["death", "DISEASE", 379, 384], ["SARS-CoV-2", "ORGANISM", 337, 347], ["CoV-", "SPECIES", 342, 346], ["SARS-CoV-2", "SPECIES", 337, 347], ["severe acute respiratory syndrome", "PROBLEM", 29, 62], ["case fatality rate", "TEST", 100, 118], ["CFR", "TEST", 120, 123], ["Middle East respiratory syndrome", "PROBLEM", 135, 167], ["cases", "TEST", 205, 210], ["CFR", "TEST", 212, 215], ["the CFR", "TEST", 224, 231], ["COVID", "TEST", 235, 240], ["cases", "TEST", 288, 293], ["CFR", "TEST", 295, 298], ["SARS", "TEST", 337, 341], ["CoV-2 infection", "PROBLEM", 342, 357], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["respiratory syndrome", "OBSERVATION", 42, 62], ["Middle", "ANATOMY_MODIFIER", 135, 141], ["respiratory syndrome", "OBSERVATION", 147, 167]]], ["Indeed, a certain percentage of COVID-19 patients (approx.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["COVID", "TEST", 32, 37]]], ["5%) were severe cases and often developed acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), and multiple organ dysfunction/failure with high mortality (CFR 49%) [179] .", [["respiratory", "ANATOMY", 48, 59], ["organ", "ANATOMY", 147, 152], ["acute respiratory distress syndrome", "DISEASE", 42, 77], ["ARDS", "DISEASE", 79, 83], ["systemic inflammatory response syndrome", "DISEASE", 86, 125], ["SIRS", "DISEASE", 127, 131], ["organ dysfunction", "DISEASE", 147, 164], ["organ", "ORGAN", 147, 152], ["severe cases", "PROBLEM", 9, 21], ["acute respiratory distress syndrome", "PROBLEM", 42, 77], ["ARDS)", "PROBLEM", 79, 84], ["systemic inflammatory response syndrome", "PROBLEM", 86, 125], ["SIRS", "PROBLEM", 127, 131], ["multiple organ dysfunction", "PROBLEM", 138, 164], ["failure", "PROBLEM", 165, 172], ["high mortality", "PROBLEM", 178, 192], ["CFR", "TEST", 194, 197], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory distress syndrome", "OBSERVATION", 48, 77], ["systemic", "OBSERVATION_MODIFIER", 86, 94], ["inflammatory response syndrome", "OBSERVATION", 95, 125], ["multiple", "OBSERVATION_MODIFIER", 138, 146], ["organ", "ANATOMY", 147, 152], ["dysfunction", "OBSERVATION", 153, 164], ["failure", "OBSERVATION", 165, 172], ["high", "OBSERVATION_MODIFIER", 178, 182]]], ["It has been suggested that respiratory failure associated with ARDS is the leading cause of death in COVID-19 cases [132] .INTRODUCTIONThe severity of COVID-19 is correlated with the levels of interleukin (IL)-6, C-reactive protein (CRP), and other proinflammatory cytokines [132, 175] .", [["respiratory", "ANATOMY", 27, 38], ["respiratory failure", "DISEASE", 27, 46], ["ARDS", "DISEASE", 63, 67], ["death", "DISEASE", 92, 97], ["COVID-19", "CHEMICAL", 151, 159], ["COVID-19", "GENE_OR_GENE_PRODUCT", 151, 159], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 193, 211], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 213, 231], ["CRP", "GENE_OR_GENE_PRODUCT", 233, 236], ["interleukin (IL)-6", "PROTEIN", 193, 211], ["C-reactive protein", "PROTEIN", 213, 231], ["CRP", "PROTEIN", 233, 236], ["proinflammatory cytokines", "PROTEIN", 249, 274], ["respiratory failure", "PROBLEM", 27, 46], ["ARDS", "PROBLEM", 63, 67], ["death", "PROBLEM", 92, 97], ["COVID", "TEST", 101, 106], ["COVID", "TEST", 151, 156], ["interleukin (IL)", "TEST", 193, 209], ["C-reactive protein", "TEST", 213, 231], ["CRP", "TEST", 233, 236], ["other proinflammatory cytokines", "TEST", 243, 274], ["respiratory failure", "OBSERVATION", 27, 46], ["ARDS", "OBSERVATION", 63, 67]]], ["It was also found that the combination of D-dimer and IL-6 can be used to distinguish severe COVID-19 patients (area under the receiver operating characteristic [ROC] curve: 0.840) [39] , suggesting that the high mortality rate of COVID-19 might be caused by the subsequent SIRS induced by a \"cytokine storm.\"", [["COVID", "DISEASE", 93, 98], ["COVID-19", "CHEMICAL", 231, 239], ["SIRS", "DISEASE", 274, 278], ["COVID-19", "CHEMICAL", 231, 239], ["D-dimer", "GENE_OR_GENE_PRODUCT", 42, 49], ["IL-6", "GENE_OR_GENE_PRODUCT", 54, 58], ["patients", "ORGANISM", 102, 110], ["COVID-19", "GENE_OR_GENE_PRODUCT", 231, 239], ["D-dimer", "PROTEIN", 42, 49], ["IL-6", "PROTEIN", 54, 58], ["cytokine", "PROTEIN", 293, 301], ["patients", "SPECIES", 102, 110], ["D-dimer and IL-6", "TREATMENT", 42, 58], ["severe COVID", "PROBLEM", 86, 98], ["ROC] curve", "TEST", 162, 172], ["COVID", "TEST", 231, 236], ["the subsequent SIRS", "PROBLEM", 259, 278]]], ["It has been indicated that early interventions to attenuate this cytokine storm may improve the clinical outcomes of severe cases of COVID-19 [185] .INTRODUCTIONAngiotensin-converting enzyme (ACE) 2 is a common binding site (\"receptor\") for both SARS-CoV and SARS-CoV-2 [60] .", [["COVID", "DISEASE", 133, 138], ["COVID-19", "CHEMICAL", 133, 141], ["INTRODUCTIONAngiotensin-converting enzyme (ACE) 2", "GENE_OR_GENE_PRODUCT", 149, 198], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 246, 254], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 259, 269], ["cytokine", "PROTEIN", 65, 73], ["INTRODUCTIONAngiotensin-converting enzyme (ACE) 2", "PROTEIN", 149, 198], ["common binding site", "DNA", 204, 223], ["SARS-CoV", "SPECIES", 246, 254], ["early interventions", "TREATMENT", 27, 46], ["this cytokine storm", "TREATMENT", 60, 79], ["COVID", "TEST", 133, 138], ["INTRODUCTIONAngiotensin-converting enzyme (ACE)", "TREATMENT", 149, 196], ["both SARS", "TEST", 241, 250], ["CoV", "TEST", 251, 254], ["SARS", "TEST", 259, 263], ["CoV", "TEST", 264, 267]]], ["The SARS-CoV-2 entry into host cells begins with its viral spike (S) protein binding to the host cell's surface transmembrane ACE2, followed by a downregulation of membrane ACE2 expression [74] .", [["cells", "ANATOMY", 31, 36], ["cell", "ANATOMY", 97, 101], ["surface transmembrane", "ANATOMY", 104, 125], ["membrane", "ANATOMY", 164, 172], ["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["host cells", "CELL", 26, 36], ["cell", "CELL", 97, 101], ["surface transmembrane", "CELLULAR_COMPONENT", 104, 125], ["ACE2", "GENE_OR_GENE_PRODUCT", 126, 130], ["membrane", "CELLULAR_COMPONENT", 164, 172], ["ACE2", "GENE_OR_GENE_PRODUCT", 173, 177], ["host cells", "CELL_TYPE", 26, 36], ["viral spike (S) protein", "PROTEIN", 53, 76], ["surface transmembrane ACE2", "PROTEIN", 104, 130], ["ACE2", "PROTEIN", 173, 177], ["The SARS", "TEST", 0, 8], ["host cells", "PROBLEM", 26, 36], ["its viral spike (S) protein binding", "PROBLEM", 49, 84], ["transmembrane ACE2", "TEST", 112, 130], ["host cells", "OBSERVATION", 26, 36], ["viral spike", "OBSERVATION", 53, 64]]], ["The normal level of ACE2 is important to protect vital organs; However, as demonstrated in the models of acute lung injury (ALI) and ARDS [53, 62] , the abnormal ACE2 levels were suggested to aggravate COVID-19 via the reninangiotensin system (RAS), including promoting pathological changes in ALI [62] and being involved in inflammatory and fibrotic responses [141] .", [["organs", "ANATOMY", 55, 61], ["lung", "ANATOMY", 111, 115], ["acute lung injury", "DISEASE", 105, 122], ["ALI", "DISEASE", 124, 127], ["ARDS", "DISEASE", 133, 137], ["ALI", "DISEASE", 294, 297], ["COVID-19", "CHEMICAL", 202, 210], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["organs", "ORGAN", 55, 61], ["lung", "ORGAN", 111, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 162, 166], ["COVID-19", "GENE_OR_GENE_PRODUCT", 202, 210], ["reninangiotensin", "GENE_OR_GENE_PRODUCT", 219, 235], ["RAS", "GENE_OR_GENE_PRODUCT", 244, 247], ["ACE2", "PROTEIN", 20, 24], ["ACE2", "PROTEIN", 162, 166], ["acute lung injury", "PROBLEM", 105, 122], ["ARDS", "PROBLEM", 133, 137], ["the abnormal ACE2 levels", "PROBLEM", 149, 173], ["COVID", "TEST", 202, 207], ["promoting pathological changes in ALI", "PROBLEM", 260, 297], ["inflammatory and fibrotic responses", "PROBLEM", 325, 360], ["normal", "OBSERVATION", 4, 10], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["lung", "ANATOMY", 111, 115], ["injury", "OBSERVATION", 116, 122], ["ALI", "ANATOMY", 294, 297], ["inflammatory", "OBSERVATION_MODIFIER", 325, 337], ["fibrotic", "OBSERVATION_MODIFIER", 342, 350]]], ["ACE2 may thus be a key disease mediator in the pathogenesis of COVID-19.", [["COVID-19", "CHEMICAL", 63, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["COVID", "TEST", 63, 68]]], ["Indeed, a recent publication indicated that higher ACE2 concentrations led to increased vulnerability to SARS-CoV-2 infection in men compared to women, and that this finding was also associated with the higher incidence and fatality rate of COVID-19 in men [133] .", [["SARS", "DISEASE", 105, 109], ["infection", "DISEASE", 116, 125], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["SARS-CoV-2", "ORGANISM", 105, 115], ["men", "ORGANISM", 129, 132], ["women", "ORGANISM", 145, 150], ["men", "ORGANISM", 253, 256], ["ACE2", "PROTEIN", 51, 55], ["men", "SPECIES", 129, 132], ["women", "SPECIES", 145, 150], ["men", "SPECIES", 253, 256], ["SARS-CoV", "SPECIES", 105, 113], ["higher ACE2 concentrations", "PROBLEM", 44, 70], ["increased vulnerability", "PROBLEM", 78, 101], ["SARS", "PROBLEM", 105, 109], ["CoV-2 infection", "PROBLEM", 110, 125], ["fatality rate", "TEST", 224, 237], ["COVID", "TEST", 241, 246], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["vulnerability", "OBSERVATION_MODIFIER", 88, 101], ["infection", "OBSERVATION", 116, 125]]], ["This review aims to summarize the multi-organ injuries and failure and the underlying mechanisms of COVID-19 that are associated with SARS-CoV-2 infection via ACE2 entry route and beyond.THE PHYSIOLOGY OF THE RENIN-ANGIOTENSIN SYSTEM AND ACE2The Systemic \"Classic\" Functions of RAS As illustrated in Fig. 1 , ACE2 is a key enzyme in the RAS, with multiple physiological functions [60] .", [["multi-organ", "ANATOMY", 34, 45], ["multi-organ injuries", "DISEASE", 34, 54], ["infection", "DISEASE", 145, 154], ["COVID-19", "GENE_OR_GENE_PRODUCT", 100, 108], ["CoV-2", "ORGANISM", 139, 144], ["ACE2", "GENE_OR_GENE_PRODUCT", 159, 163], ["ACE2", "ORGANISM", 238, 242], ["RAS", "GENE_OR_GENE_PRODUCT", 278, 281], ["ACE2", "GENE_OR_GENE_PRODUCT", 309, 313], ["RAS", "GENE_OR_GENE_PRODUCT", 337, 340], ["ACE2", "PROTEIN", 159, 163], ["ACE2", "PROTEIN", 238, 242], ["RAS", "PROTEIN", 278, 281], ["ACE2", "PROTEIN", 309, 313], ["RAS", "PROTEIN", 337, 340], ["SARS-CoV", "SPECIES", 134, 142], ["the multi-organ injuries", "PROBLEM", 30, 54], ["failure", "PROBLEM", 59, 66], ["COVID", "TEST", 100, 105], ["SARS", "PROBLEM", 134, 138], ["CoV", "PROBLEM", 139, 142], ["2 infection", "PROBLEM", 143, 154], ["ACE2", "TEST", 238, 242], ["a key enzyme", "TEST", 317, 329], ["multi-organ", "ANATOMY", 34, 45], ["injuries", "OBSERVATION", 46, 54], ["failure", "OBSERVATION", 59, 66]]], ["The RAS is known as a major regulator of a wide range of physiology and pathophysiology [38, 118] such as the mediation of fluid/electrolyte homeostasis and the maintenance of vascular tone via angiotensin type 1 receptor (AT1R) in vital organs (kidneys, vascular smooth muscle, lung, heart, brain, adrenals, pituitary gland, and liver) [53] .", [["fluid", "ANATOMY", 123, 128], ["vascular", "ANATOMY", 176, 184], ["organs", "ANATOMY", 238, 244], ["kidneys", "ANATOMY", 246, 253], ["vascular smooth muscle", "ANATOMY", 255, 277], ["lung", "ANATOMY", 279, 283], ["heart", "ANATOMY", 285, 290], ["brain", "ANATOMY", 292, 297], ["adrenals", "ANATOMY", 299, 307], ["pituitary gland", "ANATOMY", 309, 324], ["liver", "ANATOMY", 330, 335], ["angiotensin", "CHEMICAL", 194, 205], ["RAS", "GENE_OR_GENE_PRODUCT", 4, 7], ["electrolyte", "SIMPLE_CHEMICAL", 129, 140], ["vascular", "MULTI-TISSUE_STRUCTURE", 176, 184], ["angiotensin type 1 receptor", "GENE_OR_GENE_PRODUCT", 194, 221], ["AT1R", "GENE_OR_GENE_PRODUCT", 223, 227], ["organs", "ORGAN", 238, 244], ["kidneys", "ORGAN", 246, 253], ["vascular smooth muscle", "TISSUE", 255, 277], ["lung", "ORGAN", 279, 283], ["heart", "ORGAN", 285, 290], ["brain", "ORGAN", 292, 297], ["adrenals", "ORGAN", 299, 307], ["pituitary gland", "MULTI-TISSUE_STRUCTURE", 309, 324], ["liver", "ORGAN", 330, 335], ["RAS", "PROTEIN", 4, 7], ["angiotensin type 1 receptor", "PROTEIN", 194, 221], ["AT1R", "PROTEIN", 223, 227], ["fluid/electrolyte homeostasis", "PROBLEM", 123, 152], ["angiotensin type 1 receptor", "TREATMENT", 194, 221], ["vascular smooth muscle, lung, heart, brain, adrenals, pituitary gland, and liver", "PROBLEM", 255, 335], ["fluid", "OBSERVATION", 123, 128], ["electrolyte homeostasis", "OBSERVATION", 129, 152], ["vascular", "ANATOMY", 176, 184], ["kidneys", "ANATOMY", 246, 253], ["vascular", "ANATOMY_MODIFIER", 255, 263], ["smooth muscle", "ANATOMY", 264, 277], ["lung", "ANATOMY", 279, 283], ["heart", "ANATOMY", 285, 290], ["brain", "ANATOMY", 292, 297], ["adrenals", "ANATOMY", 299, 307], ["pituitary gland", "ANATOMY", 309, 324], ["liver", "ANATOMY", 330, 335]]], ["For example, when the renal blood flow is reduced, the kidneys' juxtaglomerular cells secrete renin directly into the blood circulation.", [["renal blood", "ANATOMY", 22, 33], ["kidneys", "ANATOMY", 55, 62], ["juxtaglomerular cells", "ANATOMY", 64, 85], ["blood", "ANATOMY", 118, 123], ["renal", "MULTI-TISSUE_STRUCTURE", 22, 27], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["kidneys", "ORGAN", 55, 62], ["juxtaglomerular cells", "CELL", 64, 85], ["renin", "GENE_OR_GENE_PRODUCT", 94, 99], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["juxtaglomerular cells", "CELL_TYPE", 64, 85], ["renin", "PROTEIN", 94, 99], ["the renal blood flow", "TEST", 18, 38], ["renal", "ANATOMY", 22, 27], ["reduced", "OBSERVATION_MODIFIER", 42, 49], ["kidneys", "ANATOMY", 55, 62], ["juxtaglomerular cells", "OBSERVATION", 64, 85], ["secrete renin", "OBSERVATION", 86, 99], ["blood", "ANATOMY", 118, 123], ["circulation", "ANATOMY_MODIFIER", 124, 135]]], ["This secreted renin converts angiotensinogen released by the liver to be angiotensin1 (Ang1), which is then converted to be angiotensin2 (Ang2) by ACE in pulmonary vascular endothelial cells [117, 118, 123] .", [["liver", "ANATOMY", 61, 66], ["pulmonary vascular endothelial cells", "ANATOMY", 154, 190], ["renin", "GENE_OR_GENE_PRODUCT", 14, 19], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 29, 44], ["liver", "ORGAN", 61, 66], ["angiotensin1", "GENE_OR_GENE_PRODUCT", 73, 85], ["Ang1", "GENE_OR_GENE_PRODUCT", 87, 91], ["angiotensin2", "GENE_OR_GENE_PRODUCT", 124, 136], ["Ang2", "GENE_OR_GENE_PRODUCT", 138, 142], ["ACE", "GENE_OR_GENE_PRODUCT", 147, 150], ["pulmonary vascular endothelial cells", "CELL", 154, 190], ["renin", "PROTEIN", 14, 19], ["angiotensinogen", "PROTEIN", 29, 44], ["angiotensin1", "PROTEIN", 73, 85], ["Ang1", "PROTEIN", 87, 91], ["angiotensin2", "PROTEIN", 124, 136], ["Ang2", "PROTEIN", 138, 142], ["ACE", "PROTEIN", 147, 150], ["pulmonary vascular endothelial cells", "CELL_TYPE", 154, 190], ["ACE in pulmonary vascular endothelial cells", "TEST", 147, 190], ["liver", "ANATOMY", 61, 66], ["pulmonary", "ANATOMY", 154, 163], ["vascular endothelial", "ANATOMY", 164, 184]]], ["Ang2 plays a central role in the RAS by acting on the angiotensin type 2 receptors AT1R and AT2R.THE PHYSIOLOGY OF THE RENIN-ANGIOTENSIN SYSTEM AND ACE2The Local \"Tissue\" and \"Intracellular\" RAS In addition to the systemic RAS, the physiological functions of RAS can been seen at the local \"tissue\" and even \"intracellular\" levels in the heart, lung, brain, kidney, liver, intestine and other digestive system [77, 82, 117] .", [["Tissue", "ANATOMY", 163, 169], ["tissue", "ANATOMY", 291, 297], ["intracellular", "ANATOMY", 309, 322], ["heart", "ANATOMY", 338, 343], ["lung", "ANATOMY", 345, 349], ["brain", "ANATOMY", 351, 356], ["kidney", "ANATOMY", 358, 364], ["liver", "ANATOMY", 366, 371], ["intestine", "ANATOMY", 373, 382], ["digestive system", "ANATOMY", 393, 409], ["angiotensin", "CHEMICAL", 54, 65], ["Ang2", "GENE_OR_GENE_PRODUCT", 0, 4], ["RAS", "GENE_OR_GENE_PRODUCT", 33, 36], ["angiotensin type 2", "GENE_OR_GENE_PRODUCT", 54, 72], ["AT1R", "GENE_OR_GENE_PRODUCT", 83, 87], ["AT2R", "GENE_OR_GENE_PRODUCT", 92, 96], ["ACE2", "ORGANISM", 148, 152], ["Tissue", "TISSUE", 163, 169], ["RAS", "GENE_OR_GENE_PRODUCT", 223, 226], ["RAS", "GENE_OR_GENE_PRODUCT", 259, 262], ["tissue", "TISSUE", 291, 297], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 309, 322], ["heart", "ORGAN", 338, 343], ["lung", "ORGAN", 345, 349], ["brain", "ORGAN", 351, 356], ["kidney", "ORGAN", 358, 364], ["liver", "ORGAN", 366, 371], ["intestine", "ORGAN", 373, 382], ["digestive", "ORGAN", 393, 402], ["system", "ANATOMICAL_SYSTEM", 403, 409], ["Ang2", "PROTEIN", 0, 4], ["RAS", "PROTEIN", 33, 36], ["angiotensin type 2 receptors", "PROTEIN", 54, 82], ["AT1R", "PROTEIN", 83, 87], ["AT2R", "PROTEIN", 92, 96], ["ACE2", "PROTEIN", 148, 152], ["RAS", "PROTEIN", 191, 194], ["RAS", "PROTEIN", 259, 262], ["the angiotensin type", "TREATMENT", 50, 70], ["ACE2", "TEST", 148, 152], ["the systemic RAS", "PROBLEM", 210, 226], ["\"intracellular\" levels in the heart, lung, brain, kidney, liver, intestine and other digestive system", "PROBLEM", 308, 409], ["Local", "OBSERVATION_MODIFIER", 156, 161], ["\"Tissue", "OBSERVATION", 162, 169], ["heart", "ANATOMY", 338, 343], ["lung", "ANATOMY", 345, 349], ["brain", "ANATOMY", 351, 356], ["kidney", "ANATOMY", 358, 364], ["liver", "ANATOMY", 366, 371], ["intestine", "ANATOMY", 373, 382], ["digestive system", "ANATOMY", 393, 409]]], ["The tissue RAS is involved mainly in cardiovascular regulation and inflammatory processes such as vascular permeability and tone [117] and cell apoptosis [25] , growth [26] , migration [26] , and differentiation [27, 94] .", [["tissue", "ANATOMY", 4, 10], ["cardiovascular", "ANATOMY", 37, 51], ["vascular", "ANATOMY", 98, 106], ["cell", "ANATOMY", 139, 143], ["tissue", "TISSUE", 4, 10], ["RAS", "GENE_OR_GENE_PRODUCT", 11, 14], ["cardiovascular", "ANATOMICAL_SYSTEM", 37, 51], ["vascular", "MULTI-TISSUE_STRUCTURE", 98, 106], ["cell", "CELL", 139, 143], ["tissue RAS", "PROTEIN", 4, 14], ["inflammatory processes", "PROBLEM", 67, 89], ["vascular permeability", "TEST", 98, 119], ["tone", "TEST", 124, 128], ["cell apoptosis", "TEST", 139, 153], ["growth", "TEST", 161, 167], ["migration", "TEST", 175, 184], ["inflammatory", "OBSERVATION", 67, 79], ["vascular", "ANATOMY", 98, 106]]], ["The intracellular RAS is involved in the intracellular signaling pathways; Ang2 stimulates the production of reactive oxygen species (ROS) and nuclear factor kappa B (NF\u03baB) via AT1R and the phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/Akt) pathway, leading to increases of proinflammatory cytokines such as IL-6, chemokines, and adhesion molecules in tissue-resident cells in the amplifying inflammatory cycle [38] .THE PHYSIOLOGY OF THE RENIN-ANGIOTENSIN SYSTEM AND ACE2ACE2, Angiotensin-(1-7), and the Mas Receptor Axis: Anti-inflammatory Property ACE2 exists in two forms, the full-length transmembrane ACE2 (ACE2) and the soluble ACE2 (sACE2). sACE2 is cleaved from ACE2 by ADAM17 (a disintegrin and metallopeptidase domain 17) and then released into the extracellular environment [79] .", [["intracellular", "ANATOMY", 4, 17], ["intracellular", "ANATOMY", 41, 54], ["tissue-resident cells", "ANATOMY", 376, 397], ["extracellular", "ANATOMY", 784, 797], ["oxygen", "CHEMICAL", 118, 124], ["phosphatidylinositol-4,5-bisphosphate", "CHEMICAL", 190, 227], ["Angiotensin-(1-7)", "CHEMICAL", 502, 519], ["oxygen", "CHEMICAL", 118, 124], ["phosphatidylinositol-4,5-bisphosphate", "CHEMICAL", 190, 227], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["RAS", "GENE_OR_GENE_PRODUCT", 18, 21], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 54], ["Ang2", "GENE_OR_GENE_PRODUCT", 75, 79], ["reactive oxygen species", "SIMPLE_CHEMICAL", 109, 132], ["ROS", "SIMPLE_CHEMICAL", 134, 137], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 143, 165], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 167, 171], ["AT1R", "GENE_OR_GENE_PRODUCT", 177, 181], ["phosphatidylinositol-4,5-bisphosphate 3-kinase", "GENE_OR_GENE_PRODUCT", 190, 236], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 237, 253], ["PI3K", "GENE_OR_GENE_PRODUCT", 255, 259], ["Akt", "GENE_OR_GENE_PRODUCT", 260, 263], ["IL-6", "GENE_OR_GENE_PRODUCT", 332, 336], ["tissue-resident cells", "CELL", 376, 397], ["Angiotensin-(1-7", "GENE_OR_GENE_PRODUCT", 502, 518], ["ACE2", "GENE_OR_GENE_PRODUCT", 575, 579], ["transmembrane", "CELLULAR_COMPONENT", 617, 630], ["ACE2", "GENE_OR_GENE_PRODUCT", 631, 635], ["ACE2", "GENE_OR_GENE_PRODUCT", 637, 641], ["ACE2", "GENE_OR_GENE_PRODUCT", 659, 663], ["sACE2", "GENE_OR_GENE_PRODUCT", 665, 670], ["sACE2", "GENE_OR_GENE_PRODUCT", 673, 678], ["ACE2", "GENE_OR_GENE_PRODUCT", 695, 699], ["ADAM17", "GENE_OR_GENE_PRODUCT", 703, 709], ["disintegrin and metallopeptidase domain 17", "GENE_OR_GENE_PRODUCT", 713, 755], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 784, 797], ["intracellular RAS", "PROTEIN", 4, 21], ["Ang2", "PROTEIN", 75, 79], ["nuclear factor kappa B", "PROTEIN", 143, 165], ["NF\u03baB", "PROTEIN", 167, 171], ["AT1R", "PROTEIN", 177, 181], ["phosphatidylinositol-4,5-bisphosphate 3-kinase", "PROTEIN", 190, 236], ["protein kinase B", "PROTEIN", 237, 253], ["PI3K", "PROTEIN", 255, 259], ["Akt", "PROTEIN", 260, 263], ["proinflammatory cytokines", "PROTEIN", 298, 323], ["IL-6", "PROTEIN", 332, 336], ["chemokines", "PROTEIN", 338, 348], ["adhesion molecules", "PROTEIN", 354, 372], ["tissue-resident cells", "CELL_TYPE", 376, 397], ["ACE2", "PROTEIN", 575, 579], ["full-length transmembrane ACE2", "PROTEIN", 605, 635], ["ACE2", "PROTEIN", 637, 641], ["ACE2", "PROTEIN", 659, 663], ["sACE2", "PROTEIN", 665, 670], ["sACE2", "PROTEIN", 673, 678], ["ACE2", "PROTEIN", 695, 699], ["ADAM17", "PROTEIN", 703, 709], ["disintegrin and metallopeptidase domain 17", "PROTEIN", 713, 755], ["reactive oxygen species", "PROBLEM", 109, 132], ["nuclear factor kappa B", "TEST", 143, 165], ["AT1R", "TEST", 177, 181], ["the phosphatidylinositol", "TEST", 186, 210], ["bisphosphate", "TEST", 215, 227], ["protein kinase", "TEST", 237, 251], ["proinflammatory cytokines", "PROBLEM", 298, 323], ["IL", "TEST", 332, 334], ["chemokines", "TREATMENT", 338, 348], ["ACE2ACE2, Angiotensin", "TREATMENT", 492, 513], ["Anti-inflammatory Property ACE2", "TREATMENT", 548, 579], ["the full-length transmembrane ACE2 (ACE2)", "TREATMENT", 601, 642], ["the soluble ACE2 (sACE2)", "TREATMENT", 647, 671], ["a disintegrin and metallopeptidase domain", "TREATMENT", 711, 752], ["intracellular", "OBSERVATION_MODIFIER", 4, 17], ["RAS", "OBSERVATION", 18, 21], ["reactive", "OBSERVATION_MODIFIER", 109, 117], ["oxygen species", "OBSERVATION", 118, 132], ["inflammatory", "OBSERVATION_MODIFIER", 416, 428]]], ["ACE2 is the predominant enzyme regulating the ACE2/Ang-(1-7)/Mas receptor (MasR) axis.", [["Ang", "CHEMICAL", 51, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 51, 59], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 61, 73], ["MasR", "GENE_OR_GENE_PRODUCT", 75, 79], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "PROTEIN", 46, 50], ["Mas receptor", "PROTEIN", 61, 73], ["MasR", "PROTEIN", 75, 79], ["ACE2", "TEST", 0, 4], ["the ACE2", "TEST", 42, 50], ["Ang", "TEST", 51, 54]]], ["The function of sACE2 remains unclear.", [["sACE2", "GENE_OR_GENE_PRODUCT", 16, 21], ["sACE2", "PROTEIN", 16, 21]]], ["ACE is a close homolog of ACE2 with a 42% identical sequence in the catalytic domains, which function in an opposite manner to ACE for balancing [162] .", [["ACE", "GENE_OR_GENE_PRODUCT", 0, 3], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["ACE", "GENE_OR_GENE_PRODUCT", 127, 130], ["ACE", "PROTEIN", 0, 3], ["ACE2", "PROTEIN", 26, 30], ["catalytic domains", "PROTEIN", 68, 85], ["ACE", "PROTEIN", 127, 130]]], ["ACE2 inactivates Ang2 into mainly Ang-(1-7) and converts Ang1 to Ang-(1-9), whereas ACE inactivates Ang1 into mainly , and apelin.", [["Ang-(1-7", "CHEMICAL", 34, 42], ["Ang-(1-9", "CHEMICAL", 65, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang2", "GENE_OR_GENE_PRODUCT", 17, 21], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 34, 42], ["Ang1", "GENE_OR_GENE_PRODUCT", 57, 61], ["Ang-(1-9", "GENE_OR_GENE_PRODUCT", 65, 73], ["ACE", "GENE_OR_GENE_PRODUCT", 84, 87], ["Ang1", "GENE_OR_GENE_PRODUCT", 100, 104], ["apelin", "GENE_OR_GENE_PRODUCT", 123, 129], ["ACE2", "PROTEIN", 0, 4], ["Ang2", "PROTEIN", 17, 21], ["Ang1", "PROTEIN", 57, 61], ["ACE", "PROTEIN", 84, 87], ["Ang1", "PROTEIN", 100, 104], ["ACE2", "TEST", 0, 4], ["Ang2", "TEST", 17, 21], ["Ang", "TEST", 34, 37], ["Ang", "TEST", 65, 68], ["ACE inactivates Ang1", "TREATMENT", 84, 104]]], ["Ang2 is a central regulator of the inflammatory response, mainly through AT1R.", [["Ang2", "GENE_OR_GENE_PRODUCT", 0, 4], ["AT1R", "GENE_OR_GENE_PRODUCT", 73, 77], ["Ang2", "PROTEIN", 0, 4], ["AT1R", "PROTEIN", 73, 77], ["inflammatory response", "OBSERVATION", 35, 56]]], ["As a proinflammatory modulator, Ang2 interacts on both immune cells and tissue-resident cells.", [["immune cells", "ANATOMY", 55, 67], ["tissue-resident cells", "ANATOMY", 72, 93], ["Ang2", "GENE_OR_GENE_PRODUCT", 32, 36], ["immune cells", "CELL", 55, 67], ["tissue-resident cells", "CELL", 72, 93], ["proinflammatory modulator", "PROTEIN", 5, 30], ["Ang2", "PROTEIN", 32, 36], ["immune cells", "CELL_TYPE", 55, 67], ["tissue-resident cells", "CELL_TYPE", 72, 93], ["a proinflammatory modulator", "PROBLEM", 3, 30], ["proinflammatory modulator", "OBSERVATION", 5, 30], ["immune cells", "OBSERVATION", 55, 67]]], ["The activated synthesis of Ang2 from tissue-resident cells enhances vascular permeability by promoting the productions of proinflammatory factors including prostaglandins, VEGF, NF\u03baB, TNF\u03b1, IL-1\u03b2, IL-6, and IFN\u03b3 via the activation of several pathways.", [["tissue-resident cells", "ANATOMY", 37, 58], ["vascular", "ANATOMY", 68, 76], ["prostaglandins", "CHEMICAL", 156, 170], ["prostaglandins", "CHEMICAL", 156, 170], ["Ang2", "GENE_OR_GENE_PRODUCT", 27, 31], ["tissue-resident cells", "CELL", 37, 58], ["vascular", "MULTI-TISSUE_STRUCTURE", 68, 76], ["prostaglandins", "GENE_OR_GENE_PRODUCT", 156, 170], ["VEGF", "GENE_OR_GENE_PRODUCT", 172, 176], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 178, 182], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 184, 188], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 190, 195], ["IL-6", "GENE_OR_GENE_PRODUCT", 197, 201], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 207, 211], ["Ang2", "PROTEIN", 27, 31], ["tissue-resident cells", "CELL_TYPE", 37, 58], ["proinflammatory factors", "PROTEIN", 122, 145], ["prostaglandins", "PROTEIN", 156, 170], ["VEGF", "PROTEIN", 172, 176], ["NF\u03baB", "PROTEIN", 178, 182], ["TNF\u03b1", "PROTEIN", 184, 188], ["IL-1\u03b2, IL-6", "PROTEIN", 190, 201], ["IFN\u03b3", "PROTEIN", 207, 211], ["proinflammatory factors", "PROBLEM", 122, 145], ["prostaglandins", "TREATMENT", 156, 170], ["VEGF", "TEST", 172, 176], ["TNF\u03b1", "TEST", 184, 188], ["IL", "TEST", 190, 192], ["IL", "TREATMENT", 197, 199], ["IFN", "TREATMENT", 207, 210], ["vascular", "ANATOMY", 68, 76]]], ["Ang2 also recruits immune cells into the injury site(s) and enhances the inflammatory response by stimulating the production of cytokines/chemokines, resulting in fibrosis and tissue injury.", [["immune cells", "ANATOMY", 19, 31], ["injury site", "ANATOMY", 41, 52], ["tissue", "ANATOMY", 176, 182], ["fibrosis", "DISEASE", 163, 171], ["tissue injury", "DISEASE", 176, 189], ["Ang2", "GENE_OR_GENE_PRODUCT", 0, 4], ["immune cells", "CELL", 19, 31], ["tissue", "TISSUE", 176, 182], ["Ang2", "PROTEIN", 0, 4], ["immune cells", "CELL_TYPE", 19, 31], ["cytokines", "PROTEIN", 128, 137], ["chemokines", "PROTEIN", 138, 148], ["the injury site", "PROBLEM", 37, 52], ["the inflammatory response", "PROBLEM", 69, 94], ["cytokines/chemokines", "TREATMENT", 128, 148], ["fibrosis", "PROBLEM", 163, 171], ["tissue injury", "PROBLEM", 176, 189], ["immune cells", "OBSERVATION", 19, 31], ["injury", "OBSERVATION", 41, 47], ["inflammatory", "OBSERVATION_MODIFIER", 73, 85], ["fibrosis", "OBSERVATION", 163, 171], ["tissue", "ANATOMY", 176, 182], ["injury", "OBSERVATION", 183, 189]]], ["ACE2 inactivates Ang2 into mainly Ang-(1-7), and thus the ACE2/Ang-(1-7)/MasR axis is the negative regulatory axis against the ACE/Ang2/AT1R axis in the RAS.", [["Ang-(1-7", "CHEMICAL", 34, 42], ["Ang", "CHEMICAL", 63, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang2", "GENE_OR_GENE_PRODUCT", 17, 21], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 34, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 63, 71], ["MasR", "GENE_OR_GENE_PRODUCT", 73, 77], ["ACE", "GENE_OR_GENE_PRODUCT", 127, 130], ["Ang2", "GENE_OR_GENE_PRODUCT", 131, 135], ["AT1R", "GENE_OR_GENE_PRODUCT", 136, 140], ["RAS", "GENE_OR_GENE_PRODUCT", 153, 156], ["ACE2", "PROTEIN", 0, 4], ["Ang2", "PROTEIN", 17, 21], ["ACE2", "PROTEIN", 58, 62], ["MasR", "PROTEIN", 73, 77], ["ACE", "PROTEIN", 127, 130], ["Ang2", "PROTEIN", 131, 135], ["AT1R", "PROTEIN", 136, 140], ["RAS", "PROTEIN", 153, 156], ["ACE2", "TEST", 0, 4], ["Ang2", "TEST", 17, 21], ["Ang", "TEST", 34, 37], ["the ACE2", "TEST", 54, 62], ["Ang", "TEST", 63, 66], ["the ACE", "TEST", 123, 130], ["negative", "OBSERVATION", 90, 98]]], ["Apelin antagonizes the ACE/Ang2/AT1R axis through negative feedback by ACE2 upregulation.", [["Apelin", "CHEMICAL", 0, 6], ["Apelin", "CHEMICAL", 0, 6], ["Apelin", "GENE_OR_GENE_PRODUCT", 0, 6], ["ACE", "GENE_OR_GENE_PRODUCT", 23, 26], ["Ang2", "GENE_OR_GENE_PRODUCT", 27, 31], ["AT1R", "GENE_OR_GENE_PRODUCT", 32, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["ACE", "PROTEIN", 23, 26], ["Ang2", "PROTEIN", 27, 31], ["AT1R", "PROTEIN", 32, 36], ["ACE2", "PROTEIN", 71, 75], ["Apelin", "TEST", 0, 6], ["the ACE", "TEST", 19, 26], ["Ang2/AT1R axis", "TEST", 27, 41]]], ["In addition, the molecular interaction between AT1R and APJ suppresses the activity of AT1R.", [["AT1R", "GENE_OR_GENE_PRODUCT", 47, 51], ["APJ", "GENE_OR_GENE_PRODUCT", 56, 59], ["AT1R", "GENE_OR_GENE_PRODUCT", 87, 91], ["AT1R", "PROTEIN", 47, 51], ["APJ", "PROTEIN", 56, 59], ["AT1R", "PROTEIN", 87, 91]]], ["The activation of the ACE2/Ang-(1-7)/MasR axis and the apelin/APJ axis has shown an organoprotective effect.", [["Ang", "CHEMICAL", 27, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 27, 35], ["MasR", "GENE_OR_GENE_PRODUCT", 37, 41], ["apelin", "GENE_OR_GENE_PRODUCT", 55, 61], ["APJ", "GENE_OR_GENE_PRODUCT", 62, 65], ["ACE2", "PROTEIN", 22, 26], ["MasR", "PROTEIN", 37, 41], ["apelin", "PROTEIN", 55, 61], ["APJ", "PROTEIN", 62, 65], ["the ACE2", "TEST", 18, 26], ["Ang", "TEST", 27, 30], ["the apelin/APJ axis", "TEST", 51, 70], ["an organoprotective effect", "PROBLEM", 81, 107], ["Ang", "ANATOMY", 27, 30], ["APJ axis", "ANATOMY", 62, 70], ["organoprotective effect", "OBSERVATION", 84, 107]]], ["ACE, angiotensin-converting enzyme; Ang1, angiotensin 1; Ang2, angiotensin 2; AT1R, angiotensin 1 receptor; CHOP, CCAAT/enhancer-binding protein homologous protein; Cox-2, cyclooxygenase-2; eNOS, endothelial nitric oxide synthase; ERK1/2, extracellular signalregulated kinase; GRP78, glucose-regulated protein 78; HDAC-1, histone deacetylase-1; IFN\u03b3, interferon gamma; IL-1\u03b2, interleukin-1 beta; IL-6, interleukin-6; IR-injury, ischemia reperfusion injury; JAK-STAT3, Janus kinase-signal transducer and activator of transcription system; JNK, C-jun-Nterminal kinase; MAPK, mitogen-activated protein kinase; MasR, Mas receptor; MCP-1, reactive oxygen species; MMP, matrix metalloproteinase; NADPH, nicotinamide adenine dinucleotide phosphate; NF\u03baB, nuclear factor kappa-light-chain-enhancer of activated B cells; NO, nitric oxide; PAH, pulmonary artery hypertension; PAI-1, plasminogen activator inhibitor-1; PI3K/Akt, phosphoinositide 3-kinase/protein kinase B; PKC, protein kinase C; ROS, reactive oxygen species; SOD, superoxide dismutase; TGF\u03b2, transforming growth factor-beta; TNF\u03b1, tumor necrosis factor alpha; VCAM-1, vascular cell adhesion molecule-1; VEGF, vascular endothelial cell growth factor.", [["B cells", "ANATOMY", 803, 810], ["pulmonary artery", "ANATOMY", 835, 851], ["angiotensin", "CHEMICAL", 5, 16], ["angiotensin", "CHEMICAL", 42, 53], ["angiotensin", "CHEMICAL", 63, 74], ["angiotensin", "CHEMICAL", 84, 95], ["nitric oxide", "CHEMICAL", 208, 220], ["ischemia", "DISEASE", 428, 436], ["nicotinamide adenine dinucleotide phosphate", "CHEMICAL", 697, 740], ["NO", "CHEMICAL", 812, 814], ["nitric oxide", "CHEMICAL", 816, 828], ["PAH", "CHEMICAL", 830, 833], ["pulmonary artery hypertension", "DISEASE", 835, 864], ["oxygen", "CHEMICAL", 999, 1005], ["superoxide", "CHEMICAL", 1020, 1030], ["necrosis", "DISEASE", 1093, 1101], ["nitric oxide", "CHEMICAL", 208, 220], ["glucose", "CHEMICAL", 284, 291], ["oxygen", "CHEMICAL", 643, 649], ["NADPH", "CHEMICAL", 690, 695], ["nicotinamide adenine dinucleotide phosphate", "CHEMICAL", 697, 740], ["NO", "CHEMICAL", 812, 814], ["nitric oxide", "CHEMICAL", 816, 828], ["PAH", "CHEMICAL", 830, 833], ["oxygen", "CHEMICAL", 999, 1005], ["superoxide", "CHEMICAL", 1020, 1030], ["ACE", "GENE_OR_GENE_PRODUCT", 0, 3], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 5, 34], ["Ang1", "GENE_OR_GENE_PRODUCT", 36, 40], ["angiotensin 1", "GENE_OR_GENE_PRODUCT", 42, 55], ["Ang2", "GENE_OR_GENE_PRODUCT", 57, 61], ["angiotensin 2", "GENE_OR_GENE_PRODUCT", 63, 76], ["AT1R", "GENE_OR_GENE_PRODUCT", 78, 82], ["angiotensin 1 receptor", "GENE_OR_GENE_PRODUCT", 84, 106], ["CHOP", "GENE_OR_GENE_PRODUCT", 108, 112], ["CCAAT/enhancer-binding protein homologous protein", "GENE_OR_GENE_PRODUCT", 114, 163], ["Cox-2", "GENE_OR_GENE_PRODUCT", 165, 170], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 172, 188], ["eNOS", "GENE_OR_GENE_PRODUCT", 190, 194], ["endothelial nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 196, 229], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 231, 237], ["extracellular signalregulated kinase", "GENE_OR_GENE_PRODUCT", 239, 275], ["GRP78", "GENE_OR_GENE_PRODUCT", 277, 282], ["glucose-regulated protein 78", "GENE_OR_GENE_PRODUCT", 284, 312], ["HDAC-1", "GENE_OR_GENE_PRODUCT", 314, 320], ["histone deacetylase-1", "GENE_OR_GENE_PRODUCT", 322, 343], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 345, 349], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 351, 367], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 369, 374], ["interleukin-1 beta", "GENE_OR_GENE_PRODUCT", 376, 394], ["IL-6", "GENE_OR_GENE_PRODUCT", 396, 400], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 402, 415], ["JAK-STAT3", "GENE_OR_GENE_PRODUCT", 457, 466], ["Janus kinase-signal transducer and activator of transcription", "GENE_OR_GENE_PRODUCT", 468, 529], ["JNK", "GENE_OR_GENE_PRODUCT", 538, 541], ["C-jun-Nterminal kinase", "GENE_OR_GENE_PRODUCT", 543, 565], ["MAPK", "GENE_OR_GENE_PRODUCT", 567, 571], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 573, 605], ["MasR", "GENE_OR_GENE_PRODUCT", 607, 611], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 613, 625], ["MCP-1", "GENE_OR_GENE_PRODUCT", 627, 632], ["reactive oxygen species", "SIMPLE_CHEMICAL", 634, 657], ["matrix metalloproteinase", "GENE_OR_GENE_PRODUCT", 664, 688], ["NADPH", "SIMPLE_CHEMICAL", 690, 695], ["nicotinamide adenine dinucleotide phosphate", "SIMPLE_CHEMICAL", 697, 740], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 742, 746], ["B cells", "CELL", 803, 810], ["NO", "SIMPLE_CHEMICAL", 812, 814], ["nitric oxide", "SIMPLE_CHEMICAL", 816, 828], ["PAH", "SIMPLE_CHEMICAL", 830, 833], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 835, 851], ["PAI-1", "GENE_OR_GENE_PRODUCT", 866, 871], ["plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 873, 906], ["PI3K", "GENE_OR_GENE_PRODUCT", 908, 912], ["Akt", "GENE_OR_GENE_PRODUCT", 913, 916], ["phosphoinositide 3-kinase", "GENE_OR_GENE_PRODUCT", 918, 943], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 944, 960], ["PKC", "GENE_OR_GENE_PRODUCT", 962, 965], ["protein kinase C", "GENE_OR_GENE_PRODUCT", 967, 983], ["ROS", "SIMPLE_CHEMICAL", 985, 988], ["reactive oxygen species", "SIMPLE_CHEMICAL", 990, 1013], ["SOD", "SIMPLE_CHEMICAL", 1015, 1018], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 1020, 1040], ["TGF\u03b2", "SIMPLE_CHEMICAL", 1042, 1046], ["transforming growth factor-beta", "GENE_OR_GENE_PRODUCT", 1048, 1079], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 1081, 1085], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 1087, 1114], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 1116, 1122], ["vascular cell adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 1124, 1157], ["VEGF", "GENE_OR_GENE_PRODUCT", 1159, 1163], ["vascular endothelial cell growth factor", "GENE_OR_GENE_PRODUCT", 1165, 1204], ["ACE", "PROTEIN", 0, 3], ["angiotensin-converting enzyme", "PROTEIN", 5, 34], ["Ang1", "PROTEIN", 36, 40], ["angiotensin 1", "PROTEIN", 42, 55], ["Ang2", "PROTEIN", 57, 61], ["AT1R", "PROTEIN", 78, 82], ["angiotensin 1 receptor", "PROTEIN", 84, 106], ["CHOP", "PROTEIN", 108, 112], ["CCAAT/enhancer-binding protein homologous protein", "PROTEIN", 114, 163], ["Cox-2", "PROTEIN", 165, 170], ["cyclooxygenase-2", "PROTEIN", 172, 188], ["NOS", "PROTEIN", 191, 194], ["endothelial nitric oxide synthase", "PROTEIN", 196, 229], ["ERK1/2", "PROTEIN", 231, 237], ["extracellular signalregulated kinase", "PROTEIN", 239, 275], ["GRP78", "PROTEIN", 277, 282], ["glucose-regulated protein 78", "PROTEIN", 284, 312], ["HDAC-1", "PROTEIN", 314, 320], ["histone deacetylase-1", "PROTEIN", 322, 343], ["IFN\u03b3", "PROTEIN", 345, 349], ["interferon gamma", "PROTEIN", 351, 367], ["interleukin-6", "PROTEIN", 402, 415], ["JAK", "PROTEIN", 457, 460], ["STAT3", "PROTEIN", 461, 466], ["Janus kinase", "PROTEIN", 468, 480], ["JNK", "PROTEIN", 538, 541], ["C-jun-Nterminal kinase", "PROTEIN", 543, 565], ["MAPK", "PROTEIN", 567, 571], ["mitogen-activated protein kinase", "PROTEIN", 573, 605], ["MasR", "PROTEIN", 607, 611], ["Mas receptor", "PROTEIN", 613, 625], ["MCP-1", "PROTEIN", 627, 632], ["reactive oxygen species", "PROTEIN", 634, 657], ["MMP", "PROTEIN", 659, 662], ["matrix metalloproteinase", "PROTEIN", 664, 688], ["NADPH", "PROTEIN", 690, 695], ["NF\u03baB", "PROTEIN", 742, 746], ["nuclear factor kappa-light-chain-enhancer of activated B cells", "PROTEIN", 748, 810], ["PAI-1", "PROTEIN", 866, 871], ["plasminogen activator inhibitor-1", "PROTEIN", 873, 906], ["PI3K", "PROTEIN", 908, 912], ["Akt", "PROTEIN", 913, 916], ["phosphoinositide 3-kinase", "PROTEIN", 918, 943], ["protein kinase B", "PROTEIN", 944, 960], ["PKC", "PROTEIN", 962, 965], ["protein kinase C", "PROTEIN", 967, 983], ["reactive oxygen species", "PROTEIN", 990, 1013], ["SOD", "PROTEIN", 1015, 1018], ["superoxide dismutase", "PROTEIN", 1020, 1040], ["TGF\u03b2", "PROTEIN", 1042, 1046], ["transforming growth factor-beta", "PROTEIN", 1048, 1079], ["TNF\u03b1", "PROTEIN", 1081, 1085], ["tumor necrosis factor alpha", "PROTEIN", 1087, 1114], ["VCAM-1", "PROTEIN", 1116, 1122], ["vascular cell adhesion molecule-1", "PROTEIN", 1124, 1157], ["VEGF", "PROTEIN", 1159, 1163], ["vascular endothelial cell growth factor", "PROTEIN", 1165, 1204], ["ACE", "TEST", 0, 3], ["angiotensin", "TEST", 5, 16], ["enzyme", "TEST", 28, 34], ["Ang1", "TEST", 36, 40], ["angiotensin", "TEST", 42, 53], ["Ang2", "TEST", 57, 61], ["angiotensin", "TEST", 63, 74], ["AT1R", "TEST", 78, 82], ["angiotensin 1 receptor", "TREATMENT", 84, 106], ["CHOP", "TEST", 108, 112], ["CCAAT/enhancer-binding protein homologous protein", "TEST", 114, 163], ["Cox", "TEST", 165, 168], ["cyclooxygenase", "TEST", 172, 186], ["endothelial nitric oxide synthase", "TREATMENT", 196, 229], ["ERK1", "TEST", 231, 235], ["extracellular signalregulated kinase", "TEST", 239, 275], ["GRP78", "TEST", 277, 282], ["glucose", "TEST", 284, 291], ["protein", "TEST", 302, 309], ["HDAC", "TEST", 314, 318], ["histone deacetylase", "TEST", 322, 341], ["IFN\u03b3", "TEST", 345, 349], ["interferon gamma", "TEST", 351, 367], ["IL", "TEST", 369, 371], ["interleukin", "TEST", 376, 387], ["IL", "TEST", 396, 398], ["interleukin", "TEST", 402, 413], ["injury", "PROBLEM", 420, 426], ["ischemia reperfusion injury", "PROBLEM", 428, 455], ["JAK", "TEST", 457, 460], ["Janus kinase", "TEST", 468, 480], ["signal transducer", "TEST", 481, 498], ["activator of transcription system", "TEST", 503, 536], ["JNK", "TEST", 538, 541], ["C", "TEST", 543, 544], ["jun", "TEST", 545, 548], ["Nterminal kinase", "TEST", 549, 565], ["MAPK", "TEST", 567, 571], ["mitogen", "TEST", 573, 580], ["activated protein kinase", "TEST", 581, 605], ["MasR", "TEST", 607, 611], ["MCP", "TEST", 627, 630], ["reactive oxygen species", "TREATMENT", 634, 657], ["MMP, matrix metalloproteinase", "TREATMENT", 659, 688], ["NADPH", "TREATMENT", 690, 695], ["nicotinamide adenine dinucleotide phosphate", "TREATMENT", 697, 740], ["nuclear factor kappa-light", "TEST", 748, 774], ["activated B cells", "PROBLEM", 793, 810], ["nitric oxide", "TREATMENT", 816, 828], ["PAH", "PROBLEM", 830, 833], ["pulmonary artery hypertension", "PROBLEM", 835, 864], ["PAI", "TEST", 866, 869], ["plasminogen activator inhibitor", "TEST", 873, 904], ["PI3K", "TEST", 908, 912], ["Akt", "TEST", 913, 916], ["phosphoinositide", "TEST", 918, 934], ["kinase", "TEST", 937, 943], ["protein kinase B", "TEST", 944, 960], ["PKC", "TEST", 962, 965], ["protein kinase C", "TEST", 967, 983], ["ROS", "TEST", 985, 988], ["reactive oxygen species", "TREATMENT", 990, 1013], ["SOD", "TEST", 1015, 1018], ["superoxide dismutase", "TEST", 1020, 1040], ["TGF\u03b2", "TEST", 1042, 1046], ["transforming growth factor", "TEST", 1048, 1074], ["beta", "TEST", 1075, 1079], ["TNF", "TEST", 1081, 1084], ["tumor necrosis", "PROBLEM", 1087, 1101], ["alpha", "TEST", 1109, 1114], ["VCAM", "TEST", 1116, 1120], ["vascular cell adhesion molecule", "TEST", 1124, 1155], ["VEGF", "PROBLEM", 1159, 1163], ["vascular endothelial cell growth factor", "PROBLEM", 1165, 1204], ["ischemia", "OBSERVATION", 428, 436], ["reactive", "OBSERVATION", 634, 642], ["oxygen species", "OBSERVATION", 643, 657], ["PAH", "OBSERVATION", 830, 833], ["pulmonary artery", "ANATOMY", 835, 851], ["hypertension", "OBSERVATION", 852, 864], ["reactive", "OBSERVATION", 990, 998], ["oxygen species", "OBSERVATION", 999, 1013], ["tumor necrosis", "OBSERVATION", 1087, 1101], ["vascular cell", "ANATOMY", 1124, 1137], ["VEGF", "ANATOMY", 1159, 1163], ["vascular endothelial", "ANATOMY", 1165, 1185], ["cell", "OBSERVATION", 1186, 1190]]], ["Ang2 and converts Ang (1) (2) (3) (4) (5) (6) (7) (8) (9) to Ang-(1-7) [162] .", [["Ang", "CHEMICAL", 18, 21], ["Ang-(1-7)", "CHEMICAL", 61, 70], ["Ang2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang (1) (2) (3) (4) (5) (6) (7) (8)", "SIMPLE_CHEMICAL", 18, 53], ["Ang2", "PROTEIN", 0, 4], ["Ang2 and converts Ang (1) (2) (3) (4) (5", "TREATMENT", 0, 40], ["Ang", "TEST", 61, 64]]], ["Thus, the ACE2/Ang-(1-7)/MasR axis is the negative regulatory axis against the ACE/Ang2/AT1R axis in the RAS.THE PHYSIOLOGY OF THE RENIN-ANGIOTENSIN SYSTEM AND ACE2Ang-(1-7) exerts anti-inflammatory effects via MasR and G proteins.", [["Ang", "CHEMICAL", 15, 18], ["ACE2Ang-(1-7)", "CHEMICAL", 160, 173], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 15, 23], ["MasR", "GENE_OR_GENE_PRODUCT", 25, 29], ["ACE", "GENE_OR_GENE_PRODUCT", 79, 82], ["Ang2", "GENE_OR_GENE_PRODUCT", 83, 87], ["AT1R", "GENE_OR_GENE_PRODUCT", 88, 92], ["RAS", "GENE_OR_GENE_PRODUCT", 105, 108], ["ACE2Ang-(1-7)", "SIMPLE_CHEMICAL", 160, 173], ["MasR", "GENE_OR_GENE_PRODUCT", 211, 215], ["G proteins", "GENE_OR_GENE_PRODUCT", 220, 230], ["ACE2", "PROTEIN", 10, 14], ["MasR", "PROTEIN", 25, 29], ["ACE", "PROTEIN", 79, 82], ["Ang2", "PROTEIN", 83, 87], ["AT1R", "PROTEIN", 88, 92], ["RAS", "PROTEIN", 105, 108], ["MasR", "PROTEIN", 211, 215], ["G proteins", "PROTEIN", 220, 230], ["the ACE2", "TEST", 6, 14], ["Ang", "TEST", 15, 18], ["the ACE", "TEST", 75, 82], ["THE RENIN-ANGIOTENSIN SYSTEM", "TREATMENT", 127, 155], ["ACE2Ang", "TEST", 160, 167], ["anti-inflammatory effects", "TREATMENT", 181, 206], ["MasR and G proteins", "TREATMENT", 211, 230]]], ["ACE2/Ang-(1-7)/MasR attenuated the local and systemic inflammation reported in various experimental models including sepsis [158] , acute lung injury [71] , atherosclerosis [189] , and chronic kidney disease in mice [31] .", [["lung", "ANATOMY", 138, 142], ["kidney", "ANATOMY", 193, 199], ["Ang-(1-7)", "CHEMICAL", 5, 14], ["inflammation", "DISEASE", 54, 66], ["sepsis", "DISEASE", 117, 123], ["acute lung injury", "DISEASE", 132, 149], ["atherosclerosis", "DISEASE", 157, 172], ["chronic kidney disease", "DISEASE", 185, 207], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 5, 13], ["MasR", "GENE_OR_GENE_PRODUCT", 15, 19], ["lung", "ORGAN", 138, 142], ["kidney", "ORGAN", 193, 199], ["mice", "ORGANISM", 211, 215], ["ACE2", "PROTEIN", 0, 4], ["MasR", "PROTEIN", 15, 19], ["mice", "SPECIES", 211, 215], ["mice", "SPECIES", 211, 215], ["ACE2", "TEST", 0, 4], ["Ang", "TEST", 5, 8], ["MasR", "TREATMENT", 15, 19], ["systemic inflammation", "PROBLEM", 45, 66], ["sepsis", "PROBLEM", 117, 123], ["acute lung injury", "PROBLEM", 132, 149], ["atherosclerosis", "PROBLEM", 157, 172], ["chronic kidney disease", "PROBLEM", 185, 207], ["Ang", "ANATOMY", 5, 8], ["systemic", "ANATOMY", 45, 53], ["inflammation", "OBSERVATION", 54, 66], ["sepsis", "OBSERVATION", 117, 123], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["lung", "ANATOMY", 138, 142], ["injury", "OBSERVATION", 143, 149], ["atherosclerosis", "OBSERVATION", 157, 172], ["chronic", "OBSERVATION_MODIFIER", 185, 192], ["kidney", "ANATOMY", 193, 199], ["disease", "OBSERVATION", 200, 207]]], ["Ang-(1-7) also inhibited the release of inflammatory cytokines (IL-6 and tumor necrosis factor alpha [TNF\u03b1]) from macrophages that was induced by lipopolysaccharide (LPS) in endotoxemic mice [142, 143] .", [["macrophages", "ANATOMY", 114, 125], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["necrosis", "DISEASE", 79, 87], ["lipopolysaccharide", "CHEMICAL", 146, 164], ["LPS", "CHEMICAL", 166, 169], ["Ang-(1-7", "SIMPLE_CHEMICAL", 0, 8], ["IL-6", "GENE_OR_GENE_PRODUCT", 64, 68], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 73, 100], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 102, 106], ["macrophages", "CELL", 114, 125], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 146, 164], ["LPS", "SIMPLE_CHEMICAL", 166, 169], ["mice", "ORGANISM", 186, 190], ["inflammatory cytokines", "PROTEIN", 40, 62], ["IL-6", "PROTEIN", 64, 68], ["tumor necrosis factor alpha", "PROTEIN", 73, 100], ["TNF\u03b1", "PROTEIN", 102, 106], ["macrophages", "CELL_TYPE", 114, 125], ["mice", "SPECIES", 186, 190], ["mice", "SPECIES", 186, 190], ["Ang", "TEST", 0, 3], ["inflammatory cytokines", "PROBLEM", 40, 62], ["IL", "TEST", 64, 66], ["tumor necrosis factor alpha [TNF\u03b1", "PROBLEM", 73, 106], ["macrophages", "PROBLEM", 114, 125], ["inflammatory", "OBSERVATION_MODIFIER", 40, 52], ["cytokines", "OBSERVATION", 53, 62], ["tumor", "OBSERVATION_MODIFIER", 73, 78], ["necrosis", "OBSERVATION", 79, 87], ["macrophages", "ANATOMY", 114, 125]]], ["Ang-(1-7) also bind to both AT1R and AT2R at high concentrations [163] .", [["Ang-(1-7)", "CHEMICAL", 0, 9], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["AT1R", "GENE_OR_GENE_PRODUCT", 28, 32], ["AT2R", "GENE_OR_GENE_PRODUCT", 37, 41], ["AT1R", "PROTEIN", 28, 32], ["AT2R", "PROTEIN", 37, 41], ["Ang", "TEST", 0, 3]]], ["In a rheumatoid arthritis model, the ACE2/Ang-(1-7)/AT2R axis also provided an antiinflammatory response by reducing the gene expressions of IL-1\u03b2 and IL-6 and activating NF\u03baB [157] .", [["rheumatoid arthritis", "DISEASE", 5, 25], ["Ang", "CHEMICAL", 42, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 42, 50], ["AT2R", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 141, 146], ["IL-6", "GENE_OR_GENE_PRODUCT", 151, 155], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 171, 175], ["ACE2", "PROTEIN", 37, 41], ["AT2R", "PROTEIN", 52, 56], ["IL-1\u03b2", "PROTEIN", 141, 146], ["IL-6", "PROTEIN", 151, 155], ["NF\u03baB", "PROTEIN", 171, 175], ["a rheumatoid arthritis model", "PROBLEM", 3, 31], ["the ACE2", "TEST", 33, 41], ["Ang", "TEST", 42, 45], ["an antiinflammatory response", "TREATMENT", 76, 104], ["IL", "TEST", 141, 143], ["rheumatoid arthritis", "OBSERVATION", 5, 25]]], ["Ang-(1-7) inhibited AT1R in a non-competitive manner [120] .THE PHYSIOLOGY OF THE RENIN-ANGIOTENSIN SYSTEM AND ACE2In general, the ACE2/Ang-(1-7)/A2R/MasR axis is considered to be a multi-organ protector opposing the ACE/Ang2/AT1R axis.", [["multi-organ", "ANATOMY", 182, 193], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["Ang", "CHEMICAL", 136, 139], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["AT1R", "GENE_OR_GENE_PRODUCT", 20, 24], ["ACE2", "GENE_OR_GENE_PRODUCT", 131, 135], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 136, 144], ["A2R", "GENE_OR_GENE_PRODUCT", 146, 149], ["MasR", "GENE_OR_GENE_PRODUCT", 150, 154], ["ACE", "GENE_OR_GENE_PRODUCT", 217, 220], ["Ang2", "GENE_OR_GENE_PRODUCT", 221, 225], ["AT1R", "GENE_OR_GENE_PRODUCT", 226, 230], ["AT1R", "PROTEIN", 20, 24], ["ACE2", "PROTEIN", 131, 135], ["A2R", "PROTEIN", 146, 149], ["MasR", "PROTEIN", 150, 154], ["ACE", "PROTEIN", 217, 220], ["Ang2", "PROTEIN", 221, 225], ["AT1R", "PROTEIN", 226, 230], ["Ang", "TEST", 0, 3], ["ACE2In general", "TREATMENT", 111, 125], ["the ACE2/Ang", "TREATMENT", 127, 139], ["A2R/MasR axis", "TREATMENT", 146, 159], ["a multi-organ protector", "TREATMENT", 180, 203], ["the ACE/Ang2/AT1R axis", "TREATMENT", 213, 235]]], ["The function of sACE2 remains unclear, but high levels of sACE2 were found in patients with SARS [65] , type 1 or type 2 diabetes [44] , hypertension [167] , heart failure [1] , and chronic kidney diseases [1] , suggesting that increased sACE2 may act in a protective manner to counteract the adverse effects of Ang2.", [["heart", "ANATOMY", 158, 163], ["kidney", "ANATOMY", 190, 196], ["SARS", "DISEASE", 92, 96], ["type 2 diabetes", "DISEASE", 114, 129], ["hypertension", "DISEASE", 137, 149], ["heart failure", "DISEASE", 158, 171], ["chronic kidney diseases", "DISEASE", 182, 205], ["sACE2", "GENE_OR_GENE_PRODUCT", 16, 21], ["sACE2", "GENE_OR_GENE_PRODUCT", 58, 63], ["patients", "ORGANISM", 78, 86], ["heart", "ORGAN", 158, 163], ["kidney", "ORGAN", 190, 196], ["sACE2", "GENE_OR_GENE_PRODUCT", 238, 243], ["Ang2", "GENE_OR_GENE_PRODUCT", 312, 316], ["sACE2", "PROTEIN", 16, 21], ["sACE2", "PROTEIN", 58, 63], ["sACE2", "PROTEIN", 238, 243], ["Ang2", "PROTEIN", 312, 316], ["patients", "SPECIES", 78, 86], ["high levels of sACE2", "PROBLEM", 43, 63], ["SARS", "PROBLEM", 92, 96], ["type 1", "PROBLEM", 104, 110], ["type 2 diabetes", "PROBLEM", 114, 129], ["hypertension", "PROBLEM", 137, 149], ["heart failure", "PROBLEM", 158, 171], ["chronic kidney diseases", "PROBLEM", 182, 205], ["increased sACE2", "PROBLEM", 228, 243], ["the adverse effects of Ang2", "PROBLEM", 289, 316], ["hypertension", "OBSERVATION", 137, 149], ["heart", "ANATOMY", 158, 163], ["failure", "OBSERVATION", 164, 171], ["chronic", "OBSERVATION_MODIFIER", 182, 189], ["kidney", "ANATOMY", 190, 196], ["diseases", "OBSERVATION", 197, 205], ["increased", "OBSERVATION_MODIFIER", 228, 237], ["sACE2", "OBSERVATION", 238, 243]]], ["SARS-CoV-infected wild-type mice had significantly reduced ACE2 expressions in the lung [74] and heart [110] .THE PHYSIOLOGY OF THE RENIN-ANGIOTENSIN SYSTEM AND ACE2Pulmonary infectious mice showed an ACE2dependent myocardial injury with a remarkable decrease of ACE2 expression, indicating a key role of ACE2 in mediating SARS-CoV infection in the heart [110] .", [["lung", "ANATOMY", 83, 87], ["heart", "ANATOMY", 97, 102], ["myocardial", "ANATOMY", 215, 225], ["heart", "ANATOMY", 349, 354], ["myocardial injury", "DISEASE", 215, 232], ["SARS-CoV infection", "DISEASE", 323, 341], ["SARS-CoV", "ORGANISM", 0, 8], ["mice", "ORGANISM", 28, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["lung", "ORGAN", 83, 87], ["heart", "ORGAN", 97, 102], ["ACE2Pulmonary infectious mice", "ORGANISM", 161, 190], ["myocardial", "MULTI-TISSUE_STRUCTURE", 215, 225], ["ACE2", "GENE_OR_GENE_PRODUCT", 263, 267], ["ACE2", "GENE_OR_GENE_PRODUCT", 305, 309], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 323, 331], ["heart", "ORGAN", 349, 354], ["ACE2", "PROTEIN", 59, 63], ["ACE2", "PROTEIN", 263, 267], ["ACE2", "PROTEIN", 305, 309], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 186, 190], ["SARS-CoV", "SPECIES", 0, 8], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 186, 190], ["SARS-CoV", "SPECIES", 323, 331], ["SARS", "TEST", 0, 4], ["significantly reduced ACE2 expressions in the lung", "PROBLEM", 37, 87], ["heart", "TEST", 97, 102], ["ACE2Pulmonary infectious mice", "TEST", 161, 190], ["an ACE2dependent myocardial injury", "PROBLEM", 198, 232], ["ACE2 expression", "PROBLEM", 263, 278], ["ACE2 in mediating SARS", "PROBLEM", 305, 327], ["CoV infection in the heart", "PROBLEM", 328, 354], ["lung", "ANATOMY", 83, 87], ["heart", "ANATOMY", 97, 102], ["ACE2dependent myocardial injury", "OBSERVATION", 201, 232], ["remarkable", "OBSERVATION_MODIFIER", 240, 250], ["decrease", "OBSERVATION_MODIFIER", 251, 259], ["ACE2 expression", "OBSERVATION", 263, 278], ["CoV", "OBSERVATION_MODIFIER", 328, 331], ["infection", "OBSERVATION", 332, 341], ["heart", "ANATOMY", 349, 354]]], ["Further, ace2 knockout mice exhibited enhanced vascular permeability, increased lung edema, induced neutrophil accumulation in the lung, and worsened lung function [62] .", [["vascular", "ANATOMY", 47, 55], ["lung", "ANATOMY", 80, 84], ["neutrophil", "ANATOMY", 100, 110], ["lung", "ANATOMY", 131, 135], ["lung", "ANATOMY", 150, 154], ["lung edema", "DISEASE", 80, 90], ["ace2", "GENE_OR_GENE_PRODUCT", 9, 13], ["mice", "ORGANISM", 23, 27], ["vascular", "MULTI-TISSUE_STRUCTURE", 47, 55], ["lung", "ORGAN", 80, 84], ["neutrophil", "CELL", 100, 110], ["lung", "ORGAN", 131, 135], ["lung", "ORGAN", 150, 154], ["ace2", "PROTEIN", 9, 13], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["enhanced vascular permeability", "PROBLEM", 38, 68], ["increased lung edema", "PROBLEM", 70, 90], ["neutrophil accumulation in the lung", "PROBLEM", 100, 135], ["worsened lung function", "PROBLEM", 141, 163], ["vascular", "ANATOMY", 47, 55], ["permeability", "OBSERVATION_MODIFIER", 56, 68], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["lung", "ANATOMY", 80, 84], ["edema", "OBSERVATION", 85, 90], ["neutrophil accumulation", "OBSERVATION", 100, 123], ["lung", "ANATOMY", 131, 135], ["worsened", "OBSERVATION_MODIFIER", 141, 149], ["lung", "ANATOMY", 150, 154]]], ["Notably, treatment with recombinant human ACE2 protein (rhACE2) improved the symptoms of acid aspiration-or LPS-induced acute lung injury in mice [62] .Interaction with ACE2 and the Apelin/APJ Axis: Organ ProtectionApelin is another substrate of ACE2 and an endogenous peptide ligand to the G protein-coupled receptor, the APJ [75] .", [["lung", "ANATOMY", 126, 130], ["LPS", "CHEMICAL", 108, 111], ["acute lung injury", "DISEASE", 120, 137], ["human", "ORGANISM", 36, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 42, 46], ["rhACE2", "GENE_OR_GENE_PRODUCT", 56, 62], ["LPS", "SIMPLE_CHEMICAL", 108, 111], ["lung", "ORGAN", 126, 130], ["mice", "ORGANISM", 141, 145], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["Apelin", "GENE_OR_GENE_PRODUCT", 182, 188], ["APJ", "GENE_OR_GENE_PRODUCT", 189, 192], ["ACE2", "GENE_OR_GENE_PRODUCT", 246, 250], ["G protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 291, 317], ["APJ", "GENE_OR_GENE_PRODUCT", 323, 326], ["recombinant human ACE2 protein", "PROTEIN", 24, 54], ["rhACE2", "PROTEIN", 56, 62], ["ACE2", "PROTEIN", 169, 173], ["Apelin", "PROTEIN", 182, 188], ["APJ Axis", "PROTEIN", 189, 197], ["Organ ProtectionApelin", "PROTEIN", 199, 221], ["ACE2", "PROTEIN", 246, 250], ["G protein-coupled receptor", "PROTEIN", 291, 317], ["APJ", "PROTEIN", 323, 326], ["human", "SPECIES", 36, 41], ["mice", "SPECIES", 141, 145], ["human", "SPECIES", 36, 41], ["mice", "SPECIES", 141, 145], ["treatment", "TREATMENT", 9, 18], ["recombinant human ACE2 protein (rhACE2", "TREATMENT", 24, 62], ["the symptoms", "PROBLEM", 73, 85], ["acid aspiration", "PROBLEM", 89, 104], ["LPS", "PROBLEM", 108, 111], ["acute lung injury", "PROBLEM", 120, 137], ["ACE2", "TEST", 169, 173], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["lung", "ANATOMY", 126, 130], ["injury", "OBSERVATION", 131, 137], ["APJ Axis", "ANATOMY", 189, 197], ["Organ", "ANATOMY", 199, 204], ["APJ", "ANATOMY", 323, 326]]], ["Apelin is expressed predominantly in the endothelium and acts locally via endocrine signaling to activate the APJ, which is expressed on the surface of myocardial cells and endothelial cells [18, 72] .", [["endothelium", "ANATOMY", 41, 52], ["endocrine", "ANATOMY", 74, 83], ["surface", "ANATOMY", 141, 148], ["myocardial cells", "ANATOMY", 152, 168], ["endothelial cells", "ANATOMY", 173, 190], ["Apelin", "CHEMICAL", 0, 6], ["Apelin", "GENE_OR_GENE_PRODUCT", 0, 6], ["endothelium", "TISSUE", 41, 52], ["APJ", "GENE_OR_GENE_PRODUCT", 110, 113], ["surface", "CELLULAR_COMPONENT", 141, 148], ["myocardial cells", "CELL", 152, 168], ["endothelial cells", "CELL", 173, 190], ["Apelin", "PROTEIN", 0, 6], ["APJ", "PROTEIN", 110, 113], ["myocardial cells", "CELL_TYPE", 152, 168], ["endothelial cells", "CELL_TYPE", 173, 190], ["endothelial cells", "TEST", 173, 190], ["predominantly", "OBSERVATION_MODIFIER", 20, 33], ["endothelium", "ANATOMY", 41, 52], ["APJ", "ANATOMY", 110, 113], ["myocardial cells", "ANATOMY", 152, 168], ["endothelial cells", "OBSERVATION", 173, 190]]], ["The structure of apelin is similar to that of Ang2 but without binding affinity to AT1R [153] .", [["apelin", "GENE_OR_GENE_PRODUCT", 17, 23], ["Ang2", "GENE_OR_GENE_PRODUCT", 46, 50], ["AT1R", "GENE_OR_GENE_PRODUCT", 83, 87], ["apelin", "PROTEIN", 17, 23], ["Ang2", "PROTEIN", 46, 50], ["AT1R", "PROTEIN", 83, 87], ["AT1R", "TEST", 83, 87], ["apelin", "OBSERVATION", 17, 23]]], ["Apelin-13, a predominant isoform of apelin, antagonizes the ACE/Ang2/AT1R axis through negative feedback by ACE2 upregulation [134] .", [["Apelin-13", "CHEMICAL", 0, 9], ["Apelin-13", "CHEMICAL", 0, 9], ["Apelin-13", "GENE_OR_GENE_PRODUCT", 0, 9], ["apelin", "GENE_OR_GENE_PRODUCT", 36, 42], ["ACE", "GENE_OR_GENE_PRODUCT", 60, 63], ["Ang2", "GENE_OR_GENE_PRODUCT", 64, 68], ["AT1R", "GENE_OR_GENE_PRODUCT", 69, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 108, 112], ["Apelin-13", "PROTEIN", 0, 9], ["apelin", "PROTEIN", 36, 42], ["ACE", "PROTEIN", 60, 63], ["Ang2", "PROTEIN", 64, 68], ["AT1R", "PROTEIN", 69, 73], ["ACE2", "PROTEIN", 108, 112], ["Apelin", "TEST", 0, 6], ["apelin", "TEST", 36, 42], ["the ACE", "TEST", 56, 63], ["Ang2/AT1R axis", "TEST", 64, 78], ["apelin", "OBSERVATION", 36, 42]]], ["In addition, the molecular interaction between AT1R and APJ suppresses the activity of AT1R [24] .", [["AT1R", "GENE_OR_GENE_PRODUCT", 47, 51], ["APJ", "GENE_OR_GENE_PRODUCT", 56, 59], ["AT1R", "GENE_OR_GENE_PRODUCT", 87, 91], ["AT1R", "PROTEIN", 47, 51], ["APJ", "PROTEIN", 56, 59], ["AT1R", "PROTEIN", 87, 91]]], ["The apelin/APJ axis reduces vascular tone, decreases blood pressure, regulates fluid homeostasis, improves cardiac contractility [75] , and protects against heart [124] and lung injury [35] .", [["vascular", "ANATOMY", 28, 36], ["blood", "ANATOMY", 53, 58], ["fluid", "ANATOMY", 79, 84], ["cardiac", "ANATOMY", 107, 114], ["heart", "ANATOMY", 157, 162], ["lung", "ANATOMY", 173, 177], ["lung injury", "DISEASE", 173, 184], ["apelin", "GENE_OR_GENE_PRODUCT", 4, 10], ["APJ", "GENE_OR_GENE_PRODUCT", 11, 14], ["vascular", "MULTI-TISSUE_STRUCTURE", 28, 36], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["fluid", "ORGANISM_SUBSTANCE", 79, 84], ["cardiac", "ORGAN", 107, 114], ["heart", "ORGAN", 157, 162], ["lung", "ORGAN", 173, 177], ["apelin", "PROTEIN", 4, 10], ["APJ", "PROTEIN", 11, 14], ["The apelin/APJ axis", "PROBLEM", 0, 19], ["blood pressure", "TEST", 53, 67], ["fluid homeostasis", "PROBLEM", 79, 96], ["lung injury", "PROBLEM", 173, 184], ["APJ axis", "ANATOMY", 11, 19], ["vascular tone", "OBSERVATION", 28, 41], ["pressure", "OBSERVATION_MODIFIER", 59, 67], ["fluid homeostasis", "OBSERVATION", 79, 96], ["heart", "ANATOMY", 157, 162], ["lung", "ANATOMY", 173, 177], ["injury", "OBSERVATION", 178, 184]]], ["In both oleic acid-and LPS-induced ARDS models, treatment with apelin-13 after injury attenuated the lung injury and improved oxygenation [35] .ACE, Ang2, and the AT1R Axis: Proinflammatory PropertyIn contrast to the ACE2/Ang-(1-7)/MasR axis, the ACE/Ang2/AT1R axis accelerates the inflammatory response.", [["lung", "ANATOMY", 101, 105], ["oleic acid", "CHEMICAL", 8, 18], ["LPS", "CHEMICAL", 23, 26], ["ARDS", "DISEASE", 35, 39], ["apelin-13", "CHEMICAL", 63, 72], ["lung injury", "DISEASE", 101, 112], ["oleic acid", "CHEMICAL", 8, 18], ["oleic acid", "SIMPLE_CHEMICAL", 8, 18], ["LPS", "SIMPLE_CHEMICAL", 23, 26], ["apelin-13", "GENE_OR_GENE_PRODUCT", 63, 72], ["lung", "ORGAN", 101, 105], ["ACE", "GENE_OR_GENE_PRODUCT", 144, 147], ["Ang2", "GENE_OR_GENE_PRODUCT", 149, 153], ["AT1R", "GENE_OR_GENE_PRODUCT", 163, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 217, 221], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 222, 230], ["MasR", "GENE_OR_GENE_PRODUCT", 232, 236], ["ACE", "GENE_OR_GENE_PRODUCT", 247, 250], ["Ang2", "GENE_OR_GENE_PRODUCT", 251, 255], ["AT1R", "GENE_OR_GENE_PRODUCT", 256, 260], ["ACE", "PROTEIN", 144, 147], ["Ang2", "PROTEIN", 149, 153], ["AT1R Axis", "PROTEIN", 163, 172], ["Proinflammatory PropertyIn", "PROTEIN", 174, 200], ["ACE2", "PROTEIN", 217, 221], ["MasR", "PROTEIN", 232, 236], ["ACE", "PROTEIN", 247, 250], ["Ang2", "PROTEIN", 251, 255], ["AT1R", "PROTEIN", 256, 260], ["both oleic acid", "TEST", 3, 18], ["LPS", "TREATMENT", 23, 26], ["ARDS models", "PROBLEM", 35, 46], ["apelin", "TEST", 63, 69], ["injury", "PROBLEM", 79, 85], ["the lung injury", "PROBLEM", 97, 112], ["ACE", "TEST", 144, 147], ["Ang2", "TEST", 149, 153], ["the AT1R Axis", "TEST", 159, 172], ["Proinflammatory PropertyIn contrast", "TEST", 174, 209], ["the ACE2", "TEST", 213, 221], ["Ang", "TEST", 222, 225], ["MasR axis", "TEST", 232, 241], ["the ACE/Ang2/AT1R axis", "TEST", 243, 265], ["the inflammatory response", "PROBLEM", 278, 303], ["oleic", "OBSERVATION_MODIFIER", 8, 13], ["acid", "OBSERVATION_MODIFIER", 14, 18], ["ARDS", "OBSERVATION", 35, 39], ["lung", "ANATOMY", 101, 105], ["injury", "OBSERVATION", 106, 112], ["improved", "OBSERVATION_MODIFIER", 117, 125], ["oxygenation", "OBSERVATION_MODIFIER", 126, 137], ["inflammatory response", "OBSERVATION", 282, 303]]], ["In this axis, Ang2 is a central regulator of the inflammatory response through specific cell surface receptors (mainly AT1R).", [["cell surface", "ANATOMY", 88, 100], ["Ang2", "GENE_OR_GENE_PRODUCT", 14, 18], ["cell", "CELL", 88, 92], ["AT1R", "GENE_OR_GENE_PRODUCT", 119, 123], ["Ang2", "PROTEIN", 14, 18], ["cell surface receptors", "PROTEIN", 88, 110], ["AT1R", "PROTEIN", 119, 123], ["the inflammatory response", "PROBLEM", 45, 70], ["specific cell surface receptors", "TREATMENT", 79, 110], ["inflammatory", "OBSERVATION_MODIFIER", 49, 61]]], ["As a proinflammatory modulator, Ang2 interacts with both immune cells (neutrophils, mononuclear cells, T cells, and B cells) and tissue-resident cells.", [["immune cells", "ANATOMY", 57, 69], ["neutrophils", "ANATOMY", 71, 82], ["mononuclear cells", "ANATOMY", 84, 101], ["T cells", "ANATOMY", 103, 110], ["B cells", "ANATOMY", 116, 123], ["tissue-resident cells", "ANATOMY", 129, 150], ["Ang2", "GENE_OR_GENE_PRODUCT", 32, 36], ["immune cells", "CELL", 57, 69], ["neutrophils", "CELL", 71, 82], ["mononuclear cells", "CELL", 84, 101], ["T cells", "CELL", 103, 110], ["B cells", "CELL", 116, 123], ["tissue-resident cells", "CELL", 129, 150], ["proinflammatory modulator", "PROTEIN", 5, 30], ["Ang2", "PROTEIN", 32, 36], ["immune cells", "CELL_TYPE", 57, 69], ["neutrophils", "CELL_TYPE", 71, 82], ["mononuclear cells", "CELL_TYPE", 84, 101], ["T cells", "CELL_TYPE", 103, 110], ["B cells", "CELL_TYPE", 116, 123], ["tissue-resident cells", "CELL_TYPE", 129, 150], ["a proinflammatory modulator", "TEST", 3, 30], ["neutrophils", "TEST", 71, 82], ["mononuclear cells", "TEST", 84, 101], ["T cells", "TEST", 103, 110], ["mononuclear cells", "OBSERVATION", 84, 101]]], ["The activated Ang2 synthesis from tissue-resident cells enhances vascular permeability by promoting the productions of proinflammatory factors including prostaglandins, vascular endothelial cell growth factor (VEGF) [173] , NF\u03baB, TNF\u03b1, IL-1\u03b2, IL-6, and interferon gamma (IFN\u03b3) [38] .ACE, Ang2, and the AT1R Axis: Proinflammatory PropertyAng2 also recruits immune cell infiltration into the injury site(s) and enhances the inflammatory response by stimulating the production of cytokines/chemokines.", [["tissue-resident cells", "ANATOMY", 34, 55], ["vascular", "ANATOMY", 65, 73], ["immune cell", "ANATOMY", 356, 367], ["injury site", "ANATOMY", 390, 401], ["prostaglandins", "CHEMICAL", 153, 167], ["prostaglandins", "CHEMICAL", 153, 167], ["Ang2", "GENE_OR_GENE_PRODUCT", 14, 18], ["tissue-resident cells", "CELL", 34, 55], ["vascular", "MULTI-TISSUE_STRUCTURE", 65, 73], ["prostaglandins", "SIMPLE_CHEMICAL", 153, 167], ["vascular endothelial cell growth factor (VEGF) [173]", "GENE_OR_GENE_PRODUCT", 169, 221], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 224, 228], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 230, 234], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 236, 241], ["IL-6", "GENE_OR_GENE_PRODUCT", 243, 247], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 253, 269], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 271, 275], ["ACE", "GENE_OR_GENE_PRODUCT", 283, 286], ["Ang2", "GENE_OR_GENE_PRODUCT", 288, 292], ["AT1R", "GENE_OR_GENE_PRODUCT", 302, 306], ["PropertyAng2", "GENE_OR_GENE_PRODUCT", 329, 341], ["immune cell", "CELL", 356, 367], ["Ang2", "PROTEIN", 14, 18], ["tissue-resident cells", "CELL_TYPE", 34, 55], ["proinflammatory factors", "PROTEIN", 119, 142], ["prostaglandins", "PROTEIN", 153, 167], ["vascular endothelial cell growth factor", "PROTEIN", 169, 208], ["VEGF", "PROTEIN", 210, 214], ["NF\u03baB", "PROTEIN", 224, 228], ["TNF\u03b1", "PROTEIN", 230, 234], ["IL-6", "PROTEIN", 243, 247], ["interferon gamma", "PROTEIN", 253, 269], ["IFN\u03b3", "PROTEIN", 271, 275], ["ACE", "PROTEIN", 283, 286], ["Ang2", "PROTEIN", 288, 292], ["AT1R Axis", "PROTEIN", 302, 311], ["Proinflammatory PropertyAng2", "PROTEIN", 313, 341], ["cytokines", "PROTEIN", 477, 486], ["chemokines", "PROTEIN", 487, 497], ["The activated Ang2 synthesis", "TREATMENT", 0, 28], ["proinflammatory factors", "PROBLEM", 119, 142], ["prostaglandins", "TREATMENT", 153, 167], ["vascular endothelial cell growth factor", "TEST", 169, 208], ["VEGF", "TEST", 210, 214], ["NF", "TEST", 224, 226], ["TNF\u03b1", "TEST", 230, 234], ["IL", "TEST", 236, 238], ["IL", "TEST", 243, 245], ["interferon gamma (IFN\u03b3", "TEST", 253, 275], ["ACE", "TEST", 283, 286], ["Ang2", "TEST", 288, 292], ["Proinflammatory PropertyAng2", "TREATMENT", 313, 341], ["immune cell infiltration", "PROBLEM", 356, 380], ["the injury site", "PROBLEM", 386, 401], ["the inflammatory response", "PROBLEM", 418, 443], ["cytokines/chemokines", "TREATMENT", 477, 497], ["vascular", "ANATOMY", 65, 73], ["vascular endothelial", "ANATOMY", 169, 189], ["cell", "OBSERVATION", 190, 194], ["interferon gamma", "ANATOMY", 253, 269], ["AT1R Axis", "ANATOMY", 302, 311], ["immune cell infiltration", "OBSERVATION", 356, 380], ["injury", "OBSERVATION", 390, 396], ["inflammatory", "OBSERVATION_MODIFIER", 422, 434]]], ["For example, Ang2 induced the proliferation of splenic lymphocytes via the activation of AT1R on immune cells [106] .", [["splenic lymphocytes", "ANATOMY", 47, 66], ["immune cells", "ANATOMY", 97, 109], ["Ang2", "GENE_OR_GENE_PRODUCT", 13, 17], ["splenic lymphocytes", "CELL", 47, 66], ["AT1R", "GENE_OR_GENE_PRODUCT", 89, 93], ["immune cells", "CELL", 97, 109], ["Ang2", "PROTEIN", 13, 17], ["splenic lymphocytes", "CELL_TYPE", 47, 66], ["AT1R", "PROTEIN", 89, 93], ["immune cells", "CELL_TYPE", 97, 109], ["Ang2", "PROBLEM", 13, 17], ["splenic lymphocytes", "PROBLEM", 47, 66], ["immune cells", "PROBLEM", 97, 109], ["proliferation", "OBSERVATION_MODIFIER", 30, 43], ["splenic", "ANATOMY", 47, 54], ["lymphocytes", "OBSERVATION", 55, 66]]], ["In addition, Ang2 upregulates the expression of Toll-like receptor 4 (TLR4), stimulates NF\u03baB signaling, and induces the expressions of CD40, TNF\u03b1, IL-6, and MMP9 (matrix metallopeptidases) [64, 178] .ACE, Ang2, and the AT1R Axis: Proinflammatory PropertyTNF\u03b1 is a key proinflammatory cytokine that acts to cross-link inflammation and the RAS, and its extracellular domain shedding and activation are driven by the AD-AM17 on the cell surface [13] .", [["extracellular", "ANATOMY", 351, 364], ["cell surface", "ANATOMY", 429, 441], ["inflammation", "DISEASE", 317, 329], ["Ang2", "GENE_OR_GENE_PRODUCT", 13, 17], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 48, 68], ["TLR4", "GENE_OR_GENE_PRODUCT", 70, 74], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 88, 92], ["CD40", "GENE_OR_GENE_PRODUCT", 135, 139], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 141, 145], ["IL-6", "GENE_OR_GENE_PRODUCT", 147, 151], ["MMP9", "GENE_OR_GENE_PRODUCT", 157, 161], ["matrix metallopeptidases", "GENE_OR_GENE_PRODUCT", 163, 187], ["ACE", "GENE_OR_GENE_PRODUCT", 200, 203], ["Ang2", "GENE_OR_GENE_PRODUCT", 205, 209], ["AT1R", "GENE_OR_GENE_PRODUCT", 219, 223], ["PropertyTNF\u03b1", "GENE_OR_GENE_PRODUCT", 246, 258], ["RAS", "GENE_OR_GENE_PRODUCT", 338, 341], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 351, 364], ["AD-AM17", "GENE_OR_GENE_PRODUCT", 414, 421], ["cell surface", "CELLULAR_COMPONENT", 429, 441], ["Ang2", "PROTEIN", 13, 17], ["Toll-like receptor 4", "PROTEIN", 48, 68], ["TLR4", "PROTEIN", 70, 74], ["NF\u03baB", "PROTEIN", 88, 92], ["CD40", "PROTEIN", 135, 139], ["TNF\u03b1", "PROTEIN", 141, 145], ["IL-6", "PROTEIN", 147, 151], ["MMP9", "PROTEIN", 157, 161], ["matrix metallopeptidases", "PROTEIN", 163, 187], ["ACE", "PROTEIN", 200, 203], ["Ang2", "PROTEIN", 205, 209], ["AT1R Axis", "PROTEIN", 219, 228], ["Proinflammatory PropertyTNF\u03b1", "PROTEIN", 230, 258], ["proinflammatory cytokine", "PROTEIN", 268, 292], ["RAS", "PROTEIN", 338, 341], ["AD", "PROTEIN", 414, 416], ["AM17", "PROTEIN", 417, 421], ["Toll-like receptor", "TREATMENT", 48, 66], ["CD40", "TEST", 135, 139], ["TNF", "TEST", 141, 144], ["IL", "TEST", 147, 149], ["ACE", "TEST", 200, 203], ["Ang2", "TEST", 205, 209], ["cross-link inflammation", "PROBLEM", 306, 329], ["the RAS", "PROBLEM", 334, 341], ["its extracellular domain shedding", "PROBLEM", 347, 380], ["inflammation", "OBSERVATION", 317, 329]]], ["AT1R activation by Ang2 binding phosphonates ADAM17 via the intracellular mitogen-activated protein kinase (p38/MAPK) cellular signaling pathway facilitates the cleavage of ACE2 and tends to the ACE/Ang2/AT1R axis, leading to a positive feedback mechanism in the proinflammatory response [116] .ACE, Ang2, and the AT1R Axis: Proinflammatory PropertyEpithelial and Endothelial Cells: Receptors of SARS-CoV-2 ACE2 was identified as the binding \"receptor\" of SARS-CoV and SARS-CoV-2.", [["intracellular", "ANATOMY", 60, 73], ["cellular", "ANATOMY", 118, 126], ["Endothelial Cells", "ANATOMY", 364, 381], ["phosphonates", "CHEMICAL", 32, 44], ["phosphonates", "CHEMICAL", 32, 44], ["AT1R", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang2 binding phosphonates ADAM17", "GENE_OR_GENE_PRODUCT", 19, 51], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 73], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 74, 106], ["p38", "GENE_OR_GENE_PRODUCT", 108, 111], ["MAPK", "GENE_OR_GENE_PRODUCT", 112, 116], ["cellular", "CELL", 118, 126], ["ACE2", "GENE_OR_GENE_PRODUCT", 173, 177], ["ACE", "GENE_OR_GENE_PRODUCT", 195, 198], ["Ang2", "GENE_OR_GENE_PRODUCT", 199, 203], ["AT1R", "GENE_OR_GENE_PRODUCT", 204, 208], ["ACE", "GENE_OR_GENE_PRODUCT", 295, 298], ["Ang2", "GENE_OR_GENE_PRODUCT", 300, 304], ["AT1R", "GENE_OR_GENE_PRODUCT", 314, 318], ["Endothelial Cells", "CELL", 364, 381], ["SARS-CoV-2 ACE2", "GENE_OR_GENE_PRODUCT", 396, 411], ["SARS-CoV", "ORGANISM", 456, 464], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 469, 479], ["AT1R", "PROTEIN", 0, 4], ["Ang2", "PROTEIN", 19, 23], ["ADAM17", "PROTEIN", 45, 51], ["intracellular mitogen-activated protein kinase", "PROTEIN", 60, 106], ["p38", "PROTEIN", 108, 111], ["MAPK", "PROTEIN", 112, 116], ["ACE2", "PROTEIN", 173, 177], ["ACE", "PROTEIN", 195, 198], ["Ang2", "PROTEIN", 199, 203], ["AT1R", "PROTEIN", 204, 208], ["ACE", "PROTEIN", 295, 298], ["Ang2", "PROTEIN", 300, 304], ["AT1R Axis", "PROTEIN", 314, 323], ["Proinflammatory PropertyEpithelial and Endothelial Cells", "CELL_TYPE", 325, 381], ["SARS-CoV-2 ACE2", "PROTEIN", 396, 411], ["binding \"receptor", "PROTEIN", 434, 451], ["SARS-CoV", "SPECIES", 456, 464], ["SARS-CoV", "SPECIES", 469, 477], ["AT1R activation", "TEST", 0, 15], ["Ang2 binding phosphonates", "TEST", 19, 44], ["ADAM17", "TEST", 45, 51], ["the intracellular mitogen", "TEST", 56, 81], ["activated protein kinase", "TEST", 82, 106], ["p38/MAPK", "TEST", 108, 116], ["cellular signaling pathway", "TEST", 118, 144], ["ACE2", "TEST", 173, 177], ["the ACE/Ang2/AT1R axis", "TEST", 191, 213], ["a positive feedback mechanism", "PROBLEM", 226, 255], ["ACE", "TEST", 295, 298], ["Ang2", "TEST", 300, 304], ["the AT1R Axis", "TEST", 310, 323], ["SARS", "TEST", 396, 400], ["CoV", "TEST", 401, 404], ["ACE2", "TEST", 407, 411], ["SARS", "PROBLEM", 456, 460], ["CoV", "TEST", 461, 464], ["SARS", "TEST", 469, 473], ["CoV", "TEST", 474, 477], ["Proinflammatory PropertyEpithelial", "OBSERVATION", 325, 359], ["Endothelial", "ANATOMY", 364, 375]]], ["ACE2 is expressed predominantly in the epithelial cells of the lung and intestine [54] , suggesting that these organs may be the primary infected sites of SARS-CoV-2.", [["epithelial cells", "ANATOMY", 39, 55], ["lung", "ANATOMY", 63, 67], ["intestine", "ANATOMY", 72, 81], ["organs", "ANATOMY", 111, 117], ["sites", "ANATOMY", 146, 151], ["SARS", "DISEASE", 155, 159], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["epithelial cells", "CELL", 39, 55], ["lung", "ORGAN", 63, 67], ["intestine", "ORGAN", 72, 81], ["organs", "ORGAN", 111, 117], ["SARS-CoV-2", "ORGANISM", 155, 165], ["ACE2", "PROTEIN", 0, 4], ["epithelial cells", "CELL_TYPE", 39, 55], ["SARS-CoV", "SPECIES", 155, 163], ["ACE2", "TEST", 0, 4], ["the primary infected sites of SARS", "PROBLEM", 125, 159], ["CoV", "TEST", 160, 163], ["predominantly", "OBSERVATION_MODIFIER", 18, 31], ["epithelial cells", "OBSERVATION", 39, 55], ["lung", "ANATOMY", 63, 67], ["intestine", "ANATOMY", 72, 81], ["organs", "ANATOMY", 111, 117], ["may be", "UNCERTAINTY", 118, 124], ["primary", "OBSERVATION_MODIFIER", 129, 136], ["infected", "OBSERVATION", 137, 145]]], ["ACE2 is also present in arterial and venous endothelial cells [54] .", [["arterial", "ANATOMY", 24, 32], ["venous endothelial cells", "ANATOMY", 37, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["arterial", "CELL", 24, 32], ["venous endothelial cells", "CELL", 37, 61], ["ACE2", "PROTEIN", 0, 4], ["arterial and venous endothelial cells", "CELL_TYPE", 24, 61], ["ACE2", "TEST", 0, 4], ["venous endothelial cells", "TEST", 37, 61], ["arterial", "ANATOMY_MODIFIER", 24, 32], ["venous endothelial", "ANATOMY", 37, 55]]], ["These distributions of ACE2 are very likely associated with the characteristics of COVID-19: respiratory failure, colitis, microvascular injury, and inflammation.ACE, Ang2, and the AT1R Axis: Proinflammatory PropertyIn COVID-19, the airways and lungs are the main injured organs, and respiratory failure is the leading cause of death [132] .", [["respiratory", "ANATOMY", 93, 104], ["microvascular", "ANATOMY", 123, 136], ["airways", "ANATOMY", 233, 240], ["lungs", "ANATOMY", 245, 250], ["organs", "ANATOMY", 272, 278], ["respiratory", "ANATOMY", 284, 295], ["respiratory failure", "DISEASE", 93, 112], ["colitis", "DISEASE", 114, 121], ["microvascular injury", "DISEASE", 123, 143], ["inflammation", "DISEASE", 149, 161], ["respiratory failure", "DISEASE", 284, 303], ["death", "DISEASE", 328, 333], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["colitis", "PATHOLOGICAL_FORMATION", 114, 121], ["microvascular", "MULTI-TISSUE_STRUCTURE", 123, 136], ["ACE", "GENE_OR_GENE_PRODUCT", 162, 165], ["Ang2", "GENE_OR_GENE_PRODUCT", 167, 171], ["AT1R", "GENE_OR_GENE_PRODUCT", 181, 185], ["airways", "MULTI-TISSUE_STRUCTURE", 233, 240], ["lungs", "ORGAN", 245, 250], ["organs", "ORGAN", 272, 278], ["ACE2", "PROTEIN", 23, 27], ["ACE", "PROTEIN", 162, 165], ["Ang2", "PROTEIN", 167, 171], ["AT1R Axis", "PROTEIN", 181, 190], ["COVID", "TEST", 83, 88], ["respiratory failure", "PROBLEM", 93, 112], ["colitis", "PROBLEM", 114, 121], ["microvascular injury", "PROBLEM", 123, 143], ["inflammation", "PROBLEM", 149, 161], ["ACE", "TEST", 162, 165], ["Ang2", "TEST", 167, 171], ["the AT1R Axis", "TEST", 177, 190], ["Proinflammatory PropertyIn COVID", "TEST", 192, 224], ["respiratory failure", "PROBLEM", 284, 303], ["death", "PROBLEM", 328, 333], ["very likely", "UNCERTAINTY", 32, 43], ["respiratory failure", "OBSERVATION", 93, 112], ["colitis", "OBSERVATION", 114, 121], ["microvascular injury", "OBSERVATION", 123, 143], ["inflammation", "OBSERVATION", 149, 161], ["airways", "ANATOMY", 233, 240], ["lungs", "ANATOMY", 245, 250], ["main", "OBSERVATION_MODIFIER", 259, 263], ["injured", "OBSERVATION", 264, 271], ["respiratory failure", "OBSERVATION", 284, 303]]], ["A high expression of ACE2 was identified in alveolar epithelial cells of the lungs of COVID-19 patients [54, 121, 196] .", [["alveolar epithelial cells", "ANATOMY", 44, 69], ["lungs", "ANATOMY", 77, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["alveolar epithelial cells", "CELL", 44, 69], ["lungs", "ORGAN", 77, 82], ["patients", "ORGANISM", 95, 103], ["ACE2", "PROTEIN", 21, 25], ["alveolar epithelial cells", "CELL_TYPE", 44, 69], ["patients", "SPECIES", 95, 103], ["A high expression of ACE2", "PROBLEM", 0, 25], ["COVID", "TEST", 86, 91], ["high", "OBSERVATION_MODIFIER", 2, 6], ["alveolar", "ANATOMY_MODIFIER", 44, 52], ["epithelial cells", "OBSERVATION", 53, 69], ["lungs", "ANATOMY", 77, 82]]], ["The profiling of the expression of ace2 RNA in healthy human lung tissue revealed that 83% of the ACE2expressing cells were alveolar epithelial cells [190] .", [["lung tissue", "ANATOMY", 61, 72], ["ACE2expressing cells", "ANATOMY", 98, 118], ["alveolar epithelial cells", "ANATOMY", 124, 149], ["ace2", "GENE_OR_GENE_PRODUCT", 35, 39], ["human", "ORGANISM", 55, 60], ["lung tissue", "TISSUE", 61, 72], ["cells", "CELL", 113, 118], ["alveolar epithelial cells", "CELL", 124, 149], ["ace2 RNA", "RNA", 35, 43], ["ACE2expressing cells", "CELL_LINE", 98, 118], ["alveolar epithelial cells", "CELL_TYPE", 124, 149], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["ace2 RNA in healthy human lung tissue", "PROBLEM", 35, 72], ["the ACE2expressing cells", "TEST", 94, 118], ["alveolar epithelial cells", "PROBLEM", 124, 149], ["lung", "ANATOMY", 61, 65], ["alveolar epithelial cells", "OBSERVATION", 124, 149]]], ["Multiple ESCRT (endosomal sorting complexes required for transport) machinery genes (including CHMP3, CHMP5, CHMP1A, and VPS37B genes) were shown to be related to virus budding and release [190] .", [["endosomal", "ANATOMY", 16, 25], ["ESCRT", "GENE_OR_GENE_PRODUCT", 9, 14], ["endosomal", "CELLULAR_COMPONENT", 16, 25], ["CHMP3", "GENE_OR_GENE_PRODUCT", 95, 100], ["CHMP5", "GENE_OR_GENE_PRODUCT", 102, 107], ["CHMP1A", "GENE_OR_GENE_PRODUCT", 109, 115], ["VPS37B", "GENE_OR_GENE_PRODUCT", 121, 127], ["ESCRT", "PROTEIN", 9, 14], ["endosomal sorting complexes", "PROTEIN", 16, 43], ["machinery genes", "DNA", 68, 83], ["CHMP3", "DNA", 95, 100], ["CHMP5", "DNA", 102, 107], ["CHMP1A", "DNA", 109, 115], ["VPS37B genes", "DNA", 121, 133], ["Multiple ESCRT", "PROBLEM", 0, 14], ["CHMP3", "TEST", 95, 100], ["CHMP5", "TEST", 102, 107], ["CHMP1A", "TEST", 109, 115], ["virus budding", "PROBLEM", 163, 176], ["ESCRT", "OBSERVATION", 9, 14]]], ["These findings indicate that aside from ACE2, other intracellular mechanisms in alveolar epithelial cells facilitate virus replication in the lungs.ACE, Ang2, and the AT1R Axis: Proinflammatory PropertyACE2 is also highly expressed in intestinal epithelial cells [54, 121, 196] , and the intestine may be another potential viral target organ.", [["intracellular", "ANATOMY", 52, 65], ["alveolar epithelial cells", "ANATOMY", 80, 105], ["lungs", "ANATOMY", 142, 147], ["intestinal epithelial cells", "ANATOMY", 235, 262], ["intestine", "ANATOMY", 288, 297], ["organ", "ANATOMY", 336, 341], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 52, 65], ["alveolar epithelial cells", "CELL", 80, 105], ["lungs", "ORGAN", 142, 147], ["ACE", "GENE_OR_GENE_PRODUCT", 148, 151], ["Ang2", "GENE_OR_GENE_PRODUCT", 153, 157], ["AT1R", "GENE_OR_GENE_PRODUCT", 167, 171], ["PropertyACE2", "GENE_OR_GENE_PRODUCT", 194, 206], ["intestinal epithelial cells", "CELL", 235, 262], ["intestine", "ORGAN", 288, 297], ["organ", "ORGAN", 336, 341], ["ACE2", "PROTEIN", 40, 44], ["alveolar epithelial cells", "CELL_TYPE", 80, 105], ["ACE", "PROTEIN", 148, 151], ["Ang2", "PROTEIN", 153, 157], ["AT1R Axis", "PROTEIN", 167, 176], ["PropertyACE2", "PROTEIN", 194, 206], ["intestinal epithelial cells", "CELL_TYPE", 235, 262], ["ACE2", "TEST", 40, 44], ["other intracellular mechanisms", "PROBLEM", 46, 76], ["alveolar epithelial cells", "PROBLEM", 80, 105], ["virus replication in the lungs", "PROBLEM", 117, 147], ["ACE", "TEST", 148, 151], ["Ang2", "TEST", 153, 157], ["Proinflammatory PropertyACE2", "PROBLEM", 178, 206], ["intestinal epithelial cells", "TEST", 235, 262], ["alveolar epithelial cells", "OBSERVATION", 80, 105], ["virus replication", "OBSERVATION", 117, 134], ["lungs", "ANATOMY", 142, 147], ["Proinflammatory PropertyACE2", "OBSERVATION", 178, 206], ["intestinal", "ANATOMY", 235, 245], ["epithelial cells", "OBSERVATION", 246, 262], ["intestine", "ANATOMY", 288, 297], ["may be another potential", "UNCERTAINTY", 298, 322], ["viral", "OBSERVATION", 323, 328]]], ["In an in vitro study using human small intestinal organoids, enterocytes were infected by SARS-CoV or SARS-CoV-2; these small infection clusters had spread throughout the entire organoids at 60 h post-infection, and the levels of infectious virus particles and viral RNA were significantly increased in both viruses [80] .", [["small intestinal organoids", "ANATOMY", 33, 59], ["enterocytes", "ANATOMY", 61, 72], ["organoids", "ANATOMY", 178, 187], ["infection", "DISEASE", 126, 135], ["infection", "DISEASE", 201, 210], ["human", "ORGANISM", 27, 32], ["intestinal organoids", "CELL", 39, 59], ["enterocytes", "CELL", 61, 72], ["SARS-CoV", "ORGANISM", 90, 98], ["SARS-CoV-2", "ORGANISM", 102, 112], ["organoids", "CELL", 178, 187], ["infectious virus particles", "ORGANISM", 230, 256], ["human small intestinal organoids", "CELL_TYPE", 27, 59], ["enterocytes", "CELL_TYPE", 61, 72], ["infectious virus particles", "RNA", 230, 256], ["viral RNA", "RNA", 261, 270], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["SARS-CoV", "SPECIES", 90, 98], ["SARS-CoV", "SPECIES", 102, 110], ["an in vitro study", "TEST", 3, 20], ["human small intestinal organoids", "PROBLEM", 27, 59], ["SARS", "PROBLEM", 90, 94], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110], ["these small infection clusters", "PROBLEM", 114, 144], ["infection", "PROBLEM", 201, 210], ["the levels", "TEST", 216, 226], ["infectious virus particles", "PROBLEM", 230, 256], ["viral RNA", "PROBLEM", 261, 270], ["intestinal organoids", "ANATOMY", 39, 59], ["enterocytes", "ANATOMY", 61, 72], ["small", "OBSERVATION_MODIFIER", 120, 125], ["infection", "OBSERVATION", 126, 135], ["infection", "OBSERVATION", 201, 210], ["infectious virus", "OBSERVATION", 230, 246], ["viral RNA", "OBSERVATION", 261, 270], ["increased", "OBSERVATION_MODIFIER", 290, 299]]], ["These data suggested that the intestine might also be an entry site for SARS-CoV-2, and the virus' ability to be transmitted via the mouth/food intake is thus worth investigating.ACE, Ang2, and the AT1R Axis: Proinflammatory PropertySevere cases of COVID-19 were frequently characterized by coagulopathy and microvascular injury, leading to organ dysfunction [151, 191] .", [["intestine", "ANATOMY", 30, 39], ["mouth", "ANATOMY", 133, 138], ["microvascular", "ANATOMY", 308, 321], ["organ", "ANATOMY", 341, 346], ["coagulopathy", "DISEASE", 291, 303], ["microvascular injury", "DISEASE", 308, 328], ["organ dysfunction", "DISEASE", 341, 358], ["COVID-19", "CHEMICAL", 249, 257], ["intestine", "ORGAN", 30, 39], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["mouth", "ORGANISM_SUBDIVISION", 133, 138], ["ACE", "GENE_OR_GENE_PRODUCT", 179, 182], ["Ang2", "GENE_OR_GENE_PRODUCT", 184, 188], ["AT1R", "GENE_OR_GENE_PRODUCT", 198, 202], ["COVID-19", "GENE_OR_GENE_PRODUCT", 249, 257], ["microvascular", "TISSUE", 308, 321], ["organ", "ORGAN", 341, 346], ["ACE", "PROTEIN", 179, 182], ["Ang2", "PROTEIN", 184, 188], ["AT1R Axis", "PROTEIN", 198, 207], ["SARS-CoV", "SPECIES", 72, 80], ["SARS", "PROBLEM", 72, 76], ["CoV", "TEST", 77, 80], ["the virus' ability", "PROBLEM", 88, 106], ["ACE", "TEST", 179, 182], ["Ang2", "TEST", 184, 188], ["the AT1R Axis", "TEST", 194, 207], ["COVID", "TEST", 249, 254], ["coagulopathy", "PROBLEM", 291, 303], ["microvascular injury", "PROBLEM", 308, 328], ["organ dysfunction", "PROBLEM", 341, 358], ["intestine", "ANATOMY", 30, 39], ["mouth", "ANATOMY", 133, 138], ["AT1R Axis", "ANATOMY", 198, 207], ["coagulopathy", "OBSERVATION", 291, 303], ["microvascular", "ANATOMY", 308, 321], ["injury", "OBSERVATION", 322, 328]]], ["The expression of ACE2 in vascular endothelial cells probably contributes to the pathophysiology of microcirculatory pathological changes.", [["vascular endothelial cells", "ANATOMY", 26, 52], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["vascular endothelial cells", "CELL", 26, 52], ["ACE2", "PROTEIN", 18, 22], ["vascular endothelial cells", "CELL_TYPE", 26, 52], ["ACE2 in vascular endothelial cells", "PROBLEM", 18, 52], ["microcirculatory pathological changes", "PROBLEM", 100, 137], ["vascular endothelial", "ANATOMY", 26, 46], ["microcirculatory pathological", "OBSERVATION", 100, 129]]], ["The histopathology from three cases of COVID-19 revealed a direct SARS-CoV-2 infection to the endothelial cells leading to diffuse endothelial inflammation [160] , which was similar to an earlier report in SARS-CoVinfected patients [184] .", [["endothelial cells", "ANATOMY", 94, 111], ["diffuse endothelial", "ANATOMY", 123, 142], ["infection", "DISEASE", 77, 86], ["inflammation", "DISEASE", 143, 155], ["SARS-CoVinfected", "DISEASE", 206, 222], ["CoV-2", "GENE_OR_GENE_PRODUCT", 71, 76], ["endothelial cells", "CELL", 94, 111], ["endothelial", "CELL", 131, 142], ["patients", "ORGANISM", 223, 231], ["endothelial cells", "CELL_TYPE", 94, 111], ["patients", "SPECIES", 223, 231], ["The histopathology", "TEST", 0, 18], ["COVID", "TEST", 39, 44], ["a direct SARS", "PROBLEM", 57, 70], ["CoV-2 infection", "PROBLEM", 71, 86], ["the endothelial cells", "PROBLEM", 90, 111], ["diffuse endothelial inflammation", "PROBLEM", 123, 155], ["infection", "OBSERVATION", 77, 86], ["endothelial", "ANATOMY", 94, 105], ["diffuse", "OBSERVATION_MODIFIER", 123, 130], ["endothelial", "ANATOMY", 131, 142], ["inflammation", "OBSERVATION", 143, 155]]], ["The recruitment of immune cells resulted in widespread endothelial dysfunction due to apoptosis [160] .", [["immune cells", "ANATOMY", 19, 31], ["endothelial", "ANATOMY", 55, 66], ["endothelial dysfunction", "DISEASE", 55, 78], ["immune cells", "CELL", 19, 31], ["endothelial", "TISSUE", 55, 66], ["immune cells", "CELL_TYPE", 19, 31], ["immune cells", "PROBLEM", 19, 31], ["widespread endothelial dysfunction", "PROBLEM", 44, 78], ["apoptosis", "PROBLEM", 86, 95], ["immune cells", "OBSERVATION", 19, 31], ["widespread", "OBSERVATION_MODIFIER", 44, 54], ["endothelial dysfunction", "OBSERVATION", 55, 78]]], ["It is thus very likely that microvascular inflammation and dysfunction contribute to the clinical sequelae of multiple organ failure in COVID-19 patients.THE PATHOLOGY OF THE CYTOKINE STORMThe Macro-mechanism of the Cytokine Storm in General InflammationTHE PATHOLOGY OF THE CYTOKINE STORMThe cytokine storm begins from a local site of inflammation and then spreads throughout the entire body via an overproduction of inflammatory cytokines and chemokines released by both immune and non-immune cells.", [["microvascular", "ANATOMY", 28, 41], ["organ", "ANATOMY", 119, 124], ["body", "ANATOMY", 388, 392], ["cells", "ANATOMY", 495, 500], ["microvascular inflammation", "DISEASE", 28, 54], ["multiple organ failure", "DISEASE", 110, 132], ["inflammation", "DISEASE", 336, 348], ["microvascular", "TISSUE", 28, 41], ["organ", "ORGAN", 119, 124], ["patients", "ORGANISM", 145, 153], ["body", "ORGANISM_SUBDIVISION", 388, 392], ["immune", "CELL", 473, 479], ["non-immune cells", "CELL", 484, 500], ["Cytokine", "PROTEIN", 216, 224], ["cytokine", "PROTEIN", 293, 301], ["inflammatory cytokines", "PROTEIN", 418, 440], ["chemokines", "PROTEIN", 445, 455], ["immune and non-immune cells", "CELL_TYPE", 473, 500], ["patients", "SPECIES", 145, 153], ["microvascular inflammation", "PROBLEM", 28, 54], ["dysfunction", "PROBLEM", 59, 70], ["multiple organ failure", "PROBLEM", 110, 132], ["The cytokine storm", "PROBLEM", 289, 307], ["inflammation", "PROBLEM", 336, 348], ["inflammatory cytokines", "PROBLEM", 418, 440], ["chemokines", "TREATMENT", 445, 455], ["thus very likely", "UNCERTAINTY", 6, 22], ["microvascular", "ANATOMY", 28, 41], ["inflammation", "OBSERVATION", 42, 54], ["multiple", "OBSERVATION_MODIFIER", 110, 118], ["organ", "ANATOMY", 119, 124], ["failure", "OBSERVATION", 125, 132], ["Cytokine Storm", "OBSERVATION", 216, 230], ["CYTOKINE STORM", "OBSERVATION", 275, 289], ["cytokine storm", "OBSERVATION", 293, 307], ["inflammation", "OBSERVATION", 336, 348], ["overproduction", "OBSERVATION_MODIFIER", 400, 414], ["inflammatory cytokines", "OBSERVATION", 418, 440], ["non-immune cells", "OBSERVATION", 484, 500]]], ["These events were directly correlated with organ injury and poor prognosis [101] .THE PATHOLOGY OF THE CYTOKINE STORMInnate immunity was suggested to play a central role in the pathology of this cytokine storm through pattern recognition receptors (PRRs) [23] such as the TLRs, the Nod-like receptors, the RIG-like receptors, and the C-type lectin receptors [68] .", [["organ", "ANATOMY", 43, 48], ["organ injury", "DISEASE", 43, 55], ["organ", "ORGAN", 43, 48], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 218, 247], ["TLRs", "GENE_OR_GENE_PRODUCT", 272, 276], ["RIG-like receptors", "GENE_OR_GENE_PRODUCT", 306, 324], ["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 334, 357], ["cytokine", "PROTEIN", 195, 203], ["pattern recognition receptors", "PROTEIN", 218, 247], ["PRRs", "PROTEIN", 249, 253], ["TLRs", "PROTEIN", 272, 276], ["Nod-like receptors", "PROTEIN", 282, 300], ["RIG-like receptors", "PROTEIN", 306, 324], ["C-type lectin receptors", "PROTEIN", 334, 357], ["organ injury", "PROBLEM", 43, 55], ["the RIG", "TEST", 302, 309]]], ["Leukocyte activation is mediated by the PRRs, which bind to a wide variety of molecules including pathogen-associated molecular patterns (PAMPs) and the damage-associated molecular patterns (DAMPs) released from infected cells [23, 146, 149] .THE PATHOLOGY OF THE CYTOKINE STORMIn the early stage of infectious inflammation, IL-6 is rapidly produced by monocytes/macrophages stimulated by TLRs [136] .", [["Leukocyte", "ANATOMY", 0, 9], ["cells", "ANATOMY", 221, 226], ["monocytes", "ANATOMY", 353, 362], ["macrophages", "ANATOMY", 363, 374], ["inflammation", "DISEASE", 311, 323], ["Leukocyte", "CELL", 0, 9], ["PRRs", "GENE_OR_GENE_PRODUCT", 40, 44], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 98, 136], ["damage-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 153, 189], ["DAMPs", "GENE_OR_GENE_PRODUCT", 191, 196], ["cells", "CELL", 221, 226], ["IL-6", "GENE_OR_GENE_PRODUCT", 325, 329], ["monocytes", "CELL", 353, 362], ["macrophages", "CELL", 363, 374], ["TLRs", "GENE_OR_GENE_PRODUCT", 389, 393], ["PRRs", "PROTEIN", 40, 44], ["pathogen-associated molecular patterns", "PROTEIN", 98, 136], ["PAMPs", "PROTEIN", 138, 143], ["damage-associated molecular patterns", "PROTEIN", 153, 189], ["DAMPs", "PROTEIN", 191, 196], ["infected cells", "CELL_TYPE", 212, 226], ["IL-6", "PROTEIN", 325, 329], ["monocytes", "CELL_TYPE", 353, 362], ["macrophages", "CELL_TYPE", 363, 374], ["TLRs", "PROTEIN", 389, 393], ["Leukocyte activation", "TEST", 0, 20], ["pathogen", "PROBLEM", 98, 106], ["the damage", "PROBLEM", 149, 159], ["infected cells", "PROBLEM", 212, 226], ["infectious inflammation", "PROBLEM", 300, 323], ["early stage", "OBSERVATION_MODIFIER", 285, 296], ["infectious", "OBSERVATION_MODIFIER", 300, 310], ["inflammation", "OBSERVATION", 311, 323]]], ["The membrane IL-6 receptor (mIL-6R) is expressed only in some immune cells, but the soluble IL-6 receptor (sIL-6R) is widely present in both immune and non-immune cells [131] .", [["membrane", "ANATOMY", 4, 12], ["immune cells", "ANATOMY", 62, 74], ["immune", "ANATOMY", 141, 147], ["cells", "ANATOMY", 163, 168], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 13, 26], ["mIL-6R", "GENE_OR_GENE_PRODUCT", 28, 34], ["immune cells", "CELL", 62, 74], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 92, 105], ["sIL-6R", "GENE_OR_GENE_PRODUCT", 107, 113], ["immune", "CELL", 141, 147], ["non-immune cells", "CELL", 152, 168], ["membrane IL-6 receptor", "PROTEIN", 4, 26], ["mIL", "PROTEIN", 28, 31], ["6R", "PROTEIN", 32, 34], ["immune cells", "CELL_TYPE", 62, 74], ["soluble IL-6 receptor", "PROTEIN", 84, 105], ["sIL", "PROTEIN", 107, 110], ["6R", "PROTEIN", 111, 113], ["immune and non-immune cells", "CELL_TYPE", 141, 168], ["The membrane IL", "TEST", 0, 15], ["some immune cells", "PROBLEM", 57, 74], ["the soluble IL", "TEST", 80, 94], ["immune cells", "OBSERVATION", 62, 74]]], ["IL-6 induces various actions to activate glycoprotein 130 (gp130, which is expressed in most cells) by the IL-6 receptor complex (the details of the mechanism of action are described below) [98] .", [["cells", "ANATOMY", 93, 98], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["glycoprotein 130", "GENE_OR_GENE_PRODUCT", 41, 57], ["gp130", "GENE_OR_GENE_PRODUCT", 59, 64], ["cells", "CELL", 93, 98], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 107, 120], ["IL-6", "PROTEIN", 0, 4], ["glycoprotein 130", "PROTEIN", 41, 57], ["gp130", "PROTEIN", 59, 64], ["IL-6 receptor complex", "PROTEIN", 107, 128], ["glycoprotein", "TEST", 41, 53]]], ["IL-6 is an essential cytokine for maintaining homeostasis in the body, and when stress is removed, the synthesis of IL-6 ceases but excess IL-6 production causes chronic inflammatory diseases and a severe systemic inflammatory response, i.e., the cytokine storm [101] .THE PATHOLOGY OF THE CYTOKINE STORMThe Micro-mechanism of the Cytokine Storm in COVID-19 SARS-CoV-2 binds directly to the host cells' surface ACE2.", [["body", "ANATOMY", 65, 69], ["cells", "ANATOMY", 396, 401], ["surface", "ANATOMY", 403, 410], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["IL-6", "GENE_OR_GENE_PRODUCT", 139, 143], ["Cytokine", "GENE_OR_GENE_PRODUCT", 331, 339], ["COVID-19 SARS-CoV-2", "ORGANISM", 349, 368], ["cells", "CELL", 396, 401], ["ACE2", "GENE_OR_GENE_PRODUCT", 411, 415], ["IL-6", "PROTEIN", 0, 4], ["IL-6", "PROTEIN", 116, 120], ["IL-6", "PROTEIN", 139, 143], ["cytokine", "PROTEIN", 247, 255], ["Cytokine", "PROTEIN", 331, 339], ["ACE2", "PROTEIN", 411, 415], ["the synthesis of IL", "TREATMENT", 99, 118], ["excess IL", "TREATMENT", 132, 141], ["chronic inflammatory diseases", "PROBLEM", 162, 191], ["a severe systemic inflammatory response", "PROBLEM", 196, 235], ["the cytokine storm", "TEST", 243, 261], ["the Cytokine Storm", "TEST", 327, 345], ["COVID", "TEST", 349, 354], ["CoV", "TEST", 363, 366], ["homeostasis", "OBSERVATION", 46, 57], ["body", "ANATOMY", 65, 69], ["chronic", "OBSERVATION_MODIFIER", 162, 169], ["inflammatory diseases", "OBSERVATION", 170, 191], ["severe", "OBSERVATION_MODIFIER", 198, 204], ["systemic", "OBSERVATION_MODIFIER", 205, 213], ["inflammatory response", "OBSERVATION", 214, 235], ["Cytokine Storm", "OBSERVATION", 331, 345], ["host cells", "OBSERVATION", 391, 401]]], ["The virus cleavage in the host endosome activates NF\u03baB via TLRs and the MyD88 (myeloid differentiation primary response 88) pathway [168] , which stimulates IL-6 protein transcription in the host immune cells.", [["endosome", "ANATOMY", 31, 39], ["immune cells", "ANATOMY", 196, 208], ["endosome", "CELLULAR_COMPONENT", 31, 39], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 50, 54], ["TLRs", "GENE_OR_GENE_PRODUCT", 59, 63], ["MyD88", "GENE_OR_GENE_PRODUCT", 72, 77], ["myeloid differentiation primary response 88", "GENE_OR_GENE_PRODUCT", 79, 122], ["IL-6", "GENE_OR_GENE_PRODUCT", 157, 161], ["host immune cells", "CELL", 191, 208], ["NF\u03baB", "PROTEIN", 50, 54], ["TLRs", "PROTEIN", 59, 63], ["MyD88", "PROTEIN", 72, 77], ["IL-6 protein", "PROTEIN", 157, 169], ["host immune cells", "CELL_TYPE", 191, 208], ["The virus cleavage", "PROBLEM", 0, 18], ["IL", "TEST", 157, 159], ["virus cleavage", "OBSERVATION", 4, 18], ["host immune cells", "OBSERVATION", 191, 208]]], ["Once ACE2 is occupied by the virus, free Ang2 accumulates in the plasma due to a lack of degradation by ACE2.", [["plasma", "ANATOMY", 65, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["Ang2", "GENE_OR_GENE_PRODUCT", 41, 45], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["ACE2", "PROTEIN", 5, 9], ["Ang2", "PROTEIN", 41, 45], ["ACE2", "PROTEIN", 104, 108], ["the virus", "PROBLEM", 25, 34]]], ["The mIL-6R exists only on immune cells such as T cells, monocytes, macrophages, activated B cells, neutrophils, and osteoclasts [131] , where the classic IL-6 signaling occurs following the anti-inflammatory bioreaction.", [["immune cells", "ANATOMY", 26, 38], ["T cells", "ANATOMY", 47, 54], ["monocytes", "ANATOMY", 56, 65], ["macrophages", "ANATOMY", 67, 78], ["B cells", "ANATOMY", 90, 97], ["neutrophils", "ANATOMY", 99, 110], ["osteoclasts", "ANATOMY", 116, 127], ["mIL-6R", "GENE_OR_GENE_PRODUCT", 4, 10], ["immune cells", "CELL", 26, 38], ["T cells", "CELL", 47, 54], ["monocytes", "CELL", 56, 65], ["macrophages", "CELL", 67, 78], ["B cells", "CELL", 90, 97], ["neutrophils", "CELL", 99, 110], ["osteoclasts", "CELL", 116, 127], ["IL-6", "GENE_OR_GENE_PRODUCT", 154, 158], ["mIL-6R", "PROTEIN", 4, 10], ["immune cells", "CELL_TYPE", 26, 38], ["T cells", "CELL_TYPE", 47, 54], ["monocytes", "CELL_TYPE", 56, 65], ["macrophages", "CELL_TYPE", 67, 78], ["activated B cells", "CELL_TYPE", 80, 97], ["neutrophils", "CELL_TYPE", 99, 110], ["osteoclasts", "CELL_TYPE", 116, 127], ["IL-6", "PROTEIN", 154, 158], ["The mIL", "TEST", 0, 7], ["immune cells", "PROBLEM", 26, 38], ["T cells", "TEST", 47, 54], ["monocytes", "TEST", 56, 65], ["macrophages", "TEST", 67, 78], ["activated B cells", "TEST", 80, 97], ["neutrophils", "TEST", 99, 110], ["osteoclasts", "TEST", 116, 127], ["the classic IL", "TEST", 142, 156], ["the anti-inflammatory bioreaction", "TREATMENT", 186, 219], ["immune cells", "OBSERVATION", 26, 38], ["macrophages", "ANATOMY", 67, 78], ["anti-inflammatory bioreaction", "OBSERVATION", 190, 219]]], ["After the A2R activation by excess Ang2 binding, sIL-6R is derived from the shedding of mIL-6R by ADAM10 and ADAM17 [40] .", [["A2R", "GENE_OR_GENE_PRODUCT", 10, 13], ["Ang2", "GENE_OR_GENE_PRODUCT", 35, 39], ["sIL-6R", "GENE_OR_GENE_PRODUCT", 49, 55], ["mIL-6R", "GENE_OR_GENE_PRODUCT", 88, 94], ["ADAM10", "GENE_OR_GENE_PRODUCT", 98, 104], ["ADAM17", "GENE_OR_GENE_PRODUCT", 109, 115], ["A2R", "PROTEIN", 10, 13], ["Ang2", "PROTEIN", 35, 39], ["sIL-6R", "PROTEIN", 49, 55], ["mIL", "PROTEIN", 88, 91], ["6R", "PROTEIN", 92, 94], ["ADAM10", "PROTEIN", 98, 104], ["ADAM17", "PROTEIN", 109, 115]]], ["In contrast, gp130 is expressed widely as another type of IL-6R on the surface of non-immune cells, and it can be activated by a trans-signaling of IL-6 and sIL-6R [130] or the trans-presentation of IL-6/mIL-6R complex on another immune cell [56] (Fig. 2) .THE PATHOLOGY OF THE CYTOKINE STORMThe IL-6 trans-signaling leads to an immense effect due to the widespread presence of gp130 on both immune and non-immune cells and also due to the suppression of intracellular negative feedback by SOCS (suppressor of cytokine signaling) 3 via the Janus kinase-signal transducers and activators of transcription (JAK-STAT3) pathway in the immune cells [105] .", [["surface", "ANATOMY", 71, 78], ["non-immune cells", "ANATOMY", 82, 98], ["immune cell", "ANATOMY", 230, 241], ["cells", "ANATOMY", 414, 419], ["intracellular", "ANATOMY", 455, 468], ["immune cells", "ANATOMY", 631, 643], ["gp130", "GENE_OR_GENE_PRODUCT", 13, 18], ["IL-6R", "GENE_OR_GENE_PRODUCT", 58, 63], ["surface", "CELLULAR_COMPONENT", 71, 78], ["non-immune cells", "CELL", 82, 98], ["IL-6", "GENE_OR_GENE_PRODUCT", 148, 152], ["sIL-6R", "GENE_OR_GENE_PRODUCT", 157, 163], ["IL-6", "GENE_OR_GENE_PRODUCT", 199, 203], ["mIL-6R", "GENE_OR_GENE_PRODUCT", 204, 210], ["immune cell", "CELL", 230, 241], ["IL-6", "GENE_OR_GENE_PRODUCT", 296, 300], ["gp130", "GENE_OR_GENE_PRODUCT", 378, 383], ["immune", "CELL", 392, 398], ["non-immune cells", "CELL", 403, 419], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 455, 468], ["SOCS", "GENE_OR_GENE_PRODUCT", 490, 494], ["suppressor of cytokine signaling) 3", "GENE_OR_GENE_PRODUCT", 496, 531], ["Janus kinase-signal transducers and activators of transcription", "GENE_OR_GENE_PRODUCT", 540, 603], ["JAK", "GENE_OR_GENE_PRODUCT", 605, 608], ["STAT3", "GENE_OR_GENE_PRODUCT", 609, 614], ["immune cells", "CELL", 631, 643], ["gp130", "PROTEIN", 13, 18], ["IL-6R", "PROTEIN", 58, 63], ["non-immune cells", "CELL_TYPE", 82, 98], ["IL-6", "PROTEIN", 148, 152], ["IL-6/mIL-6R complex", "PROTEIN", 199, 218], ["gp130", "PROTEIN", 378, 383], ["immune and non-immune cells", "CELL_TYPE", 392, 419], ["SOCS", "PROTEIN", 490, 494], ["suppressor of cytokine signaling) 3", "PROTEIN", 496, 531], ["Janus kinase", "PROTEIN", 540, 552], ["signal transducers and activators of transcription", "PROTEIN", 553, 603], ["JAK", "PROTEIN", 605, 608], ["STAT3", "PROTEIN", 609, 614], ["immune cells", "CELL_TYPE", 631, 643], ["non-immune cells", "PROBLEM", 82, 98], ["IL", "TEST", 148, 150], ["IL", "TEST", 199, 201], ["gp130", "PROBLEM", 378, 383], ["non-immune cells", "PROBLEM", 403, 419], ["cytokine signaling)", "TREATMENT", 510, 529], ["the Janus kinase", "TEST", 536, 552], ["activators of transcription", "TREATMENT", 576, 603], ["non-immune cells", "OBSERVATION", 82, 98]]], ["When the IL-6/IL-6R/ gp130 complex is formed, the IL-6 signal is transmitted via three intracellular signaling pathways (i.e., the JAK-STAT [especially STAT3], RAS/MAPK, and PI3K/Akt pathways), producing proinflammatory cytokines such as NF\u03baB, VEGF, MMP9, and IL-6.", [["intracellular", "ANATOMY", 87, 100], ["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["IL-6R", "GENE_OR_GENE_PRODUCT", 14, 19], ["gp130", "GENE_OR_GENE_PRODUCT", 21, 26], ["IL-6", "GENE_OR_GENE_PRODUCT", 50, 54], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 87, 100], ["JAK", "GENE_OR_GENE_PRODUCT", 131, 134], ["STAT", "GENE_OR_GENE_PRODUCT", 135, 139], ["STAT3", "GENE_OR_GENE_PRODUCT", 152, 157], ["RAS", "GENE_OR_GENE_PRODUCT", 160, 163], ["MAPK", "GENE_OR_GENE_PRODUCT", 164, 168], ["PI3K", "GENE_OR_GENE_PRODUCT", 174, 178], ["Akt", "GENE_OR_GENE_PRODUCT", 179, 182], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 238, 242], ["VEGF", "GENE_OR_GENE_PRODUCT", 244, 248], ["MMP9", "GENE_OR_GENE_PRODUCT", 250, 254], ["IL-6", "GENE_OR_GENE_PRODUCT", 260, 264], ["IL-6/IL-6R", "PROTEIN", 9, 19], ["gp130 complex", "PROTEIN", 21, 34], ["IL-6", "PROTEIN", 50, 54], ["JAK", "PROTEIN", 131, 134], ["STAT", "PROTEIN", 135, 139], ["STAT3", "PROTEIN", 152, 157], ["RAS", "PROTEIN", 160, 163], ["MAPK", "PROTEIN", 164, 168], ["PI3K", "PROTEIN", 174, 178], ["Akt", "PROTEIN", 179, 182], ["proinflammatory cytokines", "PROTEIN", 204, 229], ["NF\u03baB", "PROTEIN", 238, 242], ["VEGF", "PROTEIN", 244, 248], ["MMP9", "PROTEIN", 250, 254], ["IL-6", "PROTEIN", 260, 264], ["the IL", "TREATMENT", 5, 11], ["the JAK", "TEST", 127, 134], ["STAT3", "TEST", 152, 157], ["RAS/MAPK", "TEST", 160, 168], ["PI3K/Akt pathways", "TEST", 174, 191], ["proinflammatory cytokines", "TEST", 204, 229], ["NF", "TEST", 238, 240], ["VEGF", "TEST", 244, 248], ["MMP9", "TEST", 250, 254], ["IL", "TEST", 260, 262]]], ["In addition, non-immune cells such as endothelial cells, smooth muscle cells, and fibroblasts are activated by NF\u03baB and STAT3 and then release IL-7, which stimulates CD4-positive cells to release IL-6 and IL-17a, resulting in positive feedback to the nonimmune cells in the IL-6 amplification cycle [103] .", [["non-immune cells", "ANATOMY", 13, 29], ["endothelial cells", "ANATOMY", 38, 55], ["smooth muscle cells", "ANATOMY", 57, 76], ["fibroblasts", "ANATOMY", 82, 93], ["CD4-positive cells", "ANATOMY", 166, 184], ["nonimmune cells", "ANATOMY", 251, 266], ["non-immune cells", "CELL", 13, 29], ["endothelial cells", "CELL", 38, 55], ["smooth muscle cells", "CELL", 57, 76], ["fibroblasts", "CELL", 82, 93], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 111, 115], ["STAT3", "GENE_OR_GENE_PRODUCT", 120, 125], ["IL-7", "GENE_OR_GENE_PRODUCT", 143, 147], ["CD4", "GENE_OR_GENE_PRODUCT", 166, 169], ["IL-6", "GENE_OR_GENE_PRODUCT", 196, 200], ["IL-17a", "GENE_OR_GENE_PRODUCT", 205, 211], ["cells", "CELL", 261, 266], ["IL-6", "GENE_OR_GENE_PRODUCT", 274, 278], ["non-immune cells", "CELL_TYPE", 13, 29], ["endothelial cells", "CELL_TYPE", 38, 55], ["smooth muscle cells", "CELL_TYPE", 57, 76], ["fibroblasts", "CELL_TYPE", 82, 93], ["NF\u03baB", "PROTEIN", 111, 115], ["STAT3", "PROTEIN", 120, 125], ["IL-7", "PROTEIN", 143, 147], ["CD4", "PROTEIN", 166, 169], ["IL-6", "PROTEIN", 196, 200], ["IL-17a", "PROTEIN", 205, 211], ["nonimmune cells", "CELL_TYPE", 251, 266], ["non-immune cells", "PROBLEM", 13, 29], ["endothelial cells", "PROBLEM", 38, 55], ["smooth muscle cells", "PROBLEM", 57, 76], ["fibroblasts", "PROBLEM", 82, 93], ["release IL", "TEST", 135, 145], ["CD4", "TEST", 166, 169], ["IL", "TEST", 196, 198], ["the IL", "TEST", 270, 276], ["non-immune cells", "OBSERVATION", 13, 29], ["endothelial cells", "OBSERVATION", 38, 55], ["smooth muscle cells", "OBSERVATION", 57, 76]]], ["This IL-6 hyperactivation cycle induces the systemic status recognized clinically as the cytokine release syndrome, or cytokine storm.Organ Injury by the Cytokine StormThe lungs are the organ that is most vulnerable to the above-described cytokine storm, and ARDS is a common, fatal condition that follows a cytokine storm in the alveolar environment and systemic circulation, induced by SARS-CoV, MERS-CoV, and severe influenza as well as SARS-CoV-2 [159, 171] .", [["Organ", "ANATOMY", 134, 139], ["lungs", "ANATOMY", 172, 177], ["organ", "ANATOMY", 186, 191], ["alveolar", "ANATOMY", 330, 338], ["Injury", "DISEASE", 140, 146], ["ARDS", "DISEASE", 259, 263], ["influenza", "DISEASE", 419, 428], ["SARS", "DISEASE", 440, 444], ["IL-6", "GENE_OR_GENE_PRODUCT", 5, 9], ["Cytokine", "GENE_OR_GENE_PRODUCT", 154, 162], ["lungs", "ORGAN", 172, 177], ["organ", "ORGAN", 186, 191], ["alveolar environment", "MULTI-TISSUE_STRUCTURE", 330, 350], ["SARS-CoV", "ORGANISM", 388, 396], ["MERS-CoV", "ORGANISM", 398, 406], ["SARS-CoV", "ORGANISM", 440, 448], ["IL-6", "PROTEIN", 5, 9], ["cytokine", "PROTEIN", 89, 97], ["cytokine", "PROTEIN", 119, 127], ["Cytokine", "PROTEIN", 154, 162], ["cytokine", "PROTEIN", 239, 247], ["cytokine", "PROTEIN", 308, 316], ["SARS-CoV", "SPECIES", 388, 396], ["MERS-CoV", "SPECIES", 398, 406], ["SARS-CoV", "SPECIES", 440, 448], ["This IL-6 hyperactivation cycle", "TREATMENT", 0, 31], ["the cytokine release syndrome", "PROBLEM", 85, 114], ["cytokine storm", "PROBLEM", 119, 133], ["Organ Injury", "PROBLEM", 134, 146], ["ARDS", "PROBLEM", 259, 263], ["a common, fatal condition", "PROBLEM", 267, 292], ["a cytokine storm", "PROBLEM", 306, 322], ["SARS", "PROBLEM", 388, 392], ["MERS", "PROBLEM", 398, 402], ["CoV", "PROBLEM", 403, 406], ["severe influenza", "PROBLEM", 412, 428], ["CoV", "TEST", 445, 448], ["Injury", "OBSERVATION", 140, 146], ["Cytokine Storm", "OBSERVATION", 154, 168], ["lungs", "ANATOMY", 172, 177], ["ARDS", "OBSERVATION", 259, 263], ["alveolar", "ANATOMY", 330, 338], ["systemic circulation", "ANATOMY", 355, 375], ["severe", "OBSERVATION_MODIFIER", 412, 418], ["influenza", "OBSERVATION", 419, 428]]], ["An acute mononuclear/neutrophilic inflammatory response induced ARDS, followed by a chronic fibroproliferative phase with progressive collagen deposition in the lung.", [["mononuclear", "ANATOMY", 9, 20], ["lung", "ANATOMY", 161, 165], ["ARDS", "DISEASE", 64, 68], ["mononuclear", "CELL", 9, 20], ["collagen", "GENE_OR_GENE_PRODUCT", 134, 142], ["lung", "ORGAN", 161, 165], ["collagen", "PROTEIN", 134, 142], ["An acute mononuclear/neutrophilic inflammatory response", "PROBLEM", 0, 55], ["ARDS", "PROBLEM", 64, 68], ["a chronic fibroproliferative phase", "PROBLEM", 82, 116], ["progressive collagen deposition in the lung", "PROBLEM", 122, 165], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["mononuclear", "OBSERVATION_MODIFIER", 9, 20], ["neutrophilic", "OBSERVATION_MODIFIER", 21, 33], ["inflammatory", "OBSERVATION_MODIFIER", 34, 46], ["ARDS", "OBSERVATION", 64, 68], ["chronic", "OBSERVATION_MODIFIER", 84, 91], ["fibroproliferative", "OBSERVATION_MODIFIER", 92, 110], ["phase", "OBSERVATION_MODIFIER", 111, 116], ["progressive", "OBSERVATION_MODIFIER", 122, 133], ["collagen deposition", "OBSERVATION", 134, 153], ["lung", "ANATOMY", 161, 165]]], ["This may be explained by the findings that pulmonary endothelial cells [155, 156] and epithelial cells [78] have critical roles in both the promotion of cytokine amplification and the innate immune cell recruitment by cytokine storm during viral infection.Organ Injury by the Cytokine StormAfter N1H1 influenza infection, pulmonary endothelial cells secreted cytokines (IL-6, IFN\u03b1, IFN\u03b3, and TNF\u03b1) and chemokines (CCL-2) and recruited innate immune cells (macrophages and natural killer cells) but not lymphocytes [155] .", [["pulmonary endothelial cells", "ANATOMY", 43, 70], ["epithelial cells", "ANATOMY", 86, 102], ["immune cell", "ANATOMY", 191, 202], ["Organ", "ANATOMY", 256, 261], ["pulmonary endothelial cells", "ANATOMY", 322, 349], ["immune cells", "ANATOMY", 442, 454], ["macrophages", "ANATOMY", 456, 467], ["natural killer cells", "ANATOMY", 472, 492], ["lymphocytes", "ANATOMY", 502, 513], ["viral infection", "DISEASE", 240, 255], ["Injury", "DISEASE", 262, 268], ["influenza infection", "DISEASE", 301, 320], ["pulmonary endothelial cells", "CELL", 43, 70], ["epithelial cells", "CELL", 86, 102], ["immune cell", "CELL", 191, 202], ["Cytokine", "GENE_OR_GENE_PRODUCT", 276, 284], ["pulmonary endothelial cells", "CELL", 322, 349], ["IL-6", "GENE_OR_GENE_PRODUCT", 370, 374], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 376, 380], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 382, 386], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 392, 396], ["CCL-2", "GENE_OR_GENE_PRODUCT", 414, 419], ["innate immune cells", "CELL", 435, 454], ["macrophages", "CELL", 456, 467], ["natural killer cells", "CELL", 472, 492], ["lymphocytes", "CELL", 502, 513], ["pulmonary endothelial cells", "CELL_TYPE", 43, 70], ["epithelial cells", "CELL_TYPE", 86, 102], ["cytokine", "PROTEIN", 153, 161], ["cytokine", "PROTEIN", 218, 226], ["Cytokine", "PROTEIN", 276, 284], ["pulmonary endothelial cells", "CELL_TYPE", 322, 349], ["cytokines", "PROTEIN", 359, 368], ["IL-6", "PROTEIN", 370, 374], ["IFN\u03b1", "PROTEIN", 376, 380], ["IFN\u03b3", "PROTEIN", 382, 386], ["TNF\u03b1", "PROTEIN", 392, 396], ["chemokines", "PROTEIN", 402, 412], ["CCL", "PROTEIN", 414, 417], ["innate immune cells", "CELL_TYPE", 435, 454], ["macrophages", "CELL_TYPE", 456, 467], ["natural killer cells", "CELL_TYPE", 472, 492], ["lymphocytes", "CELL_TYPE", 502, 513], ["pulmonary endothelial cells", "TEST", 43, 70], ["epithelial cells", "TEST", 86, 102], ["cytokine amplification", "TREATMENT", 153, 175], ["the innate immune cell recruitment", "TREATMENT", 180, 214], ["cytokine storm", "PROBLEM", 218, 232], ["viral infection", "PROBLEM", 240, 255], ["Organ Injury", "PROBLEM", 256, 268], ["the Cytokine StormAfter", "TEST", 272, 295], ["influenza infection", "PROBLEM", 301, 320], ["pulmonary endothelial cells", "PROBLEM", 322, 349], ["cytokines", "TEST", 359, 368], ["IL", "TEST", 370, 372], ["IFN\u03b1", "TEST", 376, 380], ["IFN\u03b3", "TEST", 382, 386], ["TNF", "TEST", 392, 395], ["chemokines", "TEST", 402, 412], ["CCL", "TEST", 414, 417], ["natural killer cells", "TEST", 472, 492], ["lymphocytes", "TEST", 502, 513], ["may be explained", "UNCERTAINTY", 5, 21], ["pulmonary endothelial", "ANATOMY", 43, 64], ["cytokine amplification", "OBSERVATION", 153, 175], ["immune cell", "OBSERVATION", 191, 202], ["cytokine storm", "OBSERVATION", 218, 232], ["viral infection", "OBSERVATION", 240, 255], ["Injury", "OBSERVATION", 262, 268], ["pulmonary endothelial", "ANATOMY", 322, 343], ["immune cells", "OBSERVATION", 442, 454], ["natural killer cells", "OBSERVATION", 472, 492]]], ["Due to the injurious effects of these proinflammatory cytokines and chemokines, vascular permeability increases, and fluid and blood cells leak into the alveoli, resulting in dyspnea and even respiratory failure.SARS-CoV and SARS-CoV-2SARS-CoV-2 is a single-stranded RNA virus with a high similarity to SARS-CoV, sharing 80% genome sequence identity [49, 164, 174, 187] and 90% sequence identity in their N-terminals of the receptor-binding domain and similarity to other essential enzymes [109, 174] .", [["vascular", "ANATOMY", 80, 88], ["fluid", "ANATOMY", 117, 122], ["blood cells", "ANATOMY", 127, 138], ["alveoli", "ANATOMY", 153, 160], ["respiratory", "ANATOMY", 192, 203], ["dyspnea", "DISEASE", 175, 182], ["respiratory failure", "DISEASE", 192, 211], ["SARS", "DISEASE", 212, 216], ["SARS", "DISEASE", 303, 307], ["vascular", "MULTI-TISSUE_STRUCTURE", 80, 88], ["fluid", "ORGANISM_SUBSTANCE", 117, 122], ["blood cells", "CELL", 127, 138], ["alveoli", "MULTI-TISSUE_STRUCTURE", 153, 160], ["SARS-CoV", "ORGANISM", 212, 220], ["SARS-CoV-2SARS-CoV-2", "ORGANISM", 225, 245], ["SARS-CoV", "ORGANISM", 303, 311], ["proinflammatory cytokines", "PROTEIN", 38, 63], ["chemokines", "PROTEIN", 68, 78], ["blood cells", "CELL_TYPE", 127, 138], ["SARS-CoV and SARS-CoV-2SARS-CoV-2", "DNA", 212, 245], ["SARS-CoV", "DNA", 303, 311], ["receptor-binding domain", "PROTEIN", 424, 447], ["essential enzymes", "PROTEIN", 472, 489], ["SARS-CoV", "SPECIES", 212, 220], ["SARS-CoV-2SARS-CoV", "SPECIES", 225, 243], ["SARS-CoV", "SPECIES", 303, 311], ["these proinflammatory cytokines", "TREATMENT", 32, 63], ["chemokines", "TREATMENT", 68, 78], ["vascular permeability", "TEST", 80, 101], ["fluid and blood cells leak into the alveoli", "PROBLEM", 117, 160], ["dyspnea", "PROBLEM", 175, 182], ["respiratory failure", "PROBLEM", 192, 211], ["SARS", "TEST", 212, 216], ["CoV", "TEST", 217, 220], ["SARS", "TEST", 225, 229], ["CoV", "TEST", 230, 233], ["2SARS", "TEST", 234, 239], ["CoV", "TEST", 240, 243], ["a single-stranded RNA virus", "PROBLEM", 249, 276], ["CoV", "TEST", 308, 311], ["sequence identity", "TEST", 378, 395], ["other essential enzymes", "TEST", 466, 489], ["injurious", "OBSERVATION", 11, 20], ["proinflammatory cytokines", "OBSERVATION", 38, 63], ["vascular", "ANATOMY", 80, 88], ["fluid", "OBSERVATION", 117, 122], ["blood cells leak", "OBSERVATION", 127, 143], ["alveoli", "ANATOMY", 153, 160], ["dyspnea", "OBSERVATION", 175, 182], ["respiratory failure", "OBSERVATION", 192, 211]]], ["Both viruses have a nucleocapsid inside with two types of spike proteins (S1 and S2) on the viral surface.", [["surface", "ANATOMY", 98, 105], ["S1", "GENE_OR_GENE_PRODUCT", 74, 76], ["S2", "GENE_OR_GENE_PRODUCT", 81, 83], ["spike proteins", "PROTEIN", 58, 72], ["S1", "PROTEIN", 74, 76], ["S2", "PROTEIN", 81, 83], ["spike proteins (S1 and S2", "PROBLEM", 58, 83], ["viruses", "OBSERVATION", 5, 12], ["nucleocapsid", "OBSERVATION", 20, 32], ["spike proteins", "OBSERVATION", 58, 72], ["S2", "ANATOMY", 81, 83], ["viral surface", "OBSERVATION", 92, 105]]], ["S1 is involved in the attachment of the virus to host cells and is considered to be a target of neutralizing antibodies [43] .", [["cells", "ANATOMY", 54, 59], ["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["host cells", "CELL", 49, 59], ["S1", "PROTEIN", 0, 2], ["host cells", "CELL_TYPE", 49, 59], ["neutralizing antibodies", "PROTEIN", 96, 119], ["neutralizing antibodies", "TEST", 96, 119], ["virus", "OBSERVATION", 40, 45], ["host cells", "OBSERVATION", 49, 59], ["considered to be", "UNCERTAINTY", 67, 83]]], ["S2 is involved in cell membrane fusion [34] and is a potential target of fusion inhibitors.", [["cell membrane", "ANATOMY", 18, 31], ["S2", "GENE_OR_GENE_PRODUCT", 0, 2], ["cell membrane", "CELLULAR_COMPONENT", 18, 31], ["S2", "PROTEIN", 0, 2], ["cell membrane fusion", "TREATMENT", 18, 38], ["fusion inhibitors", "TREATMENT", 73, 90], ["cell membrane fusion", "OBSERVATION", 18, 38]]], ["Based on clinical analyses of the basic reproductive number (R0), SARS-CoV-2 (R0 2.2-2.7 [139, 177] ) appears to have infectivity that is comparable to that of SARS-CoV (R0 1.5-3.4 [22, 86, 128] ).", [["SARS", "DISEASE", 160, 164], ["SARS-CoV-2", "ORGANISM", 66, 76], ["SARS-CoV", "ORGANISM", 160, 168], ["SARS-CoV", "SPECIES", 66, 74], ["SARS-CoV", "SPECIES", 160, 168], ["clinical analyses", "TEST", 9, 26], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["R0", "TEST", 78, 80], ["infectivity", "PROBLEM", 118, 129], ["SARS", "TEST", 160, 164], ["CoV", "TEST", 165, 168], ["R0", "TEST", 170, 172], ["infectivity", "OBSERVATION", 118, 129]]], ["In addition, the latest genome analyses demonstrated that SARS-CoV-2 has its own sequence for furin cleavage [28, 164] .SARS-CoV and SARS-CoV-2ACE2: a Functional \"Receptor\" of SARS-CoV-2 SARS-CoV-2 can enter host cells via two mechanisms: \"endosome attachment fusion\" and \"direct-attachment fusion\" (Fig. 3) .", [["cells", "ANATOMY", 213, 218], ["endosome", "ANATOMY", 240, 248], ["SARS", "DISEASE", 120, 124], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 58, 68], ["furin", "GENE_OR_GENE_PRODUCT", 94, 99], ["SARS-CoV", "ORGANISM", 120, 128], ["SARS-CoV-2ACE2", "ORGANISM", 133, 147], ["SARS-CoV-2", "ORGANISM", 176, 186], ["SARS-CoV-2", "ORGANISM", 187, 197], ["host cells", "CELL", 208, 218], ["endosome", "CELLULAR_COMPONENT", 240, 248], ["SARS-CoV-2", "DNA", 58, 68], ["furin", "PROTEIN", 94, 99], ["2ACE2", "DNA", 142, 147], ["host cells", "CELL_TYPE", 208, 218], ["CoV-2 SARS-CoV", "SPECIES", 181, 195], ["SARS-CoV", "SPECIES", 58, 66], ["SARS-CoV", "SPECIES", 120, 128], ["SARS-CoV", "SPECIES", 133, 141], ["the latest genome analyses", "TEST", 13, 39], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["furin cleavage", "PROBLEM", 94, 108], ["SARS", "PROBLEM", 120, 124], ["SARS", "PROBLEM", 133, 137], ["SARS", "PROBLEM", 176, 180], ["CoV", "TEST", 181, 184], ["endosome attachment fusion", "TREATMENT", 240, 266], ["direct-attachment fusion", "TREATMENT", 273, 297]]], ["After virus attachment, the S1 protein of SARS-CoV-2 binds to ACE2 on the host cell membrane to enter the cell [83] after the activation of S1 protein (\"cleavage\") by host proteinase \"priming.\"", [["cell membrane", "ANATOMY", 79, 92], ["cell", "ANATOMY", 106, 110], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["cell membrane", "CELLULAR_COMPONENT", 79, 92], ["cell", "CELL", 106, 110], ["S1", "GENE_OR_GENE_PRODUCT", 140, 142], ["S1 protein", "PROTEIN", 28, 38], ["ACE2", "PROTEIN", 62, 66], ["S1 protein", "PROTEIN", 140, 150], ["proteinase", "PROTEIN", 172, 182], ["SARS-CoV", "SPECIES", 42, 50], ["virus attachment", "PROBLEM", 6, 22], ["the S1 protein", "TEST", 24, 38], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["ACE2", "TEST", 62, 66], ["S1 protein", "PROBLEM", 140, 150], ["host cell membrane", "OBSERVATION", 74, 92]]], ["The viral S1 protein priming depends on transmembrane protease serine 2 (TMPRSS2) and other host proteases including the endosomal cysteine proteases cathepsins B and L (CatB/L) [60] .", [["endosomal", "ANATOMY", 121, 130], ["serine", "CHEMICAL", 63, 69], ["cysteine", "CHEMICAL", 131, 139], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 40, 71], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 73, 80], ["cathepsins B", "GENE_OR_GENE_PRODUCT", 150, 162], ["CatB/L)", "GENE_OR_GENE_PRODUCT", 170, 177], ["viral S1 protein", "PROTEIN", 4, 20], ["transmembrane protease serine 2", "PROTEIN", 40, 71], ["TMPRSS2", "PROTEIN", 73, 80], ["host proteases", "PROTEIN", 92, 106], ["endosomal cysteine proteases", "PROTEIN", 121, 149], ["cathepsins B", "PROTEIN", 150, 162], ["L", "PROTEIN", 167, 168], ["CatB", "PROTEIN", 170, 174], ["L", "PROTEIN", 175, 176], ["The viral S1 protein priming", "TREATMENT", 0, 28], ["transmembrane protease serine", "TREATMENT", 40, 69], ["other host proteases", "TREATMENT", 86, 106], ["the endosomal cysteine proteases cathepsins", "TREATMENT", 117, 160], ["L (CatB/L)", "TREATMENT", 167, 177], ["viral S1 protein", "OBSERVATION", 4, 20]]], ["TMPRSS2 is a co-factor of ACE2 and is coexpressed in type II pneumocytes with ACE2 [9, 45, 145, 195] , bronchial transient secretory cells [88] , and nasal secretory cells [195] , which are known as enriched sources of SARS-CoV-2 to be detected clinically [193] .SARS-CoV and SARS-CoV-2The co-expression of ACE2 and TMPRSS2 was reported in type 1 pneumocytes [195] , alveolar macrophages [9, 192] , lymphocytes [9] , smooth muscle cells and enterocytes in the gastrointestinal tract [9, 195] , vessel smooth muscle cells [9] , cardiomyocytes [9, 192] , hepatocytes [169] , kidney cells [87] , proximal tubule cells [114] , and neurons [112] , all of which are in line with the common clinical symptoms of COVID-19 [15, 19, 61, 151, 166, 183, 191, 197] .", [["type II pneumocytes", "ANATOMY", 53, 72], ["bronchial", "ANATOMY", 103, 112], ["secretory cells", "ANATOMY", 123, 138], ["nasal secretory cells", "ANATOMY", 150, 171], ["type 1 pneumocytes", "ANATOMY", 340, 358], ["alveolar macrophages", "ANATOMY", 367, 387], ["lymphocytes", "ANATOMY", 399, 410], ["smooth muscle cells", "ANATOMY", 417, 436], ["enterocytes", "ANATOMY", 441, 452], ["gastrointestinal tract", "ANATOMY", 460, 482], ["vessel smooth muscle cells", "ANATOMY", 494, 520], ["cardiomyocytes", "ANATOMY", 527, 541], ["hepatocytes", "ANATOMY", 553, 564], ["kidney cells", "ANATOMY", 573, 585], ["proximal tubule cells", "ANATOMY", 593, 614], ["neurons", "ANATOMY", 627, 634], ["SARS", "DISEASE", 263, 267], ["COVID-19", "CHEMICAL", 705, 713], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 0, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["type II pneumocytes", "GENE_OR_GENE_PRODUCT", 53, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 78, 82], ["secretory cells", "CELL", 123, 138], ["nasal secretory cells", "CELL", 150, 171], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 219, 229], ["SARS-CoV", "ORGANISM", 263, 271], ["SARS-CoV-2", "ORGANISM", 276, 286], ["ACE2", "GENE_OR_GENE_PRODUCT", 307, 311], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 316, 323], ["alveolar macrophages", "CELL", 367, 387], ["lymphocytes", "CELL", 399, 410], ["smooth muscle cells", "CELL", 417, 436], ["enterocytes", "CELL", 441, 452], ["gastrointestinal", "ORGAN", 460, 476], ["tract", "ORGANISM_SUBDIVISION", 477, 482], ["vessel smooth muscle cells", "CELL", 494, 520], ["cardiomyocytes", "CELL", 527, 541], ["hepatocytes", "CELL", 553, 564], ["kidney cells", "CELL", 573, 585], ["proximal tubule cells", "CELL", 593, 614], ["neurons", "CELL", 627, 634], ["TMPRSS2", "PROTEIN", 0, 7], ["ACE2", "PROTEIN", 26, 30], ["type II pneumocytes", "CELL_TYPE", 53, 72], ["ACE2", "PROTEIN", 78, 82], ["bronchial transient secretory cells", "CELL_TYPE", 103, 138], ["nasal secretory cells", "CELL_TYPE", 150, 171], ["ACE2", "PROTEIN", 307, 311], ["TMPRSS2", "PROTEIN", 316, 323], ["alveolar macrophages", "CELL_TYPE", 367, 387], ["lymphocytes", "CELL_TYPE", 399, 410], ["smooth muscle cells", "CELL_TYPE", 417, 436], ["enterocytes", "CELL_TYPE", 441, 452], ["vessel smooth muscle cells", "CELL_TYPE", 494, 520], ["cardiomyocytes", "CELL_TYPE", 527, 541], ["hepatocytes", "CELL_TYPE", 553, 564], ["kidney cells", "CELL_TYPE", 573, 585], ["proximal tubule cells", "CELL_TYPE", 593, 614], ["SARS-CoV", "SPECIES", 263, 271], ["SARS-CoV", "SPECIES", 276, 284], ["TMPRSS2", "TEST", 0, 7], ["ACE2", "TEST", 26, 30], ["ACE2", "TEST", 78, 82], ["bronchial transient secretory cells", "PROBLEM", 103, 138], ["nasal secretory cells", "TEST", 150, 171], ["SARS", "PROBLEM", 219, 223], ["CoV", "TEST", 224, 227], ["SARS", "TEST", 263, 267], ["SARS", "PROBLEM", 276, 280], ["CoV", "TEST", 281, 284], ["ACE2", "TEST", 307, 311], ["TMPRSS2", "TEST", 316, 323], ["type 1 pneumocytes", "PROBLEM", 340, 358], ["alveolar macrophages", "TEST", 367, 387], ["lymphocytes", "TEST", 399, 410], ["smooth muscle cells", "TEST", 417, 436], ["enterocytes in the gastrointestinal tract", "PROBLEM", 441, 482], ["vessel smooth muscle cells", "TEST", 494, 520], ["cardiomyocytes", "TEST", 527, 541], ["hepatocytes", "TEST", 553, 564], ["kidney cells", "TEST", 573, 585], ["proximal tubule cells", "TEST", 593, 614], ["neurons", "TEST", 627, 634], ["COVID", "TEST", 705, 710], ["bronchial", "ANATOMY", 103, 112], ["secretory cells", "OBSERVATION", 123, 138], ["nasal", "ANATOMY", 150, 155], ["alveolar macrophages", "ANATOMY", 367, 387], ["smooth muscle", "ANATOMY", 417, 430], ["enterocytes", "ANATOMY", 441, 452], ["gastrointestinal tract", "ANATOMY", 460, 482], ["vessel", "ANATOMY", 494, 500], ["smooth", "ANATOMY_MODIFIER", 501, 507], ["muscle", "ANATOMY", 508, 514], ["hepatocytes", "ANATOMY", 553, 564], ["kidney", "ANATOMY", 573, 579], ["proximal", "ANATOMY_MODIFIER", 593, 601], ["tubule cells", "OBSERVATION", 602, 614]]], ["Single-cell RNA profiling revealed that male gender, advanced age, and smoking habit can increase the co-expression of ACE2 and TMPRESS2 The therapeutics under clinical trials targeting the cytokine storm in SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 208, 228], ["ACE2", "GENE_OR_GENE_PRODUCT", 119, 123], ["TMPRESS2", "GENE_OR_GENE_PRODUCT", 128, 136], ["SARS-CoV-2", "ORGANISM", 208, 218], ["ACE2", "PROTEIN", 119, 123], ["TMPRESS2", "PROTEIN", 128, 136], ["cytokine", "PROTEIN", 190, 198], ["SARS-CoV-2", "SPECIES", 208, 218], ["Single-cell RNA profiling", "TEST", 0, 25], ["ACE2", "TEST", 119, 123], ["clinical trials", "TREATMENT", 160, 175], ["the cytokine storm", "PROBLEM", 186, 204], ["SARS", "PROBLEM", 208, 212], ["CoV-2 infection", "PROBLEM", 213, 228], ["infection", "OBSERVATION", 219, 228]]], ["SARS-CoV-2 attaches to ACE2 and enters the host cell.", [["cell", "ANATOMY", 48, 52], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["host cell", "CELL", 43, 52], ["ACE2", "PROTEIN", 23, 27], ["SARS", "TEST", 0, 4], ["host cell", "OBSERVATION", 43, 52]]], ["Viral components are recognized by the MyD88 pathway in the endosome, leading to the releases of IL-6 and NF\u03baB from immune cells including macrophages, monocytes, and dendrites.", [["endosome", "ANATOMY", 60, 68], ["immune cells", "ANATOMY", 116, 128], ["macrophages", "ANATOMY", 139, 150], ["monocytes", "ANATOMY", 152, 161], ["dendrites", "ANATOMY", 167, 176], ["MyD88", "GENE_OR_GENE_PRODUCT", 39, 44], ["endosome", "CELLULAR_COMPONENT", 60, 68], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["NF\u03ba", "GENE_OR_GENE_PRODUCT", 106, 109], ["B", "GENE_OR_GENE_PRODUCT", 109, 110], ["immune cells", "CELL", 116, 128], ["macrophages", "CELL", 139, 150], ["monocytes", "CELL", 152, 161], ["dendrites", "CELLULAR_COMPONENT", 167, 176], ["MyD88", "PROTEIN", 39, 44], ["IL-6", "PROTEIN", 97, 101], ["NF\u03ba", "PROTEIN", 106, 109], ["immune cells", "CELL_TYPE", 116, 128], ["macrophages", "CELL_TYPE", 139, 150], ["monocytes", "CELL_TYPE", 152, 161], ["Viral components", "PROBLEM", 0, 16], ["macrophages", "PROBLEM", 139, 150], ["monocytes", "TEST", 152, 161], ["dendrites", "PROBLEM", 167, 176], ["immune cells", "OBSERVATION", 116, 128], ["macrophages", "OBSERVATION", 139, 150], ["monocytes", "ANATOMY", 152, 161]]], ["The possession of ACE2 by the virus causes the accumulation of Ang2 in the extracellular space.", [["extracellular space", "ANATOMY", 75, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["Ang2", "GENE_OR_GENE_PRODUCT", 63, 67], ["extracellular space", "CELLULAR_COMPONENT", 75, 94], ["ACE2", "PROTEIN", 18, 22], ["Ang2", "PROTEIN", 63, 67], ["ACE2", "PROBLEM", 18, 22], ["the virus", "PROBLEM", 26, 35], ["the accumulation of Ang2 in the extracellular space", "PROBLEM", 43, 94], ["accumulation of Ang2", "OBSERVATION", 47, 67], ["extracellular space", "ANATOMY", 75, 94]]], ["After the activation of AT1aR by excess Ang2 binding, sIL-6R is produced from the shedding of mIL-6R by ADAM10 and ADAM17 with a release of sTNF\u03b1 from macrophages, mesenchymal stem cells (MSCs), and dendritic cells (DCs).", [["macrophages", "ANATOMY", 151, 162], ["mesenchymal stem cells", "ANATOMY", 164, 186], ["MSCs", "ANATOMY", 188, 192], ["dendritic cells", "ANATOMY", 199, 214], ["DCs", "ANATOMY", 216, 219], ["AT1aR", "GENE_OR_GENE_PRODUCT", 24, 29], ["Ang2", "GENE_OR_GENE_PRODUCT", 40, 44], ["sIL-6R", "GENE_OR_GENE_PRODUCT", 54, 60], ["mIL-6R", "GENE_OR_GENE_PRODUCT", 94, 100], ["ADAM10", "GENE_OR_GENE_PRODUCT", 104, 110], ["ADAM17", "GENE_OR_GENE_PRODUCT", 115, 121], ["sTNF\u03b1", "GENE_OR_GENE_PRODUCT", 140, 145], ["macrophages", "CELL", 151, 162], ["mesenchymal stem cells", "CELL", 164, 186], ["MSCs", "CELL", 188, 192], ["dendritic cells", "CELL", 199, 214], ["DCs", "CELL", 216, 219], ["AT1aR", "PROTEIN", 24, 29], ["Ang2", "PROTEIN", 40, 44], ["sIL-6R", "PROTEIN", 54, 60], ["mIL", "PROTEIN", 94, 97], ["6R", "PROTEIN", 98, 100], ["ADAM10", "PROTEIN", 104, 110], ["ADAM17", "PROTEIN", 115, 121], ["sTNF\u03b1", "PROTEIN", 140, 145], ["macrophages", "CELL_TYPE", 151, 162], ["mesenchymal stem cells", "CELL_TYPE", 164, 186], ["MSCs", "CELL_TYPE", 188, 192], ["dendritic cells", "CELL_TYPE", 199, 214], ["DCs", "CELL_TYPE", 216, 219], ["mesenchymal stem cells", "PROBLEM", 164, 186], ["dendritic cells", "PROBLEM", 199, 214], ["macrophages", "ANATOMY", 151, 162], ["mesenchymal stem cells", "OBSERVATION", 164, 186], ["dendritic cells", "OBSERVATION", 199, 214]]], ["IL-6 binds to the target cells via two signaling pathways: classic signaling only for specific immune cells, and trans-signaling for any cells including the immune cells, epithelial cells, and fibroblasts.", [["cells", "ANATOMY", 25, 30], ["immune cells", "ANATOMY", 95, 107], ["cells", "ANATOMY", 137, 142], ["immune cells", "ANATOMY", 157, 169], ["epithelial cells", "ANATOMY", 171, 187], ["fibroblasts", "ANATOMY", 193, 204], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 25, 30], ["immune cells", "CELL", 95, 107], ["cells", "CELL", 137, 142], ["immune cells", "CELL", 157, 169], ["epithelial cells", "CELL", 171, 187], ["fibroblasts", "CELL", 193, 204], ["IL-6", "PROTEIN", 0, 4], ["target cells", "CELL_TYPE", 18, 30], ["immune cells", "CELL_TYPE", 95, 107], ["immune cells", "CELL_TYPE", 157, 169], ["epithelial cells", "CELL_TYPE", 171, 187], ["fibroblasts", "CELL_TYPE", 193, 204], ["IL", "TREATMENT", 0, 2], ["classic signaling", "PROBLEM", 59, 76], ["specific immune cells", "PROBLEM", 86, 107], ["any cells", "PROBLEM", 133, 142], ["the immune cells", "PROBLEM", 153, 169], ["epithelial cells", "PROBLEM", 171, 187], ["fibroblasts", "PROBLEM", 193, 204], ["immune cells", "OBSERVATION", 157, 169], ["epithelial cells", "OBSERVATION", 171, 187], ["fibroblasts", "OBSERVATION", 193, 204]]], ["In the classic signaling pathway, IL-6 binds to mIL-6R on the immune cells and activates B cells or differentiates CD8+ T cells, helper T cells, and Th17 cells, which triggers an anti-inflammation response.", [["immune cells", "ANATOMY", 62, 74], ["B cells", "ANATOMY", 89, 96], ["CD8+", "ANATOMY", 115, 119], ["T cells", "ANATOMY", 120, 127], ["helper T cells", "ANATOMY", 129, 143], ["Th17 cells", "ANATOMY", 149, 159], ["IL-6", "GENE_OR_GENE_PRODUCT", 34, 38], ["mIL-6R", "GENE_OR_GENE_PRODUCT", 48, 54], ["immune cells", "CELL", 62, 74], ["B cells", "CELL", 89, 96], ["CD8", "GENE_OR_GENE_PRODUCT", 115, 118], ["T cells", "CELL", 120, 127], ["helper T cells", "CELL", 129, 143], ["Th17 cells", "CELL", 149, 159], ["IL-6", "PROTEIN", 34, 38], ["mIL-6R", "PROTEIN", 48, 54], ["immune cells", "CELL_TYPE", 62, 74], ["B cells", "CELL_TYPE", 89, 96], ["CD8", "PROTEIN", 115, 118], ["T cells", "CELL_TYPE", 120, 127], ["helper T cells", "CELL_TYPE", 129, 143], ["Th17 cells", "CELL_TYPE", 149, 159], ["IL", "TEST", 34, 36], ["mIL", "TEST", 48, 51], ["the immune cells", "TEST", 58, 74], ["T cells", "TEST", 120, 127], ["helper T cells", "TEST", 129, 143], ["Th17 cells", "PROBLEM", 149, 159], ["Th17 cells", "OBSERVATION", 149, 159], ["anti-inflammation response", "OBSERVATION", 179, 205]]], ["There is a negative feedback mechanism to the JAK-STAT pathway by SOCS3.", [["JAK", "GENE_OR_GENE_PRODUCT", 46, 49], ["STAT", "GENE_OR_GENE_PRODUCT", 50, 54], ["SOCS3", "GENE_OR_GENE_PRODUCT", 66, 71], ["JAK", "PROTEIN", 46, 49], ["STAT", "PROTEIN", 50, 54], ["SOCS3", "PROTEIN", 66, 71]]], ["In trans-signaling, IL-6/sIL-6R complex can bind to gp130 following the release of proinflammatory cytokines and IL-6 via three intracellular pathways without SOCS3 negative feedback.", [["intracellular", "ANATOMY", 128, 141], ["IL-6", "GENE_OR_GENE_PRODUCT", 20, 24], ["sIL-6R", "GENE_OR_GENE_PRODUCT", 25, 31], ["gp130", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL-6", "GENE_OR_GENE_PRODUCT", 113, 117], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 128, 141], ["SOCS3", "GENE_OR_GENE_PRODUCT", 159, 164], ["IL-6/sIL-6R complex", "PROTEIN", 20, 39], ["gp130", "PROTEIN", 52, 57], ["proinflammatory cytokines", "PROTEIN", 83, 108], ["IL-6", "PROTEIN", 113, 117], ["SOCS3", "PROTEIN", 159, 164], ["IL-6/sIL-6R complex", "TREATMENT", 20, 39], ["proinflammatory cytokines and IL", "TREATMENT", 83, 115], ["without", "UNCERTAINTY", 151, 158]]], ["Since gp130 is highly expressed on almost all types of cells including the immune cells, sIL-6R shedding by ADAM17 provokes a surge of IL-surge mostly via trans-signaling.", [["cells", "ANATOMY", 55, 60], ["immune cells", "ANATOMY", 75, 87], ["gp130", "GENE_OR_GENE_PRODUCT", 6, 11], ["cells", "CELL", 55, 60], ["immune cells", "CELL", 75, 87], ["sIL-6R", "GENE_OR_GENE_PRODUCT", 89, 95], ["ADAM17", "GENE_OR_GENE_PRODUCT", 108, 114], ["IL", "GENE_OR_GENE_PRODUCT", 135, 137], ["gp130", "PROTEIN", 6, 11], ["immune cells", "CELL_TYPE", 75, 87], ["6R", "PROTEIN", 93, 95], ["ADAM17", "PROTEIN", 108, 114], ["IL", "PROTEIN", 135, 137], ["the immune cells", "TREATMENT", 71, 87], ["a surge of IL", "TREATMENT", 124, 137]]], ["IL-6 stimulates the production of IL-6 and IL-17\u03b1 from Th17 cells, resulting an IL-6 burst in its amplification cycle.", [["Th17 cells", "ANATOMY", 55, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-6", "GENE_OR_GENE_PRODUCT", 34, 38], ["IL-17\u03b1", "GENE_OR_GENE_PRODUCT", 43, 49], ["Th17 cells", "CELL", 55, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 80, 84], ["IL-6", "PROTEIN", 0, 4], ["IL-6", "PROTEIN", 34, 38], ["IL-17\u03b1", "PROTEIN", 43, 49], ["Th17 cells", "CELL_TYPE", 55, 65], ["IL", "TEST", 0, 2], ["IL", "TEST", 34, 36], ["IL", "TEST", 43, 45], ["an IL", "TEST", 77, 82]]], ["The proinflammation cytokines increase vascular permeability and cell migration, enhancing the inflammation response.", [["vascular", "ANATOMY", 39, 47], ["cell", "ANATOMY", 65, 69], ["inflammation", "DISEASE", 95, 107], ["vascular", "MULTI-TISSUE_STRUCTURE", 39, 47], ["cell", "CELL", 65, 69], ["proinflammation cytokines", "PROTEIN", 4, 29], ["The proinflammation cytokines", "PROBLEM", 0, 29], ["vascular permeability", "PROBLEM", 39, 60], ["cell migration", "PROBLEM", 65, 79], ["enhancing the inflammation response", "PROBLEM", 81, 116], ["proinflammation", "OBSERVATION_MODIFIER", 4, 19], ["cytokines", "OBSERVATION", 20, 29], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["vascular", "ANATOMY", 39, 47], ["permeability", "OBSERVATION_MODIFIER", 48, 60], ["cell migration", "OBSERVATION", 65, 79], ["inflammation response", "OBSERVATION", 95, 116]]], ["IL-6 also stimulates megakaryocytes, renal mesangial cells, and hepatocytes with the subsequent inflammatory response and vital organ injury.", [["megakaryocytes", "ANATOMY", 21, 35], ["renal mesangial cells", "ANATOMY", 37, 58], ["hepatocytes", "ANATOMY", 64, 75], ["organ", "ANATOMY", 128, 133], ["organ injury", "DISEASE", 128, 140], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["megakaryocytes", "CELL", 21, 35], ["renal mesangial cells", "CELL", 37, 58], ["hepatocytes", "CELL", 64, 75], ["organ", "ORGAN", 128, 133], ["IL-6", "PROTEIN", 0, 4], ["megakaryocytes", "CELL_TYPE", 21, 35], ["renal mesangial cells", "CELL_TYPE", 37, 58], ["hepatocytes", "CELL_TYPE", 64, 75], ["IL", "TEST", 0, 2], ["megakaryocytes", "PROBLEM", 21, 35], ["renal mesangial cells", "PROBLEM", 37, 58], ["hepatocytes", "PROBLEM", 64, 75], ["the subsequent inflammatory response", "PROBLEM", 81, 117], ["vital organ injury", "PROBLEM", 122, 140], ["megakaryocytes", "OBSERVATION", 21, 35], ["renal", "ANATOMY", 37, 42], ["mesangial cells", "OBSERVATION", 43, 58], ["hepatocytes", "ANATOMY", 64, 75], ["inflammatory", "OBSERVATION_MODIFIER", 96, 108], ["organ", "ANATOMY", 128, 133], ["injury", "OBSERVATION", 134, 140]]], ["ARB/ACE-I, angiotensin receptor blocker/ACE2 inhibitor; AT1aR, angiotensin receptor subtype 1a; C3, complement component 3; E-cadherin, epithelial cadherin; gp130, glycoprotein 130; IL, interleukin; JAK, Janus kinase; MAPK, mitogenactivated protein kinase; MCP-1, monocyte chemoattractant protein 1; mIL-6R, membrane interleukin 6 receptor; MMP9, matrix metallopeptidase 9; MyD88, myeloid differentiation primary response 88; NF\u03baB, nuclear factor kappa-light-chain-enhancer of activated B cells; NF\u03baB, nuclear factor kappa B; PI3K/Akt, phosphoinositide-3-kinase/protein Kinase B; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; sIL-6R, soluble interleukin 6 receptor; SOCS3, the suppressor of cytokine signaling-3; STAT3, signal transducers and activators of transcription; sTNF\u03b1, soluble tumor necrosis factor alpha; Tfh, follicular helper T cell; Th0, naive T cell; Th17, T helper 17 cell; TMPRSS2, transmembrane protease serine 2; TNF\u03b1, tumor necrosis factor alpha; TPO, thrombopoietin; VEGF, vascular endothelial growth factor.", [["B cells", "ANATOMY", 487, 494], ["follicular helper T cell", "ANATOMY", 836, 860], ["T cell", "ANATOMY", 873, 879], ["T helper 17 cell", "ANATOMY", 887, 903], ["ARB", "CHEMICAL", 0, 3], ["angiotensin", "CHEMICAL", 11, 22], ["angiotensin", "CHEMICAL", 63, 74], ["acute respiratory syndrome coronavirus", "DISEASE", 599, 637], ["necrosis", "DISEASE", 959, 967], ["serine", "CHEMICAL", 937, 943], ["ARB", "SIMPLE_CHEMICAL", 0, 3], ["ACE-I", "GENE_OR_GENE_PRODUCT", 4, 9], ["angiotensin receptor blocker", "GENE_OR_GENE_PRODUCT", 11, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["AT1aR", "GENE_OR_GENE_PRODUCT", 56, 61], ["angiotensin receptor subtype 1a", "GENE_OR_GENE_PRODUCT", 63, 94], ["C3", "GENE_OR_GENE_PRODUCT", 96, 98], ["complement component 3", "GENE_OR_GENE_PRODUCT", 100, 122], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 124, 134], ["epithelial cadherin", "GENE_OR_GENE_PRODUCT", 136, 155], ["gp130", "GENE_OR_GENE_PRODUCT", 157, 162], ["glycoprotein 130", "GENE_OR_GENE_PRODUCT", 164, 180], ["IL", "GENE_OR_GENE_PRODUCT", 182, 184], ["interleukin", "GENE_OR_GENE_PRODUCT", 186, 197], ["JAK", "GENE_OR_GENE_PRODUCT", 199, 202], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 204, 216], ["MAPK", "GENE_OR_GENE_PRODUCT", 218, 222], ["mitogenactivated protein kinase", "GENE_OR_GENE_PRODUCT", 224, 255], ["MCP-1", "GENE_OR_GENE_PRODUCT", 257, 262], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 264, 298], ["mIL-6R", "GENE_OR_GENE_PRODUCT", 300, 306], ["membrane interleukin 6 receptor", "GENE_OR_GENE_PRODUCT", 308, 339], ["MMP9", "GENE_OR_GENE_PRODUCT", 341, 345], ["matrix metallopeptidase 9", "GENE_OR_GENE_PRODUCT", 347, 372], ["MyD88", "GENE_OR_GENE_PRODUCT", 374, 379], ["myeloid differentiation primary response 88", "GENE_OR_GENE_PRODUCT", 381, 424], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 426, 430], ["nuclear factor kappa-light-chain-enhancer of activated B cells", "GENE_OR_GENE_PRODUCT", 432, 494], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 496, 500], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 502, 524], ["PI3K", "GENE_OR_GENE_PRODUCT", 526, 530], ["Akt", "GENE_OR_GENE_PRODUCT", 531, 534], ["phosphoinositide-3-kinase", "GENE_OR_GENE_PRODUCT", 536, 561], ["protein Kinase B", "GENE_OR_GENE_PRODUCT", 562, 578], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 580, 590], ["sIL-6R", "GENE_OR_GENE_PRODUCT", 641, 647], ["interleukin 6 receptor", "GENE_OR_GENE_PRODUCT", 657, 679], ["SOCS3", "GENE_OR_GENE_PRODUCT", 681, 686], ["suppressor of cytokine signaling-3", "GENE_OR_GENE_PRODUCT", 692, 726], ["STAT3", "GENE_OR_GENE_PRODUCT", 728, 733], ["sTNF\u03b1", "GENE_OR_GENE_PRODUCT", 787, 792], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 802, 829], ["Tfh", "GENE_OR_GENE_PRODUCT", 831, 834], ["follicular helper T cell", "CELL", 836, 860], ["naive T cell", "CELL", 867, 879], ["Th17", "CELL", 881, 885], ["T helper 17 cell", "GENE_OR_GENE_PRODUCT", 887, 903], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 905, 912], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 914, 945], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 947, 951], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 953, 980], ["TPO", "GENE_OR_GENE_PRODUCT", 982, 985], ["thrombopoietin", "GENE_OR_GENE_PRODUCT", 987, 1001], ["VEGF", "GENE_OR_GENE_PRODUCT", 1003, 1007], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 1009, 1043], ["ACE-I", "PROTEIN", 4, 9], ["ACE2", "PROTEIN", 40, 44], ["AT1aR", "PROTEIN", 56, 61], ["angiotensin receptor subtype 1a", "PROTEIN", 63, 94], ["C3", "PROTEIN", 96, 98], ["complement component 3", "PROTEIN", 100, 122], ["E-cadherin", "PROTEIN", 124, 134], ["epithelial cadherin", "PROTEIN", 136, 155], ["gp130", "PROTEIN", 157, 162], ["glycoprotein 130", "PROTEIN", 164, 180], ["IL", "PROTEIN", 182, 184], ["interleukin", "PROTEIN", 186, 197], ["JAK", "PROTEIN", 199, 202], ["Janus kinase", "PROTEIN", 204, 216], ["MAPK", "PROTEIN", 218, 222], ["mitogenactivated protein kinase", "PROTEIN", 224, 255], ["MCP-1", "PROTEIN", 257, 262], ["monocyte chemoattractant protein 1", "PROTEIN", 264, 298], ["mIL", "PROTEIN", 300, 303], ["6R", "PROTEIN", 304, 306], ["membrane interleukin 6 receptor", "PROTEIN", 308, 339], ["MMP9", "PROTEIN", 341, 345], ["matrix metallopeptidase 9", "PROTEIN", 347, 372], ["MyD88", "PROTEIN", 374, 379], ["myeloid differentiation primary response 88", "PROTEIN", 381, 424], ["NF\u03baB", "PROTEIN", 426, 430], ["nuclear factor kappa-light-chain-enhancer of activated B cells", "PROTEIN", 432, 494], ["NF\u03baB", "PROTEIN", 496, 500], ["nuclear factor kappa B", "PROTEIN", 502, 524], ["PI3K", "PROTEIN", 526, 530], ["Akt", "PROTEIN", 531, 534], ["phosphoinositide-3-kinase", "PROTEIN", 536, 561], ["protein Kinase B", "PROTEIN", 562, 578], ["SARS-CoV-2", "PROTEIN", 580, 590], ["interleukin 6 receptor", "PROTEIN", 657, 679], ["SOCS3", "PROTEIN", 681, 686], ["suppressor of cytokine signaling-3", "PROTEIN", 692, 726], ["STAT3", "PROTEIN", 728, 733], ["signal transducers and activators of transcription", "PROTEIN", 735, 785], ["sTNF\u03b1", "PROTEIN", 787, 792], ["soluble tumor necrosis factor alpha", "PROTEIN", 794, 829], ["Tfh", "PROTEIN", 831, 834], ["follicular helper T cell", "CELL_TYPE", 836, 860], ["Th0, naive T cell", "CELL_TYPE", 862, 879], ["Th17", "PROTEIN", 881, 885], ["T helper 17 cell", "PROTEIN", 887, 903], ["TMPRSS2", "PROTEIN", 905, 912], ["transmembrane protease serine 2", "PROTEIN", 914, 945], ["TNF\u03b1", "PROTEIN", 947, 951], ["tumor necrosis factor alpha", "PROTEIN", 953, 980], ["TPO", "PROTEIN", 982, 985], ["thrombopoietin", "PROTEIN", 987, 1001], ["VEGF", "PROTEIN", 1003, 1007], ["vascular endothelial growth factor", "PROTEIN", 1009, 1043], ["severe acute respiratory syndrome coronavirus", "SPECIES", 592, 637], ["ARB", "TREATMENT", 0, 3], ["ACE-I", "TREATMENT", 4, 9], ["angiotensin receptor blocker", "TREATMENT", 11, 39], ["ACE2 inhibitor", "TREATMENT", 40, 54], ["AT1aR", "TEST", 56, 61], ["angiotensin receptor subtype", "TEST", 63, 91], ["C3, complement component", "TEST", 96, 120], ["E-cadherin", "TEST", 124, 134], ["epithelial cadherin", "TEST", 136, 155], ["gp130", "TEST", 157, 162], ["glycoprotein", "TEST", 164, 176], ["IL", "TEST", 182, 184], ["interleukin", "TEST", 186, 197], ["JAK", "TEST", 199, 202], ["Janus kinase", "TEST", 204, 216], ["MAPK", "TEST", 218, 222], ["mitogenactivated protein kinase", "TEST", 224, 255], ["MCP", "TEST", 257, 260], ["monocyte chemoattractant protein", "TEST", 264, 296], ["mIL", "TEST", 300, 303], ["membrane interleukin 6 receptor", "TREATMENT", 308, 339], ["MMP9, matrix metallopeptidase", "TREATMENT", 341, 370], ["myeloid differentiation primary response", "TEST", 381, 421], ["nuclear factor kappa-light", "TEST", 432, 458], ["activated B cells", "PROBLEM", 477, 494], ["PI3K", "TEST", 526, 530], ["Akt", "TEST", 531, 534], ["phosphoinositide", "TEST", 536, 552], ["kinase", "TEST", 555, 561], ["protein Kinase B", "TEST", 562, 578], ["SARS", "TEST", 580, 584], ["CoV", "TEST", 585, 588], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 592, 637], ["sIL-6R, soluble interleukin 6 receptor", "TREATMENT", 641, 679], ["SOCS3", "PROBLEM", 681, 686], ["cytokine signaling", "TEST", 706, 724], ["STAT3, signal transducers and activators of transcription", "PROBLEM", 728, 785], ["sTNF", "TEST", 787, 791], ["soluble tumor necrosis", "PROBLEM", 794, 816], ["alpha", "TEST", 824, 829], ["Tfh", "TEST", 831, 834], ["follicular helper T cell", "TEST", 836, 860], ["Th0", "TEST", 862, 865], ["Th17", "TEST", 881, 885], ["TMPRSS2", "TEST", 905, 912], ["transmembrane protease serine", "TEST", 914, 943], ["TNF", "TEST", 947, 950], ["tumor necrosis factor alpha", "PROBLEM", 953, 980], ["TPO", "TEST", 982, 985], ["thrombopoietin", "TREATMENT", 987, 1001], ["VEGF", "PROBLEM", 1003, 1007], ["vascular endothelial growth factor", "PROBLEM", 1009, 1043], ["severe", "OBSERVATION_MODIFIER", 592, 598], ["acute", "OBSERVATION_MODIFIER", 599, 604], ["respiratory syndrome", "OBSERVATION", 605, 625], ["tumor", "OBSERVATION", 802, 807], ["Tfh", "ANATOMY", 831, 834], ["follicular", "ANATOMY", 836, 846], ["tumor", "ANATOMY", 953, 958], ["necrosis", "OBSERVATION", 959, 967], ["vascular endothelial", "ANATOMY", 1009, 1029]]], ["[104] , and these are known as clinical risk factors for severe 63, 151, 166, 175, 191, 194] .SARS-CoV and SARS-CoV-2Genome analyses showed that SARS-CoV-2 has a unique sequence for a furin cleavage site [28, 164] , which may determine the viral affinity to host cells [70, 165] .", [["cells", "ANATOMY", 263, 268], ["SARS", "DISEASE", 94, 98], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 94, 102], ["SARS-CoV", "ORGANISM", 107, 115], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 145, 155], ["furin", "GENE_OR_GENE_PRODUCT", 184, 189], ["host cells", "CELL", 258, 268], ["SARS-CoV and SARS-CoV-2Genome", "DNA", 94, 123], ["SARS-CoV-2", "DNA", 145, 155], ["furin cleavage site", "DNA", 184, 203], ["host cells", "CELL_TYPE", 258, 268], ["SARS-CoV", "SPECIES", 94, 102], ["SARS-CoV", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 145, 153], ["SARS", "TEST", 94, 98], ["CoV", "TEST", 99, 102], ["SARS", "PROBLEM", 107, 111], ["CoV-2Genome analyses", "TEST", 112, 132], ["SARS", "PROBLEM", 145, 149], ["a furin cleavage site", "PROBLEM", 182, 203]]], ["Furin, a peptidase that is also known as PACE (paired basic amino acid cleaving enzyme), may also be involved in this process.", [["Furin", "CHEMICAL", 0, 5], ["amino acid", "CHEMICAL", 60, 70], ["amino acid", "CHEMICAL", 60, 70], ["Furin", "GENE_OR_GENE_PRODUCT", 0, 5], ["paired basic amino acid cleaving enzyme", "GENE_OR_GENE_PRODUCT", 47, 86], ["Furin", "PROTEIN", 0, 5], ["peptidase", "PROTEIN", 9, 18], ["PACE", "PROTEIN", 41, 45], ["paired basic amino acid cleaving enzyme", "PROTEIN", 47, 86], ["Furin", "TREATMENT", 0, 5], ["a peptidase", "TREATMENT", 7, 18], ["paired basic amino acid cleaving enzyme", "TREATMENT", 47, 86]]], ["Recent research revealed that furin cleaved the S1/ S2 proteins of SARS-CoV-2 and was essential for virus fusion with the host membrane [59] .", [["membrane", "ANATOMY", 127, 135], ["furin", "GENE_OR_GENE_PRODUCT", 30, 35], ["S2", "GENE_OR_GENE_PRODUCT", 52, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 67, 77], ["furin", "PROTEIN", 30, 35], ["S1/ S2 proteins", "PROTEIN", 48, 63], ["SARS-CoV", "SPECIES", 67, 75], ["Recent research", "TEST", 0, 15], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75], ["virus fusion", "TREATMENT", 100, 112], ["S2", "ANATOMY", 52, 54], ["host membrane", "OBSERVATION", 122, 135]]], ["It has been estimated that compared to SARS-CoV, SARS-CoV-2 has 10-20fold higher affinity to host membrane ACE2 [174] , possibly due to its own FURIN sequence [34] .", [["membrane", "ANATOMY", 98, 106], ["SARS", "DISEASE", 39, 43], ["SARS", "DISEASE", 49, 53], ["SARS-CoV", "ORGANISM", 39, 47], ["SARS-CoV-2", "ORGANISM", 49, 59], ["host membrane ACE2", "GENE_OR_GENE_PRODUCT", 93, 111], ["ACE2", "PROTEIN", 107, 111], ["FURIN sequence", "DNA", 144, 158], ["SARS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 49, 57], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57]]], ["Furin is highly expressed in lung tissue [4, 28] and it was observed that 43% of furin+ bronchial transient secretory cells were coexpressed with TMPRESS2 [88] .", [["lung tissue", "ANATOMY", 29, 40], ["bronchial", "ANATOMY", 88, 97], ["secretory cells", "ANATOMY", 108, 123], ["Furin", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung tissue", "TISSUE", 29, 40], ["furin", "GENE_OR_GENE_PRODUCT", 81, 86], ["cells", "CELL", 118, 123], ["Furin", "PROTEIN", 0, 5], ["furin", "PROTEIN", 81, 86], ["bronchial transient secretory cells", "CELL_TYPE", 88, 123], ["furin", "TEST", 81, 86], ["bronchial transient secretory cells", "PROBLEM", 88, 123], ["TMPRESS2", "TEST", 146, 154], ["lung", "ANATOMY", 29, 33], ["tissue", "OBSERVATION", 34, 40], ["bronchial", "ANATOMY", 88, 97], ["secretory cells", "OBSERVATION", 108, 123]]], ["The triple expression of ACE2, TMPRSS2, and furin was detected in lung macrophages, kidney, adrenal stromal cells, intestine endocytes [192] , and nasal epithelial cells [176] , strongly suggesting that those organs are susceptible to SARS-CoV-2 infection.SARS-CoV-2 Entry Associated with Host ACE2, TMPRSS2, and FurinOnce the viral S1 protein attaches to the host cell membrane's ACE2, the virus enters the cell by host endocytosis, which is dependent on the host cell's clathrin [20, 60] .", [["lung macrophages", "ANATOMY", 66, 82], ["kidney", "ANATOMY", 84, 90], ["adrenal stromal cells", "ANATOMY", 92, 113], ["intestine endocytes", "ANATOMY", 115, 134], ["nasal epithelial cells", "ANATOMY", 147, 169], ["organs", "ANATOMY", 209, 215], ["cell membrane", "ANATOMY", 365, 378], ["cell", "ANATOMY", 408, 412], ["cell", "ANATOMY", 465, 469], ["SARS", "DISEASE", 235, 239], ["infection", "DISEASE", 246, 255], ["SARS", "DISEASE", 256, 260], ["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 31, 38], ["furin", "GENE_OR_GENE_PRODUCT", 44, 49], ["lung macrophages", "CELL", 66, 82], ["kidney", "ORGAN", 84, 90], ["adrenal stromal cells", "CELL", 92, 113], ["intestine endocytes [192]", "CELL", 115, 140], ["nasal epithelial cells", "CELL", 147, 169], ["organs", "ORGAN", 209, 215], ["SARS-CoV-2", "ORGANISM", 235, 245], ["ACE2", "GENE_OR_GENE_PRODUCT", 294, 298], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 300, 307], ["FurinOnce", "GENE_OR_GENE_PRODUCT", 313, 322], ["cell membrane", "CELLULAR_COMPONENT", 365, 378], ["ACE2", "GENE_OR_GENE_PRODUCT", 381, 385], ["cell", "CELL", 408, 412], ["cell", "CELL", 465, 469], ["clathrin", "GENE_OR_GENE_PRODUCT", 472, 480], ["ACE2", "PROTEIN", 25, 29], ["TMPRSS2", "PROTEIN", 31, 38], ["furin", "PROTEIN", 44, 49], ["lung macrophages", "CELL_TYPE", 66, 82], ["adrenal stromal cells", "CELL_TYPE", 92, 113], ["nasal epithelial cells", "CELL_TYPE", 147, 169], ["Host ACE2", "PROTEIN", 289, 298], ["TMPRSS2", "PROTEIN", 300, 307], ["FurinOnce", "PROTEIN", 313, 322], ["viral S1 protein", "PROTEIN", 327, 343], ["ACE2", "PROTEIN", 381, 385], ["clathrin", "PROTEIN", 472, 480], ["SARS-CoV", "SPECIES", 235, 243], ["ACE2", "TEST", 25, 29], ["TMPRSS2", "TEST", 31, 38], ["furin", "TEST", 44, 49], ["intestine endocytes", "TEST", 115, 134], ["nasal epithelial cells", "TEST", 147, 169], ["SARS", "PROBLEM", 235, 239], ["CoV", "PROBLEM", 240, 243], ["2 infection", "PROBLEM", 244, 255], ["SARS", "TEST", 256, 260], ["Host ACE2", "TEST", 289, 298], ["TMPRSS2", "TEST", 300, 307], ["FurinOnce", "TREATMENT", 313, 322], ["the virus", "PROBLEM", 387, 396], ["lung", "ANATOMY", 66, 70], ["macrophages", "OBSERVATION", 71, 82], ["kidney", "ANATOMY", 84, 90], ["adrenal", "ANATOMY", 92, 99], ["stromal cells", "OBSERVATION", 100, 113], ["intestine", "ANATOMY", 115, 124], ["nasal epithelial", "ANATOMY", 147, 163], ["infection", "OBSERVATION", 246, 255], ["host cell membrane", "OBSERVATION", 360, 378], ["host endocytosis", "OBSERVATION", 416, 432]]], ["Viral S2 protein is activated by the proteolysis cleavage with the host cell's CatB/L in endosomes [7, 99, 140] or with TMPRSS2, CatB/L, and furin in the extracellular space [60] , inducing viral envelope fusion to the host membrane and the release of the virus component.SARS-CoV-2 Entry Associated with Host ACE2, TMPRSS2, and FurinCatB was reported to be co-expressed in > 70-90% of human ACE2+ nasal secretory cells [144] .", [["cell", "ANATOMY", 72, 76], ["endosomes", "ANATOMY", 89, 98], ["extracellular space", "ANATOMY", 154, 173], ["membrane", "ANATOMY", 224, 232], ["nasal secretory cells", "ANATOMY", 398, 419], ["SARS", "DISEASE", 272, 276], ["Viral S2", "GENE_OR_GENE_PRODUCT", 0, 8], ["cell", "CELL", 72, 76], ["CatB/L", "GENE_OR_GENE_PRODUCT", 79, 85], ["endosomes", "CELLULAR_COMPONENT", 89, 98], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 120, 127], ["CatB/L", "GENE_OR_GENE_PRODUCT", 129, 135], ["furin", "GENE_OR_GENE_PRODUCT", 141, 146], ["extracellular", "CELLULAR_COMPONENT", 154, 167], ["host membrane", "CELLULAR_COMPONENT", 219, 232], ["ACE2", "GENE_OR_GENE_PRODUCT", 310, 314], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 316, 323], ["FurinCatB", "GENE_OR_GENE_PRODUCT", 329, 338], ["human", "ORGANISM", 386, 391], ["ACE2", "GENE_OR_GENE_PRODUCT", 392, 396], ["Viral S2 protein", "PROTEIN", 0, 16], ["CatB", "PROTEIN", 79, 83], ["L", "PROTEIN", 84, 85], ["TMPRSS2", "PROTEIN", 120, 127], ["CatB", "PROTEIN", 129, 133], ["L", "PROTEIN", 134, 135], ["furin", "PROTEIN", 141, 146], ["Host ACE2", "PROTEIN", 305, 314], ["TMPRSS2", "PROTEIN", 316, 323], ["FurinCatB", "PROTEIN", 329, 338], ["ACE2", "PROTEIN", 392, 396], ["nasal secretory cells", "CELL_TYPE", 398, 419], ["human", "SPECIES", 386, 391], ["human", "SPECIES", 386, 391], ["Viral S2 protein", "TEST", 0, 16], ["the proteolysis cleavage", "PROBLEM", 33, 57], ["the host cell's CatB", "TEST", 63, 83], ["TMPRSS2", "TEST", 120, 127], ["CatB", "TEST", 129, 133], ["viral envelope fusion", "TREATMENT", 190, 211], ["the virus component", "PROBLEM", 252, 271], ["Host ACE2", "TEST", 305, 314], ["TMPRSS2", "TEST", 316, 323], ["human ACE2", "TEST", 386, 396], ["S2 protein", "OBSERVATION", 6, 16], ["L", "ANATOMY_MODIFIER", 134, 135], ["viral", "OBSERVATION", 190, 195], ["envelope fusion", "OBSERVATION", 196, 211], ["host membrane", "OBSERVATION", 219, 232], ["virus", "OBSERVATION", 256, 261]]], ["At the same time, the virus cleavage via TLR7 and the MyD88 pathway activates the production of NF\u03baB, which stimulates IL-6 protein transcription in the h o s t i m m u n e c e l l s [ 16 8 ] .", [["TLR7", "GENE_OR_GENE_PRODUCT", 41, 45], ["MyD88", "GENE_OR_GENE_PRODUCT", 54, 59], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 96, 100], ["IL-6", "GENE_OR_GENE_PRODUCT", 119, 123], ["TLR7", "PROTEIN", 41, 45], ["MyD88", "PROTEIN", 54, 59], ["NF\u03baB", "PROTEIN", 96, 100], ["IL-6 protein", "PROTEIN", 119, 131], ["the virus cleavage via TLR7", "TREATMENT", 18, 45], ["the MyD88 pathway", "TREATMENT", 50, 67], ["l l s", "TEST", 177, 182], ["virus", "OBSERVATION", 22, 27]]], ["T h e r e p l i c a t i o ntranscription complex processes the viral genome replication in the cytoplasm, and the transcription of viral proteins is processed in the host nucleus separately.", [["cytoplasm", "ANATOMY", 95, 104], ["nucleus", "ANATOMY", 171, 178], ["cytoplasm", "ORGANISM_SUBSTANCE", 95, 104], ["nucleus", "CELLULAR_COMPONENT", 171, 178], ["viral proteins", "PROTEIN", 131, 145], ["ntranscription complex processes", "PROBLEM", 26, 58], ["the viral genome replication in the cytoplasm", "PROBLEM", 59, 104], ["viral proteins", "PROBLEM", 131, 145], ["viral genome replication", "OBSERVATION", 63, 87], ["cytoplasm", "OBSERVATION_MODIFIER", 95, 104], ["viral proteins", "OBSERVATION", 131, 145], ["host nucleus", "ANATOMY", 166, 178]]], ["The replicated viral RNA and protein are then assembled in the host cytoplasm, and the virus envelope is modified by the host components.", [["cytoplasm", "ANATOMY", 68, 77], ["cytoplasm", "ORGANISM_SUBSTANCE", 68, 77], ["viral RNA", "RNA", 15, 24], ["The replicated viral RNA and protein", "TEST", 0, 36], ["the virus envelope", "PROBLEM", 83, 101], ["viral RNA", "OBSERVATION", 15, 24], ["host cytoplasm", "OBSERVATION", 63, 77], ["virus envelope", "OBSERVATION", 87, 101], ["host", "OBSERVATION_MODIFIER", 121, 125], ["components", "OBSERVATION_MODIFIER", 126, 136]]], ["Replicated virus buds from the host cells by exocytosis or the bursting of the host cell.SARS-CoV-2 Infection Induces a Cytokine Storm with an Interaction with the RASSimultaneously, the ACE2 possession by SARS-CoV-2 induces accumulations of sACE2 in the blood and urine [12] , with the subsequent cytokine storm including the release of IL-6 from the host macrophage [14, 147] as described above.", [["buds", "ANATOMY", 17, 21], ["cells", "ANATOMY", 36, 41], ["cell", "ANATOMY", 84, 88], ["blood", "ANATOMY", 255, 260], ["urine", "ANATOMY", 265, 270], ["macrophage", "ANATOMY", 357, 367], ["SARS", "DISEASE", 89, 93], ["SARS", "DISEASE", 206, 210], ["host cells", "CELL", 31, 41], ["host cell", "CELL", 79, 88], ["SARS-CoV-2", "ORGANISM", 89, 99], ["ACE2", "GENE_OR_GENE_PRODUCT", 187, 191], ["SARS-CoV-2", "ORGANISM", 206, 216], ["sACE2", "GENE_OR_GENE_PRODUCT", 242, 247], ["blood", "ORGANISM_SUBSTANCE", 255, 260], ["urine", "ORGANISM_SUBSTANCE", 265, 270], ["IL-6", "GENE_OR_GENE_PRODUCT", 338, 342], ["macrophage", "CELL", 357, 367], ["host cells", "CELL_TYPE", 31, 41], ["host cell", "CELL_TYPE", 79, 88], ["Cytokine", "PROTEIN", 120, 128], ["ACE2", "PROTEIN", 187, 191], ["sACE2", "PROTEIN", 242, 247], ["cytokine", "PROTEIN", 298, 306], ["IL-6", "PROTEIN", 338, 342], ["SARS-CoV", "SPECIES", 206, 214], ["Replicated virus buds", "PROBLEM", 0, 21], ["SARS", "PROBLEM", 89, 93], ["Infection", "PROBLEM", 100, 109], ["CoV", "TEST", 211, 214], ["accumulations of sACE2", "PROBLEM", 225, 247], ["the blood and urine", "TEST", 251, 270], ["the subsequent cytokine storm", "TREATMENT", 283, 312], ["the release of IL", "TREATMENT", 323, 340], ["virus buds", "OBSERVATION", 11, 21], ["host cells", "OBSERVATION", 31, 41], ["bursting", "OBSERVATION_MODIFIER", 63, 71], ["host cell", "OBSERVATION", 79, 88], ["host macrophage", "OBSERVATION", 352, 367]]], ["These events are closely linked to the worsening of lymphocytopenia [30] , hypercoagulation [97] , higher mortality [175] , and poor clinical outcomes [10, 11, 61, 122] .", [["lymphocytopenia", "DISEASE", 52, 67], ["hypercoagulation", "DISEASE", 75, 91], ["lymphocytopenia", "PROBLEM", 52, 67], ["hypercoagulation", "TEST", 75, 91], ["worsening", "OBSERVATION_MODIFIER", 39, 48], ["lymphocytopenia", "OBSERVATION", 52, 67]]], ["It was shown that in SARS-CoV infection, the activation of A2R (mostly AT1aR) by Ang2 binding stimulates ADAM17 to promote the shedding of ACE2 into the extracellular space (which increases the uptake of SARS-CoV into cells [51, 52] ) and leads to the direct cleavage of SARS-CoV S protein and the induction of the release of TNF\u03b1/IL-6 [58] .", [["extracellular space", "ANATOMY", 153, 172], ["cells", "ANATOMY", 218, 223], ["SARS-CoV infection", "DISEASE", 21, 39], ["SARS-CoV", "ORGANISM", 21, 29], ["A2R", "GENE_OR_GENE_PRODUCT", 59, 62], ["AT1aR", "GENE_OR_GENE_PRODUCT", 71, 76], ["Ang2", "GENE_OR_GENE_PRODUCT", 81, 85], ["ADAM17", "GENE_OR_GENE_PRODUCT", 105, 111], ["ACE2", "GENE_OR_GENE_PRODUCT", 139, 143], ["extracellular space", "CELLULAR_COMPONENT", 153, 172], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 204, 212], ["cells", "CELL", 218, 223], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 271, 281], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 326, 330], ["IL-6", "GENE_OR_GENE_PRODUCT", 331, 335], ["A2R", "PROTEIN", 59, 62], ["AT1aR", "PROTEIN", 71, 76], ["Ang2", "PROTEIN", 81, 85], ["ADAM17", "PROTEIN", 105, 111], ["ACE2", "PROTEIN", 139, 143], ["SARS-CoV S protein", "PROTEIN", 271, 289], ["TNF\u03b1", "PROTEIN", 326, 330], ["IL", "PROTEIN", 331, 333], ["SARS-CoV", "SPECIES", 21, 29], ["SARS-CoV", "SPECIES", 204, 212], ["SARS", "PROBLEM", 21, 25], ["CoV infection", "PROBLEM", 26, 39], ["A2R", "PROBLEM", 59, 62], ["SARS", "PROBLEM", 204, 208], ["SARS", "PROBLEM", 271, 275], ["CoV S protein", "TREATMENT", 276, 289], ["the release", "TEST", 311, 322], ["TNF", "TEST", 326, 329], ["IL", "TEST", 331, 333], ["CoV", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 30, 39], ["extracellular space", "ANATOMY", 153, 172]]], ["In addition, AT1aR and ADAM17 are co-expressed on various cell types such as endothelial cells [170] and vascular smooth muscle cells [108] , which were reported to be involved in pathological lesions in COVID-19 patients [15, 61, 67, 166, 179] .SARS-CoV-2 Infection Induces a Cytokine Storm with an Interaction with the RASIn summary, SARS-CoV-2 entry is facilitated by the host cells' ACE2, TMPRSS2, and furin, inducing the activation of A2R and the cytokine storm starting with IL-6 release.", [["cell", "ANATOMY", 58, 62], ["endothelial cells", "ANATOMY", 77, 94], ["]", "ANATOMY", 99, 100], ["vascular smooth muscle cells", "ANATOMY", 105, 133], ["lesions", "ANATOMY", 193, 200], ["cells", "ANATOMY", 380, 385], ["SARS", "DISEASE", 246, 250], ["SARS", "DISEASE", 336, 340], ["AT1aR", "GENE_OR_GENE_PRODUCT", 13, 18], ["ADAM17", "GENE_OR_GENE_PRODUCT", 23, 29], ["cell", "CELL", 58, 62], ["endothelial cells", "CELL", 77, 94], ["vascular smooth muscle cells [108]", "CELL", 105, 139], ["pathological lesions", "CANCER", 180, 200], ["patients", "ORGANISM", 213, 221], ["CoV-2", "ORGANISM", 341, 346], ["host cells", "CELL", 375, 385], ["ACE2", "GENE_OR_GENE_PRODUCT", 387, 391], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 393, 400], ["furin", "GENE_OR_GENE_PRODUCT", 406, 411], ["A2R", "GENE_OR_GENE_PRODUCT", 440, 443], ["IL-6", "GENE_OR_GENE_PRODUCT", 481, 485], ["AT1aR", "PROTEIN", 13, 18], ["ADAM17", "PROTEIN", 23, 29], ["endothelial cells", "CELL_TYPE", 77, 94], ["vascular smooth muscle cells", "CELL_TYPE", 105, 133], ["Cytokine", "PROTEIN", 277, 285], ["ACE2", "PROTEIN", 387, 391], ["TMPRSS2", "PROTEIN", 393, 400], ["furin", "PROTEIN", 406, 411], ["A2R", "PROTEIN", 440, 443], ["cytokine", "PROTEIN", 452, 460], ["IL-6", "PROTEIN", 481, 485], ["patients", "SPECIES", 213, 221], ["AT1aR", "PROBLEM", 13, 18], ["ADAM17", "PROBLEM", 23, 29], ["various cell types", "TEST", 50, 68], ["endothelial cells", "TEST", 77, 94], ["vascular smooth muscle cells", "PROBLEM", 105, 133], ["pathological lesions", "PROBLEM", 180, 200], ["COVID", "TEST", 204, 209], ["SARS", "PROBLEM", 246, 250], ["Infection", "PROBLEM", 257, 266], ["SARS", "TEST", 336, 340], ["ACE2", "TEST", 387, 391], ["TMPRSS2", "TEST", 393, 400], ["furin", "TREATMENT", 406, 411], ["the cytokine storm", "TREATMENT", 448, 466], ["IL", "TREATMENT", 481, 483], ["various cell types", "OBSERVATION", 50, 68], ["endothelial cells", "OBSERVATION", 77, 94], ["vascular", "ANATOMY", 105, 113], ["smooth muscle", "ANATOMY", 114, 127]]], ["Insights into the co-expression of ACE2, TMPRSS2, and furin may help to identify the organs that are vulnerable to SARS-CoV-2 infection and may contribute to the development of potential therapeutic strategies.Respiratory Failure/ARDSAs noted above, the lungs are the organ most vulnerable to SARS-CoV-2, and importantly, respiratory failure associated with ARDS is the leading cause of death in individuals with COVID-19, contributing to 86% of the deaths [132] .", [["organs", "ANATOMY", 85, 91], ["lungs", "ANATOMY", 254, 259], ["organ", "ANATOMY", 268, 273], ["respiratory", "ANATOMY", 322, 333], ["SARS", "DISEASE", 115, 119], ["infection", "DISEASE", 126, 135], ["SARS", "DISEASE", 293, 297], ["respiratory failure", "DISEASE", 322, 341], ["ARDS", "DISEASE", 358, 362], ["death", "DISEASE", 387, 392], ["deaths", "DISEASE", 450, 456], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 41, 48], ["furin", "GENE_OR_GENE_PRODUCT", 54, 59], ["organs", "ORGAN", 85, 91], ["SARS-CoV-2", "ORGANISM", 115, 125], ["lungs", "ORGAN", 254, 259], ["organ", "ORGAN", 268, 273], ["ACE2", "PROTEIN", 35, 39], ["TMPRSS2", "PROTEIN", 41, 48], ["furin", "PROTEIN", 54, 59], ["SARS-CoV", "SPECIES", 115, 123], ["SARS-CoV", "SPECIES", 293, 301], ["ACE2", "TEST", 35, 39], ["TMPRSS2", "TEST", 41, 48], ["furin", "TREATMENT", 54, 59], ["SARS", "PROBLEM", 115, 119], ["CoV-2 infection", "PROBLEM", 120, 135], ["Respiratory Failure", "PROBLEM", 210, 229], ["ARDSAs", "PROBLEM", 230, 236], ["SARS", "TEST", 293, 297], ["CoV", "TEST", 298, 301], ["respiratory failure", "PROBLEM", 322, 341], ["ARDS", "PROBLEM", 358, 362], ["death", "PROBLEM", 387, 392], ["COVID", "TEST", 413, 418], ["organs", "ANATOMY", 85, 91], ["infection", "OBSERVATION", 126, 135], ["Failure", "OBSERVATION", 222, 229], ["lungs", "ANATOMY", 254, 259], ["respiratory failure", "OBSERVATION", 322, 341], ["ARDS", "OBSERVATION", 358, 362]]], ["In the severe or critical cases in intensive care units (ICUs), 53-95% of the patients developed ARDS [2, 183, 197] .", [["ARDS", "DISEASE", 97, 101], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["ARDS", "PROBLEM", 97, 101], ["severe", "OBSERVATION_MODIFIER", 7, 13], ["ARDS", "OBSERVATION", 97, 101]]], ["Among those, 2-11% of the patients with ARDS required extracorporeal membrane oxygenation support, and the survival rate of those patients was quite low [61, 166, 183, 191] .", [["extracorporeal membrane", "ANATOMY", 54, 77], ["ARDS", "DISEASE", 40, 44], ["patients", "ORGANISM", 26, 34], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 54, 77], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 130, 138], ["ARDS", "PROBLEM", 40, 44], ["extracorporeal membrane oxygenation support", "TREATMENT", 54, 97], ["the survival rate", "TEST", 103, 120], ["ARDS", "OBSERVATION", 40, 44]]], ["The onset time of ARDS related to COVID-19 was 8-12 days [61, 166, 191] , which is not consistent with the ARDS Berlin criteria [37] , but histological examinations revealed that the pathophysiological features are similar to the common ARDS [19] .Myocardial InjuryNumerous studies revealed that acute cardiac injury was also a common complication of COVID-19 [2, 19, 50, 61, 138, 139, 166, 183, 191, 197] and was associated with poor outcomes among severe COVID-19 patients [50, 138, 139] .", [["Myocardial", "ANATOMY", 248, 258], ["cardiac", "ANATOMY", 302, 309], ["ARDS", "DISEASE", 18, 22], ["ARDS", "DISEASE", 107, 111], ["ARDS", "DISEASE", 237, 241], ["cardiac injury", "DISEASE", 302, 316], ["COVID", "DISEASE", 457, 462], ["COVID-19", "CHEMICAL", 34, 42], ["COVID-19", "CHEMICAL", 351, 359], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 248, 258], ["cardiac", "ORGAN", 302, 309], ["patients", "ORGANISM", 466, 474], ["patients", "SPECIES", 466, 474], ["ARDS", "PROBLEM", 18, 22], ["COVID", "TEST", 34, 39], ["histological examinations", "TEST", 139, 164], ["the pathophysiological features", "PROBLEM", 179, 210], ["the common ARDS", "PROBLEM", 226, 241], ["Myocardial InjuryNumerous studies", "TEST", 248, 281], ["acute cardiac injury", "PROBLEM", 296, 316], ["COVID", "TEST", 351, 356], ["poor outcomes among severe COVID", "PROBLEM", 430, 462], ["ARDS", "OBSERVATION", 18, 22], ["not consistent with", "UNCERTAINTY", 83, 102], ["ARDS", "OBSERVATION", 107, 111], ["common", "OBSERVATION_MODIFIER", 230, 236], ["ARDS", "OBSERVATION", 237, 241], ["acute", "OBSERVATION_MODIFIER", 296, 301], ["cardiac", "ANATOMY", 302, 309], ["injury", "OBSERVATION", 310, 316]]], ["It has been proposed that this might be due to the development of heart failure [138, 191] and lethal arrhythmias [50] .", [["heart", "ANATOMY", 66, 71], ["heart failure", "DISEASE", 66, 79], ["arrhythmias", "DISEASE", 102, 113], ["heart", "ORGAN", 66, 71], ["heart failure", "PROBLEM", 66, 79], ["lethal arrhythmias", "PROBLEM", 95, 113], ["heart", "ANATOMY", 66, 71], ["failure", "OBSERVATION", 72, 79]]], ["Acute cardiac injury is defined as the elevation of cardiac troponin (high-sensitivity troponin I [hsTnI]) and/or troponin T ([TnT) to > 99th percentile alone, or a composite of troponin elevation and ECG or echocardiographic abnormalities [2, 19, 50, 61, 138, 139, 166, 183, 191, 197] .Myocardial InjuryTwo cohort studies showed that 19.7-27.8% of hospitalized COVID-19 patients exhibited myocardial injury as indicated by elevated hsTnI [139] and TnT [50] .", [["cardiac", "ANATOMY", 6, 13], ["cardiac", "ANATOMY", 52, 59], ["Myocardial", "ANATOMY", 287, 297], ["myocardial", "ANATOMY", 390, 400], ["cardiac injury", "DISEASE", 6, 20], ["Myocardial Injury", "DISEASE", 287, 304], ["myocardial injury", "DISEASE", 390, 407], ["cardiac", "ORGAN", 6, 13], ["cardiac", "ORGAN", 52, 59], ["troponin", "GENE_OR_GENE_PRODUCT", 60, 68], ["high-sensitivity troponin I", "GENE_OR_GENE_PRODUCT", 70, 97], ["hsTnI", "GENE_OR_GENE_PRODUCT", 99, 104], ["troponin T", "GENE_OR_GENE_PRODUCT", 114, 124], ["TnT", "GENE_OR_GENE_PRODUCT", 127, 130], ["troponin", "GENE_OR_GENE_PRODUCT", 178, 186], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 287, 297], ["patients", "ORGANISM", 371, 379], ["myocardial", "MULTI-TISSUE_STRUCTURE", 390, 400], ["TnI [139]", "GENE_OR_GENE_PRODUCT", 435, 444], ["TnT", "GENE_OR_GENE_PRODUCT", 449, 452], ["cardiac troponin", "PROTEIN", 52, 68], ["high-sensitivity troponin I", "PROTEIN", 70, 97], ["TnI", "PROTEIN", 101, 104], ["troponin T", "PROTEIN", 114, 124], ["TnT", "PROTEIN", 127, 130], ["troponin", "PROTEIN", 178, 186], ["TnI", "PROTEIN", 435, 438], ["patients", "SPECIES", 371, 379], ["Acute cardiac injury", "PROBLEM", 0, 20], ["cardiac troponin", "TEST", 52, 68], ["troponin I", "TEST", 87, 97], ["hsTnI", "TEST", 99, 104], ["troponin T", "TEST", 114, 124], ["TnT", "TEST", 127, 130], ["troponin elevation", "PROBLEM", 178, 196], ["ECG", "TEST", 201, 204], ["echocardiographic abnormalities", "TEST", 208, 239], ["Myocardial Injury", "PROBLEM", 287, 304], ["Two cohort studies", "TEST", 304, 322], ["COVID", "TEST", 362, 367], ["myocardial injury", "PROBLEM", 390, 407], ["elevated hsTnI", "PROBLEM", 424, 438], ["TnT", "TEST", 449, 452], ["cardiac", "ANATOMY", 6, 13], ["injury", "OBSERVATION", 14, 20], ["elevation", "OBSERVATION_MODIFIER", 39, 48], ["cardiac", "ANATOMY", 52, 59], ["Injury", "OBSERVATION", 298, 304], ["myocardial", "ANATOMY", 390, 400], ["injury", "OBSERVATION", 401, 407]]], ["The mortality rate of COVID-19 patients with cardiac injury was significantly higher than that of the patients without cardiac injury (51.2% vs. 4.5%, p < 0.001), and cardiac injury was an independent predictor of in-hospital mortality as well as ARDS [139] .", [["cardiac", "ANATOMY", 45, 52], ["cardiac", "ANATOMY", 119, 126], ["cardiac", "ANATOMY", 167, 174], ["cardiac injury", "DISEASE", 45, 59], ["cardiac injury", "DISEASE", 119, 133], ["cardiac injury", "DISEASE", 167, 181], ["ARDS", "DISEASE", 247, 251], ["patients", "ORGANISM", 31, 39], ["cardiac", "ORGAN", 45, 52], ["patients", "ORGANISM", 102, 110], ["cardiac", "ORGAN", 119, 126], ["cardiac", "ORGAN", 167, 174], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 102, 110], ["The mortality rate", "TEST", 0, 18], ["COVID", "TEST", 22, 27], ["cardiac injury", "PROBLEM", 45, 59], ["cardiac injury", "PROBLEM", 119, 133], ["cardiac injury", "PROBLEM", 167, 181], ["ARDS", "PROBLEM", 247, 251], ["cardiac", "ANATOMY", 45, 52], ["injury", "OBSERVATION", 53, 59], ["without", "UNCERTAINTY", 111, 118], ["cardiac", "ANATOMY", 119, 126], ["injury", "OBSERVATION", 127, 133], ["cardiac", "ANATOMY", 167, 174], ["injury", "OBSERVATION", 175, 181], ["ARDS", "OBSERVATION", 247, 251]]], ["The troponin level of COVID-19 patients was positively correlated with the level of NT-ProBNP (N-terminal-pro hormone B-type natriuretic peptide) l [50, 139] , indicating that cardiac injury is associated with poor clinical outcomes among COVID-19 patients.Myocardial InjuryThe mechanisms underlying cardiac injury in the context of COVID-19 remain to be investigated, but may be due to a direct injury from SARS-CoV-2 infection and then exacerbation by inflammatory responses.", [["cardiac", "ANATOMY", 176, 183], ["Myocardial", "ANATOMY", 257, 267], ["cardiac", "ANATOMY", 300, 307], ["NT-ProBNP", "CHEMICAL", 84, 93], ["cardiac injury", "DISEASE", 176, 190], ["Myocardial Injury", "DISEASE", 257, 274], ["cardiac injury", "DISEASE", 300, 314], ["COVID-19", "CHEMICAL", 333, 341], ["SARS", "DISEASE", 408, 412], ["infection", "DISEASE", 419, 428], ["COVID-19", "CHEMICAL", 333, 341], ["troponin", "GENE_OR_GENE_PRODUCT", 4, 12], ["patients", "ORGANISM", 31, 39], ["NT-ProBNP", "GENE_OR_GENE_PRODUCT", 84, 93], ["B-type natriuretic peptide", "GENE_OR_GENE_PRODUCT", 118, 144], ["cardiac", "ORGAN", 176, 183], ["patients", "ORGANISM", 248, 256], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 257, 267], ["cardiac", "ORGAN", 300, 307], ["COVID-19", "GENE_OR_GENE_PRODUCT", 333, 341], ["CoV-2", "ORGANISM", 413, 418], ["troponin", "PROTEIN", 4, 12], ["N-terminal-pro hormone B", "PROTEIN", 95, 119], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 248, 256], ["SARS-CoV", "SPECIES", 408, 416], ["The troponin level", "TEST", 0, 18], ["COVID", "TEST", 22, 27], ["NT", "TEST", 84, 86], ["ProBNP", "TEST", 87, 93], ["terminal", "TEST", 97, 105], ["type natriuretic peptide", "TEST", 120, 144], ["cardiac injury", "PROBLEM", 176, 190], ["Myocardial Injury", "PROBLEM", 257, 274], ["cardiac injury", "PROBLEM", 300, 314], ["COVID", "TEST", 333, 338], ["a direct injury", "PROBLEM", 387, 402], ["SARS", "PROBLEM", 408, 412], ["CoV", "PROBLEM", 413, 416], ["2 infection", "PROBLEM", 417, 428], ["exacerbation", "PROBLEM", 438, 450], ["inflammatory responses", "PROBLEM", 454, 476], ["cardiac", "ANATOMY", 176, 183], ["injury", "OBSERVATION", 184, 190], ["Injury", "OBSERVATION", 268, 274], ["cardiac", "ANATOMY", 300, 307], ["injury", "OBSERVATION", 308, 314], ["injury", "OBSERVATION", 396, 402], ["infection", "OBSERVATION", 419, 428], ["inflammatory", "OBSERVATION_MODIFIER", 454, 466]]], ["The expression of ACE2 on the myocardium [50] and vascular endothelial cells [54] provides a theoretical mechanism of the direct injury by SARS-COV-2 to the heart, with resultant myocarditis.", [["myocardium", "ANATOMY", 30, 40], ["vascular endothelial cells", "ANATOMY", 50, 76], ["heart", "ANATOMY", 157, 162], ["myocarditis", "DISEASE", 179, 190], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["vascular endothelial cells", "CELL", 50, 76], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 139, 149], ["heart", "ORGAN", 157, 162], ["ACE2", "PROTEIN", 18, 22], ["vascular endothelial cells", "CELL_TYPE", 50, 76], ["vascular endothelial cells", "TEST", 50, 76], ["the direct injury", "PROBLEM", 118, 135], ["SARS", "TEST", 139, 143], ["COV", "TEST", 144, 147], ["resultant myocarditis", "PROBLEM", 169, 190], ["myocardium", "ANATOMY", 30, 40], ["vascular endothelial", "ANATOMY", 50, 70], ["heart", "ANATOMY", 157, 162], ["resultant", "OBSERVATION_MODIFIER", 169, 178], ["myocarditis", "OBSERVATION", 179, 190]]], ["Indeed, the viral RNA was detected in heart autopsies [172] .", [["heart", "ANATOMY", 38, 43], ["heart", "ORGAN", 38, 43], ["viral RNA", "RNA", 12, 21], ["the viral RNA", "TEST", 8, 21], ["heart autopsies", "TEST", 38, 53], ["viral RNA", "OBSERVATION", 12, 21], ["heart", "ANATOMY", 38, 43]]], ["In addition, excess inflammation causes endothelial dysfunction and increases the prothrombotic activity of the blood, both of which may contribute to the formation of an occlusive thrombus, leading to acute coronary syndrome and myocardial injury.Acute Kidney InjuryThe prevalence of acute kidney injury (AKI) varied depending on the severity of COVID-19 [2, 21, 48, 139, 183, 191, 197] .", [["endothelial", "ANATOMY", 40, 51], ["blood", "ANATOMY", 112, 117], ["occlusive thrombus", "ANATOMY", 171, 189], ["coronary", "ANATOMY", 208, 216], ["myocardial", "ANATOMY", 230, 240], ["Kidney", "ANATOMY", 254, 260], ["kidney", "ANATOMY", 291, 297], ["inflammation", "DISEASE", 20, 32], ["endothelial dysfunction", "DISEASE", 40, 63], ["occlusive thrombus", "DISEASE", 171, 189], ["acute coronary syndrome", "DISEASE", 202, 225], ["myocardial injury", "DISEASE", 230, 247], ["Kidney Injury", "DISEASE", 254, 267], ["acute kidney injury", "DISEASE", 285, 304], ["AKI", "DISEASE", 306, 309], ["COVID-19", "CHEMICAL", 347, 355], ["endothelial", "TISSUE", 40, 51], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["occlusive thrombus", "PATHOLOGICAL_FORMATION", 171, 189], ["coronary", "MULTI-TISSUE_STRUCTURE", 208, 216], ["myocardial", "MULTI-TISSUE_STRUCTURE", 230, 240], ["Kidney", "ORGAN", 254, 260], ["kidney", "ORGAN", 291, 297], ["excess inflammation", "PROBLEM", 13, 32], ["endothelial dysfunction", "PROBLEM", 40, 63], ["the prothrombotic activity of the blood", "PROBLEM", 78, 117], ["an occlusive thrombus", "PROBLEM", 168, 189], ["acute coronary syndrome", "PROBLEM", 202, 225], ["myocardial injury", "PROBLEM", 230, 247], ["Acute Kidney Injury", "PROBLEM", 248, 267], ["acute kidney injury", "PROBLEM", 285, 304], ["AKI", "PROBLEM", 306, 309], ["COVID", "TEST", 347, 352], ["excess", "OBSERVATION_MODIFIER", 13, 19], ["inflammation", "OBSERVATION", 20, 32], ["endothelial dysfunction", "OBSERVATION", 40, 63], ["increases", "OBSERVATION_MODIFIER", 68, 77], ["prothrombotic", "OBSERVATION_MODIFIER", 82, 95], ["activity", "OBSERVATION_MODIFIER", 96, 104], ["blood", "ANATOMY", 112, 117], ["may contribute to", "UNCERTAINTY", 133, 150], ["occlusive", "OBSERVATION_MODIFIER", 171, 180], ["thrombus", "OBSERVATION", 181, 189], ["acute", "OBSERVATION_MODIFIER", 202, 207], ["coronary", "ANATOMY", 208, 216], ["syndrome", "OBSERVATION", 217, 225], ["myocardial", "ANATOMY", 230, 240], ["injury", "OBSERVATION", 241, 247], ["Kidney", "ANATOMY", 254, 260], ["Injury", "OBSERVATION", 261, 267], ["acute", "OBSERVATION_MODIFIER", 285, 290], ["kidney", "ANATOMY", 291, 297], ["injury", "OBSERVATION", 298, 304], ["AKI", "OBSERVATION", 306, 309]]], ["Two large observational studies showed that the prevalence of AKI was relatively low (0.5-5%) in hospitalized COVID-19 patients [21, 48] .", [["AKI", "DISEASE", 62, 65], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["Two large observational studies", "TEST", 0, 31], ["AKI", "PROBLEM", 62, 65], ["large", "OBSERVATION_MODIFIER", 4, 9], ["AKI", "OBSERVATION", 62, 65], ["low", "OBSERVATION_MODIFIER", 81, 84]]], ["Kidney functional abnormalities including proteinuria (43.9%) and hematuria (26.7%) were observed in many COVID-19 patients, and, importantly, the kidney abnormalities were independent predictors of in-hospital death: proteinuria of any degree, hematuria of any degree, elevated baseline blood urea nitrogen, serum creatinine, peak serum creatinine > 133 \u03bcmol/L, and AKI > stage 2 [21] .Acute Kidney InjuryThe mechanisms that underlie kidney injury/ abnormality have been hypothesized to include both direct cytotoxic effects of SARS-CoV-2 itself and cytokinemediated damage [21] .", [["Kidney", "ANATOMY", 0, 6], ["kidney", "ANATOMY", 147, 153], ["blood", "ANATOMY", 288, 293], ["serum", "ANATOMY", 309, 314], ["serum", "ANATOMY", 332, 337], ["Kidney", "ANATOMY", 393, 399], ["kidney", "ANATOMY", 435, 441], ["Kidney functional abnormalities", "DISEASE", 0, 31], ["proteinuria", "DISEASE", 42, 53], ["hematuria", "DISEASE", 66, 75], ["kidney abnormalities", "DISEASE", 147, 167], ["death", "DISEASE", 211, 216], ["proteinuria", "DISEASE", 218, 229], ["hematuria", "DISEASE", 245, 254], ["blood urea nitrogen", "CHEMICAL", 288, 307], ["creatinine", "CHEMICAL", 315, 325], ["creatinine", "CHEMICAL", 338, 348], ["AKI", "DISEASE", 367, 370], ["Kidney Injury", "DISEASE", 393, 406], ["kidney injury", "DISEASE", 435, 448], ["SARS", "DISEASE", 529, 533], ["urea", "CHEMICAL", 294, 298], ["nitrogen", "CHEMICAL", 299, 307], ["creatinine", "CHEMICAL", 315, 325], ["creatinine", "CHEMICAL", 338, 348], ["Kidney", "ORGAN", 0, 6], ["patients", "ORGANISM", 115, 123], ["kidney", "ORGAN", 147, 153], ["blood", "ORGANISM_SUBSTANCE", 288, 293], ["urea", "SIMPLE_CHEMICAL", 294, 298], ["serum", "ORGANISM_SUBSTANCE", 309, 314], ["creatinine", "SIMPLE_CHEMICAL", 315, 325], ["serum", "ORGANISM_SUBSTANCE", 332, 337], ["creatinine", "SIMPLE_CHEMICAL", 338, 348], ["Kidney", "ORGAN", 393, 399], ["kidney", "ORGAN", 435, 441], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 529, 539], ["patients", "SPECIES", 115, 123], ["Kidney functional abnormalities", "PROBLEM", 0, 31], ["proteinuria", "TEST", 42, 53], ["hematuria", "PROBLEM", 66, 75], ["the kidney abnormalities", "PROBLEM", 143, 167], ["proteinuria of any degree", "PROBLEM", 218, 243], ["hematuria of any degree", "PROBLEM", 245, 268], ["elevated baseline blood urea nitrogen", "PROBLEM", 270, 307], ["serum creatinine", "TEST", 309, 325], ["peak serum creatinine", "TEST", 327, 348], ["\u03bcmol", "TEST", 355, 359], ["AKI", "PROBLEM", 367, 370], ["Acute Kidney Injury", "PROBLEM", 387, 406], ["kidney injury", "PROBLEM", 435, 448], ["abnormality", "PROBLEM", 450, 461], ["SARS", "PROBLEM", 529, 533], ["CoV", "TEST", 534, 537], ["cytokinemediated damage", "PROBLEM", 551, 574], ["proteinuria", "OBSERVATION", 42, 53], ["hematuria", "OBSERVATION", 66, 75], ["kidney", "ANATOMY", 147, 153], ["abnormalities", "OBSERVATION", 154, 167], ["proteinuria", "OBSERVATION", 218, 229], ["hematuria", "OBSERVATION", 245, 254], ["AKI", "OBSERVATION", 367, 370], ["Kidney", "ANATOMY", 393, 399], ["Injury", "OBSERVATION", 400, 406], ["kidney", "ANATOMY", 435, 441], ["injury", "OBSERVATION", 442, 448]]], ["ACE2 was shown to express in glomerular parietal epithelial cells and epithelial basal cells in the kidneys and in kidney proximal tubules [121, 196] .", [["glomerular parietal epithelial cells", "ANATOMY", 29, 65], ["epithelial basal cells", "ANATOMY", 70, 92], ["kidneys", "ANATOMY", 100, 107], ["kidney proximal tubules", "ANATOMY", 115, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["glomerular parietal epithelial cells", "CELL", 29, 65], ["epithelial basal cells", "CELL", 70, 92], ["kidneys", "ORGAN", 100, 107], ["kidney", "ORGAN", 115, 121], ["proximal tubules", "TISSUE", 122, 138], ["ACE2", "PROTEIN", 0, 4], ["glomerular parietal epithelial cells", "CELL_TYPE", 29, 65], ["epithelial basal cells", "CELL_TYPE", 70, 92], ["ACE2", "TEST", 0, 4], ["glomerular", "ANATOMY_MODIFIER", 29, 39], ["parietal", "ANATOMY_MODIFIER", 40, 48], ["epithelial cells", "OBSERVATION", 49, 65], ["epithelial", "ANATOMY_MODIFIER", 70, 80], ["basal cells", "OBSERVATION", 81, 92], ["kidneys", "ANATOMY", 100, 107], ["kidney", "ANATOMY", 115, 121], ["proximal", "ANATOMY_MODIFIER", 122, 130], ["tubules", "ANATOMY_MODIFIER", 131, 138]]], ["SARS-CoV-2 enters the host cells via the binding of ACE2 on epithelial cells.", [["cells", "ANATOMY", 27, 32], ["epithelial cells", "ANATOMY", 60, 76], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["host cells", "CELL", 22, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["epithelial cells", "CELL", 60, 76], ["host cells", "CELL_TYPE", 22, 32], ["ACE2", "PROTEIN", 52, 56], ["epithelial cells", "CELL_TYPE", 60, 76], ["SARS-CoV", "TEST", 0, 8], ["epithelial cells", "OBSERVATION", 60, 76]]], ["Indeed, an evaluation of 12 autopsy cases revealed that six patients had viremia, and viral RNA was also detected in kidney tissues at concentrations exceeding viremia [172] .Acute Kidney InjuryThese data suggest that SARS-CoV-2 spreads through the bloodstream and directly injures the kidneys.", [["kidney tissues", "ANATOMY", 117, 131], ["Kidney", "ANATOMY", 181, 187], ["bloodstream", "ANATOMY", 249, 260], ["kidneys", "ANATOMY", 286, 293], ["viremia", "DISEASE", 73, 80], ["viremia", "DISEASE", 160, 167], ["Kidney Injury", "DISEASE", 181, 194], ["SARS", "DISEASE", 218, 222], ["patients", "ORGANISM", 60, 68], ["kidney tissues", "TISSUE", 117, 131], ["Kidney", "ORGAN", 181, 187], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 218, 228], ["kidneys", "ORGAN", 286, 293], ["viral RNA", "RNA", 86, 95], ["patients", "SPECIES", 60, 68], ["an evaluation", "TEST", 8, 21], ["12 autopsy cases", "TEST", 25, 41], ["viremia", "PROBLEM", 73, 80], ["viral RNA", "PROBLEM", 86, 95], ["viremia", "TEST", 160, 167], ["Acute Kidney Injury", "PROBLEM", 175, 194], ["These data", "TEST", 194, 204], ["SARS", "PROBLEM", 218, 222], ["CoV", "TEST", 223, 226], ["viremia", "OBSERVATION", 73, 80], ["viral RNA", "OBSERVATION", 86, 95], ["kidney", "ANATOMY", 117, 123], ["Kidney", "ANATOMY", 181, 187], ["Injury", "OBSERVATION", 188, 194], ["kidneys", "ANATOMY", 286, 293]]], ["The cytokine storm (a hyper-inflammatory status) might exert indirect effects on renal abnormalities such as hypoxia secondary due to respiratory failure, septic and cardiogenic shock, and rhabdomyolysis, all of which were reported in patients with severe influenza viral infection [76] .Liver InjurySeveral cohort studies reported that liver injury occurred in COVID-19 patients, and the liver injuries were described mainly as an increase in the level of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin accompanied by slightly decreased albumin [2, 19, 50, 61, 175, 183, 191, 197] .", [["renal", "ANATOMY", 81, 86], ["respiratory", "ANATOMY", 134, 145], ["Liver", "ANATOMY", 288, 293], ["liver", "ANATOMY", 337, 342], ["liver", "ANATOMY", 389, 394], ["renal abnormalities", "DISEASE", 81, 100], ["hypoxia", "DISEASE", 109, 116], ["respiratory failure", "DISEASE", 134, 153], ["septic and cardiogenic shock", "DISEASE", 155, 183], ["rhabdomyolysis", "DISEASE", 189, 203], ["influenza viral infection", "DISEASE", 256, 281], ["liver injury", "DISEASE", 337, 349], ["liver injuries", "DISEASE", 389, 403], ["alanine", "CHEMICAL", 457, 464], ["aspartate", "CHEMICAL", 489, 498], ["bilirubin", "CHEMICAL", 532, 541], ["alanine", "CHEMICAL", 457, 464], ["aspartate", "CHEMICAL", 489, 498], ["bilirubin", "CHEMICAL", 532, 541], ["renal", "ORGAN", 81, 86], ["patients", "ORGANISM", 235, 243], ["Liver", "ORGAN", 288, 293], ["liver", "ORGAN", 337, 342], ["patients", "ORGANISM", 371, 379], ["liver", "ORGAN", 389, 394], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 457, 481], ["ALT", "SIMPLE_CHEMICAL", 483, 486], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 489, 515], ["AST", "SIMPLE_CHEMICAL", 517, 520], ["bilirubin", "SIMPLE_CHEMICAL", 532, 541], ["albumin", "GENE_OR_GENE_PRODUCT", 576, 583], ["cytokine", "PROTEIN", 4, 12], ["alanine aminotransferase", "PROTEIN", 457, 481], ["ALT", "PROTEIN", 483, 486], ["aspartate aminotransferase", "PROTEIN", 489, 515], ["AST", "PROTEIN", 517, 520], ["patients", "SPECIES", 235, 243], ["patients", "SPECIES", 371, 379], ["The cytokine storm", "PROBLEM", 0, 18], ["a hyper-inflammatory status", "PROBLEM", 20, 47], ["renal abnormalities", "PROBLEM", 81, 100], ["hypoxia", "PROBLEM", 109, 116], ["respiratory failure", "PROBLEM", 134, 153], ["septic", "PROBLEM", 155, 161], ["cardiogenic shock", "PROBLEM", 166, 183], ["rhabdomyolysis", "PROBLEM", 189, 203], ["severe influenza viral infection", "PROBLEM", 249, 281], ["Liver InjurySeveral cohort studies", "TEST", 288, 322], ["liver injury", "PROBLEM", 337, 349], ["the liver injuries", "PROBLEM", 385, 403], ["alanine aminotransferase", "TEST", 457, 481], ["ALT", "TEST", 483, 486], ["aspartate aminotransferase", "TEST", 489, 515], ["AST", "TEST", 517, 520], ["total bilirubin", "TEST", 526, 541], ["slightly decreased albumin", "PROBLEM", 557, 583], ["cytokine storm", "OBSERVATION", 4, 18], ["renal", "ANATOMY", 81, 86], ["abnormalities", "OBSERVATION", 87, 100], ["hypoxia", "OBSERVATION", 109, 116], ["respiratory failure", "OBSERVATION", 134, 153], ["septic", "OBSERVATION_MODIFIER", 155, 161], ["cardiogenic shock", "OBSERVATION", 166, 183], ["rhabdomyolysis", "OBSERVATION", 189, 203], ["severe", "OBSERVATION_MODIFIER", 249, 255], ["influenza", "OBSERVATION", 256, 265], ["liver", "ANATOMY", 337, 342], ["injury", "OBSERVATION", 343, 349], ["liver", "ANATOMY", 389, 394], ["injuries", "OBSERVATION", 395, 403], ["increase", "OBSERVATION_MODIFIER", 432, 440], ["slightly", "OBSERVATION_MODIFIER", 557, 565], ["decreased", "OBSERVATION", 566, 575]]], ["Patient series with severe COVID-19 or non-survivors were more likely to have a higher prevalence of liver injury compared to mild cases and survivors [19, 61, 175, 191, 197] .Liver InjuryIn a retrospective study, liver injury was detected in 35.4% of non-ICU patients with COVID- 19 [61] .", [["liver", "ANATOMY", 101, 106], ["Liver", "ANATOMY", 176, 181], ["liver", "ANATOMY", 214, 219], ["liver injury", "DISEASE", 101, 113], ["liver injury", "DISEASE", 214, 226], ["COVID- 19", "CHEMICAL", 274, 283], ["liver", "ORGAN", 101, 106], ["Liver", "ORGAN", 176, 181], ["liver", "ORGAN", 214, 219], ["patients", "ORGANISM", 260, 268], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 260, 268], ["severe COVID", "PROBLEM", 20, 32], ["liver injury", "PROBLEM", 101, 113], ["mild cases", "PROBLEM", 126, 136], ["a retrospective study", "TEST", 191, 212], ["liver injury", "PROBLEM", 214, 226], ["COVID", "TEST", 274, 279], ["liver", "ANATOMY", 101, 106], ["injury", "OBSERVATION", 107, 113], ["liver", "ANATOMY", 214, 219], ["injury", "OBSERVATION", 220, 226]]], ["Male patients and patients with high levels of white blood cells, neutrophils, and CRP and a greater extent of pulmonary lesions on computed tomography were more likely to have liver injury [61] .", [["white blood cells", "ANATOMY", 47, 64], ["neutrophils", "ANATOMY", 66, 77], ["pulmonary lesions", "ANATOMY", 111, 128], ["liver", "ANATOMY", 177, 182], ["liver injury", "DISEASE", 177, 189], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 18, 26], ["white blood cells", "CELL", 47, 64], ["neutrophils", "CELL", 66, 77], ["CRP", "GENE_OR_GENE_PRODUCT", 83, 86], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 111, 128], ["liver", "ORGAN", 177, 182], ["white blood cells", "CELL_TYPE", 47, 64], ["neutrophils", "CELL_TYPE", 66, 77], ["CRP", "PROTEIN", 83, 86], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 18, 26], ["white blood cells", "TEST", 47, 64], ["neutrophils", "TEST", 66, 77], ["CRP", "TEST", 83, 86], ["pulmonary lesions", "PROBLEM", 111, 128], ["computed tomography", "TEST", 132, 151], ["liver injury", "PROBLEM", 177, 189], ["greater", "OBSERVATION_MODIFIER", 93, 100], ["pulmonary", "ANATOMY", 111, 120], ["lesions", "OBSERVATION", 121, 128], ["liver", "ANATOMY", 177, 182], ["injury", "OBSERVATION", 183, 189]]], ["The expression of ACE2 was observed on endothelial cells of the liver and cholangiocytes as well as other vital organs [54, 121] .", [["endothelial cells", "ANATOMY", 39, 56], ["liver", "ANATOMY", 64, 69], ["cholangiocytes", "ANATOMY", 74, 88], ["organs", "ANATOMY", 112, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["endothelial cells", "CELL", 39, 56], ["liver", "ORGAN", 64, 69], ["cholangiocytes", "ORGAN", 74, 88], ["organs", "ORGAN", 112, 118], ["ACE2", "PROTEIN", 18, 22], ["endothelial cells", "CELL_TYPE", 39, 56], ["ACE2", "TEST", 18, 22], ["other vital organs", "TEST", 100, 118], ["liver", "ANATOMY", 64, 69], ["cholangiocytes", "ANATOMY", 74, 88]]], ["The study of 12 autopsy cases showed high SARS-CoV-2 RNA titers in the liver [172] .", [["liver", "ANATOMY", 71, 76], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["liver", "ORGAN", 71, 76], ["The study", "TEST", 0, 9], ["autopsy cases", "TEST", 16, 29], ["high SARS", "PROBLEM", 37, 46], ["CoV", "TEST", 47, 50], ["liver", "ANATOMY", 71, 76]]], ["The liver biopsy of a COVID-19 patient revealed microvesicular steatosis and lobular and portal activity, suggesting that the injury was caused by either SARS-CoV-2 infection or drug-induced injury [19] .", [["liver", "ANATOMY", 4, 9], ["microvesicular", "ANATOMY", 48, 62], ["lobular", "ANATOMY", 77, 84], ["portal", "ANATOMY", 89, 95], ["steatosis", "DISEASE", 63, 72], ["infection", "DISEASE", 165, 174], ["drug-induced injury", "DISEASE", 178, 197], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 4, 16], ["patient", "ORGANISM", 31, 38], ["microvesicular steatosis", "PATHOLOGICAL_FORMATION", 48, 72], ["lobular", "CANCER", 77, 84], ["portal", "MULTI-TISSUE_STRUCTURE", 89, 95], ["CoV-2", "ORGANISM", 159, 164], ["patient", "SPECIES", 31, 38], ["The liver biopsy", "TEST", 0, 16], ["a COVID", "TEST", 20, 27], ["microvesicular steatosis", "PROBLEM", 48, 72], ["lobular and portal activity", "PROBLEM", 77, 104], ["the injury", "PROBLEM", 122, 132], ["SARS", "PROBLEM", 154, 158], ["CoV-2 infection", "PROBLEM", 159, 174], ["drug-induced injury", "PROBLEM", 178, 197], ["liver", "ANATOMY", 4, 9], ["biopsy", "OBSERVATION", 10, 16], ["microvesicular", "OBSERVATION_MODIFIER", 48, 62], ["steatosis", "OBSERVATION", 63, 72], ["lobular", "OBSERVATION_MODIFIER", 77, 84], ["portal activity", "ANATOMY", 89, 104], ["injury", "OBSERVATION", 126, 132]]], ["As cholangiocytes play pivotal roles in the initiation and regulation of immune responses and liver regeneration [3] , it is possible that liver injury and bile duct injury are caused directly by viral infection.The Gastrointestinal Injury/Gut-Lung AxisDigestive manifestations including lack of appetite, nausea, vomiting, diarrhea, abdominal pain, and gastrointestinal hemorrhage have been documented in patients with SARS-CoV-2 infection [19, 48, 66, 113, 166, 183, 188, 197] .", [["cholangiocytes", "ANATOMY", 3, 17], ["liver", "ANATOMY", 94, 99], ["liver", "ANATOMY", 139, 144], ["bile duct", "ANATOMY", 156, 165], ["Gastrointestinal", "ANATOMY", 216, 232], ["Lung", "ANATOMY", 244, 248], ["abdominal", "ANATOMY", 334, 343], ["gastrointestinal", "ANATOMY", 354, 370], ["liver injury", "DISEASE", 139, 151], ["bile duct injury", "DISEASE", 156, 172], ["viral infection", "DISEASE", 196, 211], ["Gastrointestinal Injury", "DISEASE", 216, 239], ["lack of appetite", "DISEASE", 288, 304], ["nausea", "DISEASE", 306, 312], ["vomiting", "DISEASE", 314, 322], ["diarrhea", "DISEASE", 324, 332], ["abdominal pain", "DISEASE", 334, 348], ["gastrointestinal hemorrhage", "DISEASE", 354, 381], ["SARS-CoV-2 infection", "DISEASE", 420, 440], ["cholangiocytes", "CELL", 3, 17], ["liver", "ORGAN", 94, 99], ["liver", "ORGAN", 139, 144], ["bile duct", "MULTI-TISSUE_STRUCTURE", 156, 165], ["abdominal", "ORGANISM_SUBDIVISION", 334, 343], ["gastrointestinal", "ORGANISM_SUBDIVISION", 354, 370], ["patients", "ORGANISM", 406, 414], ["CoV-2", "ORGANISM", 425, 430], ["patients", "SPECIES", 406, 414], ["immune responses", "PROBLEM", 73, 89], ["liver regeneration", "PROBLEM", 94, 112], ["liver injury", "PROBLEM", 139, 151], ["bile duct injury", "PROBLEM", 156, 172], ["viral infection", "PROBLEM", 196, 211], ["The Gastrointestinal Injury", "PROBLEM", 212, 239], ["Gut-Lung AxisDigestive manifestations", "PROBLEM", 240, 277], ["lack of appetite", "PROBLEM", 288, 304], ["nausea", "PROBLEM", 306, 312], ["vomiting", "PROBLEM", 314, 322], ["diarrhea", "PROBLEM", 324, 332], ["abdominal pain", "PROBLEM", 334, 348], ["gastrointestinal hemorrhage", "PROBLEM", 354, 381], ["SARS", "PROBLEM", 420, 424], ["CoV-2 infection", "PROBLEM", 425, 440], ["liver", "ANATOMY", 94, 99], ["liver", "ANATOMY", 139, 144], ["injury", "OBSERVATION", 145, 151], ["bile duct", "ANATOMY", 156, 165], ["viral", "OBSERVATION_MODIFIER", 196, 201], ["infection", "OBSERVATION", 202, 211], ["Gastrointestinal", "ANATOMY", 216, 232], ["Injury", "OBSERVATION", 233, 239], ["Lung", "ANATOMY", 244, 248], ["abdominal", "ANATOMY", 334, 343], ["pain", "OBSERVATION", 344, 348], ["gastrointestinal", "ANATOMY", 354, 370], ["hemorrhage", "OBSERVATION", 371, 381]]], ["COVID-19 patients with digestive manifestations were significantly more likely to require intensive care admission and to have ARDS compared to patients without gastrointestinal symptoms (6.8% vs. 2.1%, p = 0.034, and 6.8% vs. 2.1%, p = 0.034, respectively) [66] , indicating an association between the presence of digestive symptoms and disease severity.", [["digestive", "ANATOMY", 23, 32], ["gastrointestinal", "ANATOMY", 161, 177], ["digestive", "ANATOMY", 315, 324], ["ARDS", "DISEASE", 127, 131], ["gastrointestinal symptoms", "DISEASE", 161, 186], ["digestive symptoms", "DISEASE", 315, 333], ["patients", "ORGANISM", 9, 17], ["digestive", "ORGAN", 23, 32], ["patients", "ORGANISM", 144, 152], ["gastrointestinal", "ORGAN", 161, 177], ["digestive", "ORGAN", 315, 324], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 144, 152], ["digestive manifestations", "PROBLEM", 23, 47], ["ARDS", "PROBLEM", 127, 131], ["gastrointestinal symptoms", "PROBLEM", 161, 186], ["p", "TEST", 203, 204], ["p", "TEST", 233, 234], ["digestive symptoms", "PROBLEM", 315, 333], ["disease severity", "PROBLEM", 338, 354], ["ARDS", "OBSERVATION", 127, 131], ["digestive", "ANATOMY", 315, 324], ["symptoms", "OBSERVATION", 325, 333]]], ["The gut microbiota have been shown to affect lung health through an important crosstalk between the gut microbiota and the lungs, which is called the \"gut-lung axis\" [16] .", [["gut microbiota", "ANATOMY", 4, 18], ["lung", "ANATOMY", 45, 49], ["gut microbiota", "ANATOMY", 100, 114], ["lungs", "ANATOMY", 123, 128], ["gut", "ANATOMY", 151, 154], ["lung", "ANATOMY", 155, 159], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 4, 18], ["lung", "ORGAN", 45, 49], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 100, 114], ["lungs", "ORGAN", 123, 128], ["gut", "ORGANISM_SUBDIVISION", 151, 154], ["lung", "ORGAN", 155, 159], ["lungs", "ANATOMY", 123, 128], ["lung", "ANATOMY", 155, 159]]], ["The gut-lung axis is bidirectional, and microbial metabolites affect the lungs via the blood stream while inflammation in the lungs also affects the gut flora [16] .", [["gut", "ANATOMY", 4, 7], ["lung", "ANATOMY", 8, 12], ["lungs", "ANATOMY", 73, 78], ["blood stream", "ANATOMY", 87, 99], ["lungs", "ANATOMY", 126, 131], ["gut flora", "ANATOMY", 149, 158], ["inflammation", "DISEASE", 106, 118], ["gut", "ORGANISM_SUBDIVISION", 4, 7], ["lung", "ORGAN", 8, 12], ["lungs", "ORGAN", 73, 78], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["lungs", "ORGAN", 126, 131], ["gut", "ORGANISM_SUBDIVISION", 149, 152], ["the blood stream", "TEST", 83, 99], ["inflammation in the lungs", "PROBLEM", 106, 131], ["gut", "ANATOMY", 4, 7], ["lung", "ANATOMY", 8, 12], ["axis", "ANATOMY_MODIFIER", 13, 17], ["bidirectional", "OBSERVATION_MODIFIER", 21, 34], ["lungs", "ANATOMY", 73, 78], ["inflammation", "OBSERVATION", 106, 118], ["lungs", "ANATOMY", 126, 131], ["gut", "ANATOMY", 149, 152], ["flora", "OBSERVATION", 153, 158]]], ["This raises the interesting possibility that SARS-CoV-2 may also affect the gut microbiota.", [["gut microbiota", "ANATOMY", 76, 90], ["SARS", "DISEASE", 45, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["gut microbiota", "PATHOLOGICAL_FORMATION", 76, 90], ["SARS", "PROBLEM", 45, 49], ["raises the interesting possibility", "UNCERTAINTY", 5, 39]]], ["Viral RNA has been detected in stool samples of COVID-19 patients [148, 180] .", [["stool samples", "ANATOMY", 31, 44], ["Viral", "ORGANISM", 0, 5], ["stool samples", "ORGANISM_SUBSTANCE", 31, 44], ["patients", "ORGANISM", 57, 65], ["Viral RNA", "RNA", 0, 9], ["patients", "SPECIES", 57, 65], ["Viral RNA", "PROBLEM", 0, 9], ["stool samples", "TEST", 31, 44], ["COVID", "TEST", 48, 53], ["RNA", "OBSERVATION", 6, 9]]], ["The SARS-CoV-2 itself may cause disorders of the intestinal flora, which may result in digestive symptoms and deterioration of patients with ARDS.Neurological InjuriesNeurological injuries including central nervous system (CNS) symptoms, peripheral nervous system (PNS) symptoms, and skeletal muscle injury symptoms have been observed in patients with mild to severe COVID-19 [8, 19, 81, 92, 102, 119, 186] .", [["intestinal flora", "ANATOMY", 49, 65], ["digestive", "ANATOMY", 87, 96], ["Neurological", "ANATOMY", 146, 158], ["Neurological", "ANATOMY", 167, 179], ["central nervous system", "ANATOMY", 199, 221], ["CNS", "ANATOMY", 223, 226], ["peripheral nervous system", "ANATOMY", 238, 263], ["PNS", "ANATOMY", 265, 268], ["skeletal muscle", "ANATOMY", 284, 299], ["SARS", "DISEASE", 4, 8], ["disorders of the intestinal flora", "DISEASE", 32, 65], ["ARDS", "DISEASE", 141, 145], ["Neurological Injuries", "DISEASE", 146, 167], ["Neurological injuries", "DISEASE", 167, 188], ["central nervous system (CNS) symptoms", "DISEASE", 199, 236], ["peripheral nervous system (PNS) symptoms", "DISEASE", 238, 278], ["skeletal muscle injury", "DISEASE", 284, 306], ["COVID", "DISEASE", 367, 372], ["COVID-19", "CHEMICAL", 367, 375], ["SARS-CoV-2", "ORGANISM", 4, 14], ["intestinal flora", "PATHOLOGICAL_FORMATION", 49, 65], ["digestive", "ORGAN", 87, 96], ["patients", "ORGANISM", 127, 135], ["central nervous system", "ANATOMICAL_SYSTEM", 199, 221], ["CNS", "ANATOMICAL_SYSTEM", 223, 226], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 238, 263], ["PNS", "ANATOMICAL_SYSTEM", 265, 268], ["skeletal muscle", "TISSUE", 284, 299], ["patients", "ORGANISM", 338, 346], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 338, 346], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["disorders", "PROBLEM", 32, 41], ["the intestinal flora", "PROBLEM", 45, 65], ["digestive symptoms", "PROBLEM", 87, 105], ["ARDS", "PROBLEM", 141, 145], ["Neurological Injuries", "PROBLEM", 146, 167], ["Neurological injuries", "PROBLEM", 167, 188], ["central nervous system (CNS) symptoms", "PROBLEM", 199, 236], ["peripheral nervous system (PNS) symptoms", "PROBLEM", 238, 278], ["skeletal muscle injury symptoms", "PROBLEM", 284, 315], ["mild to severe COVID", "PROBLEM", 352, 372], ["intestinal flora", "ANATOMY", 49, 65], ["ARDS", "OBSERVATION", 141, 145], ["central", "ANATOMY_MODIFIER", 199, 206], ["nervous system", "ANATOMY", 207, 221], ["CNS", "ANATOMY", 223, 226], ["peripheral", "ANATOMY_MODIFIER", 238, 248], ["nervous system", "ANATOMY", 249, 263], ["skeletal muscle", "ANATOMY", 284, 299], ["injury", "OBSERVATION", 300, 306]]], ["Two cohort studies [19, 81] reported high prevalence of olfactory (68-86%) and gustatory (71-88%) dysfunctions in COVID-19-positive patients, and olfactory dysfunction appeared before the other symptoms in 11.8% of the cases [19] .", [["olfactory", "ANATOMY", 56, 65], ["gustatory", "ANATOMY", 79, 88], ["olfactory", "ANATOMY", 146, 155], ["olfactory dysfunction", "DISEASE", 146, 167], ["olfactory", "ANATOMICAL_SYSTEM", 56, 65], ["gustatory", "ANATOMICAL_SYSTEM", 79, 88], ["COVID-19", "GENE_OR_GENE_PRODUCT", 114, 122], ["patients", "ORGANISM", 132, 140], ["olfactory", "ORGAN", 146, 155], ["patients", "SPECIES", 132, 140], ["Two cohort studies", "TEST", 0, 18], ["olfactory", "TEST", 56, 65], ["gustatory", "TEST", 79, 88], ["dysfunctions", "TEST", 98, 110], ["COVID", "TEST", 114, 119], ["olfactory dysfunction", "PROBLEM", 146, 167], ["the other symptoms", "PROBLEM", 184, 202]]], ["These two chemosensory dysfunctions were independently and strongly associated with COVID-19 positivity [19] and should be considered to be early signs of the disease.Neurological InjuriesA retrospective analysis of neurological manifestations of COVID-19 demonstrated that of 214 patients, 36.4% of the hospitalized patients had neurologic manifestations: CNS (24.8%), PNS (8.9%), and skeletal muscle (10.7%) injury [94] .", [["neurological", "ANATOMY", 216, 228], ["neurologic", "ANATOMY", 330, 340], ["CNS", "ANATOMY", 357, 360], ["PNS", "ANATOMY", 370, 373], ["skeletal muscle", "ANATOMY", 386, 401], ["chemosensory dysfunctions", "DISEASE", 10, 35], ["PNS", "DISEASE", 370, 373], ["skeletal muscle", "DISEASE", 386, 401], ["COVID-19", "GENE_OR_GENE_PRODUCT", 84, 92], ["patients", "ORGANISM", 281, 289], ["patients", "ORGANISM", 317, 325], ["CNS", "ANATOMICAL_SYSTEM", 357, 360], ["skeletal muscle", "TISSUE", 386, 401], ["patients", "SPECIES", 281, 289], ["patients", "SPECIES", 317, 325], ["These two chemosensory dysfunctions", "PROBLEM", 0, 35], ["COVID", "TEST", 84, 89], ["the disease", "PROBLEM", 155, 166], ["neurological manifestations", "TEST", 216, 243], ["COVID", "TEST", 247, 252], ["neurologic manifestations", "PROBLEM", 330, 355], ["CNS", "TEST", 357, 360], ["PNS", "TEST", 370, 373], ["injury", "PROBLEM", 410, 416], ["chemosensory dysfunctions", "OBSERVATION", 10, 35], ["disease", "OBSERVATION", 159, 166], ["CNS", "ANATOMY", 357, 360], ["PNS", "ANATOMY", 370, 373], ["skeletal muscle", "ANATOMY", 386, 401]]], ["In the groups of patients with CNS manifestations, neurologic disorders were more common in the severe patients compared to the non-severe patients; the disorders included acute cerebrovascular diseases (5.7% vs. 0.8%), impaired consciousness (14.8% vs. 2.4%), and neural skeletal muscle injury (19.3% vs. 4.8%) [92] .", [["CNS", "ANATOMY", 31, 34], ["neurologic", "ANATOMY", 51, 61], ["cerebrovascular", "ANATOMY", 178, 193], ["neural skeletal muscle", "ANATOMY", 265, 287], ["neurologic disorders", "DISEASE", 51, 71], ["acute cerebrovascular diseases", "DISEASE", 172, 202], ["impaired consciousness", "DISEASE", 220, 242], ["skeletal muscle injury", "DISEASE", 272, 294], ["patients", "ORGANISM", 17, 25], ["CNS", "ANATOMICAL_SYSTEM", 31, 34], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 139, 147], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 178, 193], ["neural skeletal muscle", "TISSUE", 265, 287], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 139, 147], ["CNS manifestations", "PROBLEM", 31, 49], ["neurologic disorders", "PROBLEM", 51, 71], ["the disorders", "PROBLEM", 149, 162], ["acute cerebrovascular diseases", "PROBLEM", 172, 202], ["impaired consciousness", "PROBLEM", 220, 242], ["neural skeletal muscle injury", "PROBLEM", 265, 294], ["CNS", "ANATOMY", 31, 34], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["cerebrovascular", "ANATOMY", 178, 193], ["diseases", "OBSERVATION", 194, 202], ["neural", "ANATOMY_MODIFIER", 265, 271], ["skeletal muscle", "ANATOMY", 272, 287], ["injury", "OBSERVATION", 288, 294]]], ["More severe neurological manifestations were reported in a few case reports [8, 102, 119] ; for example, a 24-year-old male experienced a coma, seizures, and neck stiffness [102] .", [["neurological", "ANATOMY", 12, 24], ["neck", "ANATOMY", 158, 162], ["coma", "DISEASE", 138, 142], ["seizures", "DISEASE", 144, 152], ["neck stiffness", "DISEASE", 158, 172], ["male", "ORGANISM", 119, 123], ["neck", "ORGANISM_SUBDIVISION", 158, 162], ["More severe neurological manifestations", "PROBLEM", 0, 39], ["a coma", "PROBLEM", 136, 142], ["seizures", "PROBLEM", 144, 152], ["neck stiffness", "PROBLEM", 158, 172], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["neck", "ANATOMY", 158, 162], ["stiffness", "OBSERVATION", 163, 172]]], ["SARS-CoV-2 RNA was detected in his cerebrospinal fluid (CSF), and subsequent magnetic resonance imaging indicated right lateral ventriculitis and encephalitis mainly at the right mesial lobe and hippocampus, where SARS-CoV2-associated meningitis/encephalitis was diagnosed [102] .", [["cerebrospinal fluid", "ANATOMY", 35, 54], ["right lateral ventriculitis", "ANATOMY", 114, 141], ["right mesial lobe", "ANATOMY", 173, 190], ["hippocampus", "ANATOMY", 195, 206], ["SARS", "DISEASE", 0, 4], ["right lateral ventriculitis", "DISEASE", 114, 141], ["encephalitis", "DISEASE", 146, 158], ["SARS", "DISEASE", 214, 218], ["meningitis", "DISEASE", 235, 245], ["encephalitis", "DISEASE", 246, 258], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 35, 54], ["CSF", "ORGANISM_SUBSTANCE", 56, 59], ["mesial lobe", "MULTI-TISSUE_STRUCTURE", 179, 190], ["hippocampus", "ORGAN", 195, 206], ["CoV2", "GENE_OR_GENE_PRODUCT", 219, 223], ["SARS-CoV-2 RNA", "RNA", 0, 14], ["SARS", "TEST", 0, 4], ["his cerebrospinal fluid", "TEST", 31, 54], ["subsequent magnetic resonance imaging", "TEST", 66, 103], ["right lateral ventriculitis", "PROBLEM", 114, 141], ["encephalitis", "PROBLEM", 146, 158], ["SARS", "PROBLEM", 214, 218], ["CoV2", "PROBLEM", 219, 223], ["meningitis", "PROBLEM", 235, 245], ["encephalitis", "PROBLEM", 246, 258], ["cerebrospinal fluid", "ANATOMY", 35, 54], ["right", "ANATOMY_MODIFIER", 114, 119], ["lateral", "ANATOMY_MODIFIER", 120, 127], ["ventriculitis", "OBSERVATION", 128, 141], ["encephalitis", "OBSERVATION", 146, 158], ["right mesial lobe", "ANATOMY", 173, 190], ["hippocampus", "ANATOMY", 195, 206], ["meningitis", "OBSERVATION", 235, 245], ["encephalitis", "OBSERVATION", 246, 258]]], ["The mechanism may be a direct invasion of SARS-CoV-2, similar to SARS virus [181] .Neurological InjuriesBrain tissues highly express ACE2 [138] , and SARS-CoV-2 RNA was found in the CSF of the abovementioned COVID-19 patient [102] and in the patient's brain autopsy [172] .", [["Neurological", "ANATOMY", 83, 95], ["Brain tissues", "ANATOMY", 104, 117], ["brain", "ANATOMY", 252, 257], ["SARS", "DISEASE", 42, 46], ["SARS", "DISEASE", 65, 69], ["Neurological Injuries", "DISEASE", 83, 104], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["SARS virus", "ORGANISM", 65, 75], ["Brain tissues", "TISSUE", 104, 117], ["ACE2", "GENE_OR_GENE_PRODUCT", 133, 137], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 150, 160], ["CSF", "GENE_OR_GENE_PRODUCT", 182, 185], ["patient", "ORGANISM", 217, 224], ["patient", "ORGANISM", 242, 249], ["brain", "ORGAN", 252, 257], ["ACE2", "PROTEIN", 133, 137], ["SARS-CoV-2 RNA", "RNA", 150, 164], ["patient", "SPECIES", 217, 224], ["patient", "SPECIES", 242, 249], ["SARS-CoV", "SPECIES", 42, 50], ["SARS virus", "SPECIES", 65, 75], ["a direct invasion of SARS", "PROBLEM", 21, 46], ["CoV", "TEST", 47, 50], ["SARS virus", "PROBLEM", 65, 75], ["Neurological Injuries", "TEST", 83, 104], ["ACE2", "TEST", 133, 137], ["SARS", "TEST", 150, 154], ["CoV", "TEST", 155, 158], ["the CSF", "TEST", 178, 185], ["may be", "UNCERTAINTY", 14, 20]]], ["As with other respiratory viruses, SARS-CoV-2 may enter the CNS through a hematogenous or retrograde neural route [92] .", [["CNS", "ANATOMY", 60, 63], ["neural", "ANATOMY", 101, 107], ["SARS-CoV-2", "ORGANISM", 35, 45], ["CNS", "ANATOMICAL_SYSTEM", 60, 63], ["SARS-CoV", "SPECIES", 35, 43], ["other respiratory viruses", "PROBLEM", 8, 33], ["SARS", "PROBLEM", 35, 39], ["respiratory", "ANATOMY", 14, 25], ["viruses", "OBSERVATION", 26, 33], ["CNS", "ANATOMY", 60, 63], ["hematogenous", "OBSERVATION", 74, 86]]], ["The latter route is supported by the finding that COVID-19 patients have a high prevalence of olfactory dysfunction.", [["olfactory", "ANATOMY", 94, 103], ["olfactory dysfunction", "DISEASE", 94, 115], ["patients", "ORGANISM", 59, 67], ["olfactory", "ORGAN", 94, 103], ["patients", "SPECIES", 59, 67], ["COVID", "TEST", 50, 55], ["olfactory dysfunction", "PROBLEM", 94, 115], ["olfactory dysfunction", "OBSERVATION", 94, 115]]], ["The results of the above-cited retrospective analysis suggested that the observed neurological symptoms may likely be associated with worse prognosis in COVID-19 [92] .Neurological InjuriesA tissue profiling analysis showed that ACE2 is strongly expressed in the respiratory control center, the ventrolateral medulla, and the nucleus of the tractus solitarius [33, 111] .", [["neurological", "ANATOMY", 82, 94], ["Neurological", "ANATOMY", 168, 180], ["tissue", "ANATOMY", 191, 197], ["respiratory control center", "ANATOMY", 263, 289], ["ventrolateral medulla", "ANATOMY", 295, 316], ["nucleus", "ANATOMY", 326, 333], ["tractus solitarius", "ANATOMY", 341, 359], ["tissue", "TISSUE", 191, 197], ["ACE2", "GENE_OR_GENE_PRODUCT", 229, 233], ["ventrolateral medulla", "MULTI-TISSUE_STRUCTURE", 295, 316], ["nucleus", "CELLULAR_COMPONENT", 326, 333], ["tractus solitarius", "ORGANISM", 341, 359], ["ACE2", "PROTEIN", 229, 233], ["tractus solitarius", "SPECIES", 341, 359], ["retrospective analysis", "TEST", 31, 53], ["the observed neurological symptoms", "PROBLEM", 69, 103], ["COVID", "TEST", 153, 158], ["Neurological Injuries", "TEST", 168, 189], ["A tissue profiling analysis", "TEST", 189, 216], ["ACE2", "TEST", 229, 233], ["respiratory control", "OBSERVATION", 263, 282], ["ventrolateral", "ANATOMY_MODIFIER", 295, 308], ["medulla", "ANATOMY", 309, 316], ["nucleus", "ANATOMY_MODIFIER", 326, 333], ["tractus solitarius", "ANATOMY", 341, 359]]], ["Other coronaviruses with structures that are similar to that of SARS-CoV-2 have been reported to cause the apoptosis of neurocytes in the respiratory center to a degree that is high enough to drive the lethal nervousrespiratory malfunction [32, 85, 93, 107] .", [["neurocytes", "ANATOMY", 120, 130], ["SARS", "DISEASE", 64, 68], ["nervousrespiratory malfunction", "DISEASE", 209, 239], ["coronaviruses", "ORGANISM", 6, 19], ["SARS-CoV-2", "ORGANISM", 64, 74], ["neurocytes", "CANCER", 120, 130], ["SARS-CoV", "SPECIES", 64, 72], ["Other coronaviruses with structures", "PROBLEM", 0, 35], ["SARS", "PROBLEM", 64, 68], ["CoV", "TEST", 69, 72], ["the apoptosis of neurocytes", "PROBLEM", 103, 130], ["the lethal nervousrespiratory malfunction", "PROBLEM", 198, 239], ["coronaviruses", "OBSERVATION", 6, 19], ["high", "OBSERVATION", 177, 181]]], ["Thus, the respiratory failure in COVID-19 might be caused in part by the invasion of SARS-CoV-2 to the neurons of the cardiorespiratory center in the ventrolateral medulla.", [["respiratory", "ANATOMY", 10, 21], ["neurons", "ANATOMY", 103, 110], ["cardiorespiratory center", "ANATOMY", 118, 142], ["ventrolateral medulla", "ANATOMY", 150, 171], ["respiratory failure", "DISEASE", 10, 29], ["COVID-19", "CHEMICAL", 33, 41], ["SARS", "DISEASE", 85, 89], ["COVID-19", "CHEMICAL", 33, 41], ["COVID-19", "GENE_OR_GENE_PRODUCT", 33, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 85, 95], ["neurons", "CELL", 103, 110], ["ventrolateral medulla", "MULTI-TISSUE_STRUCTURE", 150, 171], ["the respiratory failure", "PROBLEM", 6, 29], ["COVID", "TEST", 33, 38], ["the invasion of SARS", "PROBLEM", 69, 89], ["CoV", "TEST", 90, 93], ["respiratory failure", "OBSERVATION", 10, 29], ["invasion", "OBSERVATION", 73, 81], ["SARS", "OBSERVATION", 85, 89], ["neurons", "ANATOMY_MODIFIER", 103, 110], ["cardiorespiratory center", "OBSERVATION", 118, 142], ["ventrolateral", "ANATOMY_MODIFIER", 150, 163], ["medulla", "ANATOMY", 164, 171]]], ["The findings described above may explain why, in some COVID-19 patients, their respiratory function can be deteriorated very quickly and patients die suddenly.Microvascular InjuriesHospitalized patients with severe COVID-19 had a prolonged prothrombin time (PT), a prolonged activated partial thromboplastin time (APTT), and elevated D-dimer [73, 127, 150, 151, 191] .", [["respiratory", "ANATOMY", 79, 90], ["Microvascular", "ANATOMY", 159, 172], ["D-dimer", "CHEMICAL", 334, 341], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 137, 145], ["Microvascular", "TISSUE", 159, 172], ["patients", "ORGANISM", 194, 202], ["prothrombin", "GENE_OR_GENE_PRODUCT", 240, 251], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 293, 307], ["prothrombin", "PROTEIN", 240, 251], ["APTT", "PROTEIN", 314, 318], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 194, 202], ["severe COVID", "PROBLEM", 208, 220], ["a prolonged prothrombin time", "PROBLEM", 228, 256], ["a prolonged activated partial thromboplastin time", "PROBLEM", 263, 312], ["APTT", "TEST", 314, 318], ["elevated D-dimer", "PROBLEM", 325, 341], ["severe", "OBSERVATION_MODIFIER", 208, 214]]], ["Among those patients, some developed disseminated intravascular coagulopathy (DIC) [19, 150, 151] .", [["intravascular", "ANATOMY", 50, 63], ["intravascular coagulopathy", "DISEASE", 50, 76], ["DIC", "DISEASE", 78, 81], ["patients", "ORGANISM", 12, 20], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 63], ["patients", "SPECIES", 12, 20], ["disseminated intravascular coagulopathy", "PROBLEM", 37, 76], ["disseminated", "OBSERVATION_MODIFIER", 37, 49], ["intravascular coagulopathy", "OBSERVATION", 50, 76]]], ["A higher D-dimer level or higher sepsisinduced coagulopathy (SIC) score was associated with the severity of or death from COVID-19 [19, 29, 150, 191] .", [["coagulopathy", "DISEASE", 47, 59], ["death", "DISEASE", 111, 116], ["COVID-19", "CHEMICAL", 122, 130], ["D-dimer", "GENE_OR_GENE_PRODUCT", 9, 16], ["D-dimer", "PROTEIN", 9, 16], ["A higher D-dimer level", "PROBLEM", 0, 22], ["higher sepsisinduced coagulopathy", "PROBLEM", 26, 59], ["death", "PROBLEM", 111, 116], ["COVID", "TEST", 122, 127], ["higher", "OBSERVATION_MODIFIER", 26, 32], ["sepsisinduced", "OBSERVATION_MODIFIER", 33, 46], ["coagulopathy", "OBSERVATION", 47, 59]]], ["The clinical picture of coagulopathy associated with COVID-19 appears to be prothrombotic, and a high prevalence (25-42%) of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), was observed in ICU patients with severe COVID-19 [29, 57, 73] .Microvascular InjuriesA multicenter prospective cohort study revealed that elevated D-dimer and fibrinogen levels at admission were present in 95% of COVID-19 patients in the ICU, and among 150 patients, 64 (42%) developed VTE including 25 cases of PE [57] .", [["venous", "ANATOMY", 125, 131], ["deep vein", "ANATOMY", 165, 174], ["pulmonary", "ANATOMY", 196, 205], ["Microvascular", "ANATOMY", 285, 298], ["coagulopathy", "DISEASE", 24, 36], ["COVID-19", "CHEMICAL", 53, 61], ["venous thromboembolism", "DISEASE", 125, 147], ["VTE", "DISEASE", 149, 152], ["deep vein thrombosis", "DISEASE", 165, 185], ["DVT", "DISEASE", 187, 190], ["pulmonary embolism", "DISEASE", 196, 214], ["PE", "DISEASE", 216, 218], ["COVID", "DISEASE", 262, 267], ["VTE", "DISEASE", 508, 511], ["PE", "DISEASE", 534, 536], ["COVID-19", "CHEMICAL", 53, 61], ["COVID-19", "CHEMICAL", 262, 270], ["venous", "MULTI-TISSUE_STRUCTURE", 125, 131], ["deep vein", "MULTI-TISSUE_STRUCTURE", 165, 174], ["pulmonary", "ORGAN", 196, 205], ["patients", "ORGANISM", 241, 249], ["Microvascular", "TISSUE", 285, 298], ["D-dimer", "GENE_OR_GENE_PRODUCT", 369, 376], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 381, 391], ["patients", "ORGANISM", 444, 452], ["patients", "ORGANISM", 479, 487], ["D-dimer", "PROTEIN", 369, 376], ["fibrinogen", "PROTEIN", 381, 391], ["patients", "SPECIES", 241, 249], ["patients", "SPECIES", 444, 452], ["patients", "SPECIES", 479, 487], ["coagulopathy", "PROBLEM", 24, 36], ["COVID", "TEST", 53, 58], ["prothrombotic", "PROBLEM", 76, 89], ["venous thromboembolism", "PROBLEM", 125, 147], ["VTE", "PROBLEM", 149, 152], ["deep vein thrombosis", "PROBLEM", 165, 185], ["DVT)", "PROBLEM", 187, 191], ["pulmonary embolism", "PROBLEM", 196, 214], ["PE", "PROBLEM", 216, 218], ["severe COVID", "PROBLEM", 255, 267], ["Microvascular InjuriesA multicenter prospective cohort study", "TEST", 285, 345], ["elevated D-dimer", "PROBLEM", 360, 376], ["fibrinogen levels", "TEST", 381, 398], ["COVID", "TEST", 435, 440], ["VTE", "PROBLEM", 508, 511], ["PE", "PROBLEM", 534, 536], ["coagulopathy", "OBSERVATION", 24, 36], ["prothrombotic", "OBSERVATION", 76, 89], ["venous", "ANATOMY", 125, 131], ["thromboembolism", "OBSERVATION", 132, 147], ["deep", "ANATOMY_MODIFIER", 165, 169], ["vein", "ANATOMY", 170, 174], ["thrombosis", "OBSERVATION", 175, 185], ["DVT", "OBSERVATION", 187, 190], ["pulmonary", "ANATOMY", 196, 205], ["embolism", "OBSERVATION", 206, 214], ["PE", "OBSERVATION", 216, 218], ["elevated", "OBSERVATION_MODIFIER", 360, 368], ["PE", "OBSERVATION", 534, 536]]], ["In addition, the study of 12 autopsy cases revealed DVT in seven of the 12 patients (58%), and PE was the direct cause of death in four patients [172] .", [["DVT", "DISEASE", 52, 55], ["PE", "DISEASE", 95, 97], ["death", "DISEASE", 122, 127], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 136, 144], ["the study", "TEST", 13, 22], ["autopsy cases", "TEST", 29, 42], ["DVT", "PROBLEM", 52, 55], ["PE", "PROBLEM", 95, 97], ["death", "PROBLEM", 122, 127], ["DVT", "OBSERVATION", 52, 55], ["PE", "OBSERVATION", 95, 97]]], ["It could be hypothesized that multi-organ injury is a result of microthrombus formation in the vital organs due to the prothrombotic state of COVID-19.", [["multi-organ", "ANATOMY", 30, 41], ["microthrombus", "ANATOMY", 64, 77], ["organs", "ANATOMY", 101, 107], ["multi-organ injury", "DISEASE", 30, 48], ["COVID-19", "CHEMICAL", 142, 150], ["multi-organ", "ORGAN", 30, 41], ["microthrombus", "CANCER", 64, 77], ["organs", "ORGAN", 101, 107], ["multi-organ injury", "PROBLEM", 30, 48], ["microthrombus formation in the vital organs", "PROBLEM", 64, 107], ["the prothrombotic state", "PROBLEM", 115, 138], ["COVID", "TEST", 142, 147], ["multi-organ", "ANATOMY", 30, 41], ["injury", "OBSERVATION", 42, 48], ["microthrombus", "OBSERVATION", 64, 77], ["prothrombotic", "OBSERVATION", 119, 132]]], ["It is uncertain whether the observed coagulopathy is caused by the virus or is secondary due to a cytokine storm.", [["coagulopathy", "DISEASE", 37, 49], ["cytokine", "PROTEIN", 98, 106], ["the observed coagulopathy", "PROBLEM", 24, 49], ["the virus", "PROBLEM", 63, 72], ["a cytokine storm", "PROBLEM", 96, 112], ["coagulopathy", "OBSERVATION", 37, 49], ["virus", "OBSERVATION", 67, 72], ["cytokine storm", "OBSERVATION", 98, 112]]], ["Early interventions such as anti-coagulant administration might be beneficial in severe COVID-19 patients [150] , but this warrants further study.Kawasaki-Like Disease-Related SARS-CoV-2 InfectionAccording to cohort studies, most children who are infected with SARS-CoV-2 appear to have mild clinical symptoms and better prognoses compared to infected adults [48, 137] .", [["COVID", "DISEASE", 88, 93], ["Kawasaki-Like Disease", "DISEASE", 146, 167], ["SARS", "DISEASE", 261, 265], ["patients", "ORGANISM", 97, 105], ["children", "ORGANISM", 230, 238], ["SARS-CoV-2", "ORGANISM", 261, 271], ["patients", "SPECIES", 97, 105], ["children", "SPECIES", 230, 238], ["SARS-CoV", "SPECIES", 261, 269], ["Early interventions", "TREATMENT", 0, 19], ["anti-coagulant administration", "TREATMENT", 28, 57], ["further study", "TEST", 132, 145], ["Kawasaki-Like Disease", "PROBLEM", 146, 167], ["Related SARS", "PROBLEM", 168, 180], ["cohort studies", "TEST", 209, 223], ["SARS", "PROBLEM", 261, 265], ["mild clinical symptoms", "PROBLEM", 287, 309]]], ["However, shortly after the spread of SARS-CoV-2 infection was detected, the increased incidence of Kawasaki disease or Kawasaki-like disease was documented in western countries [55, 129, 161] .", [["SARS-CoV-2 infection", "DISEASE", 37, 57], ["Kawasaki disease", "DISEASE", 99, 115], ["Kawasaki-like disease", "DISEASE", 119, 140], ["SARS-CoV-2", "ORGANISM", 37, 47], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "PROBLEM", 37, 41], ["CoV-2 infection", "PROBLEM", 42, 57], ["Kawasaki disease", "PROBLEM", 99, 115], ["Kawasaki-like disease", "PROBLEM", 119, 140], ["infection", "OBSERVATION", 48, 57], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["Kawasaki disease", "OBSERVATION", 99, 115]]], ["Eight of the ten pediatric patients identified had an antibody against SARS-CoV-2 [161] .", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["an antibody", "TEST", 51, 62], ["SARS", "TEST", 71, 75], ["CoV", "TEST", 76, 79]]], ["Children diagnosed after the SARS-CoV-2 epidemic was identified were older and had a higher rate of cardiac dysfunction, and they showed features of macrophage activation syndrome (MAS), called \"Kawasaki-like disease\" [161] .", [["cardiac", "ANATOMY", 100, 107], ["macrophage", "ANATOMY", 149, 159], ["SARS", "DISEASE", 29, 33], ["cardiac dysfunction", "DISEASE", 100, 119], ["MAS", "DISEASE", 181, 184], ["Kawasaki-like disease", "DISEASE", 195, 216], ["Children", "ORGANISM", 0, 8], ["cardiac", "ORGAN", 100, 107], ["macrophage", "CELL", 149, 159], ["Children", "SPECIES", 0, 8], ["the SARS", "PROBLEM", 25, 33], ["cardiac dysfunction", "PROBLEM", 100, 119], ["macrophage activation syndrome", "PROBLEM", 149, 179], ["cardiac", "ANATOMY", 100, 107], ["dysfunction", "OBSERVATION", 108, 119], ["macrophage activation syndrome", "OBSERVATION", 149, 179]]], ["The MAS criteria are validated for systemic juvenile idiopathic arthritis, but they are commonly used for other systemic auto-inflammatory diseases such as Kawasaki disease [41] .", [["juvenile idiopathic arthritis", "DISEASE", 44, 73], ["Kawasaki disease", "DISEASE", 156, 172], ["systemic juvenile idiopathic arthritis", "PROBLEM", 35, 73], ["other systemic auto-inflammatory diseases", "PROBLEM", 106, 147], ["Kawasaki disease", "PROBLEM", 156, 172], ["systemic", "OBSERVATION_MODIFIER", 35, 43], ["juvenile", "OBSERVATION_MODIFIER", 44, 52], ["idiopathic", "OBSERVATION_MODIFIER", 53, 63], ["arthritis", "OBSERVATION", 64, 73], ["inflammatory", "OBSERVATION", 126, 138]]], ["MAS is a form of cytokine storm in which clinical features (i.e., high fever, lymphopenia, and high levels of transaminase, lactate dehydrogenase, D-dimer, and ferritin) are shared with severe COVID-19.", [["MAS", "DISEASE", 0, 3], ["fever", "DISEASE", 71, 76], ["lymphopenia", "DISEASE", 78, 89], ["lactate", "CHEMICAL", 124, 131], ["lactate", "CHEMICAL", 124, 131], ["COVID-19", "CHEMICAL", 193, 201], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 124, 145], ["D-dimer", "GENE_OR_GENE_PRODUCT", 147, 154], ["ferritin", "GENE_OR_GENE_PRODUCT", 160, 168], ["cytokine", "PROTEIN", 17, 25], ["transaminase", "PROTEIN", 110, 122], ["lactate dehydrogenase", "PROTEIN", 124, 145], ["D-dimer", "PROTEIN", 147, 154], ["ferritin", "PROTEIN", 160, 168], ["cytokine storm", "PROBLEM", 17, 31], ["high fever", "PROBLEM", 66, 76], ["lymphopenia", "PROBLEM", 78, 89], ["high levels of transaminase", "PROBLEM", 95, 122], ["lactate dehydrogenase", "TEST", 124, 145], ["D-dimer", "TEST", 147, 154], ["ferritin", "TEST", 160, 168], ["severe COVID", "PROBLEM", 186, 198], ["lymphopenia", "OBSERVATION", 78, 89], ["severe", "OBSERVATION_MODIFIER", 186, 192]]], ["Patients diagnosed with Kawasaki-like disease after the beginning of the SARS-CoV-2 epidemic showed a severe phenotype and required early interventions including steroid treatment [161] and intravenous immunoglobulin [55] .Multi-organ Dysfunction/Injury and OutcomesClinical observational studies revealed that the organ injuries discussed above are associated with death due to COVID-19.", [["intravenous", "ANATOMY", 190, 201], ["Multi-organ", "ANATOMY", 223, 234], ["organ", "ANATOMY", 315, 320], ["Kawasaki-like disease", "DISEASE", 24, 45], ["SARS", "DISEASE", 73, 77], ["steroid", "CHEMICAL", 162, 169], ["Multi-organ Dysfunction", "DISEASE", 223, 246], ["organ injuries", "DISEASE", 315, 329], ["death", "DISEASE", 366, 371], ["steroid", "CHEMICAL", 162, 169], ["COVID-19", "CHEMICAL", 379, 387], ["Patients", "ORGANISM", 0, 8], ["steroid", "SIMPLE_CHEMICAL", 162, 169], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 190, 201], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 202, 216], ["organ", "ORGAN", 315, 320], ["Patients", "SPECIES", 0, 8], ["Kawasaki-like disease", "PROBLEM", 24, 45], ["the SARS", "TEST", 69, 77], ["CoV", "TEST", 78, 81], ["a severe phenotype", "PROBLEM", 100, 118], ["early interventions", "TREATMENT", 132, 151], ["steroid treatment", "TREATMENT", 162, 179], ["intravenous immunoglobulin", "TREATMENT", 190, 216], ["Multi-organ Dysfunction", "PROBLEM", 223, 246], ["Injury", "PROBLEM", 247, 253], ["OutcomesClinical observational studies", "TEST", 258, 296], ["the organ injuries", "PROBLEM", 311, 329], ["death", "PROBLEM", 366, 371], ["COVID", "TEST", 379, 384], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["Dysfunction", "OBSERVATION", 235, 246], ["Injury", "OBSERVATION", 247, 253]]], ["The reported prevalence of the injuries among patients with COVID-19 include ARDS (81-100%) [19, 183, 191, 197] , cardiac injury (28-77%) [19, 183, 191, 197] , AKI (38-50%) [183, 191, 197] , liver dysfunction (25-28%) [183, 197] , coagulopathy (50-71%) [151, 191] , hypoxic encephalopathy (20%) [19] , and gastrointestinal hemorrhage (6-8%) [183, 197] .", [["cardiac", "ANATOMY", 114, 121], ["liver", "ANATOMY", 191, 196], ["gastrointestinal", "ANATOMY", 306, 322], ["injuries", "DISEASE", 31, 39], ["ARDS", "DISEASE", 77, 81], ["cardiac injury", "DISEASE", 114, 128], ["AKI", "DISEASE", 160, 163], ["liver dysfunction", "DISEASE", 191, 208], ["coagulopathy", "DISEASE", 231, 243], ["encephalopathy", "DISEASE", 274, 288], ["gastrointestinal hemorrhage", "DISEASE", 306, 333], ["patients", "ORGANISM", 46, 54], ["cardiac", "ORGAN", 114, 121], ["liver", "ORGAN", 191, 196], ["gastrointestinal", "ORGAN", 306, 322], ["patients", "SPECIES", 46, 54], ["the injuries", "PROBLEM", 27, 39], ["COVID", "TEST", 60, 65], ["ARDS", "PROBLEM", 77, 81], ["cardiac injury", "TEST", 114, 128], ["AKI", "TEST", 160, 163], ["liver dysfunction", "TEST", 191, 208], ["coagulopathy", "TEST", 231, 243], ["hypoxic encephalopathy", "PROBLEM", 266, 288], ["gastrointestinal hemorrhage", "PROBLEM", 306, 333], ["injuries", "OBSERVATION", 31, 39], ["cardiac", "ANATOMY", 114, 121], ["injury", "OBSERVATION", 122, 128], ["liver", "ANATOMY", 191, 196], ["dysfunction", "OBSERVATION", 197, 208], ["hypoxic", "OBSERVATION_MODIFIER", 266, 273], ["encephalopathy", "OBSERVATION", 274, 288], ["gastrointestinal", "ANATOMY", 306, 322], ["hemorrhage", "OBSERVATION", 323, 333]]], ["The incidence of organ injury in the non-surviving patients was significantly higher than that in the surviving patients [19, 151, 183, 191, 197] .", [["organ", "ANATOMY", 17, 22], ["organ injury", "DISEASE", 17, 29], ["organ", "ORGAN", 17, 22], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 112, 120], ["organ injury", "PROBLEM", 17, 29], ["organ", "ANATOMY", 17, 22], ["injury", "OBSERVATION", 23, 29], ["higher", "OBSERVATION_MODIFIER", 78, 84]]], ["These organ injuries were independent predictors of death from COVID-19 [21, 139] (Fig. 4) .FUTURE PERSPECTIVES ON THERAPEUTICS AND ONGOING STUDIESThe Evidence About COVID-19 TreatmentFUTURE PERSPECTIVES ON THERAPEUTICS AND ONGOING STUDIESAs of the end of May 2020, almost 500 interventional studies were ongoing or planned across the world.", [["organ", "ANATOMY", 6, 11], ["organ injuries", "DISEASE", 6, 20], ["death", "DISEASE", 52, 57], ["COVID-19", "CHEMICAL", 63, 71], ["organ", "ORGAN", 6, 11], ["These organ injuries", "PROBLEM", 0, 20], ["death", "PROBLEM", 52, 57], ["COVID", "TEST", 63, 68], ["COVID", "TEST", 166, 171], ["interventional studies", "TEST", 277, 299], ["organ", "ANATOMY", 6, 11], ["injuries", "OBSERVATION", 12, 20]]], ["There is only one double-blinded, full-powered randomized trial (RCT) about COVDI-19 treatment that has been completed and published: four clinical trials of remdesivir, and one controlled prospective study and four controlled clinical trials of chloroquine.", [["COVDI-19", "CHEMICAL", 76, 84], ["remdesivir", "CHEMICAL", 158, 168], ["chloroquine", "CHEMICAL", 246, 257], ["COVDI-19", "CHEMICAL", 76, 84], ["remdesivir", "CHEMICAL", 158, 168], ["chloroquine", "CHEMICAL", 246, 257], ["remdesivir", "SIMPLE_CHEMICAL", 158, 168], ["chloroquine", "SIMPLE_CHEMICAL", 246, 257], ["COVDI-19 treatment", "TREATMENT", 76, 94], ["remdesivir", "TREATMENT", 158, 168], ["prospective study", "TEST", 189, 206], ["chloroquine", "TREATMENT", 246, 257], ["one", "OBSERVATION_MODIFIER", 14, 17], ["double", "OBSERVATION_MODIFIER", 18, 24]]], ["The US Food and Drug Administration (FDA) has not approved any drugs for COVID-19 treatment as of this writing.", [["COVID-19", "CHEMICAL", 73, 81], ["Drug Administration (FDA", "TREATMENT", 16, 40], ["any drugs", "TREATMENT", 59, 68], ["COVID-19 treatment", "TREATMENT", 73, 91]]], ["There are also no US National Institutes of Health (NIH) treatment guidelines, due to the insufficient amount of clinical data that are necessary to determine a drug's efficacy and safety.FUTURE PERSPECTIVES ON THERAPEUTICS AND ONGOING STUDIESRemdesivir, a viral RNA polymerase inhibitor, has been reported to inhibit SARS-CoV-2 polyproteolysis in vitro [191] and was administered as compassionate use in a case series [47] with clinical improvements.", [["treatment guidelines", "TREATMENT", 57, 77], ["ONGOING STUDIESRemdesivir", "TREATMENT", 228, 253], ["a viral RNA polymerase inhibitor", "TREATMENT", 255, 287], ["SARS", "PROBLEM", 318, 322], ["CoV", "TEST", 323, 326], ["no", "UNCERTAINTY", 15, 17]]], ["Four clinical trials of remdesivir were completed or the trials' preliminary results were reported.", [["remdesivir", "CHEMICAL", 24, 34], ["remdesivir", "CHEMICAL", 24, 34], ["remdesivir", "SIMPLE_CHEMICAL", 24, 34], ["remdesivir", "TREATMENT", 24, 34]]], ["The only double-blinded full-powered RCT to date is the Adaptive COVID-19 Treatment Trial (ACTT trial, n = 1063 patients, NCT04280705), which has shown that remdesivir accelerated recovery compared to the placebo (11 days vs. 15 days, p < 0.001, [6] ) with a tentative finding of a lower mortality rate (8.0% vs. 11.6%, p = 0.059, press release).", [["remdesivir", "CHEMICAL", 157, 167], ["remdesivir", "CHEMICAL", 157, 167], ["patients", "ORGANISM", 112, 120], ["remdesivir", "SIMPLE_CHEMICAL", 157, 167], ["patients", "SPECIES", 112, 120], ["the Adaptive COVID", "TREATMENT", 52, 70], ["Treatment Trial (ACTT trial", "TREATMENT", 74, 101], ["a lower mortality rate", "TEST", 280, 302]]], ["The subgroup analysis and the further outcome analysis with a larger patient number will be published eventually.FUTURE PERSPECTIVES ON THERAPEUTICS AND ONGOING STUDIESA comparison of remdesivir treatment (n = 155) and placebo (n = 78) for COVID-19 patients in China [21] (NCT04257656) was initiated for patients who exhibited severe disease within 14 days after symptom onset, but this double-blind placebo-controlled RCT was terminated early because there was no difference in clinical improvement between the remdesivir and placebo: hazard ratio (HR) 1.23, 95% confidence interval (CI), 0.87-1.75.", [["remdesivir", "CHEMICAL", 184, 194], ["remdesivir", "CHEMICAL", 512, 522], ["remdesivir", "CHEMICAL", 184, 194], ["remdesivir", "CHEMICAL", 512, 522], ["patient", "ORGANISM", 69, 76], ["remdesivir", "SIMPLE_CHEMICAL", 184, 194], ["patients", "ORGANISM", 249, 257], ["patients", "ORGANISM", 304, 312], ["patient", "SPECIES", 69, 76], ["patients", "SPECIES", 249, 257], ["patients", "SPECIES", 304, 312], ["The subgroup analysis", "TEST", 0, 21], ["the further outcome analysis", "TEST", 26, 54], ["remdesivir treatment", "TREATMENT", 184, 204], ["COVID", "TEST", 240, 245], ["severe disease", "PROBLEM", 327, 341], ["symptom onset", "PROBLEM", 363, 376], ["HR", "TEST", 550, 552], ["CI", "TEST", 585, 587], ["severe", "OBSERVATION_MODIFIER", 327, 333], ["disease", "OBSERVATION", 334, 341]]], ["Two SIMPLE trials conducted by the biopharmaceutical company Gilead (severe patients in NCT04292899 and moderate patients in NCT04292730) compared the clinical outcomes on day 14 between 5-day (n = 200) and 10-day (n = 197) remdesivir treatment starting within 4 days after the diagnosis among moderate or severe COVID-19 patients.", [["Gilead", "CHEMICAL", 61, 67], ["remdesivir", "CHEMICAL", 224, 234], ["COVID", "DISEASE", 313, 318], ["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 322, 330], ["remdesivir treatment", "TREATMENT", 224, 244], ["moderate or severe COVID", "PROBLEM", 294, 318], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["moderate", "OBSERVATION_MODIFIER", 104, 112]]], ["The primary results showed no significant difference in outcomes or adverse events overall [46] .", [["significant difference in outcomes", "PROBLEM", 30, 64], ["adverse events", "PROBLEM", 68, 82], ["no", "UNCERTAINTY", 27, 29], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["difference", "OBSERVATION", 42, 52]]], ["These trials are planning to recruit 6000 severe patients and 1600 moderate patients to be completed.FUTURE PERSPECTIVES ON THERAPEUTICS AND ONGOING STUDIESLopinavir-ritonavir (L/R) is a human immunodeficiency virus (HIV) protease inhibitor.", [["STUDIESLopinavir-ritonavir", "CHEMICAL", 149, 175], ["L/R", "CHEMICAL", 177, 180], ["human immunodeficiency virus (HIV)", "DISEASE", 187, 221], ["ritonavir", "CHEMICAL", 166, 175], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 76, 84], ["ritonavir", "SIMPLE_CHEMICAL", 166, 175], ["L/R", "SIMPLE_CHEMICAL", 177, 180], ["human immunodeficiency virus", "ORGANISM", 187, 215], ["HIV", "ORGANISM", 217, 220], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 76, 84], ["human immunodeficiency virus (HIV", "SPECIES", 187, 220], ["human immunodeficiency virus", "SPECIES", 187, 215], ["HIV", "SPECIES", 217, 220], ["THERAPEUTICS", "TREATMENT", 124, 136], ["STUDIESLopinavir", "TEST", 149, 165], ["ritonavir (L/R)", "TREATMENT", 166, 181], ["a human immunodeficiency virus (HIV) protease inhibitor", "TREATMENT", 185, 240]]], ["There is currently no large RCT testing the benefit and safety of L/R for COVID-19 patients.", [["L/R", "GENE_OR_GENE_PRODUCT", 66, 69], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["large RCT testing", "TEST", 22, 39], ["COVID", "TEST", 74, 79], ["no", "UNCERTAINTY", 19, 21], ["large", "OBSERVATION_MODIFIER", 22, 27], ["RCT", "OBSERVATION", 28, 31]]], ["The latest open-label RCT with 199 severe patients revealed that compared to the control group, treatment with lopinavir (400 mg) and ritonavir (100 mg) did not boost the patients' symptom recovery (HR 1.24, 95% CI 0.90-1.72) or their outcomes (mortality at day 28, L/R 19.2% vs. control 25%, 95% CI \u2212 17.3-5.7) [17] .Ongoing Clinical Trials Targeting ACE2Endocytosis Inhibition: Chloroquine Chloroquine (CQ) is a classic antimalarial and a potential antiviral agent [135] .", [["lopinavir", "CHEMICAL", 111, 120], ["ritonavir", "CHEMICAL", 134, 143], ["Chloroquine", "CHEMICAL", 380, 391], ["Chloroquine", "CHEMICAL", 392, 403], ["CQ", "CHEMICAL", 405, 407], ["lopinavir", "CHEMICAL", 111, 120], ["ritonavir", "CHEMICAL", 134, 143], ["Chloroquine", "CHEMICAL", 380, 391], ["Chloroquine", "CHEMICAL", 392, 403], ["CQ", "CHEMICAL", 405, 407], ["patients", "ORGANISM", 42, 50], ["lopinavir", "SIMPLE_CHEMICAL", 111, 120], ["ritonavir", "SIMPLE_CHEMICAL", 134, 143], ["patients", "ORGANISM", 171, 179], ["Chloroquine Chloroquine", "SIMPLE_CHEMICAL", 380, 403], ["CQ", "SIMPLE_CHEMICAL", 405, 407], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 171, 179], ["The latest open-label RCT", "TEST", 0, 25], ["lopinavir", "TREATMENT", 111, 120], ["ritonavir", "TREATMENT", 134, 143], ["HR", "TEST", 199, 201], ["CI", "TEST", 212, 214], ["L/R", "TEST", 266, 269], ["CI", "TEST", 297, 299], ["ACE2Endocytosis Inhibition", "TREATMENT", 352, 378], ["Chloroquine Chloroquine (CQ)", "TREATMENT", 380, 408], ["a classic antimalarial", "TREATMENT", 412, 434], ["a potential antiviral agent", "TREATMENT", 439, 466]]], ["In vitro, chloroquine effectively inhibited SARS-CoV-2 entry into cells (EC50 = 1.13 \u03bcM) [191] , possibly by binding to the host respiratory cells, which would inhibit the attachment of the virus S1 protein to the host ACE2 on the host cells [36] .", [["cells", "ANATOMY", 66, 71], ["respiratory cells", "ANATOMY", 129, 146], ["cells", "ANATOMY", 236, 241], ["chloroquine", "CHEMICAL", 10, 21], ["chloroquine", "CHEMICAL", 10, 21], ["chloroquine", "SIMPLE_CHEMICAL", 10, 21], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["cells", "CELL", 66, 71], ["respiratory cells", "CELL", 129, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 219, 223], ["cells", "CELL", 236, 241], ["host respiratory cells", "CELL_TYPE", 124, 146], ["virus S1 protein", "PROTEIN", 190, 206], ["ACE2", "PROTEIN", 219, 223], ["host cells", "CELL_TYPE", 231, 241], ["SARS-CoV", "SPECIES", 44, 52], ["chloroquine", "TREATMENT", 10, 21], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["EC50", "TEST", 73, 77], ["respiratory cells", "OBSERVATION", 129, 146]]], ["Five placebo-controlled clinical studies have described the outcomes of chloroquine treatment for COVID-19 patients.Ongoing Clinical Trials Targeting ACE2A recent large placebo-controlled RCT with 14,888 COVID-19 patients indicated that hydroxychloroquine (HCQ) or CQ or in combination with a macrolide was related to worse in-hospital mortality [96] .", [["chloroquine", "CHEMICAL", 72, 83], ["COVID", "DISEASE", 98, 103], ["hydroxychloroquine", "CHEMICAL", 237, 255], ["HCQ", "CHEMICAL", 257, 260], ["CQ", "CHEMICAL", 265, 267], ["macrolide", "CHEMICAL", 293, 302], ["chloroquine", "CHEMICAL", 72, 83], ["hydroxychloroquine", "CHEMICAL", 237, 255], ["HCQ", "CHEMICAL", 257, 260], ["CQ", "CHEMICAL", 265, 267], ["macrolide", "CHEMICAL", 293, 302], ["chloroquine", "SIMPLE_CHEMICAL", 72, 83], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 213, 221], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 237, 255], ["HCQ", "SIMPLE_CHEMICAL", 257, 260], ["CQ", "SIMPLE_CHEMICAL", 265, 267], ["macrolide", "SIMPLE_CHEMICAL", 293, 302], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 213, 221], ["Five placebo", "TREATMENT", 0, 12], ["clinical studies", "TEST", 24, 40], ["chloroquine treatment", "TREATMENT", 72, 93], ["COVID", "TEST", 98, 103], ["ACE2A recent large placebo", "TREATMENT", 150, 176], ["COVID", "TEST", 204, 209], ["hydroxychloroquine (HCQ)", "TREATMENT", 237, 261], ["CQ", "TREATMENT", 265, 267], ["a macrolide", "TREATMENT", 291, 302], ["large", "OBSERVATION_MODIFIER", 163, 168]]], ["In that RCT, 1868 patients received CQ alone, 3783 patients received CQ with a macrolide, 3016 patients received HCQ alone, and 6221 patients received HCQ with a macrolide; 81,144 patients served as the control group.", [["CQ", "CHEMICAL", 36, 38], ["CQ", "CHEMICAL", 69, 71], ["macrolide", "CHEMICAL", 79, 88], ["HCQ", "CHEMICAL", 113, 116], ["HCQ", "CHEMICAL", 151, 154], ["macrolide", "CHEMICAL", 162, 171], ["macrolide", "CHEMICAL", 79, 88], ["HCQ", "CHEMICAL", 113, 116], ["HCQ", "CHEMICAL", 151, 154], ["macrolide", "CHEMICAL", 162, 171], ["patients", "ORGANISM", 18, 26], ["CQ", "SIMPLE_CHEMICAL", 36, 38], ["patients", "ORGANISM", 51, 59], ["CQ", "SIMPLE_CHEMICAL", 69, 71], ["macrolide", "SIMPLE_CHEMICAL", 79, 88], ["patients", "ORGANISM", 95, 103], ["HCQ", "SIMPLE_CHEMICAL", 113, 116], ["patients", "ORGANISM", 133, 141], ["HCQ", "SIMPLE_CHEMICAL", 151, 154], ["macrolide", "SIMPLE_CHEMICAL", 162, 171], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 180, 188], ["a macrolide", "TREATMENT", 77, 88], ["HCQ", "TREATMENT", 113, 116], ["HCQ", "TREATMENT", 151, 154], ["a macrolide", "TREATMENT", 160, 171]]], ["The in-hospital mortality rates were higher in each treated group compared to the control after the cross-matching of the confounding factors: in-hospital mortality, control 9.3%; HCQ 18.0% (HR 1.335, 95% CI 1.223-1.457); HCQ + macrolide Organ dysfunction includes both direct cytotoxic effects of SARS-CoV-2 itself and cytokine-mediated damage.", [["HCQ", "CHEMICAL", 180, 183], ["HCQ", "CHEMICAL", 222, 225], ["macrolide", "CHEMICAL", 228, 237], ["Organ dysfunction", "DISEASE", 238, 255], ["SARS", "DISEASE", 298, 302], ["HCQ", "CHEMICAL", 180, 183], ["HCQ", "CHEMICAL", 222, 225], ["macrolide", "CHEMICAL", 228, 237], ["HCQ", "SIMPLE_CHEMICAL", 222, 225], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 298, 308], ["cytokine", "PROTEIN", 320, 328], ["HCQ", "TEST", 180, 183], ["HR", "TEST", 191, 193], ["CI", "TEST", 205, 207], ["HCQ", "TEST", 222, 225], ["macrolide Organ dysfunction", "PROBLEM", 228, 255], ["SARS", "PROBLEM", 298, 302], ["CoV", "TEST", 303, 306], ["cytokine-mediated damage", "PROBLEM", 320, 344], ["macrolide Organ dysfunction", "OBSERVATION", 228, 255], ["cytotoxic effects", "OBSERVATION", 277, 294], ["damage", "OBSERVATION", 338, 344]]], ["ACE2 was observed to be expressed in several types of tissue (including vessel endothelial and smooth muscle) and vital organs (lung, heart, intestine, brain, kidney, liver, etc.).", [["tissue", "ANATOMY", 54, 60], ["vessel endothelial", "ANATOMY", 72, 90], ["smooth muscle", "ANATOMY", 95, 108], ["organs", "ANATOMY", 120, 126], ["lung", "ANATOMY", 128, 132], ["heart", "ANATOMY", 134, 139], ["intestine", "ANATOMY", 141, 150], ["brain", "ANATOMY", 152, 157], ["kidney", "ANATOMY", 159, 165], ["liver", "ANATOMY", 167, 172], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissue", "TISSUE", 54, 60], ["vessel endothelial", "TISSUE", 72, 90], ["smooth muscle", "TISSUE", 95, 108], ["organs", "ORGAN", 120, 126], ["lung", "ORGAN", 128, 132], ["heart", "ORGAN", 134, 139], ["intestine", "ORGAN", 141, 150], ["brain", "ORGAN", 152, 157], ["kidney", "ORGAN", 159, 165], ["liver", "ORGAN", 167, 172], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["vital organs (lung, heart, intestine, brain, kidney, liver", "PROBLEM", 114, 172], ["vessel", "ANATOMY", 72, 78], ["endothelial", "ANATOMY_MODIFIER", 79, 90], ["smooth muscle", "ANATOMY", 95, 108], ["lung", "ANATOMY", 128, 132], ["heart", "ANATOMY", 134, 139], ["intestine", "ANATOMY", 141, 150], ["brain", "ANATOMY", 152, 157], ["kidney", "ANATOMY", 159, 165], ["liver", "ANATOMY", 167, 172]]], ["The SARS-CoV-2 enters the host cells by binding to ACE2 and then directly damages the target organ.", [["cells", "ANATOMY", 31, 36], ["organ", "ANATOMY", 93, 98], ["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["host cells", "CELL", 26, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["organ", "ORGAN", 93, 98], ["ACE2", "PROTEIN", 51, 55], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["ACE2", "TEST", 51, 55]]], ["SARS-CoV-2 infection induces a release of proinflammatory cytokines (TNF\u03b1, IL-6 and others), resulting in injury to the target organ.", [["organ", "ANATOMY", 127, 132], ["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["injury to the target organ", "DISEASE", 106, 132], ["SARS-CoV-2", "ORGANISM", 0, 10], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 69, 73], ["IL-6", "GENE_OR_GENE_PRODUCT", 75, 79], ["organ", "ORGAN", 127, 132], ["proinflammatory cytokines", "PROTEIN", 42, 67], ["TNF\u03b1", "PROTEIN", 69, 73], ["IL-6", "PROTEIN", 75, 79], ["SARS-CoV-2", "SPECIES", 0, 10], ["SARS", "PROBLEM", 0, 4], ["CoV-2 infection", "PROBLEM", 5, 20], ["proinflammatory cytokines", "TEST", 42, 67], ["TNF", "TEST", 69, 72], ["IL", "TEST", 75, 77], ["injury", "PROBLEM", 106, 112], ["infection", "OBSERVATION", 11, 20], ["injury", "OBSERVATION", 106, 112]]], ["ACS, acute coronary syndrome; ARDS, acute respiratory distress syndrome; BUN, blood urea nitrogen; CCL2, chemokine ligand 2; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; hsTnI, high sensitive troponin I; IFN\u03b3, interferon gamma; KDSS, Kawasaki disease shock syndrome; MAS, macrophage activation syndrome; MCP-1, monocyte chemoattractant protein 1; NT-ProBNP, N-terminal-pro hormone B-type natriuretic peptide; PAH, pulmonary artery hypertension; PE, pulmonary embolism; TnT, troponin T; VTE, venous thromboembolism.", [["coronary", "ANATOMY", 11, 19], ["blood", "ANATOMY", 78, 83], ["intravascular", "ANATOMY", 143, 156], ["deep vein", "ANATOMY", 175, 184], ["pulmonary artery", "ANATOMY", 441, 457], ["pulmonary", "ANATOMY", 476, 485], ["venous", "ANATOMY", 518, 524], ["ACS", "DISEASE", 0, 3], ["acute coronary syndrome", "DISEASE", 5, 28], ["ARDS", "DISEASE", 30, 34], ["acute respiratory distress syndrome", "DISEASE", 36, 71], ["blood urea nitrogen", "CHEMICAL", 78, 97], ["DIC", "DISEASE", 125, 128], ["disseminated intravascular coagulation", "DISEASE", 130, 168], ["DVT", "DISEASE", 170, 173], ["deep vein thrombosis", "DISEASE", 175, 195], ["Kawasaki disease shock syndrome", "DISEASE", 261, 292], ["PAH", "CHEMICAL", 436, 439], ["pulmonary artery hypertension", "DISEASE", 441, 470], ["PE", "DISEASE", 472, 474], ["pulmonary embolism", "DISEASE", 476, 494], ["VTE", "DISEASE", 513, 516], ["venous thromboembolism", "DISEASE", 518, 540], ["urea", "CHEMICAL", 84, 88], ["nitrogen", "CHEMICAL", 89, 97], ["N", "CHEMICAL", 385, 386], ["PAH", "CHEMICAL", 436, 439], ["coronary", "MULTI-TISSUE_STRUCTURE", 11, 19], ["BUN", "SIMPLE_CHEMICAL", 73, 76], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["urea nitrogen", "SIMPLE_CHEMICAL", 84, 97], ["CCL2", "GENE_OR_GENE_PRODUCT", 99, 103], ["chemokine ligand 2", "GENE_OR_GENE_PRODUCT", 105, 123], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 143, 156], ["vein", "MULTI-TISSUE_STRUCTURE", 180, 184], ["hsTnI", "GENE_OR_GENE_PRODUCT", 197, 202], ["high sensitive troponin I", "GENE_OR_GENE_PRODUCT", 204, 229], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 231, 235], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 237, 253], ["macrophage", "CELL", 299, 309], ["MCP-1", "GENE_OR_GENE_PRODUCT", 331, 336], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 338, 372], ["NT-ProBNP", "GENE_OR_GENE_PRODUCT", 374, 383], ["B-type natriuretic peptide", "GENE_OR_GENE_PRODUCT", 408, 434], ["PAH", "SIMPLE_CHEMICAL", 436, 439], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 441, 457], ["pulmonary", "ORGAN", 476, 485], ["TnT", "GENE_OR_GENE_PRODUCT", 496, 499], ["troponin T", "GENE_OR_GENE_PRODUCT", 501, 511], ["venous", "MULTI-TISSUE_STRUCTURE", 518, 524], ["CCL2", "PROTEIN", 99, 103], ["chemokine ligand 2", "PROTEIN", 105, 123], ["troponin I", "PROTEIN", 219, 229], ["IFN\u03b3", "PROTEIN", 231, 235], ["interferon gamma", "PROTEIN", 237, 253], ["MCP", "PROTEIN", 331, 334], ["monocyte chemoattractant protein 1", "PROTEIN", 338, 372], ["TnT", "PROTEIN", 496, 499], ["ACS", "PROBLEM", 0, 3], ["acute coronary syndrome", "PROBLEM", 5, 28], ["ARDS", "PROBLEM", 30, 34], ["acute respiratory distress syndrome", "PROBLEM", 36, 71], ["BUN", "TEST", 73, 76], ["blood urea nitrogen", "TEST", 78, 97], ["CCL2", "TEST", 99, 103], ["chemokine ligand", "TEST", 105, 121], ["DIC", "PROBLEM", 125, 128], ["disseminated intravascular coagulation", "PROBLEM", 130, 168], ["DVT", "PROBLEM", 170, 173], ["deep vein thrombosis", "PROBLEM", 175, 195], ["hsTnI", "PROBLEM", 197, 202], ["high sensitive troponin I", "PROBLEM", 204, 229], ["interferon gamma", "TREATMENT", 237, 253], ["KDSS", "PROBLEM", 255, 259], ["Kawasaki disease shock syndrome", "PROBLEM", 261, 292], ["MAS", "PROBLEM", 294, 297], ["macrophage activation syndrome", "PROBLEM", 299, 329], ["MCP", "TEST", 331, 334], ["monocyte chemoattractant protein", "TEST", 338, 370], ["NT", "TEST", 374, 376], ["ProBNP", "TEST", 377, 383], ["N", "TEST", 385, 386], ["terminal", "TEST", 387, 395], ["type natriuretic peptide", "PROBLEM", 410, 434], ["PAH", "PROBLEM", 436, 439], ["pulmonary artery hypertension", "PROBLEM", 441, 470], ["PE", "PROBLEM", 472, 474], ["pulmonary embolism", "PROBLEM", 476, 494], ["TnT", "PROBLEM", 496, 499], ["troponin T", "TEST", 501, 511], ["VTE", "PROBLEM", 513, 516], ["venous thromboembolism", "PROBLEM", 518, 540], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["coronary", "ANATOMY", 11, 19], ["syndrome", "OBSERVATION", 20, 28], ["ARDS", "OBSERVATION", 30, 34], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["respiratory distress", "OBSERVATION", 42, 62], ["disseminated", "OBSERVATION_MODIFIER", 130, 142], ["intravascular coagulation", "OBSERVATION", 143, 168], ["DVT", "OBSERVATION", 170, 173], ["deep", "ANATOMY_MODIFIER", 175, 179], ["vein", "ANATOMY", 180, 184], ["thrombosis", "OBSERVATION", 185, 195], ["shock syndrome", "OBSERVATION", 278, 292], ["PAH", "OBSERVATION", 436, 439], ["pulmonary artery", "ANATOMY", 441, 457], ["hypertension", "OBSERVATION", 458, 470], ["PE", "OBSERVATION", 472, 474], ["pulmonary", "ANATOMY", 476, 485], ["embolism", "OBSERVATION", 486, 494], ["venous", "ANATOMY", 518, 524], ["thromboembolism", "OBSERVATION", 525, 540]]], ["A small study of 62 patients in China indicated that CQ 400 mg/day might improve pneumonia in mild-moderate COVID-19, but a significant difference was not observed (ChiCTR2000029559) [172] .", [["CQ", "CHEMICAL", 53, 55], ["pneumonia", "DISEASE", 81, 90], ["ChiCTR2000029559", "CHEMICAL", 165, 181], ["patients", "ORGANISM", 20, 28], ["CQ", "SIMPLE_CHEMICAL", 53, 55], ["patients", "SPECIES", 20, 28], ["A small study", "TEST", 0, 13], ["CQ", "TREATMENT", 53, 55], ["pneumonia", "PROBLEM", 81, 90], ["mild-moderate COVID", "PROBLEM", 94, 113], ["small", "OBSERVATION_MODIFIER", 2, 7], ["pneumonia", "OBSERVATION", 81, 90], ["mild", "OBSERVATION_MODIFIER", 94, 98], ["moderate", "OBSERVATION_MODIFIER", 99, 107], ["significant", "OBSERVATION_MODIFIER", 124, 135]]], ["Another small controlled prospective study showed that compared to the control group (n = 20), HCQ (600 mg/day, n = 16) improved the virus conversion at day 3 and later (control vs. HCQ, 6% vs. 50%, p = 0.005) [42] .Ongoing Clinical Trials Targeting ACE2Cytokine Storm Blockades: Anti-TMPRSS2, Recombinant Human ACE2, ARB/ACE Inhibitors, JAK-STAT Inhibitor, Akt Pathway Inhibitor, and Anti-IL-6Ongoing Clinical Trials Targeting ACE2As described above, virus infection via the host ACE2 induces the release of IL-6 via AT1Rs and the JAK-STAT and Akt pathways, leading to the amplification of the virus.", [["HCQ", "CHEMICAL", 95, 98], ["HCQ", "CHEMICAL", 182, 185], ["ARB", "CHEMICAL", 318, 321], ["infection", "DISEASE", 458, 467], ["HCQ", "CHEMICAL", 95, 98], ["HCQ", "CHEMICAL", 182, 185], ["HCQ", "SIMPLE_CHEMICAL", 95, 98], ["ACE2Cytokine Storm Blockades", "SIMPLE_CHEMICAL", 250, 278], ["Anti-TMPRSS2", "SIMPLE_CHEMICAL", 280, 292], ["Human", "ORGANISM", 306, 311], ["ACE2", "GENE_OR_GENE_PRODUCT", 312, 316], ["ARB", "GENE_OR_GENE_PRODUCT", 318, 321], ["ACE", "GENE_OR_GENE_PRODUCT", 322, 325], ["JAK-STAT", "GENE_OR_GENE_PRODUCT", 338, 346], ["Akt", "GENE_OR_GENE_PRODUCT", 358, 361], ["Anti-IL-6Ongoing", "SIMPLE_CHEMICAL", 385, 401], ["ACE2As", "GENE_OR_GENE_PRODUCT", 428, 434], ["ACE2", "GENE_OR_GENE_PRODUCT", 481, 485], ["IL-6", "GENE_OR_GENE_PRODUCT", 509, 513], ["AT1Rs", "GENE_OR_GENE_PRODUCT", 518, 523], ["JAK", "GENE_OR_GENE_PRODUCT", 532, 535], ["STAT", "GENE_OR_GENE_PRODUCT", 536, 540], ["Akt", "GENE_OR_GENE_PRODUCT", 545, 548], ["Anti-TMPRSS2", "PROTEIN", 280, 292], ["Recombinant Human ACE2", "PROTEIN", 294, 316], ["ACE", "PROTEIN", 322, 325], ["JAK", "PROTEIN", 338, 341], ["Akt", "PROTEIN", 358, 361], ["ACE2As", "PROTEIN", 428, 434], ["ACE2", "PROTEIN", 481, 485], ["IL-6", "PROTEIN", 509, 513], ["AT1Rs", "PROTEIN", 518, 523], ["JAK", "PROTEIN", 532, 535], ["STAT", "PROTEIN", 536, 540], ["Akt", "PROTEIN", 545, 548], ["Human", "SPECIES", 306, 311], ["Human", "SPECIES", 306, 311], ["Another small controlled prospective study", "TEST", 0, 42], ["HCQ", "TREATMENT", 95, 98], ["the virus conversion", "TREATMENT", 129, 149], ["HCQ", "TEST", 182, 185], ["ACE2Cytokine Storm Blockades", "TREATMENT", 250, 278], ["Anti-TMPRSS2", "TREATMENT", 280, 292], ["Recombinant Human ACE2", "TREATMENT", 294, 316], ["ARB", "TREATMENT", 318, 321], ["ACE Inhibitors", "TREATMENT", 322, 336], ["JAK", "TREATMENT", 338, 341], ["STAT Inhibitor", "TREATMENT", 342, 356], ["Akt Pathway Inhibitor", "TREATMENT", 358, 379], ["Anti-IL", "TREATMENT", 385, 392], ["Clinical Trials Targeting ACE2As", "TREATMENT", 402, 434], ["virus infection", "PROBLEM", 452, 467], ["IL", "TEST", 509, 511], ["the JAK", "TEST", 528, 535], ["the virus", "PROBLEM", 591, 600], ["small", "OBSERVATION_MODIFIER", 8, 13]]], ["As of the end of May 2020, there have been only retrospective studies of reagents used to treat SARS-CoV-2.", [["SARS", "DISEASE", 96, 100], ["SARS-CoV", "SPECIES", 96, 104], ["retrospective studies", "TEST", 48, 69], ["reagents", "TREATMENT", 73, 81], ["SARS", "PROBLEM", 96, 100], ["CoV", "TEST", 101, 104]]], ["Anti-TMPRSS2 agents can inhibit the cleavage of the S protein of this virus before its attachment.", [["Anti-TMPRSS2", "SIMPLE_CHEMICAL", 0, 12], ["S protein", "PROTEIN", 52, 61], ["Anti-TMPRSS2 agents", "TREATMENT", 0, 19], ["this virus", "PROBLEM", 65, 75]]], ["A high dose (100 mg/mL) of camostat mesylate was reported to inhibit the attachment of the S protein of SARS-CoV-2 to cells and that TMPRSS2 reduced the growth of SARS-CoV-2 in vitro [60] .Ongoing Clinical Trials Targeting ACE2One retrospective clinical study reported that anticoagulant therapy with heparin improved the mortality rate among 449 severe COVID-19 patients with severe coagulopathy (D-dimer > 3.0 \u03bcg/mL, 32.8% vs. 52.4%, p = 0.017) [150] .", [["cells", "ANATOMY", 118, 123], ["camostat mesylate", "CHEMICAL", 27, 44], ["heparin", "CHEMICAL", 301, 308], ["COVID", "DISEASE", 354, 359], ["coagulopathy", "DISEASE", 384, 396], ["camostat mesylate", "CHEMICAL", 27, 44], ["camostat mesylate", "SIMPLE_CHEMICAL", 27, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["cells", "CELL", 118, 123], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 133, 140], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 163, 173], ["heparin", "SIMPLE_CHEMICAL", 301, 308], ["patients", "ORGANISM", 363, 371], ["S protein", "PROTEIN", 91, 100], ["TMPRSS2", "PROTEIN", 133, 140], ["patients", "SPECIES", 363, 371], ["SARS-CoV", "SPECIES", 104, 112], ["SARS-CoV", "SPECIES", 163, 171], ["camostat mesylate", "TREATMENT", 27, 44], ["the S protein", "TEST", 87, 100], ["SARS", "TEST", 104, 108], ["CoV", "TEST", 109, 112], ["TMPRSS2", "TEST", 133, 140], ["SARS", "TEST", 163, 167], ["CoV", "TEST", 168, 171], ["clinical study", "TEST", 245, 259], ["anticoagulant therapy", "TREATMENT", 274, 295], ["heparin", "TREATMENT", 301, 308], ["the mortality rate", "TEST", 318, 336], ["severe COVID", "TEST", 347, 359], ["severe coagulopathy", "PROBLEM", 377, 396], ["D-dimer", "TEST", 398, 405], ["p", "TEST", 436, 437], ["severe", "OBSERVATION_MODIFIER", 377, 383], ["coagulopathy", "OBSERVATION", 384, 396]]], ["Other studies showed that recombinant human ACE2 (rhACE2) was able to inhibit SARS-CoV-2 attachment to the host ACE2 by binding to the virus S protein [5] , suppress viral growth efficiently in vitro [100] , and improve severe lung inflammation in vivo [62] .", [["lung", "ANATOMY", 227, 231], ["lung inflammation", "DISEASE", 227, 244], ["human", "ORGANISM", 38, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["rhACE2", "GENE_OR_GENE_PRODUCT", 50, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 78, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["lung", "ORGAN", 227, 231], ["recombinant human ACE2", "PROTEIN", 26, 48], ["rhACE2", "PROTEIN", 50, 56], ["ACE2", "PROTEIN", 112, 116], ["virus S protein", "PROTEIN", 135, 150], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["Other studies", "TEST", 0, 13], ["recombinant human ACE2 (rhACE2)", "TREATMENT", 26, 57], ["SARS", "PROBLEM", 78, 82], ["the virus S protein", "TEST", 131, 150], ["viral growth", "PROBLEM", 166, 178], ["severe lung inflammation", "PROBLEM", 220, 244], ["severe", "OBSERVATION_MODIFIER", 220, 226], ["lung", "ANATOMY", 227, 231], ["inflammation", "OBSERVATION", 232, 244]]], ["The safety of rhACE2 has been confirmed by phase II/III studies with 39 ARDS patients (NCT01597635) [69] .Ongoing Clinical Trials Targeting ACE2Angiotensin receptor blockers (ARBs)/ACE inhibitors (ACE-Is) are widely used for the treatment of hypertension, which is commonly observed in COVID-19 patients [48] .", [["rhACE2", "CHEMICAL", 14, 20], ["ARDS", "DISEASE", 72, 76], ["ACE inhibitors", "CHEMICAL", 181, 195], ["ACE-Is", "CHEMICAL", 197, 203], ["hypertension", "DISEASE", 242, 254], ["rhACE2", "SIMPLE_CHEMICAL", 14, 20], ["patients", "ORGANISM", 77, 85], ["ACE2Angiotensin receptor blockers", "SIMPLE_CHEMICAL", 140, 173], ["ARBs", "SIMPLE_CHEMICAL", 175, 179], ["ACE inhibitors", "SIMPLE_CHEMICAL", 181, 195], ["ACE-Is", "SIMPLE_CHEMICAL", 197, 203], ["patients", "ORGANISM", 295, 303], ["rhACE2", "PROTEIN", 14, 20], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 295, 303], ["phase II/III studies", "TEST", 43, 63], ["ACE2Angiotensin receptor blockers", "TREATMENT", 140, 173], ["ARBs", "TREATMENT", 175, 179], ["ACE inhibitors", "TREATMENT", 181, 195], ["ACE-Is)", "TREATMENT", 197, 204], ["hypertension", "PROBLEM", 242, 254], ["hypertension", "OBSERVATION", 242, 254]]], ["There is no consensus as of the end of May 2020 regarding the use of ARBs/ACE-Is in COVID-19 patients, including ARBs (losartan, telmisartan) and ACE-Is (ramipril) due to insufficient clinical data about the adverse effects and outcomes.", [["losartan", "CHEMICAL", 119, 127], ["telmisartan", "CHEMICAL", 129, 140], ["ACE-Is", "CHEMICAL", 146, 152], ["ramipril", "CHEMICAL", 154, 162], ["losartan", "CHEMICAL", 119, 127], ["telmisartan", "CHEMICAL", 129, 140], ["ramipril", "CHEMICAL", 154, 162], ["ARBs", "SIMPLE_CHEMICAL", 69, 73], ["ACE-Is", "SIMPLE_CHEMICAL", 74, 80], ["patients", "ORGANISM", 93, 101], ["ARBs", "SIMPLE_CHEMICAL", 113, 117], ["losartan", "SIMPLE_CHEMICAL", 119, 127], ["telmisartan", "SIMPLE_CHEMICAL", 129, 140], ["ACE-Is", "SIMPLE_CHEMICAL", 146, 152], ["ramipril", "SIMPLE_CHEMICAL", 154, 162], ["patients", "SPECIES", 93, 101], ["ARBs", "TREATMENT", 69, 73], ["ACE", "TREATMENT", 74, 77], ["ARBs", "TREATMENT", 113, 117], ["losartan", "TREATMENT", 119, 127], ["telmisartan", "TREATMENT", 129, 140], ["ACE", "TREATMENT", 146, 149], ["ramipril", "TREATMENT", 154, 162], ["insufficient clinical data", "PROBLEM", 171, 197], ["no", "UNCERTAINTY", 9, 11]]], ["There have been several clinical studies of the relationships between ARB/ ACE-I use and COVID-19; one case-controlled study and four retrospective studies.Ongoing Clinical Trials Targeting ACE2The case-controlled study was of the ARB/ACE-I treatment of 6272 COVID-19 patients.", [["ARB", "CHEMICAL", 70, 73], ["ARB", "CHEMICAL", 231, 234], ["ACE-I", "CHEMICAL", 235, 240], ["ACE-I", "GENE_OR_GENE_PRODUCT", 75, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 190, 194], ["patients", "ORGANISM", 268, 276], ["ACE2", "PROTEIN", 190, 194], ["patients", "SPECIES", 268, 276], ["several clinical studies", "TEST", 16, 40], ["ARB", "TREATMENT", 70, 73], ["COVID", "TEST", 89, 94], ["four retrospective studies", "TEST", 129, 155], ["ACE2", "TEST", 190, 194], ["the ARB", "TREATMENT", 227, 234], ["ACE-I treatment", "TREATMENT", 235, 250], ["COVID", "TEST", 259, 264]]], ["The study results showed that ARB/ACE-I use did not change the patients' overall outcome (adjusted odds ratio [OR] 0.95, 95% CI 0.86-1.05 for ARB, 0.96, 95% CI 0.87-1.07 for ACE-I) or the rate of critical or fatal disease (adjusted OR 0.83, 95% CI 0.63-1.10 for ARB, 0.91, 95% CI 0.69-1.21 for ACE-I) [91] .", [["ARB", "CHEMICAL", 30, 33], ["ACE-I", "CHEMICAL", 34, 39], ["ARB", "CHEMICAL", 142, 145], ["ARB", "CHEMICAL", 262, 265], ["ARB", "SIMPLE_CHEMICAL", 30, 33], ["ACE-I", "GENE_OR_GENE_PRODUCT", 34, 39], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["The study", "TEST", 0, 9], ["ARB/ACE-I", "TREATMENT", 30, 39], ["CI", "TEST", 125, 127], ["ARB", "TEST", 142, 145], ["CI", "TEST", 157, 159], ["ACE", "TEST", 174, 177], ["fatal disease", "PROBLEM", 208, 221], ["CI", "TEST", 245, 247], ["ARB", "TEST", 262, 265], ["CI", "TEST", 277, 279], ["ACE", "TEST", 294, 297], ["fatal disease", "OBSERVATION", 208, 221]]], ["A large multinational retrospective study of 8910 patients indicated that the use of an ACE-I (n = 770, OR 0.33, 95% CI 0.20-0.54) or an ARB (n = 556, OR 1.23, 95% CI 0.87-1.74) had no effect on the likelihood of death from COVID-19 [95] .Ongoing Clinical Trials Targeting ACE2A large retrospective single-center study of 12,594 patients showed no association between ARB/ACE-I use and the severity/mortality of COVID-19 (24.7% vs. 24.8%, 95% CI \u2212 3.5-3.5) [125] , as did another retrospective study (severity 32.9% vs. 30.7%, p = 0.65, mortality 27.3% vs. 33.0%, p = 0.34) [84] .", [["ACE-I", "CHEMICAL", 88, 93], ["ARB", "CHEMICAL", 137, 140], ["death", "DISEASE", 213, 218], ["ARB/ACE-I", "CHEMICAL", 368, 377], ["COVID", "DISEASE", 412, 417], ["COVID-19", "CHEMICAL", 224, 232], ["patients", "ORGANISM", 50, 58], ["ACE-I", "GENE_OR_GENE_PRODUCT", 88, 93], ["patients", "ORGANISM", 329, 337], ["ACE-I", "GENE_OR_GENE_PRODUCT", 372, 377], ["ACE", "PROTEIN", 372, 375], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 329, 337], ["A large multinational retrospective study", "TEST", 0, 41], ["CI", "TEST", 117, 119], ["an ARB", "TEST", 134, 140], ["CI", "TEST", 164, 166], ["death", "PROBLEM", 213, 218], ["COVID", "TEST", 224, 229], ["center study", "TEST", 306, 318], ["ARB", "TREATMENT", 368, 371], ["ACE", "TREATMENT", 372, 375], ["the severity", "TEST", 386, 398], ["COVID", "TEST", 412, 417], ["CI", "TEST", 443, 445], ["another retrospective study", "TEST", 472, 499], ["severity", "TEST", 501, 509], ["p", "TEST", 527, 528], ["mortality", "TEST", 537, 546], ["p", "TEST", 564, 565], ["large", "OBSERVATION_MODIFIER", 2, 7]]], ["Two retrospective studies with > 100 hospitalized patients indicated that the use of an ARB/ ACE-I had no correlation with clinical outcomes (HR 0.97, 95% CI 0.68-1.39; p = 0.88) [154] or the severity of COVID-19 symptoms [182] .Ongoing Clinical Trials Targeting ACE2IL-6 has been considered a key factor in the cytokine storm observed in COVID-19, and it is a potential therapeutic target.", [["ARB", "CHEMICAL", 88, 91], ["ACE2IL-6", "CHEMICAL", 263, 271], ["ACE2IL-6", "CHEMICAL", 263, 271], ["patients", "ORGANISM", 50, 58], ["ACE-I", "GENE_OR_GENE_PRODUCT", 93, 98], ["ACE2IL-6", "GENE_OR_GENE_PRODUCT", 263, 271], ["COVID-19", "CELL", 339, 347], ["ACE2IL-6", "PROTEIN", 263, 271], ["cytokine", "PROTEIN", 312, 320], ["patients", "SPECIES", 50, 58], ["Two retrospective studies", "TEST", 0, 25], ["an ARB/ ACE", "TREATMENT", 85, 96], ["HR", "TEST", 142, 144], ["CI", "TEST", 155, 157], ["p", "TEST", 169, 170], ["COVID", "TEST", 204, 209], ["symptoms", "PROBLEM", 213, 221], ["ACE2IL", "TEST", 263, 269], ["COVID", "TEST", 339, 344]]], ["Tocilizumab is an anti-IL-6 monoclonal antibody with clinical evidence in rheumatoid arthritis treatment.", [["Tocilizumab", "CHEMICAL", 0, 11], ["rheumatoid arthritis", "DISEASE", 74, 94], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 18, 27], ["anti-IL-6 monoclonal antibody", "PROTEIN", 18, 47], ["Tocilizumab", "TREATMENT", 0, 11], ["an anti-IL", "TEST", 15, 25], ["rheumatoid arthritis treatment", "TREATMENT", 74, 104], ["rheumatoid arthritis", "OBSERVATION", 74, 94]]], ["A single-center study reported that 80-600 mg tocilizumab stabilized the symptoms in most of the 15 patients with moderate-to-severe COVID-19 [89] .", [["tocilizumab", "CHEMICAL", 46, 57], ["COVID", "DISEASE", 133, 138], ["COVID-19", "CHEMICAL", 133, 141], ["tocilizumab", "SIMPLE_CHEMICAL", 46, 57], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["A single-center study", "TEST", 0, 21], ["the symptoms", "PROBLEM", 69, 81], ["moderate-to-severe COVID", "PROBLEM", 114, 138]]], ["JAK inhibitors, which were originally used as a treatment for myelofibrosis or polycythemia vera, act by a selective inhibition of JAK1/JAK2 [115] .", [["myelofibrosis", "DISEASE", 62, 75], ["polycythemia vera", "DISEASE", 79, 96], ["JAK", "GENE_OR_GENE_PRODUCT", 0, 3], ["JAK1", "GENE_OR_GENE_PRODUCT", 131, 135], ["JAK2", "GENE_OR_GENE_PRODUCT", 136, 140], ["JAK", "PROTEIN", 0, 3], ["JAK1", "PROTEIN", 131, 135], ["JAK2", "PROTEIN", 136, 140], ["JAK inhibitors", "TREATMENT", 0, 14], ["a treatment", "TREATMENT", 46, 57], ["myelofibrosis", "PROBLEM", 62, 75], ["polycythemia vera", "PROBLEM", 79, 96], ["a selective inhibition of JAK1/JAK2", "TREATMENT", 105, 140], ["myelofibrosis", "OBSERVATION", 62, 75], ["polycythemia", "OBSERVATION", 79, 91]]], ["In vitro, the JAK-STAT inhibitor baricitinib seemed to influence the viral entry and inflammation response in COVID-19 [126] .", [["baricitinib", "CHEMICAL", 33, 44], ["inflammation", "DISEASE", 85, 97], ["COVID-19", "CHEMICAL", 110, 118], ["baricitinib", "CHEMICAL", 33, 44], ["JAK-STAT", "GENE_OR_GENE_PRODUCT", 14, 22], ["baricitinib", "SIMPLE_CHEMICAL", 33, 44], ["JAK", "PROTEIN", 14, 17], ["the JAK", "TREATMENT", 10, 17], ["STAT inhibitor baricitinib", "TREATMENT", 18, 44], ["the viral entry", "PROBLEM", 65, 80], ["inflammation response", "TEST", 85, 106], ["COVID", "TEST", 110, 115]]], ["There are no reported clinical trials, retrospective studies, or case series concerning the effects of JAK-STAT inhibitors in COVDI-19 treatment.Future PerspectivesTo date, there are no sufficient clinical data to suggest any effective treatments for COVID-19.", [["COVDI-19", "CHEMICAL", 126, 134], ["COVDI-19", "CHEMICAL", 126, 134], ["COVID-19", "CHEMICAL", 251, 259], ["JAK-STAT", "GENE_OR_GENE_PRODUCT", 103, 111], ["COVDI-19", "SIMPLE_CHEMICAL", 126, 134], ["JAK", "PROTEIN", 103, 106], ["retrospective studies", "TEST", 39, 60], ["case series", "TEST", 65, 76], ["JAK", "TREATMENT", 103, 106], ["STAT inhibitors", "TREATMENT", 107, 122], ["COVDI", "TEST", 126, 131], ["treatment", "TREATMENT", 135, 144], ["COVID", "TEST", 251, 256], ["no", "UNCERTAINTY", 10, 12]]], ["As listed on ClinicalTrials.gov., several hundred clinical trials of numerous medications are proceeding: anti-coagulants (nafamostat mesylate, camostat mesylate, heparin, enoxaparin, tinzaparin), ARBs/ ACE-Is (losartan, telmisartan, ramipril), an anti-Ang2 agent (LY3127804), anti-mIL-6R drugs (sarilumab, siltuximab, tocilizumab), anti-IL-6 medications (clazakizumab, olokizumab, sirukumab), and JAK-STAT inhibitors (ruxolitinib, baricitinib, TD-0903).", [["nafamostat mesylate", "CHEMICAL", 123, 142], ["camostat mesylate", "CHEMICAL", 144, 161], ["heparin", "CHEMICAL", 163, 170], ["enoxaparin", "CHEMICAL", 172, 182], ["tinzaparin", "CHEMICAL", 184, 194], ["ARBs/ ACE-Is", "CHEMICAL", 197, 209], ["losartan", "CHEMICAL", 211, 219], ["telmisartan", "CHEMICAL", 221, 232], ["ramipril", "CHEMICAL", 234, 242], ["LY3127804", "CHEMICAL", 265, 274], ["anti-mIL-6R", "CHEMICAL", 277, 288], ["sarilumab", "CHEMICAL", 296, 305], ["siltuximab", "CHEMICAL", 307, 317], ["tocilizumab", "CHEMICAL", 319, 330], ["clazakizumab", "CHEMICAL", 356, 368], ["olokizumab", "CHEMICAL", 370, 380], ["sirukumab", "CHEMICAL", 382, 391], ["ruxolitinib", "CHEMICAL", 419, 430], ["baricitinib", "CHEMICAL", 432, 443], ["TD-0903", "CHEMICAL", 445, 452], ["nafamostat mesylate", "CHEMICAL", 123, 142], ["camostat mesylate", "CHEMICAL", 144, 161], ["enoxaparin", "CHEMICAL", 172, 182], ["tinzaparin", "CHEMICAL", 184, 194], ["losartan", "CHEMICAL", 211, 219], ["telmisartan", "CHEMICAL", 221, 232], ["ramipril", "CHEMICAL", 234, 242], ["LY3127804", "CHEMICAL", 265, 274], ["sarilumab", "CHEMICAL", 296, 305], ["siltuximab", "CHEMICAL", 307, 317], ["clazakizumab", "CHEMICAL", 356, 368], ["olokizumab", "CHEMICAL", 370, 380], ["sirukumab", "CHEMICAL", 382, 391], ["ruxolitinib", "CHEMICAL", 419, 430], ["baricitinib", "CHEMICAL", 432, 443], ["TD-0903", "CHEMICAL", 445, 452], ["anti-coagulants", "SIMPLE_CHEMICAL", 106, 121], ["nafamostat mesylate", "SIMPLE_CHEMICAL", 123, 142], ["camostat mesylate", "SIMPLE_CHEMICAL", 144, 161], ["heparin", "SIMPLE_CHEMICAL", 163, 170], ["enoxaparin", "SIMPLE_CHEMICAL", 172, 182], ["tinzaparin", "SIMPLE_CHEMICAL", 184, 194], ["ARBs", "SIMPLE_CHEMICAL", 197, 201], ["ACE-Is", "SIMPLE_CHEMICAL", 203, 209], ["losartan", "SIMPLE_CHEMICAL", 211, 219], ["telmisartan", "SIMPLE_CHEMICAL", 221, 232], ["ramipril", "SIMPLE_CHEMICAL", 234, 242], ["anti-Ang2", "SIMPLE_CHEMICAL", 248, 257], ["LY3127804", "SIMPLE_CHEMICAL", 265, 274], ["anti-mIL-6R", "SIMPLE_CHEMICAL", 277, 288], ["sarilumab", "SIMPLE_CHEMICAL", 296, 305], ["siltuximab", "SIMPLE_CHEMICAL", 307, 317], ["tocilizumab", "SIMPLE_CHEMICAL", 319, 330], ["anti-IL-6", "SIMPLE_CHEMICAL", 333, 342], ["clazakizumab", "SIMPLE_CHEMICAL", 356, 368], ["olokizumab", "SIMPLE_CHEMICAL", 370, 380], ["sirukumab", "SIMPLE_CHEMICAL", 382, 391], ["JAK-STAT", "GENE_OR_GENE_PRODUCT", 398, 406], ["ruxolitinib", "SIMPLE_CHEMICAL", 419, 430], ["baricitinib", "SIMPLE_CHEMICAL", 432, 443], ["TD-0903", "SIMPLE_CHEMICAL", 445, 452], ["JAK", "PROTEIN", 398, 401], ["numerous medications", "TREATMENT", 69, 89], ["anti-coagulants", "TREATMENT", 106, 121], ["nafamostat mesylate", "TREATMENT", 123, 142], ["camostat mesylate", "TREATMENT", 144, 161], ["heparin", "TREATMENT", 163, 170], ["enoxaparin", "TREATMENT", 172, 182], ["tinzaparin", "TREATMENT", 184, 194], ["ARBs", "TREATMENT", 197, 201], ["ACE", "TREATMENT", 203, 206], ["losartan", "TREATMENT", 211, 219], ["telmisartan", "TREATMENT", 221, 232], ["ramipril", "TREATMENT", 234, 242], ["an anti-Ang2 agent", "TREATMENT", 245, 263], ["anti-mIL", "TREATMENT", 277, 285], ["6R drugs", "TREATMENT", 286, 294], ["sarilumab", "TREATMENT", 296, 305], ["siltuximab", "TREATMENT", 307, 317], ["tocilizumab", "TREATMENT", 319, 330], ["anti-IL", "TREATMENT", 333, 340], ["medications", "TREATMENT", 343, 354], ["clazakizumab", "TREATMENT", 356, 368], ["olokizumab", "TREATMENT", 370, 380], ["JAK-STAT inhibitors", "TREATMENT", 398, 417], ["ruxolitinib", "TREATMENT", 419, 430], ["baricitinib", "TREATMENT", 432, 443]]], ["The therapeutic targets considered thus far are summarized in Figs.", [["The therapeutic targets", "TREATMENT", 0, 23]]], ["3 and 4 .CONCLUSIONThis review has summarized the latest evidence regarding the mechanisms underlying COVID-19 and its associated multi-organ injuries and failure, plus the potential strategies for treatments to be studied/developed.", [["multi-organ", "ANATOMY", 130, 141], ["multi-organ injuries", "DISEASE", 130, 150], ["COVID-19", "CHEMICAL", 102, 110], ["multi-organ", "ORGAN", 130, 141], ["COVID", "TEST", 102, 107], ["multi-organ injuries", "PROBLEM", 130, 150], ["failure", "PROBLEM", 155, 162], ["treatments", "TREATMENT", 198, 208], ["multi-organ", "ANATOMY", 130, 141], ["injuries", "OBSERVATION", 142, 150], ["failure", "OBSERVATION", 155, 162]]], ["Since SARS-CoV-2 binds to the host ACE2 with a subsequent release of proinflammatory cytokines, the primary infection and the characteristic symptoms can occur in the lungs and nasal airway where ACE2 and TMPRSS2 are strongly co-expressed, followed by vital organ injury due to a cytokine storm that is probably initiated by IL-6.", [["lungs", "ANATOMY", 167, 172], ["nasal airway", "ANATOMY", 177, 189], ["organ", "ANATOMY", 258, 263], ["primary infection", "DISEASE", 100, 117], ["organ injury", "DISEASE", 258, 270], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 6, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["lungs", "ORGAN", 167, 172], ["nasal airway", "MULTI-TISSUE_STRUCTURE", 177, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 196, 200], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 205, 212], ["organ", "ORGAN", 258, 263], ["IL-6", "GENE_OR_GENE_PRODUCT", 325, 329], ["ACE2", "PROTEIN", 35, 39], ["proinflammatory cytokines", "PROTEIN", 69, 94], ["ACE2", "PROTEIN", 196, 200], ["TMPRSS2", "PROTEIN", 205, 212], ["cytokine", "PROTEIN", 280, 288], ["IL-6", "PROTEIN", 325, 329], ["SARS-CoV", "SPECIES", 6, 14], ["proinflammatory cytokines", "TREATMENT", 69, 94], ["the primary infection", "PROBLEM", 96, 117], ["the characteristic symptoms", "PROBLEM", 122, 149], ["ACE2", "TEST", 196, 200], ["TMPRSS2", "TEST", 205, 212], ["vital organ injury", "PROBLEM", 252, 270], ["a cytokine storm", "PROBLEM", 278, 294], ["proinflammatory cytokines", "OBSERVATION", 69, 94], ["primary", "OBSERVATION_MODIFIER", 100, 107], ["infection", "OBSERVATION", 108, 117], ["lungs", "ANATOMY", 167, 172], ["nasal airway", "ANATOMY", 177, 189], ["cytokine storm", "OBSERVATION", 280, 294]]], ["Further clinical studies of the therapeutics for COVID-19 are urgently needed as antibody drugs and vaccines that can effectively cure the disease or tackle the SARS-CoV-2 pandemic are not yet available.AUTHOR CONTRIBUTIONSM.I. and J.S. drafted the manuscript, with similar contributions.", [["COVID-19", "CHEMICAL", 49, 57], ["SARS-CoV-2 pandemic", "DISEASE", 161, 180], ["COVID-19", "CHEMICAL", 49, 57], ["COVID-19", "SIMPLE_CHEMICAL", 49, 57], ["SARS-CoV-2", "ORGANISM", 161, 171], ["Further clinical studies", "TEST", 0, 24], ["COVID", "TEST", 49, 54], ["antibody drugs", "TREATMENT", 81, 95], ["vaccines", "TREATMENT", 100, 108], ["the disease", "PROBLEM", 135, 146], ["the SARS", "TEST", 157, 165], ["CoV", "TEST", 166, 169], ["pandemic", "PROBLEM", 172, 180]]], ["D.M. conceived the study idea.", [["the study", "TEST", 15, 24]]], ["The authors declare that they have no conflict of interest.COMPLIANCE WITH ETHICAL STANDARDSReprints.", [["ETHICAL STANDARDSReprints", "TREATMENT", 75, 100]]], ["Reprints will not be available from the authors.COMPLIANCE WITH ETHICAL STANDARDSOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["ETHICAL STANDARDSOpen Access", "TREATMENT", 64, 92]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]], "PMC7461307": [["Public health emergencies in times of epidemics and the effects of contagion mitigation strategies such as emergency lockdown may cause intense fear and anxiety particularly among the at\u2010risk populations.", [["anxiety", "DISEASE", 153, 160], ["epidemics", "PROBLEM", 38, 47], ["contagion mitigation strategies", "TREATMENT", 67, 98], ["emergency lockdown", "TREATMENT", 107, 125], ["intense fear", "PROBLEM", 136, 148], ["anxiety", "PROBLEM", 153, 160]]], ["This has significantly hampered the management of other serious health issues such as mental and chronic conditions particularly in low\u2010 and middle\u2010income countries where resources for health are often limited.2This may certainly have both immediate and long\u2010term deleterious public health impacts during and even beyond the pandemic.", [["other serious health issues", "PROBLEM", 50, 77], ["mental and chronic conditions", "PROBLEM", 86, 115], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["deleterious", "OBSERVATION_MODIFIER", 264, 275], ["pandemic", "OBSERVATION", 325, 333]]], ["More importantly, the emergence of COVID\u201019 and the concomitant contagions have resulted in prejudices, community rejection and intense stigma against the infected and affected persons.3,4,5The allied neuropsychological impacts on the direct medical issues of the pandemic such disruptions, anxiety, stress, stigma and xenophobia may also cause mayhem in the society and social lives.6Pervasive social stigma and discriminatory behaviors are being demonstrated toward the frontline health and social workers and the vulnerable, at\u2010risk population including older adults.", [["anxiety", "DISEASE", 291, 298], ["xenophobia", "DISEASE", 319, 329], ["persons", "ORGANISM", 177, 184], ["persons", "SPECIES", 177, 184], ["COVID\u2010", "TREATMENT", 35, 41], ["the concomitant contagions", "PROBLEM", 48, 74], ["prejudices", "PROBLEM", 92, 102], ["community rejection", "PROBLEM", 104, 123], ["intense stigma", "PROBLEM", 128, 142], ["the pandemic such disruptions", "PROBLEM", 260, 289], ["anxiety", "PROBLEM", 291, 298], ["stress", "PROBLEM", 300, 306], ["stigma", "PROBLEM", 308, 314], ["xenophobia", "PROBLEM", 319, 329], ["community rejection", "OBSERVATION", 104, 123], ["intense", "OBSERVATION_MODIFIER", 128, 135], ["infected", "OBSERVATION", 155, 163]]]], "5bc01219f59c2fd45139b112a5405243d0e8a504": [["The idea of viruses as inert molecular entities has progressively been transformed since scientists began to discover the myriad of interactions that occur during the intracellular phase of virus life.", [["intracellular", "ANATOMY", 167, 180], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 167, 180], ["viruses", "PROBLEM", 12, 19], ["virus life", "TREATMENT", 190, 200], ["viruses", "OBSERVATION", 12, 19]]], ["Restricted by their own limited genetic repertoire, viruses need to use a number of cell factors for genome replication and morphogenesis.", [["cell", "ANATOMY", 84, 88], ["cell", "CELL", 84, 88], ["genome", "CELLULAR_COMPONENT", 101, 107], ["viruses", "PROBLEM", 52, 59], ["cell factors", "TREATMENT", 84, 96], ["genome replication", "TREATMENT", 101, 119]]], ["Identification of these factors is essential for understanding the virus morphogenetic processes that often take place in intracellular structures known as viral inclusions, virosomes or viral factories.", [["intracellular structures", "ANATOMY", 122, 146], ["virosomes", "ANATOMY", 174, 183], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 122, 135], ["virosomes", "CELLULAR_COMPONENT", 174, 183], ["these factors", "PROBLEM", 18, 31], ["the virus morphogenetic processes", "PROBLEM", 63, 96], ["viral inclusions", "PROBLEM", 156, 172], ["viral inclusions", "OBSERVATION", 156, 172], ["viral factories", "OBSERVATION", 187, 202]]], ["Viruses are generally thought to build these structures to recruit and concentrate viral and cell factors needed for replication and assembly; they are able to modify a variety of cell organelles and to create new inter-organelle contacts ( Fig. 14.1 ).", [["cell", "ANATOMY", 93, 97], ["cell organelles", "ANATOMY", 180, 195], ["inter-organelle contacts", "ANATOMY", 214, 238], ["cell", "CELL", 93, 97], ["cell organelles", "CELLULAR_COMPONENT", 180, 195], ["viral and cell factors", "PROTEIN", 83, 105], ["Viruses", "PROBLEM", 0, 7], ["concentrate viral and cell factors", "PROBLEM", 71, 105]]], ["In the mammalian cell, virus assembly can start inside the nucleus, in association with components of the secretory pathway (Golgi, endoplasmic reticulum or ER), at different points in the endocytic pathway (endosomes, multivesicular bodies or MVB) or at the plasma membrane.", [["cell", "ANATOMY", 17, 21], ["nucleus", "ANATOMY", 59, 66], ["Golgi", "ANATOMY", 125, 130], ["endoplasmic reticulum", "ANATOMY", 132, 153], ["ER", "ANATOMY", 157, 159], ["endosomes", "ANATOMY", 208, 217], ["multivesicular bodies", "ANATOMY", 219, 240], ["MVB", "ANATOMY", 244, 247], ["plasma membrane", "ANATOMY", 259, 274], ["mammalian cell", "CELL", 7, 21], ["nucleus", "CELLULAR_COMPONENT", 59, 66], ["Golgi", "CELLULAR_COMPONENT", 125, 130], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 132, 153], ["ER", "GENE_OR_GENE_PRODUCT", 157, 159], ["endosomes", "CELLULAR_COMPONENT", 208, 217], ["multivesicular bodies", "CELLULAR_COMPONENT", 219, 240], ["MVB", "CELLULAR_COMPONENT", 244, 247], ["plasma membrane", "CELLULAR_COMPONENT", 259, 274], ["ER", "PROTEIN", 157, 159], ["virus", "PROBLEM", 23, 28], ["MVB", "PROBLEM", 244, 247], ["mammalian cell", "OBSERVATION", 7, 21], ["virus", "OBSERVATION", 23, 28], ["nucleus", "ANATOMY", 59, 66], ["multivesicular bodies", "OBSERVATION", 219, 240], ["plasma membrane", "ANATOMY", 259, 274]]], ["Mitochondria and cytoskeletal elements are present in the factories built by many different viruses.", [["Mitochondria", "ANATOMY", 0, 12], ["cytoskeletal", "ANATOMY", 17, 29], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["cytoskeletal elements", "CELLULAR_COMPONENT", 17, 38], ["cytoskeletal elements", "DNA", 17, 38], ["Mitochondria and cytoskeletal elements", "PROBLEM", 0, 38], ["cytoskeletal elements", "OBSERVATION", 17, 38], ["many", "OBSERVATION_MODIFIER", 77, 81], ["different", "OBSERVATION_MODIFIER", 82, 91], ["viruses", "OBSERVATION", 92, 99]]]], "PMC7134551": [["IntroductionThe coronavirus disease 2019 (COVID-19) is an ongoing viral pandemic that emerged from East Asia and quickly spread to the rest of the world [1].", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["viral pandemic", "DISEASE", 66, 80], ["coronavirus", "ORGANISM", 16, 27], ["COVID-19", "ORGANISM", 42, 50], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["an ongoing viral pandemic", "PROBLEM", 55, 80], ["coronavirus disease", "OBSERVATION", 16, 35]]], ["This infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is so far responsible for more than 15,000 deaths worldwide [2].", [["infection", "DISEASE", 5, 14], ["acute respiratory syndrome coronavirus", "DISEASE", 35, 73], ["deaths", "DISEASE", 136, 142], ["SARS-CoV-2", "ORGANISM", 77, 87], ["severe acute respiratory syndrome coronavirus", "SPECIES", 28, 73], ["SARS-CoV-2", "SPECIES", 77, 87], ["This infection", "PROBLEM", 0, 14], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 28, 73], ["infection", "OBSERVATION", 5, 14], ["caused by", "UNCERTAINTY", 18, 27], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory syndrome coronavirus", "OBSERVATION", 41, 73]]], ["Human-to-human transmission is characterized by a troubling exponential rate, which has led to steep curves of onset in many areas [3].", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 9, 14], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14]]], ["According to the clinical studies from Asia, the most prevalent symptoms consist of fever, cough, dyspnea, sputum production, myalgia, arthralgia, headache, diarrhea, rhinorrhea, and sore throat [4, 5].", [["sputum", "ANATOMY", 107, 113], ["fever", "DISEASE", 84, 89], ["cough", "DISEASE", 91, 96], ["dyspnea", "DISEASE", 98, 105], ["sputum production", "DISEASE", 107, 124], ["myalgia", "DISEASE", 126, 133], ["arthralgia", "DISEASE", 135, 145], ["headache", "DISEASE", 147, 155], ["diarrhea", "DISEASE", 157, 165], ["rhinorrhea", "DISEASE", 167, 177], ["sore throat", "DISEASE", 183, 194], ["the clinical studies", "TEST", 13, 33], ["the most prevalent symptoms", "PROBLEM", 45, 72], ["fever", "PROBLEM", 84, 89], ["cough", "PROBLEM", 91, 96], ["dyspnea", "PROBLEM", 98, 105], ["sputum production", "PROBLEM", 107, 124], ["myalgia", "PROBLEM", 126, 133], ["arthralgia", "PROBLEM", 135, 145], ["headache", "PROBLEM", 147, 155], ["diarrhea", "PROBLEM", 157, 165], ["rhinorrhea", "PROBLEM", 167, 177], ["sore throat", "PROBLEM", 183, 194], ["myalgia", "OBSERVATION", 126, 133], ["arthralgia", "OBSERVATION", 135, 145], ["rhinorrhea", "OBSERVATION", 167, 177], ["sore throat", "ANATOMY", 183, 194]]], ["The spread of the COVID-19 infection in Europe has highlighted a new atypical presentation of the disease: patients with olfactory and gustatory dysfunctions.", [["olfactory", "ANATOMY", 121, 130], ["gustatory", "ANATOMY", 135, 144], ["COVID-19", "CHEMICAL", 18, 26], ["infection", "DISEASE", 27, 36], ["olfactory and gustatory dysfunctions", "DISEASE", 121, 157], ["COVID-19", "ORGANISM", 18, 26], ["patients", "ORGANISM", 107, 115], ["olfactory", "ORGAN", 121, 130], ["gustatory", "ORGANISM_SUBDIVISION", 135, 144], ["patients", "SPECIES", 107, 115], ["the COVID", "TEST", 14, 23], ["infection", "PROBLEM", 27, 36], ["the disease", "PROBLEM", 94, 105], ["olfactory and gustatory dysfunctions", "PROBLEM", 121, 157], ["spread", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 27, 36], ["new", "OBSERVATION_MODIFIER", 65, 68], ["atypical", "OBSERVATION_MODIFIER", 69, 77], ["disease", "OBSERVATION", 98, 105], ["gustatory dysfunctions", "OBSERVATION", 135, 157]]], ["The occurrence of smell dysfunction in viral infections is not new in otolaryngology.", [["smell dysfunction", "DISEASE", 18, 35], ["viral infections", "DISEASE", 39, 55], ["smell", "ORGANISM_SUBDIVISION", 18, 23], ["smell dysfunction", "PROBLEM", 18, 35], ["viral infections", "PROBLEM", 39, 55], ["smell dysfunction", "OBSERVATION", 18, 35], ["viral infections", "OBSERVATION", 39, 55], ["not", "UNCERTAINTY", 59, 62], ["new", "OBSERVATION_MODIFIER", 63, 66]]], ["Many viruses may lead to olfactory dysfunction (OD) through an inflammatory reaction of the nasal mucosa and the development of rhinorrhea; the most familiar agents being rhinovirus, parainfluenza Epstein\u2013Barr virus, and some coronavirus [6, 7].", [["olfactory", "ANATOMY", 25, 34], ["nasal mucosa", "ANATOMY", 92, 104], ["olfactory dysfunction", "DISEASE", 25, 46], ["rhinorrhea", "DISEASE", 128, 138], ["parainfluenza Epstein\u2013Barr virus", "DISEASE", 183, 215], ["olfactory", "ORGAN", 25, 34], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 92, 104], ["rhinovirus", "ORGANISM", 171, 181], ["parainfluenza Epstein\u2013Barr virus", "ORGANISM", 183, 215], ["parainfluenza", "SPECIES", 183, 196], ["Epstein\u2013Barr virus", "SPECIES", 197, 215], ["Many viruses", "PROBLEM", 0, 12], ["olfactory dysfunction", "PROBLEM", 25, 46], ["an inflammatory reaction of the nasal mucosa", "PROBLEM", 60, 104], ["rhinorrhea", "PROBLEM", 128, 138], ["rhinovirus", "PROBLEM", 171, 181], ["parainfluenza Epstein", "PROBLEM", 183, 204], ["Barr virus", "PROBLEM", 205, 215], ["some coronavirus", "PROBLEM", 221, 237], ["viruses", "OBSERVATION", 5, 12], ["inflammatory", "OBSERVATION", 63, 75], ["nasal mucosa", "ANATOMY", 92, 104], ["rhinorrhea", "OBSERVATION", 128, 138]]], ["However, olfactory dysfunction linked to COVID-19 infection seems particular as it is not associated with rhinorrhea.IntroductionOver the past few weeks, some European otolaryngologists observed that many patients infected by SARS-CoV-2 presented with severe olfactory and gustatory dysfunctions without rhinorrhea or nasal obstruction.", [["olfactory", "ANATOMY", 9, 18], ["olfactory", "ANATOMY", 259, 268], ["gustatory", "ANATOMY", 273, 282], ["nasal", "ANATOMY", 318, 323], ["olfactory dysfunction", "DISEASE", 9, 30], ["COVID-19", "CHEMICAL", 41, 49], ["infection", "DISEASE", 50, 59], ["rhinorrhea", "DISEASE", 106, 116], ["SARS", "DISEASE", 226, 230], ["olfactory and gustatory dysfunctions", "DISEASE", 259, 295], ["rhinorrhea", "DISEASE", 304, 314], ["nasal obstruction", "DISEASE", 318, 335], ["olfactory", "ORGAN", 9, 18], ["COVID-19", "GENE_OR_GENE_PRODUCT", 41, 49], ["patients", "ORGANISM", 205, 213], ["SARS-CoV-2", "ORGANISM", 226, 236], ["olfactory", "ORGAN", 259, 268], ["gustatory", "ORGANISM_SUBDIVISION", 273, 282], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 318, 335], ["patients", "SPECIES", 205, 213], ["SARS-CoV", "SPECIES", 226, 234], ["olfactory dysfunction", "PROBLEM", 9, 30], ["COVID", "TEST", 41, 46], ["infection", "PROBLEM", 50, 59], ["rhinorrhea", "PROBLEM", 106, 116], ["severe olfactory and gustatory dysfunctions", "PROBLEM", 252, 295], ["rhinorrhea", "PROBLEM", 304, 314], ["nasal obstruction", "PROBLEM", 318, 335], ["olfactory dysfunction", "OBSERVATION", 9, 30], ["infection", "OBSERVATION", 50, 59], ["not associated with", "UNCERTAINTY", 86, 105], ["rhinorrhea", "OBSERVATION", 106, 116], ["severe", "OBSERVATION_MODIFIER", 252, 258], ["gustatory dysfunctions", "OBSERVATION", 273, 295], ["without", "UNCERTAINTY", 296, 303], ["rhinorrhea", "OBSERVATION", 304, 314], ["nasal", "ANATOMY", 318, 323], ["obstruction", "OBSERVATION", 324, 335]]], ["At baseline, no COVID-19 was suspected in some of these patients, because they had no fever, cough, or other systemic complaints.", [["fever", "DISEASE", 86, 91], ["cough", "DISEASE", 93, 98], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["COVID", "TEST", 16, 21], ["fever", "PROBLEM", 86, 91], ["cough", "PROBLEM", 93, 98], ["other systemic complaints", "PROBLEM", 103, 128]]], ["Faced with numerous reports from otolaryngologists all around Europe, the Young-Otolaryngologists of the International Federation of Oto-rhino-laryngological Societies (YO-IFOS) decided to conduct an international epidemiological study to characterize olfactory and gustatory disorders in infected patients.IntroductionThe aim of this study is to investigate and characterize the occurrence of olfactory and gustatory disorders in patients with laboratory-confirmed COVID-19 infection.Subjects and setting ::: Materials and methodsThe clinical data of patients with laboratory-confirmed COVID-19 infection have been collected from four Belgian Hospitals (CHU Saint-Pierre, Brussels; CHU Ambroise Par\u00e9, Mons; EpiCURA, Baudour; EpiCURA, Ath), and University of Mons (Belgium).", [["olfactory", "ANATOMY", 252, 261], ["olfactory", "ANATOMY", 394, 403], ["olfactory and gustatory disorders", "DISEASE", 252, 285], ["olfactory and gustatory disorders", "DISEASE", 394, 427], ["infection", "DISEASE", 475, 484], ["infection", "DISEASE", 596, 605], ["olfactory", "ANATOMICAL_SYSTEM", 252, 261], ["gustatory", "ANATOMICAL_SYSTEM", 266, 275], ["patients", "ORGANISM", 298, 306], ["olfactory", "ANATOMICAL_SYSTEM", 394, 403], ["gustatory", "ANATOMICAL_SYSTEM", 408, 417], ["patients", "ORGANISM", 431, 439], ["patients", "ORGANISM", 552, 560], ["patients", "SPECIES", 298, 306], ["patients", "SPECIES", 431, 439], ["patients", "SPECIES", 552, 560], ["an international epidemiological study", "TEST", 197, 235], ["olfactory and gustatory disorders", "PROBLEM", 252, 285], ["this study", "TEST", 330, 340], ["olfactory and gustatory disorders", "PROBLEM", 394, 427], ["COVID", "TEST", 466, 471], ["19 infection", "PROBLEM", 472, 484], ["COVID", "TEST", 587, 592], ["19 infection", "PROBLEM", 593, 605], ["infection", "OBSERVATION", 475, 484], ["infection", "OBSERVATION", 596, 605]]], ["In addition to these ones, many other patients, infected physicians and nurses have been voluntarily enrolled in the study from the following hospitals: Foch Hospital (Paris, France); Ambroise Par\u00e9 Hospital (AP-HP, Paris), CHU Ambroise Par\u00e9 (Mons, Belgium), Hospital Universitario Donostia (Donostia, Spain); Hospital Universitario Santiago de Compostela (Santiago de Compostela, Spain); Morgagni Pierantoni Hospital (Forli, Italy), Department of Neuroscience, Audiology Unit (Padova University, Treviso, Italy), and Medical Departments of the Universit\u00e0 degli Studi della Campania \u2018Luigi Vanvitelli\u2019 (Naples, Italy).Subjects and setting ::: Materials and methodsThe following inclusion criteria have been considered: adult (> 18 years old); laboratory-confirmed COVID-19 infection (reverse transcription polymerase chain reaction, RT-PCR); native speaker patients, and patients clinically able to fulfill the questionnaire.", [["infection", "DISEASE", 772, 781], ["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 856, 864], ["patients", "ORGANISM", 870, 878], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 856, 864], ["patients", "SPECIES", 870, 878], ["COVID", "TEST", 763, 768], ["19 infection", "PROBLEM", 769, 781], ["reverse transcription polymerase chain reaction", "PROBLEM", 783, 830], ["RT-PCR", "TEST", 832, 838], ["infection", "OBSERVATION", 772, 781]]], ["The following exclusion criteria have been considered: patients with olfactory or gustatory dysfunctions before the epidemic; patients without a laboratory-confirmed COVID-19 infection diagnosis; patients who were in the intensive-care unit at the time of the study (due to their health status).", [["olfactory", "ANATOMY", 69, 78], ["gustatory", "ANATOMY", 82, 91], ["olfactory or gustatory dysfunctions", "DISEASE", 69, 104], ["infection", "DISEASE", 175, 184], ["patients", "ORGANISM", 55, 63], ["olfactory", "ORGAN", 69, 78], ["gustatory", "ORGANISM_SUBDIVISION", 82, 91], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 196, 204], ["olfactory or gustatory dysfunctions", "PROBLEM", 69, 104], ["COVID", "TEST", 166, 171], ["the study", "TEST", 256, 265], ["infection", "OBSERVATION", 175, 184]]], ["Thus, we mainly included mild-to-moderate COVID-19 patients, defined as patients without need of intensive cares.", [["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 72, 80], ["intensive cares", "TREATMENT", 97, 112], ["mild", "OBSERVATION_MODIFIER", 25, 29]]], ["Since we focused on the prevalence of olfactory and gustatory disorders, clinical presentation was not considered in as inclusion criteria.Clinical outcomes ::: Materials and methodsClinical data have been prospectively collected during the ear, nose, and throat (ENT) consultation; in the patient\u2019s room; or over the phone for house-bound patients or infected health professionals.", [["olfactory", "ANATOMY", 38, 47], ["ear", "ANATOMY", 241, 244], ["nose", "ANATOMY", 246, 250], ["olfactory and gustatory disorders", "DISEASE", 38, 71], ["olfactory", "ANATOMICAL_SYSTEM", 38, 47], ["gustatory", "ANATOMICAL_SYSTEM", 52, 61], ["ear", "ORGAN", 241, 244], ["nose", "ORGANISM_SUBDIVISION", 246, 250], ["patient", "ORGANISM", 290, 297], ["patients", "ORGANISM", 340, 348], ["patient", "SPECIES", 290, 297], ["patients", "SPECIES", 340, 348], ["olfactory and gustatory disorders", "PROBLEM", 38, 71], ["Clinical data", "TEST", 182, 195], ["ear", "ANATOMY", 241, 244], ["nose", "ANATOMY", 246, 250], ["throat", "ANATOMY", 256, 262]]], ["The data were also collected through an online form for house-bound patients.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["The data", "TEST", 0, 8]]], ["Experts analyzed the epidemiological publications of the current and the previous coronavirus infections, including SRAS-CoV-1 (2002); Middle-East respiratory syndrome-related coronavirus infection (MERS-CoV, 2012), and the COVID-19 infection.", [["coronavirus infections", "DISEASE", 82, 104], ["Middle-East respiratory syndrome", "DISEASE", 135, 167], ["coronavirus infection", "DISEASE", 176, 197], ["infection", "DISEASE", 233, 242], ["coronavirus", "ORGANISM", 82, 93], ["SRAS-CoV-1", "ORGANISM", 116, 126], ["Middle-East respiratory syndrome-related coronavirus", "ORGANISM", 135, 187], ["SRAS-CoV-1", "SPECIES", 116, 126], ["Middle-East respiratory syndrome-related coronavirus", "SPECIES", 135, 187], ["COVID-19", "SPECIES", 224, 232], ["the previous coronavirus infections", "PROBLEM", 69, 104], ["SRAS", "TEST", 116, 120], ["CoV", "TEST", 121, 124], ["Middle-East respiratory syndrome", "PROBLEM", 135, 167], ["coronavirus infection", "PROBLEM", 176, 197], ["the COVID-19 infection", "PROBLEM", 220, 242], ["coronavirus infections", "OBSERVATION", 82, 104], ["Middle", "ANATOMY_MODIFIER", 135, 141], ["respiratory syndrome", "OBSERVATION", 147, 167], ["coronavirus infection", "OBSERVATION", 176, 197], ["infection", "OBSERVATION", 233, 242]]], ["From the literature, ten experts (JRL, SS, MH, JHS, PL, TA, LD, FEA, CCH, and CMCE) developed the questionnaire, which consisted of four general questions (age, sex, ethnicity, and date of diagnosis); three general clinical questions (comorbidities, general, and ENT symptoms associated with COVID-19 infection); seven questions about olfactory function; four questions investigating gustatory function; and one question about the treatment of the COVID-19 infection.", [["olfactory", "ANATOMY", 335, 344], ["gustatory", "ANATOMY", 384, 393], ["infection", "DISEASE", 301, 310], ["infection", "DISEASE", 457, 466], ["olfactory", "ORGAN", 335, 344], ["JRL", "TEST", 34, 37], ["JHS", "TEST", 47, 50], ["ENT symptoms", "PROBLEM", 263, 275], ["COVID-19 infection", "PROBLEM", 292, 310], ["the COVID-19 infection", "PROBLEM", 444, 466], ["PL", "ANATOMY", 52, 54], ["infection", "OBSERVATION", 457, 466]]], ["All patients were asked to complete the short version of the Questionnaire of Olfactory Disorders-Negative Statements (sQOD-NS) [9].", [["Olfactory Disorders", "DISEASE", 78, 97], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["Olfactory Disorders", "PROBLEM", 78, 97]]], ["The questionnaire has been translated into Spanish, Italian, and English by two native speaker otolaryngologists for each language.Olfactory and gustatory outcomes ::: Materials and methodsThe occurrence of anosmia or hyposmia has been identified in the questionnaire.", [["Olfactory", "ANATOMY", 131, 140], ["anosmia", "DISEASE", 207, 214], ["hyposmia", "DISEASE", 218, 226], ["Olfactory", "TISSUE", 131, 140], ["gustatory", "ANATOMICAL_SYSTEM", 145, 154], ["anosmia", "PROBLEM", 207, 214], ["hyposmia", "PROBLEM", 218, 226], ["anosmia", "OBSERVATION", 207, 214], ["hyposmia", "OBSERVATION", 218, 226]]], ["The impact of olfactory dysfunction on the quality of life (QoL) of patients has been assessed through the validated sQOD-NS (Appendix 1) [9].", [["olfactory", "ANATOMY", 14, 23], ["olfactory dysfunction", "DISEASE", 14, 35], ["olfactory", "ANATOMICAL_SYSTEM", 14, 23], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["olfactory dysfunction", "PROBLEM", 14, 35], ["olfactory dysfunction", "OBSERVATION", 14, 35]]], ["This is a seven-item patient-reported outcome questionnaire including social, eating, annoyance, and anxiety questions.", [["anxiety", "DISEASE", 101, 108], ["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28]]], ["Each item is rated on a scale of 0\u20133, with higher scores reflecting better olfactory-specific QoL.", [["olfactory", "ANATOMICAL_SYSTEM", 75, 84]]], ["The total score ranges from 0 (severe impact on QoL) to 21 (no impact on QoL) [9].", [["The total score ranges", "TEST", 0, 22]]], ["The rest of the olfactory and gustatory questions were based on the smell and taste component of the National Health and Nutrition Examination Survey [10].", [["olfactory", "ANATOMY", 16, 25], ["olfactory", "ANATOMICAL_SYSTEM", 16, 25]]], ["This population survey was implemented by the Centers for Disease Control and Prevention to continuously monitor the health of adult citizens in the United States through a nationally representative sample of 5000 persons yearly [10].", [["persons", "ORGANISM", 214, 221], ["persons", "SPECIES", 214, 221], ["Disease Control", "TREATMENT", 58, 73]]], ["The questions have been chosen to characterize the variation, timing, and associated symptoms of both olfactory and gustatory dysfunctions, and, therefore, they suggest a potential etiology.", [["olfactory", "ANATOMY", 102, 111], ["gustatory", "ANATOMY", 116, 125], ["olfactory and gustatory dysfunctions", "DISEASE", 102, 138], ["olfactory", "ORGAN", 102, 111], ["gustatory", "ANATOMICAL_SYSTEM", 116, 125], ["associated symptoms", "PROBLEM", 74, 93], ["both olfactory and gustatory dysfunctions", "PROBLEM", 97, 138]]], ["Note that we assessed the mean recovery time of olfaction through four defined propositions: 1\u20134 days; 5\u20138 days; 9\u201314 days; and > 15 days.Olfactory and gustatory outcomes ::: Materials and methodsReferring to the studies that have demonstrated that the viral load was significantly decreased after 14 days [11], we assessed the short-term olfaction non-recovery rate on patients exhibiting double criteria: an onset of the infection > 14 days before the assessment and the lack of general symptoms at the time of the evaluation.Statistical methods ::: Materials and methodsStatistical Package for the Social Sciences for Windows (SPSS version 22,0; IBM Corp, Armonk, NY, USA) was used to perform the statistical analyses.", [["Olfactory", "ANATOMY", 138, 147], ["infection", "DISEASE", 423, 432], ["Olfactory", "TISSUE", 138, 147], ["gustatory", "ANATOMICAL_SYSTEM", 152, 161], ["patients", "ORGANISM", 370, 378], ["patients", "SPECIES", 370, 378], ["the studies", "TEST", 209, 220], ["the viral load", "TEST", 249, 263], ["the infection", "PROBLEM", 419, 432], ["the assessment", "TEST", 450, 464], ["general symptoms", "PROBLEM", 481, 497], ["the evaluation", "TEST", 513, 527], ["the statistical analyses", "TEST", 696, 720], ["infection", "OBSERVATION", 423, 432]]], ["The potential associations between epidemiological, clinical and olfactory and gustatory outcomes have been assessed through cross-tab generation between two variables (binary or categorical variables) and Chi-square test.", [["olfactory", "ANATOMICAL_SYSTEM", 65, 74], ["gustatory", "ANATOMICAL_SYSTEM", 79, 88], ["Chi-square test", "TEST", 206, 221]]], ["Incomplete responses were excluded from analysis.", [["analysis", "TEST", 40, 48]]], ["The differences in sQOD-NS scores between patients regarding the olfactory dysfunction were made through the Kruskal\u2013Wallis test.", [["olfactory", "ANATOMY", 65, 74], ["olfactory dysfunction", "DISEASE", 65, 86], ["patients", "ORGANISM", 42, 50], ["olfactory", "ORGAN", 65, 74], ["patients", "SPECIES", 42, 50], ["sQOD-NS scores", "TREATMENT", 19, 33], ["the olfactory dysfunction", "PROBLEM", 61, 86], ["the Kruskal\u2013Wallis test", "TEST", 105, 128]]], ["A level of p < 0.05 was used to determine statistical significance.Clinical outcomes ::: ResultsThe general symptoms of patients during the infection are described in Fig. 2.", [["infection", "DISEASE", 140, 149], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["The general symptoms", "PROBLEM", 96, 116], ["the infection", "PROBLEM", 136, 149], ["infection", "OBSERVATION", 140, 149]]], ["Cough, myalgia, loss of appetite, diarrhea, fever, headache, and asthenia were the most prevalent symptoms, accounting for more than 45% of patients.", [["Cough", "DISEASE", 0, 5], ["myalgia", "DISEASE", 7, 14], ["loss of appetite", "DISEASE", 16, 32], ["diarrhea", "DISEASE", 34, 42], ["fever", "DISEASE", 44, 49], ["headache", "DISEASE", 51, 59], ["asthenia", "DISEASE", 65, 73], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["Cough", "PROBLEM", 0, 5], ["myalgia", "PROBLEM", 7, 14], ["loss of appetite", "PROBLEM", 16, 32], ["diarrhea", "PROBLEM", 34, 42], ["fever", "PROBLEM", 44, 49], ["headache", "PROBLEM", 51, 59], ["asthenia", "PROBLEM", 65, 73], ["the most prevalent symptoms", "PROBLEM", 79, 106], ["myalgia", "OBSERVATION", 7, 14], ["most prevalent", "OBSERVATION_MODIFIER", 83, 97]]], ["The otolaryngological symptoms most related to the infection are reported in Table 2.Olfactory outcomes ::: ResultsA total of 357 patients (85.6%) had olfactory dysfunction related to the infection.", [["Olfactory", "ANATOMY", 85, 94], ["olfactory", "ANATOMY", 151, 160], ["infection", "DISEASE", 51, 60], ["olfactory dysfunction", "DISEASE", 151, 172], ["infection", "DISEASE", 188, 197], ["Olfactory", "ORGAN", 85, 94], ["patients", "ORGANISM", 130, 138], ["olfactory", "ORGAN", 151, 160], ["patients", "SPECIES", 130, 138], ["The otolaryngological symptoms", "PROBLEM", 0, 30], ["the infection", "PROBLEM", 47, 60], ["olfactory dysfunction", "PROBLEM", 151, 172], ["the infection", "PROBLEM", 184, 197], ["infection", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 188, 197]]], ["Among them, 284 (79.6%) patients were anosmic and 73 (20.4%) were hyposmic.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["anosmic", "TEST", 38, 45], ["hyposmic", "PROBLEM", 66, 74]]], ["Phantosmia and parosmia concerned 12.6% and 32.4% of patients during the disease course, respectively.", [["Phantosmia", "DISEASE", 0, 10], ["parosmia", "DISEASE", 15, 23], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Phantosmia", "TEST", 0, 10], ["parosmia", "TEST", 15, 23]]], ["The olfactory dysfunction appeared before (11.8%), after (65.4%) or at the same time as the appearance of general or ENT symptoms (22.8%).", [["olfactory", "ANATOMY", 4, 13], ["olfactory dysfunction", "DISEASE", 4, 25], ["olfactory", "ORGAN", 4, 13], ["The olfactory dysfunction", "PROBLEM", 0, 25], ["general or ENT symptoms", "PROBLEM", 106, 129], ["olfactory dysfunction", "OBSERVATION", 4, 25]]], ["Note that 9.4% of patients did not remember the time of onset of olfactory dysfunction and, therefore, were not considered for the percentage evaluation.Olfactory outcomes ::: ResultsConsidering the 247 patients with a clinically resolved infection (absence of general and ENT symptoms), the olfactory dysfunction persisted after the resolution of other symptoms in 63.0% of cases.", [["olfactory", "ANATOMY", 65, 74], ["Olfactory", "ANATOMY", 153, 162], ["olfactory", "ANATOMY", 292, 301], ["olfactory dysfunction", "DISEASE", 65, 86], ["infection", "DISEASE", 239, 248], ["olfactory dysfunction", "DISEASE", 292, 313], ["patients", "ORGANISM", 18, 26], ["olfactory", "ORGAN", 65, 74], ["Olfactory", "ORGAN", 153, 162], ["patients", "ORGANISM", 203, 211], ["olfactory", "ORGAN", 292, 301], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 203, 211], ["olfactory dysfunction", "PROBLEM", 65, 86], ["the percentage evaluation", "TEST", 127, 152], ["a clinically resolved infection", "PROBLEM", 217, 248], ["general and ENT symptoms", "PROBLEM", 261, 285], ["the olfactory dysfunction", "PROBLEM", 288, 313], ["other symptoms", "PROBLEM", 348, 362], ["dysfunction", "OBSERVATION", 75, 86], ["infection", "OBSERVATION", 239, 248]]], ["The mean time between the onset of the disease and the assessment of this group of patients was 9.77 \u00b1 5.68 days.Olfactory outcomes ::: ResultsThe short-term olfaction recovery rate, which was assessed in 59 clinically cured patients, was 44.0%.", [["Olfactory", "ANATOMY", 113, 122], ["patients", "ORGANISM", 83, 91], ["Olfactory", "ORGAN", 113, 122], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 225, 233], ["the disease", "PROBLEM", 35, 46], ["the assessment", "TEST", 51, 65], ["disease", "OBSERVATION", 39, 46]]], ["The different recovery times of the olfactory function of patients who reported a recovery of the olfactory function are available in Fig. 3.", [["olfactory", "ANATOMY", 36, 45], ["olfactory", "ANATOMY", 98, 107], ["olfactory", "ORGAN", 36, 45], ["patients", "ORGANISM", 58, 66], ["olfactory", "ORGAN", 98, 107], ["patients", "SPECIES", 58, 66], ["different", "OBSERVATION_MODIFIER", 4, 13], ["recovery", "OBSERVATION_MODIFIER", 14, 22]]], ["In total, 72.6% of these patients recovered olfactory function within the first 8 days following the resolution of the disease.", [["olfactory", "ANATOMY", 44, 53], ["patients", "ORGANISM", 25, 33], ["olfactory", "ORGAN", 44, 53], ["patients", "SPECIES", 25, 33], ["the disease", "PROBLEM", 115, 126], ["disease", "OBSERVATION", 119, 126]]], ["Among the patients who reported anosmia, then, excluding hyposmic patients, the olfactory function recovered throughout the 8 first days following the resolution of the disease in 67.8% of cases (Fig. 3).Olfactory outcomes ::: ResultsIn the present study, 76 patients did not suffer from nasal obstruction or rhinorrhea (18.2%).", [["olfactory", "ANATOMY", 80, 89], ["Olfactory", "ANATOMY", 204, 213], ["nasal", "ANATOMY", 288, 293], ["anosmia", "DISEASE", 32, 39], ["nasal obstruction", "DISEASE", 288, 305], ["rhinorrhea", "DISEASE", 309, 319], ["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 66, 74], ["olfactory", "ORGAN", 80, 89], ["Olfactory", "ORGAN", 204, 213], ["patients", "ORGANISM", 259, 267], ["nasal", "ORGANISM_SUBDIVISION", 288, 293], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 259, 267], ["anosmia", "PROBLEM", 32, 39], ["the disease", "PROBLEM", 165, 176], ["the present study", "TEST", 237, 254], ["nasal obstruction", "PROBLEM", 288, 305], ["rhinorrhea", "PROBLEM", 309, 319], ["disease", "OBSERVATION", 169, 176], ["nasal", "ANATOMY", 288, 293], ["obstruction", "OBSERVATION", 294, 305], ["rhinorrhea", "OBSERVATION", 309, 319]]], ["Among them, 20.3% did not report olfactory dysfunction, whereas 66.2% and 13.5% suffered from anosmia and hyposmia, respectively.Olfactory outcomes ::: ResultsThe impact of olfactory dysfunction on patient QoL is reported in Table 3.", [["olfactory", "ANATOMY", 33, 42], ["Olfactory", "ANATOMY", 129, 138], ["olfactory", "ANATOMY", 173, 182], ["olfactory dysfunction", "DISEASE", 33, 54], ["anosmia", "DISEASE", 94, 101], ["hyposmia", "DISEASE", 106, 114], ["olfactory dysfunction", "DISEASE", 173, 194], ["olfactory", "ORGAN", 33, 42], ["Olfactory", "ORGAN", 129, 138], ["olfactory", "ORGAN", 173, 182], ["patient", "ORGANISM", 198, 205], ["patient", "SPECIES", 198, 205], ["olfactory dysfunction", "PROBLEM", 33, 54], ["anosmia", "PROBLEM", 94, 101], ["hyposmia", "PROBLEM", 106, 114], ["olfactory dysfunction", "PROBLEM", 173, 194], ["hyposmia", "OBSERVATION", 106, 114], ["olfactory dysfunction", "OBSERVATION", 173, 194]]], ["Anosmic patients at the time of the evaluation had a significant lower sQOD-NS score compared with hyposmic and normosmic individuals (p = 0.001; Kruskal\u2013Wallis).Gustatory outcomes ::: ResultsA total of 342 patients (88.8%) reported gustatory disorders, which was characterized by impairment of the following four taste modalities: salty, sweet, bitter, and sour.", [["gustatory disorders", "DISEASE", 233, 252], ["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 207, 215], ["sweet", "ORGANISM_SUBDIVISION", 339, 344], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 207, 215], ["the evaluation", "TEST", 32, 46], ["a significant lower sQOD-NS score", "PROBLEM", 51, 84], ["hyposmic", "TEST", 99, 107], ["gustatory disorders", "PROBLEM", 233, 252]]], ["Note that 32 patients did not remember if they had gustatory dysfunction and, therefore, they were not considered for the assessment of the gustatory disorder prevalence.", [["gustatory", "ANATOMY", 51, 60], ["gustatory dysfunction", "DISEASE", 51, 72], ["gustatory disorder", "DISEASE", 140, 158], ["patients", "ORGANISM", 13, 21], ["gustatory", "ORGANISM_SUBDIVISION", 140, 149], ["patients", "SPECIES", 13, 21], ["gustatory dysfunction", "PROBLEM", 51, 72], ["the assessment", "TEST", 118, 132], ["the gustatory disorder prevalence", "PROBLEM", 136, 169]]], ["The gustatory dysfunction consisted of reduced/discontinued or distorted ability to taste flavors in 78.9% and 21.1% of patients, respectively.Gustatory outcomes ::: ResultsAmong the 43 patients without gustatory dysfunction, 19 (44.2%) have no olfactory dysfunction, whereas 16 (37.2%) and 4 (9.3%) patients had anosmia or hyposmia.Gustatory outcomes ::: ResultsThe olfactory and gustatory disorders were constant and unchanged over the days in 72.8% of patients, whereas they fluctuated in 23.4% of patients.", [["gustatory", "ANATOMY", 4, 13], ["gustatory", "ANATOMY", 203, 212], ["olfactory", "ANATOMY", 245, 254], ["olfactory", "ANATOMY", 367, 376], ["gustatory", "ANATOMY", 381, 390], ["gustatory dysfunction", "DISEASE", 4, 25], ["gustatory dysfunction", "DISEASE", 203, 224], ["olfactory dysfunction", "DISEASE", 245, 266], ["anosmia", "DISEASE", 313, 320], ["hyposmia", "DISEASE", 324, 332], ["olfactory and gustatory disorders", "DISEASE", 367, 400], ["gustatory", "ANATOMICAL_SYSTEM", 4, 13], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 186, 194], ["gustatory", "ORGANISM_SUBDIVISION", 203, 212], ["olfactory", "ORGAN", 245, 254], ["patients", "ORGANISM", 300, 308], ["olfactory", "ORGAN", 367, 376], ["gustatory", "ANATOMICAL_SYSTEM", 381, 390], ["patients", "ORGANISM", 455, 463], ["patients", "ORGANISM", 501, 509], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 300, 308], ["patients", "SPECIES", 455, 463], ["patients", "SPECIES", 501, 509], ["The gustatory dysfunction", "PROBLEM", 0, 25], ["gustatory dysfunction", "PROBLEM", 203, 224], ["olfactory dysfunction", "PROBLEM", 245, 266], ["anosmia", "PROBLEM", 313, 320], ["hyposmia", "PROBLEM", 324, 332], ["gustatory disorders", "PROBLEM", 381, 400], ["gustatory dysfunction", "OBSERVATION", 4, 25], ["reduced", "OBSERVATION_MODIFIER", 39, 46], ["no", "UNCERTAINTY", 242, 244], ["hyposmia", "OBSERVATION", 324, 332], ["unchanged", "OBSERVATION_MODIFIER", 419, 428]]], ["Among the patients who reported gustatory and olfactory disorders, 3.8% revealed that these disorders occurred during their rhinorrhea or nasal obstruction episodes.Gustatory outcomes ::: ResultsAmong the cured patients who had residual olfactory and/or gustatory dysfunction, 53.9% had isolated olfactory dysfunction, 22.5% had isolated gustatory dysfunction, and 23.6% had both olfactory and gustatory dysfunctions.Olfactory and gustatory outcome associations ::: ResultsThere was no significant association between comorbidities and the development of olfactory or gustatory dysfunctions.", [["olfactory", "ANATOMY", 46, 55], ["nasal", "ANATOMY", 138, 143], ["olfactory", "ANATOMY", 237, 246], ["gustatory", "ANATOMY", 254, 263], ["olfactory", "ANATOMY", 296, 305], ["gustatory", "ANATOMY", 338, 347], ["olfactory", "ANATOMY", 380, 389], ["gustatory", "ANATOMY", 394, 403], ["Olfactory", "ANATOMY", 417, 426], ["olfactory", "ANATOMY", 555, 564], ["gustatory", "ANATOMY", 568, 577], ["gustatory and olfactory disorders", "DISEASE", 32, 65], ["rhinorrhea", "DISEASE", 124, 134], ["nasal obstruction", "DISEASE", 138, 155], ["residual olfactory and/or gustatory dysfunction", "DISEASE", 228, 275], ["olfactory dysfunction", "DISEASE", 296, 317], ["gustatory dysfunction", "DISEASE", 338, 359], ["olfactory and gustatory dysfunctions", "DISEASE", 380, 416], ["olfactory or gustatory dysfunctions", "DISEASE", 555, 590], ["patients", "ORGANISM", 10, 18], ["olfactory", "ANATOMICAL_SYSTEM", 46, 55], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 138, 155], ["patients", "ORGANISM", 211, 219], ["olfactory", "ORGAN", 237, 246], ["gustatory", "ORGANISM_SUBDIVISION", 254, 263], ["olfactory", "ORGAN", 296, 305], ["gustatory", "ORGANISM_SUBDIVISION", 338, 347], ["olfactory", "ORGAN", 380, 389], ["gustatory", "ORGANISM_SUBDIVISION", 394, 403], ["Olfactory", "TISSUE", 417, 426], ["olfactory", "ORGAN", 555, 564], ["gustatory", "ORGANISM_SUBDIVISION", 568, 577], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 211, 219], ["olfactory disorders", "PROBLEM", 46, 65], ["these disorders", "PROBLEM", 86, 101], ["their rhinorrhea", "PROBLEM", 118, 134], ["nasal obstruction episodes", "PROBLEM", 138, 164], ["residual olfactory and/or gustatory dysfunction", "PROBLEM", 228, 275], ["isolated olfactory dysfunction", "PROBLEM", 287, 317], ["isolated gustatory dysfunction", "PROBLEM", 329, 359], ["gustatory dysfunctions", "PROBLEM", 394, 416], ["significant association between comorbidities", "PROBLEM", 486, 531], ["olfactory or gustatory dysfunctions", "PROBLEM", 555, 590], ["nasal", "ANATOMY", 138, 143], ["obstruction", "OBSERVATION", 144, 155], ["olfactory dysfunction", "OBSERVATION", 296, 317], ["gustatory dysfunction", "OBSERVATION", 338, 359], ["gustatory dysfunctions", "OBSERVATION", 394, 416], ["no", "UNCERTAINTY", 483, 485], ["significant", "OBSERVATION_MODIFIER", 486, 497], ["gustatory dysfunctions", "OBSERVATION", 568, 590]]], ["Olfactory dysfunction was not significantly associated with rhinorrhea or nasal obstruction.", [["Olfactory", "ANATOMY", 0, 9], ["nasal", "ANATOMY", 74, 79], ["Olfactory dysfunction", "DISEASE", 0, 21], ["rhinorrhea", "DISEASE", 60, 70], ["nasal obstruction", "DISEASE", 74, 91], ["Olfactory", "ORGAN", 0, 9], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 74, 91], ["Olfactory dysfunction", "PROBLEM", 0, 21], ["rhinorrhea", "PROBLEM", 60, 70], ["nasal obstruction", "PROBLEM", 74, 91], ["dysfunction", "OBSERVATION", 10, 21], ["not significantly associated with", "UNCERTAINTY", 26, 59], ["rhinorrhea", "OBSERVATION", 60, 70], ["nasal", "ANATOMY", 74, 79], ["obstruction", "OBSERVATION", 80, 91]]], ["There was a significant positive association between olfactory and gustatory dysfunctions (p < 0.001).", [["olfactory", "ANATOMY", 53, 62], ["gustatory", "ANATOMY", 67, 76], ["olfactory and gustatory dysfunctions", "DISEASE", 53, 89], ["olfactory", "ORGAN", 53, 62], ["gustatory", "ORGANISM_SUBDIVISION", 67, 76], ["a significant positive association between olfactory and gustatory dysfunctions", "PROBLEM", 10, 89], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["positive", "OBSERVATION", 24, 32], ["gustatory dysfunctions", "OBSERVATION", 67, 89]]], ["The statistical analysis identified a significant association between the fever and the anosmia (p = 0.014).", [["fever", "DISEASE", 74, 79], ["anosmia", "DISEASE", 88, 95], ["The statistical analysis", "TEST", 0, 24], ["the fever", "PROBLEM", 70, 79], ["the anosmia", "PROBLEM", 84, 95], ["significant", "OBSERVATION_MODIFIER", 38, 49]]], ["The females would be proportionally more affected by hyposmia or anosmia compared with males (p < 0.001).", [["hyposmia", "DISEASE", 53, 61], ["anosmia", "DISEASE", 65, 72], ["hyposmia", "PROBLEM", 53, 61], ["anosmia", "PROBLEM", 65, 72], ["females", "OBSERVATION", 4, 11], ["hyposmia", "OBSERVATION", 53, 61]]], ["Similar results were found for gustatory dysfunction (p = 0.001, Mann\u2013Whitney U test).Treatments of COVID-19 patients ::: ResultsThe following general treatments have been considered for patients with the COVID-19 infection: paracetamol (62.4%); non-steroidal anti-inflammatory drugs (9.8%); nasal saline irrigations (9.6%); Chloroquine (7.9%); mucolytics (5.0%); and oral corticosteroids (1.4%, with concomitant antibiotics) (Fig. 4).", [["gustatory", "ANATOMY", 31, 40], ["non-steroidal", "ANATOMY", 246, 259], ["nasal", "ANATOMY", 292, 297], ["oral", "ANATOMY", 368, 372], ["gustatory dysfunction", "DISEASE", 31, 52], ["infection", "DISEASE", 214, 223], ["paracetamol", "CHEMICAL", 225, 236], ["Chloroquine", "CHEMICAL", 325, 336], ["mucolytics", "DISEASE", 345, 355], ["paracetamol", "CHEMICAL", 225, 236], ["Chloroquine", "CHEMICAL", 325, 336], ["gustatory", "ORGANISM_SUBDIVISION", 31, 40], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 187, 195], ["paracetamol", "SIMPLE_CHEMICAL", 225, 236], ["non-steroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 246, 283], ["Chloroquine", "SIMPLE_CHEMICAL", 325, 336], ["mucolytics", "SIMPLE_CHEMICAL", 345, 355], ["oral", "ORGANISM_SUBDIVISION", 368, 372], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 187, 195], ["gustatory dysfunction", "PROBLEM", 31, 52], ["Mann\u2013Whitney U test", "TEST", 65, 84], ["the COVID-19 infection", "PROBLEM", 201, 223], ["paracetamol", "TREATMENT", 225, 236], ["non-steroidal anti-inflammatory drugs", "TREATMENT", 246, 283], ["nasal saline irrigations", "TREATMENT", 292, 316], ["Chloroquine", "TREATMENT", 325, 336], ["mucolytics", "TREATMENT", 345, 355], ["oral corticosteroids", "TREATMENT", 368, 388], ["concomitant antibiotics", "TREATMENT", 401, 424]]], ["The treatments that have been most used for olfactory dysfunction were nasal saline irrigations (16.7%); nasal corticosteroids (8.1%), oral corticosteroids (2.5%), and others (2.5%, e.g., vitamins, non-corticoid decongestants, and trace elements) (Fig. 4).", [["olfactory", "ANATOMY", 44, 53], ["nasal", "ANATOMY", 71, 76], ["nasal", "ANATOMY", 105, 110], ["oral", "ANATOMY", 135, 139], ["olfactory dysfunction", "DISEASE", 44, 65], ["corticosteroids", "CHEMICAL", 140, 155], ["corticosteroids", "CHEMICAL", 111, 126], ["corticosteroids", "CHEMICAL", 140, 155], ["olfactory", "ORGAN", 44, 53], ["nasal", "ORGANISM_SUBDIVISION", 105, 110], ["oral", "ORGANISM_SUBDIVISION", 135, 139], ["vitamins", "SIMPLE_CHEMICAL", 188, 196], ["non-corticoid decongestants", "SIMPLE_CHEMICAL", 198, 225], ["The treatments", "TREATMENT", 0, 14], ["olfactory dysfunction", "PROBLEM", 44, 65], ["nasal saline irrigations", "TREATMENT", 71, 95], ["nasal corticosteroids", "TREATMENT", 105, 126], ["oral corticosteroids", "TREATMENT", 135, 155], ["vitamins", "TREATMENT", 188, 196], ["non-corticoid decongestants", "TREATMENT", 198, 225], ["trace elements", "OBSERVATION", 231, 245]]], ["Gustatory dysfunction was treated in 1.4% of patients: four patients received treatment, consisting of l-carnitine or trace elements and vitamins.", [["Gustatory dysfunction", "DISEASE", 0, 21], ["l-carnitine", "CHEMICAL", 103, 114], ["vitamins", "CHEMICAL", 137, 145], ["l-carnitine", "CHEMICAL", 103, 114], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 60, 68], ["l-carnitine", "SIMPLE_CHEMICAL", 103, 114], ["vitamins", "SIMPLE_CHEMICAL", 137, 145], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 60, 68], ["Gustatory dysfunction", "PROBLEM", 0, 21], ["treatment", "TREATMENT", 78, 87], ["l-carnitine", "TREATMENT", 103, 114], ["trace elements", "TREATMENT", 118, 132], ["vitamins", "TREATMENT", 137, 145], ["dysfunction", "OBSERVATION", 10, 21]]], ["Telemedicine has been used in 42.6% of patients for prescribing the treatment.DiscussionOver the past few weeks, an increasing number of otolaryngologists reported sudden anosmia or hyposmia as concurrent symptoms of COVID-19 infection.", [["anosmia", "DISEASE", 171, 178], ["hyposmia", "DISEASE", 182, 190], ["COVID-19", "CHEMICAL", 217, 225], ["infection", "DISEASE", 226, 235], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["Telemedicine", "TREATMENT", 0, 12], ["the treatment", "TREATMENT", 64, 77], ["sudden anosmia", "PROBLEM", 164, 178], ["hyposmia", "PROBLEM", 182, 190], ["concurrent symptoms", "PROBLEM", 194, 213], ["COVID-19 infection", "PROBLEM", 217, 235], ["infection", "OBSERVATION", 226, 235]]], ["In these patients, the diagnosis of COVID-19 could be missed, because these symptoms were not known to be specific.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["COVID", "TEST", 36, 41], ["these symptoms", "PROBLEM", 70, 84]]], ["As a result, the patients were not isolated and the spread of the virus continued.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["the virus", "PROBLEM", 62, 71], ["virus", "OBSERVATION", 66, 71]]], ["In this context, the COVID-19 Task Force of the YO-IFOS has conducted this study to investigate the prevalence and the short-term evolution of both olfactory and gustatory disorders.DiscussionBased on the National Health and Nutrition Examination Survey questions, our results support that olfactory and gustatory dysfunctions are both prevalent in patients with mild-to-moderate COVID-19 infection.", [["olfactory", "ANATOMY", 148, 157], ["olfactory", "ANATOMY", 290, 299], ["gustatory", "ANATOMY", 304, 313], ["olfactory and gustatory disorders", "DISEASE", 148, 181], ["olfactory and gustatory dysfunctions", "DISEASE", 290, 326], ["infection", "DISEASE", 389, 398], ["olfactory", "ANATOMICAL_SYSTEM", 148, 157], ["gustatory", "ANATOMICAL_SYSTEM", 162, 171], ["olfactory", "ANATOMICAL_SYSTEM", 290, 299], ["gustatory", "ANATOMICAL_SYSTEM", 304, 313], ["patients", "ORGANISM", 349, 357], ["patients", "SPECIES", 349, 357], ["this study", "TEST", 70, 80], ["both olfactory and gustatory disorders", "PROBLEM", 143, 181], ["Nutrition Examination", "TEST", 225, 246], ["olfactory and gustatory dysfunctions", "PROBLEM", 290, 326], ["mild-to-moderate COVID-19 infection", "PROBLEM", 363, 398], ["short-term", "OBSERVATION_MODIFIER", 119, 129], ["gustatory disorders", "OBSERVATION", 162, 181], ["moderate", "OBSERVATION_MODIFIER", 371, 379], ["infection", "OBSERVATION", 389, 398]]], ["Thus, 85.6% of patients reported olfactory dysfunction; 79.6% of them having anosmia.", [["olfactory", "ANATOMY", 33, 42], ["olfactory dysfunction", "DISEASE", 33, 54], ["anosmia", "DISEASE", 77, 84], ["patients", "ORGANISM", 15, 23], ["olfactory", "ORGAN", 33, 42], ["patients", "SPECIES", 15, 23], ["olfactory dysfunction", "PROBLEM", 33, 54], ["anosmia", "PROBLEM", 77, 84]]], ["Interestingly, many profiles of patients have been identified.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["First, our data showed that 79.7% of patients without nasal obstruction or rhinorrhea reported hyposmia or anosmia, supporting the role of otolaryngologists as the first-line physicians for some COVID-19 patients.", [["nasal", "ANATOMY", 54, 59], ["nasal obstruction", "DISEASE", 54, 71], ["rhinorrhea", "DISEASE", 75, 85], ["hyposmia", "DISEASE", 95, 103], ["anosmia", "DISEASE", 107, 114], ["patients", "ORGANISM", 37, 45], ["nasal", "ORGANISM_SUBDIVISION", 54, 59], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 204, 212], ["our data", "TEST", 7, 15], ["nasal obstruction", "PROBLEM", 54, 71], ["rhinorrhea", "PROBLEM", 75, 85], ["hyposmia", "PROBLEM", 95, 103], ["anosmia", "PROBLEM", 107, 114], ["without", "UNCERTAINTY", 46, 53], ["nasal", "ANATOMY", 54, 59], ["obstruction", "OBSERVATION", 60, 71], ["rhinorrhea", "OBSERVATION", 75, 85]]], ["Second, the olfactory dysfunction may appear before, during, or after the general symptoms, with the occurrence of fever being associated with the olfactory dysfunction.", [["olfactory", "ANATOMY", 12, 21], ["olfactory", "ANATOMY", 147, 156], ["olfactory dysfunction", "DISEASE", 12, 33], ["fever", "DISEASE", 115, 120], ["olfactory dysfunction", "DISEASE", 147, 168], ["olfactory", "ORGAN", 12, 21], ["olfactory", "ORGAN", 147, 156], ["the olfactory dysfunction", "PROBLEM", 8, 33], ["the general symptoms", "PROBLEM", 70, 90], ["fever", "PROBLEM", 115, 120], ["the olfactory dysfunction", "PROBLEM", 143, 168], ["olfactory dysfunction", "OBSERVATION", 12, 33], ["may appear", "UNCERTAINTY", 34, 44], ["fever", "OBSERVATION", 115, 120], ["olfactory dysfunction", "OBSERVATION", 147, 168]]], ["There have been few studies on the occurrence of olfactory and gustatory dysfunctions in Asia, since only one study reported hyposmia as a symptom of the COVID-19 infection [12].", [["olfactory", "ANATOMY", 49, 58], ["gustatory", "ANATOMY", 63, 72], ["olfactory and gustatory dysfunctions", "DISEASE", 49, 85], ["hyposmia", "DISEASE", 125, 133], ["infection", "DISEASE", 163, 172], ["olfactory", "ANATOMICAL_SYSTEM", 49, 58], ["gustatory", "ANATOMICAL_SYSTEM", 63, 72], ["few studies", "TEST", 16, 27], ["olfactory and gustatory dysfunctions", "PROBLEM", 49, 85], ["one study", "TEST", 106, 115], ["hyposmia", "PROBLEM", 125, 133], ["the COVID-19 infection", "PROBLEM", 150, 172], ["few", "OBSERVATION_MODIFIER", 16, 19]]], ["In the study of Mao et al., patients with peripheral nervous system symptoms attributed to COVID-19 infection, the most common the most common complaints were hypogeusia (5.6%) and hyposmia (5.1%) [12].", [["peripheral nervous system", "ANATOMY", 42, 67], ["peripheral nervous system symptoms", "DISEASE", 42, 76], ["infection", "DISEASE", 100, 109], ["hypogeusia", "DISEASE", 159, 169], ["hyposmia", "DISEASE", 181, 189], ["patients", "ORGANISM", 28, 36], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 42, 67], ["patients", "SPECIES", 28, 36], ["peripheral nervous system symptoms", "PROBLEM", 42, 76], ["COVID-19 infection", "PROBLEM", 91, 109], ["hypogeusia", "PROBLEM", 159, 169], ["hyposmia", "PROBLEM", 181, 189], ["peripheral", "ANATOMY_MODIFIER", 42, 52], ["nervous", "ANATOMY", 53, 60], ["infection", "OBSERVATION", 100, 109]]], ["According to the data of the present study, the prevalence of olfactory and gustatory dysfunction is substantially higher in European COVID-19 patients.", [["olfactory", "ANATOMY", 62, 71], ["gustatory", "ANATOMY", 76, 85], ["olfactory and gustatory dysfunction", "DISEASE", 62, 97], ["olfactory", "ANATOMICAL_SYSTEM", 62, 71], ["gustatory", "ANATOMICAL_SYSTEM", 76, 85], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["the present study", "TEST", 25, 42], ["olfactory and gustatory dysfunction", "PROBLEM", 62, 97], ["gustatory dysfunction", "OBSERVATION", 76, 97], ["substantially", "OBSERVATION_MODIFIER", 101, 114], ["higher", "OBSERVATION_MODIFIER", 115, 121]]], ["In addition to the high prevalence, physicians must keep in mind that olfactory disorder may appear before the rest of the complaints in 11.8% of cases, yielding the symptoms important for the early detection of the disease.DiscussionOne of the most important questions from the otolaryngologists concerned the recovery of olfactory and gustatory functions.", [["olfactory", "ANATOMY", 70, 79], ["olfactory", "ANATOMY", 323, 332], ["gustatory", "ANATOMY", 337, 346], ["olfactory disorder", "DISEASE", 70, 88], ["olfactory", "ORGAN", 70, 79], ["olfactory", "ANATOMICAL_SYSTEM", 323, 332], ["gustatory", "ANATOMICAL_SYSTEM", 337, 346], ["olfactory disorder", "PROBLEM", 70, 88], ["the symptoms", "PROBLEM", 162, 174], ["the disease", "PROBLEM", 212, 223], ["disease", "OBSERVATION", 216, 223]]], ["Although our results are still preliminary, it seems that, at least, 25.5% of patients recovered both olfactory and gustatory functions throughout the 2 weeks after the resolution of general symptoms.", [["olfactory", "ANATOMY", 102, 111], ["gustatory", "ANATOMY", 116, 125], ["patients", "ORGANISM", 78, 86], ["olfactory", "ANATOMICAL_SYSTEM", 102, 111], ["gustatory", "ANATOMICAL_SYSTEM", 116, 125], ["patients", "SPECIES", 78, 86], ["general symptoms", "PROBLEM", 183, 199]]], ["Considering the time to get a significant reduction of the viral load [10], we have estimated that 56% of patients have persistent olfactory dysfunction over the days following the resolution of the COVID-19 general clinical manifestations.", [["olfactory", "ANATOMY", 131, 140], ["olfactory dysfunction", "DISEASE", 131, 152], ["patients", "ORGANISM", 106, 114], ["olfactory", "ORGAN", 131, 140], ["patients", "SPECIES", 106, 114], ["the viral load", "PROBLEM", 55, 69], ["persistent olfactory dysfunction", "PROBLEM", 120, 152], ["the COVID", "TEST", 195, 204], ["general clinical manifestations", "PROBLEM", 208, 239], ["viral load", "OBSERVATION", 59, 69], ["persistent", "OBSERVATION_MODIFIER", 120, 130], ["olfactory dysfunction", "OBSERVATION", 131, 152]]], ["In the same vein, some patients seemed to recover olfaction, but not taste, and vice versa.", [["vein", "ANATOMY", 12, 16], ["vein", "MULTI-TISSUE_STRUCTURE", 12, 16], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["vein", "ANATOMY", 12, 16]]], ["Naturally, there are short-term observations and it is reasonable to think that a large number of these patients will recover the olfactory or gustatory functions over the weeks following the disease resolution.", [["olfactory", "ANATOMY", 130, 139], ["gustatory", "ANATOMY", 143, 152], ["patients", "ORGANISM", 104, 112], ["olfactory", "ANATOMICAL_SYSTEM", 130, 139], ["gustatory", "ANATOMICAL_SYSTEM", 143, 152], ["patients", "SPECIES", 104, 112], ["the disease resolution", "PROBLEM", 188, 210], ["short-term", "OBSERVATION_MODIFIER", 21, 31], ["large", "OBSERVATION_MODIFIER", 82, 87]]], ["To summarize, the present study clearly supports the recent declarations of many physicians from South Korea, Iran, Germany, Italy, Spain, France, Belgium, UK, and US that olfactory and gustatory functions may be impaired in COVID-19 patients.DiscussionThe pathophysiological mechanisms leading to the olfactory and gustatory dysfunctions in the COVID-19 infection are still unknown.", [["olfactory", "ANATOMY", 172, 181], ["gustatory", "ANATOMY", 186, 195], ["olfactory", "ANATOMY", 302, 311], ["gustatory", "ANATOMY", 316, 325], ["olfactory and gustatory dysfunctions", "DISEASE", 302, 338], ["infection", "DISEASE", 355, 364], ["olfactory", "ORGAN", 172, 181], ["gustatory", "ANATOMICAL_SYSTEM", 186, 195], ["patients", "ORGANISM", 234, 242], ["olfactory", "ANATOMICAL_SYSTEM", 302, 311], ["gustatory", "ANATOMICAL_SYSTEM", 316, 325], ["COVID-19", "ORGANISM", 346, 354], ["patients", "SPECIES", 234, 242], ["the present study", "TEST", 14, 31], ["the olfactory and gustatory dysfunctions", "PROBLEM", 298, 338], ["the COVID", "TEST", 342, 351], ["infection", "PROBLEM", 355, 364], ["infection", "OBSERVATION", 355, 364]]], ["Coronavirus has already been identified as a family of viruses that may be associated with anosmia [6].", [["Coronavirus", "CHEMICAL", 0, 11], ["anosmia", "DISEASE", 91, 98], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 0, 11], ["Coronavirus", "PROBLEM", 0, 11], ["viruses", "PROBLEM", 55, 62], ["anosmia", "PROBLEM", 91, 98]]], ["In 2007, Suzuki et al. demonstrated that coronavirus may be detected in the nasal discharge of patients with olfactory dysfunction.", [["nasal", "ANATOMY", 76, 81], ["olfactory", "ANATOMY", 109, 118], ["olfactory dysfunction", "DISEASE", 109, 130], ["coronavirus", "ORGANISM", 41, 52], ["nasal", "ORGANISM_SUBDIVISION", 76, 81], ["patients", "ORGANISM", 95, 103], ["olfactory", "ORGAN", 109, 118], ["patients", "SPECIES", 95, 103], ["coronavirus", "PROBLEM", 41, 52], ["olfactory dysfunction", "PROBLEM", 109, 130], ["coronavirus", "OBSERVATION", 41, 52], ["nasal", "ANATOMY", 76, 81]]], ["Moreover, they observed that some patients with normal acoustic rhinometry did not recover their olfaction, suggesting that nasal inflammation and related obstruction were not the only etiological factors underlying the olfactory dysfunction in viral infection.DiscussionThe ability of human coronavirus to invade the olfactory bulb and, therefore, the central nervous system, is most likely a future research path for improving the knowledge about the clinical presentation of patients.", [["nasal", "ANATOMY", 124, 129], ["olfactory", "ANATOMY", 220, 229], ["olfactory bulb", "ANATOMY", 318, 332], ["central nervous system", "ANATOMY", 353, 375], ["nasal inflammation", "DISEASE", 124, 142], ["obstruction", "DISEASE", 155, 166], ["olfactory dysfunction", "DISEASE", 220, 241], ["viral infection", "DISEASE", 245, 260], ["patients", "ORGANISM", 34, 42], ["nasal", "ORGANISM_SUBDIVISION", 124, 129], ["olfactory", "ORGAN", 220, 229], ["human", "ORGANISM", 286, 291], ["coronavirus", "ORGANISM", 292, 303], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 318, 332], ["central nervous system", "ANATOMICAL_SYSTEM", 353, 375], ["patients", "ORGANISM", 478, 486], ["patients", "SPECIES", 34, 42], ["human", "SPECIES", 286, 291], ["patients", "SPECIES", 478, 486], ["human coronavirus", "SPECIES", 286, 303], ["nasal inflammation", "PROBLEM", 124, 142], ["related obstruction", "PROBLEM", 147, 166], ["the olfactory dysfunction", "PROBLEM", 216, 241], ["viral infection", "PROBLEM", 245, 260], ["human coronavirus", "PROBLEM", 286, 303], ["nasal", "ANATOMY", 124, 129], ["inflammation", "OBSERVATION", 130, 142], ["obstruction", "OBSERVATION", 155, 166], ["olfactory dysfunction", "OBSERVATION", 220, 241], ["viral", "OBSERVATION_MODIFIER", 245, 250], ["infection", "OBSERVATION", 251, 260], ["olfactory bulb", "ANATOMY", 318, 332], ["central", "ANATOMY_MODIFIER", 353, 360], ["nervous system", "ANATOMY", 361, 375], ["most likely", "UNCERTAINTY", 380, 391]]], ["From a biomolecular standpoint, viruses could infect peripheral neurons, using the cell machinery of active transport to access the central nervous system [13].", [["peripheral neurons", "ANATOMY", 53, 71], ["cell", "ANATOMY", 83, 87], ["central nervous system", "ANATOMY", 132, 154], ["peripheral neurons", "CELL", 53, 71], ["cell", "CELL", 83, 87], ["central nervous system", "ANATOMICAL_SYSTEM", 132, 154], ["peripheral neurons", "CELL_TYPE", 53, 71], ["viruses", "PROBLEM", 32, 39], ["neurons", "ANATOMY", 64, 71], ["central nervous", "ANATOMY", 132, 147]]], ["Thus, for the SARS-CoV receptor (human angiotensin-converting enzyme 2), it has been demonstrated on transgenic mice that SARS-CoV may enter the brain through the olfactory bulb, leading to rapid transneuronal spread [14].", [["brain", "ANATOMY", 145, 150], ["olfactory bulb", "ANATOMY", 163, 177], ["transneuronal", "ANATOMY", 196, 209], ["SARS", "DISEASE", 14, 18], ["angiotensin", "CHEMICAL", 39, 50], ["SARS-CoV receptor", "GENE_OR_GENE_PRODUCT", 14, 31], ["human", "ORGANISM", 33, 38], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 39, 70], ["mice", "ORGANISM", 112, 116], ["SARS-CoV", "ORGANISM", 122, 130], ["brain", "ORGAN", 145, 150], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 163, 177], ["SARS-CoV receptor", "PROTEIN", 14, 31], ["human angiotensin-converting enzyme 2", "PROTEIN", 33, 70], ["human", "SPECIES", 33, 38], ["mice", "SPECIES", 112, 116], ["SARS-CoV", "SPECIES", 14, 22], ["human", "SPECIES", 33, 38], ["mice", "SPECIES", 112, 116], ["SARS-CoV", "SPECIES", 122, 130], ["the SARS", "TEST", 10, 18], ["human angiotensin-converting enzyme", "TREATMENT", 33, 68], ["rapid transneuronal spread", "PROBLEM", 190, 216], ["brain", "ANATOMY", 145, 150], ["olfactory bulb", "ANATOMY", 163, 177], ["rapid", "OBSERVATION_MODIFIER", 190, 195]]], ["Interestingly, authors demonstrated that the virus antigen was first detected 60\u201366 h post-infection and was most abundant in the olfactory bulb.", [["olfactory bulb", "ANATOMY", 130, 144], ["infection", "DISEASE", 91, 100], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 130, 144], ["the virus antigen", "TEST", 41, 58], ["infection", "PROBLEM", 91, 100], ["infection", "OBSERVATION", 91, 100], ["olfactory bulb", "ANATOMY", 130, 144]]], ["Regions of the cortex (piriform and infralimbic cortices), basal ganglia (ventral pallidum and lateral preoptic regions), and midbrain (dorsal raphe) were also strongly infected after the virus had spread [14]; these regions are connected with the olfactory bulb.", [["cortex", "ANATOMY", 15, 21], ["piriform", "ANATOMY", 23, 31], ["infralimbic cortices", "ANATOMY", 36, 56], ["basal ganglia", "ANATOMY", 59, 72], ["ventral pallidum", "ANATOMY", 74, 90], ["lateral preoptic regions", "ANATOMY", 95, 119], ["midbrain", "ANATOMY", 126, 134], ["dorsal raphe", "ANATOMY", 136, 148], ["olfactory bulb", "ANATOMY", 248, 262], ["cortex", "CANCER", 15, 21], ["piriform", "MULTI-TISSUE_STRUCTURE", 23, 31], ["infralimbic cortices", "MULTI-TISSUE_STRUCTURE", 36, 56], ["basal ganglia", "TISSUE", 59, 72], ["ventral pallidum", "MULTI-TISSUE_STRUCTURE", 74, 90], ["lateral preoptic regions", "MULTI-TISSUE_STRUCTURE", 95, 119], ["midbrain", "ORGAN", 126, 134], ["dorsal raphe", "ORGAN", 136, 148], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 248, 262], ["the cortex (piriform and infralimbic cortices), basal ganglia (ventral pallidum and lateral preoptic regions), and midbrain (dorsal raphe)", "PROBLEM", 11, 149], ["the virus", "PROBLEM", 184, 193], ["cortex", "ANATOMY_MODIFIER", 15, 21], ["piriform", "ANATOMY_MODIFIER", 23, 31], ["infralimbic", "ANATOMY_MODIFIER", 36, 47], ["cortices", "ANATOMY_MODIFIER", 48, 56], ["basal", "ANATOMY_MODIFIER", 59, 64], ["ganglia", "ANATOMY_MODIFIER", 65, 72], ["ventral", "ANATOMY_MODIFIER", 74, 81], ["pallidum", "ANATOMY_MODIFIER", 82, 90], ["lateral", "ANATOMY_MODIFIER", 95, 102], ["preoptic", "ANATOMY_MODIFIER", 103, 111], ["regions", "ANATOMY_MODIFIER", 112, 119], ["midbrain", "ANATOMY", 126, 134], ["dorsal raphe", "ANATOMY", 136, 148], ["infected", "OBSERVATION_MODIFIER", 169, 177], ["olfactory bulb", "ANATOMY", 248, 262]]], ["The rapid spread of SARS-CoV in the brain was also associated with significant neuronal death.", [["brain", "ANATOMY", 36, 41], ["neuronal", "ANATOMY", 79, 87], ["SARS-CoV in the brain", "DISEASE", 20, 41], ["neuronal death", "DISEASE", 79, 93], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 20, 28], ["brain", "ORGAN", 36, 41], ["neuronal", "CELL", 79, 87], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["CoV in the brain", "PROBLEM", 25, 41], ["significant neuronal death", "PROBLEM", 67, 93], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["spread", "OBSERVATION_MODIFIER", 10, 16], ["SARS", "OBSERVATION", 20, 24], ["brain", "ANATOMY", 36, 41], ["associated with", "UNCERTAINTY", 51, 66], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["neuronal death", "OBSERVATION", 79, 93]]], ["In humans, autopsy samples from eight patients with SARS revealed the presence of SARS-CoV in brain samples by immunohistochemistry, electron microscopy, and real-time RT-PCR [15].", [["autopsy samples", "ANATOMY", 11, 26], ["brain samples", "ANATOMY", 94, 107], ["SARS", "DISEASE", 52, 56], ["SARS", "DISEASE", 82, 86], ["humans", "ORGANISM", 3, 9], ["autopsy samples", "CANCER", 11, 26], ["patients", "ORGANISM", 38, 46], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["brain samples", "CANCER", 94, 107], ["humans", "SPECIES", 3, 9], ["patients", "SPECIES", 38, 46], ["humans", "SPECIES", 3, 9], ["SARS-CoV", "SPECIES", 82, 90], ["autopsy samples", "TEST", 11, 26], ["SARS", "PROBLEM", 52, 56], ["SARS", "PROBLEM", 82, 86], ["CoV in brain samples", "PROBLEM", 87, 107], ["immunohistochemistry", "TEST", 111, 131], ["electron microscopy", "TEST", 133, 152], ["brain", "ANATOMY", 94, 99]]], ["It is currently suspected that the neuroinvasive potential of SARS-CoV2 plays a key role in the respiratory failure of COVID-19 patients [16].", [["respiratory", "ANATOMY", 96, 107], ["SARS", "DISEASE", 62, 66], ["respiratory failure", "DISEASE", 96, 115], ["COVID", "DISEASE", 119, 124], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 62, 71], ["patients", "ORGANISM", 128, 136], ["CoV2", "PROTEIN", 67, 71], ["patients", "SPECIES", 128, 136], ["SARS", "PROBLEM", 62, 66], ["the respiratory failure", "PROBLEM", 92, 115], ["COVID", "TEST", 119, 124], ["respiratory failure", "OBSERVATION", 96, 115]]], ["Medical imaging and neuropathology will certainly play an important rule to detect abnormalities in olfactory bulb, cranial nerves, and brain of COVID-19 patients.DiscussionThe otolaryngological symptoms in our European cohort were particularly prevalent compared with the Asian cohorts.", [["olfactory bulb", "ANATOMY", 100, 114], ["cranial nerves", "ANATOMY", 116, 130], ["brain", "ANATOMY", 136, 141], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 100, 114], ["cranial nerves", "MULTI-TISSUE_STRUCTURE", 116, 130], ["brain", "ORGAN", 136, 141], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["Medical imaging", "TEST", 0, 15], ["abnormalities in olfactory bulb", "PROBLEM", 83, 114], ["The otolaryngological symptoms", "PROBLEM", 173, 203], ["olfactory bulb", "ANATOMY", 100, 114], ["cranial nerves", "ANATOMY", 116, 130], ["brain", "ANATOMY", 136, 141]]], ["In their clinical series of 99 patients, Chen et al. reported four patients with rhinorrhea (4%) [17].", [["rhinorrhea", "DISEASE", 81, 91], ["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 67, 75], ["rhinorrhea", "PROBLEM", 81, 91], ["rhinorrhea", "OBSERVATION", 81, 91]]], ["Then, Guan et al. reported a prevalence of nasal obstruction in 5% of patients in a cohort of 1099 patients [18].", [["nasal", "ANATOMY", 43, 48], ["nasal obstruction", "DISEASE", 43, 60], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 43, 60], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 99, 107], ["nasal obstruction", "PROBLEM", 43, 60], ["nasal", "ANATOMY", 43, 48], ["obstruction", "OBSERVATION", 49, 60]]], ["The lack of otolaryngological complaints in Asian papers, e.g., nasal obstruction, rhinorrhea, and olfactory and gustatory dysfunctions, raises many questions.", [["nasal", "ANATOMY", 64, 69], ["olfactory", "ANATOMY", 99, 108], ["gustatory", "ANATOMY", 113, 122], ["nasal obstruction", "DISEASE", 64, 81], ["rhinorrhea", "DISEASE", 83, 93], ["olfactory and gustatory dysfunctions", "DISEASE", 99, 135], ["nasal", "ORGANISM_SUBDIVISION", 64, 69], ["otolaryngological complaints", "PROBLEM", 12, 40], ["nasal obstruction", "PROBLEM", 64, 81], ["rhinorrhea", "PROBLEM", 83, 93], ["olfactory and gustatory dysfunctions", "PROBLEM", 99, 135], ["nasal", "ANATOMY", 64, 69], ["obstruction", "OBSERVATION", 70, 81], ["rhinorrhea", "OBSERVATION", 83, 93]]], ["Either they did not assess the ENT complaints, or the Chinese patients had a few ENT complaints.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["the ENT complaints", "PROBLEM", 27, 45], ["a few ENT complaints", "PROBLEM", 75, 95]]], ["The second hypothesis may be likely regarding previous studies.", [["previous studies", "TEST", 46, 62], ["may be likely", "UNCERTAINTY", 22, 35]]], ["Benvenuto et al. have recently compared the complete genomes of 15 virus sequences from patients treated in different regions of China with other coronaviruses [19].", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["15 virus sequences", "PROBLEM", 64, 82], ["other coronaviruses", "PROBLEM", 140, 159]]], ["Interestingly, they observed mutations of surface proteins (spike-S-protein and nucleocapsid-N-protein), conferring stability to the viral particle.", [["surface", "ANATOMY", 42, 49], ["spike-S-protein", "GENE_OR_GENE_PRODUCT", 60, 75], ["surface proteins", "PROTEIN", 42, 58], ["spike-S-protein", "PROTEIN", 60, 75], ["nucleocapsid-N-protein", "PROTEIN", 80, 102], ["surface proteins", "TEST", 42, 58], ["spike", "TEST", 60, 65], ["protein", "TEST", 68, 75], ["nucleocapsid", "TEST", 80, 92], ["viral particle", "OBSERVATION", 133, 147]]], ["Such mutations could be clinically relevant, because the viral spike protein is responsible for virus entry into the cell, whereas the N-protein plays a pivotal role in the virus transcription and assembly efficiency.", [["cell", "ANATOMY", 117, 121], ["cell", "CELL", 117, 121], ["N-protein", "GENE_OR_GENE_PRODUCT", 135, 144], ["viral spike protein", "PROTEIN", 57, 76], ["N-protein", "PROTEIN", 135, 144], ["Such mutations", "PROBLEM", 0, 14], ["the viral spike protein", "PROBLEM", 53, 76], ["virus entry into the cell", "PROBLEM", 96, 121], ["the virus transcription", "TREATMENT", 169, 192], ["efficiency", "OBSERVATION_MODIFIER", 206, 216]]], ["Previously, Chan et al. determined five virus sequences from patients traveling in Wuhan at the end of December 2019.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["five virus sequences", "PROBLEM", 35, 55]]], ["This study reported identities, but less than 68%, with the SARS-related coronaviruses in specific domains.", [["SARS", "DISEASE", 60, 64], ["coronaviruses", "ORGANISM", 73, 86], ["This study", "TEST", 0, 10], ["the SARS-related coronaviruses in specific domains", "PROBLEM", 56, 106], ["SARS", "OBSERVATION", 60, 64], ["coronaviruses", "OBSERVATION", 73, 86]]], ["Particularly, the external subdomain region of receptor-binding domain of the S-protein only presents 39% identity, and Chan et al. propose that it might affect the choice of human receptor and, therefore, the biological behaviour of this virus [20].", [["human", "ORGANISM", 175, 180], ["external subdomain region", "PROTEIN", 18, 43], ["receptor-binding domain", "PROTEIN", 47, 70], ["S-protein", "PROTEIN", 78, 87], ["human receptor", "PROTEIN", 175, 189], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["human receptor", "TREATMENT", 175, 189], ["this virus", "PROBLEM", 234, 244], ["external", "ANATOMY_MODIFIER", 18, 26], ["binding domain", "OBSERVATION", 56, 70]]], ["The affinity of some viruses for some tissues and individuals constitutes another area to investigate and explain the potential clinical differences between patients from different world regions.", [["tissues", "ANATOMY", 38, 45], ["tissues", "TISSUE", 38, 45], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["some viruses", "PROBLEM", 16, 28], ["some tissues", "PROBLEM", 33, 45], ["viruses", "OBSERVATION", 21, 28]]], ["Recent studies suggested that the angiotensin converting enzyme 2 (ACE2), which is the receptor of SARS-CoV-2, could be specific to certain populations.", [["angiotensin", "CHEMICAL", 34, 45], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 34, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 67, 71], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 99, 109], ["angiotensin converting enzyme 2", "PROTEIN", 34, 65], ["ACE2", "PROTEIN", 67, 71], ["Recent studies", "TEST", 0, 14], ["the angiotensin converting enzyme", "TEST", 30, 63], ["SARS", "PROBLEM", 99, 103], ["CoV", "TEST", 104, 107]]], ["Li et al. demonstrated that some ACE2 variants could reduce the association between human ACE2 and SARS-CoV S-protein [21].", [["Li", "CHEMICAL", 0, 2], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["human", "ORGANISM", 84, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 99, 107], ["ACE2", "PROTEIN", 33, 37], ["human ACE2", "PROTEIN", 84, 94], ["SARS-CoV S", "PROTEIN", 99, 109], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["SARS-CoV", "SPECIES", 99, 107], ["some ACE2 variants", "PROBLEM", 28, 46], ["human ACE2", "TEST", 84, 94], ["SARS", "TEST", 99, 103], ["CoV S", "TEST", 104, 109]]], ["In other words, the expression level of ACE2 in different tissues might be critical for the susceptibility, symptoms, and outcomes of COVID-19 infection [21].", [["tissues", "ANATOMY", 58, 65], ["COVID-19", "CHEMICAL", 134, 142], ["infection", "DISEASE", 143, 152], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["tissues", "TISSUE", 58, 65], ["COVID-19", "GENE_OR_GENE_PRODUCT", 134, 142], ["ACE2", "PROTEIN", 40, 44], ["COVID-19", "SPECIES", 134, 142], ["the susceptibility", "PROBLEM", 88, 106], ["symptoms", "PROBLEM", 108, 116], ["COVID-19 infection", "PROBLEM", 134, 152]]], ["Moreover, the comparison of the 15 expression quantitative trait loci (eQTLs) variants of the ACE2 gene suggested that there will be a lot of ACE2 polymorphisms and ACE2 expression levels between Asian and European populations [22].", [["ACE2", "GENE_OR_GENE_PRODUCT", 94, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 165, 169], ["eQTLs", "DNA", 71, 76], ["ACE2 gene", "DNA", 94, 103], ["ACE2", "PROTEIN", 142, 146], ["ACE2", "PROTEIN", 165, 169], ["the 15 expression quantitative trait loci (eQTLs) variants", "PROBLEM", 28, 86], ["ACE2 polymorphisms", "PROBLEM", 142, 160], ["ACE2 expression levels", "TEST", 165, 187]]], ["According to these studies, it is conceivable that the diversity of ACE2 expression pattern in Asian and European populations could be an important track that needs further investigation.DiscussionMoreover, regarding our results, future studies have to explore the potential gender differences in the development of anosmia.", [["anosmia", "DISEASE", 316, 323], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["ACE2", "PROTEIN", 68, 72], ["these studies", "TEST", 13, 26], ["ACE2 expression pattern", "PROBLEM", 68, 91], ["further investigation", "TEST", 165, 186], ["future studies", "TEST", 230, 244], ["anosmia", "PROBLEM", 316, 323], ["anosmia", "OBSERVATION", 316, 323]]], ["The highest susceptibility of females to develop olfactory and gustatory dysfunctions would be related to the gender-related differences in the inflammatory reaction process [23].DiscussionThe present study has several limitations.", [["olfactory", "ANATOMY", 49, 58], ["gustatory", "ANATOMY", 63, 72], ["olfactory and gustatory dysfunctions", "DISEASE", 49, 85], ["olfactory", "ANATOMICAL_SYSTEM", 49, 58], ["gustatory", "ANATOMICAL_SYSTEM", 63, 72], ["olfactory and gustatory dysfunctions", "PROBLEM", 49, 85], ["the inflammatory reaction process", "PROBLEM", 140, 173], ["The present study", "TEST", 189, 206], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["inflammatory", "OBSERVATION_MODIFIER", 144, 156]]], ["First, our patients did not benefit from specific examinations for olfactory and gustatory functions, including psychophysical tests or electrophysiological methods [24, 25].", [["olfactory", "ANATOMY", 67, 76], ["gustatory", "ANATOMY", 81, 90], ["patients", "ORGANISM", 11, 19], ["olfactory", "ANATOMICAL_SYSTEM", 67, 76], ["gustatory", "ANATOMICAL_SYSTEM", 81, 90], ["patients", "SPECIES", 11, 19], ["specific examinations", "TEST", 41, 62], ["olfactory and gustatory functions", "PROBLEM", 67, 100], ["psychophysical tests", "TEST", 112, 132]]], ["The use of objective approaches makes sense for investigating both gustatory and olfactory functions in COVID-19 patients, and to avoid the confusion related to the retro-olfaction.", [["gustatory", "ANATOMY", 67, 76], ["olfactory", "ANATOMY", 81, 90], ["confusion", "DISEASE", 140, 149], ["retro-olfaction", "DISEASE", 165, 180], ["gustatory", "ANATOMICAL_SYSTEM", 67, 76], ["olfactory", "ANATOMICAL_SYSTEM", 81, 90], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["objective approaches", "TREATMENT", 11, 31], ["the confusion", "PROBLEM", 136, 149], ["the retro-olfaction", "PROBLEM", 161, 180]]], ["These approaches would provide many responses for patients who may recover olfaction, but not taste, and vice versa.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["Second, our patient sample consisted of young and mild-to-moderate COVID-19 patients with little comorbidities.", [["patient", "ORGANISM", 12, 19], ["patients", "ORGANISM", 76, 84], ["patient", "SPECIES", 12, 19], ["patients", "SPECIES", 76, 84], ["little comorbidities", "PROBLEM", 90, 110], ["mild", "OBSERVATION_MODIFIER", 50, 54]]], ["They may be not representative of the infected population.", [["the infected population", "PROBLEM", 34, 57], ["may be not", "UNCERTAINTY", 5, 15], ["infected", "OBSERVATION_MODIFIER", 38, 46], ["population", "OBSERVATION", 47, 57]]], ["However, it seems ethically difficult to investigate olfaction and gustatory function in patients in life-threatening condition, such as patients in intensive-care units.", [["gustatory", "ANATOMICAL_SYSTEM", 67, 76], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 137, 145]]], ["Note that in this study, the majority of included patients were identified from hospital laboratory results.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["this study", "TEST", 13, 23]]], ["However, many infected physicians completed the study, and, therefore, it remains possible that many infected physicians participated to the study, because they suffered from olfactory dysfunction, although the authors have been particularly vigilant to this potential bias.", [["olfactory", "ANATOMY", 175, 184], ["olfactory dysfunction", "DISEASE", 175, 196], ["olfactory", "ORGAN", 175, 184], ["the study", "TEST", 44, 53], ["the study", "TEST", 137, 146], ["olfactory dysfunction", "PROBLEM", 175, 196], ["many", "OBSERVATION_MODIFIER", 9, 13], ["infected", "OBSERVATION", 14, 22], ["olfactory dysfunction", "OBSERVATION", 175, 196]]], ["Third, the lack of consistent follow-up of our patients limits us from inquiring into the recovery time of olfactory and gustatory functions, and, therefore, the rate of permanent anosmia or ageusia.", [["olfactory", "ANATOMY", 107, 116], ["gustatory", "ANATOMY", 121, 130], ["anosmia", "DISEASE", 180, 187], ["ageusia", "DISEASE", 191, 198], ["patients", "ORGANISM", 47, 55], ["olfactory", "ANATOMICAL_SYSTEM", 107, 116], ["gustatory", "ANATOMICAL_SYSTEM", 121, 130], ["patients", "SPECIES", 47, 55], ["permanent anosmia", "PROBLEM", 170, 187], ["ageusia", "PROBLEM", 191, 198]]], ["Fourth, it seems difficult to identify the potential negative impact of nasal and oral corticosteroids on the clinical course of the disease; these treatments are usually used for anosmia or in common nasal complaints.", [["nasal", "ANATOMY", 72, 77], ["oral", "ANATOMY", 82, 86], ["nasal", "ANATOMY", 201, 206], ["corticosteroids", "CHEMICAL", 87, 102], ["anosmia", "DISEASE", 180, 187], ["corticosteroids", "CHEMICAL", 87, 102], ["nasal", "ORGANISM_SUBDIVISION", 72, 77], ["oral", "ORGANISM_SUBDIVISION", 82, 86], ["nasal", "ORGANISM_SUBDIVISION", 201, 206], ["nasal and oral corticosteroids", "TREATMENT", 72, 102], ["the disease", "PROBLEM", 129, 140], ["these treatments", "TREATMENT", 142, 158], ["anosmia", "PROBLEM", 180, 187], ["common nasal complaints", "PROBLEM", 194, 217], ["nasal", "ANATOMY", 72, 77], ["disease", "OBSERVATION", 133, 140]]], ["In the absence of such data, the precautionary principle may prevail and, according to the guidelines of the French Society of Otolaryngology, patients must avoid corticosteroids for the treatment of the COVID-19 infection.", [["infection", "DISEASE", 213, 222], ["corticosteroids", "CHEMICAL", 163, 178], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["corticosteroids", "TREATMENT", 163, 178], ["the treatment", "TREATMENT", 183, 196], ["the COVID-19 infection", "PROBLEM", 200, 222], ["infection", "OBSERVATION", 213, 222]]], ["All of these weaknesses should be considered in future studies to investigate and characterize the olfactory and gustatory functions in COVID-19 patients.ConclusionSince the disease is new and the virus is most likely associated with different mutations and clinical patterns, as of yet, there remain more questions than answers.", [["olfactory", "ANATOMY", 99, 108], ["gustatory", "ANATOMY", 113, 122], ["olfactory", "ANATOMICAL_SYSTEM", 99, 108], ["gustatory", "ANATOMICAL_SYSTEM", 113, 122], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["these weaknesses", "PROBLEM", 7, 23], ["future studies", "TEST", 48, 62], ["COVID", "TEST", 136, 141], ["the disease", "PROBLEM", 170, 181], ["the virus", "PROBLEM", 193, 202], ["different mutations", "PROBLEM", 234, 253], ["disease", "OBSERVATION", 174, 181], ["new", "OBSERVATION_MODIFIER", 185, 188], ["virus", "OBSERVATION", 197, 202], ["most likely", "UNCERTAINTY", 206, 217]]], ["This study is the first to identify both olfactory and gustatory dysfunctions as significant symptoms in the clinical presentation of the European COVID-19 infection.", [["olfactory", "ANATOMY", 41, 50], ["gustatory", "ANATOMY", 55, 64], ["olfactory and gustatory dysfunctions", "DISEASE", 41, 77], ["infection", "DISEASE", 156, 165], ["olfactory", "TISSUE", 41, 50], ["gustatory", "ANATOMICAL_SYSTEM", 55, 64], ["European COVID-19", "SPECIES", 138, 155], ["This study", "TEST", 0, 10], ["gustatory dysfunctions", "PROBLEM", 55, 77], ["significant symptoms", "PROBLEM", 81, 101], ["the European COVID", "TEST", 134, 152], ["19 infection", "PROBLEM", 153, 165], ["infection", "OBSERVATION", 156, 165]]], ["Based on our results, it seems that infected patients may just present olfactory and gustatory dysfunctions without other significant complaints.", [["olfactory", "ANATOMY", 71, 80], ["gustatory", "ANATOMY", 85, 94], ["olfactory and gustatory dysfunctions", "DISEASE", 71, 107], ["patients", "ORGANISM", 45, 53], ["olfactory", "ORGAN", 71, 80], ["gustatory", "ANATOMICAL_SYSTEM", 85, 94], ["patients", "SPECIES", 45, 53], ["gustatory dysfunctions", "PROBLEM", 85, 107], ["other significant complaints", "PROBLEM", 116, 144], ["infected", "OBSERVATION", 36, 44]]], ["The sudden anosmia or ageusia need to be recognized by the international scientific community as important symptoms of the COVID-19 infection.", [["anosmia", "DISEASE", 11, 18], ["ageusia", "DISEASE", 22, 29], ["infection", "DISEASE", 132, 141], ["COVID-19", "ORGANISM", 123, 131], ["The sudden anosmia", "PROBLEM", 0, 18], ["ageusia", "PROBLEM", 22, 29], ["the COVID-19 infection", "PROBLEM", 119, 141], ["infection", "OBSERVATION", 132, 141]]], ["Future epidemiological, clinical, and basic science studies must elucidate the mechanisms underlying the development of these symptoms in such a specific world population.", [["basic science studies", "TEST", 38, 59], ["these symptoms", "PROBLEM", 120, 134]]]], "5a49325e08fa7a2a6d9debf53d07701d74c044fb": [["IntroductionThe spread of the novel coronavirus (SARS-CoV-2) has resulted in unprecedented measures in terms of travel and socio-economic activities worldwide, while the estimated negative economic effects can be seen in many areas.", [["SARS", "DISEASE", 49, 53], ["coronavirus", "ORGANISM", 36, 47], ["SARS-CoV-2", "ORGANISM", 49, 59], ["the novel coronavirus", "PROBLEM", 26, 47]]], ["As a result, the global economy is projected to have a gross domestic product contraction of \u2212 3%, worse than the one generated by the 2008-2009 financial crisis, a reduction of the global merchandise trade volume by 13%-32% compared to 2019 and a decline in international tourism monetized with a reduction between USD 330 billion -USD 590 billion compared to 2019, mostly due to the travel restrictions applied in almost 96% of travel destinations (ICAO, 2020) .IntroductionAirplane transportation is one of the main sectors affected by the coronavirus outbreak due to the both the limitations imposed on international flights in different countries and to the reluctance of passengers to engage in air travel (Taylor, 2020) .", [["coronavirus", "DISEASE", 543, 554], ["coronavirus", "ORGANISM", 543, 554], ["the coronavirus outbreak", "PROBLEM", 539, 563], ["gross", "OBSERVATION_MODIFIER", 55, 60], ["domestic", "OBSERVATION_MODIFIER", 61, 69], ["product contraction", "OBSERVATION", 70, 89], ["reduction", "OBSERVATION_MODIFIER", 165, 174], ["coronavirus", "OBSERVATION", 543, 554]]], ["In a recent study entitled \"COVID-19 Air Transport Near Term Impacts and Scenarios\" by Fast Future and Future Travel Experience, based on a 16-question survey, completed by 269 industry professionals from 47 countries, supplemented by a series of research and expert interviews, it has been reported that the passengers' reluctance to fly would be heightened in the COVID-19 period by the confusing protocols used by different countries, airlines and airports (Taylor, 2020) .", [["a recent study", "TEST", 3, 17]]], ["As airline transport is made through enclosed spaces in which a large number of people are fit in, this type of transport has been closely associated with the potential risk of spreading the virus (Vandycke, 2020) , producing both social and economic effects because the consumers might be tempted to change their behavior and to seek private means of transport to the detriment of airline transportation.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["spreading the virus", "PROBLEM", 177, 196], ["large", "OBSERVATION_MODIFIER", 64, 69], ["number", "OBSERVATION_MODIFIER", 70, 76]]], ["As Iacus et al. (2020) have shown, the air traffic industry has been closely related to the past pandemic outbreaks such as SARS in 2003 and MERS in 2015 (Iacus et al., 2020) , while the effects of these pandemic periods have been visible at both regional and global scale.", [["SARS", "DISEASE", 124, 128], ["these pandemic periods", "TREATMENT", 198, 220]]], ["As Vandycke (2020) recently stated, a short-term chaos could bring long-term transformation in the transportation industry (Vandycke, 2020) .", [["long-term transformation", "OBSERVATION_MODIFIER", 67, 91]]], ["The measures included in the term of \"social distancing\" feature keeping a sufficient distance among the people, avoiding mass gathering and closing public places (Nguyen et al., 2020) , all of them representing an effective non-pharmaceutical approach for limiting the disease transmission (Ferguson et al., 2006) .", [["people", "ORGANISM", 105, 111], ["people", "SPECIES", 105, 111], ["mass", "PROBLEM", 122, 126], ["an effective non-pharmaceutical approach", "TREATMENT", 212, 252], ["the disease transmission", "PROBLEM", 266, 290], ["mass", "OBSERVATION", 122, 126]]], ["To be more specific, we formulate a mixed integer programming (MIP) model to assign passengers to seats on an airplane to respect two types of social distancing: keeping the passengers seated far enough away from each other and providing a safe distance between seat assignments and the aisle.", [["a mixed integer programming (MIP)", "TREATMENT", 34, 67]]], ["The primary goal of this paper is to show how the proposed model can be used to properly assign the passengers to their seats while effectively preserving the social distancing among them.IntroductionThe rest of this paper is organized as follows: the next section provides a short literature review on both airplane boarding methods research and optimization techniques used in airplane boarding.", [["optimization techniques", "TREATMENT", 347, 370]]], ["Section 3 features the proposed method and underlines the assumptions for passenger assignment and the MIP model formulation.", [["the MIP model formulation", "TREATMENT", 99, 124]]], ["Section 5 concludes the paper and provides some guidelines for further research directions.Airplane boarding and mixed integer programmingAirplane boarding techniques are the main focus concerning the research papers in the area of minimizing the airplane turn time and reducing the airline costs incurred by passenger boarding time (Delcea et al., 2018c) .", [["Airplane boarding", "TREATMENT", 91, 108], ["mixed integer programming", "TREATMENT", 113, 138], ["Airplane boarding techniques", "TREATMENT", 138, 166], ["main", "OBSERVATION_MODIFIER", 175, 179]]], ["An extensive literature is dedicated to proposing new boarding methods under different conditions, such as the presence of jet bridges (Bachmat et al., 2009; Jaehn and Neumann, 2015; Milne and Kelly, 2014; Soolaki et al., 2012; Steffen, 2008a; van den Briel et al., 2005) or the use of the apron buses (Delcea et al., 2018a (Delcea et al., , 2019 Milne et al., 2019b) .", [["jet bridges", "OBSERVATION", 123, 134]]], ["As a result, a series of methods have been recommended and analyzed under various considerations such as airplane occupancy (Kierzkowski and Kisiel, 2017; Milne and Kelly, 2014; Notomista et al., 2016; Qiang et al., 2014; Steffen and Hotchkiss, 2012; van den Briel et al., 2005; Van Landeghem and Beuselinck, 2002) , passengers boarding using one or both doors of the airplane (Bachmat et al., 2009; Bidanda et al., 2017; Delcea et al., 2018a Delcea et al., , 2019 Kuo, 2015; Milne et al., 2018; Milne and Kelly, 2014; Milne and Salari, 2016; Nyquist and McFadden, 2008; Qiang et al., 2014; Soolaki et al., 2012; Steffen, 2008a; Steiner, and Philipp, 2009; Tang et al., 2018a; van den Briel et al., 2005) , passengers' physical characteristics (Hutter et al., 2018; Kierzkowski and Kisiel, 2017; Qiang et al., 2014) , the rules for passenger movement (Steffen, 2008a (Steffen, , 2008b , seat selection (Ferrari and Nagel, 2005; Steffen, 2008b) , the presence of carry-on hand luggage (Milne et al., 2018; Milne and Kelly, 2014; Qiang et al., 2014; Steffen, 2008a; Tang et al., 2018a) , seat and aisle interferences (Delcea et al., 2018b; Qiang et al., 2017; Ren and Xu, 2018) , and group behavior Tang et al., 2018b Tang et al., , 2018a Zeineddine, 2017) .", [["hand", "ANATOMY", 971, 975], ["hand", "ORGANISM_SUBDIVISION", 971, 975], ["a series of methods", "TEST", 13, 32]]], ["In most of the approaches, the passengers boarding rules apply in the same manner for both sides of the aisle, preserving a symmetry with respect to the aisle Milne et al., 2019a) .Airplane boarding and mixed integer programmingThe literature provides a variety of techniques for evaluating boarding methods, featuring: linear programming (Bazargan, 2007; Milne et al., 2018; Milne and Salari, 2016; Soolaki et al., 2012) , computer simulation (Steffen, 2008a; Steiner, and Philipp, 2009; Tang et al., 2012; van den Briel et al., 2005; Van Landeghem and Beuselinck, 2002) , grid-based simulation and cellular automata (Qiang et al., 2014; Schultz, 2017) , agent-based and stochastic modelling (Delcea et al., 2018c (Delcea et al., , 2018d Milne et al., 2019b; Schultz, 2018a Schultz, , 2018b , simulated annealing (Wittmann, 2019) , empirical tests (Steffen and Hotchkiss, 2012) , etc.Airplane boarding and mixed integer programmingMIP modelling has been a popular choice for addressing the airplane boarding problem.", [["cellular", "ANATOMY", 600, 608], ["cellular", "CELL", 600, 608], ["Airplane boarding", "TREATMENT", 181, 198], ["mixed integer programming", "TREATMENT", 203, 228], ["agent", "TREATMENT", 656, 661], ["empirical tests", "TEST", 833, 848], ["Airplane boarding", "TREATMENT", 885, 902], ["mixed integer programmingMIP modelling", "TREATMENT", 907, 945]]], ["Milne and Salari (2016) propose a MIP model that determines the seats to assign to each passenger based on the passenger's carry-on bags.", [["a MIP model", "TREATMENT", 32, 43], ["bags", "TREATMENT", 132, 136]]], ["Numerical results show that the proposed approach reduces the boarding time with higher reductions in boarding time when the total number of luggage carried on board increases (Milne and Salari, 2016) .", [["higher", "OBSERVATION_MODIFIER", 81, 87], ["reductions", "OBSERVATION_MODIFIER", 88, 98]]], ["In another study, by considering both the passengers' carry-on hand luggage and the earlier reserved seats by the high priority passengers, Salari et al. (2019) proposed another MIP for passengers' seat assignment.", [["hand", "ANATOMY", 63, 67], ["hand", "ORGANISM_SUBDIVISION", 63, 67], ["another study", "TEST", 3, 16]]], ["The obtained results indicate an average boarding time reduction ranging between 5% and 20% when compared to a baseline situation (Salari et al., 2019) .", [["an average boarding time reduction", "TREATMENT", 30, 64], ["average", "OBSERVATION_MODIFIER", 33, 40]]], ["In the case of airplane two-door boarding using apron buses, Milne et al. (2020) uses a MIP to assign the passengers to one of the two apron buses used for passengers' transport from the airport terminal to the airplane while accounting for the passengers traveling in groups.", [["a MIP", "TREATMENT", 86, 91]]], ["As a result, they observe up to 27.31% boarding time improvement versus a baseline approach.", [["a baseline approach", "TREATMENT", 72, 91]]], ["Starting from the results obtained by Bazargan (2007) , Soolaki et al. (2012) model the problem as a MIP (minimizing interferences) which they solve with a genetic algorithm with results similar to previous methods but obtained more quickly.Social distancing in times of COVID-19Social distancing has been one of the most discussed measures taken during the COVID-19 outbreak due to the beneficial effects on reducing the coronavirus spread among humans (Sen-Crowe et al., 2020) and also due to the fact that is was one of the most controversial measures as it might affect people's mental health and emotional wellbeing (Donovan, 2020) .Social distancing in times of COVID-19A broad range of subjects related to social distancing have been addressed in the scientific literature such as: political, economic, social and religious challenges (Yezli and Khan, 2020) , adolescents' motivations to engage in social distancing (Oosterhoff et al., 2020) , sexual activity (Jacob et al., 2020) , the relation with telework implementation (Kawashima et al., 2020) , the impact on crime (Mohler et al., 2020) , personal wellbeing (Nyenhuis et al., 2020) , social and ethical basis for social distancing (Lewnard and Lo, 2020) , etc., while in the area of travel and human mobility the primary research areas focused on: travel behavior (De Vos, 2020), uncontrolled travelers effect on the spread of the coronavirus (G\u00f3mez-R\u00edos et al., 2020) , airline employment evolution (Sobieralski, 2020) , estimating and projecting air passenger traffic (Iacus et al., 2020) , and comparing classical airplane boarding methods while considering social distancing rules .Social distancing in times of COVID-19Public authorities have used different approaches to support social distancing, such as: drawing circles in public parks for delimiting personal space (Harrouk, 2020) , marking the metro seats (METROREX, 2020) and train seats (Trenitalia, 2020) that may be occupied, and creating a passenger-powered app feature to inform others of on-board passenger volumes (Intelligent Transport, 2020).Social distancing in times of COVID-19In passenger air transport management, the following measures have been taken: passengers assigned to the rear seats board first (implemented by Delta Air Lines (Writers, 2020) ); boarding based on passengers' seat numbers (trialed by EasyJet and Gatwick Airport (Future Travel Experience, 2020)); passengers assigned to the seats in front rows board first while entering an airplane from the rear door (implemented by GoAir (Ash, 2020) ); airplane passengers de-boarding will be made starting with front rows (implemented by \"Henri Coand\u0203\" Airport (Romanian Transport Ministry, 2020)).Social distancing in times of COVID-19A few researchers have developed optimization and heuristic based methods to facilitate decisions on the social distance positioning of people in several contexts.", [["coronavirus", "DISEASE", 422, 433], ["coronavirus", "DISEASE", 1395, 1406], ["COVID-19In", "CHEMICAL", 2107, 2117], ["coronavirus", "ORGANISM", 422, 433], ["humans", "ORGANISM", 447, 453], ["people", "ORGANISM", 574, 580], ["human", "ORGANISM", 1258, 1263], ["coronavirus", "ORGANISM", 1395, 1406], ["people", "ORGANISM", 2875, 2881], ["humans", "SPECIES", 447, 453], ["people", "SPECIES", 574, 580], ["adolescents", "SPECIES", 867, 878], ["human", "SPECIES", 1258, 1263], ["coronavirus", "SPECIES", 1395, 1406], ["people", "SPECIES", 2875, 2881], ["humans", "SPECIES", 447, 453], ["human", "SPECIES", 1258, 1263], ["a MIP (minimizing interferences", "TREATMENT", 99, 130], ["a genetic algorithm", "TEST", 154, 173], ["uncontrolled travelers effect", "PROBLEM", 1344, 1373], ["air transport management", "TREATMENT", 2128, 2152], ["coronavirus", "OBSERVATION", 422, 433]]], ["The wake effects from wind turbines interfering with other turbines is analogous to the expiration of COVID-19 droplets from an infected diner at a restaurant table infecting nearby diners.", [["COVID-19 droplets", "CHEMICAL", 102, 119], ["COVID-19", "CHEMICAL", 102, 110], ["wind turbines", "TREATMENT", 22, 35], ["other turbines", "TREATMENT", 53, 67], ["COVID-19 droplets", "TREATMENT", 102, 119], ["infected", "OBSERVATION", 128, 136]]], ["Lustig (2020) summarizes a prototype for determining seat assignments at a sports venue (Lusting, 2020) .Proposed methodIn this section, we focus on the details of the proposed method including the main assumptions and the proposed MIP formulation for the passengers' assignment to seats on an airplane.Assumptions and objectives for passenger assignmentAs our primary focus in this work is on the passenger assignment to seats in an airplane, we don't concentrate on the boarding sequence of passengers.", [["the proposed MIP formulation", "TREATMENT", 219, 247]]], ["To find the distance between seats, we define the seats' width, aisle width, and the distance between seats in consecutive rows (known as seat pitch) as 17.5, 22, and 32 inches (equivalent to 44.45, 55.88 and 81.28 cm), respectively 1 (Fig. 1) .", [["width", "OBSERVATION_MODIFIER", 70, 75]]], ["While it is not the exact equivalent of \"legroom\", it does give a good indication of how much leg room exists.", [["leg", "ANATOMY", 94, 97], ["leg", "ORGANISM_SUBDIVISION", 94, 97]]], ["We use the Euclidian approach to calculate the distance between the center of a seat and the center of another seat.", [["the Euclidian approach", "TREATMENT", 7, 29]]], ["Fig. 2 presents a simple algorithm to calculate the Euclidian distance between seats in an airplane.", [["a simple algorithm", "TEST", 16, 34]]], ["The algorithm also establishes the value of a binary parameter \u03b2(described below) that indicates whether the distance between seats is within a specified range of interest.Assumptions and objectives for passenger assignmentAfter finding the distance between a target seat and all other seats in the airplane, we define a parameter that exhibits the seats which are between a lower and upper bound distance from the target seat.", [["lower", "ANATOMY_MODIFIER", 375, 380], ["upper", "ANATOMY_MODIFIER", 385, 390], ["target seat", "OBSERVATION", 415, 426]]], ["The parameter l indicates seat position (l = 1 means window seat; l = 2 means middle seat, and l = 3 means aisle seat).", [["seat position", "OBSERVATION", 26, 39]]], ["For the seat l on the side s of row r, the binary parameter \u03b2 r,s,l r ' ,s ' ,l ' ,k indicates whether seat l ' , on side s ' and row r ' is within a particular range of distance from the seat represented with the superscripts (r, s, l).", [["the binary parameter", "TEST", 39, 59]]], ["For this parameter, we use the subscript k with tighter lower and upper bounds in shorter distances to greater respect the importance of social distancing in closer distances.Assumptions and objectives for passenger assignmentFor instance, we defined the lower and upper bounds distance where k = 1 as Lb 1 = 0 and Ub 1 = 3.3, so \u03b2 r,s,l r ' ,s ' ,l ' ,1 = 1 indicates seats that are in less than or equal to 3.3 feet distance from the seat l on the side s of row r of an airplane.", [["the subscript k with tighter lower and upper bounds", "TREATMENT", 27, 78], ["k", "TEST", 293, 294], ["Lb", "TEST", 302, 304], ["Ub", "TEST", 315, 317], ["upper", "ANATOMY_MODIFIER", 66, 71], ["lower", "ANATOMY_MODIFIER", 255, 260], ["upper", "ANATOMY_MODIFIER", 265, 270], ["seat l", "ANATOMY_MODIFIER", 436, 442], ["airplane", "OBSERVATION", 472, 480]]], ["We selected the 3.3 feet distance for the upper bound of k = 1 as the World Health Organization (WHO) advises people to keep at least 3.3 feet (equivalent to 100 cm) distance from each other while practicing social distancing (WHO, 2020).", [["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["upper", "ANATOMY_MODIFIER", 42, 47]]], ["For the second category (k = 2), its lower bound is equal to 3.3 feet and its upper bound is equal to 6.6 feet.", [["upper", "ORGANISM_SUBDIVISION", 78, 83], ["the second category", "TEST", 4, 23], ["k", "TEST", 25, 26], ["lower", "ANATOMY_MODIFIER", 37, 42], ["equal", "OBSERVATION_MODIFIER", 52, 57], ["upper", "ANATOMY_MODIFIER", 78, 83], ["equal", "OBSERVATION", 93, 98]]], ["Passengers within this second category are penalized but with a lower penalty value than those in the first category who are seated closer to other passenger(s).", [["a lower penalty value", "PROBLEM", 62, 83]]], ["We defined the second category based on the operational guidelines for the management of air passengers and aviation personnel in relation to the COVID-19 pandemic published by European Union Aviation Safety Agency (EASA, 2020), in which it is specified that the current scientific studies and articles confirm that in general, the distance that large respiratory droplets travel is up to 2 m (equivalent to 6.6 feet) when coughing.", [["respiratory droplets", "ANATOMY", 352, 372], ["coughing", "DISEASE", 423, 431], ["large respiratory droplets travel", "PROBLEM", 346, 379], ["coughing", "PROBLEM", 423, 431], ["large", "OBSERVATION_MODIFIER", 346, 351], ["respiratory droplets", "OBSERVATION", 352, 372]]], ["Therefore, we employed this distance (i.e., 6.6 feet) to construct the second category of passengers distancing.Assumptions and objectives for passenger assignmentAs a way of illustration, Fig. 3 shows the 6, 9, and 8 seats which are less than or equal to 3.3 feet distance from the window seat of row 17 on the left side of the aisle, the aisle seat of row 5 and the middle seat of row 14 on the right side of the airplane respectively.Assumptions and objectives for passenger assignmentIn addition to the seating location distance among passengers, we are interested in the seating location's distance from the aisle of the airplane.", [["left", "ANATOMY", 312, 316], ["less", "OBSERVATION_MODIFIER", 234, 238], ["left", "ANATOMY_MODIFIER", 312, 316], ["aisle", "ANATOMY_MODIFIER", 329, 334], ["row", "OBSERVATION_MODIFIER", 354, 357], ["middle", "ANATOMY_MODIFIER", 368, 374], ["seat", "ANATOMY_MODIFIER", 375, 379], ["row", "OBSERVATION_MODIFIER", 383, 386], ["right", "ANATOMY_MODIFIER", 397, 402]]], ["There are three levels of distance between seats and the aisle of the airplane because the aisle seats are closest to the aisle and window seats are safest in terms of the highest distance from the aisle and middle seats in between.", [["three", "OBSERVATION_MODIFIER", 10, 15], ["levels", "OBSERVATION_MODIFIER", 16, 22], ["distance", "OBSERVATION_MODIFIER", 26, 34], ["middle", "ANATOMY_MODIFIER", 208, 214]]], ["Concerning maximizing the distance from the aisle, we aim to minimize the number of passengers sitting in the aisle seats and middle seats.", [["middle", "ANATOMY_MODIFIER", 126, 132]]], ["In this regard, the aisle seats, as they are closer to the aisle, are prioritized with higher penalties than the middle seats.", [["middle", "ANATOMY_MODIFIER", 113, 119]]], ["In other words, \u03b1 l emphasize the importance of avoiding assigning aisle seats because of their close distance to the aisle compared to middle and window seats.", [["\u03b1 l", "GENE_OR_GENE_PRODUCT", 16, 19]]], ["Moreover, \u03b1 l is zero for all window seats as the window seat location is the best practice concerning the distance from the aisle of an airplane.Assumptions and objectives for passenger assignmentThe seats located in the first rows and last rows of the airplane are more penalized for violating social distancing in the airplane as these rows are closer to the flight attendants' cabin and the airplane washrooms.", [["\u03b1 l", "GENE_OR_GENE_PRODUCT", 10, 13], ["airplane", "OBSERVATION", 137, 145]]], ["To extract the value of \u03bb r 1 We employ these values averaging the seat pitch and seat width for several airlines worldwide.", [["these values", "TEST", 40, 52], ["seat pitch", "OBSERVATION", 67, 77]]], ["The higher the value of \u03b3, the more the importance of not assigning passengers to seats closer to the front/rear of the airplane.", [["higher", "OBSERVATION_MODIFIER", 4, 10]]], ["For instance, we see that \u03bb r for rows 10 and 11 are only 10% of the row 1 penalty when \u03b3 is 1 and 77.4% of the row 1 penalty when \u03b3 is 9.Mixed integer programming model formulationWe introduce X r,s,l as the main binary decision variable that shows the occupancy of the seat l at row r and side s of the airplane. we defined two separate models for passenger seat assignment.", [["Mixed integer programming model formulation", "TREATMENT", 138, 181]]], ["This will be followed by introducing the objective function and the constraints of each model.Mixed integer programming model formulationSubscript & superscript r&r ' row of the airplane s&s ' side of the airplane. s, s ' = 1 represents the left side and s, s ' = 2 indicates the right side of the aisle l&l ' seat of the airplane. l, l ' = 1, l, l ' = 2 and l, l ' = 3 respectively indicates the window, middle and aisle seat Binary variable that determines if the seat locations represented by (r, s, l) and (r ' , s ' , l ' ) are both occupied by passengers (value of 1) or at least one of them is not occupied (value of zero)Model 1: Minimizing the social distancing interferencesThe primary focus of the first model is to best practice the social distancing among passengers according to the introduced metrics with a pre-specified load of passengers.", [["left", "ANATOMY", 241, 245], ["the objective function", "TEST", 37, 59], ["Mixed integer programming model formulation", "TREATMENT", 94, 137], ["left", "ANATOMY_MODIFIER", 241, 245], ["right", "ANATOMY_MODIFIER", 280, 285], ["l", "ANATOMY_MODIFIER", 335, 336], ["l", "ANATOMY_MODIFIER", 344, 345], ["l", "ANATOMY_MODIFIER", 347, 348], ["l", "ANATOMY_MODIFIER", 359, 360], ["l", "ANATOMY_MODIFIER", 362, 363], ["window", "OBSERVATION", 397, 403], ["middle", "ANATOMY_MODIFIER", 405, 411]]], ["(4), the value of \u03b4 k , i.e., 0 < \u03b4 k < 1 \u2200k \u2208 K is a weight that decreases as k increases.", [["the value", "TEST", 5, 14], ["k", "TEST", 20, 21], ["k", "TEST", 36, 37], ["K", "TEST", 47, 48], ["a weight", "TEST", 52, 60]]], ["2.Algorithm to find the value of the binary \u03b2 that indicates the distance between seats.Fig.", [["\u03b2", "DNA", 44, 45]]], ["In this equation, we also take into account the weight \u03bb r , i.e., 0 < \u03bb r < 1 \u2200r \u2208 R, corresponding to each row of the airplane.", [["the weight", "TEST", 44, 54]]], ["With a higher value of \u03bb r for the first several rows and the last rows of the airplane, the distance from the aisle will not be penalized in the middle rows of the airplane as much as for the first and last rows.Fig.", [["\u03bb r", "GENE_OR_GENE_PRODUCT", 23, 26], ["middle", "ANATOMY_MODIFIER", 146, 152]]], ["For the Airbus A320, the capacity is 120.", [["the capacity", "TEST", 21, 33]]], ["(7) ensures that Y r,s,l r ' ,s ' ,l ' equals 1 if both binary variables X r,s,l and X r ' ,s ' ,l ' are equal to 1.Model 2: Maximizing the (safe) load of passengersPracticing social distancing in the seat assignment problem can be viewed from a different perspective where the goal is to maximize the load of passengers while limiting the number of passengers assigned to seats within a pre-specified minimum distance among passengers and/or sitting close to the aisle of airplane.", [["s", "TEST", 77, 78], ["l and X r '", "TEST", 79, 90], ["s '", "TEST", 92, 95], ["l", "ANATOMY_MODIFIER", 79, 80]]], ["(4) and (5) should be included in the list of constraints for Model 2 with specified upper bounds, i.e., \u03b7 Z1 , \u03b7 Z2 .Objective functionThe objective function introduced for model 2 in Eq.", [["upper", "ANATOMY_MODIFIER", 85, 90]]], ["Equation (6)Objective function\u03a3 l\u2208L \u03a3 s\u2208S \u03a3 r\u2208R \u03b1 l \u03bb r X r,s,l \u2264 \u03b7 Z2Objective functionThe constraints of the formulation proposed in this section should include Eq.", [["s\u2208S", "PROTEIN", 38, 41], ["Equation", "TEST", 0, 8], ["Objective function\u03a3", "TEST", 12, 31], ["l\u2208L", "TEST", 32, 35], ["\u03a3", "TEST", 36, 37], ["s\u2208S", "TEST", 38, 41], ["\u03a3", "TEST", 42, 43], ["r\u2208", "TEST", 44, 46], ["s", "TEST", 60, 61], ["Z2Objective function", "TEST", 68, 88], ["the formulation", "TREATMENT", 107, 122], ["this section", "TREATMENT", 135, 147], ["l", "ANATOMY_MODIFIER", 62, 63]]], ["The objective function variables Z 1 and Z 2 are included in Eq.", [["Z 1 and Z 2", "DNA", 33, 44], ["The objective function variables Z", "TEST", 0, 34]]], ["(10) as constraining upperbounds to limit the number of passengers who are seated to close to another passenger and to limit the number of passengers seated close to the aisle.Numerical resultsWe implemented the MIP formulation proposed in Section 4 using GUROBI 9.0 as the MIP solver on a personal computer with a 3.4 GHz Intel\u00ae Core\u2122 i7-6700 U-type processor and 16 GB of memory.", [["the MIP formulation", "TREATMENT", 208, 227], ["GUROBI", "TEST", 256, 262]]], ["We used GUROBI solver keeping the default parameter settings except that we used a zero optimization tolerance gap.Results from proposed MIP in model 1We defined different scenarios introduced in Table 2 concerning the values of the parameters in the MIP formulation in Model 1.", [["MIP", "DNA", 137, 140], ["GUROBI solver", "TREATMENT", 8, 21], ["a zero optimization tolerance gap", "TREATMENT", 81, 114]]], ["The classes include one, two, and three or more passengers sitting close to the target passenger and the corresponding cells to these classes are highlighted as yellow, orange and red, respectively.", [["cells", "ANATOMY", 119, 124], ["cells", "CELL", 119, 124]]], ["As illustrated in Fig. 4 , this is the case with the seat assignment under this scenario where no seat assignment violates the 3.3 feet social distancing policy.", [["Fig", "OBSERVATION_MODIFIER", 18, 21]]], ["Scenario II, however, minimizes the number of passengers assigned to aisle seats to emphasize the passengers distance from the aisle of an airplane.", [["airplane", "OBSERVATION", 139, 147]]], ["Under this scenario, the number of passengers assigned to aisle seats reduces to no passengers compared to 10 passengers assigned to aisle seats in scenario I.Results from proposed MIP in model 1We also evaluate the number of passengers in the first and second social distancing categories when \u03b3changes from 1 to 9 for the same load of passengers, i.e., \u03d1 = 30 (Fig. 5) .", [["MIP", "DNA", 181, 184]]], ["Because scenario II emphasizes passengers sitting further from the aisle, the downside consequence is that more passengers are sitting too close to each other than for scenario I. The disparity increases while gamma \u03b3 = 9, because the higher the value of gamma, the more severe the penalty for the assignment of passengers to seats close to the front and rear of the airplane.Results from proposed MIP in model 1Tables 3 and 4 evaluate the seat assignments under different scenarios concerning the passengers' distance from each other and their distance from the aisle for a load of passengers.", [["gamma \u03b3 = 9", "PROTEIN", 210, 221], ["gamma", "PROTEIN", 255, 260], ["MIP", "DNA", 398, 401], ["proposed MIP", "TEST", 389, 401]]], ["Note that \u03b3 = 1 the recommended seat assignments results are presented in Table 3 , while \u03b3 = 9 the results are presented in Table 4 .", [["seat assignments", "TEST", 32, 48]]], ["With heavier loads of passengers, i.e., \u03d1 = 60, \u03d1 = 90 , the number of passengers in class 3 (more than 3 persons sitting within 3.3 feet of a target passenger) increases when seat assignments are based on scenario II instead of scenario I. For instance, for the seat assignment according to scenario II and the load of 60 passengers in Table 3 , the number of passengers in class 3 is 52, while there is no passenger in this class using the first scenario for the seat assignment.", [["persons", "SPECIES", 106, 113]]], ["Moreover, comparing the other two classes for the same load of passengers in this table, it is clear that scenario I emphasizes seat assignments that minimizes the average number of passengers in classes 2 and 3.Results from proposed MIP in model 1Seat assignments based on scenario III in all loads of passengers presented in Tables 3 and 4 is more reminiscent of scenario I than scenario II.", [["MIP", "DNA", 234, 237], ["proposed MIP", "TEST", 225, 237]]], ["To find a better balance between scenarios I and II, we adjusted weights of objective function variables to 0.3 and 0.7 for the first and second objectives and the weights of each category of seat distance is updated to 0.7, 0.3 for the first and the second category, respectively, while keeping the remaining parameters' values according to the scenario III in Table 2 .", [["objective function variables", "TEST", 76, 104]]], ["Table 5 presents the effect of the updated weights on the seat assignment for a load of 60 passengers and different values of \u03b3.Results from proposed MIP in model 1According to Table 5 , the modified scenario recommends a seating layout that is generally between what scenarios I and II offer in terms of the passengers in different classes and the passengers assigned to aisle seats.", [["MIP", "PROTEIN", 150, 153]]], ["However, this value for the seat assignment recommended by the modified scenario is 19 which is a value between 8 and 36 (8 < 19<36).", [["the seat assignment", "TEST", 24, 43]]], ["The number of passengers assigned to aisle seats based on the modified scenario is 6 which is also a value between the number of passengers dedicated to the aisle seats in scenarios I and II.Results from proposed MIP in model 1To study the effect of \u03b3 value on passengers' seat assignment, in Fig. 6 , we evaluated the seat assignments when \u03b3 = 1, \u03b3 = 9 and for a load of 60 passengers based on scenario II.Results from proposed MIP in model 1According to Fig. 6 , when \u03b3 = 9, the proposed seat assignment puts more emphasis on keeping the aisle seats (especially the aisle seats in the very first/last rows) free of passengers.", [["MIP", "DNA", 213, 216], ["MIP", "DNA", 429, 432], ["proposed MIP", "TEST", 204, 216], ["the seat assignments", "TEST", 315, 335], ["proposed MIP", "TEST", 420, 432]]], ["As a result, there is no passenger assigned to aisle seats when\u03b3 = 9.", [["no", "UNCERTAINTY", 22, 24]]], ["However, when \u03b3 = 1, there are passengers assigned to aisle seats but still, the proposed seat assignment distributes most of the passengers of aisle seats to the middle rows, i.e., rows 9 and 12.", [["middle", "ANATOMY_MODIFIER", 163, 169]]], ["Therefore, comparing the seat assignments when \u03b3 = 1 and \u03b3 = 9, we observe that the number of passengers in class 2 increases from 5 when \u03b3 = 1 to 8 when \u03b3 = 9.Results from proposed MIP in model 2In model 2, with the aim of maximizing the number of passengers, we specify the maximum number of passengers that are seated too close to another passenger and too close to the aisle, as defined in the right hand side values of Eqs.", [["right hand", "ANATOMY", 398, 408], ["MIP", "DNA", 182, 185], ["the seat assignments", "TEST", 21, 41], ["proposed MIP", "TEST", 173, 185], ["right", "ANATOMY_MODIFIER", 398, 403]]], ["(9) and (10) are active (with righthand side values of zero) allowing no passenger to sit closer than 3.3 feet distance from another passenger and for no passenger to occupy an aisle seat (left side of the seating assignment in Fig. 7) .", [["active", "OBSERVATION_MODIFIER", 17, 23], ["left", "ANATOMY_MODIFIER", 189, 193]]], ["With this set of constraints, the maximum load of passengers is 20 which is one-sixth of the maximum possible load of passengers to board the airplane in the absence of social distancing.", [["social distancing", "OBSERVATION", 169, 186]]], ["We also evaluate the maximum possible load of passengers only restricting the passengers seating assignment to have no passengers seated closer than 3.3 feet distance from another passenger while permitting passengers to sit in aisle seats (right side of the seating assignment in Fig. 7) .", [["right", "ANATOMY_MODIFIER", 241, 246]]], ["Assigning passengers to aisle seats to maximize the load of passengers may be a reasonable strategy for airlines as long as they take preliminary actions to minimize activity in the aisle or if they are not particularly concerned about the risk of infection from aisle activity.Results from proposed MIP in model 2To create Table 6 , we specify a very big value for the upper bound of Eq.", [["infection", "DISEASE", 248, 257], ["MIP", "DNA", 300, 303], ["infection", "PROBLEM", 248, 257], ["proposed MIP", "TEST", 291, 303], ["infection", "OBSERVATION", 248, 257], ["upper bound", "OBSERVATION_MODIFIER", 370, 381]]], ["We also specify different upper bounds for Eq.", [["upper bounds", "OBSERVATION_MODIFIER", 26, 38]]], ["In the last column of Table 6 , we evaluate the percentage of increase in the number of passengers compared with the previous row of the table.", [["increase", "OBSERVATION_MODIFIER", 62, 70]]], ["However, once the maximum number of passengers in category 1 rises to 51 and 63, the number of class 2 and class 3 passengers dramatically rises respectively.Results from proposed MIP in model 2In Table 6 , we introduced the upper bound only for Eq.", [["MIP", "DNA", 180, 183], ["upper", "ANATOMY_MODIFIER", 225, 230]]], ["(9) and (10) on the maximum load of passengers, we also present an upper bound greater than zero for Eq.", [["an upper bound", "PROBLEM", 64, 78], ["upper", "ANATOMY_MODIFIER", 67, 72]]], ["Fig. 8 shows a resulting seating assignment layout where in the left-sided seating assignment, Eqs.", [["left", "ANATOMY_MODIFIER", 64, 68], ["sided", "ANATOMY_MODIFIER", 69, 74]]], ["The right-sided seating assignment resulted from employing the same upper bound for Eq.", [["right", "ANATOMY_MODIFIER", 4, 9], ["sided", "ANATOMY_MODIFIER", 10, 15]]], ["(9), while defining a very large value for the upper bound of Eq.", [["upper bound", "OBSERVATION_MODIFIER", 47, 58]]], ["(9) and (10) the maximum load decreases to 46.", [["the maximum load decreases", "TEST", 13, 39]]], ["(9) in the left-sided seating assignment places no passenger in class 3 while there are three passengers in this class in the other seating assignment.", [["left", "ANATOMY_MODIFIER", 11, 15], ["sided", "ANATOMY_MODIFIER", 16, 21]]], ["This reduction comes with the cost of increasing the number of passengers in classes 1 and 2.", [["This reduction", "TREATMENT", 0, 14]]], ["In the left sided seating assignment, the number of passengers in classes 1 and 2 increases to 29 and 14, respectively compared to the 27 and 8 for classes 1 and 2 in the right sided seating layout.Comparison with airlines' current policy for social distancingDuring the SARS-CoV-2 outbreak, airlines try to adjust their boarding and seat assignment policies to better follow the requirements for passengers' safety.", [["SARS", "DISEASE", 271, 275], ["SARS-CoV", "SPECIES", 271, 279], ["the SARS", "TEST", 267, 275], ["seat assignment policies", "TREATMENT", 334, 358], ["left", "ANATOMY_MODIFIER", 7, 11], ["sided", "ANATOMY_MODIFIER", 12, 17], ["right", "ANATOMY_MODIFIER", 171, 176], ["sided", "ANATOMY_MODIFIER", 177, 182], ["seating layout", "OBSERVATION", 183, 197]]], ["For instance, Delta Airlines implemented back-tofront boarding so that passengers do not have to pass seated passengers while boarding (Delta Airlines, 2020).", [["Delta Airlines", "TREATMENT", 14, 28]]], ["United Airlines as another major airline in the United States, has dedicated a full page on its website to the SARS-CoV-2 response, indicating new policies for aircraft disinfection, access to hand-sanitizer, and new protocols for boarding and checking-in to limit individual contacts (Fowler, 2020) .Comparison with airlines' current policy for social distancingIn a similar practice to keep social distancing among seated passengers, some airlines including Delta Airlines and American Airlines announced that they block 50 percent or all of the middle seats in an airplane to keep effective distancing among passengers.", [["hand", "ANATOMY", 193, 197], ["SARS", "DISEASE", 111, 115], ["the SARS", "TEST", 107, 115], ["aircraft disinfection", "TREATMENT", 160, 181], ["sanitizer", "TREATMENT", 198, 207], ["new protocols", "TREATMENT", 213, 226], ["Delta Airlines", "TREATMENT", 460, 474], ["American Airlines", "TREATMENT", 479, 496]]], ["Fig. 9 demonstrates the middle seat-blocking policy versus our proposed seat assignment based on scenarios II and I for forty passengers.", [["middle", "ANATOMY_MODIFIER", 24, 30]]], ["Concerning the middle-seat blocking policy, we assume that the passengers are seated in every other row so there is enough social distancing among passengers sitting the same distance from the aisle (i.e., either window or aisle seat).Comparison with airlines' current policy for social distancingAccording to Fig. 9 , there are 20 passengers assigned to aisle seats in the middle-seat blocking policy while it reduces to 10 and even 0 passengers using our proposed formulation in Model 1 with scenarios I and II, respectively.", [["the middle-seat blocking policy", "TREATMENT", 370, 401], ["middle", "ANATOMY_MODIFIER", 15, 21]]], ["Concerning the passengers of aisle seats in the first/last three rows of the airplane, scenarios I and II provide improvement over the middle-seat blocking policy as well.", [["aisle seats", "PROBLEM", 29, 40], ["the middle-seat blocking policy", "TREATMENT", 131, 162]]], ["There are 20 passengers (a group of two passengers) who are sitting close to another passenger (class 1) following the middle-seat blocking for seat I 0 0 0 10 3 51 II 20 0 0 0 0 66 III 0 0 0 10 3 67 60 I 26 34 0 20 6 68 II 2 5 52 2 0 56 III 22 38 0 18 4 94 90 I 0 4 86 28 8 51 II 0 0 90 10 0 44 III 0 0 90 26 8 46 Table 4 Passengers seat assignment results for different loads of passengers while \u03b3 = 9.Comparison with airlines' current policy for social distancingPassengers' Load Scenario # Passengers seated within 3.3 feet #Passengers in the aisle seat Passengers in the aisle seats first/last three rows Runtime (seconds) assignment.", [["III", "TEST", 238, 241], ["II", "TEST", 278, 280], ["III", "TEST", 296, 299], ["Passengers seat assignment", "TEST", 323, 349]]], ["Compared to scenario II, the middle-seat blocking policy seems to work better when all passengers are traveling individually rather than in groups (e.g. families).", [["the middle-seat blocking policy", "TREATMENT", 25, 56], ["middle", "ANATOMY_MODIFIER", 29, 35]]], ["Although we do not consider groups of passengers traveling together explicitly within this paper, scenario II provides a better theoretical foundation for future research involving groups of passengers boarding together in which the middle seat may be occupied.", [["middle", "ANATOMY_MODIFIER", 233, 239]]], ["Moreover, scenario I can perform (moderately) better than the middle-seat blocking policy when passengers are not traveling in groups and social distancing among seated passengers is the priority for their seating assignment.ConclusionPracticing social distancing among passengers seated in an airplane will better assure their health safety in a flight during a SARS-CoV-2 or similar outbreak.", [["SARS", "DISEASE", 363, 367], ["SARS-CoV", "SPECIES", 363, 371]]], ["The proposed MIP model addresses social distancing in an airbus A320 with twenty rows, single aisle and three seats on each side of the aisle.ConclusionIn the SARS-CoV-2 context, when social distancing is important, the proposed MIP provides a more intelligent approach for determining passenger seating assignments than simple rules of thumb such as blocking all middle seats.", [["thumb", "ANATOMY", 337, 342], ["thumb", "ORGANISM_SUBDIVISION", 337, 342], ["MIP", "DNA", 229, 232], ["the SARS", "TEST", 155, 163], ["thumb", "ANATOMY", 337, 342]]], ["We illustrate how the MIP can provide the same social distancing between seated passengers as blocking all middle seats, but with a reduced number of passengers seated close to the airplane's aisle where they may be exposed to passengers and crew members emitting COVID-19 droplets as they traverse the aisle.", [["MIP", "PROTEIN", 22, 25]]], ["We illustrate how the model parameters may be varied to generate efficient tradeoffs between an airline's relative preferences for the two metrics of social distancing.ConclusionIn particular, we defined two formulations introduced as models 1 and 2 where in model 1 we addressed aim to minimize the possible interferences in social distancing for a specified load of passengers based on the two metrics including the distance of passengers from each other and their distance from the aisle of an airplane.", [["airplane", "OBSERVATION", 497, 505]]], ["The third scenario tries to address a middle ground between two scenarios where both social distancing viewpoints equally matter.", [["middle", "ANATOMY_MODIFIER", 38, 44]]], ["Seat assignments for 40 passengers using middle-seat blocking, scenarios I and II.Conclusionaisle.", [["middle-seat blocking", "TREATMENT", 41, 61]]], ["These right-hand side values of the social distancing metrics present the acceptable level of social distancing while maximizing the load of passengers.", [["right-hand", "ANATOMY", 6, 16], ["right", "ANATOMY_MODIFIER", 6, 11]]], ["We set the upper bounds of the social distancing metrics to zero allowing no passenger in the aisle seats and no passenger to be seated closer than 3.3 feet from another passenger.", [["feet", "ORGANISM_SUBDIVISION", 152, 156], ["upper bounds", "OBSERVATION_MODIFIER", 11, 23]]], ["Results indicate that employing both metrics can effectively improve the level of social distancing among passengers while adversely affecting the maximum load of passengers.ConclusionEventually, we analyzed the proposed middle-seat blocking policy by some airlines for a load of forty passengers.", [["the proposed middle-seat blocking policy", "TREATMENT", 208, 248], ["middle", "ANATOMY_MODIFIER", 221, 227]]], ["Comparing scenario I and the middle-seat blocking policy, we observed equal number of passengers belonging to class 1 while scenario I reduced the number of passengers assigned to the aisle seats.", [["middle", "ANATOMY_MODIFIER", 29, 35]]]], "545e6995814d419e9c2e840293bb48f34f57690c": [["as well as how efficiently special care dentistry (SCD) can adapt to the present challenges, which result from the real danger of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic.Anticipated Deterioration of Medical and Dental ConditionsIt is not surprising that a vast number of patients with complex needs may suffer from further medical and/or dental problems as a result of postponed medical/dental care, rescheduled surgeries, interrupted medication regimes, and a lack of access to consultations with general medical practitioners and specialists [7, 8] .", [["SCD", "DISEASE", 51, 54], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 141, 179], ["SARS-CoV-2) pandemic", "DISEASE", 183, 203], ["SARS-CoV-2", "ORGANISM", 183, 193], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 305, 313], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 134, 193], ["the Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 130, 179], ["SARS", "TEST", 183, 187], ["CoV", "TEST", 188, 191], ["pandemic", "PROBLEM", 195, 203], ["Deterioration of Medical and Dental Conditions", "PROBLEM", 216, 262], ["further medical and/or dental problems", "PROBLEM", 349, 387], ["postponed medical/dental care", "TREATMENT", 403, 432], ["surgeries", "TREATMENT", 446, 455], ["interrupted medication regimes", "TREATMENT", 457, 487], ["Severe", "OBSERVATION_MODIFIER", 134, 140], ["Acute", "OBSERVATION_MODIFIER", 141, 146], ["Respiratory Syndrome", "OBSERVATION", 147, 167], ["not surprising", "UNCERTAINTY", 268, 282]]], ["In the United Kingdom, people who are clinically extremely vulnerable and are at the greatest risk of developing serious complications as a result of COVID-19 received a letter advising them to shield for several weeks.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["serious complications", "PROBLEM", 113, 134], ["COVID", "TEST", 150, 155], ["serious", "OBSERVATION_MODIFIER", 113, 120], ["complications", "OBSERVATION", 121, 134]]], ["The identified groups of extremely clinically vulnerable people who are at high risk of getting seriously ill from SARS-Cov-2 infection are presented in Table 1 (Public Health England, London, UK, [9] ).", [["ill", "DISEASE", 106, 109], ["SARS", "DISEASE", 115, 119], ["infection", "DISEASE", 126, 135], ["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63], ["seriously ill", "PROBLEM", 96, 109], ["SARS", "PROBLEM", 115, 119], ["Cov-2 infection", "PROBLEM", 120, 135]]], ["This includes, clinically, people living in long-term care facilities for the elderly or people with special needs.", [["people", "ORGANISM", 27, 33], ["people", "ORGANISM", 89, 95], ["people", "SPECIES", 27, 33], ["people", "SPECIES", 89, 95]]], ["It is confirmed that immunocompromised patients, such as persons undergoing anticancer therapy, those on chemotherapeutic drugs, transplant recipients, patients with underlying medical problems and comorbidities can be directly affected by the current situation, as this group of patients is undoubtedly highly vulnerable to coronavirus SARS-CoV-2 infection and subsequent health problems, including life-threatening ones [10] .", [["anticancer", "ANATOMY", 76, 86], ["SARS-CoV-2 infection", "DISEASE", 337, 357], ["patients", "ORGANISM", 39, 47], ["persons", "ORGANISM", 57, 64], ["anticancer", "CANCER", 76, 86], ["recipients", "ORGANISM", 140, 150], ["patients", "ORGANISM", 152, 160], ["patients", "ORGANISM", 280, 288], ["coronavirus SARS-CoV-2", "ORGANISM", 325, 347], ["patients", "SPECIES", 39, 47], ["persons", "SPECIES", 57, 64], ["patients", "SPECIES", 152, 160], ["patients", "SPECIES", 280, 288], ["immunocompromised", "PROBLEM", 21, 38], ["anticancer therapy", "TREATMENT", 76, 94], ["chemotherapeutic drugs", "TREATMENT", 105, 127], ["transplant recipients", "TREATMENT", 129, 150], ["underlying medical problems", "PROBLEM", 166, 193], ["comorbidities", "PROBLEM", 198, 211], ["coronavirus SARS", "PROBLEM", 325, 341], ["CoV-2 infection", "PROBLEM", 342, 357], ["subsequent health problems", "PROBLEM", 362, 388], ["immunocompromised", "OBSERVATION", 21, 38]]], ["The list of clinically extremely vulnerable groups based on expert opinions and evidence-based data (Public Health England UK, government source [9] ).Categories of Medically Compromised People at Greatest Risk of COVID-19 Serious Illness\u2022 Solid organ transplant recipients; \u2022 People with cancer who are undergoing active chemotherapy; \u2022 People with lung cancer who are undergoing radical radiotherapy; \u2022 People with cancers of the blood or bone marrow such as leukemia, lymphoma or myeloma who are at any stage of treatment; \u2022 People having immunotherapy or other continuing antibody treatments for cancer; \u2022 People having other targeted cancer treatments which can affect the immune system, such as protein kinase inhibitors or PARP inhibitors; \u2022 People who have had bone marrow or stem cell transplants in the last 6 months, or who are still taking immunosuppression drugs; \u2022 People with severe respiratory conditions including all cystic fibrosis, severe asthma and severe chronic obstructive pulmonary disease (COPD); \u2022 People with rare diseases that significantly increase the risk of infections (such as severe combined immunodeficiency (SCID), homozygous sickle cell); \u2022 People on immunosuppression therapies sufficient to significantly increase risk of infection; \u2022 Women who are pregnant with significant heart disease, congenital or acquired; \u2022 Other people have also been classed as clinically extremely vulnerable, based on clinical judgement and an assessment of their needs.", [["organ", "ANATOMY", 246, 251], ["cancer", "ANATOMY", 289, 295], ["lung cancer", "ANATOMY", 350, 361], ["cancers", "ANATOMY", 417, 424], ["blood", "ANATOMY", 432, 437], ["bone marrow", "ANATOMY", 441, 452], ["leukemia", "ANATOMY", 461, 469], ["lymphoma", "ANATOMY", 471, 479], ["myeloma", "ANATOMY", 483, 490], ["cancer", "ANATOMY", 600, 606], ["cancer", "ANATOMY", 639, 645], ["immune system", "ANATOMY", 678, 691], ["bone marrow", "ANATOMY", 769, 780], ["stem cell", "ANATOMY", 784, 793], ["respiratory", "ANATOMY", 898, 909], ["cystic", "ANATOMY", 935, 941], ["pulmonary", "ANATOMY", 997, 1006], ["sickle cell", "ANATOMY", 1163, 1174], ["heart", "ANATOMY", 1315, 1320], ["cancer", "DISEASE", 289, 295], ["lung cancer", "DISEASE", 350, 361], ["cancers of the blood or bone marrow such as leukemia, lymphoma", "DISEASE", 417, 479], ["myeloma", "DISEASE", 483, 490], ["cancer", "DISEASE", 600, 606], ["cancer", "DISEASE", 639, 645], ["respiratory conditions", "DISEASE", 898, 920], ["cystic fibrosis", "DISEASE", 935, 950], ["asthma", "DISEASE", 959, 965], ["chronic obstructive pulmonary disease", "DISEASE", 977, 1014], ["COPD", "DISEASE", 1016, 1020], ["infections", "DISEASE", 1091, 1101], ["immunodeficiency", "DISEASE", 1127, 1143], ["SCID", "DISEASE", 1145, 1149], ["sickle cell)", "DISEASE", 1163, 1175], ["infection", "DISEASE", 1262, 1271], ["heart disease", "DISEASE", 1315, 1328], ["organ", "ORGAN", 246, 251], ["People", "ORGANISM", 277, 283], ["cancer", "CANCER", 289, 295], ["People", "ORGANISM", 338, 344], ["lung cancer", "CANCER", 350, 361], ["People", "ORGANISM", 405, 411], ["cancers", "CANCER", 417, 424], ["blood", "ORGANISM_SUBSTANCE", 432, 437], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 441, 452], ["leukemia", "CANCER", 461, 469], ["lymphoma", "CANCER", 471, 479], ["myeloma", "CANCER", 483, 490], ["People", "ORGANISM", 528, 534], ["cancer", "CANCER", 600, 606], ["People", "ORGANISM", 610, 616], ["cancer", "CANCER", 639, 645], ["PARP", "GENE_OR_GENE_PRODUCT", 730, 734], ["People", "ORGANISM", 749, 755], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 769, 780], ["stem cell", "CELL", 784, 793], ["pulmonary", "ORGAN", 997, 1006], ["People", "ORGANISM", 1025, 1031], ["sickle cell", "CELL", 1163, 1174], ["People", "ORGANISM", 1179, 1185], ["Women", "ORGANISM", 1275, 1280], ["heart", "ORGAN", 1315, 1320], ["people", "ORGANISM", 1362, 1368], ["PARP", "PROTEIN", 730, 734], ["People", "SPECIES", 187, 193], ["People", "SPECIES", 277, 283], ["People", "SPECIES", 338, 344], ["People", "SPECIES", 405, 411], ["People", "SPECIES", 528, 534], ["People", "SPECIES", 610, 616], ["People", "SPECIES", 749, 755], ["People", "SPECIES", 879, 885], ["People", "SPECIES", 1025, 1031], ["People", "SPECIES", 1179, 1185], ["Women", "SPECIES", 1275, 1280], ["people", "SPECIES", 1362, 1368], ["COVID", "TEST", 214, 219], ["Serious Illness", "PROBLEM", 223, 238], ["Solid organ transplant recipients", "TREATMENT", 240, 273], ["cancer", "PROBLEM", 289, 295], ["active chemotherapy", "TREATMENT", 315, 334], ["lung cancer", "PROBLEM", 350, 361], ["radical radiotherapy", "TREATMENT", 381, 401], ["cancers of the blood or bone marrow", "PROBLEM", 417, 452], ["leukemia", "PROBLEM", 461, 469], ["lymphoma", "PROBLEM", 471, 479], ["myeloma", "PROBLEM", 483, 490], ["treatment", "TREATMENT", 515, 524], ["immunotherapy", "TREATMENT", 542, 555], ["other continuing antibody treatments", "TREATMENT", 559, 595], ["cancer", "PROBLEM", 600, 606], ["other targeted cancer treatments", "TREATMENT", 624, 656], ["protein kinase inhibitors", "TREATMENT", 701, 726], ["PARP inhibitors", "TREATMENT", 730, 745], ["bone marrow", "PROBLEM", 769, 780], ["stem cell transplants", "TREATMENT", 784, 805], ["immunosuppression drugs", "TREATMENT", 852, 875], ["severe respiratory conditions", "PROBLEM", 891, 920], ["all cystic fibrosis", "PROBLEM", 931, 950], ["severe asthma", "PROBLEM", 952, 965], ["severe chronic obstructive pulmonary disease (COPD)", "PROBLEM", 970, 1021], ["rare diseases", "PROBLEM", 1037, 1050], ["infections", "PROBLEM", 1091, 1101], ["severe combined immunodeficiency (SCID)", "PROBLEM", 1111, 1150], ["homozygous sickle cell", "PROBLEM", 1152, 1174], ["immunosuppression therapies", "TREATMENT", 1189, 1216], ["infection", "PROBLEM", 1262, 1271], ["significant heart disease", "PROBLEM", 1303, 1328], ["clinical judgement", "TEST", 1437, 1455], ["an assessment", "TEST", 1460, 1473], ["cancer", "OBSERVATION", 289, 295], ["lung", "ANATOMY", 350, 354], ["cancer", "OBSERVATION", 355, 361], ["radical radiotherapy", "OBSERVATION", 381, 401], ["cancers", "OBSERVATION", 417, 424], ["blood", "ANATOMY", 432, 437], ["bone", "ANATOMY", 441, 445], ["marrow", "OBSERVATION", 446, 452], ["leukemia", "OBSERVATION", 461, 469], ["lymphoma", "OBSERVATION", 471, 479], ["myeloma", "OBSERVATION", 483, 490], ["cancer", "OBSERVATION", 639, 645], ["bone", "ANATOMY", 769, 773], ["stem cell transplants", "OBSERVATION", 784, 805], ["severe", "OBSERVATION_MODIFIER", 891, 897], ["respiratory conditions", "OBSERVATION", 898, 920], ["cystic", "OBSERVATION_MODIFIER", 935, 941], ["fibrosis", "OBSERVATION", 942, 950], ["severe", "OBSERVATION_MODIFIER", 952, 958], ["asthma", "OBSERVATION", 959, 965], ["severe", "OBSERVATION_MODIFIER", 970, 976], ["chronic", "OBSERVATION_MODIFIER", 977, 984], ["obstructive", "OBSERVATION_MODIFIER", 985, 996], ["pulmonary", "ANATOMY", 997, 1006], ["disease", "OBSERVATION", 1007, 1014], ["COPD", "OBSERVATION", 1016, 1020], ["rare", "OBSERVATION_MODIFIER", 1037, 1041], ["diseases", "OBSERVATION", 1042, 1050], ["infections", "OBSERVATION", 1091, 1101], ["sickle cell", "OBSERVATION", 1163, 1174], ["infection", "OBSERVATION", 1262, 1271], ["heart", "ANATOMY", 1315, 1320], ["disease", "OBSERVATION", 1321, 1328]]], ["GPs and hospital clinicians have been provided with guidance to support these decisions.Categories of Medically Compromised People at Greatest Risk of COVID-19 Serious IllnessDespite the non-coherent evidence of the direct relationship between impaired immune host status and serious COVID-19 complications, individuals with impaired immunity should be considered the greatest risk group.", [["impaired immunity", "DISEASE", 325, 342], ["People", "SPECIES", 124, 130], ["COVID", "TEST", 151, 156], ["impaired immune host status", "PROBLEM", 244, 271], ["serious COVID-19 complications", "PROBLEM", 276, 306], ["impaired immunity", "PROBLEM", 325, 342]]], ["This category of patients should remain under the highest risk group label due to the severe progression of the illness.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["the severe progression of the illness", "PROBLEM", 82, 119], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["progression", "OBSERVATION_MODIFIER", 93, 104], ["illness", "OBSERVATION", 112, 119]]], ["Similarly, dental patients who suffer from chronic autoimmune and/or inflammatory conditions such as pemphigus, Sj\u00f6gren syndrome, or lupus erythematosus and who are undertaking long-term immunomodulatory therapy (using corticosteroids) are also predisposed to severe COVID-19 progression due to a reduction in host antiviral mechanisms [11] .", [["pemphigus", "DISEASE", 101, 110], ["Sj\u00f6gren syndrome", "DISEASE", 112, 128], ["lupus erythematosus", "DISEASE", 133, 152], ["COVID", "DISEASE", 267, 272], ["corticosteroids", "CHEMICAL", 219, 234], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["chronic autoimmune", "PROBLEM", 43, 61], ["inflammatory conditions", "PROBLEM", 69, 92], ["pemphigus", "PROBLEM", 101, 110], ["Sj\u00f6gren syndrome", "PROBLEM", 112, 128], ["lupus erythematosus", "PROBLEM", 133, 152], ["long-term immunomodulatory therapy", "TREATMENT", 177, 211], ["corticosteroids", "TREATMENT", 219, 234], ["severe COVID", "PROBLEM", 260, 272], ["a reduction in host antiviral mechanisms", "TREATMENT", 295, 335], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["autoimmune", "OBSERVATION", 51, 61], ["inflammatory", "OBSERVATION_MODIFIER", 69, 81], ["Sj\u00f6gren syndrome", "OBSERVATION", 112, 128], ["lupus erythematosus", "OBSERVATION", 133, 152], ["host antiviral", "OBSERVATION", 310, 324]]], ["These persons must be encouraged and advised to continue their therapy during the pandemic, as the potential exacerbation of the autoimmune-related oral lesions is likely to occur.Categories of Medically Compromised People at Greatest Risk of COVID-19 Serious IllnessApart from primary severe complications within the lower respiratory tract, according to the latest studies, SARS-Cov-2 appears to reveal neurotropic and cardiotropic affinity [12, 13] , with a potential impact on cognitive function and cardiovascular potency.", [["oral lesions", "ANATOMY", 148, 160], ["lower respiratory tract", "ANATOMY", 318, 341], ["cardiovascular", "ANATOMY", 504, 518], ["SARS", "DISEASE", 376, 380], ["persons", "ORGANISM", 6, 13], ["oral lesions", "PATHOLOGICAL_FORMATION", 148, 160], ["lower", "ORGANISM_SUBDIVISION", 318, 323], ["respiratory tract", "ORGANISM_SUBDIVISION", 324, 341], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 376, 386], ["cardiovascular", "ANATOMICAL_SYSTEM", 504, 518], ["persons", "SPECIES", 6, 13], ["People", "SPECIES", 216, 222], ["their therapy", "TREATMENT", 57, 70], ["the autoimmune-related oral lesions", "PROBLEM", 125, 160], ["COVID", "TEST", 243, 248], ["Serious Illness", "PROBLEM", 252, 267], ["primary severe complications within the lower respiratory tract", "PROBLEM", 278, 341], ["the latest studies", "TEST", 356, 374], ["SARS", "TEST", 376, 380], ["neurotropic and cardiotropic affinity", "PROBLEM", 405, 442], ["autoimmune", "OBSERVATION", 129, 139], ["oral", "ANATOMY", 148, 152], ["lesions", "OBSERVATION", 153, 160], ["primary", "OBSERVATION_MODIFIER", 278, 285], ["severe", "OBSERVATION_MODIFIER", 286, 292], ["complications", "OBSERVATION", 293, 306], ["lower", "ANATOMY_MODIFIER", 318, 323], ["respiratory tract", "ANATOMY", 324, 341], ["cardiovascular potency", "OBSERVATION", 504, 526]]], ["In addition, impaired access to some medications and secondary care may expose medically compromised patients with complex health conditions to further health problems and subsequent complications [10, 14] .", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["some medications", "TREATMENT", 32, 48], ["secondary care", "TREATMENT", 53, 67], ["subsequent complications", "PROBLEM", 172, 196]]], ["As a result, the most common chronic diseases such as diabetes, hypertension, and heart conditions may become poorly controlled, affecting the general health status and restricting indications for more complex and invasive dental care.", [["heart", "ANATOMY", 82, 87], ["diabetes", "DISEASE", 54, 62], ["hypertension", "DISEASE", 64, 76], ["heart conditions", "DISEASE", 82, 98], ["heart", "ORGAN", 82, 87], ["the most common chronic diseases", "PROBLEM", 13, 45], ["diabetes", "PROBLEM", 54, 62], ["hypertension", "PROBLEM", 64, 76], ["heart conditions", "PROBLEM", 82, 98], ["invasive dental care", "TREATMENT", 214, 234], ["most common", "OBSERVATION_MODIFIER", 17, 28], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["diseases", "OBSERVATION", 37, 45], ["diabetes", "OBSERVATION", 54, 62], ["hypertension", "OBSERVATION", 64, 76], ["heart", "ANATOMY", 82, 87]]], ["Interestingly, recently patients with lupus complained about the shortage of hydroxychloroquine in the US, a medication which is used to treat autoimmune conditions, among others, as all its supplies were redirected to hospitals [15] .", [["lupus", "DISEASE", 38, 43], ["hydroxychloroquine", "CHEMICAL", 77, 95], ["hydroxychloroquine", "CHEMICAL", 77, 95], ["patients", "ORGANISM", 24, 32], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 77, 95], ["patients", "SPECIES", 24, 32], ["lupus", "PROBLEM", 38, 43], ["hydroxychloroquine", "TREATMENT", 77, 95], ["a medication", "TREATMENT", 107, 119], ["autoimmune conditions", "PROBLEM", 143, 164]]], ["Moreover, patients who have been receiving systemic pharmacotherapy with angiotensin-converting enzyme (ACE) inhibitors, as SARS-CoV-2 revealed a certain predilection to angiotensin-converting enzyme 2 (ACE2) receptors, can be potentially more susceptible severe respiratory tract complications resulting from COVID-19 [16, 17] .", [["respiratory tract", "ANATOMY", 263, 280], ["angiotensin-converting enzyme (ACE) inhibitors", "CHEMICAL", 73, 119], ["SARS", "DISEASE", 124, 128], ["angiotensin", "CHEMICAL", 170, 181], ["respiratory tract complications", "DISEASE", 263, 294], ["COVID-19", "CHEMICAL", 310, 318], ["patients", "ORGANISM", 10, 18], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 73, 102], ["ACE", "GENE_OR_GENE_PRODUCT", 104, 107], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 170, 201], ["ACE2", "GENE_OR_GENE_PRODUCT", 203, 207], ["respiratory tract", "ORGANISM_SUBDIVISION", 263, 280], ["angiotensin-converting enzyme", "PROTEIN", 73, 102], ["ACE", "PROTEIN", 104, 107], ["angiotensin-converting enzyme 2 (ACE2) receptors", "PROTEIN", 170, 218], ["patients", "SPECIES", 10, 18], ["systemic pharmacotherapy", "TREATMENT", 43, 67], ["angiotensin", "TREATMENT", 73, 84], ["converting enzyme (ACE) inhibitors", "TREATMENT", 85, 119], ["SARS-CoV", "TEST", 124, 132], ["angiotensin", "TEST", 170, 181], ["susceptible severe respiratory tract complications", "PROBLEM", 244, 294], ["COVID", "TEST", 310, 315], ["respiratory tract", "ANATOMY", 263, 280]]], ["On the contrary, the European Medicines Agency advises continued use of medicines for hypertension, heart or kidney diseases during the COVID-19 pandemic [18] .", [["heart", "ANATOMY", 100, 105], ["kidney", "ANATOMY", 109, 115], ["hypertension", "DISEASE", 86, 98], ["heart or kidney diseases", "DISEASE", 100, 124], ["heart", "ORGAN", 100, 105], ["kidney", "ORGAN", 109, 115], ["the European Medicines", "TREATMENT", 17, 39], ["medicines", "TREATMENT", 72, 81], ["hypertension", "PROBLEM", 86, 98], ["heart or kidney diseases", "PROBLEM", 100, 124], ["the COVID", "TEST", 132, 141], ["heart", "ANATOMY", 100, 105], ["kidney", "ANATOMY", 109, 115], ["diseases", "OBSERVATION", 116, 124]]], ["Similar problems may apply to corticosteroids prescribed to suppress the immune reactions in the case of asthma; however, the recommendations of professional bodies strongly support the advice for such patients to continue taking their regular medicines in line with their personalized asthma action plan [19] .Reduced Access to Secondary Dental Care and Fear FactorThe shortage of hospital and specialist staff and resources, as well as the cancellation of routine secondary dental care appointments led to a significant reduction in dental care under sedation and general anesthesia globally.", [["asthma", "DISEASE", 105, 111], ["asthma", "DISEASE", 286, 292], ["corticosteroids", "CHEMICAL", 30, 45], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["Similar problems", "PROBLEM", 0, 16], ["corticosteroids", "TREATMENT", 30, 45], ["the immune reactions", "PROBLEM", 69, 89], ["asthma", "PROBLEM", 105, 111], ["professional bodies", "TREATMENT", 145, 164], ["their regular medicines", "TREATMENT", 230, 253], ["Secondary Dental Care", "TREATMENT", 329, 350], ["a significant reduction", "TREATMENT", 508, 531], ["dental care", "TREATMENT", 535, 546], ["sedation", "TREATMENT", 553, 561], ["general anesthesia", "TREATMENT", 566, 584], ["asthma", "OBSERVATION", 105, 111]]], ["Due to the risk of SARS-Cov-2 aerosol exposure, the use of fast-speed handpieces and three in one syringes, (ultra)sonic scaling, surgical extractions and minor oral surgery procedures involving bone structure removal cannot be carried out without enhanced personal protective equipment (PPE) [3, 20, 21] .", [["oral", "ANATOMY", 161, 165], ["bone", "ANATOMY", 195, 199], ["SARS", "DISEASE", 19, 23], ["oral", "ORGANISM_SUBDIVISION", 161, 165], ["bone", "TISSUE", 195, 199], ["SARS", "PROBLEM", 19, 23], ["Cov-2 aerosol exposure", "TREATMENT", 24, 46], ["fast-speed handpieces", "TREATMENT", 59, 80], ["ultra)sonic scaling", "TREATMENT", 109, 128], ["surgical extractions", "TREATMENT", 130, 150], ["minor oral surgery procedures", "TREATMENT", 155, 184], ["bone structure removal", "TREATMENT", 195, 217], ["bone", "ANATOMY", 195, 199]]], ["Undoubtedly, the range of dental treatment under conscious sedation is to be drastically reduced, primarily affecting children and individuals with high levels of dental anxiety, requiring anxiety management measures.", [["anxiety", "DISEASE", 170, 177], ["anxiety", "DISEASE", 189, 196], ["children", "ORGANISM", 118, 126], ["children", "SPECIES", 118, 126], ["dental treatment", "TREATMENT", 26, 42], ["conscious sedation", "TREATMENT", 49, 67], ["dental anxiety", "PROBLEM", 163, 177], ["anxiety management measures", "TREATMENT", 189, 216]]], ["New SCD guidelines launched by the Royal College of Surgeons of England recommend that non-urgent treatment must be deferred to minimize risk to patients and staff, advising to involve two clinicians in the decision-making process.", [["SCD", "DISEASE", 4, 7], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["non-urgent treatment", "TREATMENT", 87, 107], ["SCD", "OBSERVATION", 4, 7]]], ["A wider use of various sedation techniques, instead of general anaesthesia, such as intravenous sedation as a safe and cost-efficient option will secure SCD provision during COVID-19 outbreak (Royal College of Surgeons (RCS), London, UK [22] ).", [["intravenous", "ANATOMY", 84, 95], ["SCD", "DISEASE", 153, 156], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 95], ["various sedation techniques", "TREATMENT", 15, 42], ["general anaesthesia", "TREATMENT", 55, 74], ["intravenous sedation", "TREATMENT", 84, 104]]], ["This is particularly valid nowadays because of suspended dental treatment under general anesthesia in hospital settings due to the prioritization of severe COVID-19 cases.Reduced Access to Secondary Dental Care and Fear FactorMoreover, it is not difficult to imagine that the level of general anxiety in patients with mental health problems could be elevated at present, which would directly contribute to the limited dental care provision dedicated for phobic individuals [23, 24] .", [["COVID", "DISEASE", 156, 161], ["anxiety", "DISEASE", 293, 300], ["phobic", "DISEASE", 454, 460], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 304, 312], ["general anesthesia", "TREATMENT", 80, 98], ["severe COVID-19 cases", "PROBLEM", 149, 170], ["Secondary Dental Care", "TREATMENT", 189, 210], ["general anxiety", "PROBLEM", 285, 300], ["mental health problems", "PROBLEM", 318, 340]]], ["It is likely that the number of acute mental disorders is going to be higher.", [["acute mental disorders", "DISEASE", 32, 54], ["acute mental disorders", "PROBLEM", 32, 54], ["is likely", "UNCERTAINTY", 3, 12], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["mental disorders", "OBSERVATION", 38, 54]]], ["Consequently, these patients, eventually, are expected to return to primary care services, hoping to receive their planned care.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["their planned care", "TREATMENT", 109, 127]]], ["Specialist emergency care, including intravenous sedation and/or dental general anesthesia, must be rearranged somehow for those patients in constant pain who simply cannot wait any longer and for whom urgent antimicrobial and analgesic measures were not effective.", [["intravenous", "ANATOMY", 37, 48], ["pain", "DISEASE", 150, 154], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 48], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["intravenous sedation", "TREATMENT", 37, 57], ["dental general anesthesia", "TREATMENT", 65, 90], ["constant pain", "PROBLEM", 141, 154], ["urgent antimicrobial", "TREATMENT", 202, 222], ["analgesic measures", "TREATMENT", 227, 245]]], ["As a result, the diversification and/or increasing use of non-pharmacological pain and anxiety control methods needs to be encouraged and promptly implemented.", [["pain", "DISEASE", 78, 82], ["anxiety", "DISEASE", 87, 94], ["non-pharmacological pain", "PROBLEM", 58, 82], ["anxiety control methods", "TREATMENT", 87, 110]]], ["Dental teams, including SCD teams, should expand a range of various techniques and alternatives to pharmacological sedation or general anesthesia [25] .", [["SCD", "DISEASE", 24, 27], ["various techniques", "TREATMENT", 60, 78], ["pharmacological sedation", "TREATMENT", 99, 123], ["general anesthesia", "TREATMENT", 127, 145]]], ["Unfortunately, vulnerable groups of elderly individuals who decided to implement a 'shielding' strategy, staying at home for weeks, and unregistered patients with poor oral health and neglected dentition may especially face more difficult access to any kind of dental service at present.", [["oral", "ANATOMY", 168, 172], ["patients", "ORGANISM", 149, 157], ["oral", "ORGANISM_SUBDIVISION", 168, 172], ["patients", "SPECIES", 149, 157], ["a 'shielding' strategy", "TREATMENT", 81, 103], ["poor oral health", "PROBLEM", 163, 179], ["neglected dentition", "PROBLEM", 184, 203]]], ["New strategic prophylactic programs on a national scale should be promptly introduced for these groups of vulnerable persons, as the dental care sector expects oral health deterioration and the increased incidence of oral diseases in the near future.", [["oral", "ANATOMY", 160, 164], ["oral", "ANATOMY", 217, 221], ["oral diseases", "DISEASE", 217, 230], ["persons", "ORGANISM", 117, 124], ["oral", "ORGANISM_SUBDIVISION", 160, 164], ["oral", "ORGANISM_SUBDIVISION", 217, 221], ["persons", "SPECIES", 117, 124], ["New strategic prophylactic programs", "TREATMENT", 0, 35], ["a national scale", "TREATMENT", 39, 55], ["oral health deterioration", "PROBLEM", 160, 185], ["oral diseases", "PROBLEM", 217, 230], ["increased", "OBSERVATION_MODIFIER", 194, 203]]], ["On the contrary, this emphasizes the importance of prophylactic measures, prevention, regular dental assessments, follow-ups and maintenance, as persons who present with good and stable oral health usually do not require any special attention during a lockdown period.Impact on Patients and Dental Team SafetyIn light of the current COVID-19 pandemic, the principal message \"be professional, stay safe, and be helpful\" is particularly valid and up to date at present, as dental teams should at least continue to deliver emergency services equipped with strategic plans, supported by guidelines, and appropriate PPE.", [["oral", "ANATOMY", 186, 190], ["persons", "ORGANISM", 145, 152], ["oral", "ORGANISM_SUBDIVISION", 186, 190], ["Patients", "ORGANISM", 278, 286], ["persons", "SPECIES", 145, 152], ["Patients", "SPECIES", 278, 286], ["prophylactic measures", "TREATMENT", 51, 72], ["regular dental assessments", "TEST", 86, 112]]], ["When compared to the medical workforce based in intensive care units, the dental sector is already in a reasonably safe position, as long as it follows the basic recommendations provided worldwide by different bodies and organizations (Centers for Disease Control and Prevention, World Health Organization (CDC/WHO).", [["Disease Control", "TREATMENT", 248, 263]]], ["Afterall, from a cross-infection point of view, we should always protect ourselves and our patients, being well prepared against any infectious threat in dental surgery, according to the basic rule \"treat every patient in the same professional manner\".", [["patients", "ORGANISM", 91, 99], ["patient", "ORGANISM", 211, 218], ["patients", "SPECIES", 91, 99], ["patient", "SPECIES", 211, 218], ["dental surgery", "TREATMENT", 154, 168]]], ["The COVID-19 crisis shed light on aerosol generation during medical/dental procedures, including the assessment or treatment of potentially infectious cases.", [["The COVID", "TEST", 0, 9], ["aerosol generation", "TREATMENT", 34, 52], ["medical/dental procedures", "TREATMENT", 60, 85], ["the assessment", "TEST", 97, 111], ["treatment", "TREATMENT", 115, 124], ["potentially infectious cases", "PROBLEM", 128, 156], ["infectious", "OBSERVATION", 140, 150]]], ["Moreover, it is likely that there will be a reorganization in the delivery of dental services, as there will be a requirement to use measures to contain the spread of the infection in dental surgeries permanently.", [["infection", "DISEASE", 171, 180], ["dental services", "TREATMENT", 78, 93], ["measures", "TREATMENT", 133, 141], ["the infection", "PROBLEM", 167, 180], ["dental surgeries", "TREATMENT", 184, 200], ["is likely", "UNCERTAINTY", 13, 22], ["infection", "OBSERVATION", 171, 180]]], ["This seems to be the most appropriate time to reflect on the current clinical standards associated with aerosol generating procedures, with a view to reconsidering or revising them, and clinicians need to gain a clear insight into how special care dentistry maybe delivered safely in the immediate and more distant future, in light of COVID-19.", [["aerosol generating procedures", "TREATMENT", 104, 133], ["COVID", "TEST", 335, 340]]], ["Furthermore, if a patient with special needs requires a 'chaperone' to be present during their appointment due to physical or intellectual disability, it is compulsory to provide the accompanying person with standard protective means, including an apron, standard surgical mask and/or shoe covers to maximize the reduction in the exposure to aerosols within the dental surgery.Impact on Patients and Dental Team SafetySARS-CoV-2 coronavirus can be transferred via saliva [26] and, while a vaccine is not available, the standard PPE kit is fully applicable for non-aerosol-generating procedures (non-AGPs); however, it must be modified for aerosol generating procedures (AGPs) in dentistry that require higher than standard levels of protection, with the use of enhanced and additional PPE [3, 20, 21] .", [["intellectual disability", "DISEASE", 126, 149], ["patient", "ORGANISM", 18, 25], ["Patients", "ORGANISM", 387, 395], ["SafetySARS-CoV-2 coronavirus", "ORGANISM", 412, 440], ["saliva", "ORGANISM_SUBSTANCE", 464, 470], ["patient", "SPECIES", 18, 25], ["person", "SPECIES", 196, 202], ["Patients", "SPECIES", 387, 395], ["CoV-2 coronavirus", "SPECIES", 423, 440], ["CoV-2 coronavirus", "SPECIES", 423, 440], ["a 'chaperone'", "TREATMENT", 54, 67], ["standard protective means", "TREATMENT", 208, 233], ["an apron, standard surgical mask", "TREATMENT", 245, 277], ["shoe", "TREATMENT", 285, 289], ["the reduction", "TREATMENT", 309, 322], ["aerosols", "TREATMENT", 342, 350], ["the dental surgery", "TREATMENT", 358, 376], ["SafetySARS", "TEST", 412, 422], ["CoV", "TEST", 423, 426], ["coronavirus", "PROBLEM", 429, 440], ["a vaccine", "TREATMENT", 487, 496], ["the standard PPE kit", "TREATMENT", 515, 535], ["non-aerosol-generating procedures", "TREATMENT", 560, 593], ["aerosol generating procedures (AGPs", "TREATMENT", 639, 674], ["enhanced and additional PPE", "TREATMENT", 761, 788]]], ["According to the most recent recommendations, due to the fact that rapid tests are not available, risk assessment is crucial, prior to performing even an extraction or intraoral radiographs, as these procedures can be potentially aerosol generating [3] , ( Table 2) .", [["rapid tests", "TEST", 67, 78], ["risk assessment", "TEST", 98, 113], ["an extraction", "TREATMENT", 151, 164], ["intraoral radiographs", "TEST", 168, 189], ["these procedures", "TREATMENT", 194, 210]]], ["Individualized risk assessments for persons with various conditions, for instance, immunosuppression, terminal oncological care and chronic pulmonary obstructive disease, should be central to clinical care.", [["pulmonary", "ANATOMY", 140, 149], ["pulmonary obstructive disease", "DISEASE", 140, 169], ["persons", "ORGANISM", 36, 43], ["pulmonary", "ORGAN", 140, 149], ["persons", "SPECIES", 36, 43], ["Individualized risk assessments", "TEST", 0, 31], ["immunosuppression", "TREATMENT", 83, 100], ["terminal oncological care", "TREATMENT", 102, 127], ["chronic pulmonary obstructive disease", "PROBLEM", 132, 169], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["pulmonary", "ANATOMY", 140, 149], ["obstructive disease", "OBSERVATION", 150, 169]]], ["Thus, every COVID-19 asymptomatic patient needs to be appropriately triaged and managed with local urgent dental care arrangements, prior to making decision about using PPE.", [["patient", "ORGANISM", 34, 41], ["patient", "SPECIES", 34, 41], ["local urgent dental care arrangements", "TREATMENT", 93, 130], ["PPE", "TREATMENT", 169, 172]]], ["Where possible, for COVID-19-positive persons, specifically designed dental centers to secure their oral health, with additional cross-infection preventative facilities, should be established.Impact on Patients and Dental Team SafetyIt can be deduced that, for specialist dental services, standard fluid-resistant masks, long-sleeved gowns/aprons and well-designed visors are adequate to carry out non-AGP and to treat asymptomatic individuals when their COVID-19 status is unknown.", [["oral", "ANATOMY", 100, 104], ["COVID-19", "GENE_OR_GENE_PRODUCT", 20, 28], ["persons", "ORGANISM", 38, 45], ["oral", "ORGANISM_SUBDIVISION", 100, 104], ["Patients", "ORGANISM", 202, 210], ["persons", "SPECIES", 38, 45], ["Patients", "SPECIES", 202, 210], ["COVID", "TEST", 20, 25], ["additional cross-infection preventative facilities", "TREATMENT", 118, 168], ["standard fluid-resistant masks", "TREATMENT", 289, 319], ["asymptomatic individuals", "PROBLEM", 419, 443], ["their COVID", "TEST", 449, 460]]], ["Whilst some dental emergencies are considered AGP when high-speed rotors are used, the dental team would be required to wear enhanced PPE, including a surgical gown, filtering facepiece respirator (FFP3/N99), eye protection, a visor and hat, if the dental treatment was deemed to be an AGP or even if there was an increased risk that, due to procedural complications, a non-AGP clinical session may turn into an AGP one ( Table 2) .", [["eye", "ANATOMY", 209, 212], ["AGP", "GENE_OR_GENE_PRODUCT", 46, 49], ["eye", "ORGAN", 209, 212], ["AGP", "GENE_OR_GENE_PRODUCT", 286, 289], ["AGP", "PROTEIN", 46, 49], ["AGP", "PROTEIN", 286, 289], ["AGP", "PROTEIN", 412, 415], ["AGP", "TEST", 46, 49], ["enhanced PPE", "TREATMENT", 125, 137], ["a surgical gown", "TREATMENT", 149, 164], ["filtering facepiece respirator", "TREATMENT", 166, 196], ["eye protection", "TREATMENT", 209, 223], ["the dental treatment", "TREATMENT", 245, 265], ["an increased risk", "PROBLEM", 311, 328], ["procedural complications", "PROBLEM", 342, 366], ["eye", "ANATOMY", 209, 212]]], ["Risk assessments and pre-treatment planning are, as always, essential.", [["Risk assessments", "TEST", 0, 16], ["pre-treatment planning", "TREATMENT", 21, 43]]], ["In dental surgery, basic rules to mitigate aerosol generating, such as avoiding three in one syringes, the use of dental dams and high-volume suction, leaving a surgery for at least 30 min after AGP, using negative pressure facilities and booking patients who require emergency AGP at the end of the clinical session, might significantly reduce the risk of viral human-to-human transmission [1, 3, 24] .Impact on Patients and Dental Team SafetyDue to the fact that SARS-CoV-2 is most present in the nasopharyngeal region and saliva/oropharyngeal secretions are the main reservoir of the virus [26] , which can be transmitted via droplets, the implementation of preoperative measures is suggested in order to reduce the viral load inside the oral cavity, but they can be easily introduced as standard protocol.", [["nasopharyngeal region", "ANATOMY", 499, 520], ["saliva", "ANATOMY", 525, 531], ["oropharyngeal secretions", "ANATOMY", 532, 556], ["oral cavity", "ANATOMY", 741, 752], ["viral human-to-human transmission", "DISEASE", 357, 390], ["SARS", "DISEASE", 465, 469], ["patients", "ORGANISM", 247, 255], ["AGP", "GENE_OR_GENE_PRODUCT", 278, 281], ["human", "ORGANISM", 363, 368], ["human", "ORGANISM", 372, 377], ["Patients", "ORGANISM", 413, 421], ["SARS-CoV-2", "ORGANISM", 465, 475], ["nasopharyngeal", "ORGAN", 499, 513], ["saliva", "ORGANISM_SUBSTANCE", 525, 531], ["oropharyngeal secretions", "ORGAN", 532, 556], ["oral cavity", "ORGANISM_SUBDIVISION", 741, 752], ["patients", "SPECIES", 247, 255], ["human", "SPECIES", 363, 368], ["human", "SPECIES", 372, 377], ["Patients", "SPECIES", 413, 421], ["human", "SPECIES", 363, 368], ["human", "SPECIES", 372, 377], ["dental surgery", "TREATMENT", 3, 17], ["aerosol generating", "TREATMENT", 43, 61], ["dental dams", "TREATMENT", 114, 125], ["high-volume suction", "TREATMENT", 130, 149], ["a surgery", "TREATMENT", 159, 168], ["negative pressure facilities", "TREATMENT", 206, 234], ["emergency AGP", "TREATMENT", 268, 281], ["SARS", "PROBLEM", 465, 469], ["saliva/oropharyngeal secretions", "PROBLEM", 525, 556], ["preoperative measures", "TREATMENT", 661, 682], ["the viral load inside the oral cavity", "PROBLEM", 715, 752], ["standard protocol", "TREATMENT", 791, 808], ["SARS", "OBSERVATION", 465, 469], ["nasopharyngeal", "ANATOMY", 499, 513], ["region", "ANATOMY_MODIFIER", 514, 520], ["oropharyngeal", "ANATOMY", 532, 545], ["secretions", "OBSERVATION", 546, 556], ["viral load", "OBSERVATION", 719, 729], ["oral cavity", "ANATOMY", 741, 752]]], ["Pre-operational (pre-procedural) antimicrobial mouth rinse is generally believed to lower the amount of oral microbiota and it is suggested as an effective agent to reduce the risk of aerosol microbiological contamination in dental settings.", [["mouth", "ANATOMY", 47, 52], ["oral", "ANATOMY", 104, 108], ["oral", "ORGANISM_SUBDIVISION", 104, 108], ["Pre-operational (pre-procedural) antimicrobial mouth rinse", "TREATMENT", 0, 58], ["an effective agent", "TREATMENT", 143, 161], ["aerosol microbiological contamination", "PROBLEM", 184, 221]]], ["The antimicrobial efficacy of common mouthwashes depends upon the concentration of active ingredients and their acidity, as low saliva pH might accelerate virulence through endocytic entry into the host cell [28] .", [["cell", "ANATOMY", 203, 207], ["saliva", "ORGANISM_SUBSTANCE", 128, 134], ["cell", "CELL", 203, 207], ["common mouthwashes", "PROBLEM", 30, 48], ["active ingredients", "TREATMENT", 83, 101], ["their acidity", "PROBLEM", 106, 119], ["low saliva pH", "PROBLEM", 124, 137], ["antimicrobial", "OBSERVATION_MODIFIER", 4, 17], ["host cell", "OBSERVATION", 198, 207]]], ["It has been reported that SARS-CoV-2 is susceptible to oxidative compounds, and thus, subsequently, a pre-procedural mouth rinse containing oxidative agents such as those containing diluted hydrogen peroxide (1-2%), or 0.2% povidone iodine (PVP-I) are recommended [29, 30] .", [["mouth", "ANATOMY", 117, 122], ["hydrogen peroxide", "CHEMICAL", 190, 207], ["povidone iodine", "CHEMICAL", 224, 239], ["PVP-I", "CHEMICAL", 241, 246], ["hydrogen peroxide", "CHEMICAL", 190, 207], ["povidone iodine", "CHEMICAL", 224, 239], ["PVP-I", "CHEMICAL", 241, 246], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 190, 207], ["povidone iodine", "SIMPLE_CHEMICAL", 224, 239], ["PVP-I", "SIMPLE_CHEMICAL", 241, 246], ["SARS", "PROBLEM", 26, 30], ["a pre-procedural mouth rinse", "TREATMENT", 100, 128], ["oxidative agents", "TREATMENT", 140, 156], ["those containing diluted hydrogen peroxide", "TREATMENT", 165, 207], ["0.2% povidone iodine", "TREATMENT", 219, 239], ["oxidative compounds", "OBSERVATION", 55, 74]]], ["Although the efficiency of other biocidal/viricidal intraoral measures such as topical swabbing and local disinfection is under investigation, only limited data is available in this respect.", [["other biocidal/viricidal intraoral measures", "TREATMENT", 27, 70], ["topical swabbing", "TREATMENT", 79, 95], ["local disinfection", "TREATMENT", 100, 118]]], ["The exact mechanism is unknown, however it can be linked to the fact that the SARS-CoV-2 lipid 'envelope' can be disrupted when exposed to ingredients commonly found in mouthwashes, such as hydrogen peroxide and ethanol, as well as PVP-I and cetylpiridine [31] .", [["SARS", "DISEASE", 78, 82], ["hydrogen peroxide", "CHEMICAL", 190, 207], ["ethanol", "CHEMICAL", 212, 219], ["PVP-I", "CHEMICAL", 232, 237], ["cetylpiridine", "CHEMICAL", 242, 255], ["hydrogen peroxide", "CHEMICAL", 190, 207], ["ethanol", "CHEMICAL", 212, 219], ["PVP-I", "CHEMICAL", 232, 237], ["cetylpiridine", "CHEMICAL", 242, 255], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 78, 88], ["mouthwashes", "SIMPLE_CHEMICAL", 169, 180], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 190, 207], ["ethanol", "SIMPLE_CHEMICAL", 212, 219], ["PVP-I", "SIMPLE_CHEMICAL", 232, 237], ["cetylpiridine [31]", "SIMPLE_CHEMICAL", 242, 260], ["the SARS", "TEST", 74, 82], ["mouthwashes", "TREATMENT", 169, 180], ["hydrogen peroxide", "TREATMENT", 190, 207], ["ethanol", "TREATMENT", 212, 219], ["PVP", "TREATMENT", 232, 235], ["cetylpiridine", "TREATMENT", 242, 255]]], ["Ethanol-based mouthwashes, with relatively low alcohol content that ranges from 14% to 27% can be potentially efficient against enveloped viruses, preventing subsequent viral replication; however, further research is urgently required to warrant their efficacy.", [["Ethanol", "CHEMICAL", 0, 7], ["alcohol", "CHEMICAL", 47, 54], ["Ethanol", "CHEMICAL", 0, 7], ["alcohol", "CHEMICAL", 47, 54], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["alcohol", "SIMPLE_CHEMICAL", 47, 54], ["relatively low alcohol content", "PROBLEM", 32, 62], ["enveloped viruses", "PROBLEM", 128, 145], ["subsequent viral replication", "TREATMENT", 158, 186], ["viruses", "OBSERVATION", 138, 145], ["viral replication", "OBSERVATION", 169, 186]]], ["In needs to be noted that PVP-I use can be contraindicated in the case of iodine hypersensitivity, pregnancy and severe thyroid disfunction, and also, in view of the alcohol-related risk of oral cancer, the clinicians should provide their patient with adequate advice.", [["thyroid", "ANATOMY", 120, 127], ["oral cancer", "ANATOMY", 190, 201], ["PVP-I", "CHEMICAL", 26, 31], ["iodine hypersensitivity", "DISEASE", 74, 97], ["thyroid disfunction", "DISEASE", 120, 139], ["alcohol", "CHEMICAL", 166, 173], ["oral cancer", "DISEASE", 190, 201], ["PVP-I", "CHEMICAL", 26, 31], ["iodine", "CHEMICAL", 74, 80], ["alcohol", "CHEMICAL", 166, 173], ["PVP-I", "SIMPLE_CHEMICAL", 26, 31], ["iodine", "SIMPLE_CHEMICAL", 74, 80], ["thyroid", "ORGAN", 120, 127], ["alcohol", "SIMPLE_CHEMICAL", 166, 173], ["oral cancer", "CANCER", 190, 201], ["patient", "ORGANISM", 239, 246], ["patient", "SPECIES", 239, 246], ["PVP", "TREATMENT", 26, 29], ["iodine hypersensitivity", "PROBLEM", 74, 97], ["pregnancy", "PROBLEM", 99, 108], ["severe thyroid disfunction", "PROBLEM", 113, 139], ["oral cancer", "PROBLEM", 190, 201], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["thyroid", "ANATOMY", 120, 127], ["disfunction", "OBSERVATION", 128, 139], ["oral", "ANATOMY", 190, 194], ["cancer", "OBSERVATION", 195, 201]]], ["In practical scenarios, the use of pre-treatment mouthwash seems to be prudent in the current COVID-19 circumstances and, alternatively, the patient can be also advised to rinse oral cavity prior to attending dental appointment.", [["oral cavity", "ANATOMY", 178, 189], ["patient", "ORGANISM", 141, 148], ["oral cavity", "ORGANISM_SUBDIVISION", 178, 189], ["patient", "SPECIES", 141, 148], ["pre-treatment mouthwash", "TREATMENT", 35, 58]]], ["Classification of dental procedures based on the risk of generating aerosol in dental settings (own proposal, based on Faculty of General Dental Practice, UK; modified and extended).Non-Aerosol Generating Procedures Aerosol Generating Procedures Procedures Likely to Generate AerosolBasic dental examination The use of a slow-speed handpiece without suction Any procedure in patients with excessive saliva production when the use of suction is not possible Any dental procedure in, e.g., elderly patients who are prone to cough and who demonstrate a severe gag reflex Any dental procedure and significant behavioral issue which may increase the risk of AG (e.g., ADHD, ASD) Impressions for dentures, bridges, crowns, veneers and orthodontic appliancesNon-Aerosol Generating Procedures Aerosol Generating Procedures Procedures Likely to Generate AerosolOral swabbingNon-Aerosol Generating Procedures Aerosol Generating Procedures Procedures Likely to Generate AerosolIn addition, new inventions such as external portable high-volume high-efficiency particulate air (HEPA) filter technology or high-volume suction intraoral adapters used chairside can contribute to a vast reduction in aerosols released in clinical settings during dental assessment, diagnostics and/or treatment.", [["cough", "DISEASE", 522, 527], ["gag reflex", "DISEASE", 557, 567], ["AG", "DISEASE", 653, 655], ["ADHD", "DISEASE", 663, 667], ["ASD", "DISEASE", 669, 672], ["patients", "ORGANISM", 375, 383], ["saliva", "ORGANISM_SUBSTANCE", 399, 405], ["patients", "ORGANISM", 496, 504], ["patients", "SPECIES", 375, 383], ["patients", "SPECIES", 496, 504], ["dental procedures", "TREATMENT", 18, 35], ["AerosolBasic dental examination", "TEST", 276, 307], ["a slow-speed handpiece", "TREATMENT", 319, 341], ["suction", "TREATMENT", 350, 357], ["Any procedure", "TREATMENT", 358, 371], ["excessive saliva production", "PROBLEM", 389, 416], ["suction", "TREATMENT", 433, 440], ["Any dental procedure", "TREATMENT", 457, 477], ["cough", "PROBLEM", 522, 527], ["a severe gag reflex", "PROBLEM", 548, 567], ["Any dental procedure", "TREATMENT", 568, 588], ["significant behavioral issue", "PROBLEM", 593, 621], ["AG", "PROBLEM", 653, 655], ["ADHD", "PROBLEM", 663, 667], ["ASD", "PROBLEM", 669, 672], ["dentures, bridges, crowns, veneers", "TREATMENT", 690, 724], ["orthodontic appliances", "TREATMENT", 729, 751], ["Procedures Procedures", "TREATMENT", 804, 825], ["AerosolOral swabbing", "TREATMENT", 845, 865], ["new inventions", "TREATMENT", 979, 993], ["external portable high-volume high-efficiency particulate air (HEPA) filter technology", "TREATMENT", 1002, 1088], ["high-volume suction intraoral adapters", "TREATMENT", 1092, 1130], ["a vast reduction in aerosols", "TREATMENT", 1164, 1192], ["dental assessment", "TEST", 1230, 1247], ["diagnostics", "TEST", 1249, 1260], ["treatment", "TREATMENT", 1268, 1277], ["not possible", "UNCERTAINTY", 444, 456], ["severe", "OBSERVATION_MODIFIER", 550, 556], ["gag reflex", "OBSERVATION", 557, 567], ["significant", "OBSERVATION_MODIFIER", 593, 604], ["orthodontic appliances", "OBSERVATION", 729, 751]]], ["Furthermore, minimizing staff exposure to potentially COVID-19 infected (but asymptomatic) patients, by implementation of pre-procedural point-of-care (POC) rapid and accurate molecular testing [32] for SARS-CoV-2 in SCD clinics, would support risk assessments, clinical management and save resources.Time for Change and Adaptation for Dental ServicesAmid all this confusion and uncertainty, the attitude of reassurance, accurate professional advice and appropriate care provision-even if this is restricted emergency and urgent cases only-are still the core elements of good dental practice and an ethical approach [33] .", [["SCD", "DISEASE", 217, 220], ["confusion", "DISEASE", 365, 374], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 203, 211], ["COVID", "TEST", 54, 59], ["accurate molecular testing", "TEST", 167, 193], ["SARS", "PROBLEM", 203, 207], ["risk assessments", "TEST", 244, 260], ["clinical management", "TREATMENT", 262, 281], ["Dental Services", "TREATMENT", 336, 351], ["reassurance", "TREATMENT", 408, 419], ["appropriate care provision", "TREATMENT", 454, 480]]], ["Dental teams are required to be creative, practical, and patient-minded, as the COVID-19 crisis underpins the shift from a repair model of care to a wellness-based model.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["the COVID", "TEST", 76, 85], ["a repair model of care", "TREATMENT", 121, 143]]], ["Whilst the traditional 'repair' model of care concentrates strictly on solving a primary health problem 'ad hoc', the recovery wellness model of care provides a rationale for a long-term and permanent positive outcome, focusing on a holistic, person-centered approach.", [["the traditional 'repair", "TREATMENT", 7, 30], ["permanent positive outcome", "PROBLEM", 191, 217]]], ["This model equally demonstrates health/dental care staff's understanding and compassion while providing care, and also offers psychological support.", [["psychological support", "TREATMENT", 126, 147]]], ["We believe that being not only a competent, but also a truly empathetic clinician, is our main role in society.", [["main", "OBSERVATION_MODIFIER", 90, 94]]], ["The idea of a patient-centered approach has gained its true definition, as everyone must be treated in a special way, while also taking into consideration their COVID-19 status.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["their COVID", "TEST", 155, 166]]], ["Clinicians dealing with vulnerable patients with underlying medical conditions should appreciate the value of AGP risk assessment in the informed care pathways in contemporary special care dentistry.", [["patients", "ORGANISM", 35, 43], ["AGP", "GENE_OR_GENE_PRODUCT", 110, 113], ["patients", "SPECIES", 35, 43], ["underlying medical conditions", "PROBLEM", 49, 78], ["AGP risk assessment", "TEST", 110, 129]]], ["On the other hand, there is a substantial impact of individualized feedback on their own oral health care.", [["oral", "ANATOMY", 89, 93], ["oral", "ORGANISM_SUBDIVISION", 89, 93], ["substantial", "OBSERVATION_MODIFIER", 30, 41], ["impact", "OBSERVATION_MODIFIER", 42, 48]]], ["This is coherent with the most recent Public Health England initiative, named 'Making Every Contact Count', to provide support for patients to make positive behavior changes to their health and wellbeing [34] , with its aim being to reduce the prevalence of long-term diseases in the population that are associated with behavioral and modifiable risk factors.Time for Change and Adaptation for Dental ServicesDespite some controversies, remote advice and 'teleconsultations'-sometimes underestimated-underpin the management of patients who may feel abandoned or less cared for.", [["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 527, 535], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 527, 535], ["positive behavior changes", "PROBLEM", 148, 173], ["long-term diseases", "PROBLEM", 258, 276], ["behavioral and modifiable risk factors", "PROBLEM", 320, 358], ["long-term", "OBSERVATION_MODIFIER", 258, 267], ["diseases", "OBSERVATION", 268, 276]]], ["Online consultations arranged utilizing patients' self-described symptoms and photos provided by themselves could undoubtedly be an essential element of patient support.", [["patients", "ORGANISM", 40, 48], ["patient", "ORGANISM", 153, 160], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 153, 160], ["symptoms", "PROBLEM", 65, 73], ["photos", "TREATMENT", 78, 84], ["patient support", "TREATMENT", 153, 168]]], ["A plain conversation and professional advice, including oral hygiene and maintenance issues, may vastly contribute to the patient's wellbeing, or to preventing the deterioration of oral health.", [["oral", "ANATOMY", 56, 60], ["oral", "ANATOMY", 181, 185], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["patient", "ORGANISM", 122, 129], ["oral", "ORGANISM_SUBDIVISION", 181, 185], ["patient", "SPECIES", 122, 129], ["oral hygiene", "TREATMENT", 56, 68], ["the deterioration of oral health", "PROBLEM", 160, 192]]], ["For patients who suffer from chronic or acute oral mucosa diseases, basic advice, including the consumption of a balanced diet and nutrition, a reduction in smoking and alcohol, following the doctors' instructions, and continuing prescribed pharmacotherapy, along with maintaining a positive mood and an appropriate level of exercise, should constitute the core professional recommendations.", [["oral mucosa", "ANATOMY", 46, 57], ["oral mucosa diseases", "DISEASE", 46, 66], ["smoking", "CHEMICAL", 157, 164], ["alcohol", "CHEMICAL", 169, 176], ["alcohol", "CHEMICAL", 169, 176], ["patients", "ORGANISM", 4, 12], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 46, 57], ["alcohol", "SIMPLE_CHEMICAL", 169, 176], ["patients", "SPECIES", 4, 12], ["chronic or acute oral mucosa diseases", "PROBLEM", 29, 66], ["nutrition", "TREATMENT", 131, 140], ["pharmacotherapy", "TREATMENT", 241, 256], ["a positive mood", "PROBLEM", 281, 296], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["oral mucosa", "ANATOMY", 46, 57]]], ["Nevertheless, these individuals often require a differential diagnosis, which might be crucial from a triaging point of view, as some of oral medicine cases are associated with a fever/elevated temperature, symptoms that are difficult to distinguish from respiratory tract infections [35] .", [["oral", "ANATOMY", 137, 141], ["respiratory tract", "ANATOMY", 255, 272], ["fever", "DISEASE", 179, 184], ["respiratory tract infections", "DISEASE", 255, 283], ["individuals", "ORGANISM", 20, 31], ["oral", "ORGANISM_SUBDIVISION", 137, 141], ["tract", "ORGANISM_SUBDIVISION", 267, 272], ["oral medicine", "TREATMENT", 137, 150], ["a fever", "PROBLEM", 177, 184], ["elevated temperature", "PROBLEM", 185, 205], ["symptoms", "PROBLEM", 207, 215], ["respiratory tract infections", "PROBLEM", 255, 283], ["respiratory tract", "ANATOMY", 255, 272]]], ["Virtual consultations can be particularly valuable to arrange a 'best interest meeting' with peers involved in the care of a person who lacks capacity.Time for Change and Adaptation for Dental ServicesIt is worth noting that, by establishing more flexible dental care environments, through adapting or expanding the existing facilities, dental sectors can quickly adjust to the current demands.", [["person", "SPECIES", 125, 131], ["Dental Services", "TREATMENT", 186, 201], ["dental sectors", "TREATMENT", 337, 351]]], ["Dental teams would welcome the involvement of professional bodies, including the International Association of Special Care Dentistry (IASCD) and the British Society of Disability and Oral Health (BSDH) in the provision of up-to-date recommendations for SCD specialty, supporting secondary health care during the COVID-19 crisis.", [["SCD", "DISEASE", 253, 256], ["SCD specialty", "TREATMENT", 253, 266]]], ["The most recent guidance for SCD during the pandemic, provided by the Royal College of Surgeons (RCS, London) of England, is an excellent example of professional support.", [["SCD", "DISEASE", 29, 32], ["SCD", "PROBLEM", 29, 32], ["professional support", "TREATMENT", 149, 169]]], ["With this in mind, a significant reorganization of SCD might be required, accompanied by investments, to address the COVID-19 crisis at adequate levels of safety, considering the high risk, and complex medical profile of patients with special needs.Empathy and Leadership above AllDue to the unprecedented extent of care provision suspension during the COVID-19 pandemic, the 'empathy scale' needs to be even broader, leading to a better understanding of patients' problems that goes beyond standard practice.", [["SCD", "DISEASE", 51, 54], ["patients", "ORGANISM", 221, 229], ["patients", "ORGANISM", 455, 463], ["patients", "SPECIES", 221, 229], ["patients", "SPECIES", 455, 463], ["SCD", "PROBLEM", 51, 54], ["the COVID", "TEST", 113, 122], ["care provision suspension", "TREATMENT", 316, 341], ["patients' problems", "PROBLEM", 455, 473], ["significant", "OBSERVATION_MODIFIER", 21, 32]]], ["Dental services and service providers must support, devise, execute, and opt for difficult choices concerning priority patients, and give their patients confidence that the decisions taken are correct.", [["patients", "ORGANISM", 119, 127], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 144, 152]]], ["Above all, we must show genuine empathy in light of the difficulties our patients face, and resolve their dental problems promptly, without any delay.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["genuine empathy", "PROBLEM", 24, 39]]], ["Even clinically well-justified remote antibiotic or analgesic prescriptions faxed to local pharmacies may not be sufficient in the long term and, more importantly, this emergency protocol may significantly contribute to antibiotic resistance and/or other systemic complications.", [["remote antibiotic", "TREATMENT", 31, 48], ["analgesic prescriptions", "TREATMENT", 52, 75], ["this emergency protocol", "TREATMENT", 164, 187], ["antibiotic resistance", "PROBLEM", 220, 241], ["other systemic complications", "PROBLEM", 249, 277], ["systemic", "OBSERVATION_MODIFIER", 255, 263], ["complications", "OBSERVATION", 264, 277]]], ["As a direct result of the reduced availability of dental care and the difficulty in accessing dental services due to deferred routine care during the COVID-19 pandemic, there is a significant risk of accidental analgesic overdose, particularly in self-isolating persons who try to self-manage their acute symptoms, with the use of over-the-counter acetaminophen (paracetamol) and nonsteroidal anti-inflammatory drugs (NSAIDs).Empathy and Leadership above AllThe more organized and supportive we are now on all dental service fronts, the more likely it is that the lockdown measures for routine dentistry are lifted earlier.", [["nonsteroidal", "ANATOMY", 380, 392], ["overdose", "DISEASE", 221, 229], ["acetaminophen", "CHEMICAL", 348, 361], ["paracetamol", "CHEMICAL", 363, 374], ["acetaminophen", "CHEMICAL", 348, 361], ["paracetamol", "CHEMICAL", 363, 374], ["persons", "ORGANISM", 262, 269], ["acetaminophen", "SIMPLE_CHEMICAL", 348, 361], ["paracetamol", "SIMPLE_CHEMICAL", 363, 374], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 380, 416], ["NSAIDs", "SIMPLE_CHEMICAL", 418, 424], ["persons", "SPECIES", 262, 269], ["dental care", "TREATMENT", 50, 61], ["the COVID", "TEST", 146, 155], ["accidental analgesic overdose", "PROBLEM", 200, 229], ["their acute symptoms", "PROBLEM", 293, 313], ["acetaminophen (paracetamol)", "TREATMENT", 348, 375], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 380, 416], ["NSAIDs", "TREATMENT", 418, 424], ["the lockdown measures", "TREATMENT", 560, 581], ["routine dentistry", "TREATMENT", 586, 603], ["analgesic overdose", "OBSERVATION", 211, 229], ["acute", "OBSERVATION_MODIFIER", 299, 304], ["symptoms", "OBSERVATION", 305, 313], ["more organized", "OBSERVATION_MODIFIER", 462, 476]]], ["We need to send a clear message that we will do everything we can to protect patients, while, on the other hand, patients should understand and try to do all they can to protect all of us.", [["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 113, 121]]], ["As we know, in some parts of the world, the 'coronavirus plan' has been working well because clinic leads, hospital managers, owners of dental practices and academic staff heads behave like true leaders and appear to be capable of tackling the health crisis.", [["the 'coronavirus plan", "TREATMENT", 40, 61], ["dental practices", "TREATMENT", 136, 152]]], ["Leaders should do all that is feasible to help dental services get through the pandemic and not leave any patient without appropriate care.", [["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113]]], ["This can be achieved by service conversion, adaptation to the anticipated demands of specialist procedures in future, and utilizing basic infection control measures, including advanced PPE for all staff involved in dental care, if clinically justified.", [["infection", "DISEASE", 138, 147], ["specialist procedures", "TREATMENT", 85, 106], ["basic infection control measures", "TREATMENT", 132, 164], ["infection", "OBSERVATION", 138, 147]]], ["In addition, promoting online consultations and advice, along with the broader use of recovery wellness and patient-focused models are easily applicable by any service, including primary medical care (general medical practice), mental health care, and most specialist secondary services.", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["mental health care", "TREATMENT", 228, 246]]], ["So-called rapport building, a technique used to manage anxious patients that involves, i.e., sending a letter to the patient, would be equally supportive for reassurance and advice purposes.", [["anxious", "DISEASE", 55, 62], ["patients", "ORGANISM", 63, 71], ["patient", "ORGANISM", 117, 124], ["patients", "SPECIES", 63, 71], ["patient", "SPECIES", 117, 124], ["a technique", "TREATMENT", 28, 39], ["reassurance", "TREATMENT", 158, 169]]], ["We are convinced that the partial transition from a general anesthesia-based model to the more common use of sedation methods (intravenous, transmucosal) in outpatient clinics can be implemented by minor surgery units during the pandemic, including otorhinolaryngology gastro-enterology and dermatology disciplines.", [["intravenous", "ANATOMY", 127, 138], ["gastro-enterology", "DISEASE", 269, 286], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 127, 138], ["transmucosal", "IMMATERIAL_ANATOMICAL_ENTITY", 140, 152], ["a general anesthesia", "TREATMENT", 50, 70], ["sedation methods", "TREATMENT", 109, 125]]], ["In the coming months, we need to take the opportunity to reflect on the challenge of the COVID-19 pandemic crisis.", [["the COVID", "TEST", 85, 94]]], ["As the wellbeing of health professionals is going to be inevitably affected, it will be necessary to care not only for those people who need care, but also those who deliver it.ConclusionsBy providing safe dental care with the use of dedicated special measures, and redefining our role, special care dentistry services are obliged to meet the oral health needs among those who are the most vulnerable and who are at risk of health decline.", [["oral", "ANATOMY", 343, 347], ["people", "ORGANISM", 125, 131], ["oral", "ORGANISM_SUBDIVISION", 343, 347], ["people", "SPECIES", 125, 131]]], ["The most compromised patients expect continuous support, with the provision of-at the very least-emergency dental care that is fit for purpose, verifying the preparedness of dental providers.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["continuous support", "TREATMENT", 37, 55], ["emergency dental care", "TREATMENT", 97, 118], ["most compromised", "OBSERVATION_MODIFIER", 4, 20]]], ["In particular, at present, special care dentistry seems to play an ever more important role, dealing with a wide range of patients with underlying co-morbidities, phobic individuals, and persons with learning/physical disabilities.", [["phobic", "DISEASE", 163, 169], ["learning/physical disabilities", "DISEASE", 200, 230], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["persons", "SPECIES", 187, 194], ["underlying co-morbidities", "PROBLEM", 136, 161]]], ["The effective and rapid adaptation of health services to the current new reality, based on an empathetic approach and recent guidelines, will allow for adequate and safe care provision.", [["safe care provision", "TREATMENT", 165, 184]]]], "0eeb2abfebb989c35868332a9091df6bcb62c836": [["IntroductionNegative spillover effects have been a popular topic in productharm crisis research because such crises are both unexpected and devastating for firms.", [["such crises", "PROBLEM", 104, 115], ["spillover effects", "OBSERVATION", 21, 38]]], ["In this context, a spillover effect refers to the phenomenon in which information about brand A influences a consumer's beliefs regarding brand B, even if the impact is not explicit (Ahluwalia et al., 2001) .", [["a spillover effect", "PROBLEM", 17, 35], ["spillover", "OBSERVATION", 19, 28]]], ["Previous research has demonstrated the presence of spillover effect within the same brand family or product category (Balachander and Ghose, 2003) , across product categories (Erdem, 1998) , and from one product attribute to another (Ahluwalia et al., 2001) .", [["spillover effect", "PROBLEM", 51, 67], ["spillover effect", "OBSERVATION", 51, 67]]], ["However, researchers have paid little attention to spillover effect at the firm level, which occurs across companies in the same category.", [["firm", "OBSERVATION", 75, 79]]], ["For example, negative publicity regarding an Escherichia coli (E. coli hereafter) scare at Wendy's may negatively affect Jack in the Box, because of the indirect influence of negative publicity and the latter restaurant's prior association with E. coli.IntroductionPrevious research suggests the presence of spillover effects among competitors.", [["Escherichia coli", "ORGANISM", 45, 61], ["E. coli", "ORGANISM", 63, 70], ["E. coli", "ORGANISM", 245, 252], ["Escherichia coli", "SPECIES", 45, 61], ["E. coli", "SPECIES", 63, 70], ["E. coli", "SPECIES", 245, 252], ["Escherichia coli", "SPECIES", 45, 61], ["E. coli", "SPECIES", 63, 70], ["E. coli", "SPECIES", 245, 252], ["an Escherichia coli", "PROBLEM", 42, 61], ["E. coli", "PROBLEM", 63, 70], ["E. coli", "PROBLEM", 245, 252], ["spillover effects", "PROBLEM", 308, 325], ["Escherichia coli", "OBSERVATION", 45, 61], ["E. coli", "OBSERVATION_MODIFIER", 63, 70], ["negative publicity", "OBSERVATION", 175, 193], ["E. coli", "OBSERVATION", 245, 252], ["spillover", "OBSERVATION", 308, 317]]], ["Siomkos et al. (2010) assert that a product harm crisis is an opportunity for competitors to take advantage of their weakened rivals, which implies a positive spillover effect.", [["a positive spillover effect", "PROBLEM", 148, 175], ["positive", "OBSERVATION", 150, 158], ["spillover effect", "OBSERVATION", 159, 175]]], ["During rival firms' crises, competitors can grab more market shares (Tsang, 2000; van Heerde et al., 2007) and increase consumer awareness through aggressive advertising (Dawar, 1998) .", [["crises", "PROBLEM", 20, 26]]], ["Roehm and Tybout (2006) also find a negative spillover effect, demonstrating that negative consumer perceptions about one brand can spill over to competing brands in the same product category.", [["spillover effect", "OBSERVATION", 45, 61]]], ["Moreover, when a firm A has a crisis history, the advantage of being a competitor during a firm B's (rival firm) crisis may be offset by negative associations between the firm A and a crisis of firm B. In this respect, a rival's product harm crisis may become a threat if the firm is associated with a negative past event.IntroductionCrisis management researchers consider a firm's crisis history a critical factor (Coombs, 2004) .", [["crisis", "PROBLEM", 113, 119], ["a crisis of firm B.", "PROBLEM", 182, 201], ["IntroductionCrisis management", "TREATMENT", 322, 351], ["a firm's crisis", "PROBLEM", 373, 388], ["firm", "OBSERVATION", 171, 175], ["firm", "OBSERVATION", 276, 280]]], ["Situational crisis communication theory posits that a history of crises becomes an important cue for determining reputational threats to firms Holladay, 2001, 2002) .", [["crises", "PROBLEM", 65, 71]]], ["Moreover, existing information on a past crisis can shape consumers' perceptions of current crises and influence http://dx.doi.org/10.1016/j.ijhm.2014.02.011 0278-4319/\u00a9 2014 Elsevier Ltd.", [["current crises", "PROBLEM", 84, 98]]], ["Thus, a history of crises may amplify reputational threats and harm firms' financial performance, even long after a crisis outbreak is over.", [["crises", "PROBLEM", 19, 25], ["a crisis outbreak", "PROBLEM", 114, 131]]], ["Because 59% of all reported foodborne illness outbreaks in the United States are attributed to the restaurant industry (CDC, 2006) , it is critical to investigate possible negative spillovers among restaurant firms.", [["foodborne illness", "DISEASE", 28, 45]]], ["To that end, this study examines how negative spillover from unrelated crises influences a restaurant firm with a history of crisis.IntroductionThe Jack in the Box E. coli scare, Tylenol poisoning, Firestone's tire accidents, and Taco Bell's contaminated food incident were among the most cited examples of crises associated with well-known brands.", [["Tylenol", "CHEMICAL", 179, 186], ["poisoning", "DISEASE", 187, 196], ["accidents", "DISEASE", 215, 224], ["E. coli", "SPECIES", 164, 171], ["Box E. coli", "SPECIES", 160, 171], ["this study", "TEST", 13, 23], ["unrelated crises", "PROBLEM", 61, 77], ["crisis", "PROBLEM", 125, 131], ["the Box E. coli scare", "TREATMENT", 156, 177], ["Tylenol poisoning", "TREATMENT", 179, 196], ["Firestone", "TREATMENT", 198, 207], ["crises", "PROBLEM", 307, 313], ["coli scare", "OBSERVATION", 167, 177]]], ["Those incidents caused illnesses and deaths, resulted in negative consumer perceptions of quality, decreased sales revenues, tarnished firm reputations, and lower marketing efficiency (Dawar and Pillutla, 2000; van Heerde et al., 2007) .", [["deaths", "DISEASE", 37, 43], ["illnesses", "PROBLEM", 23, 32], ["tarnished firm reputations", "TREATMENT", 125, 151], ["firm", "OBSERVATION_MODIFIER", 135, 139]]], ["Coombs (2004) suggested that despite its disastrous results, the unexpected and accidental nature of a crisis can serve as a cushion for affected firms in rebuilding consumer trust.", [["Coombs", "TEST", 0, 6], ["a crisis", "PROBLEM", 101, 109]]], ["However, empirical evidence shows that the media tend to report on past crises in relation to similar crises for very long time.", [["similar crises", "PROBLEM", 94, 108]]], ["Fig. 1 displays the number of news articles containing words \"Jack in the Box\" and \"E. coli\" using LexisNexis database, evidencing that Jack in the Box still appears in media reporting in relation to E. coli up to present.IntroductionIf the media repeatedly mentions a restaurant firm with a crisis history, this is likely to evoke or reinforce negative images of the restaurant brand for consumers.", [["E. coli", "ORGANISM", 84, 91], ["E. coli", "ORGANISM", 200, 207], ["E. coli", "SPECIES", 84, 91], ["E. coli", "SPECIES", 200, 207], ["E. coli", "SPECIES", 84, 91], ["E. coli", "SPECIES", 200, 207], ["E. coli", "PROBLEM", 84, 91], ["E. coli", "PROBLEM", 200, 207], ["coli", "OBSERVATION", 203, 207]]], ["Psychological research asserts that people access negative memories more easily and quickly than positive memories (Richins, 1983) .", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42]]], ["Brands also depend heavily on publicity through widespread mass media, yet negative publicity is more powerful and salient in media reporting than positive publicity (Weinberger et al., 1991) .", [["widespread mass media", "PROBLEM", 48, 69], ["heavily", "OBSERVATION_MODIFIER", 19, 26], ["widespread", "OBSERVATION_MODIFIER", 48, 58], ["mass", "OBSERVATION", 59, 63], ["negative", "OBSERVATION", 75, 83], ["more powerful", "OBSERVATION_MODIFIER", 97, 110]]], ["Constant negative publicity can drive firms into a downward spiral (Weinberger and Romeo, 1989) , and media attention may make a crisis more visible to the general public (Ahluwalia et al., 2000) .", [["a crisis", "PROBLEM", 127, 135], ["negative", "OBSERVATION_MODIFIER", 9, 17], ["publicity", "OBSERVATION", 18, 27]]], ["In responding to other firms' food crises, a firm with a food crisis history may be affected by unrelated crises, that is, by a negative spillover effect.", [["unrelated crises", "PROBLEM", 96, 112], ["firm", "OBSERVATION_MODIFIER", 45, 49]]], ["Seo et al. (2013) examined the impact of food safety events on firms, asserting that it takes approximately one year to recover from a crisis after an outbreak.", [["a crisis", "PROBLEM", 133, 141]]], ["Although their study investigated the impact of food crises on firms' financial performance, the findings were limited to short-term impacts.", [["their study", "TEST", 9, 20], ["short-term impacts", "PROBLEM", 122, 140]]], ["To identify the long-term impact, the current study features an exploratory case study, using Jack in the Box, and investigates whether the firm's stock prices have been influenced by other restaurant firms' food crises between 1994 and 2010.", [["the current study", "TEST", 34, 51], ["an exploratory case study", "TEST", 61, 86], ["the firm's stock prices", "TREATMENT", 136, 159], ["long-term impact", "OBSERVATION_MODIFIER", 16, 32]]], ["In addition, this study empirically tests for the presence of negative spillover on Jack in the Box's stock returns, while attempting to quantify the magnitude of spillover effect in terms of time, similarity, and recall execution.Negative spillover effectNoting the prevalence of multiproduct systems, business researchers have paid substantial attention to negative spillover effects across multiple products or brands.", [["this study empirically tests", "TEST", 13, 41], ["spillover effect", "PROBLEM", 240, 256], ["multiproduct systems", "PROBLEM", 281, 301], ["spillover", "OBSERVATION", 71, 80], ["spillover", "OBSERVATION", 163, 172], ["spillover effect", "OBSERVATION", 240, 256]]], ["Initially, researchers considered positive side effects from line or brand extension strategies (Balachander and Ghose, 2003) .", [["positive side effects", "PROBLEM", 34, 55], ["line or brand extension strategies", "TREATMENT", 61, 95]]], ["Marketing practitioners cultivate brand relatedness and strength in their brand portfolio to increase marketing efficiency through positive spillovers.Negative spillover effectOn the other hand, circumstances also can activate negative spillover effects.", [["positive spillovers", "PROBLEM", 131, 150], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["positive spillovers", "OBSERVATION", 131, 150], ["spillover effectOn", "OBSERVATION", 160, 178]]], ["Unexpected product harm crises or brand scandals may evoke a negative spillover effect on the products or brands if consumers perceive that products in a brand family share similar quality standards and brand images (Lei et al., 2008) .", [["Unexpected product harm crises", "PROBLEM", 0, 30], ["brand scandals", "TREATMENT", 34, 48], ["harm crises", "OBSERVATION", 19, 30]]], ["As brands come to depend more on publicity, the possibility of negative spillovers onto competitors when a firm experiences a crisis also increases.", [["a crisis", "PROBLEM", 124, 132]]], ["For example, even if brand A has little to do with the crisis associated with brand B, it may still be affected by negative publicity if there is any association between the two brands.Negative spillover effectConsidering the devastating results of Jack in the Box E. coli scare in 1993, which killed four children and sickened more than seven hundred people, it is expected that Jack in the Box may have experienced negative spillover effects from other firms' food crises due to the association with other firms.", [["coli", "ORGANISM", 268, 272], ["children", "ORGANISM", 306, 314], ["people", "ORGANISM", 352, 358], ["E. coli", "SPECIES", 265, 272], ["children", "SPECIES", 306, 314], ["people", "SPECIES", 352, 358], ["Box E. coli", "SPECIES", 261, 272], ["the crisis", "PROBLEM", 51, 61], ["spillover effect", "PROBLEM", 194, 210], ["negative", "OBSERVATION", 115, 123], ["spillover effect", "OBSERVATION", 194, 210], ["devastating", "OBSERVATION_MODIFIER", 226, 237], ["spillover", "OBSERVATION", 426, 435]]], ["Thus, this study proposes a hypothesis on the negative spillover effect from other firms' food crises on Jack in the Box:Negative spillover effectH1.", [["H1", "GENE_OR_GENE_PRODUCT", 146, 148], ["H1", "PROTEIN", 146, 148], ["this study", "TEST", 6, 16], ["a hypothesis", "PROBLEM", 26, 38], ["H1", "PROBLEM", 146, 148], ["Negative", "OBSERVATION", 121, 129], ["spillover effect", "OBSERVATION", 130, 146]]], ["There has been a negative spillover effect from other firms' food crises on Jack in the Box.Time and negative spillover effectsPrior crisis management research identified time as a crucial influence on consumers' memory-based information processing (Standop, 2006; Vassilikopoulou et al., 2009) .", [["a negative spillover effect", "PROBLEM", 15, 42], ["Prior crisis management", "TREATMENT", 127, 150], ["negative", "OBSERVATION_MODIFIER", 17, 25], ["spillover effect", "OBSERVATION", 26, 42], ["spillover effects", "OBSERVATION", 110, 127]]], ["Unfavorable attitudes toward a crisis likely diminish over time; however, a longer period between a crisis and a product recall makes it more difficult for firms to regain consumers' trust (Standop, 2006) .", [["a crisis", "PROBLEM", 29, 37], ["a crisis", "PROBLEM", 98, 106], ["diminish", "OBSERVATION_MODIFIER", 45, 53]]], ["Consumers thus perceive less danger and adopt better impressions and future purchase intentions one year after a crisis, such that time helps reduce the negative effects of a crisis on consumer responses.", [["a crisis", "PROBLEM", 111, 119]]], ["Accordingly, a firm may be able to recover from a crisis.", [["a crisis", "PROBLEM", 48, 56], ["firm", "OBSERVATION", 15, 19], ["crisis", "OBSERVATION", 50, 56]]], ["Thus, we hypothesize the time influence on negative spillover effect on Jack in the Box as:Time and negative spillover effectsH2.", [["H2", "CHEMICAL", 126, 128], ["H2", "CHEMICAL", 126, 128], ["H2", "GENE_OR_GENE_PRODUCT", 126, 128], ["H2", "PROBLEM", 126, 128], ["spillover effect", "OBSERVATION", 52, 68], ["spillover effects", "OBSERVATION", 109, 126]]], ["The negative spillover effect from other firms' food crises on Jack in the Box is stronger when the negative spillover event is closer in time to the 1993 Jack in the Box E. coli outbreak (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) as compared to a negative spillover event that is farther away in time (2004) (2005) (2006) (2007) (2008) (2009) (2010) .Similarity and negative spillover effectsThe accessibility-diagnosticity framework offers a theoretical explanation of this negative spillover effect (Feldman and Lynch, 1988) .", [["E. coli outbreak", "SPECIES", 171, 187], ["Box E. coli", "SPECIES", 167, 178], ["a negative spillover event", "PROBLEM", 280, 306], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["spillover effect", "OBSERVATION", 13, 29], ["spillover", "OBSERVATION", 109, 118], ["coli outbreak", "OBSERVATION", 174, 187], ["spillover", "OBSERVATION", 291, 300], ["negative", "OBSERVATION", 401, 409], ["spillover effects", "OBSERVATION", 410, 427]]], ["For example, attribute-level similarities have a greater effect than overall product similarity does on consumer perceptions (Broniarczyk and Alba, 1994; Roehm and Tybout, 2006) .", [["greater effect", "OBSERVATION_MODIFIER", 49, 63]]], ["Moreover, categorization theory asserts that product similarity provides strong cues for categorization, which lead to higher levels of both diagnosticity and accessibility (Mervis and Rosch, 1981; Sujan, 1985) .", [["categorization", "TEST", 89, 103]]], ["It also supports the notion that the spillover effect is promoted by product similarity.", [["spillover", "OBSERVATION", 37, 46]]], ["Thus, when Lei et al. (2008) examined the effects of the strength and directionality of brand relatedness on spillovers within a brand family, they found that negative spillover within a brand family was stronger and more salient with a higher number of associations.", [["spillover", "OBSERVATION", 168, 177]]], ["They found a moderating effect of product/brand similarity on perception spillovers, revealing that perception spillovers occurred when brands were sufficiently similar.", [["perception spillovers", "PROBLEM", 62, 83], ["perception spillovers", "PROBLEM", 100, 121]]], ["Thus, this study proposes the effect of similarity in terms of operation type and type of foodborne illness on negative spillover effect on Jack in the Box:H3.The negative spillover effect from other firms' food crises on Jack in the Box is stronger when the similarity in terms of type of illness between the two events is greater.H4.The negative spillover effect from other firms' food crises on Jack in the Box is stronger when the similarity in terms of type of operation between the two events is greater.Recall execution and negative spillover effectsWhen a firm fails to control the quality of products, the firm often results in product recalls.", [["foodborne illness", "DISEASE", 90, 107], ["illness", "DISEASE", 290, 297], ["Box:H3", "GENE_OR_GENE_PRODUCT", 152, 158], ["H4", "GENE_OR_GENE_PRODUCT", 332, 334], ["H4", "PROTEIN", 332, 334], ["this study", "TEST", 6, 16], ["foodborne illness", "PROBLEM", 90, 107], ["H3", "PROBLEM", 156, 158], ["illness", "PROBLEM", 290, 297], ["H4", "PROBLEM", 332, 334], ["operation", "TREATMENT", 466, 475], ["spillover effect", "OBSERVATION", 120, 136], ["H3", "ANATOMY", 156, 158], ["negative", "OBSERVATION_MODIFIER", 163, 171], ["spillover effect", "OBSERVATION", 172, 188], ["illness", "OBSERVATION", 290, 297], ["greater", "OBSERVATION_MODIFIER", 324, 331], ["negative", "OBSERVATION_MODIFIER", 339, 347], ["spillover effect", "OBSERVATION", 348, 364], ["operation", "OBSERVATION", 466, 475], ["greater", "OBSERVATION_MODIFIER", 502, 509], ["spillover effects", "OBSERVATION", 540, 557], ["firm", "OBSERVATION", 564, 568]]], ["The underlying reasons of increase in product recalls include the globalization of production, the increased complexity of products, and closer attention of firms and government agencies (Berman, 1999) .", [["increase", "OBSERVATION_MODIFIER", 26, 34], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["complexity", "OBSERVATION_MODIFIER", 109, 119]]], ["Notable examples of product recalls include Tylenol tampering in 1983, Jack in the Box's recall of contaminated beef in 1993, tire recalls of Firestone in 2000, Chinese milk scandal recalling baby products in 2008, and Toyota's recall of 7 million cars in 2009.", [["Tylenol", "CHEMICAL", 44, 51], ["Tylenol", "CHEMICAL", 44, 51], ["Tylenol", "SIMPLE_CHEMICAL", 44, 51], ["beef", "SPECIES", 112, 116], ["Tylenol", "TREATMENT", 44, 51]]], ["Of those recalls, food product recalls are of great concern to the public due to its devastating influence threatening the public health.Recall execution and negative spillover effectsAlthough the goal of recall execution is to safeguard the public and reduce consumers' risk perception, the recall strategy often caused negative stock returns of a firm that announces the recall.", [["spillover effects", "OBSERVATION", 167, 184]]], ["In contrast, previous literature suggested positive consequences of recall execution such as increasing perceived responsiveness of a firm, reducing consumers' risk perception, and maintaining future purchase intentions (Dawar and Pillutla, 2000; Siomkos and Kurzbard, 1994) .", [["firm", "OBSERVATION_MODIFIER", 134, 138]]], ["More importantly, while previous research focused on the effect of recall strategy on a firm that announces the recall, the effect of recall announcement on other firms has not been explored.Recall execution and negative spillover effectsFinance research has emphasized the role of industry factor, an industry-specific correlation among firms in the same field, as a significant driver influencing stock returns (Cavaglia et al., 2000) .", [["spillover effects", "OBSERVATION", 221, 238]]], ["When a firm A deals with a crisis, the event may influence the stock returns of a firm B which is in the same industry with a firm A due to the high correlation that exists between firms in the same industry.", [["a crisis", "PROBLEM", 25, 33], ["a firm B", "PROBLEM", 80, 88], ["firm", "OBSERVATION", 82, 86], ["firm", "OBSERVATION", 126, 130]]], ["The market evaluation of a firm A becomes a determinant of evaluation of a firm B by market investors.", [["The market evaluation", "TEST", 0, 21], ["evaluation", "TEST", 59, 69], ["firm", "OBSERVATION", 27, 31], ["firm", "OBSERVATION", 75, 79]]], ["Considering the positive effect of recall execution in reducing consumers' risk perception (Dawar and Pillutla, 2000; Siomkos and Kurzbard, 1994) , an announcement of a hospitality firm recalling suspected products may be perceived as positive signal by market investors which may reduce negative spillovers on other hospitality firms.", [["positive effect", "OBSERVATION_MODIFIER", 16, 31]]], ["Thus, this study proposes a hypothesis as:H5.The negative spillover effect from other firms' food crises on Jack in the Box is stronger when there is no recall execution as compared to when there is a recall execution.Measuring the impact of crisesPrevious crisis management research has examined factors that influence the impact of crises, such as the amount, intensity, and type of media attention (Jolly and Mowen, 1985; Weinberger and Romeo, 1989) ; the number of injuries or deaths (Mowen, 1980) ; the firm's reputation (Siomkos and Shrivartara, 1993) ; the type of crisis (Coombs, 1995; Mitroff and Pearson, 1993) ; and the company's response (Siomkos and Kurzbard, 1994) .", [["injuries", "DISEASE", 469, 477], ["deaths", "DISEASE", 481, 487], ["H5", "PROTEIN", 42, 44], ["this study", "TEST", 6, 16], ["H5", "PROBLEM", 42, 44], ["Previous crisis management", "TREATMENT", 248, 274], ["crises", "PROBLEM", 334, 340], ["negative", "OBSERVATION_MODIFIER", 49, 57], ["spillover effect", "OBSERVATION", 58, 74], ["no", "UNCERTAINTY", 150, 152]]], ["Whereas many studies focus on economic impacts, by examining changes in sales revenue or reductions in production volume (Janakiraman et al., 2009; Tsang, 2000; van Heerde et al., 2007) , little research uses stock market measures to assess the economic impacts of food crises.Measuring the impact of crisesA few studies use accounting indicators, such as return on assets and return on investment, to measure the impact of specific events (Dickerson et al., 1997; Hsu and Jang, 2007) .", [["food crises", "DISEASE", 265, 276], ["stock market measures", "TREATMENT", 209, 230], ["reductions", "OBSERVATION_MODIFIER", 89, 99], ["food crises", "OBSERVATION", 265, 276]]], ["In addition, accounting measures reflect the impacts of both firm-and market-specific events, making it difficult to tease out the impact of firm-specific events.", [["impacts", "OBSERVATION_MODIFIER", 45, 52], ["both", "OBSERVATION_MODIFIER", 56, 60], ["firm", "OBSERVATION", 61, 65], ["firm", "OBSERVATION", 141, 145]]], ["Coombs (2004) uses a scenario-based survey to examine the impact of crisis history on consumers' perceptions of crises.", [["Coombs", "TEST", 0, 6], ["crises", "PROBLEM", 112, 118]]], ["Although Coombs reports significant findings, such as an intensifying effect of a past crisis on consumers' responses, measuring consumer intentions cannot fully capture the impact on associated firms.", [["Coombs", "TEST", 9, 15], ["significant findings", "PROBLEM", 24, 44], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["findings", "OBSERVATION", 36, 44], ["firms", "OBSERVATION", 195, 200]]], ["In contrast, event studies that investigate stock price movements (Chang and Zeng, 2011; Chen et al., 2007; Salin and Hooker, 2001) suggest that market measures capture immediate and direct reactions to crisis outbreaks.", [["event studies", "TEST", 13, 26], ["crisis outbreaks", "PROBLEM", 203, 219]]], ["According to the efficient market hypothesis, changes in stock prices represent the economic impacts of a particular event, based on the market's evaluation of the firm's future cash flows (Fama, 1970) .", [["changes in stock prices", "TREATMENT", 46, 69], ["the market's evaluation", "TEST", 133, 156], ["stock prices", "OBSERVATION", 57, 69]]], ["Thus, stock returns were selected for the current study to measure the economic impact of food crises on an associated firm.Event study methodThe efficient market hypothesis assumes that the stock market rapidly incorporates all available information into a firm's value (Mizik and Jacobson, 2004) .", [["the current study", "TEST", 38, 55], ["food crises", "PROBLEM", 90, 101], ["Event study method", "TEST", 124, 142], ["food crises", "OBSERVATION", 90, 101], ["firm", "OBSERVATION", 119, 123]]], ["Because of the efficiency of the market, abnormal returns (ARs) provide an unbiased estimate of future earnings (i.e., changes in market value) due to an event (Fama, 1970) .", [["abnormal returns (ARs", "PROBLEM", 41, 62], ["efficiency", "OBSERVATION_MODIFIER", 15, 25]]], ["A surprising event such as a crisis can strongly influence investors' decisions and thus ARs, because estimations underscore the long-term future cash flows of firms under crises.Event study methodThe event study method (ESM), pioneered by Fama et al. (1969) , is widely used to measure changes in stock prices (i.e., changes in market expectations of a firm's future value) associated with the release of new information.", [["a crisis", "PROBLEM", 27, 35], ["crises", "PROBLEM", 172, 178], ["Event study", "TEST", 179, 190]]], ["Crisis management research has extensively used ESM to explore the impact of product recall announcements (Chen et al., 2009; Thomsen and McKenzie, 2001) , the announcements of mergers or acquisitions (Dodd and Warner, 1983) , positive and negative economic news (Chan, 2003) , and the financial crisis in Japan (Miyajima and Yafeh, 2007) .Event study methodDespite the advantages of using the event study analysis, there are constraints when using the method such as the availability of precise event dates and the price-sensitivity of the events.", [["Crisis management", "TREATMENT", 0, 17], ["Event study", "TEST", 340, 351], ["the event study analysis", "TEST", 390, 414]]], ["In addition, although most event studies rely on parametric test statistics, the parametric tests are considered to lack detailed assumptions about the probability distribution of returns.", [["parametric test statistics", "TEST", 49, 75], ["the parametric tests", "TEST", 77, 97]]], ["Instead, the use of non-parametric tests such as sign test and rank test is suggested by Cowan (1992) to ensure the results of parametric test statistics.", [["non-parametric tests", "TEST", 20, 40], ["sign test", "TEST", 49, 58], ["rank test", "TEST", 63, 72], ["parametric test statistics", "TEST", 127, 153]]], ["In order to overcome such shortfalls of using event study method, the current study identifies the event dates using Marler Clark's website while cross-referencing the Lexis-Nexis database.", [["Lexis-Nexis database", "DNA", 168, 188], ["study method", "TEST", 52, 64], ["the current study", "TEST", 66, 83]]], ["To eliminate the confounding effects, treatments are made as explained in the methodology section.", [["treatments", "TREATMENT", 38, 48]]], ["Lastly, both parametric and non-parametric tests are performed to confirm the reported test results as suggested by Peterson (1989) .Event study methodWhile ESM has often appeared in hospitality research, most previous hospitality research measuring stock price movements has investigated the short-term impact of a specific event on hospitality firms.", [["both parametric and non-parametric tests", "TEST", 8, 48], ["Event study method", "TEST", 133, 151], ["short-term", "OBSERVATION_MODIFIER", 293, 303]]], ["For example, Chen et al. (2007) examined the impact of severe acute respiratory syndrome (SARS) outbreaks on the stock returns of seven hotels in Taiwan within one month after the outbreak.", [["acute respiratory syndrome", "DISEASE", 62, 88], ["SARS", "DISEASE", 90, 94], ["severe acute respiratory syndrome", "PROBLEM", 55, 88], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory syndrome", "OBSERVATION", 68, 88]]], ["Salin and Hooker (2001) investigated the influence of food recalls on stock prices of four food-related firms after 10, 20, 30 and 40 days since the recall announcements.", [["Salin", "CHEMICAL", 0, 5], ["Salin", "SIMPLE_CHEMICAL", 0, 5]]], ["Although a number of studies examined the short-term impact of crises or events, research on the long-term effects of a food crisis is lacking.", [["studies", "TEST", 21, 28], ["crises", "PROBLEM", 63, 69], ["a food crisis", "PROBLEM", 118, 131], ["long-term", "OBSERVATION_MODIFIER", 97, 106]]], ["Thus, the current study investigates the longterm impact of food crises on a firm with a past crisis history.Event study methodAlthough conducting a case study may not fully explain the impact of events on firms, the results obtained from a case study provide important empirical evidence about the severity of food crises and its impact on associated firms in the long run.", [["food crises", "DISEASE", 60, 71], ["food crises", "DISEASE", 311, 322], ["the current study", "TEST", 6, 23], ["Event study", "TEST", 109, 120], ["a case study", "TEST", 147, 159], ["a case study", "TEST", 239, 251], ["food crises", "PROBLEM", 311, 322], ["food crises", "OBSERVATION", 311, 322]]], ["This method is effective and widely used to examine crises, which tend to occur infrequently.", [["crises", "PROBLEM", 52, 58]]], ["For example, van Heerde et al. (2007) examined the impact of product harm crises on marketing efficiency by using Kraft Food Australia's 1996 salmonella food poisoning case.", [["salmonella food poisoning", "DISEASE", 142, 167]]], ["In turn, this study examines the negative spillover effects reflected in stock returns due to food crises, using a case study of Jack in the Box, by adopting ESM.DataJack in the Box, founded in 1951, is among the nation's leading fast food restaurant chains, currently with more than 2200 restaurants operating in 19 states in the United States.", [["food crises", "DISEASE", 94, 105], ["this study", "TEST", 9, 19], ["food crises", "PROBLEM", 94, 105], ["a case study", "TEST", 113, 125], ["spillover effects", "OBSERVATION", 42, 59]]], ["In January 1993, Jack in the Box suffered a major corporate crisis from an E. coli outbreak that gained tremendous media attention and shocked millions of customers.", [["E. coli", "ORGANISM", 75, 82], ["E. coli", "SPECIES", 75, 82], ["E. coli", "SPECIES", 75, 82], ["a major corporate crisis", "PROBLEM", 42, 66], ["an E. coli outbreak", "PROBLEM", 72, 91], ["E. coli", "OBSERVATION_MODIFIER", 75, 82]]], ["The Jack in the Box E. coli outbreak remains the largest and deadliest food crisis associated with restaurants.", [["Box E. coli", "ORGANISM", 16, 27], ["E. coli", "SPECIES", 20, 27], ["Box E. coli", "SPECIES", 16, 27], ["the Box E. coli outbreak", "PROBLEM", 12, 36], ["coli outbreak", "OBSERVATION", 23, 36], ["largest", "OBSERVATION_MODIFIER", 49, 56], ["deadliest", "OBSERVATION_MODIFIER", 61, 70], ["food crisis", "OBSERVATION", 71, 82]]], ["It resulted in the deaths of four children and sickened more than 700 people in multiple states.", [["deaths", "DISEASE", 19, 25], ["children", "ORGANISM", 34, 42], ["people", "ORGANISM", 70, 76], ["children", "SPECIES", 34, 42], ["people", "SPECIES", 70, 76]]], ["Jack in the Box lost millions of dollars in sales and revenue as a result of the crisis (Braun-latour et al., 2006) .", [["the crisis", "PROBLEM", 77, 87]]], ["Accordingly, it is frequently considered a successful case of recovering from a food-related crisis.", [["a food-related crisis", "PROBLEM", 78, 99]]], ["However, are there possible negative spillovers from other firms' food crises on Jack in the Box? or did Jack in the Box fully recover from the devastating memory of E. coli?DataThe Jack in the Box incident still remains the primary example of restaurant-associated food crises in U.S. history.", [["food crises", "DISEASE", 266, 277], ["E. coli", "ORGANISM", 166, 173], ["E. coli", "SPECIES", 166, 173], ["E. coli", "SPECIES", 166, 173], ["negative spillovers", "PROBLEM", 28, 47], ["E. coli", "PROBLEM", 166, 173], ["possible", "UNCERTAINTY", 19, 27], ["negative", "OBSERVATION_MODIFIER", 28, 36], ["spillovers", "OBSERVATION", 37, 47], ["devastating", "OBSERVATION_MODIFIER", 144, 155], ["E. coli", "OBSERVATION", 166, 173]]], ["To examine how Jack in the Box has been influenced by unrelated food crises since 1993, this study identified food crises in the past 18 years (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) that were associated with food-related firms, such as restaurants, food manufacturers, and food distributors.", [["food crises", "DISEASE", 110, 121], ["this study", "TEST", 88, 98], ["food crises", "OBSERVATION", 110, 121]]], ["Because the purpose of this study is to examine the spillover effect from other firms' food crises on the market value of Jack in the Box, thus, we excluded the 1993 incident from the data set and focused only on food crises associated with other firms.DataA list of foodborne illness outbreaks that had occurred since 1993 was obtained from the website of Marler Clark, a major law firm handling lawsuits related to foodborne illness outbreaks (http://www.marlerclark.com/).", [["foodborne illness", "DISEASE", 267, 284], ["foodborne illness", "DISEASE", 417, 434], ["this study", "TEST", 23, 33], ["the spillover effect", "PROBLEM", 48, 68], ["the data", "TEST", 180, 188], ["foodborne illness outbreaks", "PROBLEM", 267, 294], ["firm", "OBSERVATION", 383, 387]]], ["Marler Clark attorneys have represented victims of most foodborne illness outbreaks since 1993, when the law firm was established to handle the Jack in the Box case.", [["foodborne illness", "DISEASE", 56, 73], ["most foodborne", "OBSERVATION_MODIFIER", 51, 65], ["firm", "OBSERVATION", 109, 113]]], ["Marler Clark's archive is considered a reliable source for restaurant-associated foodborne illness outbreaks (Seo et al., 2013) .", [["foodborne illness", "DISEASE", 81, 98]]], ["When a lawsuit has been filed following a food crisis, it indicates that the crisis is serious, creating the possibility of a spillover effect on Jack in the Box.", [["a food crisis", "PROBLEM", 40, 53], ["the crisis", "PROBLEM", 73, 83], ["a spillover effect", "PROBLEM", 124, 142], ["spillover", "OBSERVATION", 126, 135]]], ["Using the Marler Clark's archive, food crisisrelated information was collected including the year, date, type of foodborne illness, associated firm, recall execution, and the number of people sickened or killed by the illness.DataIn order to eliminate any confounding effects, two treatments were put in place.", [["foodborne illness", "DISEASE", 113, 130], ["illness", "DISEASE", 218, 225], ["people", "ORGANISM", 185, 191], ["people", "SPECIES", 185, 191], ["any confounding effects", "PROBLEM", 252, 275], ["two treatments", "TREATMENT", 277, 291], ["firm", "OBSERVATION_MODIFIER", 143, 147]]], ["Second, any cases overlapped with significant events of Jack in the Box were removed from the data.", [["Box", "DNA", 68, 71], ["significant events of Jack in the Box", "PROBLEM", 34, 71]]], ["The events of Jack in the Box included announcements of implementing HACCP (Hazard Analysis & Critical Control Points) to manage food safety and quality of foods, changing the company name from Foodmaker to Jack in the Box Inc, conducting a new advertising campaign, and winning food safety award during the period from 1993 to 2010 (Miller, 2007) .", [["Hazard Analysis", "TEST", 76, 91], ["Critical Control Points", "TREATMENT", 94, 117]]], ["As a result, the total number of cases was reduced from 85 to 73 after removing twelve confounding cases.DataThe sample for this study thus consisted of 73 food crises associated with restaurants, food manufacturers, and food distributors.", [["The sample", "TEST", 109, 119], ["this study", "TEST", 124, 134]]], ["This sample size was comparable with that of other event studies; for example, Salin and Hooker (2001) used 4 observations, Horsky and Swyngedouw (1987) used 58, Lane and Jacobson (1995) used 89, and Geyskens et al. (2002) used 93.AnalysesWe used ESM and subsequent analyses to compute the ARs and cumulative abnormal returns (CARs), then conducted a series of t-statistic tests to investigate the effects of similarity (restaurant/non-restaurant, E. coli/non-E. coli), time (within 10 years/20 years), and recall execution (recall/non-recall) on ARs and CARs.", [["sample", "ANATOMY", 5, 11], ["E. coli", "ORGANISM", 448, 455], ["non-E. coli", "ORGANISM", 456, 467], ["E. coli", "SPECIES", 448, 455], ["non-E. coli", "SPECIES", 456, 467], ["E. coli", "SPECIES", 448, 455], ["non-E. coli", "SPECIES", 456, 467], ["This sample size", "TEST", 0, 16], ["other event studies", "TEST", 45, 64], ["subsequent analyses", "TEST", 255, 274], ["cumulative abnormal returns", "PROBLEM", 298, 325], ["t-statistic tests", "TEST", 361, 378], ["E. coli/non-E. coli", "PROBLEM", 448, 467], ["size", "OBSERVATION_MODIFIER", 12, 16]]], ["Following Brown and Warner (1980) , a market model was chosen to obtain the estimates of expected returns.AnalysesSpecifically, the returns for Jack in the Box (JACK) were computed as the difference between the closing price on day t (P t ) and day t \u2212 1 (P t -1 ) (Eq.", [["a market model", "TREATMENT", 36, 50]]], ["(2)):Analyseswhere R t = the return of JACK on day t; P t = the closing price of JACK on day t; and R mt = the market return on day t.", [["JACK", "PROTEIN", 39, 43]]], ["Next, the expected returns were calculated by performing ordinary least squares regression analysis using the \u02c7 estimate obtained from Eq.", [["regression analysis", "TEST", 80, 99], ["the \u02c7 estimate", "TEST", 106, 120]]], ["The AR was calculated by subtracting the expected returns (ER t ) from the stock returns (R t ) (Eq.", [["AR", "GENE_OR_GENE_PRODUCT", 4, 6], ["ER", "GENE_OR_GENE_PRODUCT", 59, 61], ["AR", "PROTEIN", 4, 6], ["ER t", "PROTEIN", 59, 63]]], ["As ESM specifies, AR refers to the difference between actual and expected returns, such that it can reflect the isolated effects of a firm-specific event, separate from overall market movements.", [["AR", "GENE_OR_GENE_PRODUCT", 18, 20], ["AR", "PROTEIN", 18, 20], ["AR", "PROBLEM", 18, 20], ["firm", "OBSERVATION", 134, 138]]], ["In the current study, AR is calculated as the average value of JACK's stock prices in response to 73 events.", [["AR", "GENE_OR_GENE_PRODUCT", 22, 24], ["AR", "PROTEIN", 22, 24], ["JACK", "PROTEIN", 63, 67], ["the current study", "TEST", 3, 20], ["AR", "PROBLEM", 22, 24]]], ["We calculated CAR as the sum of daily ARs (Eq.", [["CAR", "GENE_OR_GENE_PRODUCT", 14, 17], ["CAR", "PROTEIN", 14, 17]]], ["For example, CAR 1 is calculated as the sum of AR on day 0 and AR on day 1, CAR 2 is the sum of AR on day 0, AR on day 1, and AR on day 2.", [["CAR 1", "GENE_OR_GENE_PRODUCT", 13, 18], ["AR", "GENE_OR_GENE_PRODUCT", 47, 49], ["CAR 2", "GENE_OR_GENE_PRODUCT", 76, 81], ["AR", "GENE_OR_GENE_PRODUCT", 96, 98], ["CAR 1", "PROTEIN", 13, 18], ["AR", "PROTEIN", 47, 49], ["AR", "PROTEIN", 63, 65], ["AR", "PROTEIN", 96, 98], ["AR", "PROTEIN", 109, 111], ["AR", "PROTEIN", 126, 128]]], ["Thus, CARs represent the average cumulative impacts on JACK from 73 others' events.Analyseswhere AR is abnormal return of stock prices; CAR is cumulative abnormal return of stock prices.AnalysesTo test the significance of ARs and CARs, the t-statistic on any day t in the event window was performed.", [["CARs", "PROTEIN", 6, 10], ["JACK", "PROTEIN", 55, 59], ["AR", "PROTEIN", 97, 99], ["CAR", "PROTEIN", 136, 139], ["AR", "PROBLEM", 97, 99], ["abnormal", "OBSERVATION_MODIFIER", 103, 111], ["stock prices", "OBSERVATION", 173, 185]]], ["If the outbreak of others' crises caused abnormal returns, the t-statistics should be significantly different from zero, otherwise, the t-statistics should not be significantly different from zero.", [["crises", "PROBLEM", 27, 33], ["abnormal returns", "PROBLEM", 41, 57]]], ["In addition, if results show negative significance, it is assumed that others' crises had negative impacts on stock returns of Jack in the Box.", [["others' crises", "PROBLEM", 71, 85]]], ["In other words, the market perceived the others' crises as negative information when evaluating the value of Jack in the Box.Cross-sectional analysisTo identify significant factors influencing negative spillovers, a cross-sectional analysis was performed as suggested by Root and Contractor (1981) , Brown et al. (2003) , and Graf (2009) .", [["a cross-sectional analysis", "TEST", 214, 240], ["significant", "OBSERVATION_MODIFIER", 161, 172], ["negative spillovers", "OBSERVATION", 193, 212]]], ["In order to perform the cross-sectional analysis, data were categorized into two groups in terms of four variables including the (1) recentness of outbreak time to the time of Jack in the Box event (whether an event occurred between 1993 and 2003 or 2004 and 2010), (2) similarity with Jack in the Box in terms of the type of foodborne illness (whether an event was associated with E. coli or non-E. coli), (3) similarity with Jack in the Box in terms of the operation type (whether an event was associated with restaurant or non-restaurant), and (4) recall execution (whether an event was accompanies with recall execution or not).Cross-sectional analysisThere were two control variables which may have influenced the impacts of events on stock returns: (1) severity of risks and (2) level of media attention.", [["foodborne illness", "DISEASE", 326, 343], ["E. coli", "ORGANISM", 382, 389], ["non-E. coli", "ORGANISM", 393, 404], ["E. coli", "SPECIES", 382, 389], ["non-E. coli", "SPECIES", 393, 404], ["E. coli", "SPECIES", 382, 389], ["non-E. coli", "SPECIES", 393, 404], ["the cross-sectional analysis", "TEST", 20, 48], ["foodborne illness", "PROBLEM", 326, 343], ["E. coli", "PROBLEM", 382, 389], ["non-E. coli", "PROBLEM", 393, 404], ["Cross-sectional analysis", "TEST", 632, 656], ["media attention", "TREATMENT", 794, 809], ["foodborne", "OBSERVATION", 326, 335], ["operation", "OBSERVATION", 459, 468]]], ["The severity of risks was coded as the number of illnesses caused by each event, and media attention was recorded as the number of news articles covering each event, which were obtained using LexisNexis database.", [["illnesses", "PROBLEM", 49, 58]]], ["Those two control variables were used as covariate variables when running the analysis of covariance (ANCOVA).Cross-sectional analysisTo test the effect of time (within 10/20 years), similarity in terms of foodborne illness type (high/low), similarity in terms of operation type (high/low), and recall execution (yes/no) on ARs and CARs for JACK, we performed ANCOVA as a parametric test.", [["foodborne illness", "DISEASE", 206, 223], ["JACK", "PROTEIN", 341, 345], ["Cross-sectional analysis", "TEST", 110, 134], ["a parametric test", "TEST", 370, 387]]], ["Unlike previous studies using a regression analysis for cross-sectional analysis (Borde et al., 1999; Chang and Zeng, 2011) , this study used ANCOVA because of dichotomized nature of testing variables as well as the benefit of ANCOVA in showing the pattern of changes in ARs and CARs over time.", [["previous studies", "TEST", 7, 23], ["a regression analysis", "TEST", 30, 51], ["cross-sectional analysis", "TEST", 56, 80], ["this study", "TEST", 126, 136], ["testing variables", "TEST", 183, 200], ["ANCOVA", "TREATMENT", 227, 233], ["changes in ARs", "PROBLEM", 260, 274]]], ["With the ANCOVA, we can compare and test for the significance of the differences between the two groups.", [["test", "TEST", 36, 40]]], ["In addition, considering the small sample size of each group, we performed a nonparametric Mann-Whitney U test to verify the results of the ANCOVA; as Corrado (1989) notes, it is advantageous to use nonparametric tests in event studies.Cross-sectional analysisPrevious literature using ESM has suggested the appropriate use of event window depending on the nature of research.", [["nonparametric tests", "TEST", 199, 218], ["event studies", "TEST", 222, 235], ["event window", "TREATMENT", 327, 339], ["small", "OBSERVATION_MODIFIER", 29, 34], ["sample", "OBSERVATION_MODIFIER", 35, 41], ["size", "OBSERVATION_MODIFIER", 42, 46]]], ["For example, Chen et al. (2007) used a 20-day event window to test the impact of SARS outbreaks, Salin and Hooker (2001) adopted a 40-day event window to investigate the impact of food recalls, and Chang and Zeng (2011) used a 40-day event window to measure the impact of terrorism on hospitality stock returns.", [["SARS", "DISEASE", 81, 85], ["Salin", "CHEMICAL", 97, 102], ["Salin", "TREATMENT", 97, 102]]], ["Thus, a 30-day event window was used to examine the stock prices of JACK in responding to the outbreaks of seventy-three events.Impact of the E. coli scare in 1993 on Jack in the Box (JACK)We examined stock prices for Jack in the Box (JACK, hereafter) since 1993 to identify the seriousness and duration of a food crisis.", [["JACK", "CHEMICAL", 68, 72], ["JACK", "SIMPLE_CHEMICAL", 68, 72], ["E. coli", "ORGANISM", 142, 149], ["E. coli", "SPECIES", 142, 149], ["E. coli", "SPECIES", 142, 149], ["the E. coli scare", "TREATMENT", 138, 155], ["a food crisis", "PROBLEM", 307, 320], ["E. coli scare", "OBSERVATION", 142, 155]]], ["Because positive (negative) abnormal returns (AR) or cumulative abnormal returns (CAR) indicate a positive (negative) market evaluation of the firm's future value, we pinpointed when CARs for Jack in the Box showed positive values, to find the point at which recovery from the E. coli outbreak occurred.", [["E. coli", "ORGANISM", 277, 284], ["AR", "PROTEIN", 46, 48], ["CAR", "PROTEIN", 82, 85], ["E. coli", "SPECIES", 277, 284], ["E. coli", "SPECIES", 277, 284], ["abnormal returns (AR", "PROBLEM", 28, 48], ["cumulative abnormal returns", "PROBLEM", 53, 80], ["market evaluation", "TEST", 118, 135], ["Jack in the Box", "TEST", 192, 207], ["positive values", "PROBLEM", 215, 230], ["the E. coli outbreak", "PROBLEM", 273, 293], ["positive", "OBSERVATION", 215, 223], ["E. coli outbreak", "OBSERVATION", 277, 293]]], ["The first news report that covered the E. coli scare associated with Jack in the Box was released on January 18, 1993.", [["E. coli", "ORGANISM", 39, 46], ["E. coli", "SPECIES", 39, 46], ["E. coli", "SPECIES", 39, 46], ["the E. coli scare", "TREATMENT", 35, 52], ["E. coli scare", "OBSERVATION", 39, 52]]], ["For example, the calculated AR for Jack in the Box was \u22121.9018 for January 18, 1993 (t 0 ), and \u221211.6767 for January 19, 1993 (t 1 ).", [["AR", "GENE_OR_GENE_PRODUCT", 28, 30], ["AR", "PROTEIN", 28, 30], ["the Box", "TEST", 43, 50]]], ["Between January 18, 1993, and January 19, 1993 (t 0 \u2212 t 1 ), the CAR was \u221213.5785, or the sum of \u22121.9018 and \u221211.6767.Impact of the E. coli scare in 1993 on Jack in the Box (JACK)As Fig. 2 indicates, CAR for JACK turned positive on June 16, 1997, the 1,114th day since the first outbreak day, indicating that it took JACK almost 4.5 years to recover from the E. coli outbreak.", [["CAR", "GENE_OR_GENE_PRODUCT", 65, 68], ["E. coli", "ORGANISM", 132, 139], ["CAR", "GENE_OR_GENE_PRODUCT", 200, 203], ["E. coli", "ORGANISM", 359, 366], ["CAR", "PROTEIN", 65, 68], ["CAR", "PROTEIN", 200, 203], ["E. coli", "SPECIES", 132, 139], ["E. coli", "SPECIES", 359, 366], ["E. coli", "SPECIES", 132, 139], ["E. coli", "SPECIES", 359, 366], ["the CAR", "TEST", 61, 68], ["the E. coli scare", "TREATMENT", 128, 145], ["the E. coli outbreak", "PROBLEM", 355, 375], ["E. coli scare", "OBSERVATION", 132, 145], ["E. coli outbreak", "OBSERVATION", 359, 375]]], ["Even acknowledging that JACK's E. coli outbreak was notable, as the first and most devastating food safety event at the time, similar crises could easily affect other restaurants in the future.", [["JACK", "GENE_OR_GENE_PRODUCT", 24, 28], ["E. coli", "ORGANISM", 31, 38], ["E. coli", "SPECIES", 31, 38], ["E. coli", "SPECIES", 31, 38], ["JACK's E. coli outbreak", "PROBLEM", 24, 47], ["similar crises", "PROBLEM", 126, 140]]], ["Although it is not possible to generalize results from a single case, the results of this study offer a warning to restaurant managers, by highlighting the detrimental impact of a one-time food safety event.Impacts of other firms' food crises on JACKAs Fig. 3 presents, ARs of JACK were significantly negative in response to other food crises on the outbreak day (day 0) and the following day (day 1).", [["JACK", "GENE_OR_GENE_PRODUCT", 277, 281], ["this study", "TEST", 85, 95], ["other food crises", "PROBLEM", 325, 342], ["not possible", "UNCERTAINTY", 15, 27]]], ["Moreover, CARs were significantly negative until the 31st day.", [["CARs", "GENE_OR_GENE_PRODUCT", 10, 14]]], ["This result demonstrates that unrelated food crisis outbreaks caused JACK to experience negative market evaluations, even though JACK had nothing to do with the food crises.Is the negative spillover effect on JACK stronger than on other chain restaurant firms?To determine whether ARs and CARs for JACK are significantly more negative than those for other firms, we examined four national chain restaurant firms in terms of ARs and CARs in response to the same 73 food crises.", [["JACK", "CHEMICAL", 129, 133], ["CARs", "GENE_OR_GENE_PRODUCT", 289, 293], ["JACK", "GENE_OR_GENE_PRODUCT", 298, 302], ["JACK", "PROTEIN", 298, 302], ["unrelated food crisis outbreaks", "PROBLEM", 30, 61], ["market evaluations", "TEST", 97, 115], ["the food crises", "PROBLEM", 157, 172], ["ARs", "PROBLEM", 281, 284], ["JACK", "TEST", 298, 302], ["food crisis", "OBSERVATION", 40, 51], ["negative", "OBSERVATION_MODIFIER", 180, 188], ["spillover effect", "OBSERVATION", 189, 205]]], ["McDonald's, Wendy's, Darden Restaurants (which owns Olive Garden and other chains), and Yum Brands (owner of KFC and Taco Bell) were selected because these four companies are leading restaurant chain firms compatible with Jack in the Box.", [["KFC and Taco Bell", "TREATMENT", 109, 126]]], ["Following the same data collection procedure used for JACK, we obtained historical stock prices for the four restaurant firms from CRSP in line with previous literature (Chen et al., 2009) .", [["collection procedure", "TREATMENT", 24, 44], ["historical stock prices", "TREATMENT", 72, 95]]], ["In order to eliminate the confounding effect, any cases within the period of 10 days before and after foodborne illness outbreaks of Wendy's, Darden, Yum, and McDonald's were removed from data prior to the analysis.", [["foodborne illness", "DISEASE", 102, 119], ["McDonald's", "TREATMENT", 159, 169], ["the analysis", "TEST", 202, 214]]], ["Those events include, for instance, foodborne illnesses associated with McDonald's in 1998 , Wendy's in 2000 , KFC in 2002 , Olive Garden in 2005 , and Taco Bell in 2006 .", [["foodborne illnesses", "DISEASE", 36, 55], ["foodborne illnesses", "PROBLEM", 36, 55]]], ["This elimination enables us to remove the possibility of negative spillover of other firms on themselves regardless of the influence of Jack in the Box.", [["negative spillover of other firms", "PROBLEM", 57, 90], ["spillover", "OBSERVATION", 66, 75]]], ["The ARs and CARs of the four restaurant firms (hereafter, OTHER) were calculated using the same event windows to determine whether the changes in ARs and CARs for OTHER differed from those for JACK.", [["JACK", "PROTEIN", 193, 197], ["the changes in ARs", "PROBLEM", 131, 149]]], ["Significance of ARs and CARs of Jack in the Box in response to 73 other food crises.", [["ARs", "PROBLEM", 16, 19]]], ["Note: The figure shows ARs and CARs of JACK in response to 73 food crises associated with other food-related firms which occurred from 1993 to 2010.", [["JACK", "PROTEIN", 39, 43], ["ARs", "PROBLEM", 23, 26]]], ["AR is an indicator of abnormal stock returns, and CAR is an indicator of cumulative impacts since the outbreak of events.", [["AR", "GENE_OR_GENE_PRODUCT", 0, 2], ["CAR", "GENE_OR_GENE_PRODUCT", 50, 53], ["AR", "PROTEIN", 0, 2], ["CAR", "PROTEIN", 50, 53], ["abnormal stock returns", "PROBLEM", 22, 44], ["abnormal", "OBSERVATION_MODIFIER", 22, 30], ["stock", "OBSERVATION", 31, 36]]], ["ARs or CARs which are below 0 indicate the occurrence of negative events, and those over 0 indicate the occurrence of positive events.", [["positive events", "PROBLEM", 118, 133], ["negative", "OBSERVATION", 57, 65], ["positive", "OBSERVATION", 118, 126]]], ["Significantly negative t-value evidences the negative impacts of events. * p < .05, ** p < .01, *** p < .001.Is the negative spillover effect on JACK stronger than on other chain restaurant firms?The results indicate that JACK showed significantly lower ARs on the outbreak day (day 0) and the following day (day 1) compared with OTHER (Fig. 4) .", [["JACK", "SIMPLE_CHEMICAL", 222, 226], ["JACK", "PROTEIN", 222, 226], ["significantly lower ARs", "PROBLEM", 234, 257], ["negative impacts", "OBSERVATION_MODIFIER", 45, 61], ["negative", "OBSERVATION_MODIFIER", 116, 124], ["spillover effect", "OBSERVATION", 125, 141], ["significantly", "OBSERVATION_MODIFIER", 234, 247], ["lower ARs", "OBSERVATION_MODIFIER", 248, 257]]], ["The pattern of CARs shows that JACK had significantly more negative CARs than OTHER, consistent with the changes in ARs.", [["JACK", "GENE_OR_GENE_PRODUCT", 31, 35], ["ARs", "GENE_OR_GENE_PRODUCT", 116, 119], ["CARs", "PROTEIN", 15, 19], ["JACK", "PROTEIN", 31, 35], ["the changes in ARs", "PROBLEM", 101, 119], ["consistent with", "UNCERTAINTY", 85, 100]]], ["The results imply that the negative spillover effect on JACK was much more pronounced than on OTHER.", [["JACK", "GENE_OR_GENE_PRODUCT", 56, 60], ["the negative spillover effect", "PROBLEM", 23, 52], ["negative", "OBSERVATION_MODIFIER", 27, 35], ["spillover", "OBSERVATION", 36, 45], ["more pronounced", "OBSERVATION_MODIFIER", 70, 85]]], ["Fig. 5 shows that JACK experienced more negative ARs from events that occurred between 1993 and 2003 (within 10 years of JACK's E. coli outbreak) than from events that occurred between 2004 and 2010 (within 20 years after JACK's E. coli outbreak).", [["JACK", "GENE_OR_GENE_PRODUCT", 18, 22], ["E. coli", "ORGANISM", 128, 135], ["E. coli", "ORGANISM", 229, 236], ["E. coli", "SPECIES", 128, 135], ["E. coli", "SPECIES", 229, 236], ["E. coli", "SPECIES", 128, 135], ["E. coli", "SPECIES", 229, 236], ["JACK's E. coli outbreak", "PROBLEM", 121, 144], ["JACK's E. coli outbreak", "PROBLEM", 222, 245]]], ["The trend of changes in CAR indicates a more negative impact on JACK of events that occurred in the first 10 years after the outbreak compared with that of events that occurred in the next 10 years.", [["CAR", "GENE_OR_GENE_PRODUCT", 24, 27], ["CAR", "PROTEIN", 24, 27]]], ["The difference between CARs of JACK for both periods was significant until the ninth day, according to ANCOVA results, or until the fifth day, according to the Mann-Whitney U test results.", [["JACK", "GENE_OR_GENE_PRODUCT", 31, 35], ["JACK", "PROTEIN", 31, 35]]], ["Changes in CARs indicated that JACK was more likely to suffer from events that occurred closer to the original event (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) compared with events occurring further from the original event (2004) (2005) (2006) (2007) (2008) (2009) (2010) , in support of the proposition that the time effect reduces the negative spillover effect on JACK.The effect of time on negative spillover effectPeople tend to recall negative events less as time goes by (Vassilikopoulou et al., 2009) , which may be why the effect of negative spillovers on JACK's market values decreased.", [["JACK", "GENE_OR_GENE_PRODUCT", 31, 35], ["People", "ORGANISM", 445, 451], ["JACK", "GENE_OR_GENE_PRODUCT", 591, 595], ["JACK", "PROTEIN", 31, 35], ["JACK", "PROTEIN", 393, 397], ["People", "SPECIES", 445, 451], ["negative", "OBSERVATION", 364, 372], ["spillover effect", "OBSERVATION", 373, 389], ["spillover effect", "OBSERVATION", 429, 445]]], ["By highlighting the effect of time on spillover effects, these results provide empirical evidence that time heals, but spillover effects never completely disappear.", [["spillover effects", "TREATMENT", 38, 55]]], ["If a firm experiences a food safety event, time may help .000*** .005** .006** .002** .007** .001** .000*** .000*** .000*** .000*** .000*** .000*** Inc., Yum Brands Inc.) to 73 food safety events.", [["*** .005** .006** .002** .007** .001** .000*** .000*** .000*** .000*** .000*** .000**", "DISEASE", 61, 146], ["firm", "OBSERVATION_MODIFIER", 5, 9]]], ["As a parametric test, one-way ANOVA was performed to test the difference between Jack in the Box and others.", [["a parametric test", "TEST", 3, 20]]], ["Significant FF value indicates the presence of significant differences between two groups (Jack versus OTHER).", [["Significant FF value", "TEST", 0, 20], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["differences", "OBSERVATION", 59, 70]]], ["Additionally, an analysis comparing Jack in the Box and Wendy's which are relatively similar in firm size is performed because the size of five firms varies considerably.", [["an analysis", "TEST", 14, 25], ["relatively", "OBSERVATION_MODIFIER", 74, 84], ["similar", "OBSERVATION_MODIFIER", 85, 92], ["firm", "OBSERVATION_MODIFIER", 96, 100], ["size", "OBSERVATION_MODIFIER", 101, 105], ["size", "OBSERVATION_MODIFIER", 131, 135], ["five", "OBSERVATION_MODIFIER", 139, 143], ["firms", "OBSERVATION_MODIFIER", 144, 149], ["varies", "OBSERVATION_MODIFIER", 150, 156], ["considerably", "OBSERVATION_MODIFIER", 157, 169]]], ["The result of the additional analysis confirms that the negative spillover on Jack in the Box was significantly greater than that on Wendy's. * p < .05, ** p < .01, *** p < .001.The effect of time on negative spillover effectit recover.", [["the additional analysis", "TEST", 14, 37], ["spillover", "OBSERVATION", 65, 74], ["significantly", "OBSERVATION_MODIFIER", 98, 111], ["greater", "OBSERVATION_MODIFIER", 112, 119], ["spillover effectit", "OBSERVATION", 209, 227]]], ["However, the time effect alone cannot guarantee a full recovery.The effect of similarity in operation type on negative spillover effectThe effects of similarity in operation type (restaurant events vs. non-restaurant events) on spillovers on JACK were examined (Fig. 6) .", [["spillover effect", "OBSERVATION", 119, 135]]], ["Overall, changes in CARs suggest that JACK showed more negative CARs in response to restaurant events than to non-restaurant events.", [["JACK", "GENE_OR_GENE_PRODUCT", 38, 42], ["JACK", "PROTEIN", 38, 42]]], ["The differences between both cases were significant from day 4 to day 10, supported by both ANCOVA and Mann-Whitney U test results.The effect of similarity in operation type on negative spillover effectThe results imply that restaurant-associated food crises have a stronger spillover effect on JACK, revealing the similarity effect on negative spillover.", [["JACK", "GENE_OR_GENE_PRODUCT", 295, 299], ["JACK", "PROTEIN", 295, 299], ["food crises", "PROBLEM", 247, 258], ["a stronger spillover effect on JACK", "PROBLEM", 264, 299], ["spillover effect", "OBSERVATION", 186, 202], ["negative spillover", "OBSERVATION", 336, 354]]], ["When a food crisis was associated with restaurants, JACK suffered from more severe spillover effects than it did from nonrestaurant-associated food crises.", [["JACK", "CHEMICAL", 52, 56], ["food crises", "DISEASE", 143, 154], ["a food crisis", "PROBLEM", 5, 18], ["more severe spillover effects", "PROBLEM", 71, 100], ["food crises", "PROBLEM", 143, 154], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["spillover", "OBSERVATION", 83, 92]]], ["Consistent with previous studies using the accessibility-diagnosticity framework (Broniarczyk and Alba, 1994; Roehm and Tybout, 2006) , greater attribute similarity leads to stronger impacts on perceptions.The effect of similarity in risk type on negative spillover effectThe ANCOVA results revealed that ARs for JACK were significantly lower for events associated with E. coli than events not associated with it on day 5 (Fig. 7) Overall, JACK showed more negative ARs and CARs to 10 years events (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) than those of 20 years events (2004) (2005) (2006) (2007) (2008) (2009) (2010) .", [["JACK", "GENE_OR_GENE_PRODUCT", 313, 317], ["E. coli", "ORGANISM", 370, 377], ["JACK", "PROTEIN", 313, 317], ["JACK", "PROTEIN", 440, 444], ["E. coli", "SPECIES", 370, 377], ["E. coli", "SPECIES", 370, 377], ["previous studies", "TEST", 16, 32], ["negative spillover effect", "PROBLEM", 247, 272], ["The ANCOVA", "TEST", 272, 282], ["ARs", "PROBLEM", 305, 308], ["JACK", "TEST", 313, 317], ["E. coli", "PROBLEM", 370, 377], ["spillover effect", "OBSERVATION", 256, 272], ["coli", "OBSERVATION", 373, 377]]], ["The tables show the significance of difference between JACK's ARs and CARs to 10 years events and 20 years events.", [["JACK", "PROTEIN", 55, 59]]], ["In consistent with previous analyses, both parametric test (ANCOVA) and non-parametric test (Mann-Whitney U test) were performed to test the difference between two groups considering small sample size. * p < .05, ** p < .01, *** p < .001.The effect of similarity in risk type on negative spillover effectcompared with non-E. coli events, and we found significant differences from day 6 to day 20 (ANCOVA) and from day 6 to day 9 (Mann-Whitney U test).The effect of similarity in risk type on negative spillover effectA similar risk type also influences the magnitude of spillover effects on JACK.", [["non-E. coli", "ORGANISM", 318, 329], ["JACK", "GENE_OR_GENE_PRODUCT", 591, 595], ["JACK", "PROTEIN", 591, 595], ["non-E. coli", "SPECIES", 318, 329], ["non-E. coli", "SPECIES", 318, 329], ["previous analyses", "TEST", 19, 36], ["both parametric test", "TEST", 38, 58], ["non-parametric test", "TEST", 72, 91], ["Whitney U test)", "TEST", 98, 113], ["small sample size", "PROBLEM", 183, 200], ["non-E. coli events", "PROBLEM", 318, 336], ["negative spillover effect", "PROBLEM", 492, 517], ["spillover effects on JACK", "PROBLEM", 570, 595], ["consistent with", "UNCERTAINTY", 3, 18], ["small", "OBSERVATION_MODIFIER", 183, 188], ["sample", "OBSERVATION_MODIFIER", 189, 195], ["size", "OBSERVATION_MODIFIER", 196, 200], ["significant", "OBSERVATION_MODIFIER", 351, 362], ["spillover effect", "OBSERVATION", 501, 517], ["spillover", "OBSERVATION", 570, 579]]], ["Consistently, we found that similarity at the attribute level influenced perceptions and market evaluations of the future value of firms reflected in stock returns.", [["market evaluations", "TEST", 89, 107]]], ["When a food crisis was associated with E. coli, JACK experienced more severe impacts from the crisis than when a food crisis was related to other bacteria or viruses, such as Salmonella, Shigella, hepatitis A, or norovirus.The effect of recall execution on negative spillover effectResults indicated that recall execution of others caused less negative spillovers on JACK (Fig. 8) .", [["JACK", "CHEMICAL", 48, 52], ["Shigella, hepatitis A", "DISEASE", 187, 208], ["norovirus", "DISEASE", 213, 222], ["E. coli", "ORGANISM", 39, 46], ["Shigella, hepatitis A", "ORGANISM", 187, 208], ["JACK", "PROTEIN", 367, 371], ["E. coli", "SPECIES", 39, 46], ["E. coli", "SPECIES", 39, 46], ["Salmonella", "SPECIES", 175, 185], ["hepatitis A", "SPECIES", 197, 208], ["a food crisis", "PROBLEM", 5, 18], ["E. coli", "PROBLEM", 39, 46], ["the crisis", "PROBLEM", 90, 100], ["a food crisis", "PROBLEM", 111, 124], ["other bacteria", "PROBLEM", 140, 154], ["viruses", "PROBLEM", 158, 165], ["Salmonella", "PROBLEM", 175, 185], ["Shigella", "PROBLEM", 187, 195], ["hepatitis A", "PROBLEM", 197, 208], ["norovirus", "PROBLEM", 213, 222], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["viruses", "OBSERVATION", 158, 165], ["hepatitis", "OBSERVATION", 197, 206], ["norovirus", "OBSERVATION", 213, 222]]], ["The result also indicates the presence of a time lag effect, implying that the effect of recall execution became more salient over time.The effect of recall execution on negative spillover effectThis result unveils the role of recall execution in diminishing negative spillover effects on other firms.", [["a time lag effect", "PROBLEM", 42, 59], ["spillover effects", "OBSERVATION", 268, 285]]], ["Overall, JACK's ARs and CARs were more negative to restaurant events than those of non-restaurant events.", [["JACK", "PROTEIN", 9, 13], ["JACK's ARs", "TEST", 9, 19]]], ["The tables show the significance of difference between restaurant events and non-restaurant events.", [["non-restaurant events", "PROBLEM", 77, 98]]], ["Consistently, both parametric test (ANCOVA) and non-parametric test (Mann-Whitney U test) were performed to test the difference between restaurant events and non-restaurant events. * p < .05, ** p < .01, *** p < .001.The effect of recall execution on negative spillover effectnegative spillover from this event than from events without recalls, which emphasizes the important role of recall execution to other firms.Summary of findingsWhereas previous research has explored the negative spillover effect within the same brand family, this study extends the scope to negative spillovers from one firm to another unrelated firm.", [["both parametric test", "TEST", 14, 34], ["non-parametric test", "TEST", 48, 67], ["Whitney U test", "TEST", 74, 88], ["non-restaurant events", "PROBLEM", 158, 179], ["this study", "TEST", 534, 544], ["spillover effect", "OBSERVATION", 487, 503], ["firm", "OBSERVATION", 621, 625]]], ["Specifically, we anticipated that a firm with a crisis history may experience negative spillovers from unrelated crises, perhaps activated by consumer memory mechanisms and salient media reporting.", [["unrelated crises", "PROBLEM", 103, 119], ["firm", "OBSERVATION_MODIFIER", 36, 40]]], ["The results of this study showed negative spillovers on Jack in the Box up to the present, as evidenced by stock return movements (ARs and CARs) in response to the outbreak of unrelated food crises.", [["food crises", "DISEASE", 186, 197], ["this study", "TEST", 15, 25], ["unrelated food crises", "PROBLEM", 176, 197], ["spillovers", "OBSERVATION", 42, 52], ["food crises", "OBSERVATION", 186, 197]]], ["The negative spillover effect was influenced by time, the level of similarity in operation type (restaurant) and risk type (E. coli), and the recall execution.", [["E. coli", "ORGANISM", 124, 131], ["E. coli", "SPECIES", 124, 131], ["E. coli", "SPECIES", 124, 131], ["risk type (E. coli)", "PROBLEM", 113, 132], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["spillover effect", "OBSERVATION", 13, 29]]], ["The negative spillover was stronger (weaker) when the crisis occurred within 10 years of the outbreak (10-20 years after the outbreak), when the crisis was associated with a restaurant (non-restaurant), was related to E. coli (non-E. coli), and there was no recall execution (recall execution).DiscussionThis research is among the first to examine the long-term impact of a food crisis on a restaurant firm using the case of Jack in the Note: The figure and table show the significance of difference between JACK's responses (ARs and CARs) to events associated with E. coli (n = 34) and to events associated with non-E. coli (n = 39).", [["E. coli", "ORGANISM", 218, 225], ["non-E. coli", "ORGANISM", 227, 238], ["JACK", "GENE_OR_GENE_PRODUCT", 508, 512], ["E. coli", "ORGANISM", 566, 573], ["non-E. coli", "ORGANISM", 613, 624], ["JACK", "PROTEIN", 508, 512], ["E. coli", "SPECIES", 218, 225], ["non-E. coli", "SPECIES", 227, 238], ["E. coli", "SPECIES", 566, 573], ["non-E. coli", "SPECIES", 613, 624], ["E. coli", "SPECIES", 218, 225], ["non-E. coli", "SPECIES", 227, 238], ["E. coli", "SPECIES", 566, 573], ["non-E. coli", "SPECIES", 613, 624], ["the crisis", "PROBLEM", 50, 60], ["the crisis", "PROBLEM", 141, 151], ["E. coli (non-E. coli", "PROBLEM", 218, 238], ["E. coli", "PROBLEM", 566, 573], ["non-E. coli", "PROBLEM", 613, 624], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["spillover", "OBSERVATION", 13, 22], ["no", "UNCERTAINTY", 255, 257]]], ["Non-E. coli events include Salmonella, Shigella, hepatitis A, and norovirus.", [["Salmonella, Shigella, hepatitis A", "DISEASE", 27, 60], ["norovirus", "DISEASE", 66, 75], ["Non-E. coli", "ORGANISM", 0, 11], ["Shigella, hepatitis A", "ORGANISM", 39, 60], ["norovirus", "ORGANISM", 66, 75], ["Non-E. coli", "SPECIES", 0, 11], ["Non-E. coli", "SPECIES", 0, 11], ["Salmonella", "SPECIES", 27, 37], ["hepatitis A", "SPECIES", 49, 60], ["Non-E. coli events", "PROBLEM", 0, 18], ["Salmonella", "PROBLEM", 27, 37], ["Shigella", "PROBLEM", 39, 47], ["hepatitis A", "PROBLEM", 49, 60], ["norovirus", "PROBLEM", 66, 75], ["coli", "OBSERVATION", 7, 11], ["Salmonella", "OBSERVATION", 27, 37], ["Shigella", "OBSERVATION_MODIFIER", 39, 47], ["hepatitis", "OBSERVATION", 49, 58], ["norovirus", "OBSERVATION", 66, 75]]], ["Consistently, both parametric test (ANCOVA) and non-parametric test (Mann-Whitney U test) were performed to test the difference between E. coli and non-E. coli groups. * p < .05, ** p < .01, *** p < .001.DiscussionBox.", [["E. coli", "ORGANISM", 136, 143], ["non-E. coli", "ORGANISM", 148, 159], ["E. coli", "SPECIES", 136, 143], ["non-E. coli", "SPECIES", 148, 159], ["E. coli", "SPECIES", 136, 143], ["non-E. coli", "SPECIES", 148, 159], ["both parametric test", "TEST", 14, 34], ["non-parametric test", "TEST", 48, 67], ["Whitney U test", "TEST", 74, 88], ["E. coli", "PROBLEM", 136, 143], ["non-E. coli groups", "PROBLEM", 148, 166], ["coli groups", "OBSERVATION", 155, 166]]], ["This explanatory case study provides empirical evidence of negative spillover effects over a span of 18 years, indicating that a one-time food crisis may have long-term negative consequences on restaurant firms.", [["This explanatory case study", "TEST", 0, 27], ["negative spillover effects", "PROBLEM", 59, 85], ["negative spillover", "OBSERVATION", 59, 77]]], ["However, the negative spillover effect on Jack in the Box has decreased over time; time heals wounds, though not completely.", [["wounds", "ANATOMY", 94, 100], ["wounds", "PATHOLOGICAL_FORMATION", 94, 100], ["the negative spillover effect on Jack in the Box", "PROBLEM", 9, 57], ["time heals wounds", "PROBLEM", 83, 100], ["negative", "OBSERVATION_MODIFIER", 13, 21], ["spillover effect", "OBSERVATION", 22, 38], ["decreased", "OBSERVATION_MODIFIER", 62, 71], ["wounds", "OBSERVATION", 94, 100]]], ["Although Jack in the Box was thought to handle the crisis effectively, it is unlikely that the restaurant chain can recover completely from the crisis.", [["the crisis", "PROBLEM", 140, 150], ["crisis", "OBSERVATION", 51, 57]]], ["Time heals wounds but the scar remains.", [["wounds", "ANATOMY", 11, 17], ["scar", "ANATOMY", 26, 30], ["wounds", "PATHOLOGICAL_FORMATION", 11, 17], ["scar", "PATHOLOGICAL_FORMATION", 26, 30], ["Time heals wounds", "PROBLEM", 0, 17], ["the scar", "PROBLEM", 22, 30], ["wounds", "OBSERVATION", 11, 17], ["scar", "OBSERVATION", 26, 30]]], ["This study indicates the presence of negative spillovers on Jack in the Box, up to the present.", [["This study", "TEST", 0, 10], ["negative", "OBSERVATION_MODIFIER", 37, 45], ["spillovers", "OBSERVATION", 46, 56]]], ["Although the direct impact of its own E. coli outbreak event lasted less than five years, the negative spillover effect still has indirectly influenced Jack in the Box.DiscussionThis finding illuminates the severity of food crises on restaurant firms.", [["food crises", "DISEASE", 219, 230], ["E. coli", "ORGANISM", 38, 45], ["E. coli", "SPECIES", 38, 45], ["E. coli", "SPECIES", 38, 45], ["coli outbreak", "OBSERVATION", 41, 54], ["spillover effect", "OBSERVATION", 103, 119], ["severity", "OBSERVATION_MODIFIER", 207, 215], ["food crises", "OBSERVATION", 219, 230]]], ["It also evidences that consumers' brand evaluations tend to be heavily influenced by publicity, especially negative publicity, which is consistent with previous literature (Weinberger and Romeo, 1989; Weinberger et al., 1991) .DiscussionA positive message, however, for firms such as Jack in the Box comes from the time effect, which indicates that the negative spillover effect diminishes over time.", [["brand evaluations", "TEST", 34, 51], ["the negative spillover effect", "PROBLEM", 349, 378], ["consistent with", "UNCERTAINTY", 136, 151], ["spillover effect", "OBSERVATION", 362, 378]]], ["For example, Jack in the Box suffered less negative ARs and CARs after recent crises, between 2004 and 2010, compared to those between 1993 and 2003 .", [["recent crises", "PROBLEM", 71, 84], ["less", "OBSERVATION_MODIFIER", 38, 42], ["negative", "OBSERVATION", 43, 51]]], ["The findings provide useful cues to help crisis managers predict the severity and duration of their potential crises more accurately.", [["their potential crises", "PROBLEM", 94, 116]]], ["Although there are exceptional cases, in which restaurant firms have gone out of business due to a crisis (e.g., Note: The table shows the significance of difference between JACK's responses (ARs and CARs) to events that were accompanied with recall execution and events without recall execution.", [["JACK", "PROTEIN", 174, 178], ["a crisis", "PROBLEM", 97, 105]]], ["Consistently, both parametric test (ANCOVA) and non-parametric test (Mann-Whitney U test) were performed to test the difference between groups with recall and without recall. * p < .05, ** p < .01, *** p < .001.DiscussionChi-Chi's restaurant), the general trend is that negative spillovers subside over time.", [["both parametric test", "TEST", 14, 34], ["non-parametric test", "TEST", 48, 67], ["Whitney U test", "TEST", 74, 88]]], ["Thus, the current research indicates that time heals wounds somewhat but not completely.DiscussionHigh similarity leads to a strong negative spillover effect.", [["wounds", "ANATOMY", 53, 59], ["wounds", "PATHOLOGICAL_FORMATION", 53, 59], ["time heals wounds", "PROBLEM", 42, 59], ["wounds", "OBSERVATION", 53, 59], ["spillover effect", "OBSERVATION", 141, 157]]], ["Similarity amplifies the negative spillover effect.", [["negative", "OBSERVATION_MODIFIER", 25, 33], ["spillover effect", "OBSERVATION", 34, 50]]], ["This similarity effect, in terms of the magnitude and duration of negative spillovers on Jack in the Box, is consistent with previous literature (Janakiraman et al., 2009; Lei et al., 2008) , which asserts that greater similarity between a current event and a past event evokes a stronger psychological association, resulting in a more pronounced negative spillover effect.", [["a more pronounced negative spillover effect", "PROBLEM", 329, 372], ["effect", "OBSERVATION_MODIFIER", 16, 22], ["consistent with", "UNCERTAINTY", 109, 124], ["spillover effect", "OBSERVATION", 356, 372]]], ["Specifically, we found that similarity at the attribute level, such as operation type and risk type, affected the magnitude of the negative spillover effect on Jack in the Box (Broniarczyk and Alba, 1994; Roehm and Tybout, 2006) .", [["negative", "OBSERVATION", 131, 139], ["spillover effect", "OBSERVATION", 140, 156]]], ["Following the accessibility-diagnosticity framework (Feldman and Lynch, 1988) , the greater the similarity between a later crisis and the earlier Jack in the Box crisis, the stronger the negative spillover affects Jack in the Box.", [["Box", "DNA", 226, 229], ["a later crisis", "PROBLEM", 115, 129], ["the Box crisis", "PROBLEM", 154, 168], ["negative spillover", "OBSERVATION", 187, 205]]], ["Therefore, if a crisis occurs in another firm that is similar to the firm's past crisis, a crisis manager must engage in crisis management efforts.", [["a crisis", "PROBLEM", 14, 22], ["crisis", "PROBLEM", 81, 87], ["crisis management", "TREATMENT", 121, 138]]], ["This finding should help restaurant firms more effectively anticipate the magnitude of negative spillovers on their firms, depending on the level of similarity between a food crisis and their own crisis.DiscussionA firm's recall execution reduces negative spillover on other firms.", [["a food crisis", "PROBLEM", 168, 181]]], ["The positive effect of recall execution provides evidence on the indirect influence of a firm's recall announcement which reduces the negative spillover on other firms.", [["recall execution", "TEST", 23, 39], ["positive effect", "OBSERVATION_MODIFIER", 4, 19], ["negative spillover", "OBSERVATION", 134, 152]]], ["Although the current study did not examined the direct relationship between recall execution and negative spillover, the results of CARs responding to recall execution imply that stock returns are positively influenced by others' recall announcements.", [["the current study", "TEST", 9, 26]]], ["When a hospitality firm announces a recall strategy, the recall is perceived as positive by investors which positively influence the market evaluation of other firms in the hospitality industry.", [["the market evaluation", "TEST", 129, 150]]], ["Given the positive consequences of recall execution, effective communication among hospitality firms during crises becomes more crucial to protect each other during one's crisis.DiscussionTime-lag effect is detected in the pattern of negative spillover.", [["crises", "PROBLEM", 108, 114], ["lag effect", "PROBLEM", 193, 203], ["negative spillover", "OBSERVATION", 234, 252]]], ["One interesting finding is that the significant differences between two groups tend to be found after a certain length of time rather than immediately, which is called \"time-lag effect\" (Gail, 2005) .", [["significant", "OBSERVATION_MODIFIER", 36, 47]]], ["Such intensified impact of crises was detected earlier by Chen et al. (2007) , supporting that the negative influence of SARS on stock prices was worse after 20 days than those of after 10 days since the outbreak.", [["SARS", "DISEASE", 121, 125], ["crises", "PROBLEM", 27, 33], ["SARS on stock prices", "TREATMENT", 121, 141], ["crises", "OBSERVATION", 27, 33]]], ["The authors noted that the impact of a foodborne illness outbreak is intensified because of the increasing number of illnesses or deaths over time.", [["foodborne illness", "DISEASE", 39, 56], ["deaths", "DISEASE", 130, 136], ["a foodborne illness outbreak", "PROBLEM", 37, 65], ["increasing", "OBSERVATION_MODIFIER", 96, 106], ["number", "OBSERVATION_MODIFIER", 107, 113]]], ["The finding of this study also supported that the negative spillover tends to be gradually influencing other firms' stock price movements over a period of time.DiscussionThe tendency may be explained using social amplification theory which argues that crises often evoke public fear and outrage (Sandman, 1993) .", [["this study", "TEST", 15, 25], ["spillover", "OBSERVATION", 59, 68]]], ["The anger and outrage toward a firm can be amplified over time, which drives crisis managers to be unable to recover from a crisis.", [["a crisis", "PROBLEM", 122, 130], ["firm", "OBSERVATION", 31, 35]]], ["Considering the presence of time-lag effect caused by other firms' food crises, the impacts are more likely to gradually spread and amplify.", [["other firms' food crises", "PROBLEM", 54, 78], ["food crises", "OBSERVATION", 67, 78], ["more likely", "UNCERTAINTY", 96, 107]]], ["Acknowledging the possible presence of negative spillover effect may enable crisis managers to better prepare crisis communication strategies to prevent negative spillover from others' crises.Theoretical contributions and practical implicationsThis study contributes to crisis management literature in several important ways.", [["negative spillover effect", "PROBLEM", 39, 64], ["communication strategies", "TREATMENT", 117, 141], ["negative spillover from others' crises", "PROBLEM", 153, 191], ["This study", "TEST", 244, 254], ["crisis management", "TREATMENT", 270, 287], ["spillover effect", "OBSERVATION", 48, 64]]], ["The major contribution of the study is to uncover the presence of negative spillover effect on hospitality firms with past history, which extends the existing theoretical frameworks on hospitality crisis management.", [["the study", "TEST", 26, 35], ["hospitality crisis management", "TREATMENT", 185, 214], ["negative", "OBSERVATION_MODIFIER", 66, 74], ["spillover effect", "OBSERVATION", 75, 91]]], ["The present study shed lights on the hidden long-term impacts from food crises on hospitality firms by providing empirical results opposing the widely known successful story of Jack in the Box.", [["The present study", "TEST", 0, 17], ["long-term", "OBSERVATION_MODIFIER", 44, 53]]], ["Whether a firm has a past crisis history is considered a critical factor in Situational crisis communication theory (SCCT), influencing the type of appropriate crisis response strategies (Coombs, 2004) .", [["firm", "OBSERVATION_MODIFIER", 10, 14]]], ["Considering that the SCCT model deals with the crisis of own company, the model can be extended by including factors influencing the negative spillover from others' crises.", [["the negative spillover from others' crises", "PROBLEM", 129, 171], ["negative spillover", "OBSERVATION", 133, 151]]], ["Moreover, unlike previous research focusing on short-term impacts of crises, the examination on the long-term impact of crisis enriches the crisisrelated hospitality literature.", [["crises", "PROBLEM", 69, 75], ["the examination", "TEST", 77, 92], ["crisis", "PROBLEM", 120, 126], ["short-term impacts", "OBSERVATION_MODIFIER", 47, 65], ["crises", "OBSERVATION", 69, 75]]], ["The idea of negative spillover effect in a long-term perspective can be further applied to other crises threatening the hospitality industry such as natural disasters and business fraud.", [["a long-term perspective", "TREATMENT", 41, 64], ["negative", "OBSERVATION_MODIFIER", 12, 20], ["spillover effect", "OBSERVATION", 21, 37]]], ["In addition, the magnitude of negative spillover effect may differ depending on the type of crises, which may be a focus for future research.Theoretical contributions and practical implicationsThe current study extends the usage of event study method.", [["negative spillover effect", "PROBLEM", 30, 55], ["crises", "PROBLEM", 92, 98], ["The current study", "TEST", 193, 210], ["event study method", "TEST", 232, 250], ["negative", "OBSERVATION", 30, 38], ["spillover effect", "OBSERVATION", 39, 55]]], ["While previous research used changes in sales revenue or consumer behavioral intentions as the indicator of impacts of crises (Lei et al., 2008; Roehm and Tybout, 2006; van Heerde et al., 2007) , this study adopted the ESM and provided empirical evidence of the impact of food crises on a firm's stock prices.", [["crises", "PROBLEM", 119, 125], ["this study", "TEST", 196, 206], ["food crises", "PROBLEM", 272, 283], ["a firm's stock prices", "TREATMENT", 287, 308]]], ["Moreover, the current study also proves that event study method can be used for examining the long-term impacts of events not only the short-term events.", [["the current study", "TEST", 10, 27], ["the short-term events", "PROBLEM", 131, 152]]], ["While previous research introduced the event study method as a useful tool for short-term events (Chen et al., 2007; Chang and Zeng, 2011) , the method can be an instrument examining long-term impacts of events.Theoretical contributions and practical implicationsThe present study also offers practical implications to restaurant crisis managers.", [["short-term events", "PROBLEM", 79, 96], ["The present study", "TEST", 263, 280]]], ["Others' crises can be a severe threat if a firm has a crisis history.", [["firm", "OBSERVATION", 43, 47]]], ["Restaurant crisis managers should first identify the magnitude of the predicted negative spillover by examining the similarity of the ongoing crisis with their own crisis history, in terms of operation or crisis type.", [["the ongoing crisis", "PROBLEM", 130, 148], ["crisis type", "PROBLEM", 205, 216]]], ["In addition, they should examine the seriousness of the crisis, which could drive negative publicity threatening firms during a time of crises.", [["the crisis", "PROBLEM", 52, 62], ["crises", "PROBLEM", 136, 142]]], ["If a firm has a pre-developed crisis management plan, crisis managers should conduct appropriate crisis management strategies, such as communicating with the media and the public.", [["a pre-developed crisis management", "TREATMENT", 14, 47], ["crisis managers", "TREATMENT", 54, 69], ["appropriate crisis management strategies", "TREATMENT", 85, 125], ["firm", "OBSERVATION_MODIFIER", 5, 9]]], ["Because social media has become a key businessto-customer communication tool, crisis managers could consider using this method to avoid possible negative spillovers from others' food crises.", [["this method", "TREATMENT", 115, 126], ["negative spillovers", "PROBLEM", 145, 164]]], ["Considering the importance of firms' responses to crises (Siomkos, 1999; Siomkos and Shrivartara, 1993) , performing an immediate crisis response may be a key strategy in successful crisis management.Theoretical contributions and practical implicationsFirms developing pre-and post-crisis management strategies can implement practical methods, such as a simulation-based scenario method.", [["crises", "PROBLEM", 50, 56], ["successful crisis management", "TREATMENT", 171, 199], ["pre-and post-crisis management", "TREATMENT", 269, 299], ["practical methods", "TREATMENT", 325, 342], ["a simulation-based scenario method", "TREATMENT", 352, 386]]], ["Medical and health care researchers have developed a simulation-based curriculum for clinical education and training in response to crises (Gaba et al., 2001; Gaba, 2004) , and radiology crisis management researchers have developed a computerized realistic simulation (Sica et al., 1999) .", [["clinical education", "TREATMENT", 85, 103], ["crises", "PROBLEM", 132, 138]]], ["Using scenario-based crisis management strategies to train managers may enable restaurant and hotel managers to deal more appropriately with an unexpected crisis.", [["scenario-based crisis management", "TREATMENT", 6, 38], ["an unexpected crisis", "PROBLEM", 141, 161]]], ["In developing crisis scenarios, case studies may be especially effective as a means to predict diverse crisis situations and suggest appropriate response strategies.", [["developing crisis scenarios", "PROBLEM", 3, 30], ["case studies", "TEST", 32, 44], ["diverse crisis situations", "PROBLEM", 95, 120], ["crisis scenarios", "OBSERVATION", 14, 30]]], ["This unique advertising strategy helped it recover from its tainted brand image and might be useful when applied to other restaurant brands that suffer ill effects from rumors, hoaxes, and negative publicity.", [["ill effects from rumors", "PROBLEM", 152, 175], ["negative publicity", "OBSERVATION", 189, 207]]], ["Chien and Law (2003) also investigated the responses of Hong Kong hotels to the SARS outbreak in March 2003, which provided good examples of appropriate responses by hotels during crises.", [["SARS", "DISEASE", 80, 84]]], ["Case studies offer various examples to use in developing scenario-based crisis management strategies.", [["Case studies", "TEST", 0, 12], ["crisis management strategies", "TREATMENT", 72, 100]]], ["In this sense, the current study provides essential guidelines for restaurant crisis managers by not only warning of the danger of food crises but also offering response strategies when others experience their own crises.Theoretical contributions and practical implicationsConsidering the immense impact of food crises, managers should pay more attention when determining their firms' branding strategy.", [["the current study", "TEST", 15, 32], ["response strategies", "TREATMENT", 161, 180], ["their own crises", "PROBLEM", 204, 220]]], ["Restaurant firms should consider their branding strategy as a marketing tool that can not only increase brand awareness but also protect brands in case of crises (Rao et al., 2004) .", [["crises", "PROBLEM", 155, 161]]], ["Although corporate branding can be an effective strategy to facilitate brand awareness, it also can endanger the whole brand family when faced with a crisis.", [["a crisis", "PROBLEM", 148, 156]]], ["Although Jack in the Box's crisis was a severe event, the images of other brands were not negatively influenced, because Foodmaker used the house-of-brand strategy causing weak associations among brands.", [["a severe event", "PROBLEM", 38, 52], ["severe", "OBSERVATION_MODIFIER", 40, 46]]], ["If the parent company had used a corporate branding strategy, the results of the crisis might have been more severe.Limitations and recommendations for future studiesAlthough this study makes several important theoretical and practical contributions, it is not without limitations.", [["a corporate branding strategy", "TREATMENT", 31, 60], ["the crisis", "PROBLEM", 77, 87], ["future studies", "TEST", 152, 166], ["this study", "TEST", 175, 185], ["more severe", "OBSERVATION_MODIFIER", 104, 115], ["not without", "UNCERTAINTY", 257, 268]]], ["First, a case study approach limits the generalizability of these findings to other firms.", [["a case study approach", "TEST", 7, 28]]], ["By demonstrating the presence of negative spillovers on Jack in the Box, this study provides a snapshot of the impact of food crises on restaurant firms.", [["this study", "TEST", 73, 83], ["negative", "OBSERVATION_MODIFIER", 33, 41], ["spillovers", "OBSERVATION", 42, 52]]], ["Second, in addition to stock prices, there are other potential measures of the impact of a crisis on firms, such as return on assets, return on investment, or consumer perceptions.", [["stock prices", "TREATMENT", 23, 35], ["a crisis on firms", "PROBLEM", 89, 106], ["stock prices", "OBSERVATION", 23, 35]]], ["Although stock prices are immediate and direct measures, further studies may adopt other approaches to clarify the long-term impact of food crises on restaurant firms.Limitations and recommendations for future studiesConsidering that the current study only focused on food crises, future research may focus on other types of crises such as natural disaster, human-caused accidents, or business fraud.", [["accidents", "DISEASE", 371, 380], ["human", "ORGANISM", 358, 363], ["human", "SPECIES", 358, 363], ["human", "SPECIES", 358, 363], ["direct measures", "TREATMENT", 40, 55], ["further studies", "TEST", 57, 72], ["future studies", "TEST", 203, 217], ["the current study", "TEST", 234, 251], ["crises", "PROBLEM", 325, 331], ["long-term", "OBSERVATION_MODIFIER", 115, 124]]], ["For instance, hotel industry has suffered from an accident like MGM Grand fire in Las Vegas in 1980 which killed 85 people, and 9/11 crisis from terrorist attacks in 2001 resulting in almost 3000 deaths (Stafford et al., 2002) .", [["deaths", "DISEASE", 196, 202], ["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122]]], ["The enhanced understanding on the impacts of such crises on hospitality industry may help crisis managers design effective crisis communication strategies.", [["communication strategies", "TREATMENT", 130, 154]]], ["In terms of methodology, one method of examining the impact of crises on firms may be a longitudinal study which enables researchers to compare consumers' intentions before and after the outbreak of crises.", [["crises", "PROBLEM", 63, 69], ["a longitudinal study", "TEST", 86, 106], ["crises", "PROBLEM", 199, 205]]], ["Despite the difficulty of conducting a longitudinal study, the method may overcome the limitation of the manipulated nature of scenario-based survey by maximizing the reality of survey.", [["a longitudinal study", "TEST", 37, 57]]], ["Lastly, although the current study used only one company, Jack in the Box, future studies may select more than one hospitality company that had similar crises in the past.", [["the current study", "TEST", 17, 34], ["future studies", "TEST", 75, 89], ["similar", "OBSERVATION_MODIFIER", 144, 151], ["crises", "OBSERVATION", 152, 158]]], ["For example, there were a number of hospitality companies suffered from foodborne illnesses such as salmonella and E. coli.", [["foodborne illnesses such as salmonella and E. coli", "DISEASE", 72, 122], ["E. coli", "ORGANISM", 115, 122], ["E. coli", "SPECIES", 115, 122], ["E. coli", "SPECIES", 115, 122], ["foodborne illnesses", "PROBLEM", 72, 91], ["salmonella", "PROBLEM", 100, 110], ["E. coli", "PROBLEM", 115, 122], ["foodborne illnesses", "OBSERVATION", 72, 91], ["E. coli", "OBSERVATION", 115, 122]]], ["The use of ESM along with the focus on other types of crises may enrich the existing crisis-related hospitality research.", [["crises", "PROBLEM", 54, 60]]]], "ccd7968e1854e90d9786a4734498b2d3fa3856e9": [["In conclusion, further studies are needed to address this specific aspect of overall health and to try to recalibrate STDs prevention and treatment services during the pandemic.", [["STDs", "DISEASE", 118, 122], ["further studies", "TEST", 15, 30], ["STDs prevention", "TREATMENT", 118, 133], ["treatment services", "TREATMENT", 138, 156]]], ["Dedicated multidisciplinary questionnaires regarding sexual behaviors should be implemented, as it has already happened in some high-rate HIV/AIDS countries, 8 as well as COVID-19 serology among asymptomatic STDs patients.CONFLICT OF INTERESTThe authors declare no conflict of interest.AUTHOR CONTRIBUTIONSValeria Gaspari, Beatrice Raone, Federico Bardazzi, and Anna Lanzoni contributed to the letter conception and design.", [["AIDS", "DISEASE", 142, 146], ["STDs", "DISEASE", 208, 212], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["HIV", "SPECIES", 138, 141], ["sexual behaviors", "PROBLEM", 53, 69], ["COVID", "TEST", 171, 176], ["Gaspari", "TREATMENT", 314, 321], ["Federico Bardazzi", "TREATMENT", 339, 356], ["Anna Lanzoni", "TREATMENT", 362, 374]]], ["The first draft of the manuscript was written by Valeria Gaspari, Gionathan Orioni, and Filippo Viviani.", [["Gionathan Orioni", "TREATMENT", 66, 82], ["Filippo Viviani", "TREATMENT", 88, 103]]]], "eb8ad60756a2a49167148a0e754b5c6d615a5171": [["Seuche -ein Kommunikationsph\u00e4nomenDie Differenzierung von Kommunikation zwischen Anwesenden und Abwesenden hat in diesen Ostertagen des Jahres \uf63a\uf639\uf63a\uf639 eine sehr allt\u00e4gliche Plausibilit\u00e4t gewonnen.", [["Seuche -ein Kommunikationsph\u00e4nomenDie Differenzierung von Kommunikation zwischen Anwesenden und Abwesenden hat in diesen Ostertagen des Jahres \uf63a\uf639\uf63a\uf639 eine sehr allt\u00e4gliche Plausibilit\u00e4t gewonnen", "SPECIES", 0, 192], ["Seuche -ein Kommunikationsph\u00e4nomenDie", "TREATMENT", 0, 37], ["diesen Ostertagen des", "TREATMENT", 114, 135]]], ["\"Seuche\" -das ist in mehrfacher Hinsicht ein Ph\u00e4nomen der Kommunikation:Seuche -ein Kommunikationsph\u00e4nomen\uf6dc.", [["Seuche -ein Kommunikationsph\u00e4nomen\uf6dc", "TREATMENT", 72, 107]]], ["Als Metakommunikation werden Vorstellungen und Theorien von der kommunizierbaren und kommunizierten Krankheitsmaterie entwickelt, modifiziert und verworfen. \uf63c.", [["Als Metakommunikation", "PROBLEM", 0, 21]]], ["Damit begr\u00fcndet wird die Reorganisation der Interaktion mit dem Ziel, das Kommunizieren der Erkrankung (\"die Ansteckung\") auszuschlie\u00dfen. \uf63d.", [["Damit begr\u00fcndet wird die Reorganisation der Interaktion mit dem Ziel, das Kommunizieren der Erkrankung (\"die Ansteckung\") auszuschlie\u00dfen", "SPECIES", 0, 136]]], ["Der somit begr\u00fcndete Verzicht auf zentrale Sozialisationsinstanzen vom feierlichen Begr\u00e4bnis bis zum samst\u00e4glichen Shopping, f\u00fchrt zu einer Krisenkommunikation.Sterben und \u00dcberlebenAm Anfang jeder Seuche steht das gro\u00dfe Sterben.", [["Der somit begr\u00fcndete Verzicht auf zentrale Sozialisationsinstanzen vom feierlichen Begr\u00e4bnis bis zum samst\u00e4glichen Shopping, f\u00fchrt zu einer Krisenkommunikation", "SPECIES", 0, 159], ["Verzicht auf zentrale", "TREATMENT", 21, 42], ["Sterben", "TREATMENT", 160, 167]]], ["Dabei ist es unerheblich, ob sich post factum herausstellt, dass ganz andere Todesursachen in einem bestimmten Zeitabschnitt de facto h\u00e4ufiger waren.", [["dass ganz", "TREATMENT", 60, 69], ["ob", "ANATOMY", 26, 28]]], ["Die Seuchengeschichte ist bislang zu wenig als Teil der Geschichte der Katastrophen und ihrer Kommunikation betrachtet worden (Jankrift \uf63a\uf639\uf639\uf63b) .", [["Die Seuchengeschichte ist bislang zu wenig als Teil der Geschichte der Katastrophen und ihrer Kommunikation betrachtet worden", "SPECIES", 0, 125], ["Seuchengeschichte ist bislang", "TREATMENT", 4, 33]]], ["W\u00fcrden wir uns ernsthafter mit der Wahrnehmung und Kommunikation der Zeitgenossen befassen, k\u00e4me auch mittelalterliches Seuchen-als kommunikatives Geschehen massenhaft wieder ins Bild.", [["W\u00fcrden wir uns ernsthafter mit der Wahrnehmung und Kommunikation der Zeitgenossen befassen, k\u00e4me auch mittelalterliches Seuchen-als kommunikatives Geschehen massenhaft wieder ins Bild", "SPECIES", 0, 183]]], ["G\u00e4ngige \u00dcberblickswerke verbreiten das falsche Bild, zwischen der \"Justinianischen Pest\" im \uf63e.", [["G\u00e4ngige \u00dcberblickswerke verbreiten das falsche Bild, zwischen der \"Justinianischen Pest\" im \uf63e.", "SPECIES", 0, 94]]], ["Jahrhundert, die auch als \"Ende der Antike\" gedeutet wurde, und dem \"schwarzen Tod\" in der Mitte des \uf6dc\uf63c.", [["auch als \"Ende der Antike\" gedeutet wurde, und dem \"schwarzen Tod\" in der Mitte des \uf6dc\uf63c", "SPECIES", 17, 103]]], ["Jahrhunderts, der seinerseits den Beginn eines Endes des Mittelalters markiert, h\u00e4tten keine \"Seuchen\" stattgefunden, weil zu selten von der uns vermeintlich bekannten \"Pest\" die Rede ist (Jankrift \uf63a\uf639\uf639\uf63d; Jankrift \uf63a\uf639\uf63a\uf639).Sterben und \u00dcberlebenMassenhaftes Sterben war in der langen Vormoderne ein in allen Generationen bekanntes Ph\u00e4nomen.", [["der seinerseits den Beginn eines Endes des Mittelalters markiert, h\u00e4tten keine \"Seuchen\" stattgefunden, weil zu selten von der uns vermeintlich bekannten \"Pest\" die Rede ist (Jankrift \uf63a\uf639\uf639\uf63d; Jankrift \uf63a\uf639\uf63a\uf639", "SPECIES", 14, 217]]], ["\u00dcbliche Todesursache: Hunger.", [["Hunger", "PROBLEM", 22, 28], ["Hunger", "OBSERVATION", 22, 28]]], ["Sowohl mit Seuchen als auch mit Hunger stets in einem Zug ist vor allem f\u00fcr die Fr\u00fche Neuzeit der Krieg zu nennen -drei apokalyptische Reiter (Cunningham & Grell \uf63a\uf639\uf639\uf639) .", [["Sowohl mit Seuchen als auch mit Hunger stets in einem Zug ist vor allem f\u00fcr die Fr\u00fche Neuzeit der Krieg zu nennen -drei apokalyptische Reiter (Cunningham & Grell \uf63a\uf639\uf639\uf639)", "SPECIES", 0, 167]]], ["Tief in die kollektive Erinnerung eingedrungen ist der Zusammenhang insbesondere im Zusammenhang mit dem Drei\u00dfigj\u00e4hrigen Krieg (B\u00e4hr \uf63a\uf639\uf6dc\uf63b).Sterben und \u00dcberlebenDass mangelern\u00e4hrte Menschen, untergebracht in erb\u00e4rmlichen Behausungen, leicht Opfer von (Infektions-) Krankheiten werden, sich unter diesen Bedingungen schwerere Verl\u00e4ufe einstellen und erheblich h\u00f6here Todesraten, war bereits im \uf6dc\uf63e.", [["kollektive Erinnerung eingedrungen ist der Zusammenhang insbesondere im Zusammenhang mit dem Drei\u00dfigj\u00e4hrigen Krieg (B\u00e4hr \uf63a\uf639\uf6dc\uf63b)", "SPECIES", 12, 138]]], ["Das Z\u00e4hlen macht den Unterschied als Wahrnehmungsund kommunikative Praxis der Kontingenzbeherrschung.Sterben und \u00dcberlebenEin davon abweichendes Bild bietet die Influenza-Epidemie \uf6dc\uf641\uf6dc\uf640-\uf6dc\uf641\uf63a\uf639 in weiten Teilen Deutschlands (Rengeling \uf63a\uf639\uf6dc\uf63f) , die erst in der historischen Betrachtung zur \"skandalisierten\" Seuche gemacht wurde.", [["Influenza", "PROBLEM", 161, 170]]], ["Das Geschehen l\u00e4sst sich nur vor Ort studieren, und erneut wurde in Stadt und Land sehr unterschiedlich gez\u00e4hlt (Angerer et al. \uf63a\uf639\uf6dc\uf641; Witte \uf63a\uf639\uf6dc\uf640; Thie\u00dfen \uf63a\uf639\uf6dc\uf63e).Sterben und \u00dcberlebenDie Medizingeschichte ist weitgehend davon abgekommen, historisches Massensterben auf dem Wege der \"retrospektiven Diagnose\" unbek\u00fcmmert modernen Krankheitsbegriffen zuzuordnen (Krischel \uf63a\uf639\uf6dc\uf641; Metzger \uf63a\uf639\uf6dc\uf63c; Cohn \uf63a\uf639\uf6dc\uf63b).", [["Sterben und \u00dcberlebenDie Medizingeschichte ist weitgehend davon abgekommen, historisches Massensterben auf dem Wege der \"retrospektiven Diagnose\" unbek\u00fcmmert modernen Krankheitsbegriffen zuzuordnen (Krischel \uf63a\uf639\uf6dc\uf641; Metzger \uf63a\uf639\uf6dc\uf63c; Cohn \uf63a\uf639\uf6dc\uf63b", "SPECIES", 160, 397], ["Krankheitsbegriffen zuzuordnen (Krischel \uf63a\uf639\uf6dc\uf641", "TREATMENT", 327, 372]]], ["Allerdings sind Vorg\u00e4nge, f\u00fcr die sich keinerlei Analogien im zeitgen\u00f6ssischen terminologischen Apparat finden, gr\u00f6\u00dftenteils nicht untersucht, wie etwa der r\u00e4tselhafte N\u00fcrnberger \"portzel\", dessen Todesopfer f\u00fcr das Jahr \uf6dc\uf63c\uf640\uf63b mit \u00fcber \uf63c\uf639\uf639\uf639 in der Chronistik vermerkt wurden (Dross \uf63a\uf639\uf6dc\uf63e).Sterben und \u00dcberlebenIn der langen Geschichte der Vormoderne waren Menschen indes \u00fcblicherweise \u00dcberlebende von Seuchen -jede \uf63c\uf639-j\u00e4hrige Person hatte wohl mindestens zwei schwere \"Sterbsl\u00e4ufte\" \u00fcberlebt.", [["Sterben und \u00dcberleben", "SPECIES", 287, 308]]], ["Die Geschichtswissenschaft hat sich dem Aspekt des \u00dcberlebens von Seuchen bislang nicht hinreichend gewidmet (Henderson \uf63a\uf639\uf6dc\uf641) .", [["Die Geschichtswissenschaft hat sich dem Aspekt des \u00dcberlebens von Seuchen bislang nicht hinreichend gewidmet (Henderson \uf63a\uf639\uf6dc\uf641)", "SPECIES", 0, 125]]], ["Jahrhundert dagegen unvorbereitet, alle Strategien der (post-?) modernen \"Risikogesellschaft\" versagen (Contzen et al. \uf63a\uf639\uf6dc\uf640).Gesund und krank\"Infektionstheorien\" unterlaufen herk\u00f6mmliche Begriffe von \"gesund\" und \"krank\".", [["Gesund und krank\"Infektionstheorien\" unterlaufen herk\u00f6mmliche Begriffe von \"gesund\" und \"krank", "SPECIES", 125, 219]]], ["Infektionstheorien erzeugen also soziale Unsicherheit, um sie anschlie\u00dfend zu erkl\u00e4ren.", [["Infektionstheorien erzeugen", "TREATMENT", 0, 27]]], ["Das Sprechen dar\u00fcber im Duktus des Krieges und die exzeptionelle Dramatik eines \"unsichtbaren Feindes\" (Gradmann \uf63a\uf639\uf639\uf63f; Berger Ziauddin \uf63a\uf639\uf639\uf641) kam mit der Bakteriologie zum Ende des \uf6dc\uf641.", [["Das Sprechen dar\u00fcber im Duktus des Krieges und die exzeptionelle Dramatik eines \"unsichtbaren Feindes\" (Gradmann \uf63a\uf639\uf639\uf63f; Berger Ziauddin \uf63a\uf639\uf639\uf641) kam mit der Bakteriologie zum Ende des \uf6dc\uf641", "SPECIES", 0, 182], ["Das Sprechen dar\u00fcber im Duktus des", "TREATMENT", 0, 34]]], ["Jahrhunderts in die Medizin.", [["Medizin", "TREATMENT", 20, 27]]], ["Dort werden auch Visualisierungsstrategien deutlich, die dem unsichtbaren Feind einen K\u00f6rper und ein Gesicht geben (Sarasin \uf63a\uf639\uf639\uf63c).Gesund und krankVergesellschaftung unter Ansteckenden -f\u00fcr eine K\u00f6rpergeschichte der Seuche Forum Die Vormoderne verf\u00fcgte \u00fcber den Begriff eines \"Miasma\" im Sinne einer Unreinheit, Befleckung oder auch F\u00e4rbung, der fortwirkt.", [["Dort werden auch Visualisierungsstrategien deutlich, die dem unsichtbaren Feind einen K\u00f6rper und ein Gesicht geben", "SPECIES", 0, 114], ["Vergesellschaftung unter Ansteckenden -f\u00fcr eine K\u00f6rpergeschichte der Seuche Forum Die Vormoderne verf\u00fcgte \u00fcber den Begriff eines \"Miasma\" im Sinne einer Unreinheit, Befleckung oder auch F\u00e4rbung, der fortwirkt", "SPECIES", 146, 354]]], ["Aus dem individuellen Makel, der die Gemeinschaft, speziell die Gemeinschaft mit Gott sch\u00e4digte, konnte abstrahierend eine ung\u00fcnstige Eigenschaft der Luft gewonnen werden, die das gleichzeitige Erkranken mehrerer Personen innerhalb eines Bezirks gut erkl\u00e4rte (Potter \uf63a\uf639\uf639\uf63d; Gudermann \uf63a\uf639\uf639\uf640) .", [["Aus dem individuellen Makel, der die Gemeinschaft, speziell die Gemeinschaft mit Gott sch\u00e4digte, konnte abstrahierend eine ung\u00fcnstige Eigenschaft der Luft gewonnen werden, die das gleichzeitige Erkranken mehrerer Personen innerhalb eines Bezirks gut erkl\u00e4rte (Potter \uf63a\uf639\uf639\uf63d; Gudermann \uf63a\uf639\uf639\uf640", "SPECIES", 0, 287]]], ["Erg\u00e4nzend konnte ein durch Ber\u00fchrung oder die Luft vermitteltes \"Kontagium\" im Sinne eines Ansteckungsgifts konkretisiert werden (Leven \uf63a\uf639\uf639\uf63d) .", [["Erg\u00e4nzend konnte ein durch Ber\u00fchrung oder die Luft vermitteltes \"Kontagium\" im Sinne eines Ansteckungsgifts konkretisiert werden (Leven \uf63a\uf639\uf639\uf63d)", "SPECIES", 0, 141], ["Erg\u00e4nzend konnte ein durch", "TREATMENT", 0, 26]]], ["Insbesondere von Exkrementen und den Pestleichen, aber auch aus den K\u00f6rpern der Erkrankten konnte erneut eine Luftverunreinigung an die Umgebung kommuniziert werden.", [["Insbesondere von Exkrementen und den Pestleichen, aber auch aus den K\u00f6rpern der Erkrankten konnte erneut eine Luftverunreinigung an die Umgebung kommuniziert werden", "SPECIES", 0, 164]]], ["Kultisch-rituell begr\u00fcndete Ber\u00fchrungsverbote sind von einer \"medizinischen\" Ansteckungstheorie nicht trennscharf zu scheiden.Gesund und krankUnabh\u00e4ngig von der jeweils zu Grunde gelegten \u00dcbertragungstheorie figuriert der Ansteckungsstoff vom Krankheitssamen der Vormoderne bis zu Bakterium und Virus der Moderne \u00fcber die Jahrhunderte als das im fremden K\u00f6rper versteckte Andere.", [["Unabh\u00e4ngig von der jeweils zu Grunde gelegten \u00dcbertragungstheorie figuriert der Ansteckungsstoff vom Krankheitssamen der Vormoderne bis zu Bakterium und Virus der Moderne \u00fcber die Jahrhunderte als das im fremden K\u00f6rper versteckte Andere", "SPECIES", 142, 378], ["Kultisch", "TREATMENT", 0, 8], ["Unabh\u00e4ngig von der jeweils", "TREATMENT", 142, 168], ["Krankheitssamen der Vormoderne bis zu Bakterium", "TREATMENT", 243, 290]]], ["Der erste Versuch jeder Seuchenpolizei gilt dem Verhindern des Zuzugs von au\u00dfen.", [["Der erste Versuch jeder Seuchenpolizei gilt dem Verhindern des Zuzugs von au\u00dfen", "SPECIES", 0, 79], ["Der erste Versuch jeder Seuchenpolizei gilt dem", "TREATMENT", 0, 47]]], ["Das schafft Identit\u00e4t bis in die Papierform -die seit dem \uf6dc\uf63e.", [["schafft Identit\u00e4t bis", "CHEMICAL", 4, 25]]], ["Jahrhundert ausgestellten, gepr\u00fcften (und bald auch gef\u00e4lschten) Zeugnisse, aus einer \"unverd\u00e4chtigen\" Gegend angereist zu kommen, k\u00f6nnen als ma\u00dfgebliche Vorl\u00e4ufer moderner Identit\u00e4tsausweise gelten (Groebner \uf63a\uf639\uf639\uf63c) .Gesund und krankBemerkenswert ist die seit Jahrhunderten beobachtbare Fokussierung auf medizinische Spezialexpertise bei der Umgestaltung \u00f6ffentlicher Ordnung.", [["Gesund und krankBemerkenswert ist die seit Jahrhunderten beobachtbare Fokussierung auf medizinische Spezialexpertise bei der Umgestaltung \u00f6ffentlicher Ordnung", "SPECIES", 216, 374]]], ["Deutlich wird dies erst werden, wenn Normsetzung als soziale Praxis der Autorisierung einerseits analysiert wird, vor allem aber deren Praxis in Akzeptanz, Resilienz und Renitenz pr\u00e4ziser gezeichnet sind (Ulbricht \uf63a\uf639\uf639\uf63c: \uf63b\uf63e-\uf63d\uf641; Dinges \uf6dc\uf641\uf641\uf63d: \uf640\uf63d-\uf641\uf63f).Gesund und krankSeuchenkommunikation erlaubt \u00fcber die Jahrhunderte die Analyse eines Metaordnungsprinzips \"Gesundheit\", das andere, sonst als zentral geltende Ordnungskriterien wie \"Gerechtigkeit\" oder \"Freiheit\" situativ dominiert, ohne in den herrschenden Ordnungsdiskursen, der jeweiligen Gesellschaftstheorie expliziert zu sein.", [["Resilienz und Renitenz pr\u00e4ziser gezeichnet sind (Ulbricht \uf63a\uf639\uf639\uf63c: \uf63b\uf63e-\uf63d\uf641; Dinges \uf6dc\uf641\uf641\uf63d: \uf640\uf63d-\uf641\uf63f)", "SPECIES", 156, 246], ["Deutlich wird dies erst werden", "PROBLEM", 0, 30], ["Akzeptanz", "TREATMENT", 145, 154], ["Resilienz", "TREATMENT", 156, 165]]], ["Pr\u00e4vention als Verhaltenssteuerung und sozialr\u00e4umliche Organisation indes beginnt mit der antiken Di\u00e4tetik und war als obrigkeitliche Politik auch vor dem \"schwarzen Tod\" bereits g\u00e4ngig (Geltner \uf63a\uf639\uf6dc\uf641) .Gesund und krankSeuchenpolizei aber bedeutet noch immer auch deren Scheitern.", [["Pr\u00e4vention als Verhaltenssteuerung und sozialr\u00e4umliche Organisation indes beginnt mit der antiken Di\u00e4tetik und war als obrigkeitliche Politik auch vor dem \"schwarzen Tod\" bereits g\u00e4ngig", "SPECIES", 0, 185], ["Pr\u00e4vention als Verhaltenssteuerung und sozialr\u00e4umliche Organisation", "TREATMENT", 0, 67]]], ["Die Scheidung der \"Reinen\" von den \"Unreinen\" funktioniert nicht.", [["Die Scheidung der \"Reinen\" von den \"Unreinen\" funktioniert nicht", "SPECIES", 0, 64]]], ["In der Seuchenkommunikation werden aus \"Gesunden\" \"Noch-nicht-Erkrankte\", denen das Bestatten ihrer Angeh\u00f6rigen und der Besuch von Gottesdiensten wie von Volksfesten verboten wird, das Reisen erschwert oder untersagt, (nur) sie werden geimpft (Thie\u00dfen \uf63a\uf639\uf6dc\uf63f) , sie werden zu \"Gef\u00e4hrdeten\", \"Verd\u00e4chtigen\" und \"Gef\u00e4hrdern\".", [["Seuchenkommunikation werden aus \"Gesunden\" \"Noch-nicht-Erkrankte\", denen das Bestatten ihrer Angeh\u00f6rigen und der Besuch von Gottesdiensten wie von Volksfesten verboten wird, das Reisen erschwert oder untersagt, (nur) sie werden geimpft (Thie\u00dfen \uf63a\uf639\uf6dc\uf63f) , sie werden zu \"Gef\u00e4hrdeten\", \"Verd\u00e4chtigen\" und \"Gef\u00e4hrdern", "SPECIES", 7, 319]]]], "PMC7112520": [["IntroductionPeroxiredoxin (PRDX)s are thiol-specific antioxidant enzymes that reduce various cellular peroxide substrates using cysteine-containing active sites (Fatma et al., 2005, Wood et al., 2003b, Wood et al., 2003a).", [["cellular", "ANATOMY", 93, 101], ["IntroductionPeroxiredoxin", "CHEMICAL", 0, 25], ["thiol", "CHEMICAL", 38, 43], ["cysteine", "CHEMICAL", 128, 136], ["thiol", "CHEMICAL", 38, 43], ["peroxide", "CHEMICAL", 102, 110], ["cysteine", "CHEMICAL", 128, 136], ["IntroductionPeroxiredoxin", "SIMPLE_CHEMICAL", 0, 25], ["PRDX", "SIMPLE_CHEMICAL", 27, 31], ["thiol", "SIMPLE_CHEMICAL", 38, 43], ["cellular", "CELL", 93, 101], ["cysteine", "SIMPLE_CHEMICAL", 128, 136], ["antioxidant enzymes", "PROTEIN", 53, 72], ["IntroductionPeroxiredoxin (PRDX)s", "TREATMENT", 0, 33], ["specific antioxidant enzymes", "TREATMENT", 44, 72], ["various cellular peroxide substrates", "TREATMENT", 85, 121], ["cysteine", "TREATMENT", 128, 136]]], ["PRDXs refer to a family of small (22\u201327 kDa) non-seleno peroxidases currently known to possess six isozymes, namely, PRDX1\u20136 in mammalian systems (Chae et al., 2012, Wood et al., 2003a).", [["PRDXs", "GENE_OR_GENE_PRODUCT", 0, 5], ["PRDX1\u20136", "GENE_OR_GENE_PRODUCT", 117, 124], ["PRDXs", "PROTEIN", 0, 5], ["non-seleno peroxidases", "PROTEIN", 45, 67], ["isozymes", "PROTEIN", 99, 107], ["PRDX1\u20136", "PROTEIN", 117, 124], ["non-seleno peroxidases", "PROBLEM", 45, 67]]], ["These proteins contain either one (1-Cys PRDX) or two (2-Cys PRDX) redox-active cysteine residues (Schr\u00f6der et al., 2000, Wood et al., 2003a).", [["Cys", "CHEMICAL", 37, 40], ["Cys", "CHEMICAL", 57, 60], ["cysteine", "CHEMICAL", 80, 88], ["1-Cys PRDX", "SIMPLE_CHEMICAL", 35, 45], ["2-Cys PRDX", "SIMPLE_CHEMICAL", 55, 65], ["cysteine", "AMINO_ACID", 80, 88], ["These proteins", "TEST", 0, 14], ["redox-active cysteine residues", "PROBLEM", 67, 97], ["redox-active", "OBSERVATION", 67, 79], ["cysteine residues", "OBSERVATION", 80, 97]]], ["The 2-Cys group includes PRDX1 to PRDX5, whereas PRDX6 is the sole member of the 1-Cys group (Immenschuh and Baumgart-Vogt, 2005, Rhee et al., 2005).", [["2-Cys", "CHEMICAL", 4, 9], ["2-Cys", "CHEMICAL", 4, 9], ["Cys", "CHEMICAL", 83, 86], ["2-Cys", "SIMPLE_CHEMICAL", 4, 9], ["PRDX1", "GENE_OR_GENE_PRODUCT", 25, 30], ["PRDX5", "GENE_OR_GENE_PRODUCT", 34, 39], ["PRDX6", "GENE_OR_GENE_PRODUCT", 49, 54], ["PRDX1", "PROTEIN", 25, 30], ["PRDX5", "PROTEIN", 34, 39], ["PRDX6", "PROTEIN", 49, 54], ["PRDX1", "TREATMENT", 25, 30]]], ["Despite this difference, peroxidase activities of both 1-Cys and 2-Cys groups commonly contribute to cellular protection against oxidative stress (Dayer et al., 2008, Monteiro et al., 2007).", [["cellular", "ANATOMY", 101, 109], ["1-Cys", "CHEMICAL", 55, 60], ["2-Cys", "CHEMICAL", 65, 70], ["1-Cys", "CHEMICAL", 55, 60], ["2-Cys", "CHEMICAL", 65, 70], ["peroxidase", "GENE_OR_GENE_PRODUCT", 25, 35], ["1-Cys", "SIMPLE_CHEMICAL", 55, 60], ["2-Cys", "SIMPLE_CHEMICAL", 65, 70], ["cellular", "CELL", 101, 109], ["peroxidase", "PROTEIN", 25, 35], ["this difference", "PROBLEM", 8, 23], ["peroxidase activities", "TEST", 25, 46], ["oxidative stress", "PROBLEM", 129, 145]]], ["During reaction with oxidant substrates, the cys-residues of PRDXs are oxidized (Chevallet et al., 2003, Schr\u00f6der et al., 2008).", [["PRDXs", "SIMPLE_CHEMICAL", 61, 66], ["PRDXs", "PROTEIN", 61, 66], ["oxidant substrates", "TREATMENT", 21, 39]]], ["Thioredoxin (Trx) provides the electron for reducing the oxidized PRDX1-5, whereas glutathione is likely to be employed to reduce the oxidized PRDX6 (Poole et al., 2001, Turner-Ivey et al., 2013).", [["glutathione", "CHEMICAL", 83, 94], ["PRDX1-5", "CHEMICAL", 66, 73], ["glutathione", "CHEMICAL", 83, 94], ["Thioredoxin", "GENE_OR_GENE_PRODUCT", 0, 11], ["Trx", "GENE_OR_GENE_PRODUCT", 13, 16], ["electron", "SIMPLE_CHEMICAL", 31, 39], ["PRDX1-5", "GENE_OR_GENE_PRODUCT", 66, 73], ["glutathione", "SIMPLE_CHEMICAL", 83, 94], ["PRDX6", "SIMPLE_CHEMICAL", 143, 148], ["Thioredoxin", "PROTEIN", 0, 11], ["Trx", "PROTEIN", 13, 16], ["PRDX1", "PROTEIN", 66, 71], ["Thioredoxin (Trx)", "TREATMENT", 0, 17], ["the electron", "TREATMENT", 27, 39], ["reducing the oxidized PRDX1", "TREATMENT", 44, 71]]], ["Peroxiredoxins (PRDXs) are a ubiquitous family of antioxidant enzymes, known to catalyze peroxide reduction to balance cellular hydrogen peroxide (H2O2) levels, which is essential for cell signaling and metabolism and act as a regulator of redox signaling (Chen et al., 2014, Perkins et al., 2015).", [["cellular", "ANATOMY", 119, 127], ["cell", "ANATOMY", 184, 188], ["hydrogen peroxide", "CHEMICAL", 128, 145], ["H2O2", "CHEMICAL", 147, 151], ["peroxide", "CHEMICAL", 89, 97], ["hydrogen peroxide", "CHEMICAL", 128, 145], ["H2O2", "CHEMICAL", 147, 151], ["Peroxiredoxins", "GENE_OR_GENE_PRODUCT", 0, 14], ["PRDXs", "GENE_OR_GENE_PRODUCT", 16, 21], ["peroxide", "SIMPLE_CHEMICAL", 89, 97], ["cellular", "CELL", 119, 127], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 128, 145], ["H2O2", "SIMPLE_CHEMICAL", 147, 151], ["cell", "CELL", 184, 188], ["Peroxiredoxins", "PROTEIN", 0, 14], ["PRDXs", "PROTEIN", 16, 21], ["antioxidant enzymes", "PROTEIN", 50, 69], ["Peroxiredoxins (PRDXs", "TREATMENT", 0, 21], ["antioxidant enzymes", "TREATMENT", 50, 69], ["catalyze peroxide reduction", "TREATMENT", 80, 107], ["balance cellular hydrogen peroxide", "TREATMENT", 111, 145], ["cell signaling", "PROBLEM", 184, 198], ["essential for", "UNCERTAINTY", 170, 183], ["cell signaling", "OBSERVATION", 184, 198]]], ["Redox signaling is a critical component of cell signaling pathways that are involved in the regulation of cell growth, metabolism, hormone signaling, immune regulation and a variety of other physiological functions (Mishra et al., 2015, Shadel and Horvath, 2015, Trachootham et al., 2008).", [["cell", "ANATOMY", 43, 47], ["cell", "ANATOMY", 106, 110], ["cell", "CELL", 43, 47], ["cell", "CELL", 106, 110], ["Redox signaling", "PROBLEM", 0, 15], ["cell signaling pathways", "PROBLEM", 43, 66], ["cell growth", "PROBLEM", 106, 117], ["metabolism, hormone signaling", "PROBLEM", 119, 148], ["immune regulation", "PROBLEM", 150, 167], ["critical", "OBSERVATION_MODIFIER", 21, 29], ["component", "OBSERVATION_MODIFIER", 30, 39], ["cell", "OBSERVATION", 43, 47], ["signaling pathways", "OBSERVATION", 48, 66], ["cell", "OBSERVATION", 106, 110], ["growth", "OBSERVATION_MODIFIER", 111, 117]]], ["Therefore, PRDXs are involved in the regulation of cell proliferation, apoptosis, embryonic development, lipid metabolism and immune responses.IntroductionPRDXs are involved in particular pathological condition.", [["cell", "ANATOMY", 51, 55], ["embryonic", "ANATOMY", 82, 91], ["PRDXs", "GENE_OR_GENE_PRODUCT", 11, 16], ["cell", "CELL", 51, 55], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 82, 91], ["lipid", "SIMPLE_CHEMICAL", 105, 110], ["PRDXs", "GENE_OR_GENE_PRODUCT", 155, 160], ["PRDXs", "PROTEIN", 11, 16], ["PRDXs", "PROTEIN", 155, 160], ["PRDXs", "TREATMENT", 11, 16], ["cell proliferation", "PROBLEM", 51, 69], ["apoptosis", "PROBLEM", 71, 80], ["embryonic development", "PROBLEM", 82, 103], ["cell proliferation", "OBSERVATION", 51, 69]]], ["PRDX isoforms can be considered good therapeutic targets in several cancers such as lung cancer (Jo et al., 2013, Kim et al., 2007, Soini and Kinnula, 2012, Wei et al., 2011), glioblastoma (Deighton et al., 2014, Khalil, 2007), colorectal cancer (Lu et al., 2014a, Lu et al., 2014b, Song et al., 2015), prostate cancer (Riddell et al., 2011, Ummanni et al., 2012) and ovarian cancer (Chung et al., 2010, Wang et al., 2013) where they protect tumor cells, PRDXs are involved in a variety of signaling pathways such as NF-\u03baB signaling pathway, STAT3 pathway, wnt/\u03b2-catenin pathway and MAPK kinase pathways (Brigelius-Floh\u00e9 and Floh\u00e9, 2011, Jo et al., 2013, Lu et al., 2014b, Riddell et al., 2010, Yun et al., 2015c, Yun et al., 2015b, Yun et al., 2015a) that are involved in cancer development.", [["cancers", "ANATOMY", 68, 75], ["lung cancer", "ANATOMY", 84, 95], ["glioblastoma", "ANATOMY", 176, 188], ["colorectal cancer", "ANATOMY", 228, 245], ["prostate cancer", "ANATOMY", 303, 318], ["ovarian cancer", "ANATOMY", 368, 382], ["tumor cells", "ANATOMY", 442, 453], ["cancer", "ANATOMY", 773, 779], ["cancers", "DISEASE", 68, 75], ["lung cancer", "DISEASE", 84, 95], ["glioblastoma", "DISEASE", 176, 188], ["colorectal cancer", "DISEASE", 228, 245], ["prostate cancer", "DISEASE", 303, 318], ["ovarian cancer", "DISEASE", 368, 382], ["tumor", "DISEASE", 442, 447], ["cancer", "DISEASE", 773, 779], ["PRDX", "GENE_OR_GENE_PRODUCT", 0, 4], ["cancers", "CANCER", 68, 75], ["lung cancer", "CANCER", 84, 95], ["glioblastoma", "CANCER", 176, 188], ["colorectal cancer", "CANCER", 228, 245], ["prostate cancer", "CANCER", 303, 318], ["ovarian cancer", "CANCER", 368, 382], ["tumor cells", "CELL", 442, 453], ["PRDXs", "GENE_OR_GENE_PRODUCT", 455, 460], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 517, 522], ["STAT3", "GENE_OR_GENE_PRODUCT", 542, 547], ["wnt/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 557, 570], ["MAPK kinase", "GENE_OR_GENE_PRODUCT", 583, 594], ["cancer", "CANCER", 773, 779], ["PRDX isoforms", "PROTEIN", 0, 13], ["tumor cells", "CELL_TYPE", 442, 453], ["PRDXs", "PROTEIN", 455, 460], ["NF-\u03baB", "PROTEIN", 517, 522], ["STAT3", "PROTEIN", 542, 547], ["wnt", "PROTEIN", 557, 560], ["\u03b2-catenin", "PROTEIN", 561, 570], ["MAPK kinase", "PROTEIN", 583, 594], ["several cancers", "PROBLEM", 60, 75], ["lung cancer", "PROBLEM", 84, 95], ["glioblastoma", "PROBLEM", 176, 188], ["colorectal cancer", "PROBLEM", 228, 245], ["prostate cancer", "PROBLEM", 303, 318], ["ovarian cancer", "PROBLEM", 368, 382], ["tumor cells", "PROBLEM", 442, 453], ["STAT3 pathway", "TEST", 542, 555], ["wnt", "TEST", 557, 560], ["catenin pathway", "TEST", 563, 578], ["MAPK kinase pathways", "TEST", 583, 603], ["several", "OBSERVATION_MODIFIER", 60, 67], ["cancers", "OBSERVATION", 68, 75], ["lung", "ANATOMY", 84, 88], ["cancer", "OBSERVATION", 89, 95], ["glioblastoma", "OBSERVATION", 176, 188], ["colorectal", "ANATOMY", 228, 238], ["cancer", "OBSERVATION", 239, 245], ["prostate", "ANATOMY", 303, 311], ["cancer", "OBSERVATION", 312, 318], ["ovarian", "ANATOMY", 368, 375], ["cancer", "OBSERVATION", 376, 382], ["tumor cells", "OBSERVATION", 442, 453], ["cancer", "OBSERVATION", 773, 779]]], ["So, PRDXs can be explored as therapeutic targets as well as therapeutic tools depending on their role in particular pathological conditions.", [["PRDXs", "GENE_OR_GENE_PRODUCT", 4, 9], ["PRDXs", "PROTEIN", 4, 9], ["PRDXs", "TREATMENT", 4, 9]]], ["Several studies have suggested that PRDXs are related with the development of neurodegenerative diseases.", [["neurodegenerative diseases", "DISEASE", 78, 104], ["PRDXs", "GENE_OR_GENE_PRODUCT", 36, 41], ["PRDXs", "PROTEIN", 36, 41], ["Several studies", "TEST", 0, 15], ["neurodegenerative diseases", "PROBLEM", 78, 104], ["neurodegenerative", "OBSERVATION_MODIFIER", 78, 95], ["diseases", "OBSERVATION", 96, 104]]], ["PRDXs are involved in neurodegenerative diseases such as AD and PD that are regulated by oxidative stress and redox signaling (Cimini et al., 2013, Yun et al., 2013).", [["neurodegenerative diseases", "DISEASE", 22, 48], ["AD", "DISEASE", 57, 59], ["PD", "DISEASE", 64, 66], ["PRDXs", "GENE_OR_GENE_PRODUCT", 0, 5], ["PRDXs", "PROTEIN", 0, 5], ["neurodegenerative diseases", "PROBLEM", 22, 48], ["AD and PD", "PROBLEM", 57, 66], ["neurodegenerative", "OBSERVATION_MODIFIER", 22, 39], ["diseases", "OBSERVATION", 40, 48]]], ["PRDXs have distinct functional roles in the brain and provide differential contributions to neuropathologic conditions.", [["brain", "ANATOMY", 44, 49], ["PRDXs", "GENE_OR_GENE_PRODUCT", 0, 5], ["brain", "ORGAN", 44, 49], ["PRDXs", "PROTEIN", 0, 5], ["distinct functional roles in the brain", "PROBLEM", 11, 49], ["neuropathologic conditions", "PROBLEM", 92, 118], ["distinct", "OBSERVATION_MODIFIER", 11, 19], ["functional roles", "OBSERVATION", 20, 36], ["brain", "ANATOMY", 44, 49]]], ["The expression patterns of PRDXs are in fact highly variable in different regions of the brain during neurodegenerative disease processes (Hattori & Oikawa, 2007).", [["brain", "ANATOMY", 89, 94], ["neurodegenerative disease", "DISEASE", 102, 127], ["PRDXs", "GENE_OR_GENE_PRODUCT", 27, 32], ["brain", "ORGAN", 89, 94], ["PRDXs", "PROTEIN", 27, 32], ["neurodegenerative disease processes", "PROBLEM", 102, 137], ["highly", "OBSERVATION_MODIFIER", 45, 51], ["variable", "OBSERVATION_MODIFIER", 52, 60], ["brain", "ANATOMY", 89, 94], ["neurodegenerative", "OBSERVATION_MODIFIER", 102, 119], ["disease", "OBSERVATION", 120, 127]]], ["Given that oxidative damage is involved in the pathogenesis of neurodegenerative diseases, the alteration in PRDX expression would appear to be primarily a consequence of cellular resistance to the oxidative damage.", [["cellular", "ANATOMY", 171, 179], ["neurodegenerative diseases", "DISEASE", 63, 89], ["PRDX", "GENE_OR_GENE_PRODUCT", 109, 113], ["cellular", "CELL", 171, 179], ["PRDX", "PROTEIN", 109, 113], ["oxidative damage", "PROBLEM", 11, 27], ["neurodegenerative diseases", "PROBLEM", 63, 89], ["the alteration in PRDX expression", "PROBLEM", 91, 124], ["cellular resistance", "PROBLEM", 171, 190], ["the oxidative damage", "PROBLEM", 194, 214], ["oxidative damage", "OBSERVATION", 11, 27], ["neurodegenerative", "OBSERVATION_MODIFIER", 63, 80], ["diseases", "OBSERVATION", 81, 89], ["cellular resistance", "OBSERVATION", 171, 190], ["oxidative damage", "OBSERVATION", 198, 214]]], ["PRDXs are also important regulators of inflammatory diseases such as obesity (Huh et al., 2012, Murri et al., 2013), atherosclerosis (Guo et al., 2012, Park et al., 2011) and rheumatoid arthritis (RA) (Kim et al., 2015, Szab\u00f3-Taylor et al., 2012).", [["obesity", "DISEASE", 69, 76], ["atherosclerosis", "DISEASE", 117, 132], ["rheumatoid arthritis", "DISEASE", 175, 195], ["RA", "DISEASE", 197, 199], ["PRDXs", "GENE_OR_GENE_PRODUCT", 0, 5], ["inflammatory diseases", "PROBLEM", 39, 60], ["obesity", "PROBLEM", 69, 76], ["atherosclerosis", "PROBLEM", 117, 132], ["rheumatoid arthritis", "PROBLEM", 175, 195], ["inflammatory", "OBSERVATION_MODIFIER", 39, 51], ["atherosclerosis", "OBSERVATION", 117, 132], ["rheumatoid arthritis", "OBSERVATION", 175, 195], ["RA", "ANATOMY", 197, 199]]], ["Inflammation is a complex biological self-defense reaction triggered by tissue damage or infection by pathogens.", [["tissue", "ANATOMY", 72, 78], ["Inflammation", "DISEASE", 0, 12], ["tissue damage", "DISEASE", 72, 85], ["infection", "DISEASE", 89, 98], ["tissue", "TISSUE", 72, 78], ["Inflammation", "PROBLEM", 0, 12], ["a complex biological self-defense reaction", "PROBLEM", 16, 58], ["tissue damage", "PROBLEM", 72, 85], ["infection", "PROBLEM", 89, 98], ["pathogens", "PROBLEM", 102, 111], ["complex", "OBSERVATION_MODIFIER", 18, 25], ["tissue", "ANATOMY", 72, 78], ["damage", "OBSERVATION", 79, 85], ["infection", "OBSERVATION", 89, 98]]], ["Redox-regulated transcription factors and protein kinases play important roles in the regulation of inflammation.", [["inflammation", "DISEASE", 100, 112], ["Redox-regulated transcription factors", "PROTEIN", 0, 37], ["protein kinases", "PROTEIN", 42, 57], ["Redox-regulated transcription factors", "TREATMENT", 0, 37], ["protein kinases", "TREATMENT", 42, 57], ["inflammation", "PROBLEM", 100, 112], ["inflammation", "OBSERVATION", 100, 112]]], ["NF-\u03baB is a well-characterized redox-sensitive transcription factor important in the initiation and progression of inflammation through the production of various cytokines and prostaglandins.", [["inflammation", "DISEASE", 114, 126], ["prostaglandins", "CHEMICAL", 175, 189], ["prostaglandins", "CHEMICAL", 175, 189], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["prostaglandins", "SIMPLE_CHEMICAL", 175, 189], ["NF-\u03baB", "PROTEIN", 0, 5], ["transcription factor", "PROTEIN", 46, 66], ["cytokines", "PROTEIN", 161, 170], ["inflammation", "PROBLEM", 114, 126], ["various cytokines", "TREATMENT", 153, 170], ["prostaglandins", "TREATMENT", 175, 189], ["inflammation", "OBSERVATION", 114, 126]]], ["PRDXs induce NF-\u03baB activation that is important for the expression of inflammatory proteins (Kim et al., 2013a, Kim et al., 2013b, Riddell et al., 2010).", [["PRDXs", "SIMPLE_CHEMICAL", 0, 5], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 13, 18], ["NF-\u03baB", "PROTEIN", 13, 18], ["inflammatory proteins", "PROTEIN", 70, 91], ["NF", "PROBLEM", 13, 15], ["inflammatory proteins", "PROBLEM", 70, 91]]], ["Also, PRDXs are secreted from cells under mild oxidative stress binds Toll-like receptor 4, suggesting that PRDXs are involved in inflammation related disease (Kuang et al., 2014, Riddell et al., 2012, Shichita et al., 2012a).IntroductionAlthough several studies of PRDXs have been published, a comprehensive review of the various features and functions of PRDXs is lacking.", [["cells", "ANATOMY", 30, 35], ["inflammation", "DISEASE", 130, 142], ["PRDXs", "GENE_OR_GENE_PRODUCT", 6, 11], ["cells", "CELL", 30, 35], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 70, 90], ["PRDXs", "GENE_OR_GENE_PRODUCT", 108, 113], ["PRDXs", "GENE_OR_GENE_PRODUCT", 266, 271], ["PRDXs", "GENE_OR_GENE_PRODUCT", 357, 362], ["PRDXs", "PROTEIN", 6, 11], ["Toll-like receptor 4", "PROTEIN", 70, 90], ["PRDXs", "PROTEIN", 108, 113], ["PRDXs", "PROTEIN", 266, 271], ["PRDXs", "PROTEIN", 357, 362], ["mild oxidative stress binds", "PROBLEM", 42, 69], ["inflammation related disease", "PROBLEM", 130, 158], ["several studies of PRDXs", "TEST", 247, 271], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["oxidative stress binds", "OBSERVATION", 47, 69], ["inflammation", "OBSERVATION", 130, 142]]], ["In this review article, we will discuss recent findings regarding PRDXs in the development of several diseases and therapeutic approaches.Structure of PRDXs ::: PRDXsBased on its conserved cysteine residues and their catalytic mechanisms, mammalian PRDXs can be divided into three subgroup, namely typical 2-Cys, atypical 2-Cys, and 1-Cys PRDXs.", [["cysteine", "CHEMICAL", 189, 197], ["Cys", "CHEMICAL", 308, 311], ["2-Cys", "CHEMICAL", 322, 327], ["1-Cys", "CHEMICAL", 333, 338], ["PRDXs", "GENE_OR_GENE_PRODUCT", 66, 71], ["PRDXs", "GENE_OR_GENE_PRODUCT", 151, 156], ["PRDXsBased", "SIMPLE_CHEMICAL", 161, 171], ["cysteine", "AMINO_ACID", 189, 197], ["PRDXs", "GENE_OR_GENE_PRODUCT", 249, 254], ["2-Cys", "SIMPLE_CHEMICAL", 306, 311], ["atypical 2-Cys", "SIMPLE_CHEMICAL", 313, 327], ["1-Cys PRDXs", "SIMPLE_CHEMICAL", 333, 344], ["PRDXs", "PROTEIN", 151, 156], ["PRDXsBased", "PROTEIN", 161, 171], ["mammalian PRDXs", "PROTEIN", 239, 254], ["PRDXs", "TREATMENT", 66, 71], ["several diseases", "PROBLEM", 94, 110], ["therapeutic approaches", "TREATMENT", 115, 137], ["PRDXsBased", "PROBLEM", 161, 171], ["its conserved cysteine residues", "TREATMENT", 175, 206], ["mammalian PRDXs", "TREATMENT", 239, 254], ["atypical", "TEST", 313, 321], ["Cys", "TEST", 324, 327], ["several", "OBSERVATION_MODIFIER", 94, 101], ["diseases", "OBSERVATION", 102, 110], ["cysteine residues", "OBSERVATION", 189, 206]]], ["PRDX1-4 belong to typical 2-Cys and PRDX5 belongs to atypical 2-Cys group, within which all members contain two conserved cysteine residues.", [["Cys", "CHEMICAL", 28, 31], ["2-Cys", "CHEMICAL", 62, 67], ["cysteine", "CHEMICAL", 122, 130], ["PRDX1-4", "GENE_OR_GENE_PRODUCT", 0, 7], ["2-Cys", "SIMPLE_CHEMICAL", 26, 31], ["PRDX5", "GENE_OR_GENE_PRODUCT", 36, 41], ["2-Cys", "SIMPLE_CHEMICAL", 62, 67], ["cysteine", "AMINO_ACID", 122, 130], ["PRDX1-4", "DNA", 0, 7], ["PRDX5", "PROTEIN", 36, 41], ["PRDX1", "TEST", 0, 5], ["cysteine residues", "OBSERVATION", 122, 139]]], ["PRDX6 belongs to 1-Cys PRDXs subgroup in which one cysteine residue is conserved.", [["Cys", "CHEMICAL", 19, 22], ["cysteine", "CHEMICAL", 51, 59], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["cysteine", "AMINO_ACID", 51, 59], ["PRDX6", "PROTEIN", 0, 5], ["cysteine residue", "OBSERVATION", 51, 67]]], ["Moreover, another subgroup named PRDX-Q was extensively found in plants, which also contains two cysteine residues.", [["cysteine", "CHEMICAL", 97, 105], ["PRDX-Q", "GENE_OR_GENE_PRODUCT", 33, 39], ["PRDX", "PROTEIN", 33, 37], ["Q", "DNA", 38, 39], ["two cysteine residues", "PROBLEM", 93, 114], ["plants", "OBSERVATION", 65, 71], ["two", "OBSERVATION_MODIFIER", 93, 96], ["cysteine residues", "OBSERVATION", 97, 114]]], ["These structures reveal PRDXs to be very similar, each containing a thioredoxin fold with a few additional secondary-structure elements present as insertions.", [["PRDXs", "GENE_OR_GENE_PRODUCT", 24, 29], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 68, 79], ["PRDXs", "PROTEIN", 24, 29], ["thioredoxin", "PROTEIN", 68, 79], ["PRDXs", "PROBLEM", 24, 29], ["a thioredoxin fold", "PROBLEM", 66, 84], ["a few additional secondary-structure elements", "PROBLEM", 90, 135], ["PRDXs", "OBSERVATION", 24, 29], ["very", "OBSERVATION_MODIFIER", 36, 40], ["similar", "OBSERVATION", 41, 48], ["thioredoxin fold", "OBSERVATION", 68, 84], ["few", "OBSERVATION_MODIFIER", 92, 95], ["secondary", "OBSERVATION_MODIFIER", 107, 116], ["structure elements", "OBSERVATION", 117, 135], ["insertions", "OBSERVATION_MODIFIER", 147, 157]]], ["The most striking differences involve their oligomeric states.", [["most striking", "OBSERVATION_MODIFIER", 4, 17], ["oligomeric states", "OBSERVATION", 44, 61]]], ["The atypical 2-Cys PRDXs are monomeric enzymes, whereas both the typical 2-Cys and the 1-Cys PRDXs are domain-swapped homodimers in which the C terminus of one subunit reaches across the dimer interface to interact with the other subunit (Hirotsu et al., 1999, Schr\u00f6der et al., 2000, Wood et al., 2003a).", [["1-Cys", "CHEMICAL", 87, 92], ["2-Cys", "CHEMICAL", 13, 18], ["2-Cys", "CHEMICAL", 73, 78], ["Cys", "CHEMICAL", 89, 92], ["C", "CHEMICAL", 142, 143], ["2-Cys PRDXs", "SIMPLE_CHEMICAL", 13, 24], ["2-Cys", "SIMPLE_CHEMICAL", 73, 78], ["1-Cys PRDXs", "SIMPLE_CHEMICAL", 87, 98], ["atypical 2-Cys PRDXs", "PROTEIN", 4, 24], ["monomeric enzymes", "PROTEIN", 29, 46], ["PRDXs", "PROTEIN", 93, 98], ["domain-swapped homodimers", "PROTEIN", 103, 128], ["C terminus", "PROTEIN", 142, 152], ["monomeric enzymes", "TEST", 29, 46]]], ["In the typical 2-Cys PRDXs, the resolving cysteine is located in the C-terminal arm.", [["cysteine", "CHEMICAL", 42, 50], ["2-Cys", "CHEMICAL", 15, 20], ["cysteine", "CHEMICAL", 42, 50], ["C", "CHEMICAL", 69, 70], ["2-Cys PRDXs", "SIMPLE_CHEMICAL", 15, 26], ["cysteine", "AMINO_ACID", 42, 50], ["C-terminal arm", "PROTEIN", 69, 83], ["the resolving cysteine", "PROBLEM", 28, 50], ["resolving", "OBSERVATION_MODIFIER", 32, 41], ["cysteine", "OBSERVATION", 42, 50], ["C-", "ANATOMY_MODIFIER", 69, 71], ["terminal", "ANATOMY_MODIFIER", 71, 79], ["arm", "ANATOMY", 80, 83]]], ["Three of the typical 2-Cys PRDXs crystallized as toroid-shaped complexes consisting of a pentameric arrangement of dimers ((a2)5 decamer), consistent with observations that 2-Cys PRDX dimers can form discrete higher-order oligomers (Kitano, Niimura, Nishiyama, & Miki, 1999).", [["2-Cys", "CHEMICAL", 173, 178], ["2-Cys", "CHEMICAL", 21, 26], ["2-Cys", "CHEMICAL", 173, 178], ["2-Cys PRDXs", "SIMPLE_CHEMICAL", 21, 32], ["(a2)5 decamer", "SIMPLE_CHEMICAL", 123, 136], ["2-Cys PRDX dimers", "SIMPLE_CHEMICAL", 173, 190], ["Cys PRDXs", "PROTEIN", 23, 32], ["toroid-shaped complexes", "PROTEIN", 49, 72], ["Cys PRDXs", "TEST", 23, 32], ["Cys PRDX dimers", "TEST", 175, 190], ["pentameric arrangement", "OBSERVATION", 89, 111], ["consistent with", "UNCERTAINTY", 139, 154], ["discrete", "OBSERVATION_MODIFIER", 200, 208], ["higher", "OBSERVATION_MODIFIER", 209, 215]]], ["AhpC from Amphibacillus xylanus, another 2-Cys PRDX, also crystallizes as an (a2)5 decamer, although no crystal structure for this enzyme has been reported.", [["AhpC", "CHEMICAL", 0, 4], ["2-Cys", "CHEMICAL", 41, 46], ["2-Cys", "CHEMICAL", 41, 46], ["AhpC", "GENE_OR_GENE_PRODUCT", 0, 4], ["Amphibacillus xylanus", "ORGANISM", 10, 31], ["2-Cys PRDX", "SIMPLE_CHEMICAL", 41, 51], ["AhpC", "PROTEIN", 0, 4], ["enzyme", "PROTEIN", 131, 137], ["Amphibacillus xylanus", "SPECIES", 10, 31], ["Amphibacillus xylanus", "SPECIES", 10, 31], ["AhpC", "TEST", 0, 4], ["Amphibacillus xylanus", "TREATMENT", 10, 31], ["crystal structure", "PROBLEM", 104, 121], ["this enzyme", "TEST", 126, 137], ["no", "UNCERTAINTY", 101, 103]]], ["The structure and sequence of the peroxidatic active site is highly conserved among the PRDX classes (Nelson et al., 2011).General functions of PRDXs ::: PRDXsPRDXs contain an active site cysteine that is sensitive to oxidation by H2O2.", [["H2O2", "CHEMICAL", 231, 235], ["cysteine", "CHEMICAL", 188, 196], ["H2O2", "CHEMICAL", 231, 235], ["PRDXs", "GENE_OR_GENE_PRODUCT", 144, 149], ["PRDXsPRDXs", "SIMPLE_CHEMICAL", 154, 164], ["cysteine", "AMINO_ACID", 188, 196], ["H2O2", "SIMPLE_CHEMICAL", 231, 235], ["peroxidatic active site", "PROTEIN", 34, 57], ["PRDXs", "PROTEIN", 144, 149], ["PRDXsPRDXs", "PROTEIN", 154, 164], ["the peroxidatic active site", "PROBLEM", 30, 57], ["PRDXsPRDXs", "PROBLEM", 154, 164], ["an active site cysteine", "PROBLEM", 173, 196], ["peroxidatic", "OBSERVATION_MODIFIER", 34, 45], ["active", "OBSERVATION", 46, 52], ["active", "OBSERVATION_MODIFIER", 176, 182], ["site cysteine", "OBSERVATION", 183, 196]]], ["Mammalian cells express six PRDX isoforms that are localized to various cellular compartments.", [["cells", "ANATOMY", 10, 15], ["cellular compartments", "ANATOMY", 72, 93], ["Mammalian cells", "CELL", 0, 15], ["PRDX", "GENE_OR_GENE_PRODUCT", 28, 32], ["cellular", "CELL", 72, 80], ["Mammalian cells", "CELL_TYPE", 0, 15], ["PRDX isoforms", "PROTEIN", 28, 41], ["Mammalian cells express six PRDX isoforms", "PROBLEM", 0, 41], ["cellular compartments", "OBSERVATION", 72, 93]]], ["The oxidized active site cysteine of PRDX can be reduced by a cellular thiol, thus enabling PRDX to function as a locally constrained peroxidase (Rhee, Woo, Kil, & Bae, 2012).", [["cellular", "ANATOMY", 62, 70], ["cysteine", "CHEMICAL", 25, 33], ["PRDX", "CHEMICAL", 37, 41], ["thiol", "CHEMICAL", 71, 76], ["cysteine", "CHEMICAL", 25, 33], ["thiol", "CHEMICAL", 71, 76], ["cysteine", "AMINO_ACID", 25, 33], ["PRDX", "GENE_OR_GENE_PRODUCT", 37, 41], ["cellular", "CELL", 62, 70], ["PRDX", "GENE_OR_GENE_PRODUCT", 92, 96], ["peroxidase", "GENE_OR_GENE_PRODUCT", 134, 144], ["PRDX", "PROTEIN", 37, 41], ["PRDX", "PROTEIN", 92, 96], ["peroxidase", "PROTEIN", 134, 144], ["The oxidized active site cysteine of PRDX", "TREATMENT", 0, 41], ["oxidized", "OBSERVATION_MODIFIER", 4, 12], ["active", "OBSERVATION_MODIFIER", 13, 19], ["site cysteine", "OBSERVATION", 20, 33]]], ["Regulation of PRDX via phosphorylation in response to extracellular signals allows the local accumulation of H2O2 and thereby enables its messenger function (Rhee et al., 2012, Woo et al., 2010).", [["extracellular", "ANATOMY", 54, 67], ["H2O2", "CHEMICAL", 109, 113], ["H2O2", "CHEMICAL", 109, 113], ["PRDX", "GENE_OR_GENE_PRODUCT", 14, 18], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 67], ["H2O2", "SIMPLE_CHEMICAL", 109, 113], ["PRDX", "PROTEIN", 14, 18], ["PRDX via phosphorylation", "TREATMENT", 14, 38], ["extracellular signals", "TEST", 54, 75], ["the local accumulation of H2O2", "TREATMENT", 83, 113]]], ["The fact that the oxidation state of the active site cysteine of PRDX can be transferred to other proteins that are less intrinsically susceptible to H2O2 also allows PRDX to function as an H2O2 sensor.", [["PRDX", "CHEMICAL", 65, 69], ["H2O2", "CHEMICAL", 150, 154], ["H2O2", "CHEMICAL", 190, 194], ["cysteine", "CHEMICAL", 53, 61], ["H2O2", "CHEMICAL", 150, 154], ["H2O2", "CHEMICAL", 190, 194], ["cysteine", "AMINO_ACID", 53, 61], ["PRDX", "GENE_OR_GENE_PRODUCT", 65, 69], ["H2O2", "SIMPLE_CHEMICAL", 150, 154], ["PRDX", "SIMPLE_CHEMICAL", 167, 171], ["H2O2", "SIMPLE_CHEMICAL", 190, 194], ["PRDX", "PROTEIN", 65, 69], ["PRDX", "PROTEIN", 167, 171], ["the active site cysteine of PRDX", "PROBLEM", 37, 69], ["H2O2", "TREATMENT", 150, 154], ["an H2O2 sensor", "TEST", 187, 201]]], ["PRDXs are a ubiquitous family of antioxidant enzymes, known to catalyze peroxide reduction to balance cellular H2O2 levels, which is essential for cell signaling and metabolism.", [["cellular", "ANATOMY", 102, 110], ["cell", "ANATOMY", 147, 151], ["H2O2", "CHEMICAL", 111, 115], ["peroxide", "CHEMICAL", 72, 80], ["H2O2", "CHEMICAL", 111, 115], ["PRDXs", "GENE_OR_GENE_PRODUCT", 0, 5], ["peroxide", "SIMPLE_CHEMICAL", 72, 80], ["cellular", "CELL", 102, 110], ["H2O2", "SIMPLE_CHEMICAL", 111, 115], ["cell", "CELL", 147, 151], ["PRDXs", "PROTEIN", 0, 5], ["antioxidant enzymes", "PROTEIN", 33, 52], ["antioxidant enzymes", "TEST", 33, 52], ["catalyze peroxide reduction", "TREATMENT", 63, 90], ["balance cellular H2O2 levels", "TEST", 94, 122], ["cell signaling", "PROBLEM", 147, 161], ["balance cellular", "OBSERVATION", 94, 110], ["H2O2 levels", "OBSERVATION", 111, 122], ["essential for", "UNCERTAINTY", 133, 146], ["cell signaling", "OBSERVATION", 147, 161]]], ["The general function and mechanism of action of the PRDX redox system is in Fig. 1.General functions of PRDXs ::: PRDXsPRDX1 is a multifunctional protein originally identified as an intracellular scavenger of H2O2 (Yang et al., 2002).", [["intracellular", "ANATOMY", 182, 195], ["H2O2", "CHEMICAL", 209, 213], ["H2O2", "CHEMICAL", 209, 213], ["PRDX", "SIMPLE_CHEMICAL", 52, 56], ["PRDXs", "GENE_OR_GENE_PRODUCT", 104, 109], ["PRDXsPRDX1", "GENE_OR_GENE_PRODUCT", 114, 124], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 182, 195], ["H2O2", "SIMPLE_CHEMICAL", 209, 213], ["PRDX", "PROTEIN", 52, 56], ["PRDXs", "PROTEIN", 104, 109], ["PRDXsPRDX1", "PROTEIN", 114, 124], ["multifunctional protein", "PROTEIN", 130, 153], ["the PRDX redox system", "PROBLEM", 48, 69], ["a multifunctional protein", "PROBLEM", 128, 153]]], ["PRDX1 is involved in redox regulation of the cells and reduces peroxides with reducing equivalents provided through the Trx system but not from glutaredoxin (Lehtonen et al., 2004, Neumann et al., 2003).", [["cells", "ANATOMY", 45, 50], ["peroxides", "CHEMICAL", 63, 72], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 45, 50], ["peroxides", "SIMPLE_CHEMICAL", 63, 72], ["Trx", "GENE_OR_GENE_PRODUCT", 120, 123], ["glutaredoxin", "GENE_OR_GENE_PRODUCT", 144, 156], ["PRDX1", "PROTEIN", 0, 5], ["Trx", "PROTEIN", 120, 123], ["glutaredoxin", "PROTEIN", 144, 156], ["reduces peroxides", "TREATMENT", 55, 72], ["reducing equivalents", "TREATMENT", 78, 98], ["the Trx system", "TREATMENT", 116, 130]]], ["The Trx system is comprised of NADPH, Trx and TrxR, and forms the Trx peroxidase system with PRDXs, and reduces peroxides by NADPH (Watanabe, Nakamura, Masutani, & Yodoi, 2010).", [["NADPH", "CHEMICAL", 31, 36], ["NADPH", "CHEMICAL", 125, 130], ["NADPH", "CHEMICAL", 31, 36], ["peroxides", "CHEMICAL", 112, 121], ["NADPH", "CHEMICAL", 125, 130], ["Trx", "GENE_OR_GENE_PRODUCT", 4, 7], ["NADPH", "GENE_OR_GENE_PRODUCT", 31, 36], ["Trx", "GENE_OR_GENE_PRODUCT", 38, 41], ["TrxR", "GENE_OR_GENE_PRODUCT", 46, 50], ["Trx", "GENE_OR_GENE_PRODUCT", 66, 69], ["PRDXs", "SIMPLE_CHEMICAL", 93, 98], ["peroxides", "SIMPLE_CHEMICAL", 112, 121], ["NADPH", "SIMPLE_CHEMICAL", 125, 130], ["Trx", "PROTEIN", 4, 7], ["NADPH", "PROTEIN", 31, 36], ["Trx", "PROTEIN", 38, 41], ["TrxR", "PROTEIN", 46, 50], ["Trx peroxidase", "PROTEIN", 66, 80], ["NADPH", "PROBLEM", 31, 36], ["TrxR", "TEST", 46, 50], ["NADPH", "OBSERVATION", 31, 36]]], ["PRDX1 is involved in this system.", [["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["PRDX1", "PROTEIN", 0, 5]]], ["PRDX1 gene is mapped on chromosome 1p34.1 and is a member of the peroxiredoxin family that contains a consensus site (Thr(90)-Pro-Lys-Lys) for phosphorylation by cyclin dependent kinases (Chang et al., 2002, Gisin et al., 2005).", [["chromosome 1p34.1", "ANATOMY", 24, 41], ["Thr", "CHEMICAL", 118, 121], ["Lys", "CHEMICAL", 130, 133], ["Lys", "CHEMICAL", 134, 137], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["chromosome 1p34.1", "CELLULAR_COMPONENT", 24, 41], ["peroxiredoxin", "GENE_OR_GENE_PRODUCT", 65, 78], ["Lys", "AMINO_ACID", 134, 137], ["cyclin dependent kinases", "GENE_OR_GENE_PRODUCT", 162, 186], ["PRDX1 gene", "DNA", 0, 10], ["chromosome 1p34.1", "DNA", 24, 41], ["peroxiredoxin family", "PROTEIN", 65, 85], ["consensus site", "DNA", 102, 116], ["cyclin dependent kinases", "PROTEIN", 162, 186], ["Pro-Lys-Lys", "TREATMENT", 126, 137], ["phosphorylation by cyclin dependent kinases", "TREATMENT", 143, 186]]], ["PRDX1 is phosphorylated on Thr-90 during the M-phase, which leads to a more than 80% decrease in enzymatic activity through the Trx system (Jang et al., 2006, Neumann et al., 2009).", [["Thr", "CHEMICAL", 27, 30], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Thr-90", "AMINO_ACID", 27, 33], ["Trx", "GENE_OR_GENE_PRODUCT", 128, 131], ["PRDX1", "PROTEIN", 0, 5], ["Trx", "PROTEIN", 128, 131], ["Thr", "TEST", 27, 30], ["decrease", "OBSERVATION_MODIFIER", 85, 93], ["enzymatic activity", "OBSERVATION", 97, 115]]], ["PRDX1 is implicated in redox regulation of the cell and plays an important role in eliminating peroxides produced during metabolism that participates in the signaling of growth factors and tumor necrosis factor-alpha (TNF-\u03b1) through regulating the intracellular concentrations of H2O2 (Jamaluddin et al., 2010, Liou and Storz, 2010).", [["cell", "ANATOMY", 47, 51], ["intracellular", "ANATOMY", 248, 261], ["PRDX1", "CHEMICAL", 0, 5], ["tumor", "DISEASE", 189, 194], ["H2O2", "CHEMICAL", 280, 284], ["peroxides", "CHEMICAL", 95, 104], ["H2O2", "CHEMICAL", 280, 284], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 47, 51], ["peroxides", "SIMPLE_CHEMICAL", 95, 104], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 189, 216], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 218, 223], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 248, 261], ["H2O2", "SIMPLE_CHEMICAL", 280, 284], ["PRDX1", "PROTEIN", 0, 5], ["growth factors", "PROTEIN", 170, 184], ["tumor necrosis factor-alpha", "PROTEIN", 189, 216], ["TNF", "PROTEIN", 218, 221], ["\u03b1", "PROTEIN", 222, 223], ["PRDX1", "PROBLEM", 0, 5], ["growth factors", "PROBLEM", 170, 184], ["tumor necrosis factor", "PROBLEM", 189, 210], ["alpha (TNF", "TEST", 211, 221], ["tumor", "OBSERVATION_MODIFIER", 189, 194], ["necrosis", "OBSERVATION", 195, 203]]], ["PRDX1 is overexpressed in several cancer cells including esophageal, pancreatic, lung, thyroid and oral cancer (Gong et al., 2015, Jiang et al., 2014b, Jiang et al., 2014a, Taniuchi et al., 2015, Yanagawa et al., 1999, Zhang et al., 2012b, Zhang et al., 2012a).", [["cancer cells", "ANATOMY", 34, 46], ["esophageal", "ANATOMY", 57, 67], ["pancreatic", "ANATOMY", 69, 79], ["lung", "ANATOMY", 81, 85], ["thyroid", "ANATOMY", 87, 94], ["oral cancer", "ANATOMY", 99, 110], ["cancer", "DISEASE", 34, 40], ["esophageal, pancreatic, lung, thyroid and oral cancer", "DISEASE", 57, 110], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cancer cells", "CELL", 34, 46], ["esophageal", "CANCER", 57, 67], ["pancreatic", "CANCER", 69, 79], ["lung", "ORGAN", 81, 85], ["thyroid", "ORGAN", 87, 94], ["oral cancer", "CANCER", 99, 110], ["PRDX1", "PROTEIN", 0, 5], ["cancer cells", "CELL_TYPE", 34, 46], ["several cancer cells", "PROBLEM", 26, 46], ["esophageal, pancreatic, lung, thyroid and oral cancer", "PROBLEM", 57, 110], ["several", "OBSERVATION_MODIFIER", 26, 33], ["cancer cells", "OBSERVATION", 34, 46], ["esophageal", "ANATOMY", 57, 67], ["pancreatic", "ANATOMY", 69, 79], ["lung", "ANATOMY", 81, 85], ["thyroid", "ANATOMY", 87, 94], ["oral", "ANATOMY", 99, 103], ["cancer", "OBSERVATION", 104, 110]]], ["Concentrated PRDX1 can be secreted by non-small cell lung cancer cells via unusual pathway (Chang et al., 2005).General functions of PRDXs ::: PRDXsPRDX2 has a high reactivity for H2O2.", [["non-small cell lung cancer cells", "ANATOMY", 38, 70], ["PRDX1", "CHEMICAL", 13, 18], ["non-small cell lung cancer", "DISEASE", 38, 64], ["PRDXsPRDX2", "CHEMICAL", 143, 153], ["H2O2", "CHEMICAL", 180, 184], ["H2O2", "CHEMICAL", 180, 184], ["PRDX1", "GENE_OR_GENE_PRODUCT", 13, 18], ["non-small cell lung cancer cells", "CELL", 38, 70], ["PRDXs", "SIMPLE_CHEMICAL", 133, 138], ["PRDXsPRDX2", "SIMPLE_CHEMICAL", 143, 153], ["H2O2", "SIMPLE_CHEMICAL", 180, 184], ["PRDX1", "PROTEIN", 13, 18], ["non-small cell lung cancer cells", "CELL_TYPE", 38, 70], ["non-small cell lung cancer cells", "PROBLEM", 38, 70], ["non-small cell", "OBSERVATION", 38, 52], ["lung", "ANATOMY", 53, 57], ["cancer", "OBSERVATION", 58, 64]]], ["An active Cys on one PRDX2 subunit forms a disulphide bond with the other subunit in the presence of H2O2 (K\u00f6nig et al., 2013, Peskin et al., 2007).", [["H2O2", "CHEMICAL", 101, 105], ["Cys", "CHEMICAL", 10, 13], ["disulphide", "CHEMICAL", 43, 53], ["H2O2", "CHEMICAL", 101, 105], ["Cys", "AMINO_ACID", 10, 13], ["PRDX2", "GENE_OR_GENE_PRODUCT", 21, 26], ["H2O2", "SIMPLE_CHEMICAL", 101, 105], ["PRDX2 subunit", "PROTEIN", 21, 34], ["active", "OBSERVATION_MODIFIER", 3, 9], ["Cys", "OBSERVATION", 10, 13]]], ["PRDX2 appears to modulate growth factors and the tumor necrosis factor-alpha-mediated signaling pathwayviamodulating endogenous H2O2 signaling (Zhao & Wang, 2012).", [["PRDX2", "CHEMICAL", 0, 5], ["tumor", "DISEASE", 49, 54], ["necrosis", "DISEASE", 55, 63], ["H2O2", "CHEMICAL", 128, 132], ["H2O2", "CHEMICAL", 128, 132], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 49, 76], ["H2O2", "SIMPLE_CHEMICAL", 128, 132], ["PRDX2", "PROTEIN", 0, 5], ["growth factors", "PROTEIN", 26, 40], ["tumor necrosis factor-alpha", "PROTEIN", 49, 76], ["PRDX2", "TREATMENT", 0, 5], ["modulate growth factors", "PROBLEM", 17, 40], ["the tumor necrosis factor", "PROBLEM", 45, 70], ["endogenous H2O2 signaling", "PROBLEM", 117, 142], ["growth", "OBSERVATION_MODIFIER", 26, 32], ["tumor", "OBSERVATION_MODIFIER", 49, 54], ["necrosis", "OBSERVATION", 55, 63], ["endogenous", "OBSERVATION_MODIFIER", 117, 127], ["H2O2 signaling", "OBSERVATION", 128, 142]]], ["When PRDX2 reacts with peroxide, the peroxidatic cysteine at the active site on one subunit is oxidized to a sulfenic acid (Low, Hampton, Peskin, & Winterbourn, 2007).", [["PRDX2", "CHEMICAL", 5, 10], ["peroxide", "CHEMICAL", 23, 31], ["cysteine", "CHEMICAL", 49, 57], ["sulfenic acid", "CHEMICAL", 109, 122], ["peroxide", "CHEMICAL", 23, 31], ["cysteine", "CHEMICAL", 49, 57], ["sulfenic acid", "CHEMICAL", 109, 122], ["PRDX2", "SIMPLE_CHEMICAL", 5, 10], ["peroxide", "SIMPLE_CHEMICAL", 23, 31], ["cysteine", "AMINO_ACID", 49, 57], ["sulfenic acid", "SIMPLE_CHEMICAL", 109, 122], ["PRDX2", "PROTEIN", 5, 10], ["peroxide", "TREATMENT", 23, 31], ["the peroxidatic cysteine", "TREATMENT", 33, 57], ["a sulfenic acid", "TEST", 107, 122], ["peroxidatic cysteine", "OBSERVATION", 37, 57], ["active", "OBSERVATION_MODIFIER", 65, 71], ["site", "OBSERVATION_MODIFIER", 72, 76]]], ["Through the reduction process of disulphide by Trx, PRDX2 is regenerated and completes the cycle and Trx is in turn regenerated by thioredoxin reductase (TrxR), with reducing equivalents derived from NADPH (Low et al., 2007).", [["PRDX2", "CHEMICAL", 52, 57], ["NADPH", "CHEMICAL", 200, 205], ["disulphide", "CHEMICAL", 33, 43], ["NADPH", "CHEMICAL", 200, 205], ["Trx", "GENE_OR_GENE_PRODUCT", 47, 50], ["PRDX2", "GENE_OR_GENE_PRODUCT", 52, 57], ["Trx", "GENE_OR_GENE_PRODUCT", 101, 104], ["thioredoxin reductase", "GENE_OR_GENE_PRODUCT", 131, 152], ["TrxR", "GENE_OR_GENE_PRODUCT", 154, 158], ["NADPH", "SIMPLE_CHEMICAL", 200, 205], ["Trx", "PROTEIN", 47, 50], ["PRDX2", "PROTEIN", 52, 57], ["Trx", "PROTEIN", 101, 104], ["thioredoxin reductase", "PROTEIN", 131, 152], ["TrxR", "PROTEIN", 154, 158], ["the reduction process of disulphide", "TREATMENT", 8, 43], ["thioredoxin reductase", "TEST", 131, 152]]], ["PRDX2 reduces hydrogen peroxide and alkyl hydroperoxides involved in cell protection and antiviral activity through the Trx system (Pillay et al., 2011, Sobotta et al., 2015, Watanabe et al., 2010).", [["cell", "ANATOMY", 69, 73], ["PRDX2", "CHEMICAL", 0, 5], ["hydrogen peroxide", "CHEMICAL", 14, 31], ["alkyl hydroperoxides", "CHEMICAL", 36, 56], ["hydrogen peroxide", "CHEMICAL", 14, 31], ["alkyl hydroperoxides", "CHEMICAL", 36, 56], ["PRDX2", "SIMPLE_CHEMICAL", 0, 5], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 14, 31], ["alkyl hydroperoxides", "SIMPLE_CHEMICAL", 36, 56], ["cell", "CELL", 69, 73], ["Trx", "GENE_OR_GENE_PRODUCT", 120, 123], ["Trx", "PROTEIN", 120, 123], ["PRDX2", "TREATMENT", 0, 5], ["hydrogen peroxide", "TREATMENT", 14, 31], ["alkyl hydroperoxides", "TREATMENT", 36, 56], ["cell protection", "TREATMENT", 69, 84], ["antiviral activity", "TREATMENT", 89, 107], ["hydrogen peroxide", "OBSERVATION", 14, 31], ["alkyl hydroperoxides", "OBSERVATION", 36, 56], ["cell protection", "OBSERVATION", 69, 84], ["antiviral activity", "OBSERVATION", 89, 107]]], ["PRDX2 acts as a H2O2 signal receptor and transmitter in transcription factor redox regulation.", [["PRDX2", "CHEMICAL", 0, 5], ["H2O2", "CHEMICAL", 16, 20], ["H2O2", "CHEMICAL", 16, 20], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["H2O2", "SIMPLE_CHEMICAL", 16, 20], ["PRDX2", "PROTEIN", 0, 5], ["H2O2 signal receptor", "PROTEIN", 16, 36], ["transcription factor", "PROTEIN", 56, 76], ["a H2O2 signal receptor", "TREATMENT", 14, 36]]], ["PRDX2 forms a redox relay with the transcription factor STAT3 in which oxidative equivalents flow from PRDX2 to STAT3, and the redox relay generates disulphide-linked STAT3 oligomers with attenuated transcriptional activity.", [["disulphide", "CHEMICAL", 149, 159], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["STAT3", "GENE_OR_GENE_PRODUCT", 56, 61], ["PRDX2", "GENE_OR_GENE_PRODUCT", 103, 108], ["STAT3", "GENE_OR_GENE_PRODUCT", 112, 117], ["STAT3", "GENE_OR_GENE_PRODUCT", 167, 172], ["PRDX2", "PROTEIN", 0, 5], ["transcription factor", "PROTEIN", 35, 55], ["STAT3", "PROTEIN", 56, 61], ["PRDX2", "PROTEIN", 103, 108], ["STAT3", "PROTEIN", 112, 117], ["STAT3", "PROTEIN", 167, 172], ["linked STAT3 oligomers", "PROBLEM", 160, 182], ["transcriptional activity", "OBSERVATION", 199, 223]]], ["Cytokine-induced STAT3 signaling is accompanied by PRDX2 and STAT3 oxidation and is modulated by PRDX2 expression levels (Sobotta et al., 2015).", [["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["STAT3", "GENE_OR_GENE_PRODUCT", 17, 22], ["PRDX2", "GENE_OR_GENE_PRODUCT", 51, 56], ["STAT3", "GENE_OR_GENE_PRODUCT", 61, 66], ["PRDX2", "GENE_OR_GENE_PRODUCT", 97, 102], ["Cytokine", "PROTEIN", 0, 8], ["STAT3", "PROTEIN", 17, 22], ["PRDX2", "PROTEIN", 51, 56], ["STAT3", "PROTEIN", 61, 66], ["PRDX2", "PROTEIN", 97, 102], ["Cytokine-induced STAT3 signaling", "PROBLEM", 0, 32], ["PRDX2", "PROBLEM", 51, 56], ["STAT3 oxidation", "PROBLEM", 61, 76], ["STAT3 oxidation", "OBSERVATION", 61, 76]]], ["Moon et al demonstrated that PRDX2 inhibits general immune cell responsiveness, which may be regulated by scavenging low levels of reactive oxygen species (ROS) (Moon et al., 2006).", [["immune cell", "ANATOMY", 52, 63], ["PRDX2", "CHEMICAL", 29, 34], ["oxygen", "CHEMICAL", 140, 146], ["ROS", "CHEMICAL", 156, 159], ["oxygen", "CHEMICAL", 140, 146], ["PRDX2", "GENE_OR_GENE_PRODUCT", 29, 34], ["immune cell", "CELL", 52, 63], ["reactive oxygen species", "SIMPLE_CHEMICAL", 131, 154], ["ROS", "SIMPLE_CHEMICAL", 156, 159], ["PRDX2", "PROTEIN", 29, 34], ["reactive oxygen species", "PROBLEM", 131, 154], ["immune cell responsiveness", "OBSERVATION", 52, 78], ["reactive", "OBSERVATION_MODIFIER", 131, 139], ["oxygen species", "OBSERVATION", 140, 154]]], ["PRDX2 also enhances the activation of platelet-derived growth factor (PDGF) receptor and phospholipase C\u03b31 in PDGF signaling via the modulation of H2O2 (Choi et al., 2005).General functions of PRDXs ::: PRDXsPRDX3 (MER-5, SP22, AOP-1) is known as c-myc, miR-383 and miR-23b target gene and is required for mitochondrial homoeostasis and neoplastic transformation (Pablo et al., 2009; Wonsey, Zeller, & Dang, 2002).", [["mitochondrial", "ANATOMY", 306, 319], ["neoplastic", "ANATOMY", 337, 347], ["PRDX2", "CHEMICAL", 0, 5], ["H2O2", "CHEMICAL", 147, 151], ["H2O2", "CHEMICAL", 147, 151], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["platelet-derived growth factor (PDGF) receptor", "GENE_OR_GENE_PRODUCT", 38, 84], ["phospholipase C\u03b31", "GENE_OR_GENE_PRODUCT", 89, 106], ["PDGF", "GENE_OR_GENE_PRODUCT", 110, 114], ["H2O2", "SIMPLE_CHEMICAL", 147, 151], ["PRDXs", "GENE_OR_GENE_PRODUCT", 193, 198], ["PRDXsPRDX3", "GENE_OR_GENE_PRODUCT", 203, 213], ["MER-5", "GENE_OR_GENE_PRODUCT", 215, 220], ["SP22", "GENE_OR_GENE_PRODUCT", 222, 226], ["AOP-1", "GENE_OR_GENE_PRODUCT", 228, 233], ["c-myc", "GENE_OR_GENE_PRODUCT", 247, 252], ["miR-383", "GENE_OR_GENE_PRODUCT", 254, 261], ["miR-23b", "GENE_OR_GENE_PRODUCT", 266, 273], ["mitochondrial", "CELLULAR_COMPONENT", 306, 319], ["PRDX2", "PROTEIN", 0, 5], ["platelet-derived growth factor (PDGF) receptor", "PROTEIN", 38, 84], ["phospholipase C\u03b31", "PROTEIN", 89, 106], ["PDGF", "PROTEIN", 110, 114], ["PRDXs", "DNA", 193, 198], ["PRDXsPRDX3", "PROTEIN", 203, 213], ["SP22", "PROTEIN", 222, 226], ["AOP", "PROTEIN", 228, 231], ["c-myc, miR-383", "DNA", 247, 261], ["miR-23b target gene", "DNA", 266, 285], ["platelet", "TEST", 38, 46], ["PDGF", "TEST", 70, 74], ["receptor", "TEST", 76, 84], ["phospholipase C", "TEST", 89, 104], ["MER", "TEST", 215, 218], ["AOP", "TEST", 228, 231], ["mitochondrial homoeostasis", "PROBLEM", 306, 332], ["neoplastic transformation", "PROBLEM", 337, 362], ["neoplastic transformation", "OBSERVATION", 337, 362]]], ["PRDX3 contains a mitochondrial localization sequence, which is found exclusively in the mitochondrion, comprises 5% of the total mitochondrial matrix, and uses mitochondrial Trx2 as the electron donor for its peroxidase activity (Gourlay, Bhella, Kelly, Price, & Lindsay, 2003).", [["mitochondrial", "ANATOMY", 17, 30], ["mitochondrion", "ANATOMY", 88, 101], ["mitochondrial matrix", "ANATOMY", 129, 149], ["mitochondrial", "ANATOMY", 160, 173], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["mitochondrion", "CELLULAR_COMPONENT", 88, 101], ["mitochondrial matrix", "CELLULAR_COMPONENT", 129, 149], ["mitochondrial", "CELLULAR_COMPONENT", 160, 173], ["Trx2", "GENE_OR_GENE_PRODUCT", 174, 178], ["peroxidase", "GENE_OR_GENE_PRODUCT", 209, 219], ["PRDX3", "PROTEIN", 0, 5], ["mitochondrial localization sequence", "PROTEIN", 17, 52], ["mitochondrial Trx2", "PROTEIN", 160, 178], ["peroxidase", "PROTEIN", 209, 219], ["a mitochondrial localization sequence", "TEST", 15, 52], ["mitochondrial Trx2", "TREATMENT", 160, 178], ["the electron donor", "TREATMENT", 182, 200], ["mitochondrial matrix", "OBSERVATION", 129, 149]]], ["PRDX3 has been known to eliminate approximately 90% of mitochondrial H2O2 and plays a key role in mitochondrial redox regulation (Chang et al., 2004).", [["mitochondrial", "ANATOMY", 55, 68], ["mitochondrial", "ANATOMY", 98, 111], ["PRDX3", "CHEMICAL", 0, 5], ["H2O2", "CHEMICAL", 69, 73], ["H2O2", "CHEMICAL", 69, 73], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 55, 68], ["H2O2", "SIMPLE_CHEMICAL", 69, 73], ["mitochondrial", "CELLULAR_COMPONENT", 98, 111], ["PRDX3", "PROTEIN", 0, 5], ["mitochondrial H2O2", "TREATMENT", 55, 73]]], ["The overexpression of PRDX3 has been shown to protect cells from oxidative stress and apoptosis, and knockout studies show an increase in intracellular ROS levels and oxidative stress (Mukhopadhyay et al., 2006, Nonn et al., 2003).", [["cells", "ANATOMY", 54, 59], ["intracellular", "ANATOMY", 138, 151], ["PRDX3", "CHEMICAL", 22, 27], ["ROS", "CHEMICAL", 152, 155], ["PRDX3", "GENE_OR_GENE_PRODUCT", 22, 27], ["cells", "CELL", 54, 59], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 138, 151], ["ROS", "SIMPLE_CHEMICAL", 152, 155], ["PRDX3", "PROTEIN", 22, 27], ["The overexpression of PRDX3", "PROBLEM", 0, 27], ["oxidative stress", "PROBLEM", 65, 81], ["apoptosis", "PROBLEM", 86, 95], ["knockout studies", "TEST", 101, 117], ["an increase in intracellular ROS levels", "PROBLEM", 123, 162], ["oxidative stress", "PROBLEM", 167, 183], ["oxidative stress", "OBSERVATION", 65, 81], ["increase", "OBSERVATION_MODIFIER", 126, 134], ["intracellular ROS levels", "OBSERVATION", 138, 162]]], ["PRDX3 protects radical-sensitive enzymes from oxidative damage by a radical-generating system, and acts synergistically with MAP3K13 to regulate the activation of NF-kappa-B in the cytosol (Lin et al., 2007).", [["cytosol", "ANATOMY", 181, 188], ["PRDX3", "CHEMICAL", 0, 5], ["PRDX3", "SIMPLE_CHEMICAL", 0, 5], ["MAP3K13", "GENE_OR_GENE_PRODUCT", 125, 132], ["NF-kappa-B", "GENE_OR_GENE_PRODUCT", 163, 173], ["cytosol", "ORGANISM_SUBSTANCE", 181, 188], ["PRDX3", "PROTEIN", 0, 5], ["radical-sensitive enzymes", "PROTEIN", 15, 40], ["MAP3K13", "PROTEIN", 125, 132], ["NF-kappa-B", "PROTEIN", 163, 173], ["PRDX3", "TREATMENT", 0, 5], ["oxidative damage", "PROBLEM", 46, 62], ["MAP3K13", "TREATMENT", 125, 132], ["NF", "TEST", 163, 165], ["kappa", "TEST", 166, 171], ["radical", "OBSERVATION_MODIFIER", 15, 22], ["cytosol", "ANATOMY", 181, 188]]], ["PRDX3 is involved in the regulation of cellular proliferation, differentiation and antioxidant functions that has been localized in the mitochondria (Huh et al., 2012, Song et al., 2011).", [["cellular", "ANATOMY", 39, 47], ["mitochondria", "ANATOMY", 136, 148], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 39, 47], ["mitochondria", "CELLULAR_COMPONENT", 136, 148], ["PRDX3", "PROTEIN", 0, 5], ["cellular proliferation", "PROBLEM", 39, 61], ["cellular proliferation", "OBSERVATION", 39, 61]]], ["Increased expression of PRDX3 was found to be associated with hormonal receptors (estrogen receptor and progesterone receptor) (Karihtala, M\u00e4ntyniemi, Kang, Kinnula, & Soini, 2003).General functions of PRDXs ::: PRDXsPRDX4 (AOE372, TRANK) is a ubiquitously expressed member of the peroxiredoxin family that is mainly localized in the endoplasmic reticulum (ER), but is also present in the cytosol, lysosome, nucleus, or secreted (Leyens, Donnay, & Knoops, 2003).", [["endoplasmic reticulum", "ANATOMY", 334, 355], ["ER", "ANATOMY", 357, 359], ["cytosol", "ANATOMY", 389, 396], ["lysosome", "ANATOMY", 398, 406], ["nucleus", "ANATOMY", 408, 415], ["estrogen", "CHEMICAL", 82, 90], ["progesterone", "CHEMICAL", 104, 116], ["estrogen", "CHEMICAL", 82, 90], ["progesterone", "CHEMICAL", 104, 116], ["PRDX3", "GENE_OR_GENE_PRODUCT", 24, 29], ["estrogen receptor", "GENE_OR_GENE_PRODUCT", 82, 99], ["progesterone receptor", "GENE_OR_GENE_PRODUCT", 104, 125], ["PRDXs", "GENE_OR_GENE_PRODUCT", 202, 207], ["PRDXsPRDX4", "GENE_OR_GENE_PRODUCT", 212, 222], ["AOE372", "GENE_OR_GENE_PRODUCT", 224, 230], ["TRANK", "GENE_OR_GENE_PRODUCT", 232, 237], ["peroxiredoxin", "GENE_OR_GENE_PRODUCT", 281, 294], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 334, 355], ["ER", "GENE_OR_GENE_PRODUCT", 357, 359], ["cytosol", "CELLULAR_COMPONENT", 389, 396], ["lysosome", "CELLULAR_COMPONENT", 398, 406], ["nucleus", "CELLULAR_COMPONENT", 408, 415], ["PRDX3", "PROTEIN", 24, 29], ["hormonal receptors", "PROTEIN", 62, 80], ["estrogen receptor", "PROTEIN", 82, 99], ["progesterone receptor", "PROTEIN", 104, 125], ["PRDXs", "PROTEIN", 202, 207], ["PRDXsPRDX4", "PROTEIN", 212, 222], ["AOE372", "PROTEIN", 224, 230], ["TRANK", "PROTEIN", 232, 237], ["peroxiredoxin family", "PROTEIN", 281, 301], ["ER", "PROTEIN", 357, 359], ["Increased expression of PRDX3", "PROBLEM", 0, 29], ["hormonal receptors", "TREATMENT", 62, 80], ["estrogen receptor", "TREATMENT", 82, 99], ["progesterone receptor", "TREATMENT", 104, 125], ["Karihtala", "TREATMENT", 128, 137], ["M\u00e4ntyniemi", "TREATMENT", 139, 149], ["endoplasmic reticulum", "ANATOMY", 334, 355], ["lysosome", "OBSERVATION", 398, 406], ["nucleus", "ANATOMY", 408, 415]]], ["PRDX4 plays an essential role in the redox balance in the ER.", [["ER", "ANATOMY", 58, 60], ["PRDX4", "CHEMICAL", 0, 5], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["ER", "GENE_OR_GENE_PRODUCT", 58, 60], ["PRDX4", "PROTEIN", 0, 5], ["ER", "PROTEIN", 58, 60]]], ["The Cysteine residue of PRDX4 is first oxidized to sulfenic acid form and then forms intermolecular disulphide bond with another PRDX molecule, which can be reversed by the reducing activity of the Trx-Trx reductase system (Mehmeti et al., 2014, Tavender and Bulleid, 2010).", [["Cysteine", "CHEMICAL", 4, 12], ["PRDX4", "CHEMICAL", 24, 29], ["sulfenic acid", "CHEMICAL", 51, 64], ["Cysteine", "CHEMICAL", 4, 12], ["sulfenic acid", "CHEMICAL", 51, 64], ["disulphide", "CHEMICAL", 100, 110], ["Cysteine", "AMINO_ACID", 4, 12], ["PRDX4", "GENE_OR_GENE_PRODUCT", 24, 29], ["sulfenic acid", "SIMPLE_CHEMICAL", 51, 64], ["PRDX", "SIMPLE_CHEMICAL", 129, 133], ["Trx-Trx reductase", "GENE_OR_GENE_PRODUCT", 198, 215], ["PRDX4", "PROTEIN", 24, 29], ["PRDX molecule", "PROTEIN", 129, 142], ["Trx", "PROTEIN", 198, 201], ["Trx reductase", "PROTEIN", 202, 215], ["The Cysteine residue of PRDX4", "TREATMENT", 0, 29], ["another PRDX molecule", "PROBLEM", 121, 142], ["Cysteine residue", "OBSERVATION", 4, 20], ["Trx", "ANATOMY", 198, 201]]], ["Under oxidative stress conditions, however, the Cysteine of PRDX4 undergoes further oxidation to sulfinic/sulfonic acid forms which can only be reduced by sulfiredoxin (Srx) (Jeong, Bae, Toledano, & Rhee, 2012).", [["Cysteine", "CHEMICAL", 48, 56], ["PRDX4", "CHEMICAL", 60, 65], ["sulfinic/sulfonic acid", "CHEMICAL", 97, 119], ["sulfiredoxin", "CHEMICAL", 155, 167], ["Srx", "CHEMICAL", 169, 172], ["Cysteine", "CHEMICAL", 48, 56], ["sulfinic/sulfonic acid", "CHEMICAL", 97, 119], ["sulfiredoxin", "CHEMICAL", 155, 167], ["Srx", "CHEMICAL", 169, 172], ["PRDX4", "GENE_OR_GENE_PRODUCT", 60, 65], ["sulfinic/sulfonic acid", "SIMPLE_CHEMICAL", 97, 119], ["sulfiredoxin", "SIMPLE_CHEMICAL", 155, 167], ["Srx", "SIMPLE_CHEMICAL", 169, 172], ["Under oxidative stress conditions", "PROBLEM", 0, 33], ["the Cysteine of PRDX4", "TREATMENT", 44, 65], ["further oxidation", "TREATMENT", 76, 93], ["sulfinic/sulfonic acid forms", "TREATMENT", 97, 125], ["oxidative", "OBSERVATION", 6, 15], ["stress conditions", "OBSERVATION", 16, 33]]], ["The hyperoxidized form of PRDX4 loses its antioxidant property but may function as molecular chaperone to facilitate protein folding (Rhee and Woo, 2010, Zito et al., 2010).", [["PRDX4", "CHEMICAL", 26, 31], ["PRDX4", "GENE_OR_GENE_PRODUCT", 26, 31], ["PRDX4", "PROTEIN", 26, 31], ["PRDX4", "TREATMENT", 26, 31]]], ["PRDX4 diminishes oxidative stress by reducing hydrogen peroxide to water in a thiol-dependent catalytic cycle (Schulte, 2011) and has been linked to the regulation of the key pro-inflammatory transcription factor, NF-\u03baB in the cytosol by a modulation of I\u03baB-\u03b1 phosphorylation (Haridas et al., 1998, Jin et al., 1997).", [["cytosol", "ANATOMY", 227, 234], ["PRDX4", "CHEMICAL", 0, 5], ["hydrogen peroxide", "CHEMICAL", 46, 63], ["thiol", "CHEMICAL", 78, 83], ["hydrogen peroxide", "CHEMICAL", 46, 63], ["thiol", "CHEMICAL", 78, 83], ["PRDX4", "SIMPLE_CHEMICAL", 0, 5], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 46, 63], ["water", "SIMPLE_CHEMICAL", 67, 72], ["thiol", "SIMPLE_CHEMICAL", 78, 83], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 214, 219], ["cytosol", "CELLULAR_COMPONENT", 227, 234], ["I\u03baB-\u03b1", "GENE_OR_GENE_PRODUCT", 254, 259], ["PRDX4", "PROTEIN", 0, 5], ["pro-inflammatory transcription factor", "PROTEIN", 175, 212], ["NF-\u03baB", "PROTEIN", 214, 219], ["I\u03baB", "PROTEIN", 254, 257], ["\u03b1", "PROTEIN", 258, 259], ["oxidative stress", "PROBLEM", 17, 33], ["hydrogen peroxide", "TREATMENT", 46, 63], ["a thiol-dependent catalytic cycle", "TREATMENT", 76, 109], ["NF", "TEST", 214, 216], ["oxidative stress", "OBSERVATION", 17, 33]]], ["PRDX4 is abundantly expressed in the pancreas, liver and heart, while the lowest expression in blood leukocytes and the brain (Schulte, 2011).General functions of PRDXs ::: PRDXsPRDX5 (ACR1, PMP20 or AOEB166) is an antioxidant enzyme implicated as a protective role against oxidative stress through reduction of hydrogen peroxide and alkyl hydroperoxides with reducing equivalents provided through the Trx system and is involved in intracellular redox signaling (Knoops, Goemaere, Van der Eecken, & Declercq, 2010).", [["pancreas", "ANATOMY", 37, 45], ["liver", "ANATOMY", 47, 52], ["heart", "ANATOMY", 57, 62], ["blood leukocytes", "ANATOMY", 95, 111], ["brain", "ANATOMY", 120, 125], ["intracellular", "ANATOMY", 432, 445], ["hydrogen peroxide", "CHEMICAL", 312, 329], ["alkyl hydroperoxides", "CHEMICAL", 334, 354], ["hydrogen peroxide", "CHEMICAL", 312, 329], ["alkyl hydroperoxides", "CHEMICAL", 334, 354], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["pancreas", "ORGAN", 37, 45], ["liver", "ORGAN", 47, 52], ["heart", "ORGAN", 57, 62], ["blood leukocytes", "CELL", 95, 111], ["brain", "ORGAN", 120, 125], ["PRDXs", "GENE_OR_GENE_PRODUCT", 163, 168], ["PRDXsPRDX5", "GENE_OR_GENE_PRODUCT", 173, 183], ["ACR1", "GENE_OR_GENE_PRODUCT", 185, 189], ["PMP20", "GENE_OR_GENE_PRODUCT", 191, 196], ["AOEB166", "GENE_OR_GENE_PRODUCT", 200, 207], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 312, 329], ["alkyl hydroperoxides", "SIMPLE_CHEMICAL", 334, 354], ["Trx", "GENE_OR_GENE_PRODUCT", 402, 405], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 432, 445], ["PRDX4", "PROTEIN", 0, 5], ["blood leukocytes", "CELL_TYPE", 95, 111], ["PRDXs", "PROTEIN", 163, 168], ["PRDXsPRDX5", "PROTEIN", 173, 183], ["ACR1", "PROTEIN", 185, 189], ["PMP20", "PROTEIN", 191, 196], ["Trx", "PROTEIN", 402, 405], ["blood leukocytes", "TEST", 95, 111], ["an antioxidant enzyme", "PROBLEM", 212, 233], ["oxidative stress", "PROBLEM", 274, 290], ["hydrogen peroxide", "TREATMENT", 312, 329], ["alkyl hydroperoxides", "TREATMENT", 334, 354], ["reducing equivalents", "TREATMENT", 360, 380], ["the Trx system", "TREATMENT", 398, 412], ["pancreas", "ANATOMY", 37, 45], ["liver", "ANATOMY", 47, 52], ["heart", "ANATOMY", 57, 62], ["blood leukocytes", "ANATOMY", 95, 111], ["brain", "ANATOMY", 120, 125]]], ["PRDX5 is a thiol peroxidase that reduces H2O2 105 times faster than free cysteine that shows hydrogen bonds in the active sites (Stephanie et al., 2014).", [["PRDX5", "CHEMICAL", 0, 5], ["thiol", "CHEMICAL", 11, 16], ["H2O2", "CHEMICAL", 41, 45], ["cysteine", "CHEMICAL", 73, 81], ["thiol", "CHEMICAL", 11, 16], ["H2O2", "CHEMICAL", 41, 45], ["cysteine", "CHEMICAL", 73, 81], ["hydrogen", "CHEMICAL", 93, 101], ["PRDX5", "GENE_OR_GENE_PRODUCT", 0, 5], ["peroxidase", "GENE_OR_GENE_PRODUCT", 17, 27], ["H2O2", "SIMPLE_CHEMICAL", 41, 45], ["cysteine", "AMINO_ACID", 73, 81], ["PRDX5", "PROTEIN", 0, 5], ["thiol peroxidase", "PROTEIN", 11, 27], ["a thiol peroxidase", "TREATMENT", 9, 27], ["H2O2", "TREATMENT", 41, 45], ["free cysteine", "TREATMENT", 68, 81], ["hydrogen bonds", "OBSERVATION", 93, 107], ["active", "OBSERVATION_MODIFIER", 115, 121], ["sites", "OBSERVATION_MODIFIER", 122, 127]]], ["The PRDX5 gene is mapped on chromosome on 11q13.1 that displays mitochondrial presequence and 3 cysteines involved in antioxidant activity with C-terminal peroxisomal sequence (Knoops et al., 2010, Nguy\u00ean-nhu et al., 2007).", [["chromosome", "ANATOMY", 28, 38], ["mitochondrial", "ANATOMY", 64, 77], ["cysteines", "CHEMICAL", 96, 105], ["C", "CHEMICAL", 144, 145], ["PRDX5", "GENE_OR_GENE_PRODUCT", 4, 9], ["chromosome", "CELLULAR_COMPONENT", 28, 38], ["mitochondrial presequence", "CELLULAR_COMPONENT", 64, 89], ["PRDX5 gene", "DNA", 4, 14], ["11q13.1", "DNA", 42, 49], ["C-terminal peroxisomal sequence", "DNA", 144, 175], ["mitochondrial presequence", "TEST", 64, 89], ["antioxidant activity", "TEST", 118, 138], ["C-terminal peroxisomal sequence", "PROBLEM", 144, 175]]], ["PRDX5 interacts with peroxisome receptor 1 which uses translation initiation sites to produce mitochondrial forms.", [["mitochondrial", "ANATOMY", 94, 107], ["PRDX5", "GENE_OR_GENE_PRODUCT", 0, 5], ["peroxisome receptor 1", "GENE_OR_GENE_PRODUCT", 21, 42], ["mitochondrial", "CELLULAR_COMPONENT", 94, 107], ["PRDX5", "PROTEIN", 0, 5], ["peroxisome receptor 1", "PROTEIN", 21, 42], ["translation initiation sites", "DNA", 54, 82], ["peroxisome receptor", "TREATMENT", 21, 40], ["translation initiation sites", "TREATMENT", 54, 82]]], ["PRDX5 acts as an antioxidant on different tissues under normal conditions and inflammatory processes through Trx system.", [["tissues", "ANATOMY", 42, 49], ["PRDX5", "CHEMICAL", 0, 5], ["PRDX5", "GENE_OR_GENE_PRODUCT", 0, 5], ["tissues", "TISSUE", 42, 49], ["Trx", "GENE_OR_GENE_PRODUCT", 109, 112], ["PRDX5", "PROTEIN", 0, 5], ["Trx", "PROTEIN", 109, 112], ["PRDX5 acts", "TREATMENT", 0, 10], ["inflammatory processes through Trx system", "PROBLEM", 78, 119], ["normal conditions", "OBSERVATION", 56, 73], ["inflammatory", "OBSERVATION", 78, 90]]], ["The analysis of the 5\u2019-flanking region of human PRDX5 revealed the presence of several putative response elements for transcription factors involved in the response of mammalian cells to oxidative stress such as Nrf2 or NF-\u03baB (Kropotov et al., 2007, Nguy\u00ean-nhu et al., 2007).", [["cells", "ANATOMY", 178, 183], ["human", "ORGANISM", 42, 47], ["PRDX5", "GENE_OR_GENE_PRODUCT", 48, 53], ["mammalian cells", "CELL", 168, 183], ["Nrf2", "GENE_OR_GENE_PRODUCT", 212, 216], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 220, 225], ["5\u2019-flanking region", "DNA", 20, 38], ["human PRDX5", "PROTEIN", 42, 53], ["putative response elements", "DNA", 87, 113], ["transcription factors", "PROTEIN", 118, 139], ["mammalian cells", "CELL_TYPE", 168, 183], ["Nrf2", "PROTEIN", 212, 216], ["NF-\u03baB", "PROTEIN", 220, 225], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["The analysis", "TEST", 0, 12], ["human PRDX5", "TEST", 42, 53], ["several putative response elements", "PROBLEM", 79, 113], ["transcription factors", "PROBLEM", 118, 139], ["mammalian cells", "PROBLEM", 168, 183], ["oxidative stress", "PROBLEM", 187, 203], ["Nrf2", "TEST", 212, 216], ["NF", "TEST", 220, 222], ["response elements", "OBSERVATION", 96, 113], ["mammalian cells", "OBSERVATION", 168, 183]]], ["PRDX5 expression is highly increased in vitro in primary macrophages exposed to lipopolysaccharide (LPS) and IFN-\u03b3 (Abbas et al., 2009, Diet et al., 2007).", [["primary macrophages", "ANATOMY", 49, 68], ["lipopolysaccharide", "CHEMICAL", 80, 98], ["LPS", "CHEMICAL", 100, 103], ["PRDX5", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophages", "CELL", 57, 68], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 80, 98], ["LPS", "SIMPLE_CHEMICAL", 100, 103], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 109, 114], ["PRDX5", "PROTEIN", 0, 5], ["primary macrophages", "CELL_TYPE", 49, 68], ["IFN", "PROTEIN", 109, 112], ["LPS", "TEST", 100, 103], ["IFN", "TEST", 109, 112], ["highly", "OBSERVATION_MODIFIER", 20, 26], ["increased", "OBSERVATION_MODIFIER", 27, 36]]], ["Downstream of the LPS/TLR pathway, p38 and c-Jun N-terminal kinase (JNK) were shown also to be major contributors to PRDX5 up-regulation (Diet et al., 2007).General functions of PRDXs ::: PRDXsPRDX6 belongs to the ahpC/TSA family and contains 1 Trx domain (Poole, Hall, & Nelson, 2011).", [["N", "CHEMICAL", 49, 50], ["LPS", "GENE_OR_GENE_PRODUCT", 18, 21], ["TLR", "GENE_OR_GENE_PRODUCT", 22, 25], ["p38", "GENE_OR_GENE_PRODUCT", 35, 38], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 43, 66], ["JNK", "GENE_OR_GENE_PRODUCT", 68, 71], ["PRDX5", "GENE_OR_GENE_PRODUCT", 117, 122], ["PRDXs", "GENE_OR_GENE_PRODUCT", 178, 183], ["PRDXsPRDX6", "GENE_OR_GENE_PRODUCT", 188, 198], ["ahpC", "GENE_OR_GENE_PRODUCT", 214, 218], ["TSA", "GENE_OR_GENE_PRODUCT", 219, 222], ["Trx", "GENE_OR_GENE_PRODUCT", 245, 248], ["TLR", "PROTEIN", 22, 25], ["p38", "PROTEIN", 35, 38], ["Jun N-terminal kinase", "PROTEIN", 45, 66], ["JNK", "PROTEIN", 68, 71], ["PRDX5", "PROTEIN", 117, 122], ["PRDXs", "PROTEIN", 178, 183], ["PRDXsPRDX6", "PROTEIN", 188, 198], ["ahpC", "PROTEIN", 214, 218], ["TSA family", "PROTEIN", 219, 229], ["Trx domain", "PROTEIN", 245, 255], ["the LPS/TLR pathway", "TEST", 14, 33], ["p38", "TEST", 35, 38], ["c", "TEST", 43, 44], ["PRDX5", "TEST", 117, 122]]], ["Among the six mammalian members of PRDX, PRDX6 has a unique property as a bifunctional enzyme that has glutathione peroxidase and iPLA2 activities (Fisher, 2011).", [["PRDX6", "CHEMICAL", 41, 46], ["glutathione", "CHEMICAL", 103, 114], ["glutathione", "CHEMICAL", 103, 114], ["PRDX", "GENE_OR_GENE_PRODUCT", 35, 39], ["PRDX6", "GENE_OR_GENE_PRODUCT", 41, 46], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 103, 125], ["iPLA2", "GENE_OR_GENE_PRODUCT", 130, 135], ["PRDX", "PROTEIN", 35, 39], ["PRDX6", "PROTEIN", 41, 46], ["bifunctional enzyme", "PROTEIN", 74, 93], ["glutathione peroxidase", "PROTEIN", 103, 125], ["iPLA2", "PROTEIN", 130, 135], ["a bifunctional enzyme", "TEST", 72, 93], ["glutathione peroxidase", "TREATMENT", 103, 125]]], ["PRDX6 involved in redox regulation of the cell can reduce H2O2 and short chain organic, fatty acid, and phospholipid hydroperoxides (Fisher, 2011).", [["cell", "ANATOMY", 42, 46], ["PRDX6", "CHEMICAL", 0, 5], ["H2O2", "CHEMICAL", 58, 62], ["fatty acid", "CHEMICAL", 88, 98], ["phospholipid hydroperoxides", "CHEMICAL", 104, 131], ["H2O2", "CHEMICAL", 58, 62], ["fatty acid", "CHEMICAL", 88, 98], ["hydroperoxides", "CHEMICAL", 117, 131], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 42, 46], ["H2O2", "SIMPLE_CHEMICAL", 58, 62], ["fatty acid", "SIMPLE_CHEMICAL", 88, 98], ["phospholipid hydroperoxides", "SIMPLE_CHEMICAL", 104, 131], ["PRDX6", "PROTEIN", 0, 5], ["PRDX6", "PROBLEM", 0, 5], ["H2O2", "TREATMENT", 58, 62], ["short chain organic", "TREATMENT", 67, 86], ["fatty acid", "TEST", 88, 98]]], ["PRDX6 plays a role in the regulation of phospholipid turnover as well as in protection against oxidative injury (Wang, Feinstein, Manevich, Ho, & Fisher, 2006).", [["PRDX6", "CHEMICAL", 0, 5], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["phospholipid", "SIMPLE_CHEMICAL", 40, 52], ["PRDX6", "PROTEIN", 0, 5], ["phospholipid turnover", "TREATMENT", 40, 61], ["oxidative injury", "PROBLEM", 95, 111]]], ["Site directed mutation analysis has clearly shown that activities of PRDX6 require two distinct active sites, namely, a Cys 47-dependent peroxidase activity and a Ser 32-dependent iPLA2 activity (Chen, Dodia, Feinstein, Jain, & Fisher, 2000). iPLA2 catalyzes the hydrolysis of the sn-2 fatty acyl ester bond of glycerophospholipides to produce free fatty acids and lysophospholipids (Markova et al., 2005, Shalini et al., 2014).", [["sn-2 fatty acyl ester", "CHEMICAL", 281, 302], ["glycerophospholipides", "CHEMICAL", 311, 332], ["fatty acids", "CHEMICAL", 349, 360], ["lysophospholipids", "CHEMICAL", 365, 382], ["Cys", "CHEMICAL", 120, 123], ["Ser", "CHEMICAL", 163, 166], ["sn-2 fatty acyl ester", "CHEMICAL", 281, 302], ["glycerophospholipides", "CHEMICAL", 311, 332], ["fatty acids", "CHEMICAL", 349, 360], ["lysophospholipids", "CHEMICAL", 365, 382], ["PRDX6", "GENE_OR_GENE_PRODUCT", 69, 74], ["peroxidase", "GENE_OR_GENE_PRODUCT", 137, 147], ["Ser 32", "SIMPLE_CHEMICAL", 163, 169], ["iPLA2", "GENE_OR_GENE_PRODUCT", 180, 185], ["iPLA2", "GENE_OR_GENE_PRODUCT", 243, 248], ["sn-2 fatty acyl ester", "SIMPLE_CHEMICAL", 281, 302], ["glycerophospholipides", "SIMPLE_CHEMICAL", 311, 332], ["free fatty acids", "SIMPLE_CHEMICAL", 344, 360], ["lysophospholipids", "SIMPLE_CHEMICAL", 365, 382], ["PRDX6", "PROTEIN", 69, 74], ["Cys 47-dependent peroxidase", "PROTEIN", 120, 147], ["Ser 32", "PROTEIN", 163, 169], ["iPLA2", "PROTEIN", 180, 185], ["iPLA2", "PROTEIN", 243, 248], ["Site directed mutation analysis", "TEST", 0, 31], ["a Cys", "TEST", 118, 123], ["iPLA2", "TEST", 243, 248], ["the sn-2 fatty acyl ester bond of glycerophospholipides", "TREATMENT", 277, 332], ["free fatty acids", "TREATMENT", 344, 360]]], ["PRDX6 prefers phosphatidylcholines as substrates, particularly those with arachidonic acid (AA) or palmitic acid at the sn-2 position (Chen et al., 2000, Manevich and Fisher, 2005).", [["PRDX6", "CHEMICAL", 0, 5], ["phosphatidylcholines", "CHEMICAL", 14, 34], ["arachidonic acid", "CHEMICAL", 74, 90], ["AA", "CHEMICAL", 92, 94], ["palmitic acid", "CHEMICAL", 99, 112], ["phosphatidylcholines", "CHEMICAL", 14, 34], ["arachidonic acid", "CHEMICAL", 74, 90], ["palmitic acid", "CHEMICAL", 99, 112], ["PRDX6", "SIMPLE_CHEMICAL", 0, 5], ["phosphatidylcholines", "SIMPLE_CHEMICAL", 14, 34], ["arachidonic acid", "SIMPLE_CHEMICAL", 74, 90], ["AA", "SIMPLE_CHEMICAL", 92, 94], ["palmitic acid", "SIMPLE_CHEMICAL", 99, 112], ["PRDX6", "PROTEIN", 0, 5], ["PRDX6 prefers phosphatidylcholines", "TREATMENT", 0, 34], ["arachidonic acid (AA", "TREATMENT", 74, 94], ["palmitic acid", "TEST", 99, 112]]], ["The ability of PRDX6 to release AA seems important, given the crucial role of AA in phospholipid metabolism and cell signaling (Hooks & Cummings, 2008).", [["cell", "ANATOMY", 112, 116], ["PRDX6", "CHEMICAL", 15, 20], ["AA", "CHEMICAL", 32, 34], ["AA", "CHEMICAL", 78, 80], ["PRDX6", "GENE_OR_GENE_PRODUCT", 15, 20], ["AA", "SIMPLE_CHEMICAL", 32, 34], ["AA", "SIMPLE_CHEMICAL", 78, 80], ["phospholipid", "SIMPLE_CHEMICAL", 84, 96], ["cell", "CELL", 112, 116], ["PRDX6", "PROTEIN", 15, 20]]], ["PRDX6 also protects cells via reducing peroxidazed membrane phospholipids and return to the cytosolic compartment (Wang, Feinstein, & Fisher, 2008).", [["cells", "ANATOMY", 20, 25], ["membrane", "ANATOMY", 51, 59], ["cytosolic compartment", "ANATOMY", 92, 113], ["PRDX6", "CHEMICAL", 0, 5], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 20, 25], ["membrane phospholipids", "CELLULAR_COMPONENT", 51, 73], ["PRDX6", "PROTEIN", 0, 5], ["PRDX6", "TREATMENT", 0, 5], ["reducing peroxidazed membrane phospholipids", "TREATMENT", 30, 73], ["cytosolic compartment", "ANATOMY", 92, 113]]], ["General properties of peroxiredoxin isoforms are briefly summarized in Table 1, and the cellular localization and the roles of PRDXs are in Fig. 2.Regulation of PRDXs expression ::: PRDXsGeneral regulatory pathway of PRDX expression is in Fig. 3.", [["cellular", "ANATOMY", 88, 96], ["peroxiredoxin", "GENE_OR_GENE_PRODUCT", 22, 35], ["cellular", "CELL", 88, 96], ["PRDXs", "GENE_OR_GENE_PRODUCT", 127, 132], ["PRDXs", "GENE_OR_GENE_PRODUCT", 161, 166], ["PRDXsGeneral", "GENE_OR_GENE_PRODUCT", 182, 194], ["PRDX", "GENE_OR_GENE_PRODUCT", 217, 221], ["peroxiredoxin isoforms", "PROTEIN", 22, 44], ["PRDXs", "PROTEIN", 127, 132], ["PRDXs", "PROTEIN", 161, 166], ["PRDX", "PROTEIN", 217, 221], ["peroxiredoxin isoforms", "TREATMENT", 22, 44], ["the cellular localization", "TEST", 84, 109]]], ["PRDXs are regulated at multiple levels, including both transcriptional regulation and post-translational modifications (Klotz et al., 2015, Riquier et al., 2014).", [["PRDXs", "GENE_OR_GENE_PRODUCT", 0, 5], ["PRDXs", "PROTEIN", 0, 5], ["multiple", "OBSERVATION_MODIFIER", 23, 31], ["levels", "OBSERVATION_MODIFIER", 32, 38], ["transcriptional regulation", "OBSERVATION", 55, 81], ["post-translational modifications", "OBSERVATION", 86, 118]]], ["PRDX1 peroxidase activity is regulated by Pin1.", [["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["peroxidase", "GENE_OR_GENE_PRODUCT", 6, 16], ["Pin1", "GENE_OR_GENE_PRODUCT", 42, 46], ["PRDX1 peroxidase", "PROTEIN", 0, 16], ["Pin1", "PROTEIN", 42, 46]]], ["Pin1 facilitates the protein phosphatase 2A-mediated dephosphorylation of PRDX1, which helps to explain the accumulation of the inactive phosphorylated form of PRDX1 in Pin1-/- MEFs (Chu et al., 2013).", [["MEFs", "ANATOMY", 177, 181], ["Pin1", "GENE_OR_GENE_PRODUCT", 0, 4], ["protein phosphatase 2A", "GENE_OR_GENE_PRODUCT", 21, 43], ["PRDX1", "GENE_OR_GENE_PRODUCT", 74, 79], ["PRDX1", "GENE_OR_GENE_PRODUCT", 160, 165], ["Pin1", "GENE_OR_GENE_PRODUCT", 169, 173], ["MEFs", "CELL", 177, 181], ["Pin1", "PROTEIN", 0, 4], ["protein phosphatase 2A", "PROTEIN", 21, 43], ["PRDX1", "PROTEIN", 74, 79], ["PRDX1", "PROTEIN", 160, 165], ["Pin1", "PROTEIN", 169, 173], ["the protein phosphatase", "TEST", 17, 40], ["dephosphorylation of PRDX1", "TREATMENT", 53, 79]]], ["PRDX2 is silenced by a decreased histone H3 acetylation and DNA hypermethylation in AML (Agrawal Singh et al., 2012).", [["AML", "ANATOMY", 84, 87], ["AML", "DISEASE", 84, 87], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["histone H3", "GENE_OR_GENE_PRODUCT", 33, 43], ["DNA", "CELLULAR_COMPONENT", 60, 63], ["AML", "CANCER", 84, 87], ["PRDX2", "PROTEIN", 0, 5], ["histone H3", "PROTEIN", 33, 43], ["a decreased histone H3 acetylation", "TREATMENT", 21, 55], ["DNA hypermethylation in AML", "PROBLEM", 60, 87], ["decreased histone", "OBSERVATION", 23, 40], ["H3 acetylation", "OBSERVATION", 41, 55]]], ["A recent study also demonstrated a critical role for Foxo3a in regulating the gene expression of PRDX3 in human cardiac fibroblasts (Chiribau et al., 2008).", [["cardiac fibroblasts", "ANATOMY", 112, 131], ["Foxo3a", "GENE_OR_GENE_PRODUCT", 53, 59], ["PRDX3", "GENE_OR_GENE_PRODUCT", 97, 102], ["human", "ORGANISM", 106, 111], ["cardiac fibroblasts", "CELL", 112, 131], ["Foxo3a", "PROTEIN", 53, 59], ["PRDX3", "PROTEIN", 97, 102], ["human cardiac fibroblasts", "CELL_TYPE", 106, 131], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["A recent study", "TEST", 0, 14], ["Foxo3a", "TREATMENT", 53, 59], ["cardiac", "ANATOMY", 112, 119], ["fibroblasts", "OBSERVATION", 120, 131]]], ["In the promoter of human PRDX5 gene, the binding sites for both nuclear respiratory factor 1 and nuclear respiratory factor 2 have been predicted (Kropotov et al., 2007).", [["human", "ORGANISM", 19, 24], ["PRDX5", "GENE_OR_GENE_PRODUCT", 25, 30], ["nuclear respiratory factor 1", "GENE_OR_GENE_PRODUCT", 64, 92], ["nuclear respiratory factor 2", "GENE_OR_GENE_PRODUCT", 97, 125], ["promoter", "DNA", 7, 15], ["human PRDX5 gene", "DNA", 19, 35], ["binding sites", "DNA", 41, 54], ["nuclear respiratory factor 1", "PROTEIN", 64, 92], ["nuclear respiratory factor 2", "PROTEIN", 97, 125], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["human PRDX5 gene", "TREATMENT", 19, 35], ["the binding sites", "PROBLEM", 37, 54], ["both nuclear respiratory factor", "TEST", 59, 90], ["nuclear respiratory factor", "TEST", 97, 123], ["respiratory", "ANATOMY", 72, 83], ["respiratory", "ANATOMY", 105, 116]]], ["Increased transcription of PRDX6 has been reported to be mediated by Nrf2 via an antioxidant response element-driven mechanism (Chowdhury et al., 2009).", [["PRDX6", "GENE_OR_GENE_PRODUCT", 27, 32], ["Nrf2", "GENE_OR_GENE_PRODUCT", 69, 73], ["PRDX6", "PROTEIN", 27, 32], ["Nrf2", "PROTEIN", 69, 73], ["antioxidant response element", "DNA", 81, 109], ["Increased transcription of PRDX6", "PROBLEM", 0, 32], ["an antioxidant response element", "TREATMENT", 78, 109]]], ["The MAPKs can mediate phosphorylation of PRDX6 at Thr-177 with a consequent marked increase in its aiPLA2 activity (Wu et al., 2009).", [["Thr-177", "CHEMICAL", 50, 57], ["Thr", "CHEMICAL", 50, 53], ["MAPKs", "GENE_OR_GENE_PRODUCT", 4, 9], ["PRDX6", "GENE_OR_GENE_PRODUCT", 41, 46], ["Thr-177", "AMINO_ACID", 50, 57], ["aiPLA2", "GENE_OR_GENE_PRODUCT", 99, 105], ["MAPKs", "PROTEIN", 4, 9], ["PRDX6", "PROTEIN", 41, 46], ["aiPLA2", "PROTEIN", 99, 105], ["The MAPKs", "TEST", 0, 9], ["PRDX6", "TEST", 41, 46], ["Thr", "TEST", 50, 53], ["a consequent marked increase in its aiPLA2 activity", "PROBLEM", 63, 114], ["marked", "OBSERVATION_MODIFIER", 76, 82], ["increase", "OBSERVATION_MODIFIER", 83, 91]]], ["SP-A and PRDX6 directly interact, which provides a mechanism for regulation of the aiPLA2 activity of PRDX6 by SP-A (Wu et al., 2006).", [["SP-A", "GENE_OR_GENE_PRODUCT", 0, 4], ["PRDX6", "GENE_OR_GENE_PRODUCT", 9, 14], ["aiPLA2", "GENE_OR_GENE_PRODUCT", 83, 89], ["PRDX6", "GENE_OR_GENE_PRODUCT", 102, 107], ["SP-A", "GENE_OR_GENE_PRODUCT", 111, 115], ["SP", "PROTEIN", 0, 2], ["PRDX6", "PROTEIN", 9, 14], ["aiPLA2", "PROTEIN", 83, 89], ["PRDX6", "PROTEIN", 102, 107], ["SP", "PROTEIN", 111, 113]]], ["Recent findings suggest that Fkbp52 deficiency diminishes the threshold against OS by reducing PRDX6 levels (Hirota et al., 2010).", [["Fkbp52", "GENE_OR_GENE_PRODUCT", 29, 35], ["PRDX6", "GENE_OR_GENE_PRODUCT", 95, 100], ["Fkbp52", "PROTEIN", 29, 35], ["PRDX6", "PROTEIN", 95, 100], ["Fkbp52 deficiency", "PROBLEM", 29, 46], ["PRDX6 levels", "TEST", 95, 107], ["Fkbp52 deficiency", "OBSERVATION", 29, 46]]], ["A recent study also suggested that 67 (phox) binds to phospho-PRDX6 and inhibits its PLA2 activity, an interaction that could function to terminate the PLA2-mediated NOX2 activation signal (Krishnaiah, Dodia, Feinstein, & Fisher, 2013).", [["phox", "GENE_OR_GENE_PRODUCT", 39, 43], ["phospho-PRDX6", "GENE_OR_GENE_PRODUCT", 54, 67], ["PLA2", "GENE_OR_GENE_PRODUCT", 85, 89], ["PLA2", "GENE_OR_GENE_PRODUCT", 152, 156], ["NOX2", "GENE_OR_GENE_PRODUCT", 166, 170], ["67 (phox)", "PROTEIN", 35, 44], ["phospho-PRDX6", "PROTEIN", 54, 67], ["PLA2", "PROTEIN", 85, 89], ["PLA2", "PROTEIN", 152, 156], ["NOX2", "PROTEIN", 166, 170], ["A recent study", "TEST", 0, 14], ["phospho-PRDX6", "TEST", 54, 67], ["its PLA2 activity", "PROBLEM", 81, 98], ["the PLA2", "TEST", 148, 156]]], ["Moreover, the expression of PRDXs is induced by several factors.", [["PRDXs", "GENE_OR_GENE_PRODUCT", 28, 33], ["PRDXs", "PROTEIN", 28, 33], ["PRDXs", "PROBLEM", 28, 33]]], ["PRDX1 is also detected in mouse body fluids, and the secretion of PRDX1 from cultured cells was enhanced following the treatment with cytokines such as TGF-\u03b2, oncostatin M and IL1-\u03b2 (Ishii, Warabi, & Yanagawa, 2012).", [["body fluids", "ANATOMY", 32, 43], ["cells", "ANATOMY", 86, 91], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["mouse", "ORGANISM", 26, 31], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["fluids", "ORGANISM_SUBSTANCE", 37, 43], ["PRDX1", "GENE_OR_GENE_PRODUCT", 66, 71], ["cells", "CELL", 86, 91], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 152, 157], ["oncostatin M", "GENE_OR_GENE_PRODUCT", 159, 171], ["IL1-\u03b2", "SIMPLE_CHEMICAL", 176, 181], ["PRDX1", "PROTEIN", 0, 5], ["PRDX1", "PROTEIN", 66, 71], ["cultured cells", "CELL_LINE", 77, 91], ["cytokines", "PROTEIN", 134, 143], ["TGF-\u03b2", "PROTEIN", 152, 157], ["oncostatin M", "PROTEIN", 159, 171], ["IL1", "PROTEIN", 176, 179], ["mouse", "SPECIES", 26, 31], ["mouse", "SPECIES", 26, 31], ["PRDX1", "PROBLEM", 0, 5], ["mouse body fluids", "TREATMENT", 26, 43], ["the secretion of PRDX1 from cultured cells", "TEST", 49, 91], ["the treatment", "TREATMENT", 115, 128], ["cytokines", "TREATMENT", 134, 143], ["TGF", "TEST", 152, 155], ["oncostatin M", "TREATMENT", 159, 171], ["IL1", "TEST", 176, 179]]], ["Another recent study showed PRDX1 and PRDX2 can be secreted from cells as disulphide homodimers in association with exosomes following stimulation by LPS or TNF-\u03b1 (Mullen, Hanschmann, Lillig, Herzenberg, & Ghezzi, 2015).", [["cells", "ANATOMY", 65, 70], ["exosomes", "ANATOMY", 116, 124], ["LPS", "CHEMICAL", 150, 153], ["disulphide", "CHEMICAL", 74, 84], ["PRDX1", "GENE_OR_GENE_PRODUCT", 28, 33], ["PRDX2", "GENE_OR_GENE_PRODUCT", 38, 43], ["cells", "CELL", 65, 70], ["exosomes", "CELL", 116, 124], ["LPS", "SIMPLE_CHEMICAL", 150, 153], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 157, 162], ["PRDX1", "PROTEIN", 28, 33], ["PRDX2", "PROTEIN", 38, 43], ["disulphide homodimers", "PROTEIN", 74, 95], ["exosomes", "CELL_TYPE", 116, 124], ["TNF", "PROTEIN", 157, 160], ["Another recent study", "TEST", 0, 20], ["PRDX1", "PROBLEM", 28, 33], ["PRDX2", "PROBLEM", 38, 43], ["disulphide homodimers", "TREATMENT", 74, 95]]], ["PRDX1 is up-regulated in cells under oxidative stress conditions.", [["cells", "ANATOMY", 25, 30], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 25, 30], ["PRDX1", "PROTEIN", 0, 5], ["oxidative stress conditions", "OBSERVATION", 37, 64]]], ["The transcription factor Nrf2 and its inhibitor Keap1 play an essential role in the regulation of the stress-induced PRDX1 gene activation through the antioxidant/electrophile response element (ARE/EpRE) (Takeuchi et al., 2013).", [["Nrf2", "GENE_OR_GENE_PRODUCT", 25, 29], ["Keap1", "GENE_OR_GENE_PRODUCT", 48, 53], ["PRDX1", "GENE_OR_GENE_PRODUCT", 117, 122], ["transcription factor", "PROTEIN", 4, 24], ["Nrf2", "PROTEIN", 25, 29], ["Keap1", "PROTEIN", 48, 53], ["PRDX1", "PROTEIN", 117, 122], ["electrophile response element", "DNA", 163, 192], ["ARE", "DNA", 194, 197], ["EpRE", "DNA", 198, 202], ["The transcription factor Nrf2", "TEST", 0, 29], ["its inhibitor Keap1", "TREATMENT", 34, 53], ["the stress-induced PRDX1 gene activation", "TREATMENT", 98, 138], ["the antioxidant/electrophile response element", "TREATMENT", 147, 192]]], ["The expression levels of PRDX2 and PRDX3 are also up-regulated under oxidative stress conditions (Stresing et al., 2013).", [["PRDX2", "GENE_OR_GENE_PRODUCT", 25, 30], ["PRDX3", "GENE_OR_GENE_PRODUCT", 35, 40], ["PRDX2", "PROTEIN", 25, 30], ["PRDX3", "PROTEIN", 35, 40], ["PRDX2", "TREATMENT", 25, 30], ["PRDX3", "TREATMENT", 35, 40]]], ["PRDX6 is an oxidative stress inducible protein regulated by Nrf2 and activation of the gene expression was observed in mouse lungs by hyperoxia and in cultured lung epithelial cells following treatment with H2O2 or paraquat (Chowdhury et al., 2009).", [["lungs", "ANATOMY", 125, 130], ["lung epithelial cells", "ANATOMY", 160, 181], ["hyperoxia", "CHEMICAL", 134, 143], ["H2O2", "CHEMICAL", 207, 211], ["paraquat", "CHEMICAL", 215, 223], ["H2O2", "CHEMICAL", 207, 211], ["paraquat", "CHEMICAL", 215, 223], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["Nrf2", "GENE_OR_GENE_PRODUCT", 60, 64], ["mouse", "ORGANISM", 119, 124], ["lungs", "ORGAN", 125, 130], ["lung epithelial cells", "CELL", 160, 181], ["H2O2", "SIMPLE_CHEMICAL", 207, 211], ["paraquat", "SIMPLE_CHEMICAL", 215, 223], ["PRDX6", "PROTEIN", 0, 5], ["oxidative stress inducible protein", "PROTEIN", 12, 46], ["Nrf2", "PROTEIN", 60, 64], ["cultured lung epithelial cells", "CELL_LINE", 151, 181], ["mouse", "SPECIES", 119, 124], ["mouse", "SPECIES", 119, 124], ["an oxidative stress inducible protein regulated", "PROBLEM", 9, 56], ["the gene expression", "PROBLEM", 83, 102], ["hyperoxia", "PROBLEM", 134, 143], ["H2O2", "TREATMENT", 207, 211], ["oxidative stress inducible protein regulated", "OBSERVATION", 12, 56], ["lungs", "ANATOMY", 125, 130], ["hyperoxia", "OBSERVATION", 134, 143], ["lung", "ANATOMY", 160, 164], ["epithelial cells", "OBSERVATION", 165, 181]]], ["In addition to oxidative stress, keratinocyte growth factor also regulates PRDX6 gene expression (Chowdhury et al., 2014).", [["keratinocyte growth factor", "GENE_OR_GENE_PRODUCT", 33, 59], ["PRDX6", "GENE_OR_GENE_PRODUCT", 75, 80], ["keratinocyte growth factor", "PROTEIN", 33, 59], ["PRDX6 gene", "DNA", 75, 85], ["oxidative stress", "PROBLEM", 15, 31], ["keratinocyte growth factor", "PROBLEM", 33, 59], ["oxidative stress", "OBSERVATION", 15, 31]]], ["PRDX6 expression is down regulated upon serum deprivation and subsequently induced in a time-dependent manner in response to KGF, dexamethasone and H2O2 (Gallagher & Phelan, 2007).", [["serum", "ANATOMY", 40, 45], ["dexamethasone", "CHEMICAL", 130, 143], ["H2O2", "CHEMICAL", 148, 152], ["dexamethasone", "CHEMICAL", 130, 143], ["H2O2", "CHEMICAL", 148, 152], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["KGF", "GENE_OR_GENE_PRODUCT", 125, 128], ["dexamethasone", "SIMPLE_CHEMICAL", 130, 143], ["H2O2", "SIMPLE_CHEMICAL", 148, 152], ["PRDX6", "PROTEIN", 0, 5], ["KGF", "PROTEIN", 125, 128], ["PRDX6 expression", "PROBLEM", 0, 16], ["serum deprivation", "TEST", 40, 57], ["KGF", "TREATMENT", 125, 128], ["dexamethasone", "TREATMENT", 130, 143], ["H2O2", "TREATMENT", 148, 152]]], ["TNF-\u03b1 regulates the expression of PRDX6 to influence neuroplasticity (Zhang et al., 2015).Dual function of PRDX1 in cancer ::: Roles of PRDXs in the cancer development ::: PRDXs and cancerFirst, the anti-tumor effect of PRDX1 is well established in breast cancers.", [["cancer", "ANATOMY", 116, 122], ["cancer", "ANATOMY", 149, 155], ["breast cancers", "ANATOMY", 249, 263], ["cancer", "DISEASE", 116, 122], ["cancer", "DISEASE", 149, 155], ["PRDX1", "CHEMICAL", 220, 225], ["breast cancers", "DISEASE", 249, 263], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["PRDX6", "GENE_OR_GENE_PRODUCT", 34, 39], ["PRDX1", "GENE_OR_GENE_PRODUCT", 107, 112], ["cancer", "CANCER", 116, 122], ["PRDXs", "GENE_OR_GENE_PRODUCT", 136, 141], ["cancer", "CANCER", 149, 155], ["PRDXs", "GENE_OR_GENE_PRODUCT", 172, 177], ["anti-tumor", "CANCER", 199, 209], ["PRDX1", "GENE_OR_GENE_PRODUCT", 220, 225], ["breast cancers", "CANCER", 249, 263], ["TNF", "PROTEIN", 0, 3], ["\u03b1", "PROTEIN", 4, 5], ["PRDX6", "PROTEIN", 34, 39], ["PRDX1", "PROTEIN", 107, 112], ["PRDXs", "PROTEIN", 136, 141], ["PRDX1", "PROTEIN", 220, 225], ["TNF", "TEST", 0, 3], ["PRDX1", "PROBLEM", 220, 225], ["breast cancers", "PROBLEM", 249, 263], ["PRDX1", "OBSERVATION", 107, 112], ["cancer", "OBSERVATION", 116, 122], ["cancer", "OBSERVATION", 149, 155], ["breast", "ANATOMY", 249, 255], ["cancers", "OBSERVATION", 256, 263]]], ["Several evidences suggest that PRDX1 may act as a tumor suppressor in breast cancer.", [["tumor", "ANATOMY", 50, 55], ["breast cancer", "ANATOMY", 70, 83], ["PRDX1", "CHEMICAL", 31, 36], ["tumor", "DISEASE", 50, 55], ["breast cancer", "DISEASE", 70, 83], ["PRDX1", "GENE_OR_GENE_PRODUCT", 31, 36], ["tumor", "CANCER", 50, 55], ["breast cancer", "CANCER", 70, 83], ["PRDX1", "PROTEIN", 31, 36], ["PRDX1", "PROBLEM", 31, 36], ["a tumor suppressor in breast cancer", "PROBLEM", 48, 83], ["tumor", "OBSERVATION", 50, 55], ["breast", "ANATOMY", 70, 76], ["cancer", "OBSERVATION", 77, 83]]], ["PRDX1 interacts with the c-Myc oncogene and suppresses its transcriptional activity (Egler et al., 2005).", [["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["c-Myc", "GENE_OR_GENE_PRODUCT", 25, 30], ["PRDX1", "PROTEIN", 0, 5], ["c-Myc oncogene", "DNA", 25, 39], ["the c-Myc oncogene", "TREATMENT", 21, 39]]], ["Cao et al. demonstrated that PRDX1 protects the tumor suppressive function of PTEN phosphatase, likely due to the presence of a ROS sensitive cysteine in the catalytic domain, and reduces predisposition of genetically modified mice to develop Ras-induced mammary tumors (Cao et al., 2009).", [["tumor", "ANATOMY", 48, 53], ["mammary tumors", "ANATOMY", 255, 269], ["PRDX1", "CHEMICAL", 29, 34], ["tumor", "DISEASE", 48, 53], ["ROS", "CHEMICAL", 128, 131], ["cysteine", "CHEMICAL", 142, 150], ["mammary tumors", "DISEASE", 255, 269], ["cysteine", "CHEMICAL", 142, 150], ["PRDX1", "GENE_OR_GENE_PRODUCT", 29, 34], ["tumor", "CANCER", 48, 53], ["PTEN", "GENE_OR_GENE_PRODUCT", 78, 82], ["ROS", "SIMPLE_CHEMICAL", 128, 131], ["cysteine", "AMINO_ACID", 142, 150], ["mice", "ORGANISM", 227, 231], ["mammary tumors", "CANCER", 255, 269], ["PRDX1", "PROTEIN", 29, 34], ["PTEN phosphatase", "PROTEIN", 78, 94], ["catalytic domain", "PROTEIN", 158, 174], ["mice", "SPECIES", 227, 231], ["mice", "SPECIES", 227, 231], ["PRDX1", "PROBLEM", 29, 34], ["PTEN phosphatase", "TEST", 78, 94], ["a ROS sensitive cysteine in the catalytic domain", "PROBLEM", 126, 174], ["Ras-induced mammary tumors", "PROBLEM", 243, 269], ["tumor", "OBSERVATION", 48, 53], ["mammary", "ANATOMY", 255, 262], ["tumors", "OBSERVATION", 263, 269]]], ["PRDX1-deficient mice suffer from shortened survival due to the development of hemolytic anemia and multiple tumors, including mammary carcinomas (Neumann et al., 2003).", [["tumors", "ANATOMY", 108, 114], ["mammary carcinomas", "ANATOMY", 126, 144], ["hemolytic anemia", "DISEASE", 78, 94], ["tumors", "DISEASE", 108, 114], ["mammary carcinomas", "DISEASE", 126, 144], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 16, 20], ["tumors", "CANCER", 108, 114], ["mammary carcinomas", "CANCER", 126, 144], ["PRDX1", "PROTEIN", 0, 5], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["shortened survival", "PROBLEM", 33, 51], ["hemolytic anemia", "PROBLEM", 78, 94], ["multiple tumors", "PROBLEM", 99, 114], ["mammary carcinomas", "PROBLEM", 126, 144], ["hemolytic", "OBSERVATION_MODIFIER", 78, 87], ["anemia", "OBSERVATION", 88, 94], ["multiple", "OBSERVATION_MODIFIER", 99, 107], ["tumors", "OBSERVATION", 108, 114], ["mammary", "ANATOMY", 126, 133], ["carcinomas", "OBSERVATION", 134, 144]]], ["These studies suggest that the breast tumor suppressive role of PRDX1 is mediated via c-Myc or PTEN pathways.Dual function of PRDX1 in cancer ::: Roles of PRDXs in the cancer development ::: PRDXs and cancerNext, the tumor promoting effect of PRDX1 is well established in breast cancer, oral squamous cell carcinoma, bladder cancer, lung cancer, prostate cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma and pancreatic cancer.", [["breast tumor", "ANATOMY", 31, 43], ["cancer", "ANATOMY", 135, 141], ["cancer", "ANATOMY", 168, 174], ["tumor", "ANATOMY", 217, 222], ["breast cancer", "ANATOMY", 272, 285], ["oral squamous cell carcinoma", "ANATOMY", 287, 315], ["bladder cancer", "ANATOMY", 317, 331], ["lung cancer", "ANATOMY", 333, 344], ["prostate cancer", "ANATOMY", 346, 361], ["hepatocellular carcinoma", "ANATOMY", 363, 387], ["esophageal squamous cell carcinoma", "ANATOMY", 389, 423], ["pancreatic cancer", "ANATOMY", 428, 445], ["breast tumor", "DISEASE", 31, 43], ["cancer", "DISEASE", 135, 141], ["cancer", "DISEASE", 168, 174], ["tumor", "DISEASE", 217, 222], ["breast cancer", "DISEASE", 272, 285], ["oral squamous cell carcinoma", "DISEASE", 287, 315], ["bladder cancer", "DISEASE", 317, 331], ["lung cancer", "DISEASE", 333, 344], ["prostate cancer", "DISEASE", 346, 361], ["hepatocellular carcinoma", "DISEASE", 363, 387], ["esophageal squamous cell carcinoma", "DISEASE", 389, 423], ["pancreatic cancer", "DISEASE", 428, 445], ["breast tumor", "CANCER", 31, 43], ["PRDX1", "GENE_OR_GENE_PRODUCT", 64, 69], ["c-Myc", "GENE_OR_GENE_PRODUCT", 86, 91], ["PTEN", "GENE_OR_GENE_PRODUCT", 95, 99], ["PRDX1", "GENE_OR_GENE_PRODUCT", 126, 131], ["cancer", "CANCER", 135, 141], ["PRDXs", "GENE_OR_GENE_PRODUCT", 155, 160], ["cancer", "CANCER", 168, 174], ["PRDXs", "GENE_OR_GENE_PRODUCT", 191, 196], ["tumor", "CANCER", 217, 222], ["PRDX1", "GENE_OR_GENE_PRODUCT", 243, 248], ["breast cancer", "CANCER", 272, 285], ["oral squamous cell carcinoma", "CANCER", 287, 315], ["bladder cancer", "CANCER", 317, 331], ["lung cancer", "CANCER", 333, 344], ["prostate cancer", "CANCER", 346, 361], ["hepatocellular carcinoma", "CANCER", 363, 387], ["esophageal squamous cell carcinoma", "CANCER", 389, 423], ["pancreatic cancer", "CANCER", 428, 445], ["PRDX1", "PROTEIN", 64, 69], ["Myc", "PROTEIN", 88, 91], ["PTEN", "PROTEIN", 95, 99], ["PRDX1", "PROTEIN", 126, 131], ["PRDXs", "PROTEIN", 155, 160], ["PRDX1", "PROTEIN", 243, 248], ["These studies", "TEST", 0, 13], ["the breast tumor", "PROBLEM", 27, 43], ["cancerNext", "TREATMENT", 201, 211], ["the tumor", "PROBLEM", 213, 222], ["PRDX1", "PROBLEM", 243, 248], ["breast cancer", "PROBLEM", 272, 285], ["oral squamous cell carcinoma", "PROBLEM", 287, 315], ["bladder cancer", "PROBLEM", 317, 331], ["lung cancer", "PROBLEM", 333, 344], ["prostate cancer", "PROBLEM", 346, 361], ["hepatocellular carcinoma", "PROBLEM", 363, 387], ["esophageal squamous cell carcinoma", "PROBLEM", 389, 423], ["pancreatic cancer", "PROBLEM", 428, 445], ["breast", "ANATOMY", 31, 37], ["tumor", "OBSERVATION", 38, 43], ["PRDX1", "OBSERVATION", 126, 131], ["cancer", "OBSERVATION", 135, 141], ["cancer", "OBSERVATION", 168, 174], ["tumor", "OBSERVATION", 217, 222], ["breast", "ANATOMY", 272, 278], ["cancer", "OBSERVATION", 279, 285], ["squamous cell carcinoma", "OBSERVATION", 292, 315], ["bladder", "ANATOMY", 317, 324], ["cancer", "OBSERVATION", 325, 331], ["lung", "ANATOMY", 333, 337], ["cancer", "OBSERVATION", 338, 344], ["prostate", "ANATOMY", 346, 354], ["cancer", "OBSERVATION", 355, 361], ["hepatocellular", "ANATOMY", 363, 377], ["carcinoma", "OBSERVATION", 378, 387], ["esophageal", "ANATOMY", 389, 399], ["squamous cell carcinoma", "OBSERVATION", 400, 423], ["pancreatic", "ANATOMY", 428, 438], ["cancer", "OBSERVATION", 439, 445]]], ["The role of PRDX1 in breast cancer has been controversial.", [["breast cancer", "ANATOMY", 21, 34], ["breast cancer", "DISEASE", 21, 34], ["PRDX1", "GENE_OR_GENE_PRODUCT", 12, 17], ["breast cancer", "CANCER", 21, 34], ["PRDX1", "PROTEIN", 12, 17], ["PRDX1 in breast cancer", "PROBLEM", 12, 34], ["breast", "ANATOMY", 21, 27], ["cancer", "OBSERVATION", 28, 34]]], ["Recent studies have shown that overexpression of PRDX1 mRNA in human breast carcinoma is associated with higher tumor grade (Cha, Suh, & Kim, 2009), and high expression of cytoplasmic PRDX1 protein correlated with an increased risk of local recurrence after radiotherapy (Woolston, Storr, Ellis, Morgan, & Martin, 2011).", [["breast carcinoma", "ANATOMY", 69, 85], ["tumor", "ANATOMY", 112, 117], ["cytoplasmic", "ANATOMY", 172, 183], ["breast carcinoma", "DISEASE", 69, 85], ["tumor", "DISEASE", 112, 117], ["PRDX1", "GENE_OR_GENE_PRODUCT", 49, 54], ["human", "ORGANISM", 63, 68], ["breast carcinoma", "CANCER", 69, 85], ["tumor", "CANCER", 112, 117], ["cytoplasmic", "ORGANISM_SUBSTANCE", 172, 183], ["PRDX1", "GENE_OR_GENE_PRODUCT", 184, 189], ["PRDX1 mRNA", "RNA", 49, 59], ["cytoplasmic PRDX1 protein", "PROTEIN", 172, 197], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["Recent studies", "TEST", 0, 14], ["PRDX1 mRNA in human breast carcinoma", "PROBLEM", 49, 85], ["higher tumor grade", "PROBLEM", 105, 123], ["cytoplasmic PRDX1 protein", "PROBLEM", 172, 197], ["local recurrence", "PROBLEM", 235, 251], ["radiotherapy (Woolston", "TREATMENT", 258, 280], ["PRDX1 mRNA", "OBSERVATION", 49, 59], ["breast", "ANATOMY", 69, 75], ["carcinoma", "OBSERVATION", 76, 85], ["higher", "OBSERVATION_MODIFIER", 105, 111], ["tumor", "OBSERVATION", 112, 117], ["cytoplasmic PRDX1", "OBSERVATION", 172, 189], ["increased", "OBSERVATION_MODIFIER", 217, 226], ["local", "OBSERVATION_MODIFIER", 235, 240], ["recurrence", "OBSERVATION", 241, 251]]], ["PRDX1 enhances p65-mediated cyclooxygenase (COX)-2 gene expression in estrogen receptor (ER) deficient human breast cancer cells (MDA-MB-231), and knockdown of PRDX1 can attenuate COX-2 expression by reducing the occupancy of NF-\u03baB transactivation potential of NF-\u03baB in ER-deficient-breast cancer cells (Wang et al., 2010).", [["breast cancer cells", "ANATOMY", 109, 128], ["MDA-MB-231", "ANATOMY", 130, 140], ["ER-deficient-breast cancer cells", "ANATOMY", 270, 302], ["estrogen", "CHEMICAL", 70, 78], ["breast cancer", "DISEASE", 109, 122], ["MDA-MB-231", "CHEMICAL", 130, 140], ["PRDX1", "CHEMICAL", 160, 165], ["breast cancer", "DISEASE", 283, 296], ["estrogen", "CHEMICAL", 70, 78], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["p65", "GENE_OR_GENE_PRODUCT", 15, 18], ["cyclooxygenase (COX)-2", "GENE_OR_GENE_PRODUCT", 28, 50], ["estrogen receptor", "GENE_OR_GENE_PRODUCT", 70, 87], ["ER", "GENE_OR_GENE_PRODUCT", 89, 91], ["human", "ORGANISM", 103, 108], ["MDA-MB-231", "CELL", 130, 140], ["PRDX1", "GENE_OR_GENE_PRODUCT", 160, 165], ["COX-2", "GENE_OR_GENE_PRODUCT", 180, 185], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 226, 231], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 261, 266], ["ER", "GENE_OR_GENE_PRODUCT", 270, 272], ["PRDX1", "PROTEIN", 0, 5], ["p65", "PROTEIN", 15, 18], ["cyclooxygenase (COX)-2 gene", "DNA", 28, 55], ["estrogen receptor (ER) deficient human breast cancer cells", "CELL_LINE", 70, 128], ["MDA-MB-231", "CELL_LINE", 130, 140], ["PRDX1", "PROTEIN", 160, 165], ["COX", "PROTEIN", 180, 183], ["NF-\u03baB", "PROTEIN", 226, 231], ["NF-\u03baB", "PROTEIN", 261, 266], ["ER", "PROTEIN", 270, 272], ["breast cancer cells", "CELL_TYPE", 283, 302], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["p65", "TEST", 15, 18], ["cyclooxygenase (COX)", "TREATMENT", 28, 48], ["gene expression in estrogen receptor", "TREATMENT", 51, 87], ["deficient human breast cancer cells", "PROBLEM", 93, 128], ["MDA-MB", "TEST", 130, 136], ["PRDX1", "PROBLEM", 160, 165], ["COX", "TEST", 180, 183], ["NF", "TEST", 261, 263], ["breast cancer cells", "PROBLEM", 283, 302], ["breast", "ANATOMY", 109, 115], ["cancer", "OBSERVATION", 116, 122], ["breast", "ANATOMY", 283, 289], ["cancer", "OBSERVATION", 290, 296]]], ["PRDX1 is also overexpressed in oral squamous cell carcinoma (Yanagawa et al., 2005).", [["oral squamous cell carcinoma", "ANATOMY", 31, 59], ["oral squamous cell carcinoma", "DISEASE", 31, 59], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["oral squamous cell carcinoma", "CANCER", 31, 59], ["PRDX1", "PROTEIN", 0, 5], ["PRDX1", "PROBLEM", 0, 5], ["oral squamous cell carcinoma", "PROBLEM", 31, 59], ["overexpressed", "OBSERVATION_MODIFIER", 14, 27], ["oral", "ANATOMY", 31, 35], ["squamous cell carcinoma", "OBSERVATION", 36, 59]]], ["A recent study provides experimental evidence that overexpression of PRDX1 is involved in oral carcinogenesis by upregulation of hemeoxygenase 1 and activation of NF-\u03baB pathway (Zhang et al., 2014).", [["oral", "ANATOMY", 90, 94], ["carcinogenesis", "DISEASE", 95, 109], ["PRDX1", "GENE_OR_GENE_PRODUCT", 69, 74], ["oral", "ORGANISM_SUBDIVISION", 90, 94], ["hemeoxygenase 1", "GENE_OR_GENE_PRODUCT", 129, 144], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 163, 168], ["PRDX1", "PROTEIN", 69, 74], ["hemeoxygenase 1", "PROTEIN", 129, 144], ["NF-\u03baB", "PROTEIN", 163, 168], ["A recent study", "TEST", 0, 14], ["overexpression of PRDX1", "PROBLEM", 51, 74], ["oral carcinogenesis", "PROBLEM", 90, 109], ["upregulation of hemeoxygenase", "TREATMENT", 113, 142]]], ["PRDX1 is also related with bladder cancer.", [["bladder cancer", "ANATOMY", 27, 41], ["bladder cancer", "DISEASE", 27, 41], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["bladder cancer", "CANCER", 27, 41], ["PRDX1", "PROTEIN", 0, 5], ["PRDX1", "PROBLEM", 0, 5], ["bladder cancer", "PROBLEM", 27, 41], ["bladder", "ANATOMY", 27, 34], ["cancer", "OBSERVATION", 35, 41]]], ["PRDX1 is highly expressed in bladder cancer tissues than in the bladder mucosa of normal controls or in normal mucosa surrounding cancer tissues (Quan et al., 2006).", [["bladder cancer tissues", "ANATOMY", 29, 51], ["bladder mucosa", "ANATOMY", 64, 78], ["mucosa", "ANATOMY", 111, 117], ["cancer tissues", "ANATOMY", 130, 144], ["bladder cancer", "DISEASE", 29, 43], ["cancer", "DISEASE", 130, 136], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["bladder cancer tissues", "TISSUE", 29, 51], ["bladder mucosa", "MULTI-TISSUE_STRUCTURE", 64, 78], ["normal mucosa", "TISSUE", 104, 117], ["surrounding cancer tissues", "TISSUE", 118, 144], ["PRDX1", "PROTEIN", 0, 5], ["PRDX1", "PROBLEM", 0, 5], ["bladder cancer tissues", "PROBLEM", 29, 51], ["bladder", "ANATOMY", 29, 36], ["cancer", "OBSERVATION", 37, 43], ["bladder mucosa", "ANATOMY", 64, 78], ["normal controls", "OBSERVATION", 82, 97], ["normal mucosa", "OBSERVATION", 104, 117], ["cancer", "OBSERVATION", 130, 136]]], ["Jiang et al showed that PRDX1 silencing by transfection of PRDX1 shRNA significantly suppressed growth, promoted apoptosis and regulated the cell cycle in bladder cancer cells and reduced the phospho-NF-\u03baB p50 and p65 protein expression suggesting that PRDX1 is related with bladder cancers by regulation of phosphorylation of NF-\u03baB subunit (Jiang et al., 2014a, b).", [["cell", "ANATOMY", 141, 145], ["bladder cancer cells", "ANATOMY", 155, 175], ["bladder cancers", "ANATOMY", 275, 290], ["bladder cancer", "DISEASE", 155, 169], ["bladder cancers", "DISEASE", 275, 290], ["PRDX1", "GENE_OR_GENE_PRODUCT", 24, 29], ["PRDX1", "GENE_OR_GENE_PRODUCT", 59, 64], ["cell", "CELL", 141, 145], ["bladder cancer cells", "CELL", 155, 175], ["NF-\u03baB p50", "GENE_OR_GENE_PRODUCT", 200, 209], ["p65", "GENE_OR_GENE_PRODUCT", 214, 217], ["PRDX1", "GENE_OR_GENE_PRODUCT", 253, 258], ["bladder cancers", "CANCER", 275, 290], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 327, 332], ["PRDX1", "PROTEIN", 24, 29], ["PRDX1 shRNA", "DNA", 59, 70], ["bladder cancer cells", "CELL_TYPE", 155, 175], ["NF-\u03baB p50", "PROTEIN", 200, 209], ["p65", "PROTEIN", 214, 217], ["PRDX1", "PROTEIN", 253, 258], ["NF-\u03baB subunit", "PROTEIN", 327, 340], ["PRDX1 silencing", "PROBLEM", 24, 39], ["PRDX1 shRNA", "PROBLEM", 59, 70], ["suppressed growth", "PROBLEM", 85, 102], ["promoted apoptosis", "PROBLEM", 104, 122], ["the cell cycle", "TEST", 137, 151], ["bladder cancer cells", "PROBLEM", 155, 175], ["the phospho", "TEST", 188, 199], ["p65 protein expression", "TEST", 214, 236], ["PRDX1", "PROBLEM", 253, 258], ["bladder cancers", "PROBLEM", 275, 290], ["phosphorylation of NF", "TREATMENT", 308, 329], ["bladder", "ANATOMY", 155, 162], ["cancer", "OBSERVATION", 163, 169], ["bladder", "ANATOMY", 275, 282], ["cancers", "OBSERVATION", 283, 290]]], ["PRDX1 is also related with lung cancer.", [["lung cancer", "ANATOMY", 27, 38], ["lung cancer", "DISEASE", 27, 38], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung cancer", "CANCER", 27, 38], ["PRDX1", "PROTEIN", 0, 5], ["PRDX1", "PROBLEM", 0, 5], ["lung cancer", "PROBLEM", 27, 38], ["also related with", "UNCERTAINTY", 9, 26], ["lung", "ANATOMY", 27, 31], ["cancer", "OBSERVATION", 32, 38]]], ["Abnormal up-regulation of PRDX1 by environmental redox change leads to lung cancer progression and radiotherapy resistance by controlling critical molecules (Kim et al., 2007).", [["lung cancer", "ANATOMY", 71, 82], ["lung cancer", "DISEASE", 71, 82], ["PRDX1", "GENE_OR_GENE_PRODUCT", 26, 31], ["lung cancer", "CANCER", 71, 82], ["PRDX1", "PROTEIN", 26, 31], ["Abnormal up-regulation of PRDX1", "PROBLEM", 0, 31], ["environmental redox change", "PROBLEM", 35, 61], ["lung cancer progression", "PROBLEM", 71, 94], ["radiotherapy resistance", "TREATMENT", 99, 122], ["up-regulation", "OBSERVATION_MODIFIER", 9, 22], ["environmental redox", "OBSERVATION", 35, 54], ["lung", "ANATOMY", 71, 75], ["cancer", "OBSERVATION", 76, 82], ["radiotherapy resistance", "OBSERVATION", 99, 122]]], ["Another recent study suggested that down-regulation of PRDX1 significantly inhibited tumor growth and reduced the incidence of spontaneous pulmonary metastasis (Chen et al., 2006).", [["tumor", "ANATOMY", 85, 90], ["pulmonary", "ANATOMY", 139, 148], ["PRDX1", "CHEMICAL", 55, 60], ["tumor", "DISEASE", 85, 90], ["pulmonary metastasis", "DISEASE", 139, 159], ["PRDX1", "GENE_OR_GENE_PRODUCT", 55, 60], ["tumor", "CANCER", 85, 90], ["pulmonary", "ORGAN", 139, 148], ["PRDX1", "PROTEIN", 55, 60], ["Another recent study", "TEST", 0, 20], ["PRDX1", "PROBLEM", 55, 60], ["tumor growth", "PROBLEM", 85, 97], ["spontaneous pulmonary metastasis", "PROBLEM", 127, 159], ["tumor", "OBSERVATION", 85, 90], ["growth", "OBSERVATION_MODIFIER", 91, 97], ["reduced", "OBSERVATION_MODIFIER", 102, 109], ["spontaneous", "OBSERVATION_MODIFIER", 127, 138], ["pulmonary", "ANATOMY", 139, 148], ["metastasis", "OBSERVATION", 149, 159]]], ["PRDX1 provides resistance to docetaxel treatment through the suppression of FOXO1-induced apoptosis in A549 xenograft tumors, suggesting PRDX1 may be an attractive target in the development of more effective docetaxel-based therapies in lung cancer treatment (Hwang et al., 2013).", [["A549 xenograft tumors", "ANATOMY", 103, 124], ["lung cancer", "ANATOMY", 237, 248], ["PRDX1", "CHEMICAL", 0, 5], ["docetaxel", "CHEMICAL", 29, 38], ["tumors", "DISEASE", 118, 124], ["PRDX1", "CHEMICAL", 137, 142], ["docetaxel", "CHEMICAL", 208, 217], ["lung cancer", "DISEASE", 237, 248], ["docetaxel", "CHEMICAL", 29, 38], ["docetaxel", "CHEMICAL", 208, 217], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["docetaxel", "SIMPLE_CHEMICAL", 29, 38], ["FOXO1", "GENE_OR_GENE_PRODUCT", 76, 81], ["A549 xenograft tumors", "CANCER", 103, 124], ["PRDX1", "GENE_OR_GENE_PRODUCT", 137, 142], ["docetaxel", "SIMPLE_CHEMICAL", 208, 217], ["lung cancer", "CANCER", 237, 248], ["PRDX1", "PROTEIN", 0, 5], ["FOXO1", "PROTEIN", 76, 81], ["PRDX1", "PROTEIN", 137, 142], ["PRDX1", "TREATMENT", 0, 5], ["docetaxel treatment", "TREATMENT", 29, 48], ["FOXO1-induced apoptosis", "TREATMENT", 76, 99], ["A549 xenograft tumors", "PROBLEM", 103, 124], ["PRDX1", "PROBLEM", 137, 142], ["more effective docetaxel", "TREATMENT", 193, 217], ["based therapies", "TREATMENT", 218, 233], ["lung cancer treatment", "TREATMENT", 237, 258], ["A549 xenograft tumors", "OBSERVATION", 103, 124], ["lung", "ANATOMY", 237, 241], ["cancer", "OBSERVATION", 242, 248]]], ["PRDX1 is also related with prostate cancer.", [["prostate cancer", "ANATOMY", 27, 42], ["prostate cancer", "DISEASE", 27, 42], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["prostate cancer", "CANCER", 27, 42], ["PRDX1", "PROTEIN", 0, 5], ["prostate cancer", "PROBLEM", 27, 42], ["prostate", "ANATOMY", 27, 35], ["cancer", "OBSERVATION", 36, 42]]], ["PRDX1 interacts with the androgen receptor and enhances its transactivation that plays a critical role in prostate cancer (Park et al., 2007).", [["prostate cancer", "ANATOMY", 106, 121], ["prostate cancer", "DISEASE", 106, 121], ["androgen", "CHEMICAL", 25, 33], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["androgen receptor", "GENE_OR_GENE_PRODUCT", 25, 42], ["prostate cancer", "CANCER", 106, 121], ["PRDX1", "PROTEIN", 0, 5], ["androgen receptor", "PROTEIN", 25, 42], ["the androgen receptor", "TREATMENT", 21, 42], ["prostate cancer", "PROBLEM", 106, 121], ["prostate", "ANATOMY", 106, 114], ["cancer", "OBSERVATION", 115, 121]]], ["One previous study reported that hypoxia increases AR activity in prostate cancer cells, and that PRDX1, which is up-regulated by hypoxia, interacts with AR to enhance the expression of androgen-regulated genes (Chhipa et al., 2009, Park et al., 2006).", [["prostate cancer cells", "ANATOMY", 66, 87], ["hypoxia", "DISEASE", 33, 40], ["prostate cancer", "DISEASE", 66, 81], ["hypoxia", "DISEASE", 130, 137], ["androgen", "CHEMICAL", 186, 194], ["AR", "GENE_OR_GENE_PRODUCT", 51, 53], ["prostate cancer cells", "CELL", 66, 87], ["PRDX1", "GENE_OR_GENE_PRODUCT", 98, 103], ["AR", "GENE_OR_GENE_PRODUCT", 154, 156], ["androgen", "GENE_OR_GENE_PRODUCT", 186, 194], ["AR", "PROTEIN", 51, 53], ["prostate cancer cells", "CELL_TYPE", 66, 87], ["PRDX1", "PROTEIN", 98, 103], ["AR", "PROTEIN", 154, 156], ["androgen-regulated genes", "DNA", 186, 210], ["One previous study", "TEST", 0, 18], ["hypoxia", "PROBLEM", 33, 40], ["AR activity in prostate cancer cells", "PROBLEM", 51, 87], ["PRDX1", "TEST", 98, 103], ["hypoxia", "PROBLEM", 130, 137], ["hypoxia", "OBSERVATION", 33, 40], ["increases", "OBSERVATION_MODIFIER", 41, 50], ["activity", "OBSERVATION_MODIFIER", 54, 62], ["prostate", "ANATOMY", 66, 74], ["cancer cells", "OBSERVATION", 75, 87], ["hypoxia", "OBSERVATION", 130, 137]]], ["PRDX1 is highly expressed in hepatocellular carcinoma.", [["hepatocellular carcinoma", "ANATOMY", 29, 53], ["hepatocellular carcinoma", "DISEASE", 29, 53], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["hepatocellular carcinoma", "CANCER", 29, 53], ["PRDX1", "PROTEIN", 0, 5], ["PRDX1", "PROBLEM", 0, 5], ["hepatocellular carcinoma", "PROBLEM", 29, 53], ["hepatocellular", "ANATOMY", 29, 43], ["carcinoma", "OBSERVATION", 44, 53]]], ["PRDX1-positive rate was significantly higher in hepatocellular carcinoma than in adjacent non-tumorous liver tissues (Sun et al., 2013).", [["hepatocellular carcinoma", "ANATOMY", 48, 72], ["non-tumorous liver tissues", "ANATOMY", 90, 116], ["hepatocellular carcinoma", "DISEASE", 48, 72], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["hepatocellular carcinoma", "CANCER", 48, 72], ["non-tumorous liver tissues", "TISSUE", 90, 116], ["PRDX1", "PROTEIN", 0, 5], ["PRDX1", "TEST", 0, 5], ["positive rate", "PROBLEM", 6, 19], ["hepatocellular carcinoma", "PROBLEM", 48, 72], ["significantly", "OBSERVATION_MODIFIER", 24, 37], ["higher", "OBSERVATION_MODIFIER", 38, 44], ["hepatocellular", "ANATOMY", 48, 62], ["carcinoma", "OBSERVATION", 63, 72], ["non-tumorous", "ANATOMY_MODIFIER", 90, 102], ["liver", "ANATOMY", 103, 108]]], ["Actually, PRDX1 immunoreactivity was positively correlated with tumor vascular endothelial growth factor (VEGF) expression and microvessel density (Sun et al., 2013).", [["microvessel", "ANATOMY", 127, 138], ["tumor", "DISEASE", 64, 69], ["PRDX1", "GENE_OR_GENE_PRODUCT", 10, 15], ["tumor", "CANCER", 64, 69], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 70, 104], ["VEGF", "GENE_OR_GENE_PRODUCT", 106, 110], ["microvessel", "TISSUE", 127, 138], ["PRDX1", "PROTEIN", 10, 15], ["tumor vascular endothelial growth factor", "PROTEIN", 64, 104], ["VEGF", "PROTEIN", 106, 110], ["PRDX1 immunoreactivity", "TEST", 10, 32], ["tumor vascular endothelial growth factor (VEGF) expression and microvessel density", "PROBLEM", 64, 146], ["tumor", "OBSERVATION", 64, 69], ["vascular endothelial", "ANATOMY", 70, 90], ["microvessel", "ANATOMY", 127, 138], ["density", "OBSERVATION", 139, 146]]], ["PRDX1 expression was significantly associated with tumor size, microvascular invasion, Edmondson grade, tumor capsula status, serum AFP, and tumor-node-metastasis stage (Sun et al., 2013).", [["tumor", "ANATOMY", 51, 56], ["microvascular", "ANATOMY", 63, 76], ["tumor capsula", "ANATOMY", 104, 117], ["serum", "ANATOMY", 126, 131], ["tumor-node", "ANATOMY", 141, 151], ["tumor", "DISEASE", 51, 56], ["tumor", "DISEASE", 104, 109], ["tumor", "DISEASE", 141, 146], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor", "CANCER", 51, 56], ["microvascular", "TISSUE", 63, 76], ["tumor", "CANCER", 104, 109], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["AFP", "GENE_OR_GENE_PRODUCT", 132, 135], ["tumor", "CANCER", 141, 146], ["PRDX1", "PROTEIN", 0, 5], ["serum AFP", "PROTEIN", 126, 135], ["tumor size", "PROBLEM", 51, 61], ["microvascular invasion", "PROBLEM", 63, 85], ["Edmondson grade", "PROBLEM", 87, 102], ["tumor capsula status", "PROBLEM", 104, 124], ["serum AFP", "TEST", 126, 135], ["tumor-node", "PROBLEM", 141, 151], ["metastasis stage", "PROBLEM", 152, 168], ["tumor", "OBSERVATION", 51, 56], ["size", "OBSERVATION_MODIFIER", 57, 61], ["microvascular", "ANATOMY", 63, 76], ["invasion", "OBSERVATION", 77, 85], ["tumor", "OBSERVATION", 104, 109], ["tumor", "OBSERVATION", 141, 146], ["node", "ANATOMY", 147, 151], ["metastasis", "OBSERVATION", 152, 162]]], ["PRDX1 is involved in esophageal squamous cell carcinoma tumorigenesis through regulation of the mTOR/p70S6K pathway (Gong et al., 2015).", [["esophageal squamous cell carcinoma", "ANATOMY", 21, 55], ["esophageal squamous cell carcinoma", "DISEASE", 21, 55], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["esophageal squamous cell carcinoma", "CANCER", 21, 55], ["mTOR", "GENE_OR_GENE_PRODUCT", 96, 100], ["p70S6K", "GENE_OR_GENE_PRODUCT", 101, 107], ["PRDX1", "PROTEIN", 0, 5], ["mTOR", "PROTEIN", 96, 100], ["p70S6K", "PROTEIN", 101, 107], ["PRDX1", "PROBLEM", 0, 5], ["esophageal squamous cell carcinoma tumorigenesis", "PROBLEM", 21, 69], ["esophageal", "ANATOMY", 21, 31], ["squamous cell carcinoma", "OBSERVATION", 32, 55]]], ["PRDX1 is also significantly increased in pancreatic cancer by upregulation of angiogenesis (Cai et al., 2015).", [["pancreatic cancer", "ANATOMY", 41, 58], ["pancreatic cancer", "DISEASE", 41, 58], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["pancreatic cancer", "CANCER", 41, 58], ["PRDX1", "PROTEIN", 0, 5], ["PRDX1", "PROBLEM", 0, 5], ["pancreatic cancer", "PROBLEM", 41, 58], ["angiogenesis", "PROBLEM", 78, 90], ["significantly", "OBSERVATION_MODIFIER", 14, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["pancreatic", "ANATOMY", 41, 51], ["cancer", "OBSERVATION", 52, 58], ["upregulation", "OBSERVATION_MODIFIER", 62, 74], ["angiogenesis", "OBSERVATION", 78, 90]]], ["These studies indicate that PRDX1 has a tumor promoting effect through NF-\u03baB pathway, FOXO1 mediated pathway and mTOR/p70S6K pathway in breast cancer, oral squamous cell carcinoma, bladder cancer, lung cancer, prostate cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma and pancreatic cancer, which suggest that PRDX1 is a potential therapeutic target in these cancer types.Tumor promoting effect of PRDX2 ::: Roles of PRDXs in the cancer development ::: PRDXs and cancerThe tumor promoting effect of PRDX2 is well established in colorectal carcinoma, prostate cancer, breast cancer and cervical cancer.", [["tumor", "ANATOMY", 40, 45], ["breast cancer", "ANATOMY", 136, 149], ["oral squamous cell carcinoma", "ANATOMY", 151, 179], ["bladder cancer", "ANATOMY", 181, 195], ["lung cancer", "ANATOMY", 197, 208], ["prostate cancer", "ANATOMY", 210, 225], ["hepatocellular carcinoma", "ANATOMY", 227, 251], ["esophageal squamous cell carcinoma", "ANATOMY", 253, 287], ["pancreatic cancer", "ANATOMY", 292, 309], ["cancer", "ANATOMY", 379, 385], ["Tumor", "ANATOMY", 392, 397], ["cancer", "ANATOMY", 450, 456], ["cancer", "ANATOMY", 483, 489], ["tumor", "ANATOMY", 493, 498], ["colorectal carcinoma", "ANATOMY", 548, 568], ["prostate cancer", "ANATOMY", 570, 585], ["breast cancer", "ANATOMY", 587, 600], ["cervical cancer", "ANATOMY", 605, 620], ["PRDX1", "CHEMICAL", 28, 33], ["tumor", "DISEASE", 40, 45], ["breast cancer", "DISEASE", 136, 149], ["squamous cell carcinoma", "DISEASE", 156, 179], ["bladder cancer", "DISEASE", 181, 195], ["lung cancer", "DISEASE", 197, 208], ["prostate cancer", "DISEASE", 210, 225], ["hepatocellular carcinoma", "DISEASE", 227, 251], ["esophageal squamous cell carcinoma", "DISEASE", 253, 287], ["pancreatic cancer", "DISEASE", 292, 309], ["PRDX1", "CHEMICAL", 330, 335], ["cancer", "DISEASE", 379, 385], ["cancer", "DISEASE", 450, 456], ["cancer", "DISEASE", 483, 489], ["tumor", "DISEASE", 493, 498], ["PRDX2", "CHEMICAL", 519, 524], ["colorectal carcinoma", "DISEASE", 548, 568], ["prostate cancer", "DISEASE", 570, 585], ["breast cancer", "DISEASE", 587, 600], ["cervical cancer", "DISEASE", 605, 620], ["PRDX1", "GENE_OR_GENE_PRODUCT", 28, 33], ["tumor", "CANCER", 40, 45], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 71, 76], ["FOXO1", "GENE_OR_GENE_PRODUCT", 86, 91], ["mTOR", "GENE_OR_GENE_PRODUCT", 113, 117], ["p70S6K", "GENE_OR_GENE_PRODUCT", 118, 124], ["breast cancer", "CANCER", 136, 149], ["oral squamous cell carcinoma", "CANCER", 151, 179], ["bladder cancer", "CANCER", 181, 195], ["lung cancer", "CANCER", 197, 208], ["prostate cancer", "CANCER", 210, 225], ["hepatocellular carcinoma", "CANCER", 227, 251], ["esophageal squamous cell carcinoma", "CANCER", 253, 287], ["pancreatic cancer", "CANCER", 292, 309], ["PRDX1", "GENE_OR_GENE_PRODUCT", 330, 335], ["cancer", "CANCER", 379, 385], ["Tumor", "CANCER", 392, 397], ["PRDX2", "SIMPLE_CHEMICAL", 418, 423], ["PRDXs", "GENE_OR_GENE_PRODUCT", 437, 442], ["cancer", "CANCER", 450, 456], ["PRDXs", "GENE_OR_GENE_PRODUCT", 473, 478], ["cancer", "CANCER", 483, 489], ["tumor", "CANCER", 493, 498], ["PRDX2", "GENE_OR_GENE_PRODUCT", 519, 524], ["colorectal carcinoma", "CANCER", 548, 568], ["prostate cancer", "CANCER", 570, 585], ["breast cancer", "CANCER", 587, 600], ["cervical cancer", "CANCER", 605, 620], ["PRDX1", "PROTEIN", 28, 33], ["NF-\u03baB", "PROTEIN", 71, 76], ["FOXO1", "PROTEIN", 86, 91], ["mTOR", "PROTEIN", 113, 117], ["70S6K", "PROTEIN", 119, 124], ["PRDX1", "PROTEIN", 330, 335], ["PRDX2", "PROTEIN", 418, 423], ["PRDXs", "PROTEIN", 437, 442], ["PRDX2", "PROTEIN", 519, 524], ["These studies", "TEST", 0, 13], ["PRDX1", "PROBLEM", 28, 33], ["a tumor", "PROBLEM", 38, 45], ["breast cancer", "PROBLEM", 136, 149], ["oral squamous cell carcinoma", "PROBLEM", 151, 179], ["bladder cancer", "PROBLEM", 181, 195], ["lung cancer", "PROBLEM", 197, 208], ["prostate cancer", "PROBLEM", 210, 225], ["hepatocellular carcinoma", "PROBLEM", 227, 251], ["esophageal squamous cell carcinoma", "PROBLEM", 253, 287], ["pancreatic cancer", "PROBLEM", 292, 309], ["PRDX1", "PROBLEM", 330, 335], ["these cancer types", "PROBLEM", 373, 391], ["PRDXs", "PROBLEM", 473, 478], ["cancer", "PROBLEM", 483, 489], ["The tumor", "PROBLEM", 489, 498], ["PRDX2", "PROBLEM", 519, 524], ["colorectal carcinoma", "PROBLEM", 548, 568], ["prostate cancer", "PROBLEM", 570, 585], ["breast cancer", "PROBLEM", 587, 600], ["cervical cancer", "PROBLEM", 605, 620], ["tumor", "OBSERVATION", 40, 45], ["breast", "ANATOMY", 136, 142], ["cancer", "OBSERVATION", 143, 149], ["squamous cell carcinoma", "OBSERVATION", 156, 179], ["bladder", "ANATOMY", 181, 188], ["cancer", "OBSERVATION", 189, 195], ["lung", "ANATOMY", 197, 201], ["cancer", "OBSERVATION", 202, 208], ["prostate", "ANATOMY", 210, 218], ["cancer", "OBSERVATION", 219, 225], ["hepatocellular", "ANATOMY", 227, 241], ["carcinoma", "OBSERVATION", 242, 251], ["esophageal", "ANATOMY", 253, 263], ["squamous cell carcinoma", "OBSERVATION", 264, 287], ["pancreatic", "ANATOMY", 292, 302], ["cancer", "OBSERVATION", 303, 309], ["therapeutic", "OBSERVATION_MODIFIER", 351, 362], ["target", "OBSERVATION_MODIFIER", 363, 369], ["cancer", "OBSERVATION", 379, 385], ["cancer", "OBSERVATION", 450, 456], ["cancer", "OBSERVATION", 483, 489], ["tumor", "OBSERVATION", 493, 498], ["colorectal", "ANATOMY", 548, 558], ["carcinoma", "OBSERVATION", 559, 568], ["prostate", "ANATOMY", 570, 578], ["cancer", "OBSERVATION", 579, 585], ["breast", "ANATOMY", 587, 593], ["cancer", "OBSERVATION", 594, 600], ["cervical", "ANATOMY", 605, 613], ["cancer", "OBSERVATION", 614, 620]]], ["PRDX2 is overexpressed in colorectal carcinoma tissues compared with the matched non-cancer colorectal mucosa tissues and that expression is positively associated with tumor metastasis and the TNM stage by regulation of oxidation induced apoptosis (Lu et al., 2014a).", [["colorectal carcinoma tissues", "ANATOMY", 26, 54], ["non-cancer colorectal mucosa tissues", "ANATOMY", 81, 117], ["tumor", "ANATOMY", 168, 173], ["colorectal carcinoma", "DISEASE", 26, 46], ["tumor", "DISEASE", 168, 173], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["colorectal carcinoma tissues", "TISSUE", 26, 54], ["colorectal mucosa tissues", "TISSUE", 92, 117], ["tumor", "CANCER", 168, 173], ["PRDX2", "PROTEIN", 0, 5], ["PRDX2", "TREATMENT", 0, 5], ["colorectal carcinoma tissues", "PROBLEM", 26, 54], ["the matched non-cancer colorectal mucosa tissues", "PROBLEM", 69, 117], ["tumor metastasis", "PROBLEM", 168, 184], ["the TNM stage", "PROBLEM", 189, 202], ["oxidation induced apoptosis", "PROBLEM", 220, 247], ["colorectal carcinoma", "OBSERVATION", 26, 46], ["colorectal mucosa tissues", "OBSERVATION", 92, 117], ["positively associated with", "UNCERTAINTY", 141, 167], ["tumor", "OBSERVATION_MODIFIER", 168, 173], ["metastasis", "OBSERVATION", 174, 184], ["oxidation", "OBSERVATION_MODIFIER", 220, 229], ["apoptosis", "OBSERVATION_MODIFIER", 238, 247]]], ["Other researchers also demonstrated that PRDX2 knockdown using a lentiviral vector-mediated specific shRNA inhibited cell growth, stimulated apoptosis, and augmented the production of endogenous ROS that led to an altered expression of proteins associated with the Wnt signaling pathway (Lu et al., 2014b).", [["cell", "ANATOMY", 117, 121], ["ROS", "CHEMICAL", 195, 198], ["PRDX2", "GENE_OR_GENE_PRODUCT", 41, 46], ["lentiviral", "ORGANISM", 65, 75], ["cell", "CELL", 117, 121], ["ROS", "SIMPLE_CHEMICAL", 195, 198], ["Wnt", "GENE_OR_GENE_PRODUCT", 265, 268], ["PRDX2", "PROTEIN", 41, 46], ["PRDX2 knockdown", "TREATMENT", 41, 56], ["a lentiviral vector", "TREATMENT", 63, 82], ["cell growth", "PROBLEM", 117, 128], ["stimulated apoptosis", "PROBLEM", 130, 150], ["endogenous ROS", "PROBLEM", 184, 198], ["an altered expression of proteins", "PROBLEM", 211, 244]]], ["PRDX2 is also important in prostate cancer.", [["prostate cancer", "ANATOMY", 27, 42], ["prostate cancer", "DISEASE", 27, 42], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["prostate cancer", "CANCER", 27, 42], ["PRDX2", "PROTEIN", 0, 5], ["prostate cancer", "PROBLEM", 27, 42], ["prostate", "ANATOMY", 27, 35], ["cancer", "OBSERVATION", 36, 42]]], ["Shiota et al demonstrated that the expression of PRDX2 is most significantly elevated among the PRDX family in prostate cancer (Shiota et al., 2011).", [["prostate cancer", "ANATOMY", 111, 126], ["prostate cancer", "DISEASE", 111, 126], ["PRDX2", "GENE_OR_GENE_PRODUCT", 49, 54], ["PRDX", "GENE_OR_GENE_PRODUCT", 96, 100], ["prostate cancer", "CANCER", 111, 126], ["PRDX2", "PROTEIN", 49, 54], ["PRDX family", "PROTEIN", 96, 107], ["significantly elevated", "PROBLEM", 63, 85], ["prostate cancer", "PROBLEM", 111, 126], ["prostate", "ANATOMY", 111, 119], ["cancer", "OBSERVATION", 120, 126]]], ["They showed that PRDX2 in the nucleus and cytoplasm distinctively regulated AR activity and is involved in the proliferation of AR-expressing prostate cancer cells and in the progression to castration-resistant prostate cancer, suggesting PRDX2 to be a key factor in prostate carcinogenesis and in the progression to castration-resistant prostate cancer (Shiota et al., 2011).", [["nucleus", "ANATOMY", 30, 37], ["cytoplasm", "ANATOMY", 42, 51], ["prostate cancer cells", "ANATOMY", 142, 163], ["prostate cancer", "ANATOMY", 211, 226], ["prostate", "ANATOMY", 267, 275], ["prostate cancer", "ANATOMY", 338, 353], ["prostate cancer", "DISEASE", 142, 157], ["prostate cancer", "DISEASE", 211, 226], ["prostate carcinogenesis", "DISEASE", 267, 290], ["prostate cancer", "DISEASE", 338, 353], ["PRDX2", "GENE_OR_GENE_PRODUCT", 17, 22], ["nucleus", "CELLULAR_COMPONENT", 30, 37], ["cytoplasm", "ORGANISM_SUBSTANCE", 42, 51], ["AR", "GENE_OR_GENE_PRODUCT", 76, 78], ["AR", "GENE_OR_GENE_PRODUCT", 128, 130], ["prostate cancer cells", "CELL", 142, 163], ["prostate cancer", "CANCER", 211, 226], ["PRDX2", "GENE_OR_GENE_PRODUCT", 239, 244], ["prostate", "CANCER", 267, 275], ["castration-resistant prostate cancer", "CANCER", 317, 353], ["PRDX2", "PROTEIN", 17, 22], ["AR", "PROTEIN", 76, 78], ["AR", "PROTEIN", 128, 130], ["expressing prostate cancer cells", "CELL_TYPE", 131, 163], ["PRDX2", "PROTEIN", 239, 244], ["PRDX2 in the nucleus", "PROBLEM", 17, 37], ["the proliferation of AR", "PROBLEM", 107, 130], ["prostate cancer cells", "PROBLEM", 142, 163], ["castration", "TREATMENT", 190, 200], ["resistant prostate cancer", "PROBLEM", 201, 226], ["PRDX2", "PROBLEM", 239, 244], ["prostate carcinogenesis", "PROBLEM", 267, 290], ["castration", "TREATMENT", 317, 327], ["resistant prostate cancer", "PROBLEM", 328, 353], ["nucleus", "ANATOMY", 30, 37], ["cytoplasm distinctively", "OBSERVATION", 42, 65], ["activity", "OBSERVATION_MODIFIER", 79, 87], ["proliferation", "OBSERVATION_MODIFIER", 111, 124], ["prostate", "ANATOMY", 142, 150], ["cancer cells", "OBSERVATION", 151, 163], ["progression", "OBSERVATION_MODIFIER", 175, 186], ["castration", "OBSERVATION", 190, 200], ["resistant", "OBSERVATION_MODIFIER", 201, 210], ["prostate", "ANATOMY", 211, 219], ["cancer", "OBSERVATION", 220, 226], ["prostate", "ANATOMY", 267, 275], ["carcinogenesis", "OBSERVATION", 276, 290], ["resistant", "OBSERVATION_MODIFIER", 328, 337], ["prostate", "ANATOMY", 338, 346], ["cancer", "OBSERVATION", 347, 353]]], ["PRDX2 is highly inducible by therapeutic radiation and drugs in breast cancer cells (Wang et al., 2014b, Wang et al., 2014a).", [["breast cancer cells", "ANATOMY", 64, 83], ["breast cancer", "DISEASE", 64, 77], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["breast cancer cells", "CELL", 64, 83], ["PRDX2", "PROTEIN", 0, 5], ["breast cancer cells", "CELL_TYPE", 64, 83], ["therapeutic radiation", "TREATMENT", 29, 50], ["drugs", "TREATMENT", 55, 60], ["breast cancer cells", "PROBLEM", 64, 83], ["breast", "ANATOMY", 64, 70], ["cancer", "OBSERVATION", 71, 77]]], ["Several resistant tumor cells have shown upregulated PRDX2 levels in breast cancer.", [["tumor cells", "ANATOMY", 18, 29], ["breast cancer", "ANATOMY", 69, 82], ["tumor", "DISEASE", 18, 23], ["breast cancer", "DISEASE", 69, 82], ["tumor cells", "CELL", 18, 29], ["PRDX2", "GENE_OR_GENE_PRODUCT", 53, 58], ["breast cancer", "CANCER", 69, 82], ["resistant tumor cells", "CELL_TYPE", 8, 29], ["PRDX2", "PROTEIN", 53, 58], ["Several resistant tumor cells", "PROBLEM", 0, 29], ["upregulated PRDX2 levels in breast cancer", "PROBLEM", 41, 82], ["resistant", "OBSERVATION_MODIFIER", 8, 17], ["tumor cells", "OBSERVATION", 18, 29], ["upregulated", "OBSERVATION_MODIFIER", 41, 52], ["PRDX2", "OBSERVATION_MODIFIER", 53, 58], ["levels", "OBSERVATION_MODIFIER", 59, 65], ["breast", "ANATOMY", 69, 75], ["cancer", "OBSERVATION", 76, 82]]], ["PRDX2 plays a role in protecting the cell membrane from IR-induced oxidative radioresistant breast cancer cells (Diaz, Tamae, Yen, Li, & Wang, 2013).", [["cell membrane", "ANATOMY", 37, 50], ["breast cancer cells", "ANATOMY", 92, 111], ["PRDX2", "CHEMICAL", 0, 5], ["IR", "CHEMICAL", 56, 58], ["breast cancer", "DISEASE", 92, 105], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell membrane", "CELLULAR_COMPONENT", 37, 50], ["IR", "SIMPLE_CHEMICAL", 56, 58], ["breast cancer cells", "CELL", 92, 111], ["PRDX2", "PROTEIN", 0, 5], ["oxidative radioresistant breast cancer cells", "CELL_TYPE", 67, 111], ["oxidative radioresistant breast cancer cells", "PROBLEM", 67, 111], ["oxidative radioresistant", "OBSERVATION", 67, 91], ["breast", "ANATOMY", 92, 98], ["cancer cells", "OBSERVATION", 99, 111], ["Li", "ANATOMY", 131, 133]]], ["PRDX2 is also significantly upregulated in the early diagnosis of Hepatitis B Virus (HBV) related fibrosis (Lu et al., 2010).", [["Hepatitis B Virus", "DISEASE", 66, 83], ["fibrosis", "DISEASE", 98, 106], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Hepatitis B Virus", "ORGANISM", 66, 83], ["HBV", "ORGANISM", 85, 88], ["PRDX2", "PROTEIN", 0, 5], ["Hepatitis B Virus", "SPECIES", 66, 83], ["Hepatitis B Virus", "SPECIES", 66, 83], ["HBV", "SPECIES", 85, 88], ["Hepatitis B Virus (HBV) related fibrosis", "PROBLEM", 66, 106], ["significantly upregulated", "OBSERVATION_MODIFIER", 14, 39], ["Hepatitis", "OBSERVATION", 66, 75], ["fibrosis", "OBSERVATION", 98, 106]]], ["PRDX2 is markedly upregulated in neutrophils of refractory cytopenia with multilineage dysplasia (RCMD) patients compared to healthy donors.", [["neutrophils", "ANATOMY", 33, 44], ["multilineage dysplasia", "ANATOMY", 74, 96], ["RCMD", "ANATOMY", 98, 102], ["cytopenia", "DISEASE", 59, 68], ["multilineage dysplasia", "DISEASE", 74, 96], ["RCMD", "DISEASE", 98, 102], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["neutrophils", "CELL", 33, 44], ["multilineage dysplasia", "PATHOLOGICAL_FORMATION", 74, 96], ["patients", "ORGANISM", 104, 112], ["donors", "ORGANISM", 133, 139], ["PRDX2", "PROTEIN", 0, 5], ["neutrophils", "CELL_TYPE", 33, 44], ["patients", "SPECIES", 104, 112], ["refractory cytopenia", "PROBLEM", 48, 68], ["multilineage dysplasia", "PROBLEM", 74, 96], ["markedly", "OBSERVATION_MODIFIER", 9, 17], ["upregulated", "OBSERVATION_MODIFIER", 18, 29], ["neutrophils", "OBSERVATION_MODIFIER", 33, 44], ["refractory cytopenia", "OBSERVATION", 48, 68], ["multilineage dysplasia", "OBSERVATION", 74, 96]]], ["In addition, white blood cell and neutrophil counts in RCMD patients correlated inversely with PRDX2 expression (Kazama et al., 2014).", [["white blood cell", "ANATOMY", 13, 29], ["neutrophil", "ANATOMY", 34, 44], ["white blood cell", "CELL", 13, 29], ["neutrophil", "CELL", 34, 44], ["patients", "ORGANISM", 60, 68], ["PRDX2", "GENE_OR_GENE_PRODUCT", 95, 100], ["PRDX2", "PROTEIN", 95, 100], ["patients", "SPECIES", 60, 68], ["white blood cell", "TEST", 13, 29], ["neutrophil counts", "TEST", 34, 51], ["neutrophil counts", "OBSERVATION", 34, 51]]], ["Among PRDXs, PRDX2 specifically regulates breast cancer cell colonization in lungs by acting on the oxidative and metabolic stress responses of metastatic cells (Stresing et al., 2013).", [["breast cancer cell", "ANATOMY", 42, 60], ["lungs", "ANATOMY", 77, 82], ["metastatic cells", "ANATOMY", 144, 160], ["PRDX2", "CHEMICAL", 13, 18], ["breast cancer", "DISEASE", 42, 55], ["PRDXs", "GENE_OR_GENE_PRODUCT", 6, 11], ["PRDX2", "GENE_OR_GENE_PRODUCT", 13, 18], ["breast cancer cell", "CELL", 42, 60], ["lungs", "ORGAN", 77, 82], ["cells", "CELL", 155, 160], ["PRDXs", "PROTEIN", 6, 11], ["PRDX2", "PROTEIN", 13, 18], ["metastatic cells", "CELL_TYPE", 144, 160], ["Among PRDXs", "PROBLEM", 0, 11], ["PRDX2", "TREATMENT", 13, 18], ["breast cancer cell colonization in lungs", "PROBLEM", 42, 82], ["metastatic cells", "PROBLEM", 144, 160], ["breast", "ANATOMY", 42, 48], ["cancer", "OBSERVATION", 49, 55], ["cell colonization", "OBSERVATION", 56, 73], ["lungs", "ANATOMY", 77, 82], ["metastatic cells", "OBSERVATION", 144, 160]]], ["PRDX2 has a strong pattern of increased expression with increasing severity of the lesion, thus PRDX2 is up-regulated in response to cervical cancer development (Kim et al., 2009).", [["lesion", "ANATOMY", 83, 89], ["cervical cancer", "ANATOMY", 133, 148], ["cervical cancer", "DISEASE", 133, 148], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["lesion", "PATHOLOGICAL_FORMATION", 83, 89], ["PRDX2", "GENE_OR_GENE_PRODUCT", 96, 101], ["cervical cancer", "CANCER", 133, 148], ["PRDX2", "PROTEIN", 0, 5], ["PRDX2", "PROTEIN", 96, 101], ["increased expression", "PROBLEM", 30, 50], ["increasing severity of the lesion", "PROBLEM", 56, 89], ["cervical cancer development", "PROBLEM", 133, 160], ["strong", "OBSERVATION_MODIFIER", 12, 18], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["expression", "OBSERVATION", 40, 50], ["increasing", "OBSERVATION_MODIFIER", 56, 66], ["severity", "OBSERVATION_MODIFIER", 67, 75], ["lesion", "OBSERVATION", 83, 89], ["cervical", "ANATOMY", 133, 141], ["cancer", "OBSERVATION", 142, 148]]], ["These data indicate that PRDX2 is involved in the proliferation or metastasis of cancer, involved in radio- and drug-resistance, and suggest that designing therapeutics targeting PRDX2 may offer a novel strategy for developing treatment for cancer.Promoting effect of PRDX3 in several cancer types ::: Roles of PRDXs in the cancer development ::: PRDXs and cancerThe tumor promoting effect of PRDX3 is well established in breast cancer, prostate cancer, cervical cancer, hepatocellular carcinoma and ovarian cancer.", [["cancer", "ANATOMY", 81, 87], ["cancer", "ANATOMY", 241, 247], ["cancer", "ANATOMY", 285, 291], ["cancer", "ANATOMY", 324, 330], ["cancer", "ANATOMY", 357, 363], ["tumor", "ANATOMY", 367, 372], ["breast cancer", "ANATOMY", 422, 435], ["prostate cancer", "ANATOMY", 437, 452], ["cervical cancer", "ANATOMY", 454, 469], ["hepatocellular carcinoma", "ANATOMY", 471, 495], ["ovarian cancer", "ANATOMY", 500, 514], ["cancer", "DISEASE", 81, 87], ["PRDX2", "CHEMICAL", 179, 184], ["cancer", "DISEASE", 241, 247], ["PRDX3", "CHEMICAL", 268, 273], ["cancer", "DISEASE", 285, 291], ["cancer", "DISEASE", 324, 330], ["cancer", "DISEASE", 357, 363], ["tumor", "DISEASE", 367, 372], ["PRDX3", "CHEMICAL", 393, 398], ["breast cancer", "DISEASE", 422, 435], ["prostate cancer", "DISEASE", 437, 452], ["cervical cancer", "DISEASE", 454, 469], ["hepatocellular carcinoma", "DISEASE", 471, 495], ["ovarian cancer", "DISEASE", 500, 514], ["PRDX2", "GENE_OR_GENE_PRODUCT", 25, 30], ["cancer", "CANCER", 81, 87], ["PRDX2", "GENE_OR_GENE_PRODUCT", 179, 184], ["cancer", "CANCER", 241, 247], ["PRDX3", "GENE_OR_GENE_PRODUCT", 268, 273], ["cancer", "CANCER", 285, 291], ["PRDXs", "GENE_OR_GENE_PRODUCT", 311, 316], ["cancer", "CANCER", 324, 330], ["PRDXs", "GENE_OR_GENE_PRODUCT", 347, 352], ["cancer", "CANCER", 357, 363], ["tumor", "CANCER", 367, 372], ["PRDX3", "GENE_OR_GENE_PRODUCT", 393, 398], ["breast cancer", "CANCER", 422, 435], ["prostate cancer", "CANCER", 437, 452], ["cervical cancer", "CANCER", 454, 469], ["hepatocellular carcinoma", "CANCER", 471, 495], ["ovarian cancer", "CANCER", 500, 514], ["PRDX2", "PROTEIN", 25, 30], ["PRDX2", "PROTEIN", 179, 184], ["PRDX3", "PROTEIN", 268, 273], ["PRDXs", "PROTEIN", 311, 316], ["PRDX3", "PROTEIN", 393, 398], ["PRDX2", "PROBLEM", 25, 30], ["the proliferation", "PROBLEM", 46, 63], ["metastasis of cancer", "PROBLEM", 67, 87], ["therapeutics targeting PRDX2", "TREATMENT", 156, 184], ["a novel strategy", "TREATMENT", 195, 211], ["developing treatment", "TREATMENT", 216, 236], ["cancer", "PROBLEM", 241, 247], ["PRDXs", "PROBLEM", 347, 352], ["cancer", "PROBLEM", 357, 363], ["The tumor", "PROBLEM", 363, 372], ["breast cancer", "PROBLEM", 422, 435], ["prostate cancer", "PROBLEM", 437, 452], ["cervical cancer", "PROBLEM", 454, 469], ["hepatocellular carcinoma", "PROBLEM", 471, 495], ["ovarian cancer", "PROBLEM", 500, 514], ["proliferation", "OBSERVATION_MODIFIER", 50, 63], ["metastasis", "OBSERVATION", 67, 77], ["cancer", "OBSERVATION", 81, 87], ["cancer", "OBSERVATION", 241, 247], ["cancer", "OBSERVATION", 285, 291], ["cancer", "OBSERVATION", 324, 330], ["cancer", "OBSERVATION", 357, 363], ["tumor", "OBSERVATION", 367, 372], ["breast", "ANATOMY", 422, 428], ["cancer", "OBSERVATION", 429, 435], ["prostate", "ANATOMY", 437, 445], ["cancer", "OBSERVATION", 446, 452], ["cervical", "ANATOMY", 454, 462], ["cancer", "OBSERVATION", 463, 469], ["hepatocellular", "ANATOMY", 471, 485], ["carcinoma", "OBSERVATION", 486, 495], ["ovarian", "ANATOMY", 500, 507], ["cancer", "OBSERVATION", 508, 514]]], ["In a gene silencing study in breast cancer cells, silencing the PRDX3 gene inhibits cell proliferation and induces cell cycle arrest in breast cancers (Chua et al., 2010).", [["breast cancer cells", "ANATOMY", 29, 48], ["cell", "ANATOMY", 84, 88], ["cell", "ANATOMY", 115, 119], ["breast cancers", "ANATOMY", 136, 150], ["breast cancer", "DISEASE", 29, 42], ["breast cancers", "DISEASE", 136, 150], ["breast cancer cells", "CELL", 29, 48], ["PRDX3", "GENE_OR_GENE_PRODUCT", 64, 69], ["cell", "CELL", 84, 88], ["cell", "CELL", 115, 119], ["breast cancers", "CANCER", 136, 150], ["breast cancer cells", "CELL_TYPE", 29, 48], ["PRDX3 gene", "DNA", 64, 74], ["a gene silencing study", "TREATMENT", 3, 25], ["breast cancer cells", "PROBLEM", 29, 48], ["silencing the PRDX3 gene", "TREATMENT", 50, 74], ["cell proliferation", "PROBLEM", 84, 102], ["induces cell cycle arrest", "TREATMENT", 107, 132], ["breast cancers", "PROBLEM", 136, 150], ["breast", "ANATOMY", 29, 35], ["cancer", "OBSERVATION", 36, 42], ["cell proliferation", "OBSERVATION", 84, 102], ["cell cycle arrest", "OBSERVATION", 115, 132], ["breast", "ANATOMY", 136, 142], ["cancers", "OBSERVATION", 143, 150]]], ["PRDX3 is also involved in prostate cancer.", [["prostate cancer", "ANATOMY", 26, 41], ["prostate cancer", "DISEASE", 26, 41], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["prostate cancer", "CANCER", 26, 41], ["PRDX3", "PROTEIN", 0, 5], ["prostate cancer", "PROBLEM", 26, 41], ["prostate", "ANATOMY", 26, 34], ["cancer", "OBSERVATION", 35, 41]]], ["PRDX3 is upregulated in endocrine-regulated tumors and in particular prostatic intraepithelial neoplasia and prostate cancer (Whitaker et al., 2013).", [["endocrine-regulated tumors", "ANATOMY", 24, 50], ["prostatic intraepithelial neoplasia", "ANATOMY", 69, 104], ["prostate cancer", "ANATOMY", 109, 124], ["tumors", "DISEASE", 44, 50], ["prostatic intraepithelial neoplasia", "DISEASE", 69, 104], ["prostate cancer", "DISEASE", 109, 124], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["endocrine", "ANATOMICAL_SYSTEM", 24, 33], ["tumors", "CANCER", 44, 50], ["prostatic intraepithelial neoplasia", "CANCER", 69, 104], ["prostate cancer", "CANCER", 109, 124], ["PRDX3", "PROTEIN", 0, 5], ["regulated tumors", "PROBLEM", 34, 50], ["particular prostatic intraepithelial neoplasia", "PROBLEM", 58, 104], ["prostate cancer", "PROBLEM", 109, 124], ["upregulated", "OBSERVATION_MODIFIER", 9, 20], ["endocrine", "ANATOMY", 24, 33], ["tumors", "OBSERVATION", 44, 50], ["prostatic", "ANATOMY", 69, 78], ["intraepithelial neoplasia", "OBSERVATION", 79, 104], ["prostate", "ANATOMY", 109, 117], ["cancer", "OBSERVATION", 118, 124]]], ["Also, the PRDX3 protein is significantly upregulated in antiandrogen-resistant prostate cancer cell lines, resulting in an increased resistance to oxidative stress and failure to activate pro-apoptotic pathways (Whitaker et al., 2013).", [["prostate cancer cell lines", "ANATOMY", 79, 105], ["antiandrogen", "CHEMICAL", 56, 68], ["prostate cancer", "DISEASE", 79, 94], ["antiandrogen", "CHEMICAL", 56, 68], ["PRDX3", "GENE_OR_GENE_PRODUCT", 10, 15], ["antiandrogen", "SIMPLE_CHEMICAL", 56, 68], ["prostate cancer cell lines", "CELL", 79, 105], ["PRDX3 protein", "PROTEIN", 10, 23], ["antiandrogen-resistant prostate cancer cell lines", "CELL_LINE", 56, 105], ["the PRDX3 protein", "TEST", 6, 23], ["antiandrogen", "TREATMENT", 56, 68], ["resistant prostate cancer cell lines", "PROBLEM", 69, 105], ["an increased resistance", "PROBLEM", 120, 143], ["oxidative stress", "PROBLEM", 147, 163], ["failure to activate pro-apoptotic pathways", "PROBLEM", 168, 210], ["significantly", "OBSERVATION_MODIFIER", 27, 40], ["upregulated", "OBSERVATION_MODIFIER", 41, 52], ["resistant", "OBSERVATION_MODIFIER", 69, 78], ["prostate", "ANATOMY", 79, 87], ["cancer cell lines", "OBSERVATION", 88, 105], ["increased", "OBSERVATION_MODIFIER", 123, 132], ["resistance", "OBSERVATION", 133, 143], ["oxidative stress", "OBSERVATION", 147, 163]]], ["Antiandrogen-resistant prostate cancer cells also possess an upregulation of the tricarboxylic acid (TCA) pathway and resistance to H2O2-induced apoptosis through a failure to activate pro-apoptotic pathways, but knockdown of PRDX3 restored H2O2 sensitivity (Whitaker et al., 2013).", [["prostate cancer cells", "ANATOMY", 23, 44], ["Antiandrogen", "CHEMICAL", 0, 12], ["prostate cancer", "DISEASE", 23, 38], ["tricarboxylic acid", "CHEMICAL", 81, 99], ["TCA", "CHEMICAL", 101, 104], ["H2O2", "CHEMICAL", 132, 136], ["H2O2", "CHEMICAL", 241, 245], ["Antiandrogen", "CHEMICAL", 0, 12], ["tricarboxylic acid", "CHEMICAL", 81, 99], ["TCA", "CHEMICAL", 101, 104], ["H2O2", "CHEMICAL", 132, 136], ["H2O2", "CHEMICAL", 241, 245], ["Antiandrogen", "SIMPLE_CHEMICAL", 0, 12], ["prostate cancer cells", "CELL", 23, 44], ["tricarboxylic acid", "SIMPLE_CHEMICAL", 81, 99], ["TCA", "SIMPLE_CHEMICAL", 101, 104], ["H2O2", "SIMPLE_CHEMICAL", 132, 136], ["PRDX3", "GENE_OR_GENE_PRODUCT", 226, 231], ["H2O2", "SIMPLE_CHEMICAL", 241, 245], ["Antiandrogen-resistant prostate cancer cells", "CELL_LINE", 0, 44], ["PRDX3", "PROTEIN", 226, 231], ["Antiandrogen", "TREATMENT", 0, 12], ["resistant prostate cancer cells", "PROBLEM", 13, 44], ["the tricarboxylic acid (TCA) pathway", "TREATMENT", 77, 113], ["H2O2", "TREATMENT", 132, 136], ["induced apoptosis", "PROBLEM", 137, 154], ["a failure", "PROBLEM", 163, 172], ["pro-apoptotic pathways", "TREATMENT", 185, 207], ["resistant", "OBSERVATION_MODIFIER", 13, 22], ["prostate", "ANATOMY", 23, 31], ["cancer", "OBSERVATION", 32, 38]]], ["PRDX3 is upregulated in response to the development of cervical cancer.", [["cervical cancer", "ANATOMY", 55, 70], ["cervical cancer", "DISEASE", 55, 70], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["cervical cancer", "CANCER", 55, 70], ["PRDX3", "PROTEIN", 0, 5], ["cervical cancer", "PROBLEM", 55, 70], ["upregulated", "OBSERVATION_MODIFIER", 9, 20], ["cervical", "ANATOMY", 55, 63], ["cancer", "OBSERVATION", 64, 70]]], ["The expression of PRDX3 is increased in cervical carcinoma and the pattern of PRDX3 expression in cervical carcinoma was consistent with that of cell proliferation marker, Ki67 (Hu, Gao, & Li, 2013).", [["cervical carcinoma", "ANATOMY", 40, 58], ["cervical carcinoma", "ANATOMY", 98, 116], ["cell", "ANATOMY", 145, 149], ["cervical carcinoma", "DISEASE", 40, 58], ["cervical carcinoma", "DISEASE", 98, 116], ["PRDX3", "GENE_OR_GENE_PRODUCT", 18, 23], ["cervical carcinoma", "CANCER", 40, 58], ["PRDX3", "GENE_OR_GENE_PRODUCT", 78, 83], ["cervical carcinoma", "CANCER", 98, 116], ["cell", "CELL", 145, 149], ["Ki67", "GENE_OR_GENE_PRODUCT", 172, 176], ["PRDX3", "PROTEIN", 18, 23], ["PRDX3", "PROTEIN", 78, 83], ["Ki67", "PROTEIN", 172, 176], ["PRDX3", "PROBLEM", 18, 23], ["cervical carcinoma", "PROBLEM", 40, 58], ["PRDX3 expression", "PROBLEM", 78, 94], ["cervical carcinoma", "PROBLEM", 98, 116], ["Ki67", "TEST", 172, 176], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["cervical", "ANATOMY", 40, 48], ["carcinoma", "OBSERVATION", 49, 58], ["cervical", "ANATOMY", 98, 106], ["carcinoma", "OBSERVATION", 107, 116], ["consistent with", "UNCERTAINTY", 121, 136], ["cell proliferation", "OBSERVATION", 145, 163]]], ["Nonn et al reported that PRDX3 played a drug-resistant role against drug-induced oxidative stress and subsequent apoptosis of thymoma cells (Nonn et al., 2003).", [["thymoma cells", "ANATOMY", 126, 139], ["PRDX3", "CHEMICAL", 25, 30], ["thymoma", "DISEASE", 126, 133], ["PRDX3", "GENE_OR_GENE_PRODUCT", 25, 30], ["thymoma cells", "CELL", 126, 139], ["PRDX3", "PROTEIN", 25, 30], ["thymoma cells", "CELL_TYPE", 126, 139], ["induced oxidative stress", "PROBLEM", 73, 97], ["thymoma cells", "PROBLEM", 126, 139], ["thymoma cells", "OBSERVATION", 126, 139]]], ["PRDX3 is also involved in hepatocellular carcinoma development.", [["hepatocellular carcinoma", "ANATOMY", 26, 50], ["hepatocellular carcinoma", "DISEASE", 26, 50], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["hepatocellular carcinoma", "CANCER", 26, 50], ["PRDX3", "PROTEIN", 0, 5], ["hepatocellular carcinoma development", "PROBLEM", 26, 62], ["hepatocellular", "ANATOMY", 26, 40], ["carcinoma", "OBSERVATION", 41, 50]]], ["The overexpression of PRDX3 is associated with 94.9% hepatocellular carcinoma, and correlated with poor differentiation (Qiao et al., 2012).", [["hepatocellular carcinoma", "ANATOMY", 53, 77], ["hepatocellular carcinoma", "DISEASE", 53, 77], ["PRDX3", "GENE_OR_GENE_PRODUCT", 22, 27], ["hepatocellular carcinoma", "CANCER", 53, 77], ["PRDX3", "PROTEIN", 22, 27], ["The overexpression of PRDX3", "PROBLEM", 0, 27], ["94.9% hepatocellular carcinoma", "PROBLEM", 47, 77], ["hepatocellular carcinoma", "OBSERVATION", 53, 77], ["poor differentiation", "OBSERVATION_MODIFIER", 99, 119]]], ["Also, PRDX3 is resistant to oxidation-induced apoptosis of Hep-3b cells (Wang et al., 2014a, b).", [["Hep-3b cells", "ANATOMY", 59, 71], ["PRDX3", "CHEMICAL", 6, 11], ["PRDX3", "GENE_OR_GENE_PRODUCT", 6, 11], ["Hep-3b cells", "CELL", 59, 71], ["PRDX3", "PROTEIN", 6, 11], ["Hep-3b cells", "CELL_LINE", 59, 71], ["oxidation", "TEST", 28, 37], ["Hep", "TEST", 59, 62], ["resistant", "OBSERVATION_MODIFIER", 15, 24]]], ["After a low-dose of H2O2 treatment, the ROS level was significantly higher in PRDX3-knockdown Hep-3b cells than in controls.", [["Hep-3b cells", "ANATOMY", 94, 106], ["H2O2", "CHEMICAL", 20, 24], ["ROS", "CHEMICAL", 40, 43], ["H2O2", "CHEMICAL", 20, 24], ["H2O2", "SIMPLE_CHEMICAL", 20, 24], ["ROS", "SIMPLE_CHEMICAL", 40, 43], ["PRDX3", "GENE_OR_GENE_PRODUCT", 78, 83], ["PRDX3-knockdown Hep-3b cells", "CELL_LINE", 78, 106], ["a low-dose of H2O2 treatment", "TREATMENT", 6, 34], ["the ROS level", "TEST", 36, 49], ["PRDX3", "TEST", 78, 83], ["Hep", "TEST", 94, 97]]], ["In addition, PRDX3 down-regulation resulted in decreased proliferation, increased apoptosis, and increased caspase 3 activity of Hep-3b cells (Wang et al., 2014a, b).", [["Hep-3b cells", "ANATOMY", 129, 141], ["PRDX3", "GENE_OR_GENE_PRODUCT", 13, 18], ["caspase 3", "GENE_OR_GENE_PRODUCT", 107, 116], ["Hep-3b cells", "CELL", 129, 141], ["PRDX3", "PROTEIN", 13, 18], ["caspase 3", "PROTEIN", 107, 116], ["Hep-3b cells", "CELL_LINE", 129, 141], ["PRDX3", "TEST", 13, 18], ["decreased proliferation", "PROBLEM", 47, 70], ["increased apoptosis", "PROBLEM", 72, 91], ["increased caspase", "PROBLEM", 97, 114], ["Hep", "TEST", 129, 132], ["decreased", "OBSERVATION_MODIFIER", 47, 56], ["proliferation", "OBSERVATION_MODIFIER", 57, 70], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["apoptosis", "OBSERVATION_MODIFIER", 82, 91]]], ["The PRDX3 is also overexpressed in ovarian cancer.", [["ovarian cancer", "ANATOMY", 35, 49], ["ovarian cancer", "DISEASE", 35, 49], ["PRDX3", "GENE_OR_GENE_PRODUCT", 4, 9], ["ovarian cancer", "CANCER", 35, 49], ["PRDX3", "PROTEIN", 4, 9], ["ovarian cancer", "PROBLEM", 35, 49], ["overexpressed", "OBSERVATION_MODIFIER", 18, 31], ["ovarian", "ANATOMY", 35, 42], ["cancer", "OBSERVATION", 43, 49]]], ["Downregulation of PRDX3 upregulated pro-apoptotic proteins Bax, Caspase\u20113 and Caspase\u20119, and the silencing of PRDX3 triggered cisplatin\u2011mediated apoptosis in the ovarian cancer cells through suppression of the NF-\u03baB signaling pathway (Duan et al., 2013).", [["ovarian cancer cells", "ANATOMY", 162, 182], ["ovarian cancer", "DISEASE", 162, 176], ["PRDX3", "GENE_OR_GENE_PRODUCT", 18, 23], ["Bax", "GENE_OR_GENE_PRODUCT", 59, 62], ["Caspase\u20113", "GENE_OR_GENE_PRODUCT", 64, 73], ["Caspase\u20119", "GENE_OR_GENE_PRODUCT", 78, 87], ["PRDX3", "GENE_OR_GENE_PRODUCT", 110, 115], ["ovarian cancer cells", "CELL", 162, 182], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 210, 215], ["PRDX3", "PROTEIN", 18, 23], ["pro-apoptotic proteins", "PROTEIN", 36, 58], ["Bax", "PROTEIN", 59, 62], ["Caspase\u20113", "PROTEIN", 64, 73], ["Caspase\u20119", "PROTEIN", 78, 87], ["PRDX3", "PROTEIN", 110, 115], ["ovarian cancer cells", "CELL_TYPE", 162, 182], ["NF-\u03baB", "PROTEIN", 210, 215], ["PRDX3", "TREATMENT", 18, 23], ["pro-apoptotic proteins Bax", "TREATMENT", 36, 62], ["Caspase\u20113", "TREATMENT", 64, 73], ["Caspase\u20119", "TREATMENT", 78, 87], ["PRDX3", "PROBLEM", 110, 115], ["cisplatin\u2011mediated apoptosis", "PROBLEM", 126, 154], ["the ovarian cancer cells", "PROBLEM", 158, 182], ["pro-apoptotic proteins Bax", "OBSERVATION", 36, 62], ["cisplatin\u2011mediated apoptosis", "OBSERVATION", 126, 154], ["ovarian", "ANATOMY", 162, 169], ["cancer", "OBSERVATION", 170, 176]]], ["These data indicate that PRDX3 is accordingly up-regulated in cancer cells to remove cellular ROS and inhibit apoptosis, which provides a favorable microenvironment for cell proliferation.", [["cancer cells", "ANATOMY", 62, 74], ["cellular", "ANATOMY", 85, 93], ["cell", "ANATOMY", 169, 173], ["cancer", "DISEASE", 62, 68], ["PRDX3", "GENE_OR_GENE_PRODUCT", 25, 30], ["cancer cells", "CELL", 62, 74], ["cellular", "CELL", 85, 93], ["ROS", "SIMPLE_CHEMICAL", 94, 97], ["cell", "CELL", 169, 173], ["PRDX3", "PROTEIN", 25, 30], ["cancer cells", "CELL_TYPE", 62, 74], ["These data", "TEST", 0, 10], ["PRDX3", "PROBLEM", 25, 30], ["cancer cells", "PROBLEM", 62, 74], ["cellular ROS", "PROBLEM", 85, 97], ["apoptosis", "PROBLEM", 110, 119], ["cell proliferation", "PROBLEM", 169, 187], ["cell proliferation", "OBSERVATION", 169, 187]]], ["Therefore, PRDX3 can be a therapeutic target for several cancer treatments.Tumor promoting effect of PRDX4 ::: Roles of PRDXs in the cancer development ::: PRDXs and cancerThe tumor promoting effect of PRDX4 is well established in lung cancer, leukemia, glioblastoma, oral squamous cell carcinoma, cardiovascular disease, hepatic diseases and colorectal carcinoma.", [["cancer", "ANATOMY", 57, 63], ["Tumor", "ANATOMY", 75, 80], ["cancer", "ANATOMY", 133, 139], ["cancer", "ANATOMY", 166, 172], ["tumor", "ANATOMY", 176, 181], ["lung cancer", "ANATOMY", 231, 242], ["leukemia", "ANATOMY", 244, 252], ["glioblastoma", "ANATOMY", 254, 266], ["oral squamous cell carcinoma", "ANATOMY", 268, 296], ["cardiovascular", "ANATOMY", 298, 312], ["hepatic", "ANATOMY", 322, 329], ["colorectal carcinoma", "ANATOMY", 343, 363], ["PRDX3", "CHEMICAL", 11, 16], ["cancer", "DISEASE", 57, 63], ["cancer", "DISEASE", 133, 139], ["cancer", "DISEASE", 166, 172], ["tumor", "DISEASE", 176, 181], ["PRDX4", "CHEMICAL", 202, 207], ["lung cancer", "DISEASE", 231, 242], ["leukemia", "DISEASE", 244, 252], ["glioblastoma", "DISEASE", 254, 266], ["oral squamous cell carcinoma", "DISEASE", 268, 296], ["cardiovascular disease", "DISEASE", 298, 320], ["hepatic diseases", "DISEASE", 322, 338], ["colorectal carcinoma", "DISEASE", 343, 363], ["PRDX3", "GENE_OR_GENE_PRODUCT", 11, 16], ["cancer", "CANCER", 57, 63], ["Tumor", "CANCER", 75, 80], ["PRDX4", "SIMPLE_CHEMICAL", 101, 106], ["PRDXs", "GENE_OR_GENE_PRODUCT", 120, 125], ["cancer", "CANCER", 133, 139], ["PRDXs", "GENE_OR_GENE_PRODUCT", 156, 161], ["cancer", "CANCER", 166, 172], ["tumor", "CANCER", 176, 181], ["PRDX4", "GENE_OR_GENE_PRODUCT", 202, 207], ["lung cancer", "CANCER", 231, 242], ["leukemia", "CANCER", 244, 252], ["glioblastoma", "CANCER", 254, 266], ["oral squamous cell carcinoma", "CANCER", 268, 296], ["cardiovascular", "ANATOMICAL_SYSTEM", 298, 312], ["hepatic", "ORGAN", 322, 329], ["colorectal carcinoma", "CANCER", 343, 363], ["PRDX3", "PROTEIN", 11, 16], ["PRDX4", "PROTEIN", 101, 106], ["PRDXs", "PROTEIN", 120, 125], ["PRDX4", "PROTEIN", 202, 207], ["PRDX3", "TREATMENT", 11, 16], ["several cancer treatments", "TREATMENT", 49, 74], ["PRDXs", "PROBLEM", 156, 161], ["cancer", "PROBLEM", 166, 172], ["The tumor", "PROBLEM", 172, 181], ["PRDX4", "PROBLEM", 202, 207], ["lung cancer", "PROBLEM", 231, 242], ["leukemia", "PROBLEM", 244, 252], ["glioblastoma", "PROBLEM", 254, 266], ["oral squamous cell carcinoma", "PROBLEM", 268, 296], ["cardiovascular disease", "PROBLEM", 298, 320], ["hepatic diseases", "PROBLEM", 322, 338], ["colorectal carcinoma", "PROBLEM", 343, 363], ["cancer", "OBSERVATION", 57, 63], ["cancer", "OBSERVATION", 133, 139], ["cancer", "OBSERVATION", 166, 172], ["tumor", "OBSERVATION", 176, 181], ["lung", "ANATOMY", 231, 235], ["cancer", "OBSERVATION", 236, 242], ["leukemia", "OBSERVATION", 244, 252], ["glioblastoma", "OBSERVATION", 254, 266], ["squamous cell carcinoma", "OBSERVATION", 273, 296], ["hepatic", "ANATOMY", 322, 329], ["diseases", "OBSERVATION", 330, 338], ["colorectal", "ANATOMY", 343, 353], ["carcinoma", "OBSERVATION", 354, 363]]], ["PRDX4 is associated with lung cancer.", [["lung cancer", "ANATOMY", 25, 36], ["lung cancer", "DISEASE", 25, 36], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung cancer", "CANCER", 25, 36], ["PRDX4", "PROTEIN", 0, 5], ["lung cancer", "PROBLEM", 25, 36], ["associated with", "UNCERTAINTY", 9, 24], ["lung", "ANATOMY", 25, 29], ["cancer", "OBSERVATION", 30, 36]]], ["Wei et al demonstrated that PRDX4 along with Srx plays a very important role in tumor progression and metastasis in lung cancer (Wei et al., 2011).", [["tumor", "ANATOMY", 80, 85], ["lung cancer", "ANATOMY", 116, 127], ["tumor", "DISEASE", 80, 85], ["lung cancer", "DISEASE", 116, 127], ["PRDX4", "GENE_OR_GENE_PRODUCT", 28, 33], ["Srx", "GENE_OR_GENE_PRODUCT", 45, 48], ["tumor", "CANCER", 80, 85], ["lung cancer", "CANCER", 116, 127], ["PRDX4", "PROTEIN", 28, 33], ["Srx", "PROTEIN", 45, 48], ["tumor progression", "PROBLEM", 80, 97], ["metastasis in lung cancer", "PROBLEM", 102, 127], ["tumor", "OBSERVATION", 80, 85], ["metastasis", "OBSERVATION", 102, 112], ["lung", "ANATOMY", 116, 120], ["cancer", "OBSERVATION", 121, 127]]], ["Wei et al. showed that Srx preferentially binds to PRDX4 and the Srx-PRDX4 axis contributes significantly to the maintenance of lung tumor phenotype in vitro and the formation of metastases in vivo and also they suggested the Srx-PRDX4 axis in activation of intracellular phosphokinase signaling including AP-1/MMP-9 axis and MAPK signaling (Wei et al., 2011).", [["lung tumor", "ANATOMY", 128, 138], ["metastases", "ANATOMY", 179, 189], ["intracellular", "ANATOMY", 258, 271], ["Srx", "CHEMICAL", 23, 26], ["tumor", "DISEASE", 133, 138], ["metastases", "DISEASE", 179, 189], ["Srx", "GENE_OR_GENE_PRODUCT", 23, 26], ["PRDX4", "GENE_OR_GENE_PRODUCT", 51, 56], ["Srx-PRDX4", "GENE_OR_GENE_PRODUCT", 65, 74], ["lung tumor", "CANCER", 128, 138], ["Srx-PRDX4", "GENE_OR_GENE_PRODUCT", 226, 235], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 258, 271], ["phosphokinase", "GENE_OR_GENE_PRODUCT", 272, 285], ["AP-1", "GENE_OR_GENE_PRODUCT", 306, 310], ["MMP-9", "GENE_OR_GENE_PRODUCT", 311, 316], ["MAPK", "GENE_OR_GENE_PRODUCT", 326, 330], ["Srx", "PROTEIN", 23, 26], ["PRDX4", "PROTEIN", 51, 56], ["Srx-PRDX4", "PROTEIN", 65, 74], ["Srx-PRDX4", "PROTEIN", 226, 235], ["intracellular phosphokinase", "PROTEIN", 258, 285], ["MMP", "PROTEIN", 311, 314], ["MAPK", "PROTEIN", 326, 330], ["PRDX4", "TREATMENT", 51, 56], ["the Srx-PRDX4 axis", "PROBLEM", 61, 79], ["lung tumor phenotype", "PROBLEM", 128, 148], ["metastases", "PROBLEM", 179, 189], ["intracellular phosphokinase signaling", "TEST", 258, 295], ["AP", "TEST", 306, 308], ["MMP", "TEST", 311, 314], ["MAPK signaling", "TEST", 326, 340], ["lung", "ANATOMY", 128, 132], ["tumor", "OBSERVATION", 133, 138], ["metastases", "OBSERVATION", 179, 189]]], ["The expression of PRDX4 is at least 1.5 fold higher in tumor cells compared to control and this finding applies most frequently to adenocarcinoma and modestly to squamous cell carcinoma (Lehtonen et al., 2004).", [["tumor cells", "ANATOMY", 55, 66], ["adenocarcinoma", "ANATOMY", 131, 145], ["squamous cell carcinoma", "ANATOMY", 162, 185], ["tumor", "DISEASE", 55, 60], ["adenocarcinoma", "DISEASE", 131, 145], ["squamous cell carcinoma", "DISEASE", 162, 185], ["PRDX4", "GENE_OR_GENE_PRODUCT", 18, 23], ["tumor cells", "CELL", 55, 66], ["adenocarcinoma", "CANCER", 131, 145], ["squamous cell carcinoma", "CANCER", 162, 185], ["PRDX4", "PROTEIN", 18, 23], ["tumor cells", "CELL_TYPE", 55, 66], ["PRDX4", "PROBLEM", 18, 23], ["tumor cells", "PROBLEM", 55, 66], ["adenocarcinoma", "PROBLEM", 131, 145], ["squamous cell carcinoma", "PROBLEM", 162, 185], ["tumor cells", "OBSERVATION", 55, 66], ["adenocarcinoma", "OBSERVATION", 131, 145], ["squamous cell carcinoma", "OBSERVATION", 162, 185]]], ["Alteration in expression of PRDX4 results in an alteration to the rate of tumor progression and metastasis which is indicated by anchorage independent colony formation, cell migration and invasion of human lung cancer cells (Park et al., 2008).", [["tumor", "ANATOMY", 74, 79], ["colony", "ANATOMY", 151, 157], ["cell", "ANATOMY", 169, 173], ["lung cancer cells", "ANATOMY", 206, 223], ["tumor", "DISEASE", 74, 79], ["lung cancer", "DISEASE", 206, 217], ["PRDX4", "GENE_OR_GENE_PRODUCT", 28, 33], ["tumor", "CANCER", 74, 79], ["cell", "CELL", 169, 173], ["human", "ORGANISM", 200, 205], ["lung cancer cells", "CELL", 206, 223], ["PRDX4", "PROTEIN", 28, 33], ["human lung cancer cells", "CELL_TYPE", 200, 223], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 200, 205], ["Alteration in expression of PRDX4", "PROBLEM", 0, 33], ["tumor progression", "PROBLEM", 74, 91], ["metastasis", "PROBLEM", 96, 106], ["anchorage independent colony formation", "PROBLEM", 129, 167], ["cell migration", "PROBLEM", 169, 183], ["invasion of human lung cancer cells", "PROBLEM", 188, 223], ["tumor", "OBSERVATION", 74, 79], ["metastasis", "OBSERVATION", 96, 106], ["colony formation", "OBSERVATION", 151, 167], ["cell migration", "OBSERVATION", 169, 183], ["invasion", "OBSERVATION_MODIFIER", 188, 196], ["lung", "ANATOMY", 206, 210], ["cancer", "OBSERVATION", 211, 217]]], ["The ability of PRDX4 to promote tumor progression and metastasis is supposed to be due to its antioxidant properties (Dando et al., 2015).", [["tumor", "ANATOMY", 32, 37], ["PRDX4", "CHEMICAL", 15, 20], ["tumor", "DISEASE", 32, 37], ["metastasis", "DISEASE", 54, 64], ["PRDX4", "GENE_OR_GENE_PRODUCT", 15, 20], ["tumor", "CANCER", 32, 37], ["PRDX4", "PROTEIN", 15, 20], ["PRDX4", "TREATMENT", 15, 20], ["tumor progression", "PROBLEM", 32, 49], ["metastasis", "PROBLEM", 54, 64], ["tumor", "OBSERVATION", 32, 37], ["metastasis", "OBSERVATION", 54, 64]]], ["Alteration of PRDX4 expression is proposed to play a role in the development of different types of leukemia (Palande et al., 2011).", [["leukemia", "ANATOMY", 99, 107], ["leukemia", "DISEASE", 99, 107], ["PRDX4", "GENE_OR_GENE_PRODUCT", 14, 19], ["leukemia", "CANCER", 99, 107], ["PRDX4", "PROTEIN", 14, 19], ["leukemia", "PROBLEM", 99, 107], ["leukemia", "OBSERVATION", 99, 107]]], ["Palande et al. found that the alteration in genomic sequence and expression level of PRDX4 is rare in acute myeloid leukemia but have found strong reduction in PRDX4 expression in acute promyelocytic leukemia (Palande et al., 2011).", [["acute myeloid leukemia", "ANATOMY", 102, 124], ["acute promyelocytic leukemia", "ANATOMY", 180, 208], ["acute myeloid leukemia", "DISEASE", 102, 124], ["acute promyelocytic leukemia", "DISEASE", 180, 208], ["PRDX4", "GENE_OR_GENE_PRODUCT", 85, 90], ["acute myeloid leukemia", "CANCER", 102, 124], ["PRDX4", "GENE_OR_GENE_PRODUCT", 160, 165], ["acute promyelocytic leukemia", "CANCER", 180, 208], ["PRDX4", "PROTEIN", 85, 90], ["PRDX4", "PROTEIN", 160, 165], ["the alteration in genomic sequence", "PROBLEM", 26, 60], ["expression level of PRDX4", "PROBLEM", 65, 90], ["acute myeloid leukemia", "PROBLEM", 102, 124], ["strong reduction in PRDX4 expression", "PROBLEM", 140, 176], ["acute promyelocytic leukemia", "PROBLEM", 180, 208], ["alteration", "OBSERVATION", 30, 40], ["acute myeloid leukemia", "OBSERVATION", 102, 124], ["strong", "OBSERVATION_MODIFIER", 140, 146], ["reduction", "OBSERVATION_MODIFIER", 147, 156], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["promyelocytic leukemia", "OBSERVATION", 186, 208]]], ["Also, it was suggested that due to the alteration in PRDX4 expression, the signal transduction from a myeloid growth factor receptor i.e. the granulocyte colony stimulating factor receptor is affected (Palande et al., 2011).", [["PRDX4", "GENE_OR_GENE_PRODUCT", 53, 58], ["myeloid growth factor receptor", "GENE_OR_GENE_PRODUCT", 102, 132], ["granulocyte colony stimulating factor receptor", "GENE_OR_GENE_PRODUCT", 142, 188], ["PRDX4", "PROTEIN", 53, 58], ["myeloid growth factor receptor", "PROTEIN", 102, 132], ["granulocyte colony stimulating factor receptor", "PROTEIN", 142, 188], ["the alteration in PRDX4 expression", "PROBLEM", 35, 69], ["the signal transduction", "PROBLEM", 71, 94], ["a myeloid growth factor receptor", "TREATMENT", 100, 132], ["the granulocyte colony", "TEST", 138, 160], ["granulocyte colony", "OBSERVATION", 142, 160]]], ["In acute myeloid leukemia (AML) patients, the PRDX4 gene is fused with the AML1 gene between exon 5 and 6 of AML1 and exon 2 of PRDX4 (Zhang et al., 2004).", [["acute myeloid leukemia", "ANATOMY", 3, 25], ["AML", "ANATOMY", 27, 30], ["acute myeloid leukemia", "DISEASE", 3, 25], ["AML", "DISEASE", 27, 30], ["acute myeloid leukemia", "CANCER", 3, 25], ["AML", "CANCER", 27, 30], ["patients", "ORGANISM", 32, 40], ["PRDX4", "GENE_OR_GENE_PRODUCT", 46, 51], ["AML1", "GENE_OR_GENE_PRODUCT", 75, 79], ["AML1", "GENE_OR_GENE_PRODUCT", 109, 113], ["PRDX4", "GENE_OR_GENE_PRODUCT", 128, 133], ["PRDX4 gene", "DNA", 46, 56], ["AML1 gene", "DNA", 75, 84], ["exon 5 and 6", "DNA", 93, 105], ["AML1", "DNA", 109, 113], ["exon 2", "DNA", 118, 124], ["PRDX4", "DNA", 128, 133], ["patients", "SPECIES", 32, 40], ["acute myeloid leukemia", "PROBLEM", 3, 25], ["the PRDX4 gene", "TREATMENT", 42, 56], ["the AML1 gene between exon", "TREATMENT", 71, 97], ["AML1 and exon", "TREATMENT", 109, 122], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["myeloid leukemia", "OBSERVATION", 9, 25]]], ["This fusion of AML1 gene with the PRDX4 gene is supposed to play a role in the altered expression of PRDX4 in acute myeloid leukemia (Zhang et al., 2004).", [["acute myeloid leukemia", "ANATOMY", 110, 132], ["acute myeloid leukemia", "DISEASE", 110, 132], ["AML1", "GENE_OR_GENE_PRODUCT", 15, 19], ["PRDX4", "GENE_OR_GENE_PRODUCT", 34, 39], ["PRDX4", "GENE_OR_GENE_PRODUCT", 101, 106], ["acute myeloid leukemia", "CANCER", 110, 132], ["AML1 gene", "DNA", 15, 24], ["PRDX4 gene", "DNA", 34, 44], ["PRDX4", "PROTEIN", 101, 106], ["This fusion of AML1 gene", "TREATMENT", 0, 24], ["acute myeloid leukemia", "PROBLEM", 110, 132], ["AML1 gene", "OBSERVATION", 15, 24], ["acute myeloid leukemia", "OBSERVATION", 110, 132]]], ["PRDX4 is supposed to play a role in the most aggressive primary brain malignancy (Kim et al., 2012).", [["primary brain malignancy", "ANATOMY", 56, 80], ["PRDX4", "CHEMICAL", 0, 5], ["primary brain malignancy", "DISEASE", 56, 80], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["brain", "ORGAN", 64, 69], ["malignancy", "CANCER", 70, 80], ["PRDX4", "PROTEIN", 0, 5], ["brain", "ANATOMY", 64, 69], ["malignancy", "OBSERVATION", 70, 80]]], ["They found that the knockdown of PRDX4 results in reduced Glioblastoma multiform cell growth and radiation resistance along with increased ROS level, DNA damage and apoptosis in in-vitro model, suggesting the importance of PRDX4 in radiation resistance and tumor maintenance of GBM (Kim et al., 2012).", [["Glioblastoma multiform cell", "ANATOMY", 58, 85], ["tumor", "ANATOMY", 257, 262], ["GBM", "ANATOMY", 278, 281], ["PRDX4", "CHEMICAL", 33, 38], ["Glioblastoma", "DISEASE", 58, 70], ["ROS", "CHEMICAL", 139, 142], ["PRDX4", "CHEMICAL", 223, 228], ["tumor", "DISEASE", 257, 262], ["GBM", "DISEASE", 278, 281], ["PRDX4", "GENE_OR_GENE_PRODUCT", 33, 38], ["Glioblastoma multiform cell", "CELL", 58, 85], ["ROS", "SIMPLE_CHEMICAL", 139, 142], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["PRDX4", "GENE_OR_GENE_PRODUCT", 223, 228], ["tumor", "CANCER", 257, 262], ["GBM", "CANCER", 278, 281], ["PRDX4", "PROTEIN", 33, 38], ["PRDX4", "PROTEIN", 223, 228], ["the knockdown of PRDX4", "PROBLEM", 16, 38], ["reduced Glioblastoma multiform cell growth", "PROBLEM", 50, 92], ["radiation resistance", "PROBLEM", 97, 117], ["increased ROS level", "PROBLEM", 129, 148], ["DNA damage", "PROBLEM", 150, 160], ["apoptosis", "PROBLEM", 165, 174], ["PRDX4", "TREATMENT", 223, 228], ["radiation resistance", "TREATMENT", 232, 252], ["GBM", "PROBLEM", 278, 281], ["reduced", "OBSERVATION_MODIFIER", 50, 57], ["Glioblastoma multiform cell", "OBSERVATION", 58, 85], ["growth", "OBSERVATION_MODIFIER", 86, 92], ["radiation resistance", "OBSERVATION", 97, 117], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["ROS", "OBSERVATION_MODIFIER", 139, 142], ["apoptosis", "OBSERVATION_MODIFIER", 165, 174], ["radiation resistance", "OBSERVATION", 232, 252], ["tumor", "OBSERVATION", 257, 262]]], ["PRDX4 is also studied for its role in tumor progression, cell migration and invasiveness in oral cavity squamous cell carcinoma (Chang et al., 2011a, b).", [["tumor", "ANATOMY", 38, 43], ["cell", "ANATOMY", 57, 61], ["oral cavity squamous cell carcinoma", "ANATOMY", 92, 127], ["tumor", "DISEASE", 38, 43], ["squamous cell carcinoma", "DISEASE", 104, 127], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor", "CANCER", 38, 43], ["cell", "CELL", 57, 61], ["oral cavity squamous cell carcinoma", "CANCER", 92, 127], ["PRDX4", "PROTEIN", 0, 5], ["tumor progression", "PROBLEM", 38, 55], ["cell migration", "PROBLEM", 57, 71], ["invasiveness in oral cavity squamous cell carcinoma", "PROBLEM", 76, 127], ["tumor", "OBSERVATION", 38, 43], ["cell migration", "OBSERVATION", 57, 71], ["invasiveness", "OBSERVATION_MODIFIER", 76, 88], ["oral cavity", "ANATOMY", 92, 103], ["squamous cell carcinoma", "OBSERVATION", 104, 127]]], ["Along with the prognostic value of PRDX4, PRDX4 can also be a good therapeutic target in OSCC by virtue of its ability to mediate cell migration and/or metastasis (Liao et al., 2011).", [["OSCC", "ANATOMY", 89, 93], ["cell", "ANATOMY", 130, 134], ["OSCC", "DISEASE", 89, 93], ["PRDX4", "GENE_OR_GENE_PRODUCT", 35, 40], ["PRDX4", "GENE_OR_GENE_PRODUCT", 42, 47], ["OSCC", "CANCER", 89, 93], ["cell", "CELL", 130, 134], ["PRDX4", "PROTEIN", 35, 40], ["PRDX4", "PROTEIN", 42, 47], ["PRDX4", "TREATMENT", 42, 47], ["metastasis", "PROBLEM", 152, 162], ["cell migration", "OBSERVATION", 130, 144], ["metastasis", "OBSERVATION", 152, 162]]], ["Also, PRDX4 is secreted into an extracellular environment, therefore, its plasma concentration may be used as a molecular indicator of various cardiovascular disease and other disorders involving oxidative stress (Schulte, 2011).", [["extracellular", "ANATOMY", 32, 45], ["plasma", "ANATOMY", 74, 80], ["cardiovascular", "ANATOMY", 143, 157], ["cardiovascular disease", "DISEASE", 143, 165], ["PRDX4", "GENE_OR_GENE_PRODUCT", 6, 11], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["plasma", "ORGANISM_SUBSTANCE", 74, 80], ["cardiovascular", "ANATOMICAL_SYSTEM", 143, 157], ["PRDX4", "PROTEIN", 6, 11], ["its plasma concentration", "TREATMENT", 70, 94], ["various cardiovascular disease", "PROBLEM", 135, 165], ["other disorders", "PROBLEM", 170, 185], ["extracellular environment", "OBSERVATION", 32, 57], ["cardiovascular disease", "OBSERVATION", 143, 165]]], ["The increased serum PRDX4 concentration is considered as a good indicator of risk to cardiovascular disease because cardiovascular disease have higher level of oxidative stress and PRDX4 is over-expressed in these conditions (Abbasi et al., 2012).", [["serum", "ANATOMY", 14, 19], ["cardiovascular", "ANATOMY", 85, 99], ["cardiovascular", "ANATOMY", 116, 130], ["cardiovascular disease", "DISEASE", 85, 107], ["cardiovascular disease", "DISEASE", 116, 138], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["PRDX4", "GENE_OR_GENE_PRODUCT", 20, 25], ["cardiovascular", "ANATOMICAL_SYSTEM", 85, 99], ["cardiovascular", "ANATOMICAL_SYSTEM", 116, 130], ["PRDX4", "GENE_OR_GENE_PRODUCT", 181, 186], ["PRDX4", "PROTEIN", 20, 25], ["PRDX4", "PROTEIN", 181, 186], ["The increased serum PRDX4 concentration", "PROBLEM", 0, 39], ["cardiovascular disease", "PROBLEM", 85, 107], ["cardiovascular disease", "PROBLEM", 116, 138], ["oxidative stress", "PROBLEM", 160, 176], ["PRDX4", "PROBLEM", 181, 186], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["serum PRDX4", "OBSERVATION_MODIFIER", 14, 25], ["cardiovascular", "ANATOMY", 85, 99], ["disease", "OBSERVATION", 100, 107], ["oxidative stress", "OBSERVATION", 160, 176]]], ["A study in a rat model of Wilson's disease has demonstrated that this disease has a lower level of PRDX4 expression as compared to normal (Ito et al., 2012).", [["Wilson's disease", "DISEASE", 26, 42], ["rat", "ORGANISM", 13, 16], ["PRDX4", "GENE_OR_GENE_PRODUCT", 99, 104], ["PRDX4", "PROTEIN", 99, 104], ["rat", "SPECIES", 13, 16], ["A study", "TEST", 0, 7], ["Wilson's disease", "PROBLEM", 26, 42], ["this disease", "PROBLEM", 65, 77]]], ["PRDX4 can protect the hepatic tissue against the Hydrogen peroxide as well as other ROS causing oxidative stress.", [["hepatic tissue", "ANATOMY", 22, 36], ["PRDX4", "CHEMICAL", 0, 5], ["Hydrogen peroxide", "CHEMICAL", 49, 66], ["ROS", "CHEMICAL", 84, 87], ["Hydrogen peroxide", "CHEMICAL", 49, 66], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["hepatic tissue", "TISSUE", 22, 36], ["Hydrogen peroxide", "SIMPLE_CHEMICAL", 49, 66], ["ROS", "SIMPLE_CHEMICAL", 84, 87], ["PRDX4", "PROTEIN", 0, 5], ["PRDX4", "TREATMENT", 0, 5], ["the Hydrogen peroxide", "TREATMENT", 45, 66], ["oxidative stress", "PROBLEM", 96, 112], ["hepatic", "ANATOMY", 22, 29], ["Hydrogen peroxide", "OBSERVATION", 49, 66], ["oxidative stress", "OBSERVATION", 96, 112]]], ["The same study has proposed that PRDX4 can be used as a potential biomarker of hepatic diseases as the PRDX4 serum concentration in this model was found to be quite low.", [["hepatic", "ANATOMY", 79, 86], ["serum", "ANATOMY", 109, 114], ["hepatic diseases", "DISEASE", 79, 95], ["PRDX4", "GENE_OR_GENE_PRODUCT", 33, 38], ["hepatic", "ORGAN", 79, 86], ["PRDX4", "GENE_OR_GENE_PRODUCT", 103, 108], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["PRDX4", "PROTEIN", 33, 38], ["PRDX4", "PROTEIN", 103, 108], ["The same study", "TEST", 0, 14], ["PRDX4", "TREATMENT", 33, 38], ["hepatic diseases", "PROBLEM", 79, 95], ["the PRDX4 serum concentration", "TEST", 99, 128], ["hepatic", "ANATOMY", 79, 86], ["diseases", "OBSERVATION", 87, 95]]], ["Genomic loss of PRDX4 in mice results in testicular atrophy due to elevated spermatogenic cell death (Iuchi et al., 2009).", [["testicular", "ANATOMY", 41, 51], ["spermatogenic cell", "ANATOMY", 76, 94], ["testicular atrophy", "DISEASE", 41, 59], ["elevated spermatogenic cell death", "DISEASE", 67, 100], ["PRDX4", "GENE_OR_GENE_PRODUCT", 16, 21], ["mice", "ORGANISM", 25, 29], ["testicular", "ORGAN", 41, 51], ["spermatogenic cell", "CELL", 76, 94], ["PRDX4", "PROTEIN", 16, 21], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["Genomic loss of PRDX4", "PROBLEM", 0, 21], ["testicular atrophy", "PROBLEM", 41, 59], ["elevated spermatogenic cell death", "PROBLEM", 67, 100], ["loss", "OBSERVATION_MODIFIER", 8, 12], ["testicular", "ANATOMY", 41, 51], ["atrophy", "OBSERVATION", 52, 59], ["elevated", "OBSERVATION_MODIFIER", 67, 75], ["spermatogenic cell death", "OBSERVATION", 76, 100]]], ["PRDX4 is also related with colorectal carcinoma.", [["colorectal carcinoma", "ANATOMY", 27, 47], ["colorectal carcinoma", "DISEASE", 27, 47], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["colorectal carcinoma", "CANCER", 27, 47], ["PRDX4", "PROTEIN", 0, 5], ["PRDX4", "TREATMENT", 0, 5], ["colorectal carcinoma", "PROBLEM", 27, 47], ["also related with", "UNCERTAINTY", 9, 26], ["colorectal carcinoma", "OBSERVATION", 27, 47]]], ["The expressions of the PRDX4 gene and protein were higher in colorectal carcinoma compared to those in the adjacent normal tissues and the expression intensity of the PRDX4 protein was correlated with depth of invasion and lymph node metastasis in CRC, and high PRDX4 expression was correlated with short survival time (Yi et al., 2014).", [["colorectal carcinoma", "ANATOMY", 61, 81], ["tissues", "ANATOMY", 123, 130], ["lymph node", "ANATOMY", 223, 233], ["CRC", "ANATOMY", 248, 251], ["colorectal carcinoma", "DISEASE", 61, 81], ["CRC", "DISEASE", 248, 251], ["PRDX4", "GENE_OR_GENE_PRODUCT", 23, 28], ["colorectal carcinoma", "CANCER", 61, 81], ["normal tissues", "TISSUE", 116, 130], ["PRDX4", "GENE_OR_GENE_PRODUCT", 167, 172], ["lymph node", "MULTI-TISSUE_STRUCTURE", 223, 233], ["CRC", "CANCER", 248, 251], ["PRDX4", "GENE_OR_GENE_PRODUCT", 262, 267], ["PRDX4 gene", "DNA", 23, 33], ["PRDX4 protein", "PROTEIN", 167, 180], ["PRDX4", "PROTEIN", 262, 267], ["the PRDX4 gene and protein", "PROBLEM", 19, 45], ["colorectal carcinoma", "PROBLEM", 61, 81], ["the PRDX4 protein", "TEST", 163, 180], ["invasion", "PROBLEM", 210, 218], ["lymph node metastasis", "PROBLEM", 223, 244], ["CRC", "TEST", 248, 251], ["high PRDX4 expression", "PROBLEM", 257, 278], ["higher", "OBSERVATION_MODIFIER", 51, 57], ["colorectal carcinoma", "OBSERVATION", 61, 81], ["normal tissues", "OBSERVATION", 116, 130], ["invasion", "OBSERVATION", 210, 218], ["lymph node metastasis", "OBSERVATION", 223, 244], ["high", "OBSERVATION_MODIFIER", 257, 261]]], ["These studies suggest that PRDX4 is involved in the tumor promoting effect through formation of Srx-PRDX4 via AP-1/MMP-9 and MAPK signaling, and remove cellular ROS which provides a favorable microenvironment for cell proliferation.", [["tumor", "ANATOMY", 52, 57], ["cellular", "ANATOMY", 152, 160], ["cell", "ANATOMY", 213, 217], ["PRDX4", "CHEMICAL", 27, 32], ["tumor", "DISEASE", 52, 57], ["ROS", "CHEMICAL", 161, 164], ["PRDX4", "GENE_OR_GENE_PRODUCT", 27, 32], ["tumor", "CANCER", 52, 57], ["Srx-PRDX4", "GENE_OR_GENE_PRODUCT", 96, 105], ["AP-1", "GENE_OR_GENE_PRODUCT", 110, 114], ["MMP-9", "GENE_OR_GENE_PRODUCT", 115, 120], ["MAPK", "GENE_OR_GENE_PRODUCT", 125, 129], ["cellular", "CELL", 152, 160], ["ROS", "SIMPLE_CHEMICAL", 161, 164], ["cell", "CELL", 213, 217], ["PRDX4", "PROTEIN", 27, 32], ["Srx-PRDX4", "PROTEIN", 96, 105], ["MMP", "PROTEIN", 115, 118], ["MAPK", "PROTEIN", 125, 129], ["These studies", "TEST", 0, 13], ["PRDX4", "PROBLEM", 27, 32], ["the tumor", "PROBLEM", 48, 57], ["Srx-", "TEST", 96, 100], ["AP", "TEST", 110, 112], ["MMP", "TEST", 115, 118], ["MAPK signaling", "TEST", 125, 139], ["cellular ROS", "TEST", 152, 164], ["cell proliferation", "PROBLEM", 213, 231], ["tumor", "OBSERVATION", 52, 57], ["cell proliferation", "OBSERVATION", 213, 231]]], ["Hence, PRDX4 can be a therapeutic target for several cancer treatments.Beneficial or non-beneficial role of PRDX5 in cancer ::: Roles of PRDXs in the cancer development ::: PRDXs and cancerThe anti-tumor effect of PRDX5 is well established in breast cancer.", [["cancer", "ANATOMY", 53, 59], ["cancer", "ANATOMY", 117, 123], ["cancer", "ANATOMY", 150, 156], ["cancer", "ANATOMY", 183, 189], ["breast cancer", "ANATOMY", 243, 256], ["PRDX4", "CHEMICAL", 7, 12], ["cancer", "DISEASE", 53, 59], ["cancer", "DISEASE", 117, 123], ["cancer", "DISEASE", 150, 156], ["cancer", "DISEASE", 183, 189], ["PRDX5", "CHEMICAL", 214, 219], ["breast cancer", "DISEASE", 243, 256], ["PRDX4", "GENE_OR_GENE_PRODUCT", 7, 12], ["cancer", "CANCER", 53, 59], ["PRDX5", "GENE_OR_GENE_PRODUCT", 108, 113], ["cancer", "CANCER", 117, 123], ["PRDXs", "GENE_OR_GENE_PRODUCT", 137, 142], ["cancer", "CANCER", 150, 156], ["PRDXs", "GENE_OR_GENE_PRODUCT", 173, 178], ["cancer", "CANCER", 183, 189], ["anti-tumor", "CANCER", 193, 203], ["PRDX5", "GENE_OR_GENE_PRODUCT", 214, 219], ["breast cancer", "CANCER", 243, 256], ["PRDX4", "PROTEIN", 7, 12], ["PRDX5", "PROTEIN", 108, 113], ["PRDXs", "PROTEIN", 137, 142], ["PRDX5", "PROTEIN", 214, 219], ["PRDX4", "TREATMENT", 7, 12], ["several cancer treatments", "TREATMENT", 45, 70], ["PRDXs", "PROBLEM", 173, 178], ["cancer", "PROBLEM", 183, 189], ["PRDX5", "TREATMENT", 214, 219], ["breast cancer", "PROBLEM", 243, 256], ["cancer", "OBSERVATION", 53, 59], ["cancer", "OBSERVATION", 117, 123], ["cancer", "OBSERVATION", 150, 156], ["cancer", "OBSERVATION", 183, 189], ["anti-tumor effect", "OBSERVATION", 193, 210], ["breast", "ANATOMY", 243, 249], ["cancer", "OBSERVATION", 250, 256]]], ["Recent data showed that of the various PRDX family members, PRDX5 was the only one that was significantly downregulated in tumor samples obtained from Sudanese breast cancer patients (Elamin, Zhu, Hassan, Xu, & Ibrahim, 2013).Beneficial or non-beneficial role of PRDX5 in cancer ::: Roles of PRDXs in the cancer development ::: PRDXs and cancerThe tumor promoting effect of PRDX5 is established in Graves\u2019 disease.", [["tumor samples", "ANATOMY", 123, 136], ["breast cancer", "ANATOMY", 160, 173], ["cancer", "ANATOMY", 272, 278], ["cancer", "ANATOMY", 305, 311], ["cancer", "ANATOMY", 338, 344], ["tumor", "ANATOMY", 348, 353], ["tumor", "DISEASE", 123, 128], ["breast cancer", "DISEASE", 160, 173], ["cancer", "DISEASE", 272, 278], ["cancer", "DISEASE", 305, 311], ["cancer", "DISEASE", 338, 344], ["tumor", "DISEASE", 348, 353], ["PRDX5", "CHEMICAL", 374, 379], ["Graves\u2019 disease", "DISEASE", 398, 413], ["PRDX", "GENE_OR_GENE_PRODUCT", 39, 43], ["PRDX5", "GENE_OR_GENE_PRODUCT", 60, 65], ["tumor samples", "CANCER", 123, 136], ["breast cancer", "CANCER", 160, 173], ["patients", "ORGANISM", 174, 182], ["PRDX5", "GENE_OR_GENE_PRODUCT", 263, 268], ["cancer", "CANCER", 272, 278], ["PRDXs", "GENE_OR_GENE_PRODUCT", 292, 297], ["cancer", "CANCER", 305, 311], ["PRDXs", "GENE_OR_GENE_PRODUCT", 328, 333], ["cancer", "CANCER", 338, 344], ["tumor", "CANCER", 348, 353], ["PRDX5", "GENE_OR_GENE_PRODUCT", 374, 379], ["Graves\u2019 disease", "CANCER", 398, 413], ["PRDX family members", "PROTEIN", 39, 58], ["PRDX5", "PROTEIN", 60, 65], ["PRDX5", "PROTEIN", 263, 268], ["PRDXs", "PROTEIN", 292, 297], ["PRDX5", "PROTEIN", 374, 379], ["patients", "SPECIES", 174, 182], ["Recent data", "TEST", 0, 11], ["PRDXs", "PROBLEM", 328, 333], ["cancer", "PROBLEM", 338, 344], ["PRDX5", "TREATMENT", 374, 379], ["Graves\u2019 disease", "PROBLEM", 398, 413], ["tumor", "OBSERVATION", 123, 128], ["breast", "ANATOMY", 160, 166], ["cancer", "OBSERVATION", 167, 173], ["cancer", "OBSERVATION", 272, 278], ["cancer", "OBSERVATION", 305, 311], ["cancer", "OBSERVATION", 338, 344], ["tumor", "OBSERVATION", 348, 353]]], ["PRDX5 expression is higher in the thyroid gland of patients with Graves' disease compared to multinodular goiters, and the level of expression is directly correlated with the functional status of epithelial cells, being higher in multinodular goiters, and even more pronounced in hyperthyroid tissues, such as Graves\u2019 disease (G\u00e9rard, Many, Daumerie, Knoops, & Colin, 2005).", [["thyroid gland", "ANATOMY", 34, 47], ["multinodular goiters", "ANATOMY", 93, 113], ["epithelial cells", "ANATOMY", 196, 212], ["multinodular goiters", "ANATOMY", 230, 250], ["hyperthyroid tissues", "ANATOMY", 280, 300], ["Graves' disease", "DISEASE", 65, 80], ["goiters", "DISEASE", 106, 113], ["goiters", "DISEASE", 243, 250], ["hyperthyroid", "DISEASE", 280, 292], ["Graves\u2019 disease", "DISEASE", 310, 325], ["PRDX5", "GENE_OR_GENE_PRODUCT", 0, 5], ["thyroid gland", "ORGAN", 34, 47], ["patients", "ORGANISM", 51, 59], ["Graves' disease", "CANCER", 65, 80], ["multinodular goiters", "CANCER", 93, 113], ["epithelial cells", "CELL", 196, 212], ["multinodular goiters", "CANCER", 230, 250], ["hyperthyroid tissues", "TISSUE", 280, 300], ["PRDX5", "PROTEIN", 0, 5], ["epithelial cells", "CELL_TYPE", 196, 212], ["patients", "SPECIES", 51, 59], ["Graves' disease", "PROBLEM", 65, 80], ["multinodular goiters", "PROBLEM", 93, 113], ["epithelial cells", "PROBLEM", 196, 212], ["multinodular goiters", "PROBLEM", 230, 250], ["hyperthyroid tissues", "PROBLEM", 280, 300], ["Graves\u2019 disease", "PROBLEM", 310, 325], ["higher", "OBSERVATION_MODIFIER", 20, 26], ["thyroid gland", "ANATOMY", 34, 47], ["Graves", "OBSERVATION", 65, 71], ["multinodular", "OBSERVATION_MODIFIER", 93, 105], ["goiters", "OBSERVATION", 106, 113], ["epithelial cells", "OBSERVATION", 196, 212], ["higher", "OBSERVATION_MODIFIER", 220, 226], ["multinodular", "OBSERVATION_MODIFIER", 230, 242], ["goiters", "OBSERVATION", 243, 250], ["more pronounced", "OBSERVATION_MODIFIER", 261, 276], ["hyperthyroid tissues", "OBSERVATION", 280, 300]]], ["Wang et al showed that PRDX5 expression is increased in a degenerative tendon compared with normal tendon (Wang et al., 2001).", [["tendon", "ANATOMY", 71, 77], ["tendon", "ANATOMY", 99, 105], ["PRDX5", "GENE_OR_GENE_PRODUCT", 23, 28], ["tendon", "TISSUE", 71, 77], ["tendon", "MULTI-TISSUE_STRUCTURE", 99, 105], ["PRDX5", "PROTEIN", 23, 28], ["a degenerative tendon", "PROBLEM", 56, 77], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["degenerative", "OBSERVATION_MODIFIER", 58, 70], ["tendon", "ANATOMY", 71, 77], ["tendon", "ANATOMY", 99, 105]]], ["They showed that while PRDX5 was localized to fibroblasts in a normal tendon, it was localized to fibroblasts and endothelial cells in a degenerative tendon (Wang et al., 2001).Beneficial or non-beneficial role of PRDX5 in cancer ::: Roles of PRDXs in the cancer development ::: PRDXs and cancerThese data indicate that PRDX5 may inhibit breast cancers, but promotes Graves\u2019 disease.Tumor promoting effect of PRDX6 ::: Roles of PRDXs in the cancer development ::: PRDXs and cancerThe tumor promoting effect of PRDX6 is well established in lung cancer, ovarian cancer, liver cancer and gastric cancer.", [["fibroblasts", "ANATOMY", 46, 57], ["tendon", "ANATOMY", 70, 76], ["fibroblasts", "ANATOMY", 98, 109], ["endothelial cells", "ANATOMY", 114, 131], ["tendon", "ANATOMY", 150, 156], ["cancer", "ANATOMY", 223, 229], ["cancer", "ANATOMY", 256, 262], ["breast cancers", "ANATOMY", 338, 352], ["Tumor", "ANATOMY", 383, 388], ["cancer", "ANATOMY", 441, 447], ["cancer", "ANATOMY", 474, 480], ["tumor", "ANATOMY", 484, 489], ["lung cancer", "ANATOMY", 539, 550], ["ovarian cancer", "ANATOMY", 552, 566], ["liver cancer", "ANATOMY", 568, 580], ["gastric cancer", "ANATOMY", 585, 599], ["cancer", "DISEASE", 223, 229], ["cancer", "DISEASE", 256, 262], ["PRDX5", "CHEMICAL", 320, 325], ["breast cancers", "DISEASE", 338, 352], ["Graves\u2019 disease", "DISEASE", 367, 382], ["cancer", "DISEASE", 441, 447], ["cancer", "DISEASE", 474, 480], ["tumor", "DISEASE", 484, 489], ["PRDX6", "CHEMICAL", 510, 515], ["lung cancer", "DISEASE", 539, 550], ["ovarian cancer", "DISEASE", 552, 566], ["liver cancer", "DISEASE", 568, 580], ["gastric cancer", "DISEASE", 585, 599], ["PRDX5", "GENE_OR_GENE_PRODUCT", 23, 28], ["fibroblasts", "CELL", 46, 57], ["tendon", "ORGAN", 70, 76], ["fibroblasts", "CELL", 98, 109], ["endothelial cells", "CELL", 114, 131], ["tendon", "TISSUE", 150, 156], ["PRDX5", "GENE_OR_GENE_PRODUCT", 214, 219], ["cancer", "CANCER", 223, 229], ["PRDXs", "GENE_OR_GENE_PRODUCT", 243, 248], ["cancer", "CANCER", 256, 262], ["PRDXs", "GENE_OR_GENE_PRODUCT", 279, 284], ["PRDX5", "GENE_OR_GENE_PRODUCT", 320, 325], ["breast cancers", "CANCER", 338, 352], ["Graves\u2019 disease", "CANCER", 367, 382], ["Tumor", "CANCER", 383, 388], ["PRDX6", "SIMPLE_CHEMICAL", 409, 414], ["PRDXs", "GENE_OR_GENE_PRODUCT", 428, 433], ["cancer", "CANCER", 441, 447], ["PRDXs", "GENE_OR_GENE_PRODUCT", 464, 469], ["cancer", "CANCER", 474, 480], ["tumor", "CANCER", 484, 489], ["PRDX6", "GENE_OR_GENE_PRODUCT", 510, 515], ["lung cancer", "CANCER", 539, 550], ["ovarian cancer", "CANCER", 552, 566], ["liver cancer", "CANCER", 568, 580], ["gastric cancer", "CANCER", 585, 599], ["PRDX5", "PROTEIN", 23, 28], ["fibroblasts", "CELL_TYPE", 46, 57], ["fibroblasts", "CELL_TYPE", 98, 109], ["endothelial cells", "CELL_TYPE", 114, 131], ["PRDX5", "PROTEIN", 214, 219], ["PRDXs", "PROTEIN", 243, 248], ["PRDX5", "PROTEIN", 320, 325], ["PRDX6", "PROTEIN", 409, 414], ["PRDXs", "PROTEIN", 428, 433], ["PRDX6", "PROTEIN", 510, 515], ["a degenerative tendon", "PROBLEM", 135, 156], ["breast cancers", "PROBLEM", 338, 352], ["Graves\u2019 disease", "PROBLEM", 367, 382], ["PRDXs", "PROBLEM", 464, 469], ["cancer", "PROBLEM", 474, 480], ["PRDX6", "PROBLEM", 510, 515], ["lung cancer", "PROBLEM", 539, 550], ["ovarian cancer", "PROBLEM", 552, 566], ["liver cancer", "PROBLEM", 568, 580], ["gastric cancer", "PROBLEM", 585, 599], ["normal tendon", "ANATOMY", 63, 76], ["endothelial cells", "OBSERVATION", 114, 131], ["degenerative", "OBSERVATION_MODIFIER", 137, 149], ["tendon", "ANATOMY", 150, 156], ["cancer", "OBSERVATION", 223, 229], ["cancer", "OBSERVATION", 256, 262], ["breast", "ANATOMY", 338, 344], ["cancers", "OBSERVATION", 345, 352], ["Graves", "OBSERVATION", 367, 373], ["cancer", "OBSERVATION", 441, 447], ["cancer", "OBSERVATION", 474, 480], ["tumor", "OBSERVATION", 484, 489], ["lung", "ANATOMY", 539, 543], ["cancer", "OBSERVATION", 544, 550], ["ovarian", "ANATOMY", 552, 559], ["cancer", "OBSERVATION", 560, 566], ["liver", "ANATOMY", 568, 573], ["cancer", "OBSERVATION", 574, 580], ["gastric", "ANATOMY", 585, 592], ["cancer", "OBSERVATION", 593, 599]]], ["PRDX6 has been found at higher levels in lung squamous cell carcinoma patients compared with healthy controls (Zhang et al., 2009).", [["lung squamous cell carcinoma", "ANATOMY", 41, 69], ["PRDX6", "CHEMICAL", 0, 5], ["lung squamous cell carcinoma", "DISEASE", 41, 69], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung squamous cell carcinoma", "CANCER", 41, 69], ["patients", "ORGANISM", 70, 78], ["PRDX6", "PROTEIN", 0, 5], ["patients", "SPECIES", 70, 78], ["PRDX6", "PROBLEM", 0, 5], ["lung squamous cell carcinoma", "PROBLEM", 41, 69], ["higher levels", "OBSERVATION_MODIFIER", 24, 37], ["lung", "ANATOMY", 41, 45], ["squamous cell carcinoma", "OBSERVATION", 46, 69]]], ["PRDX6 is elevated in several lung diseases including lung cancer, mesothelioma and sarcoidosis (Yun et al., 2014a, b).", [["lung", "ANATOMY", 29, 33], ["lung cancer", "ANATOMY", 53, 64], ["mesothelioma", "ANATOMY", 66, 78], ["lung diseases", "DISEASE", 29, 42], ["lung cancer", "DISEASE", 53, 64], ["mesothelioma", "DISEASE", 66, 78], ["sarcoidosis", "DISEASE", 83, 94], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung", "ORGAN", 29, 33], ["lung cancer", "CANCER", 53, 64], ["mesothelioma", "CANCER", 66, 78], ["PRDX6", "PROTEIN", 0, 5], ["PRDX6", "PROBLEM", 0, 5], ["elevated", "PROBLEM", 9, 17], ["several lung diseases", "PROBLEM", 21, 42], ["lung cancer", "PROBLEM", 53, 64], ["mesothelioma", "PROBLEM", 66, 78], ["sarcoidosis", "PROBLEM", 83, 94], ["elevated", "OBSERVATION_MODIFIER", 9, 17], ["several", "OBSERVATION_MODIFIER", 21, 28], ["lung", "ANATOMY", 29, 33], ["diseases", "OBSERVATION", 34, 42], ["lung", "ANATOMY", 53, 57], ["cancer", "OBSERVATION", 58, 64], ["mesothelioma", "OBSERVATION", 66, 78], ["sarcoidosis", "OBSERVATION", 83, 94]]], ["Invasion- and metastasis-promoting actions of PRDX6 have been found in lung cancer cells (Abbas et al., 2009).", [["lung cancer cells", "ANATOMY", 71, 88], ["PRDX6", "CHEMICAL", 46, 51], ["lung cancer", "DISEASE", 71, 82], ["PRDX6", "GENE_OR_GENE_PRODUCT", 46, 51], ["lung cancer cells", "CELL", 71, 88], ["PRDX6", "PROTEIN", 46, 51], ["lung cancer cells", "CELL_TYPE", 71, 88], ["Invasion", "PROBLEM", 0, 8], ["metastasis", "PROBLEM", 14, 24], ["PRDX6", "PROBLEM", 46, 51], ["lung cancer cells", "PROBLEM", 71, 88], ["metastasis", "OBSERVATION", 14, 24], ["lung", "ANATOMY", 71, 75], ["cancer", "OBSERVATION", 76, 82]]], ["The evidence indicates that the activity of PRDX6 contributes to the invasion, promotion, and metastatic ability of lung cancer cells (Ho et al., 2010).", [["lung cancer cells", "ANATOMY", 116, 133], ["lung cancer", "DISEASE", 116, 127], ["PRDX6", "GENE_OR_GENE_PRODUCT", 44, 49], ["lung cancer cells", "CELL", 116, 133], ["PRDX6", "PROTEIN", 44, 49], ["lung cancer cells", "CELL_TYPE", 116, 133], ["the activity of PRDX6", "PROBLEM", 28, 49], ["the invasion", "PROBLEM", 65, 77], ["metastatic ability of lung cancer cells", "PROBLEM", 94, 133], ["invasion", "OBSERVATION", 69, 77], ["metastatic", "OBSERVATION_MODIFIER", 94, 104], ["lung", "ANATOMY", 116, 120], ["cancer", "OBSERVATION", 121, 127]]], ["We previously found that iPLA2 activity of PRDX6 is critical for lung tumor development in in vivo allograft (Yun et al., 2014a, Yun et al., 2014b).", [["lung tumor", "ANATOMY", 65, 75], ["allograft", "ANATOMY", 99, 108], ["tumor", "DISEASE", 70, 75], ["iPLA2", "GENE_OR_GENE_PRODUCT", 25, 30], ["PRDX6", "GENE_OR_GENE_PRODUCT", 43, 48], ["lung tumor", "CANCER", 65, 75], ["allograft", "TISSUE", 99, 108], ["iPLA2", "PROTEIN", 25, 30], ["PRDX6", "PROTEIN", 43, 48], ["lung tumor", "PROBLEM", 65, 75], ["critical for", "UNCERTAINTY", 52, 64], ["lung", "ANATOMY", 65, 69], ["tumor", "OBSERVATION", 70, 75]]], ["Our recent study demonstrated that PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethane-induced lung tumor model (Yun et al., 2015a, Yun et al., 2015b, Yun et al., 2015c).", [["tumor", "ANATOMY", 50, 55], ["lung tumor", "ANATOMY", 117, 127], ["PRDX6", "CHEMICAL", 35, 40], ["tumor", "DISEASE", 50, 55], ["urethane", "CHEMICAL", 100, 108], ["lung tumor", "DISEASE", 117, 127], ["urethane", "CHEMICAL", 100, 108], ["PRDX6", "GENE_OR_GENE_PRODUCT", 35, 40], ["tumor", "CANCER", 50, 55], ["JAK2", "GENE_OR_GENE_PRODUCT", 76, 80], ["STAT3", "GENE_OR_GENE_PRODUCT", 81, 86], ["urethane", "SIMPLE_CHEMICAL", 100, 108], ["lung tumor", "CANCER", 117, 127], ["PRDX6", "PROTEIN", 35, 40], ["JAK2", "PROTEIN", 76, 80], ["STAT3", "PROTEIN", 81, 86], ["Our recent study", "TEST", 0, 16], ["the JAK2/STAT3 pathway", "TREATMENT", 72, 94], ["a urethane-induced lung tumor model", "TREATMENT", 98, 133], ["tumor", "OBSERVATION", 50, 55], ["lung", "ANATOMY", 117, 121], ["tumor", "OBSERVATION", 122, 127]]], ["Also, PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities (Yun et al., 2014a, Yun et al., 2014b).", [["lung tumor", "ANATOMY", 21, 31], ["PRDX6", "CHEMICAL", 6, 11], ["tumor", "DISEASE", 26, 31], ["PRDX6", "GENE_OR_GENE_PRODUCT", 6, 11], ["lung tumor", "CANCER", 21, 31], ["GPx", "GENE_OR_GENE_PRODUCT", 52, 55], ["iPLA2", "GENE_OR_GENE_PRODUCT", 60, 65], ["PRDX6", "PROTEIN", 6, 11], ["GPx", "PROTEIN", 52, 55], ["iPLA2", "PROTEIN", 60, 65], ["lung tumor progression", "PROBLEM", 21, 43], ["lung", "ANATOMY", 21, 25], ["tumor", "OBSERVATION", 26, 31]]], ["In a recent study, the overexpression of PRDX6 attenuated cisplatin-induced apoptosis in human ovarian cancer cells, whereas the reduction of PRDX6 expression increased cell death in liver cancer cells (Pak et al., 2011).", [["ovarian cancer cells", "ANATOMY", 95, 115], ["cell", "ANATOMY", 169, 173], ["liver cancer cells", "ANATOMY", 183, 201], ["PRDX6", "CHEMICAL", 41, 46], ["cisplatin", "CHEMICAL", 58, 67], ["ovarian cancer", "DISEASE", 95, 109], ["death", "DISEASE", 174, 179], ["liver cancer", "DISEASE", 183, 195], ["cisplatin", "CHEMICAL", 58, 67], ["PRDX6", "GENE_OR_GENE_PRODUCT", 41, 46], ["cisplatin", "SIMPLE_CHEMICAL", 58, 67], ["human", "ORGANISM", 89, 94], ["ovarian cancer cells", "CELL", 95, 115], ["PRDX6", "GENE_OR_GENE_PRODUCT", 142, 147], ["cell", "CELL", 169, 173], ["liver cancer cells", "CELL", 183, 201], ["PRDX6", "PROTEIN", 41, 46], ["human ovarian cancer cells", "CELL_TYPE", 89, 115], ["PRDX6", "PROTEIN", 142, 147], ["liver cancer cells", "CELL_TYPE", 183, 201], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["a recent study", "TEST", 3, 17], ["PRDX6 attenuated cisplatin", "TREATMENT", 41, 67], ["apoptosis in human ovarian cancer cells", "PROBLEM", 76, 115], ["PRDX6 expression increased cell death in liver cancer cells", "PROBLEM", 142, 201], ["human ovarian cancer cells", "OBSERVATION", 89, 115], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["cell death", "OBSERVATION", 169, 179], ["liver", "ANATOMY", 183, 188], ["cancer", "OBSERVATION", 189, 195]]], ["PRDX6 is highly upregulated in metastatic gastric cancer cells, which are relatively resistant to TRAIL as compared with primary cancer cells (Choi, Chang, & Jung, 2011).", [["metastatic gastric cancer cells", "ANATOMY", 31, 62], ["primary cancer cells", "ANATOMY", 121, 141], ["gastric cancer", "DISEASE", 42, 56], ["TRAIL", "CHEMICAL", 98, 103], ["primary cancer", "DISEASE", 121, 135], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["gastric cancer cells", "CELL", 42, 62], ["TRAIL", "GENE_OR_GENE_PRODUCT", 98, 103], ["cancer cells", "CELL", 129, 141], ["PRDX6", "PROTEIN", 0, 5], ["metastatic gastric cancer cells", "CELL_TYPE", 31, 62], ["TRAIL", "PROTEIN", 98, 103], ["primary cancer cells", "CELL_TYPE", 121, 141], ["PRDX6", "PROBLEM", 0, 5], ["metastatic gastric cancer cells", "PROBLEM", 31, 62], ["TRAIL", "TREATMENT", 98, 103], ["highly", "OBSERVATION_MODIFIER", 9, 15], ["upregulated", "OBSERVATION_MODIFIER", 16, 27], ["metastatic", "OBSERVATION_MODIFIER", 31, 41], ["gastric", "ANATOMY", 42, 49], ["cancer cells", "OBSERVATION", 50, 62], ["resistant", "OBSERVATION_MODIFIER", 85, 94]]], ["Overexpression of PRDX6 leads to a more invasive phenotype and metastatic potential in human breast cancer through regulation of the levels of Upar, Est-1, MMP-9, RhoC and TIMP-2 expression (Chang et al., 2007).", [["breast cancer", "ANATOMY", 93, 106], ["breast cancer", "DISEASE", 93, 106], ["PRDX6", "GENE_OR_GENE_PRODUCT", 18, 23], ["human", "ORGANISM", 87, 92], ["breast cancer", "CANCER", 93, 106], ["Upar", "GENE_OR_GENE_PRODUCT", 143, 147], ["Est-1", "GENE_OR_GENE_PRODUCT", 149, 154], ["MMP-9", "GENE_OR_GENE_PRODUCT", 156, 161], ["RhoC", "GENE_OR_GENE_PRODUCT", 163, 167], ["TIMP-2", "GENE_OR_GENE_PRODUCT", 172, 178], ["PRDX6", "PROTEIN", 18, 23], ["Upar", "PROTEIN", 143, 147], ["MMP-9", "PROTEIN", 156, 161], ["RhoC", "PROTEIN", 163, 167], ["TIMP", "PROTEIN", 172, 176], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["Overexpression of PRDX6", "PROBLEM", 0, 23], ["a more invasive phenotype", "PROBLEM", 33, 58], ["metastatic potential in human breast cancer", "PROBLEM", 63, 106], ["Upar", "TEST", 143, 147], ["Est", "TEST", 149, 152], ["MMP", "TEST", 156, 159], ["RhoC", "TEST", 163, 167], ["TIMP", "TEST", 172, 176], ["invasive", "OBSERVATION_MODIFIER", 40, 48], ["metastatic", "OBSERVATION_MODIFIER", 63, 73], ["breast", "ANATOMY", 93, 99], ["cancer", "OBSERVATION", 100, 106]]], ["PRDX6 phosphorylation and subsequent phospholipase A2 activity are required for agonist-mediated activation of NADPH oxidase in mouse pulmonary microvascular endothelium and alveolar macrophages (Chatterjee et al., 2011).", [["pulmonary microvascular endothelium", "ANATOMY", 134, 169], ["alveolar macrophages", "ANATOMY", 174, 194], ["NADPH", "CHEMICAL", 111, 116], ["NADPH", "CHEMICAL", 111, 116], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["phospholipase A2", "GENE_OR_GENE_PRODUCT", 37, 53], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 111, 124], ["mouse", "ORGANISM", 128, 133], ["pulmonary microvascular endothelium", "CELL", 134, 169], ["alveolar macrophages", "CELL", 174, 194], ["PRDX6", "PROTEIN", 0, 5], ["phospholipase A2", "PROTEIN", 37, 53], ["NADPH oxidase", "PROTEIN", 111, 124], ["alveolar macrophages", "CELL_TYPE", 174, 194], ["mouse", "SPECIES", 128, 133], ["mouse", "SPECIES", 128, 133], ["PRDX6 phosphorylation", "TREATMENT", 0, 21], ["subsequent phospholipase A2 activity", "TREATMENT", 26, 62], ["agonist", "TREATMENT", 80, 87], ["NADPH oxidase", "TREATMENT", 111, 124], ["alveolar macrophages", "PROBLEM", 174, 194], ["NADPH oxidase", "OBSERVATION", 111, 124], ["mouse", "ANATOMY_MODIFIER", 128, 133], ["pulmonary", "ANATOMY", 134, 143], ["microvascular endothelium", "ANATOMY", 144, 169], ["alveolar macrophages", "OBSERVATION", 174, 194]]], ["These studies, as well as our own, suggest that PRDX6 promotes lung tumor development via JAK2/STAT3 pathway, its GPx and iPLA2 activities, and is involved in drug resistance of several cancer types, suggesting that PRDX6 can be a therapeutic target for cancer treatmentExpression of PRDXs in the human cancer patients ::: PRDXs and cancerPRDX1 is overexpressed or downregulated in the tissue of various cancer patients.", [["lung tumor", "ANATOMY", 63, 73], ["cancer", "ANATOMY", 186, 192], ["cancer", "ANATOMY", 254, 260], ["cancer", "ANATOMY", 303, 309], ["tissue", "ANATOMY", 386, 392], ["cancer", "ANATOMY", 404, 410], ["PRDX6", "CHEMICAL", 48, 53], ["tumor", "DISEASE", 68, 73], ["cancer", "DISEASE", 186, 192], ["PRDX6", "CHEMICAL", 216, 221], ["cancer", "DISEASE", 254, 260], ["cancer", "DISEASE", 303, 309], ["cancer", "DISEASE", 404, 410], ["PRDX6", "GENE_OR_GENE_PRODUCT", 48, 53], ["lung tumor", "CANCER", 63, 73], ["JAK2", "GENE_OR_GENE_PRODUCT", 90, 94], ["STAT3", "GENE_OR_GENE_PRODUCT", 95, 100], ["GPx", "GENE_OR_GENE_PRODUCT", 114, 117], ["iPLA2", "GENE_OR_GENE_PRODUCT", 122, 127], ["cancer", "CANCER", 186, 192], ["PRDX6", "GENE_OR_GENE_PRODUCT", 216, 221], ["cancer", "CANCER", 254, 260], ["PRDXs", "GENE_OR_GENE_PRODUCT", 284, 289], ["human", "ORGANISM", 297, 302], ["cancer", "CANCER", 303, 309], ["patients", "ORGANISM", 310, 318], ["PRDXs", "GENE_OR_GENE_PRODUCT", 323, 328], ["cancerPRDX1", "GENE_OR_GENE_PRODUCT", 333, 344], ["tissue", "TISSUE", 386, 392], ["cancer", "CANCER", 404, 410], ["patients", "ORGANISM", 411, 419], ["PRDX6", "PROTEIN", 48, 53], ["JAK2", "PROTEIN", 90, 94], ["STAT3", "PROTEIN", 95, 100], ["GPx", "PROTEIN", 114, 117], ["iPLA2", "PROTEIN", 122, 127], ["PRDX6", "PROTEIN", 216, 221], ["PRDXs", "PROTEIN", 284, 289], ["PRDXs", "PROTEIN", 323, 328], ["cancerPRDX1", "PROTEIN", 333, 344], ["human", "SPECIES", 297, 302], ["patients", "SPECIES", 310, 318], ["patients", "SPECIES", 411, 419], ["human", "SPECIES", 297, 302], ["These studies", "TEST", 0, 13], ["PRDX6 promotes lung tumor development", "PROBLEM", 48, 85], ["JAK2/STAT3 pathway", "TREATMENT", 90, 108], ["several cancer types", "PROBLEM", 178, 198], ["PRDX6", "PROBLEM", 216, 221], ["cancer treatment", "TREATMENT", 254, 270], ["PRDXs", "PROBLEM", 323, 328], ["lung", "ANATOMY", 63, 67], ["tumor", "OBSERVATION", 68, 73], ["several", "OBSERVATION_MODIFIER", 178, 185], ["cancer", "OBSERVATION", 186, 192], ["human", "ANATOMY", 297, 302], ["cancer", "OBSERVATION", 303, 309], ["tissue", "ANATOMY", 386, 392], ["various", "OBSERVATION_MODIFIER", 396, 403], ["cancer", "OBSERVATION", 404, 410]]], ["Cases exhibiting a low PRDX1 expression level included significantly larger tumor mass cases (P < 0.004), positive lymph node metastasis (P < 0.015), advanced stage (P < 0.002), and poorly differentiated cells (P < 0.020) in oral squamous cell carcinoma (Yanagawa et al., 2000).", [["tumor mass", "ANATOMY", 76, 86], ["lymph node", "ANATOMY", 115, 125], ["cells", "ANATOMY", 204, 209], ["oral squamous cell carcinoma", "ANATOMY", 225, 253], ["tumor", "DISEASE", 76, 81], ["oral squamous cell carcinoma", "DISEASE", 225, 253], ["PRDX1", "GENE_OR_GENE_PRODUCT", 23, 28], ["tumor", "CANCER", 76, 81], ["lymph node", "MULTI-TISSUE_STRUCTURE", 115, 125], ["cells", "CELL", 204, 209], ["oral squamous cell carcinoma", "CANCER", 225, 253], ["PRDX1", "PROTEIN", 23, 28], ["poorly differentiated cells", "CELL_TYPE", 182, 209], ["a low PRDX1 expression level", "PROBLEM", 17, 45], ["significantly larger tumor mass cases", "PROBLEM", 55, 92], ["positive lymph node metastasis", "PROBLEM", 106, 136], ["advanced stage (P < 0.002), and poorly differentiated cells", "PROBLEM", 150, 209], ["oral squamous cell carcinoma", "PROBLEM", 225, 253], ["larger", "OBSERVATION_MODIFIER", 69, 75], ["tumor", "OBSERVATION_MODIFIER", 76, 81], ["mass", "OBSERVATION", 82, 86], ["positive", "OBSERVATION_MODIFIER", 106, 114], ["lymph node metastasis", "OBSERVATION", 115, 136], ["poorly differentiated", "OBSERVATION_MODIFIER", 182, 203], ["cells", "OBSERVATION", 204, 209], ["oral", "ANATOMY", 225, 229], ["squamous cell carcinoma", "OBSERVATION", 230, 253]]], ["PRDX1 is highly expressed in human bladder cancer tissues than in the bladder mucosa of normal controls or in normal mucosa surrounding cancer tissues which correlates with development, recurrence and progression of bladder cancer (Quan et al., 2006).", [["bladder cancer tissues", "ANATOMY", 35, 57], ["bladder mucosa", "ANATOMY", 70, 84], ["mucosa", "ANATOMY", 117, 123], ["cancer tissues", "ANATOMY", 136, 150], ["bladder cancer", "ANATOMY", 216, 230], ["bladder cancer", "DISEASE", 35, 49], ["cancer", "DISEASE", 136, 142], ["bladder cancer", "DISEASE", 216, 230], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 29, 34], ["bladder cancer tissues", "TISSUE", 35, 57], ["bladder mucosa", "MULTI-TISSUE_STRUCTURE", 70, 84], ["normal mucosa", "TISSUE", 110, 123], ["cancer tissues", "TISSUE", 136, 150], ["bladder cancer", "CANCER", 216, 230], ["PRDX1", "PROTEIN", 0, 5], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["PRDX1", "PROBLEM", 0, 5], ["human bladder cancer tissues", "PROBLEM", 29, 57], ["recurrence", "PROBLEM", 186, 196], ["bladder cancer", "PROBLEM", 216, 230], ["bladder", "ANATOMY", 35, 42], ["cancer", "OBSERVATION", 43, 49], ["bladder mucosa", "ANATOMY", 70, 84], ["normal controls", "OBSERVATION", 88, 103], ["normal mucosa", "OBSERVATION", 110, 123], ["cancer tissues", "OBSERVATION", 136, 150], ["recurrence", "OBSERVATION", 186, 196], ["progression", "OBSERVATION_MODIFIER", 201, 212], ["bladder", "ANATOMY", 216, 223], ["cancer", "OBSERVATION", 224, 230]]], ["Sun et al reported that PRDX1 positive rate was significantly higher (77.1 %) in human hepatocellular carcinoma than in adjacent non-tumorous liver tissues (18.4 %) (Sun et al., 2013).", [["hepatocellular carcinoma", "ANATOMY", 87, 111], ["non-tumorous liver tissues", "ANATOMY", 129, 155], ["hepatocellular carcinoma", "DISEASE", 87, 111], ["PRDX1", "GENE_OR_GENE_PRODUCT", 24, 29], ["human", "ORGANISM", 81, 86], ["hepatocellular carcinoma", "CANCER", 87, 111], ["non-tumorous liver tissues", "TISSUE", 129, 155], ["PRDX1", "PROTEIN", 24, 29], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["PRDX1 positive rate", "TEST", 24, 43], ["human hepatocellular carcinoma", "PROBLEM", 81, 111], ["hepatocellular", "ANATOMY", 87, 101], ["carcinoma", "OBSERVATION", 102, 111], ["non-tumorous", "ANATOMY_MODIFIER", 129, 141], ["liver", "ANATOMY", 142, 147]]], ["PRDX1 immunoreactivity was positively correlated with VEGF expression and microvessel density and PRDX1 expression was significantly associated with tumor size, microvascular invasion, Edmondson grade, tumor capsula status, serum AFP, and tumor-node-metastasis stage (Sun et al., 2013).Expression of PRDXs in the human cancer patients ::: PRDXs and cancerPRDX2 is upregulated in human colorectal carcinoma tissues compared with the matched non cancer colorectal mucosa tissues (Lu et al., 2014a).", [["microvessel", "ANATOMY", 74, 85], ["tumor", "ANATOMY", 149, 154], ["microvascular", "ANATOMY", 161, 174], ["tumor capsula", "ANATOMY", 202, 215], ["serum", "ANATOMY", 224, 229], ["tumor-node", "ANATOMY", 239, 249], ["cancer", "ANATOMY", 319, 325], ["colorectal carcinoma tissues", "ANATOMY", 385, 413], ["non cancer colorectal mucosa tissues", "ANATOMY", 440, 476], ["tumor", "DISEASE", 149, 154], ["tumor", "DISEASE", 202, 207], ["tumor", "DISEASE", 239, 244], ["cancer", "DISEASE", 319, 325], ["colorectal carcinoma", "DISEASE", 385, 405], ["cancer", "DISEASE", 444, 450], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["VEGF", "GENE_OR_GENE_PRODUCT", 54, 58], ["microvessel", "TISSUE", 74, 85], ["PRDX1", "GENE_OR_GENE_PRODUCT", 98, 103], ["tumor", "CANCER", 149, 154], ["microvascular", "TISSUE", 161, 174], ["tumor", "CANCER", 202, 207], ["serum", "ORGANISM_SUBSTANCE", 224, 229], ["AFP", "GENE_OR_GENE_PRODUCT", 230, 233], ["tumor", "CANCER", 239, 244], ["PRDXs", "GENE_OR_GENE_PRODUCT", 300, 305], ["human", "ORGANISM", 313, 318], ["cancer", "CANCER", 319, 325], ["patients", "ORGANISM", 326, 334], ["PRDXs", "GENE_OR_GENE_PRODUCT", 339, 344], ["cancerPRDX2", "GENE_OR_GENE_PRODUCT", 349, 360], ["human", "ORGANISM", 379, 384], ["colorectal carcinoma tissues", "TISSUE", 385, 413], ["cancer colorectal mucosa tissues", "TISSUE", 444, 476], ["PRDX1", "PROTEIN", 0, 5], ["VEGF", "PROTEIN", 54, 58], ["PRDX1", "PROTEIN", 98, 103], ["serum AFP", "PROTEIN", 224, 233], ["PRDXs", "PROTEIN", 300, 305], ["PRDXs", "PROTEIN", 339, 344], ["cancerPRDX2", "PROTEIN", 349, 360], ["human", "SPECIES", 313, 318], ["patients", "SPECIES", 326, 334], ["human", "SPECIES", 379, 384], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 379, 384], ["PRDX1 immunoreactivity", "TEST", 0, 22], ["VEGF expression", "TEST", 54, 69], ["microvessel density", "TEST", 74, 93], ["PRDX1 expression", "TEST", 98, 114], ["tumor size", "PROBLEM", 149, 159], ["microvascular invasion", "PROBLEM", 161, 183], ["Edmondson grade", "PROBLEM", 185, 200], ["tumor capsula status", "PROBLEM", 202, 222], ["serum AFP", "TEST", 224, 233], ["tumor-node", "PROBLEM", 239, 249], ["metastasis stage", "PROBLEM", 250, 266], ["PRDXs", "PROBLEM", 339, 344], ["human colorectal carcinoma tissues", "PROBLEM", 379, 413], ["the matched non cancer colorectal mucosa tissues", "PROBLEM", 428, 476], ["microvessel", "ANATOMY", 74, 85], ["density", "OBSERVATION", 86, 93], ["tumor", "OBSERVATION", 149, 154], ["size", "OBSERVATION_MODIFIER", 155, 159], ["microvascular", "ANATOMY", 161, 174], ["invasion", "OBSERVATION", 175, 183], ["tumor", "OBSERVATION", 202, 207], ["tumor", "OBSERVATION", 239, 244], ["node", "ANATOMY", 245, 249], ["metastasis", "OBSERVATION", 250, 260], ["human", "ANATOMY", 313, 318], ["cancer", "OBSERVATION", 319, 325], ["colorectal carcinoma", "OBSERVATION", 385, 405], ["cancer", "OBSERVATION", 444, 450], ["colorectal mucosa", "ANATOMY", 451, 468]]], ["PRDX2 is markedly upregulated in neutrophils of refractory cytopenia with RCMD patients compared to healthy donors.", [["neutrophils", "ANATOMY", 33, 44], ["cytopenia", "DISEASE", 59, 68], ["RCMD", "DISEASE", 74, 78], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["neutrophils", "CELL", 33, 44], ["patients", "ORGANISM", 79, 87], ["donors", "ORGANISM", 108, 114], ["PRDX2", "PROTEIN", 0, 5], ["neutrophils", "CELL_TYPE", 33, 44], ["patients", "SPECIES", 79, 87], ["refractory cytopenia", "PROBLEM", 48, 68], ["markedly", "OBSERVATION_MODIFIER", 9, 17], ["upregulated", "OBSERVATION_MODIFIER", 18, 29], ["neutrophils", "OBSERVATION_MODIFIER", 33, 44], ["refractory", "OBSERVATION_MODIFIER", 48, 58], ["cytopenia", "OBSERVATION", 59, 68]]], ["In addition, white blood cell and neutrophil counts in RCMD patients correlated inversely with the PRDX2 expression (Kazama et al., 2014).Expression of PRDXs in the human cancer patients ::: PRDXs and cancerIHC revealed significant overexpression of PRDX3 in prostate cancer, associated with age, increased prostate specific antigen (PSA), tumor stage, or Gleason score, and high PRDX3 staining was associated with early age and elevated Gleason score at time of radical prostatectomy in African-American patients but not in Caucasian patients with prostate cancer (Basu et al., 2011).", [["white blood cell", "ANATOMY", 13, 29], ["neutrophil", "ANATOMY", 34, 44], ["cancer", "ANATOMY", 171, 177], ["PRDXs", "ANATOMY", 191, 196], ["prostate cancer", "ANATOMY", 259, 274], ["prostate", "ANATOMY", 307, 315], ["tumor", "ANATOMY", 340, 345], ["prostate cancer", "ANATOMY", 549, 564], ["cancer", "DISEASE", 171, 177], ["prostate cancer", "DISEASE", 259, 274], ["tumor", "DISEASE", 340, 345], ["prostate cancer", "DISEASE", 549, 564], ["white blood cell", "CELL", 13, 29], ["neutrophil", "CELL", 34, 44], ["patients", "ORGANISM", 60, 68], ["PRDX2", "GENE_OR_GENE_PRODUCT", 99, 104], ["PRDXs", "GENE_OR_GENE_PRODUCT", 152, 157], ["human", "ORGANISM", 165, 170], ["cancer", "CANCER", 171, 177], ["patients", "ORGANISM", 178, 186], ["PRDXs", "CELL", 191, 196], ["cancerIHC", "CANCER", 201, 210], ["PRDX3", "GENE_OR_GENE_PRODUCT", 250, 255], ["prostate cancer", "CANCER", 259, 274], ["prostate specific antigen", "GENE_OR_GENE_PRODUCT", 307, 332], ["PSA", "GENE_OR_GENE_PRODUCT", 334, 337], ["tumor", "CANCER", 340, 345], ["PRDX3", "GENE_OR_GENE_PRODUCT", 380, 385], ["patients", "ORGANISM", 505, 513], ["patients", "ORGANISM", 535, 543], ["prostate cancer", "CANCER", 549, 564], ["PRDX2", "PROTEIN", 99, 104], ["PRDXs", "PROTEIN", 152, 157], ["PRDX3", "PROTEIN", 250, 255], ["prostate specific antigen", "PROTEIN", 307, 332], ["PSA", "PROTEIN", 334, 337], ["PRDX3", "PROTEIN", 380, 385], ["patients", "SPECIES", 60, 68], ["human", "SPECIES", 165, 170], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 505, 513], ["patients", "SPECIES", 535, 543], ["human", "SPECIES", 165, 170], ["white blood cell", "TEST", 13, 29], ["neutrophil counts", "TEST", 34, 51], ["PRDX3 in prostate cancer", "PROBLEM", 250, 274], ["increased prostate specific antigen (PSA)", "PROBLEM", 297, 338], ["tumor stage", "PROBLEM", 340, 351], ["Gleason score", "PROBLEM", 356, 369], ["high PRDX3 staining", "PROBLEM", 375, 394], ["elevated Gleason score", "PROBLEM", 429, 451], ["radical prostatectomy", "TREATMENT", 463, 484], ["prostate cancer", "PROBLEM", 549, 564], ["neutrophil counts", "OBSERVATION", 34, 51], ["human", "ANATOMY", 165, 170], ["cancer", "OBSERVATION", 171, 177], ["significant", "OBSERVATION_MODIFIER", 220, 231], ["overexpression", "OBSERVATION", 232, 246], ["prostate", "ANATOMY", 259, 267], ["cancer", "OBSERVATION", 268, 274], ["increased", "OBSERVATION_MODIFIER", 297, 306], ["prostate", "ANATOMY", 307, 315], ["tumor", "OBSERVATION", 340, 345], ["high PRDX3", "OBSERVATION_MODIFIER", 375, 385], ["radical prostatectomy", "OBSERVATION", 463, 484], ["prostate", "ANATOMY", 549, 557], ["cancer", "OBSERVATION", 558, 564]]], ["PRDX3 is upregulated in human endocrine-regulated tumours and in particular prostatic intraepithelial neoplasia and prostate cancer (Whitaker et al., 2013).", [["endocrine-regulated tumours", "ANATOMY", 30, 57], ["prostatic intraepithelial neoplasia", "ANATOMY", 76, 111], ["prostate cancer", "ANATOMY", 116, 131], ["endocrine-regulated tumours", "DISEASE", 30, 57], ["prostatic intraepithelial neoplasia", "DISEASE", 76, 111], ["prostate cancer", "DISEASE", 116, 131], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 24, 29], ["endocrine", "ANATOMICAL_SYSTEM", 30, 39], ["tumours", "CANCER", 50, 57], ["prostatic intraepithelial neoplasia", "CANCER", 76, 111], ["prostate cancer", "CANCER", 116, 131], ["PRDX3", "PROTEIN", 0, 5], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["particular prostatic intraepithelial neoplasia", "PROBLEM", 65, 111], ["prostate cancer", "PROBLEM", 116, 131], ["tumours", "OBSERVATION", 50, 57], ["prostatic", "ANATOMY", 76, 85], ["intraepithelial neoplasia", "OBSERVATION", 86, 111], ["prostate", "ANATOMY", 116, 124], ["cancer", "OBSERVATION", 125, 131]]], ["The overexpression of PRDX3 is associated with 94.9% hepatocellular carcinoma, and correlated with poor differentiation (Qiao et al., 2012).", [["hepatocellular carcinoma", "ANATOMY", 53, 77], ["hepatocellular carcinoma", "DISEASE", 53, 77], ["PRDX3", "GENE_OR_GENE_PRODUCT", 22, 27], ["hepatocellular carcinoma", "CANCER", 53, 77], ["PRDX3", "PROTEIN", 22, 27], ["The overexpression of PRDX3", "PROBLEM", 0, 27], ["94.9% hepatocellular carcinoma", "PROBLEM", 47, 77], ["hepatocellular carcinoma", "OBSERVATION", 53, 77], ["poor differentiation", "OBSERVATION_MODIFIER", 99, 119]]], ["The platinum-resistant ovarian cancer patient group had significantly higher PRDX3 protein compared to the platinum-sensitive ovarian cancer patient group, suggesting PRDX3 may be associated with drug resistance in ovarian cancer (Wang et al., 2013).Expression of PRDXs in the human cancer patients ::: PRDXs and cancerThe expression of PRDX4 is at least 1.5 fold higher in human tumor cells compared to control and this finding applies most frequently to adenocarcinoma and modestly to squamous cell carcinoma (Lehtonen et al., 2004).", [["ovarian cancer", "ANATOMY", 23, 37], ["ovarian cancer", "ANATOMY", 126, 140], ["ovarian cancer", "ANATOMY", 215, 229], ["cancer", "ANATOMY", 283, 289], ["PRDXs", "ANATOMY", 303, 308], ["cancer", "ANATOMY", 313, 319], ["tumor cells", "ANATOMY", 380, 391], ["adenocarcinoma", "ANATOMY", 456, 470], ["squamous cell carcinoma", "ANATOMY", 487, 510], ["platinum", "CHEMICAL", 4, 12], ["ovarian cancer", "DISEASE", 23, 37], ["platinum", "CHEMICAL", 107, 115], ["ovarian cancer", "DISEASE", 126, 140], ["PRDX3", "CHEMICAL", 167, 172], ["ovarian cancer", "DISEASE", 215, 229], ["cancer", "DISEASE", 283, 289], ["cancer", "DISEASE", 313, 319], ["tumor", "DISEASE", 380, 385], ["adenocarcinoma", "DISEASE", 456, 470], ["squamous cell carcinoma", "DISEASE", 487, 510], ["platinum", "CHEMICAL", 4, 12], ["platinum", "CHEMICAL", 107, 115], ["platinum", "SIMPLE_CHEMICAL", 4, 12], ["ovarian cancer", "CANCER", 23, 37], ["patient", "ORGANISM", 38, 45], ["PRDX3", "GENE_OR_GENE_PRODUCT", 77, 82], ["platinum", "CANCER", 107, 115], ["ovarian cancer", "CANCER", 126, 140], ["patient", "ORGANISM", 141, 148], ["PRDX3", "GENE_OR_GENE_PRODUCT", 167, 172], ["ovarian cancer", "CANCER", 215, 229], ["PRDXs", "GENE_OR_GENE_PRODUCT", 264, 269], ["human", "ORGANISM", 277, 282], ["cancer", "CANCER", 283, 289], ["patients", "ORGANISM", 290, 298], ["PRDXs", "CELL", 303, 308], ["cancer", "CANCER", 313, 319], ["PRDX4", "GENE_OR_GENE_PRODUCT", 337, 342], ["human", "ORGANISM", 374, 379], ["tumor cells", "CELL", 380, 391], ["adenocarcinoma", "CANCER", 456, 470], ["squamous cell carcinoma", "CANCER", 487, 510], ["PRDX3 protein", "PROTEIN", 77, 90], ["PRDX3", "PROTEIN", 167, 172], ["PRDXs", "PROTEIN", 264, 269], ["PRDX4", "PROTEIN", 337, 342], ["human tumor cells", "CELL_TYPE", 374, 391], ["patient", "SPECIES", 38, 45], ["patient", "SPECIES", 141, 148], ["human", "SPECIES", 277, 282], ["patients", "SPECIES", 290, 298], ["human", "SPECIES", 374, 379], ["human", "SPECIES", 277, 282], ["human", "SPECIES", 374, 379], ["The platinum-resistant ovarian cancer", "PROBLEM", 0, 37], ["significantly higher PRDX3 protein", "PROBLEM", 56, 90], ["the platinum", "TEST", 103, 115], ["sensitive ovarian cancer", "PROBLEM", 116, 140], ["PRDX3", "PROBLEM", 167, 172], ["drug resistance in ovarian cancer", "PROBLEM", 196, 229], ["PRDXs", "PROBLEM", 303, 308], ["cancer", "PROBLEM", 313, 319], ["PRDX4", "PROBLEM", 337, 342], ["human tumor cells", "PROBLEM", 374, 391], ["adenocarcinoma", "PROBLEM", 456, 470], ["squamous cell carcinoma", "PROBLEM", 487, 510], ["platinum", "OBSERVATION_MODIFIER", 4, 12], ["resistant", "OBSERVATION_MODIFIER", 13, 22], ["ovarian", "ANATOMY", 23, 30], ["cancer", "OBSERVATION", 31, 37], ["ovarian", "ANATOMY", 126, 133], ["cancer", "OBSERVATION", 134, 140], ["may be associated with", "UNCERTAINTY", 173, 195], ["drug resistance", "OBSERVATION", 196, 211], ["ovarian", "ANATOMY", 215, 222], ["cancer", "OBSERVATION", 223, 229], ["human", "ANATOMY", 277, 282], ["cancer", "OBSERVATION", 283, 289], ["cancer", "OBSERVATION", 313, 319], ["tumor cells", "OBSERVATION", 380, 391], ["adenocarcinoma", "OBSERVATION", 456, 470], ["squamous cell carcinoma", "OBSERVATION", 487, 510]]], ["PRDX4 expression is elevated in human lung carcinomas compared to nonmalignant tissue, and is mainly associated with adenocarcinoma (Hwang et al., 2015).", [["lung carcinomas", "ANATOMY", 38, 53], ["nonmalignant tissue", "ANATOMY", 66, 85], ["adenocarcinoma", "ANATOMY", 117, 131], ["lung carcinomas", "DISEASE", 38, 53], ["adenocarcinoma", "DISEASE", 117, 131], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 32, 37], ["lung carcinomas", "CANCER", 38, 53], ["nonmalignant tissue", "TISSUE", 66, 85], ["adenocarcinoma", "CANCER", 117, 131], ["PRDX4", "PROTEIN", 0, 5], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["elevated in human lung carcinomas", "PROBLEM", 20, 53], ["nonmalignant tissue", "PROBLEM", 66, 85], ["adenocarcinoma", "PROBLEM", 117, 131], ["elevated", "OBSERVATION_MODIFIER", 20, 28], ["lung", "ANATOMY", 38, 42], ["carcinomas", "OBSERVATION", 43, 53], ["nonmalignant tissue", "OBSERVATION_MODIFIER", 66, 85], ["mainly associated with", "UNCERTAINTY", 94, 116], ["adenocarcinoma", "OBSERVATION", 117, 131]]], ["PRDX4 is also related with colorectal carcinoma.", [["colorectal carcinoma", "ANATOMY", 27, 47], ["colorectal carcinoma", "DISEASE", 27, 47], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["colorectal carcinoma", "CANCER", 27, 47], ["PRDX4", "PROTEIN", 0, 5], ["PRDX4", "TREATMENT", 0, 5], ["colorectal carcinoma", "PROBLEM", 27, 47], ["also related with", "UNCERTAINTY", 9, 26], ["colorectal carcinoma", "OBSERVATION", 27, 47]]], ["The expressions of the PRDX4 gene and protein were higher in CRC compared to those in the adjacent normal tissues (Yi et al., 2014).", [["CRC", "ANATOMY", 61, 64], ["tissues", "ANATOMY", 106, 113], ["CRC", "DISEASE", 61, 64], ["PRDX4", "GENE_OR_GENE_PRODUCT", 23, 28], ["CRC", "CANCER", 61, 64], ["normal tissues", "TISSUE", 99, 113], ["PRDX4 gene", "DNA", 23, 33], ["the PRDX4 gene and protein", "PROBLEM", 19, 45], ["higher", "OBSERVATION_MODIFIER", 51, 57], ["CRC", "OBSERVATION", 61, 64], ["normal tissues", "ANATOMY", 99, 113]]], ["The expression intensity of the PRDX4 protein was correlated with depth of invasion, lymph node metastasis and Dukes\u2019 classification in CRC (Yi et al., 2014).Expression of PRDXs in the human cancer patients ::: PRDXs and cancerPRDX5 expression in bladder cancer was significantly higher than in normal tissue, as well as corresponding normal bladder mucosa surrounding the cancer (Quan et al., 2006).", [["lymph node", "ANATOMY", 85, 95], ["CRC", "ANATOMY", 136, 139], ["cancer", "ANATOMY", 191, 197], ["bladder cancer", "ANATOMY", 247, 261], ["tissue", "ANATOMY", 302, 308], ["bladder mucosa", "ANATOMY", 342, 356], ["cancer", "ANATOMY", 373, 379], ["CRC", "DISEASE", 136, 139], ["cancer", "DISEASE", 191, 197], ["bladder cancer", "DISEASE", 247, 261], ["cancer", "DISEASE", 373, 379], ["PRDX4", "GENE_OR_GENE_PRODUCT", 32, 37], ["lymph node", "MULTI-TISSUE_STRUCTURE", 85, 95], ["CRC", "CANCER", 136, 139], ["PRDXs", "GENE_OR_GENE_PRODUCT", 172, 177], ["human", "ORGANISM", 185, 190], ["cancer", "CANCER", 191, 197], ["patients", "ORGANISM", 198, 206], ["PRDXs", "GENE_OR_GENE_PRODUCT", 211, 216], ["cancerPRDX5", "GENE_OR_GENE_PRODUCT", 221, 232], ["bladder cancer", "CANCER", 247, 261], ["normal tissue", "TISSUE", 295, 308], ["bladder mucosa", "MULTI-TISSUE_STRUCTURE", 342, 356], ["cancer", "CANCER", 373, 379], ["PRDX4 protein", "PROTEIN", 32, 45], ["PRDXs", "PROTEIN", 172, 177], ["cancerPRDX5", "PROTEIN", 221, 232], ["human", "SPECIES", 185, 190], ["patients", "SPECIES", 198, 206], ["human", "SPECIES", 185, 190], ["the PRDX4 protein", "TEST", 28, 45], ["invasion", "PROBLEM", 75, 83], ["lymph node metastasis", "PROBLEM", 85, 106], ["PRDXs", "PROBLEM", 211, 216], ["bladder cancer", "PROBLEM", 247, 261], ["intensity", "OBSERVATION_MODIFIER", 15, 24], ["invasion", "OBSERVATION", 75, 83], ["lymph node metastasis", "OBSERVATION", 85, 106], ["CRC", "ANATOMY", 136, 139], ["human", "ANATOMY", 185, 190], ["cancer", "OBSERVATION", 191, 197], ["bladder", "ANATOMY", 247, 254], ["cancer", "OBSERVATION", 255, 261], ["significantly", "OBSERVATION_MODIFIER", 266, 279], ["higher", "OBSERVATION_MODIFIER", 280, 286], ["normal tissue", "OBSERVATION_MODIFIER", 295, 308], ["normal", "OBSERVATION", 335, 341], ["bladder mucosa", "ANATOMY", 342, 356], ["cancer", "OBSERVATION", 373, 379]]], ["A recent study demonstrated that PRDX5 expression was higher in the thyroid gland of patients with Graves' disease compared to multinodular goiters (G\u00e9rard et al., 2005).Expression of PRDXs in the human cancer patients ::: PRDXs and cancerPRDX6 has also been found at higher levels in lung squamous cell carcinoma patients compared with healthy controls (Zhang et al., 2009).", [["thyroid gland", "ANATOMY", 68, 81], ["multinodular goiters", "ANATOMY", 127, 147], ["cancer", "ANATOMY", 203, 209], ["lung squamous cell carcinoma", "ANATOMY", 285, 313], ["Graves' disease", "DISEASE", 99, 114], ["goiters", "DISEASE", 140, 147], ["cancer", "DISEASE", 203, 209], ["lung squamous cell carcinoma", "DISEASE", 285, 313], ["PRDX5", "GENE_OR_GENE_PRODUCT", 33, 38], ["thyroid gland", "ORGAN", 68, 81], ["patients", "ORGANISM", 85, 93], ["PRDXs", "GENE_OR_GENE_PRODUCT", 184, 189], ["human", "ORGANISM", 197, 202], ["cancer", "CANCER", 203, 209], ["patients", "ORGANISM", 210, 218], ["PRDXs", "GENE_OR_GENE_PRODUCT", 223, 228], ["cancerPRDX6", "GENE_OR_GENE_PRODUCT", 233, 244], ["lung squamous cell carcinoma", "CANCER", 285, 313], ["patients", "ORGANISM", 314, 322], ["PRDX5", "PROTEIN", 33, 38], ["PRDXs", "PROTEIN", 184, 189], ["PRDXs", "PROTEIN", 223, 228], ["cancerPRDX6", "PROTEIN", 233, 244], ["patients", "SPECIES", 85, 93], ["human", "SPECIES", 197, 202], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 314, 322], ["human", "SPECIES", 197, 202], ["A recent study", "TEST", 0, 14], ["PRDX5 expression", "PROBLEM", 33, 49], ["Graves' disease", "PROBLEM", 99, 114], ["multinodular goiters", "PROBLEM", 127, 147], ["lung squamous cell carcinoma", "PROBLEM", 285, 313], ["higher", "OBSERVATION_MODIFIER", 54, 60], ["thyroid gland", "ANATOMY", 68, 81], ["Graves", "OBSERVATION", 99, 105], ["multinodular", "OBSERVATION_MODIFIER", 127, 139], ["goiters", "OBSERVATION", 140, 147], ["human", "ANATOMY", 197, 202], ["cancer", "OBSERVATION", 203, 209], ["lung", "ANATOMY", 285, 289], ["squamous cell carcinoma", "OBSERVATION", 290, 313]]], ["Our recent study also showed that the PRDX6 is overexpressed in lung cancer patients (Yun et al., 2015a, Yun et al., 2015b, Yun et al., 2015c).", [["lung cancer", "ANATOMY", 64, 75], ["lung cancer", "DISEASE", 64, 75], ["PRDX6", "GENE_OR_GENE_PRODUCT", 38, 43], ["lung cancer", "CANCER", 64, 75], ["patients", "ORGANISM", 76, 84], ["PRDX6", "PROTEIN", 38, 43], ["patients", "SPECIES", 76, 84], ["Our recent study", "TEST", 0, 16], ["overexpressed", "OBSERVATION_MODIFIER", 47, 60], ["lung", "ANATOMY", 64, 68], ["cancer", "OBSERVATION", 69, 75]]], ["Overexpression of PRDX6 leads to a more invasive phenotype and metastatic potential in human breast cancer (Chang et al., 2007).Signaling pathway of PRDXs in the development of cancer ::: PRDXs and cancerPRDXs are involved in several cancer related signal pathways.", [["breast cancer", "ANATOMY", 93, 106], ["cancer", "ANATOMY", 177, 183], ["cancer", "ANATOMY", 234, 240], ["breast cancer", "DISEASE", 93, 106], ["cancer", "DISEASE", 177, 183], ["cancer", "DISEASE", 234, 240], ["PRDX6", "GENE_OR_GENE_PRODUCT", 18, 23], ["human", "ORGANISM", 87, 92], ["breast cancer", "CANCER", 93, 106], ["PRDXs", "GENE_OR_GENE_PRODUCT", 149, 154], ["cancer", "CANCER", 177, 183], ["PRDXs", "GENE_OR_GENE_PRODUCT", 188, 193], ["cancerPRDXs", "GENE_OR_GENE_PRODUCT", 198, 209], ["cancer", "CANCER", 234, 240], ["PRDX6", "PROTEIN", 18, 23], ["PRDXs", "PROTEIN", 149, 154], ["PRDXs", "PROTEIN", 188, 193], ["cancerPRDXs", "PROTEIN", 198, 209], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["Overexpression of PRDX6", "PROBLEM", 0, 23], ["a more invasive phenotype", "PROBLEM", 33, 58], ["metastatic potential in human breast cancer", "PROBLEM", 63, 106], ["Signaling pathway of PRDXs", "PROBLEM", 128, 154], ["cancer", "PROBLEM", 177, 183], ["several cancer related signal pathways", "PROBLEM", 226, 264], ["invasive", "OBSERVATION_MODIFIER", 40, 48], ["metastatic", "OBSERVATION_MODIFIER", 63, 73], ["breast", "ANATOMY", 93, 99], ["cancer", "OBSERVATION", 100, 106], ["cancer", "OBSERVATION", 177, 183], ["several", "OBSERVATION_MODIFIER", 226, 233], ["cancer", "OBSERVATION", 234, 240]]], ["Several studies suggested that NF-\u03baB is related with redox signaling pathway.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 31, 36], ["NF-\u03baB", "PROTEIN", 31, 36], ["Several studies", "TEST", 0, 15], ["NF", "PROBLEM", 31, 33]]], ["During redox signaling, some PRDXs have been implicated in the regulation of NF-\u03baB through the initial activation in the cytoplasm by controlling the components affecting I\u03baB phosphorylation and subsequent dissociation.", [["cytoplasm", "ANATOMY", 121, 130], ["PRDXs", "GENE_OR_GENE_PRODUCT", 29, 34], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 77, 82], ["cytoplasm", "ORGANISM_SUBSTANCE", 121, 130], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 171, 174], ["PRDXs", "PROTEIN", 29, 34], ["NF-\u03baB", "PROTEIN", 77, 82], ["I\u03baB", "PROTEIN", 171, 174], ["some PRDXs", "PROBLEM", 24, 34], ["subsequent dissociation", "PROBLEM", 195, 218]]], ["In principle, PRDXs could have a different function in the nucleus because NF-\u03baB interactions with DNA are governed by a redox-sensitive cysteine (Cys62) on the p50 subunit of the NF-\u03baB dimer.", [["nucleus", "ANATOMY", 59, 66], ["cysteine", "CHEMICAL", 137, 145], ["Cys62", "CHEMICAL", 147, 152], ["PRDXs", "GENE_OR_GENE_PRODUCT", 14, 19], ["nucleus", "CELLULAR_COMPONENT", 59, 66], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 75, 80], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["cysteine", "AMINO_ACID", 137, 145], ["Cys62", "AMINO_ACID", 147, 152], ["p50", "GENE_OR_GENE_PRODUCT", 161, 164], ["NF-\u03baB dimer", "GENE_OR_GENE_PRODUCT", 180, 191], ["PRDXs", "PROTEIN", 14, 19], ["NF-\u03baB", "PROTEIN", 75, 80], ["p50 subunit", "PROTEIN", 161, 172], ["NF-\u03baB dimer", "PROTEIN", 180, 191], ["DNA", "PROBLEM", 99, 102], ["a redox", "TEST", 119, 126], ["nucleus", "ANATOMY", 59, 66]]], ["Oxidation of Cys62 inhibits NF-\u03baB binding and decreases the effectiveness of NF-\u03baB signaling.", [["Cys62", "CHEMICAL", 13, 18], ["Cys62", "CHEMICAL", 13, 18], ["Cys62", "SIMPLE_CHEMICAL", 13, 18], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 28, 33], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 77, 82], ["NF-\u03baB", "PROTEIN", 28, 33], ["NF-\u03baB", "PROTEIN", 77, 82], ["NF", "PROBLEM", 28, 30], ["B binding", "PROBLEM", 32, 41]]], ["Also, some PRDXs have also been implicated in the regulation of MAPK pathway during redox signaling.", [["PRDXs", "GENE_OR_GENE_PRODUCT", 11, 16], ["MAPK", "GENE_OR_GENE_PRODUCT", 64, 68], ["PRDXs", "PROTEIN", 11, 16], ["MAPK", "PROTEIN", 64, 68]]], ["Although inhibiting PRDX appears to have different effects on MAPK activation depending on the cell or stimuli, in some cases the use of different stimuli, or time-points at which MAPK activation is assessed, make comparisons between studies difficult.", [["cell", "ANATOMY", 95, 99], ["PRDX", "CHEMICAL", 20, 24], ["PRDX", "GENE_OR_GENE_PRODUCT", 20, 24], ["MAPK", "GENE_OR_GENE_PRODUCT", 62, 66], ["cell", "CELL", 95, 99], ["MAPK", "GENE_OR_GENE_PRODUCT", 180, 184], ["PRDX", "PROTEIN", 20, 24], ["MAPK", "PROTEIN", 62, 66], ["MAPK", "PROTEIN", 180, 184], ["MAPK activation", "TREATMENT", 62, 77], ["different stimuli", "TREATMENT", 137, 154], ["studies", "TEST", 234, 241]]], ["In any case, the consequence of inhibiting PRDX in any given cell is likely to be determined by the levels of intracellular ROS and intrinsic features of the cell/compartment, such as the capacity to regenerate reduced PRDX, using Srx, or Trx using TrxR and NADPH.", [["cell", "ANATOMY", 61, 65], ["intracellular", "ANATOMY", 110, 123], ["cell", "ANATOMY", 158, 162], ["compartment", "ANATOMY", 163, 174], ["PRDX", "CHEMICAL", 43, 47], ["NADPH", "CHEMICAL", 258, 263], ["NADPH", "CHEMICAL", 258, 263], ["PRDX", "GENE_OR_GENE_PRODUCT", 43, 47], ["cell", "CELL", 61, 65], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 123], ["ROS", "SIMPLE_CHEMICAL", 124, 127], ["cell", "CELL", 158, 162], ["PRDX", "GENE_OR_GENE_PRODUCT", 219, 223], ["Srx", "GENE_OR_GENE_PRODUCT", 231, 234], ["Trx", "GENE_OR_GENE_PRODUCT", 239, 242], ["TrxR", "GENE_OR_GENE_PRODUCT", 249, 253], ["NADPH", "SIMPLE_CHEMICAL", 258, 263], ["PRDX", "PROTEIN", 43, 47], ["PRDX", "PROTEIN", 219, 223], ["Srx", "PROTEIN", 231, 234], ["Trx", "PROTEIN", 239, 242], ["TrxR", "PROTEIN", 249, 253], ["NADPH", "PROTEIN", 258, 263], ["inhibiting PRDX", "PROBLEM", 32, 47], ["intracellular ROS", "PROBLEM", 110, 127], ["the cell/compartment", "PROBLEM", 154, 174], ["the capacity", "PROBLEM", 184, 196], ["reduced PRDX", "PROBLEM", 211, 223], ["Srx", "TREATMENT", 231, 234], ["NADPH", "TEST", 258, 263]]], ["Besides these pathways, PRDXs also are involved in several cancer related pathways.", [["cancer", "ANATOMY", 59, 65], ["cancer", "DISEASE", 59, 65], ["PRDXs", "GENE_OR_GENE_PRODUCT", 24, 29], ["cancer", "CANCER", 59, 65], ["PRDXs", "PROTEIN", 24, 29], ["several", "OBSERVATION_MODIFIER", 51, 58], ["cancer", "OBSERVATION", 59, 65]]], ["Fig. 4illustrates the roles of PRDXs in the signaling pathways for the development of cancers.Signaling pathway of PRDXs in the development of cancer ::: PRDXs and cancerIt was shown that overexpression of PRDX1 and PRDX2 suppresses PDGF- and EGF-dependent H2O2 production as well as TNF-\u03b1-induced NF-\u03baB transcriptional activity (Kang et al., 1998).", [["cancers", "ANATOMY", 86, 93], ["cancer", "ANATOMY", 143, 149], ["cancer", "ANATOMY", 164, 170], ["cancers", "DISEASE", 86, 93], ["cancer", "DISEASE", 143, 149], ["cancer", "DISEASE", 164, 170], ["H2O2", "CHEMICAL", 257, 261], ["H2O2", "CHEMICAL", 257, 261], ["PRDXs", "GENE_OR_GENE_PRODUCT", 31, 36], ["cancers", "CANCER", 86, 93], ["PRDXs", "GENE_OR_GENE_PRODUCT", 115, 120], ["cancer", "CANCER", 143, 149], ["PRDXs", "GENE_OR_GENE_PRODUCT", 154, 159], ["cancer", "CANCER", 164, 170], ["PRDX1", "GENE_OR_GENE_PRODUCT", 206, 211], ["PRDX2", "GENE_OR_GENE_PRODUCT", 216, 221], ["PDGF", "GENE_OR_GENE_PRODUCT", 233, 237], ["EGF", "GENE_OR_GENE_PRODUCT", 243, 246], ["H2O2", "SIMPLE_CHEMICAL", 257, 261], ["TNF-\u03b1-", "GENE_OR_GENE_PRODUCT", 284, 290], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 298, 303], ["PRDXs", "PROTEIN", 31, 36], ["PRDXs", "PROTEIN", 115, 120], ["PRDX1", "PROTEIN", 206, 211], ["PRDX2", "PROTEIN", 216, 221], ["PDGF", "PROTEIN", 233, 237], ["TNF", "PROTEIN", 284, 287], ["NF-\u03baB", "PROTEIN", 298, 303], ["PRDXs", "TREATMENT", 31, 36], ["cancers", "PROBLEM", 86, 93], ["Signaling pathway of PRDXs", "PROBLEM", 94, 120], ["cancer", "PROBLEM", 143, 149], ["PRDXs", "PROBLEM", 154, 159], ["cancer", "PROBLEM", 164, 170], ["PRDX1", "TEST", 206, 211], ["PRDX2", "TREATMENT", 216, 221], ["PDGF", "TEST", 233, 237], ["EGF", "TEST", 243, 246], ["dependent H2O2 production", "PROBLEM", 247, 272], ["TNF", "TEST", 284, 287], ["cancers", "OBSERVATION", 86, 93], ["cancer", "OBSERVATION", 143, 149], ["cancer", "OBSERVATION", 164, 170]]], ["Similar studies have since followed using other ligands, such as thyrotropin (TSH), TNF-\u03b1, and TNF-related apoptosis-inducing ligand (TRAIL), as well as further work on EGF dependent H2O2 production, in various cell types (Benvenga & Koch, 2014).", [["cell", "ANATOMY", 211, 215], ["H2O2", "CHEMICAL", 183, 187], ["H2O2", "CHEMICAL", 183, 187], ["thyrotropin", "GENE_OR_GENE_PRODUCT", 65, 76], ["TSH", "GENE_OR_GENE_PRODUCT", 78, 81], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 84, 89], ["TNF-related apoptosis-inducing ligand", "GENE_OR_GENE_PRODUCT", 95, 132], ["TRAIL", "GENE_OR_GENE_PRODUCT", 134, 139], ["EGF", "GENE_OR_GENE_PRODUCT", 169, 172], ["H2O2", "SIMPLE_CHEMICAL", 183, 187], ["cell", "CELL", 211, 215], ["TNF", "PROTEIN", 84, 87], ["TNF-related apoptosis-inducing ligand", "PROTEIN", 95, 132], ["TRAIL", "PROTEIN", 134, 139], ["Similar studies", "TEST", 0, 15], ["other ligands", "TEST", 42, 55], ["thyrotropin", "TEST", 65, 76], ["TSH", "TEST", 78, 81], ["TNF", "TEST", 84, 87], ["TNF", "TEST", 95, 98], ["EGF dependent H2O2 production", "PROBLEM", 169, 198], ["various cell", "OBSERVATION_MODIFIER", 203, 215]]], ["Collectively, these studies show that 2-Cys PRDXs not only eliminate the levels of intracellular H2O2 that were increased upon receptor stimulation, but also suppress the downstream signaling responses, including NF-\u03baB transcriptional activity, JNK activity and apoptosis (Yang et al., 2007).Signaling pathway of PRDXs in the development of cancer ::: PRDXs and cancerPRDX2 is involved in differential regulation of different MAP kinases.", [["intracellular", "ANATOMY", 83, 96], ["cancer", "ANATOMY", 341, 347], ["2-Cys", "CHEMICAL", 38, 43], ["H2O2", "CHEMICAL", 97, 101], ["cancer", "DISEASE", 341, 347], ["2-Cys", "CHEMICAL", 38, 43], ["H2O2", "CHEMICAL", 97, 101], ["2-Cys PRDXs", "SIMPLE_CHEMICAL", 38, 49], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 96], ["H2O2", "SIMPLE_CHEMICAL", 97, 101], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 213, 218], ["JNK", "GENE_OR_GENE_PRODUCT", 245, 248], ["PRDXs", "GENE_OR_GENE_PRODUCT", 313, 318], ["cancer", "CANCER", 341, 347], ["PRDXs", "GENE_OR_GENE_PRODUCT", 352, 357], ["cancerPRDX2", "GENE_OR_GENE_PRODUCT", 362, 373], ["MAP kinases", "GENE_OR_GENE_PRODUCT", 426, 437], ["NF-\u03baB", "PROTEIN", 213, 218], ["JNK", "PROTEIN", 245, 248], ["PRDXs", "PROTEIN", 313, 318], ["PRDXs", "PROTEIN", 352, 357], ["cancerPRDX2", "PROTEIN", 362, 373], ["MAP kinases", "PROTEIN", 426, 437], ["these studies", "TEST", 14, 27], ["Cys PRDXs", "TEST", 40, 49], ["intracellular H2O2", "TREATMENT", 83, 101], ["receptor stimulation", "TREATMENT", 127, 147], ["NF", "TEST", 213, 215], ["apoptosis", "PROBLEM", 262, 271], ["Signaling pathway of PRDXs", "PROBLEM", 292, 318], ["cancer", "PROBLEM", 341, 347], ["transcriptional activity", "OBSERVATION", 219, 243], ["JNK activity", "OBSERVATION", 245, 257], ["cancer", "OBSERVATION", 341, 347]]], ["Under conditions of TNF-\u03b1 stimulation in which PRDX2 activity was either partially blocked using a dominant negative mutant version or was completely abolished by gene knockout, JNK and p38 MAP kinase activation were enhanced whereas the activation of extracellular signal related kinase (ERK) was suppressed (Hanschmann, Godoy, Berndt, Hudemann, & Lillig, 2013).", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 20, 25], ["PRDX2", "GENE_OR_GENE_PRODUCT", 47, 52], ["JNK", "GENE_OR_GENE_PRODUCT", 178, 181], ["p38 MAP kinase", "GENE_OR_GENE_PRODUCT", 186, 200], ["extracellular signal related kinase", "GENE_OR_GENE_PRODUCT", 252, 287], ["ERK", "GENE_OR_GENE_PRODUCT", 289, 292], ["TNF", "PROTEIN", 20, 23], ["PRDX2", "PROTEIN", 47, 52], ["JNK", "PROTEIN", 178, 181], ["p38 MAP kinase", "PROTEIN", 186, 200], ["extracellular signal related kinase", "PROTEIN", 252, 287], ["ERK", "PROTEIN", 289, 292], ["TNF-\u03b1 stimulation", "TREATMENT", 20, 37], ["JNK", "TEST", 178, 181], ["p38 MAP kinase activation", "TEST", 186, 211]]], ["It was asserted that the endogenous H2O2 regulated by PRDX2 targets the phosphorylation of the tyrosines at sites 579/581 and 857 in the PDGF receptor, but has no effect on any of the other tyrosine sites that are known to be phosphorylated, whereas exogenously added H2O2 was shown to induce the phosphorylation of all possible tyrosine sites (Choi et al., 2005).", [["H2O2", "CHEMICAL", 36, 40], ["PRDX2", "CHEMICAL", 54, 59], ["tyrosine", "CHEMICAL", 190, 198], ["H2O2", "CHEMICAL", 268, 272], ["tyrosine", "CHEMICAL", 329, 337], ["H2O2", "CHEMICAL", 36, 40], ["tyrosines", "CHEMICAL", 95, 104], ["tyrosine", "CHEMICAL", 190, 198], ["H2O2", "CHEMICAL", 268, 272], ["tyrosine", "CHEMICAL", 329, 337], ["H2O2", "SIMPLE_CHEMICAL", 36, 40], ["PRDX2", "GENE_OR_GENE_PRODUCT", 54, 59], ["PDGF receptor", "GENE_OR_GENE_PRODUCT", 137, 150], ["H2O2", "SIMPLE_CHEMICAL", 268, 272], ["PRDX2", "PROTEIN", 54, 59], ["PDGF receptor", "PROTEIN", 137, 150], ["the endogenous H2O2", "TREATMENT", 21, 40], ["the PDGF receptor", "TEST", 133, 150], ["the other tyrosine sites", "PROBLEM", 180, 204], ["H2O2", "TREATMENT", 268, 272], ["endogenous H2O2", "OBSERVATION", 25, 40], ["no", "UNCERTAINTY", 160, 162]]], ["It was also shown that the site selective response is controlled solely by PRDX2 and not by other peroxidases, and is achieved through the inactivation of the membrane-associated protein tyrosine phosphatases (PTPs) (Rhee et al., 2012).Signaling pathway of PRDXs in the development of cancer ::: PRDXs and cancerXi et al reported that the protein levels of PRDX3 are significantly reduced in VHL-deficient clear cell renal cell carcinoma (CCRCC) (Xi et al., 2014).", [["membrane", "ANATOMY", 159, 167], ["cancer", "ANATOMY", 285, 291], ["VHL-deficient clear cell renal cell carcinoma", "ANATOMY", 392, 437], ["CCRCC", "ANATOMY", 439, 444], ["tyrosine", "CHEMICAL", 187, 195], ["cancer", "DISEASE", 285, 291], ["clear cell renal cell carcinoma", "DISEASE", 406, 437], ["CCRCC", "DISEASE", 439, 444], ["tyrosine", "CHEMICAL", 187, 195], ["PRDX2", "GENE_OR_GENE_PRODUCT", 75, 80], ["peroxidases", "GENE_OR_GENE_PRODUCT", 98, 109], ["membrane", "CELLULAR_COMPONENT", 159, 167], ["protein tyrosine phosphatases", "GENE_OR_GENE_PRODUCT", 179, 208], ["PTPs", "GENE_OR_GENE_PRODUCT", 210, 214], ["PRDXs", "GENE_OR_GENE_PRODUCT", 257, 262], ["cancer", "CANCER", 285, 291], ["PRDXs", "GENE_OR_GENE_PRODUCT", 296, 301], ["PRDX3", "GENE_OR_GENE_PRODUCT", 357, 362], ["clear cell renal cell carcinoma", "CANCER", 406, 437], ["CCRCC", "CANCER", 439, 444], ["PRDX2", "PROTEIN", 75, 80], ["peroxidases", "PROTEIN", 98, 109], ["membrane-associated protein tyrosine phosphatases", "PROTEIN", 159, 208], ["PTPs", "PROTEIN", 210, 214], ["PRDXs", "PROTEIN", 257, 262], ["PRDX3", "PROTEIN", 357, 362], ["protein tyrosine phosphatases", "TEST", 179, 208], ["Signaling pathway of PRDXs", "PROBLEM", 236, 262], ["cancer", "PROBLEM", 285, 291], ["PRDXs", "PROBLEM", 296, 301], ["the protein levels", "TEST", 335, 353], ["PRDX3", "TEST", 357, 362], ["VHL", "PROBLEM", 392, 395], ["deficient clear cell renal cell carcinoma", "PROBLEM", 396, 437], ["selective", "OBSERVATION_MODIFIER", 32, 41], ["cancer", "OBSERVATION", 285, 291], ["significantly", "OBSERVATION_MODIFIER", 367, 380], ["reduced", "OBSERVATION_MODIFIER", 381, 388], ["VHL", "OBSERVATION", 392, 395], ["deficient", "OBSERVATION_MODIFIER", 396, 405], ["clear", "OBSERVATION_MODIFIER", 406, 411], ["cell", "OBSERVATION", 412, 416], ["renal", "ANATOMY", 417, 422], ["cell carcinoma", "OBSERVATION", 423, 437]]], ["Furthermore, stabilization of HIF-1\u03b1 protein, caused either by VHL deficiency under normoxia, or by hypoxia, significantly reduced PRDX3 expression.", [["VHL deficiency", "DISEASE", 63, 77], ["hypoxia", "DISEASE", 100, 107], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 30, 36], ["VHL", "GENE_OR_GENE_PRODUCT", 63, 66], ["PRDX3", "GENE_OR_GENE_PRODUCT", 131, 136], ["HIF-1\u03b1 protein", "PROTEIN", 30, 44], ["VHL", "PROTEIN", 63, 66], ["PRDX3", "PROTEIN", 131, 136], ["HIF", "TEST", 30, 33], ["VHL deficiency", "PROBLEM", 63, 77], ["hypoxia", "PROBLEM", 100, 107], ["significantly reduced PRDX3 expression", "PROBLEM", 109, 147], ["VHL deficiency", "OBSERVATION", 63, 77], ["hypoxia", "OBSERVATION", 100, 107]]], ["Luciferase-reporter and chromatin-immunoprecipitation assays indicated that HIF-1\u03b1 binds to the hypoxia-responsive elements of PRDX3 promoter and represses its transcription.", [["chromatin", "ANATOMY", 24, 33], ["chromatin", "CELLULAR_COMPONENT", 24, 33], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 76, 82], ["PRDX3", "GENE_OR_GENE_PRODUCT", 127, 132], ["chromatin", "DNA", 24, 33], ["HIF-1\u03b1", "PROTEIN", 76, 82], ["hypoxia-responsive elements", "DNA", 96, 123], ["PRDX3 promoter", "DNA", 127, 141], ["immunoprecipitation assays", "TEST", 34, 60], ["the hypoxia", "PROBLEM", 92, 103], ["PRDX3 promoter", "TREATMENT", 127, 141]]], ["Finally, shRNA-based assays suggested that PRDX3 downregulation is required for the HIF-1\u03b1-dependent proliferation of CCRCC cells (Xi et al., 2014).", [["CCRCC cells", "ANATOMY", 118, 129], ["PRDX3", "GENE_OR_GENE_PRODUCT", 43, 48], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 84, 90], ["CCRCC cells", "CELL", 118, 129], ["PRDX3", "PROTEIN", 43, 48], ["HIF", "PROTEIN", 84, 87], ["1\u03b1", "PROTEIN", 88, 90], ["CCRCC cells", "CELL_LINE", 118, 129], ["shRNA", "TEST", 9, 14], ["PRDX3 downregulation", "PROBLEM", 43, 63], ["the HIF", "TEST", 80, 87], ["dependent proliferation of CCRCC cells", "PROBLEM", 91, 129], ["dependent", "OBSERVATION_MODIFIER", 91, 100], ["proliferation", "OBSERVATION", 101, 114], ["CCRCC cells", "OBSERVATION", 118, 129]]], ["Ovarian cancer cells transfected with PRDX3/small interfering (Si)\u20111 efficiently downregulated the expression of PRDX3 and thus decreased the growth of the ovarian cancer cells in vitro and in vivo.", [["Ovarian cancer cells", "ANATOMY", 0, 20], ["ovarian cancer cells", "ANATOMY", 156, 176], ["Ovarian cancer", "DISEASE", 0, 14], ["ovarian cancer", "DISEASE", 156, 170], ["Ovarian cancer cells", "CELL", 0, 20], ["PRDX3", "GENE_OR_GENE_PRODUCT", 38, 43], ["small interfering (Si)\u20111", "GENE_OR_GENE_PRODUCT", 44, 68], ["PRDX3", "GENE_OR_GENE_PRODUCT", 113, 118], ["ovarian cancer cells", "CELL", 156, 176], ["Ovarian cancer cells", "CELL_TYPE", 0, 20], ["PRDX3", "PROTEIN", 38, 43], ["small interfering (Si)\u20111", "PROTEIN", 44, 68], ["PRDX3", "PROTEIN", 113, 118], ["ovarian cancer cells", "CELL_TYPE", 156, 176], ["Ovarian cancer cells", "PROBLEM", 0, 20], ["PRDX3", "TREATMENT", 38, 43], ["small interfering", "PROBLEM", 44, 61], ["PRDX3", "TREATMENT", 113, 118], ["the ovarian cancer cells", "PROBLEM", 152, 176], ["cancer", "OBSERVATION", 8, 14], ["small", "OBSERVATION_MODIFIER", 44, 49], ["interfering", "OBSERVATION", 50, 61], ["growth", "OBSERVATION_MODIFIER", 142, 148], ["ovarian", "ANATOMY", 156, 163], ["cancer", "OBSERVATION", 164, 170]]], ["Furthermore, the silencing of PRDX3 triggered cisplatin\u2011mediated apoptosis in the ovarian cancer cells, which may act through suppression of the NF\u2011\u03baB signaling pathway (Song et al., 2011).", [["ovarian cancer cells", "ANATOMY", 82, 102], ["PRDX3", "CHEMICAL", 30, 35], ["ovarian cancer", "DISEASE", 82, 96], ["PRDX3", "GENE_OR_GENE_PRODUCT", 30, 35], ["ovarian cancer cells", "CELL", 82, 102], ["NF\u2011\u03baB", "GENE_OR_GENE_PRODUCT", 145, 150], ["PRDX3", "PROTEIN", 30, 35], ["ovarian cancer cells", "CELL_TYPE", 82, 102], ["NF\u2011\u03baB", "PROTEIN", 145, 150], ["PRDX3", "PROBLEM", 30, 35], ["cisplatin\u2011mediated apoptosis", "PROBLEM", 46, 74], ["the ovarian cancer cells", "PROBLEM", 78, 102], ["cisplatin\u2011mediated apoptosis", "OBSERVATION", 46, 74], ["ovarian", "ANATOMY", 82, 89], ["cancer cells", "OBSERVATION", 90, 102]]], ["In antiandrogen-resistant LNCaP cell lines, PRDX3 is upregulated and the resistant cells also possess an upregulation of the TCA pathway and resistance to H\u2082O\u2082-induced apoptosis through a failure to activate pro-apoptotic pathways.", [["LNCaP cell lines", "ANATOMY", 26, 42], ["cells", "ANATOMY", 83, 88], ["antiandrogen", "CHEMICAL", 3, 15], ["H\u2082O\u2082", "CHEMICAL", 155, 159], ["antiandrogen", "CHEMICAL", 3, 15], ["H\u2082O\u2082", "CHEMICAL", 155, 159], ["antiandrogen", "SIMPLE_CHEMICAL", 3, 15], ["LNCaP cell lines", "CELL", 26, 42], ["PRDX3", "GENE_OR_GENE_PRODUCT", 44, 49], ["cells", "CELL", 83, 88], ["TCA", "SIMPLE_CHEMICAL", 125, 128], ["H\u2082O\u2082", "SIMPLE_CHEMICAL", 155, 159], ["antiandrogen-resistant LNCaP cell lines", "CELL_LINE", 3, 42], ["PRDX3", "PROTEIN", 44, 49], ["resistant cells", "CELL_LINE", 73, 88], ["H\u2082O\u2082", "PROTEIN", 155, 159], ["antiandrogen-resistant LNCaP cell lines", "TREATMENT", 3, 42], ["PRDX3", "TREATMENT", 44, 49], ["the resistant cells", "PROBLEM", 69, 88], ["the TCA pathway", "TEST", 121, 136], ["H\u2082O\u2082", "TEST", 155, 159], ["induced apoptosis", "PROBLEM", 160, 177], ["a failure to activate pro-apoptotic pathways", "PROBLEM", 186, 230], ["resistant", "OBSERVATION_MODIFIER", 16, 25], ["LNCaP cell lines", "OBSERVATION", 26, 42], ["resistant cells", "OBSERVATION", 73, 88]]], ["Also, knockdown of PRDX3 restored H\u2082O\u2082 sensitivity, and PRDX3 has been identified as a gene induced by oncogenic c-Myc (Whitaker et al., 2013).", [["PRDX3", "CHEMICAL", 19, 24], ["PRDX3", "CHEMICAL", 56, 61], ["PRDX3", "GENE_OR_GENE_PRODUCT", 19, 24], ["H\u2082O\u2082", "GENE_OR_GENE_PRODUCT", 34, 38], ["PRDX3", "GENE_OR_GENE_PRODUCT", 56, 61], ["c-Myc", "GENE_OR_GENE_PRODUCT", 113, 118], ["PRDX3", "PROTEIN", 19, 24], ["H\u2082O\u2082", "PROTEIN", 34, 38], ["PRDX3", "PROTEIN", 56, 61], ["Myc", "PROTEIN", 115, 118]]], ["Its specific localization to mitochondria suggests that PRDX3, together with its mitochondrion-specific electron suppliers Trx2 and Trx reductase (TrxR) 2, might provide a primary line of defense against H2O2 produced by the mitochondrial respiratory chain, as SOD2 does against the superoxide radical.", [["mitochondria", "ANATOMY", 29, 41], ["mitochondrial", "ANATOMY", 225, 238], ["H2O2", "CHEMICAL", 204, 208], ["superoxide", "CHEMICAL", 283, 293], ["H2O2", "CHEMICAL", 204, 208], ["superoxide", "CHEMICAL", 283, 293], ["mitochondria", "CELLULAR_COMPONENT", 29, 41], ["PRDX3", "GENE_OR_GENE_PRODUCT", 56, 61], ["mitochondrion", "CELLULAR_COMPONENT", 81, 94], ["Trx2", "GENE_OR_GENE_PRODUCT", 123, 127], ["Trx reductase", "GENE_OR_GENE_PRODUCT", 132, 145], ["TrxR) 2", "GENE_OR_GENE_PRODUCT", 147, 154], ["H2O2", "SIMPLE_CHEMICAL", 204, 208], ["mitochondrial", "CELLULAR_COMPONENT", 225, 238], ["SOD2", "GENE_OR_GENE_PRODUCT", 261, 265], ["superoxide radical", "SIMPLE_CHEMICAL", 283, 301], ["PRDX3", "PROTEIN", 56, 61], ["Trx2", "PROTEIN", 123, 127], ["Trx reductase (TrxR) 2", "PROTEIN", 132, 154], ["mitochondrial respiratory chain", "PROTEIN", 225, 256], ["SOD2", "PROTEIN", 261, 265], ["Trx reductase (TrxR)", "TREATMENT", 132, 152], ["H2O2", "TREATMENT", 204, 208], ["the mitochondrial respiratory chain", "PROBLEM", 221, 256], ["the superoxide radical", "TREATMENT", 279, 301], ["respiratory chain", "OBSERVATION", 239, 256]]], ["In addition, Srx plays a crucial role by reducing hyperoxidized PRDX3 via translocation into mitochondria.", [["mitochondria", "ANATOMY", 93, 105], ["Srx", "CHEMICAL", 13, 16], ["Srx", "GENE_OR_GENE_PRODUCT", 13, 16], ["PRDX3", "GENE_OR_GENE_PRODUCT", 64, 69], ["mitochondria", "CELLULAR_COMPONENT", 93, 105], ["Srx", "PROTEIN", 13, 16], ["PRDX3", "PROTEIN", 64, 69]]], ["Noh et al. reported that the overexpression of mitochondrion-targeted Srx efficiently promotes the restoration of PRDX3 and results in cellular resistance to apoptosis, with enhanced elimination of mitochondrial H2O2 and decreased rates of \u0394\u03a8m collapse (Noh, Baek, Jeong, Rhee, & Chang, 2009).", [["cellular", "ANATOMY", 135, 143], ["mitochondrial", "ANATOMY", 198, 211], ["H2O2", "CHEMICAL", 212, 216], ["H2O2", "CHEMICAL", 212, 216], ["mitochondrion", "CELLULAR_COMPONENT", 47, 60], ["Srx", "GENE_OR_GENE_PRODUCT", 70, 73], ["PRDX3", "GENE_OR_GENE_PRODUCT", 114, 119], ["cellular", "CELL", 135, 143], ["mitochondrial", "CELLULAR_COMPONENT", 198, 211], ["H2O2", "SIMPLE_CHEMICAL", 212, 216], ["\u0394\u03a8m", "SIMPLE_CHEMICAL", 240, 243], ["Srx", "PROTEIN", 70, 73], ["PRDX3", "PROTEIN", 114, 119], ["PRDX3", "TREATMENT", 114, 119], ["cellular resistance to apoptosis", "PROBLEM", 135, 167], ["mitochondrial H2O2", "PROBLEM", 198, 216], ["\u0394\u03a8m collapse", "PROBLEM", 240, 252], ["cellular resistance", "OBSERVATION", 135, 154], ["mitochondrial H2O2", "OBSERVATION", 198, 216], ["decreased", "OBSERVATION_MODIFIER", 221, 230], ["collapse", "OBSERVATION", 244, 252]]], ["Thus, a Trx-related antioxidant system composed of Trx2, TrxR2, and PRDX3 has been closely associated with the regulation of apoptosis and the redox control of MPT pores for the release of cytochrome c (Noh et al., 2009).Signaling pathway of PRDXs in the development of cancer ::: PRDXs and cancerPRDX4 is associated with lung cancer.", [["cancer", "ANATOMY", 270, 276], ["lung cancer", "ANATOMY", 322, 333], ["cancer", "DISEASE", 270, 276], ["lung cancer", "DISEASE", 322, 333], ["Trx", "GENE_OR_GENE_PRODUCT", 8, 11], ["Trx2", "GENE_OR_GENE_PRODUCT", 51, 55], ["TrxR2", "GENE_OR_GENE_PRODUCT", 57, 62], ["PRDX3", "GENE_OR_GENE_PRODUCT", 68, 73], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 189, 201], ["PRDXs", "GENE_OR_GENE_PRODUCT", 242, 247], ["cancer", "CANCER", 270, 276], ["PRDXs", "GENE_OR_GENE_PRODUCT", 281, 286], ["cancerPRDX4", "GENE_OR_GENE_PRODUCT", 291, 302], ["lung cancer", "CANCER", 322, 333], ["Trx", "PROTEIN", 8, 11], ["Trx2", "PROTEIN", 51, 55], ["TrxR2", "PROTEIN", 57, 62], ["PRDX3", "PROTEIN", 68, 73], ["cytochrome c", "PROTEIN", 189, 201], ["PRDXs", "PROTEIN", 242, 247], ["PRDXs", "PROTEIN", 281, 286], ["cancerPRDX4", "PROTEIN", 291, 302], ["a Trx-related antioxidant system", "TREATMENT", 6, 38], ["Trx2", "TREATMENT", 51, 55], ["TrxR2", "TREATMENT", 57, 62], ["PRDX3", "TREATMENT", 68, 73], ["apoptosis", "PROBLEM", 125, 134], ["the redox control of MPT pores", "TREATMENT", 139, 169], ["Signaling pathway of PRDXs", "PROBLEM", 221, 247], ["cancer", "PROBLEM", 270, 276], ["lung cancer", "PROBLEM", 322, 333], ["apoptosis", "OBSERVATION", 125, 134], ["cancer", "OBSERVATION", 270, 276], ["associated with", "UNCERTAINTY", 306, 321], ["lung", "ANATOMY", 322, 326], ["cancer", "OBSERVATION", 327, 333]]], ["Srx preferentially binds to PRDX4 and the Srx\u2013PRDX4 axis promotes human lung cancer progression through modulation of receptor tyrosine kinase related signaling (Wei et al., 2011).", [["lung cancer", "ANATOMY", 72, 83], ["Srx", "CHEMICAL", 0, 3], ["lung cancer", "DISEASE", 72, 83], ["tyrosine", "CHEMICAL", 127, 135], ["tyrosine", "CHEMICAL", 127, 135], ["Srx", "GENE_OR_GENE_PRODUCT", 0, 3], ["PRDX4", "GENE_OR_GENE_PRODUCT", 28, 33], ["Srx\u2013PRDX4", "GENE_OR_GENE_PRODUCT", 42, 51], ["human", "ORGANISM", 66, 71], ["lung cancer", "CANCER", 72, 83], ["receptor tyrosine kinase", "GENE_OR_GENE_PRODUCT", 118, 142], ["Srx", "PROTEIN", 0, 3], ["PRDX4", "PROTEIN", 28, 33], ["Srx\u2013PRDX4", "PROTEIN", 42, 51], ["receptor tyrosine kinase", "PROTEIN", 118, 142], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["human lung cancer", "PROBLEM", 66, 83], ["receptor tyrosine kinase", "TREATMENT", 118, 142], ["lung", "ANATOMY", 72, 76], ["cancer", "OBSERVATION", 77, 83]]], ["The same study has also shown the role of Srx-PRDX4 axis in activation of intracellular phosphokinase signaling including AP-1/MMP-9 axis and MAPK signaling (Wei et al., 2011).", [["intracellular", "ANATOMY", 74, 87], ["Srx-", "GENE_OR_GENE_PRODUCT", 42, 46], ["PRDX4", "GENE_OR_GENE_PRODUCT", 46, 51], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 87], ["phosphokinase", "GENE_OR_GENE_PRODUCT", 88, 101], ["AP-1", "GENE_OR_GENE_PRODUCT", 122, 126], ["MMP-9", "GENE_OR_GENE_PRODUCT", 127, 132], ["MAPK", "GENE_OR_GENE_PRODUCT", 142, 146], ["PRDX4", "PROTEIN", 46, 51], ["intracellular phosphokinase", "PROTEIN", 74, 101], ["MMP", "PROTEIN", 127, 130], ["MAPK", "PROTEIN", 142, 146], ["The same study", "TEST", 0, 14], ["intracellular phosphokinase signaling", "TEST", 74, 111], ["AP", "TEST", 122, 124], ["MMP", "TEST", 127, 130], ["MAPK signaling", "TEST", 142, 156], ["intracellular phosphokinase", "OBSERVATION", 74, 101]]], ["Also, the Srx-PRDX4 plays a very important role in tumor progression and metastasis in lung cancer.", [["tumor", "ANATOMY", 51, 56], ["lung cancer", "ANATOMY", 87, 98], ["Srx-PRDX4", "CHEMICAL", 10, 19], ["tumor", "DISEASE", 51, 56], ["lung cancer", "DISEASE", 87, 98], ["Srx-PRDX4", "GENE_OR_GENE_PRODUCT", 10, 19], ["tumor", "CANCER", 51, 56], ["lung cancer", "CANCER", 87, 98], ["Srx-PRDX4", "PROTEIN", 10, 19], ["tumor progression", "PROBLEM", 51, 68], ["metastasis in lung cancer", "PROBLEM", 73, 98], ["tumor", "OBSERVATION", 51, 56], ["metastasis", "OBSERVATION", 73, 83], ["lung", "ANATOMY", 87, 91], ["cancer", "OBSERVATION", 92, 98]]], ["Wei et al demonstrated that an alteration in the expression of PRDX4 results in an alteration in the rate of tumor progression and metastasis which is indicated by anchorage independent colony formation, cell migration and invasion of human lung cancer cells (Wei et al., 2011).", [["tumor", "ANATOMY", 109, 114], ["colony", "ANATOMY", 186, 192], ["cell", "ANATOMY", 204, 208], ["lung cancer cells", "ANATOMY", 241, 258], ["tumor", "DISEASE", 109, 114], ["metastasis", "DISEASE", 131, 141], ["lung cancer", "DISEASE", 241, 252], ["PRDX4", "GENE_OR_GENE_PRODUCT", 63, 68], ["tumor", "CANCER", 109, 114], ["cell", "CELL", 204, 208], ["human", "ORGANISM", 235, 240], ["lung cancer cells", "CELL", 241, 258], ["PRDX4", "PROTEIN", 63, 68], ["human lung cancer cells", "CELL_TYPE", 235, 258], ["human", "SPECIES", 235, 240], ["human", "SPECIES", 235, 240], ["an alteration", "PROBLEM", 28, 41], ["an alteration", "PROBLEM", 80, 93], ["tumor progression", "PROBLEM", 109, 126], ["metastasis", "PROBLEM", 131, 141], ["anchorage independent colony formation", "PROBLEM", 164, 202], ["cell migration", "PROBLEM", 204, 218], ["invasion of human lung cancer cells", "PROBLEM", 223, 258], ["alteration", "OBSERVATION", 31, 41], ["tumor", "OBSERVATION", 109, 114], ["metastasis", "OBSERVATION", 131, 141], ["colony formation", "OBSERVATION", 186, 202], ["cell migration", "OBSERVATION", 204, 218], ["invasion", "OBSERVATION_MODIFIER", 223, 231], ["lung", "ANATOMY", 241, 245], ["cancer cells", "OBSERVATION", 246, 258]]], ["This ability of PRDX4 to promote tumor progression and metastasis is supposedly due to its antioxidant properties.Signaling pathway of PRDXs in the development of cancer ::: PRDXs and cancerAnalysis of the promoter region of the PRDX5 gene and reporter gene assays revealed the promoter region critical for PRDX5 gene regulation to which the novel negative transcription regulator, GATA1 binds in human breast cancer cell lines (Seo, Liu, Chang, & Park, 2012).", [["tumor", "ANATOMY", 33, 38], ["cancer", "ANATOMY", 163, 169], ["breast cancer cell lines", "ANATOMY", 403, 427], ["PRDX4", "CHEMICAL", 16, 21], ["tumor", "DISEASE", 33, 38], ["metastasis", "DISEASE", 55, 65], ["cancer", "DISEASE", 163, 169], ["breast cancer", "DISEASE", 403, 416], ["PRDX4", "GENE_OR_GENE_PRODUCT", 16, 21], ["tumor", "CANCER", 33, 38], ["PRDXs", "GENE_OR_GENE_PRODUCT", 135, 140], ["cancer", "CANCER", 163, 169], ["PRDXs", "GENE_OR_GENE_PRODUCT", 174, 179], ["PRDX5", "GENE_OR_GENE_PRODUCT", 229, 234], ["PRDX5", "GENE_OR_GENE_PRODUCT", 307, 312], ["GATA1", "GENE_OR_GENE_PRODUCT", 382, 387], ["human", "ORGANISM", 397, 402], ["breast cancer cell lines", "CELL", 403, 427], ["PRDX4", "PROTEIN", 16, 21], ["PRDXs", "PROTEIN", 135, 140], ["promoter region", "DNA", 206, 221], ["PRDX5 gene", "DNA", 229, 239], ["reporter gene", "DNA", 244, 257], ["promoter region", "DNA", 278, 293], ["PRDX5 gene", "DNA", 307, 317], ["novel negative transcription regulator", "PROTEIN", 342, 380], ["GATA1", "PROTEIN", 382, 387], ["human breast cancer cell lines", "CELL_LINE", 397, 427], ["human", "SPECIES", 397, 402], ["human", "SPECIES", 397, 402], ["PRDX4", "TREATMENT", 16, 21], ["tumor progression", "PROBLEM", 33, 50], ["metastasis", "PROBLEM", 55, 65], ["Signaling pathway of PRDXs", "PROBLEM", 114, 140], ["cancer", "PROBLEM", 163, 169], ["PRDXs", "PROBLEM", 174, 179], ["reporter gene assays", "TEST", 244, 264], ["PRDX5 gene regulation", "TREATMENT", 307, 328], ["GATA1 binds in human breast cancer", "PROBLEM", 382, 416], ["tumor", "OBSERVATION", 33, 38], ["metastasis", "OBSERVATION", 55, 65], ["cancer", "OBSERVATION", 163, 169], ["breast", "ANATOMY", 403, 409], ["cancer cell lines", "OBSERVATION", 410, 427]]], ["They showed that knockdown of GATA1 led to an increased expression of PRDX5 and inhibition of apoptosis, suggesting that PRDX5 may protect cells from oxidative stress-mediated apoptosis in a GATA1-regulated manner.Signaling pathway of PRDXs in the development of cancer ::: PRDXs and cancerIn a recent study, overexpression of PRDX6 attenuates cisplatin-induced apoptosis in human ovarian cancer cells (Pak et al., 2011).", [["cells", "ANATOMY", 139, 144], ["cancer", "ANATOMY", 263, 269], ["ovarian cancer cells", "ANATOMY", 381, 401], ["PRDX5", "CHEMICAL", 121, 126], ["cancer", "DISEASE", 263, 269], ["PRDX6", "CHEMICAL", 327, 332], ["cisplatin", "CHEMICAL", 344, 353], ["ovarian cancer", "DISEASE", 381, 395], ["cisplatin", "CHEMICAL", 344, 353], ["GATA1", "GENE_OR_GENE_PRODUCT", 30, 35], ["PRDX5", "GENE_OR_GENE_PRODUCT", 70, 75], ["PRDX5", "GENE_OR_GENE_PRODUCT", 121, 126], ["cells", "CELL", 139, 144], ["GATA1", "GENE_OR_GENE_PRODUCT", 191, 196], ["PRDXs", "GENE_OR_GENE_PRODUCT", 235, 240], ["cancer", "CANCER", 263, 269], ["PRDXs", "GENE_OR_GENE_PRODUCT", 274, 279], ["PRDX6", "GENE_OR_GENE_PRODUCT", 327, 332], ["cisplatin", "SIMPLE_CHEMICAL", 344, 353], ["human", "ORGANISM", 375, 380], ["ovarian cancer cells", "CELL", 381, 401], ["GATA1", "PROTEIN", 30, 35], ["PRDX5", "PROTEIN", 70, 75], ["PRDX5", "PROTEIN", 121, 126], ["GATA1", "PROTEIN", 191, 196], ["PRDXs", "PROTEIN", 235, 240], ["PRDX6", "PROTEIN", 327, 332], ["human ovarian cancer cells", "CELL_TYPE", 375, 401], ["human", "SPECIES", 375, 380], ["human", "SPECIES", 375, 380], ["knockdown of GATA1", "PROBLEM", 17, 35], ["an increased expression of PRDX5", "PROBLEM", 43, 75], ["apoptosis", "PROBLEM", 94, 103], ["PRDX5", "TREATMENT", 121, 126], ["oxidative stress-mediated apoptosis", "PROBLEM", 150, 185], ["Signaling pathway of PRDXs", "PROBLEM", 214, 240], ["cancer", "PROBLEM", 263, 269], ["a recent study", "TEST", 293, 307], ["PRDX6 attenuates cisplatin", "TREATMENT", 327, 353], ["apoptosis in human ovarian cancer cells", "PROBLEM", 362, 401], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["cancer", "OBSERVATION", 263, 269], ["human ovarian", "ANATOMY", 375, 388], ["cancer cells", "OBSERVATION", 389, 401]]], ["Pak et al showed that cisplatin-induced cytotoxicity in ovarian cancer cells cytotoxicity was associated with increased accumulation of intracellular (ROS) and apoptosis mediated by proteolytically activated caspase 3 and 9.", [["ovarian cancer cells", "ANATOMY", 56, 76], ["intracellular", "ANATOMY", 136, 149], ["cisplatin", "CHEMICAL", 22, 31], ["ovarian cancer", "DISEASE", 56, 70], ["ROS", "CHEMICAL", 151, 154], ["cisplatin", "CHEMICAL", 22, 31], ["cisplatin", "SIMPLE_CHEMICAL", 22, 31], ["ovarian cancer cells", "CELL", 56, 76], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 149], ["ROS", "SIMPLE_CHEMICAL", 151, 154], ["caspase 3", "GENE_OR_GENE_PRODUCT", 208, 217], ["ovarian cancer cells", "CELL_TYPE", 56, 76], ["proteolytically activated caspase 3 and 9", "PROTEIN", 182, 223], ["Pak et al", "TEST", 0, 9], ["cisplatin", "TREATMENT", 22, 31], ["induced cytotoxicity", "PROBLEM", 32, 52], ["ovarian cancer cells cytotoxicity", "PROBLEM", 56, 89], ["increased accumulation of intracellular (ROS", "PROBLEM", 110, 154], ["apoptosis", "PROBLEM", 160, 169], ["proteolytically activated caspase", "TREATMENT", 182, 215], ["cytotoxicity", "OBSERVATION_MODIFIER", 40, 52], ["ovarian", "ANATOMY", 56, 63], ["cancer cells", "OBSERVATION", 64, 76], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["accumulation", "OBSERVATION_MODIFIER", 120, 132], ["intracellular", "OBSERVATION_MODIFIER", 136, 149]]], ["Moreover, overexpression of PRDX 6 protein or exposure to N-acetylcysteine (NAC) reversed the apoptotic effect of cisplatin by reducing ROS levels and suppressing the caspase signaling pathway.", [["N-acetylcysteine", "CHEMICAL", 58, 74], ["NAC", "CHEMICAL", 76, 79], ["cisplatin", "CHEMICAL", 114, 123], ["ROS", "CHEMICAL", 136, 139], ["N-acetylcysteine", "CHEMICAL", 58, 74], ["NAC", "CHEMICAL", 76, 79], ["cisplatin", "CHEMICAL", 114, 123], ["PRDX 6", "GENE_OR_GENE_PRODUCT", 28, 34], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 58, 74], ["NAC", "SIMPLE_CHEMICAL", 76, 79], ["cisplatin", "SIMPLE_CHEMICAL", 114, 123], ["ROS", "SIMPLE_CHEMICAL", 136, 139], ["caspase", "GENE_OR_GENE_PRODUCT", 167, 174], ["PRDX 6 protein", "PROTEIN", 28, 42], ["caspase", "PROTEIN", 167, 174], ["PRDX 6 protein", "PROBLEM", 28, 42], ["N-acetylcysteine (NAC", "TREATMENT", 58, 79], ["cisplatin", "TREATMENT", 114, 123], ["ROS levels", "TEST", 136, 146], ["the caspase signaling pathway", "TREATMENT", 163, 192]]], ["In contrast, reduction of PRDX6 expression increased peroxide-induced cell death in liver cancer cells (Walsh et al., 2009).", [["cell", "ANATOMY", 70, 74], ["liver cancer cells", "ANATOMY", 84, 102], ["peroxide", "CHEMICAL", 53, 61], ["death", "DISEASE", 75, 80], ["liver cancer", "DISEASE", 84, 96], ["peroxide", "CHEMICAL", 53, 61], ["PRDX6", "GENE_OR_GENE_PRODUCT", 26, 31], ["peroxide", "SIMPLE_CHEMICAL", 53, 61], ["cell", "CELL", 70, 74], ["liver cancer cells", "CELL", 84, 102], ["PRDX6", "PROTEIN", 26, 31], ["liver cancer cells", "CELL_TYPE", 84, 102], ["PRDX6 expression", "PROBLEM", 26, 42], ["increased peroxide-induced cell death in liver cancer cells", "PROBLEM", 43, 102], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["peroxide", "OBSERVATION_MODIFIER", 53, 61], ["cell death", "OBSERVATION", 70, 80], ["liver", "ANATOMY", 84, 89], ["cancer", "OBSERVATION", 90, 96]]], ["They showed that the cancerous hepatoma cell line is significantly more resistant to peroxide-induced cytotoxicity than the non-cancerous cell line, and hepatoma cell line expresses approximately 3-fold PRDX6 than non-cancerous cell line.", [["cancerous hepatoma cell line", "ANATOMY", 21, 49], ["non-cancerous cell line", "ANATOMY", 124, 147], ["hepatoma cell line", "ANATOMY", 153, 171], ["non-cancerous cell line", "ANATOMY", 214, 237], ["peroxide", "CHEMICAL", 85, 93], ["peroxide", "CHEMICAL", 85, 93], ["cancerous hepatoma cell line", "CELL", 21, 49], ["peroxide", "SIMPLE_CHEMICAL", 85, 93], ["non-cancerous cell line", "CELL", 124, 147], ["hepatoma cell line", "CELL", 153, 171], ["PRDX6", "GENE_OR_GENE_PRODUCT", 203, 208], ["non-cancerous cell line", "CELL", 214, 237], ["cancerous hepatoma cell line", "CELL_LINE", 21, 49], ["non-cancerous cell line", "CELL_LINE", 124, 147], ["hepatoma cell line", "CELL_LINE", 153, 171], ["PRDX6", "PROTEIN", 203, 208], ["non-cancerous cell line", "CELL_LINE", 214, 237], ["the cancerous hepatoma cell line", "PROBLEM", 17, 49], ["peroxide", "TREATMENT", 85, 93], ["cytotoxicity", "PROBLEM", 102, 114], ["the non-cancerous cell line", "PROBLEM", 120, 147], ["hepatoma cell line", "PROBLEM", 153, 171], ["non-cancerous cell line", "TREATMENT", 214, 237], ["cancerous", "OBSERVATION_MODIFIER", 21, 30], ["hepatoma cell line", "OBSERVATION", 31, 49], ["significantly", "OBSERVATION_MODIFIER", 53, 66], ["more resistant", "OBSERVATION_MODIFIER", 67, 81], ["cytotoxicity", "OBSERVATION_MODIFIER", 102, 114], ["non-cancerous cell line", "OBSERVATION", 124, 147], ["hepatoma", "ANATOMY", 153, 161], ["cell line", "OBSERVATION", 162, 171], ["non-cancerous cell line", "OBSERVATION", 214, 237]]], ["Also, they showed that transient transfection of cancerous hepatoma cell line with PRDX6 siRNA led to an increase in peroxide-induced cytotoxicity by apoptosis.", [["cancerous hepatoma cell line", "ANATOMY", 49, 77], ["peroxide", "CHEMICAL", 117, 125], ["peroxide", "CHEMICAL", 117, 125], ["cancerous hepatoma cell line", "CELL", 49, 77], ["PRDX6", "GENE_OR_GENE_PRODUCT", 83, 88], ["peroxide", "SIMPLE_CHEMICAL", 117, 125], ["cancerous hepatoma cell line", "CELL_LINE", 49, 77], ["transient transfection of cancerous hepatoma cell line", "PROBLEM", 23, 77], ["PRDX6 siRNA", "TREATMENT", 83, 94], ["peroxide-induced cytotoxicity", "TREATMENT", 117, 146], ["apoptosis", "PROBLEM", 150, 159], ["transient", "OBSERVATION_MODIFIER", 23, 32], ["transfection", "OBSERVATION_MODIFIER", 33, 45], ["cancerous", "OBSERVATION_MODIFIER", 49, 58], ["hepatoma cell line", "OBSERVATION", 59, 77], ["PRDX6 siRNA", "OBSERVATION", 83, 94], ["increase", "OBSERVATION_MODIFIER", 105, 113], ["cytotoxicity", "OBSERVATION_MODIFIER", 134, 146], ["apoptosis", "OBSERVATION_MODIFIER", 150, 159]]], ["The invasion-promoting action of PRDX6 has also been confirmed using lung cancer cells, in which upregulation of PRDX6 results in the activation of Akt via phosphoinositide 3-kinase (PI3K) and p38 kinase, which promotes cell invasion by inducing urokinase-type plasminogen activator (uPA) (Ho et al., 2010; Seung et al., 2009).", [["lung cancer cells", "ANATOMY", 69, 86], ["cell", "ANATOMY", 220, 224], ["PRDX6", "CHEMICAL", 33, 38], ["lung cancer", "DISEASE", 69, 80], ["PRDX6", "GENE_OR_GENE_PRODUCT", 33, 38], ["lung cancer cells", "CELL", 69, 86], ["PRDX6", "GENE_OR_GENE_PRODUCT", 113, 118], ["Akt", "GENE_OR_GENE_PRODUCT", 148, 151], ["phosphoinositide 3-kinase", "GENE_OR_GENE_PRODUCT", 156, 181], ["PI3K", "GENE_OR_GENE_PRODUCT", 183, 187], ["p38 kinase", "GENE_OR_GENE_PRODUCT", 193, 203], ["cell", "CELL", 220, 224], ["urokinase-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 246, 282], ["uPA", "GENE_OR_GENE_PRODUCT", 284, 287], ["PRDX6", "PROTEIN", 33, 38], ["lung cancer cells", "CELL_TYPE", 69, 86], ["PRDX6", "PROTEIN", 113, 118], ["Akt", "PROTEIN", 148, 151], ["phosphoinositide 3-kinase", "PROTEIN", 156, 181], ["PI3K", "PROTEIN", 183, 187], ["p38 kinase", "PROTEIN", 193, 203], ["urokinase-type plasminogen activator", "PROTEIN", 246, 282], ["uPA", "PROTEIN", 284, 287], ["The invasion", "PROBLEM", 0, 12], ["lung cancer cells", "PROBLEM", 69, 86], ["PRDX6", "TEST", 113, 118], ["phosphoinositide", "TEST", 156, 172], ["p38 kinase", "TEST", 193, 203], ["urokinase-type plasminogen activator", "TREATMENT", 246, 282], ["invasion", "OBSERVATION", 4, 12], ["lung", "ANATOMY", 69, 73], ["cancer cells", "OBSERVATION", 74, 86], ["cell invasion", "OBSERVATION", 220, 233]]], ["Our study demonstrated that PRDX6 promoted lung tumor growth in an in vivo allograft model.", [["lung tumor", "ANATOMY", 43, 53], ["allograft", "ANATOMY", 75, 84], ["PRDX6", "CHEMICAL", 28, 33], ["tumor", "DISEASE", 48, 53], ["PRDX6", "GENE_OR_GENE_PRODUCT", 28, 33], ["lung tumor", "CANCER", 43, 53], ["PRDX6", "PROTEIN", 28, 33], ["Our study", "TEST", 0, 9], ["PRDX6", "PROBLEM", 28, 33], ["lung tumor growth", "PROBLEM", 43, 60], ["an in vivo allograft model", "TREATMENT", 64, 90], ["lung", "ANATOMY", 43, 47], ["tumor", "OBSERVATION", 48, 53], ["growth", "OBSERVATION_MODIFIER", 54, 60], ["allograft model", "OBSERVATION", 75, 90]]], ["Histopathological and Western blotting examination demonstrated that expression of proliferating cell nuclear antigen, VEGF, MMP-2 and -9, and cyclin-dependent kinases accompanied by increased iPLA2 and GPx activities were increased in the tumor tissues of PRDX6-overexpressing nude mice (Jo et al., 2013).", [["tumor tissues", "ANATOMY", 240, 253], ["tumor", "DISEASE", 240, 245], ["proliferating cell nuclear antigen", "GENE_OR_GENE_PRODUCT", 83, 117], ["VEGF", "GENE_OR_GENE_PRODUCT", 119, 123], ["MMP-2", "GENE_OR_GENE_PRODUCT", 125, 130], ["-9", "GENE_OR_GENE_PRODUCT", 135, 137], ["cyclin-dependent kinases", "GENE_OR_GENE_PRODUCT", 143, 167], ["iPLA2", "GENE_OR_GENE_PRODUCT", 193, 198], ["GPx", "GENE_OR_GENE_PRODUCT", 203, 206], ["tumor tissues", "TISSUE", 240, 253], ["PRDX6", "GENE_OR_GENE_PRODUCT", 257, 262], ["nude mice", "ORGANISM", 278, 287], ["proliferating cell nuclear antigen", "PROTEIN", 83, 117], ["VEGF", "PROTEIN", 119, 123], ["MMP-2 and -9", "PROTEIN", 125, 137], ["cyclin-dependent kinases", "PROTEIN", 143, 167], ["iPLA2", "PROTEIN", 193, 198], ["GPx", "PROTEIN", 203, 206], ["PRDX6", "PROTEIN", 257, 262], ["mice", "SPECIES", 283, 287], ["mice", "SPECIES", 283, 287], ["Western blotting examination", "TEST", 22, 50], ["proliferating cell nuclear antigen", "TEST", 83, 117], ["VEGF", "TEST", 119, 123], ["MMP", "TEST", 125, 128], ["cyclin-dependent kinases", "PROBLEM", 143, 167], ["increased iPLA2", "PROBLEM", 183, 198], ["GPx activities", "PROBLEM", 203, 217], ["proliferating cell", "OBSERVATION", 83, 101], ["increased", "OBSERVATION_MODIFIER", 183, 192], ["iPLA2", "OBSERVATION", 193, 198], ["increased", "OBSERVATION_MODIFIER", 223, 232], ["tumor", "OBSERVATION", 240, 245]]], ["In tumor tissues of PRDX6-overexpressing mice, the activation of mitogen-activated protein kinases and AP-1 DNA binding were also increased (Yun et al., 2014a, Yun et al., 2014b).", [["tumor tissues", "ANATOMY", 3, 16], ["tumor", "DISEASE", 3, 8], ["tumor tissues", "TISSUE", 3, 16], ["PRDX6", "GENE_OR_GENE_PRODUCT", 20, 25], ["mice", "ORGANISM", 41, 45], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 65, 98], ["AP-1", "GENE_OR_GENE_PRODUCT", 103, 107], ["DNA", "CELLULAR_COMPONENT", 108, 111], ["PRDX6", "PROTEIN", 20, 25], ["mitogen-activated protein kinases", "PROTEIN", 65, 98], ["AP", "PROTEIN", 103, 105], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["PRDX6", "TEST", 20, 25], ["mitogen", "TEST", 65, 72], ["activated protein kinases", "TEST", 73, 98], ["AP", "TEST", 103, 105], ["1 DNA binding", "PROBLEM", 106, 119], ["tumor", "OBSERVATION", 3, 8]]], ["And the growth of lung cancer cell lines (A549 and NCI-H460) was enhanced by the increase in iPLA2 and GPx activities of PRDX6.", [["lung cancer cell lines", "ANATOMY", 18, 40], ["A549", "ANATOMY", 42, 46], ["NCI-H460", "ANATOMY", 51, 59], ["lung cancer", "DISEASE", 18, 29], ["lung cancer cell lines", "CELL", 18, 40], ["A549", "CELL", 42, 46], ["NCI-H460", "CELL", 51, 59], ["iPLA2", "GENE_OR_GENE_PRODUCT", 93, 98], ["GPx", "GENE_OR_GENE_PRODUCT", 103, 106], ["PRDX6", "GENE_OR_GENE_PRODUCT", 121, 126], ["lung cancer cell lines", "CELL_LINE", 18, 40], ["A549", "CELL_LINE", 42, 46], ["NCI", "CELL_LINE", 51, 54], ["H460", "CELL_LINE", 55, 59], ["iPLA2", "PROTEIN", 93, 98], ["GPx", "PROTEIN", 103, 106], ["PRDX6", "PROTEIN", 121, 126], ["lung cancer cell lines", "PROBLEM", 18, 40], ["NCI", "TEST", 51, 54], ["the increase in iPLA2", "PROBLEM", 77, 98], ["GPx activities of PRDX6", "TREATMENT", 103, 126], ["growth", "OBSERVATION_MODIFIER", 8, 14], ["lung", "ANATOMY", 18, 22], ["cancer cell lines", "OBSERVATION", 23, 40], ["increase", "OBSERVATION_MODIFIER", 81, 89]]], ["In addition, mutant PRDX6 (C47S) attenuated PRDX6-mediated p38, ERK1/2, and AP-1 activities as well as its enzyme activities in the A549 and NCI-H460 lines.", [["A549", "ANATOMY", 132, 136], ["NCI-H460 lines", "ANATOMY", 141, 155], ["PRDX6", "GENE_OR_GENE_PRODUCT", 20, 25], ["PRDX6", "GENE_OR_GENE_PRODUCT", 44, 49], ["p38", "GENE_OR_GENE_PRODUCT", 59, 62], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 64, 70], ["AP-1", "GENE_OR_GENE_PRODUCT", 76, 80], ["A549", "CELL", 132, 136], ["NCI-H460 lines", "CELL", 141, 155], ["mutant PRDX6", "PROTEIN", 13, 25], ["PRDX6", "PROTEIN", 44, 49], ["p38", "PROTEIN", 59, 62], ["ERK1", "PROTEIN", 64, 68], ["AP", "PROTEIN", 76, 78], ["A549", "CELL_LINE", 132, 136], ["NCI-H460 lines", "CELL_LINE", 141, 155], ["mutant PRDX6", "TEST", 13, 25], ["PRDX6", "TEST", 44, 49], ["ERK1", "TEST", 64, 68], ["AP", "TEST", 76, 78], ["its enzyme activities", "TEST", 103, 124], ["A549", "ANATOMY", 132, 136], ["H460 lines", "OBSERVATION", 145, 155]]], ["Furthermore, tumor growth and p38, ERK1/2, and AP-1 activities were also inhibited in nude mice bearing mutant PRDX6 (C47S) compared to PRDX6.", [["tumor", "ANATOMY", 13, 18], ["tumor", "DISEASE", 13, 18], ["tumor", "CANCER", 13, 18], ["p38", "GENE_OR_GENE_PRODUCT", 30, 33], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 35, 41], ["AP-1", "GENE_OR_GENE_PRODUCT", 47, 51], ["nude mice", "ORGANISM", 86, 95], ["PRDX6", "GENE_OR_GENE_PRODUCT", 111, 116], ["PRDX6", "GENE_OR_GENE_PRODUCT", 136, 141], ["p38", "PROTEIN", 30, 33], ["ERK1", "PROTEIN", 35, 39], ["AP", "PROTEIN", 47, 49], ["mutant PRDX6", "PROTEIN", 104, 116], ["C47S", "PROTEIN", 118, 122], ["PRDX6", "PROTEIN", 136, 141], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["tumor growth", "TEST", 13, 25], ["p38", "TEST", 30, 33], ["ERK1", "TEST", 35, 39], ["AP", "TEST", 47, 49], ["PRDX6", "TEST", 136, 141], ["tumor", "OBSERVATION", 13, 18]]], ["Previously, we showed that urethane (1g/kg)-induced tumor incidence in PRDX6-Tg mice was significantly higher compared to non-Tg mice (Yun et al., 2015a, Yun et al., 2015b, Yun et al., 2015c).", [["tumor", "ANATOMY", 52, 57], ["urethane", "CHEMICAL", 27, 35], ["tumor", "DISEASE", 52, 57], ["urethane", "CHEMICAL", 27, 35], ["urethane", "SIMPLE_CHEMICAL", 27, 35], ["tumor", "CANCER", 52, 57], ["PRDX6", "GENE_OR_GENE_PRODUCT", 71, 76], ["mice", "ORGANISM", 80, 84], ["non-Tg mice", "ORGANISM", 122, 133], ["PRDX6", "PROTEIN", 71, 76], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["tumor incidence", "PROBLEM", 52, 67], ["PRDX6", "TEST", 71, 76], ["tumor", "OBSERVATION", 52, 57]]], ["In the tumors of PRDX6-Tg mice, the activation of JAK2/STAT3 and STAT3 DNA binding were also increased, accompanied by increased GPx and iPLA2 activities.", [["tumors", "ANATOMY", 7, 13], ["tumors", "DISEASE", 7, 13], ["tumors", "CANCER", 7, 13], ["PRDX6", "GENE_OR_GENE_PRODUCT", 17, 22], ["JAK2", "GENE_OR_GENE_PRODUCT", 50, 54], ["STAT3", "GENE_OR_GENE_PRODUCT", 55, 60], ["STAT3", "GENE_OR_GENE_PRODUCT", 65, 70], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["GPx", "GENE_OR_GENE_PRODUCT", 129, 132], ["iPLA2", "GENE_OR_GENE_PRODUCT", 137, 142], ["PRDX6", "PROTEIN", 17, 22], ["JAK2", "PROTEIN", 50, 54], ["STAT3", "PROTEIN", 55, 60], ["STAT3", "PROTEIN", 65, 70], ["GPx", "PROTEIN", 129, 132], ["iPLA2", "PROTEIN", 137, 142], ["mice", "SPECIES", 26, 30], ["PRDX6", "TEST", 17, 22], ["JAK2", "PROBLEM", 50, 54], ["STAT3", "PROBLEM", 55, 60], ["STAT3 DNA binding", "PROBLEM", 65, 82], ["increased GPx and iPLA2 activities", "PROBLEM", 119, 153], ["tumors", "OBSERVATION", 7, 13], ["JAK2", "ANATOMY", 50, 54], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["increased GPx", "OBSERVATION", 119, 132]]], ["PRDX6 was colocalized with JAK2 in tumor tissues and lung cancer cells and also showed physical interaction with JAK2, and increased levels of PRDX6 increase the activation of the JAK2/STAT3 pathway.", [["tumor tissues", "ANATOMY", 35, 48], ["lung cancer cells", "ANATOMY", 53, 70], ["tumor", "DISEASE", 35, 40], ["lung cancer", "DISEASE", 53, 64], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["JAK2", "GENE_OR_GENE_PRODUCT", 27, 31], ["tumor tissues", "TISSUE", 35, 48], ["lung cancer cells", "CELL", 53, 70], ["JAK2", "GENE_OR_GENE_PRODUCT", 113, 117], ["PRDX6", "GENE_OR_GENE_PRODUCT", 143, 148], ["JAK2", "GENE_OR_GENE_PRODUCT", 180, 184], ["STAT3", "GENE_OR_GENE_PRODUCT", 185, 190], ["PRDX6", "PROTEIN", 0, 5], ["JAK2", "PROTEIN", 27, 31], ["lung cancer cells", "CELL_TYPE", 53, 70], ["JAK2", "PROTEIN", 113, 117], ["PRDX6", "PROTEIN", 143, 148], ["JAK2", "PROTEIN", 180, 184], ["STAT3", "PROTEIN", 185, 190], ["PRDX6", "PROBLEM", 0, 5], ["JAK2 in tumor tissues", "PROBLEM", 27, 48], ["lung cancer cells", "PROBLEM", 53, 70], ["physical interaction with JAK2", "PROBLEM", 87, 117], ["increased levels of PRDX6", "PROBLEM", 123, 148], ["the JAK2/STAT3 pathway", "TREATMENT", 176, 198], ["JAK2", "OBSERVATION", 27, 31], ["tumor tissues", "OBSERVATION", 35, 48], ["lung", "ANATOMY", 53, 57], ["cancer cells", "OBSERVATION", 58, 70]]], ["Furthermore, PRDX6-Tg mice showed altered cytokine levels in the tumors, especially leading to increased CCL5 levels.", [["tumors", "ANATOMY", 65, 71], ["tumors", "DISEASE", 65, 71], ["PRDX6", "GENE_OR_GENE_PRODUCT", 13, 18], ["tumors", "CANCER", 65, 71], ["CCL5", "GENE_OR_GENE_PRODUCT", 105, 109], ["PRDX6", "PROTEIN", 13, 18], ["cytokine", "PROTEIN", 42, 50], ["CCL5", "PROTEIN", 105, 109], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["PRDX6", "TEST", 13, 18], ["altered cytokine levels in the tumors", "PROBLEM", 34, 71], ["increased CCL5 levels", "PROBLEM", 95, 116], ["altered", "OBSERVATION_MODIFIER", 34, 41], ["cytokine levels", "OBSERVATION", 42, 57], ["tumors", "OBSERVATION", 65, 71], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["CCL5 levels", "OBSERVATION", 105, 116]]], ["We validated that the activation of JAK2 was also decreased in lung tumors of CCR5-/- mice, and CCL5 increased the JAK2/STAT3 pathway in the lung cancer cells, suggesting that PRDX6 promotes lung tumor development via its mediated and CCL5-associated activation of the JAK2/STAT3 pathway.Dual function of PRDX1 in neurodegenerative diseases ::: Roles of PRDXs in the development of neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesThe neuroprotective role of PRDX1 is well established.", [["lung tumors", "ANATOMY", 63, 74], ["lung cancer cells", "ANATOMY", 141, 158], ["lung tumor", "ANATOMY", 191, 201], ["lung tumors", "DISEASE", 63, 74], ["lung cancer", "DISEASE", 141, 152], ["PRDX6", "CHEMICAL", 176, 181], ["tumor", "DISEASE", 196, 201], ["neurodegenerative diseases", "DISEASE", 314, 340], ["neurodegenerative diseases", "DISEASE", 382, 408], ["neurodegenerative diseases", "DISEASE", 423, 449], ["JAK2", "GENE_OR_GENE_PRODUCT", 36, 40], ["lung tumors", "CANCER", 63, 74], ["CCR5", "GENE_OR_GENE_PRODUCT", 78, 82], ["mice", "ORGANISM", 86, 90], ["CCL5", "GENE_OR_GENE_PRODUCT", 96, 100], ["JAK2", "GENE_OR_GENE_PRODUCT", 115, 119], ["STAT3", "GENE_OR_GENE_PRODUCT", 120, 125], ["lung cancer cells", "CELL", 141, 158], ["PRDX6", "GENE_OR_GENE_PRODUCT", 176, 181], ["lung tumor", "CANCER", 191, 201], ["CCL5", "GENE_OR_GENE_PRODUCT", 235, 239], ["JAK2", "GENE_OR_GENE_PRODUCT", 269, 273], ["STAT3", "GENE_OR_GENE_PRODUCT", 274, 279], ["PRDX1", "GENE_OR_GENE_PRODUCT", 305, 310], ["PRDXs", "GENE_OR_GENE_PRODUCT", 354, 359], ["PRDX1", "GENE_OR_GENE_PRODUCT", 477, 482], ["JAK2", "PROTEIN", 36, 40], ["CCR5", "PROTEIN", 78, 82], ["CCL5", "PROTEIN", 96, 100], ["JAK2", "PROTEIN", 115, 119], ["STAT3", "PROTEIN", 120, 125], ["lung cancer cells", "CELL_TYPE", 141, 158], ["PRDX6", "PROTEIN", 176, 181], ["CCL5", "PROTEIN", 235, 239], ["JAK2", "PROTEIN", 269, 273], ["STAT3", "PROTEIN", 274, 279], ["PRDX1", "PROTEIN", 305, 310], ["PRDXs", "PROTEIN", 354, 359], ["PRDX1", "PROTEIN", 477, 482], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["the activation of JAK2", "PROBLEM", 18, 40], ["lung tumors", "PROBLEM", 63, 74], ["CCL5", "TEST", 96, 100], ["the JAK2", "TEST", 111, 119], ["the lung cancer cells", "PROBLEM", 137, 158], ["PRDX6", "PROBLEM", 176, 181], ["lung tumor development", "PROBLEM", 191, 213], ["STAT3 pathway", "TREATMENT", 274, 287], ["neurodegenerative diseases", "PROBLEM", 382, 408], ["PRDXs", "PROBLEM", 413, 418], ["neurodegenerative diseases", "PROBLEM", 423, 449], ["decreased", "OBSERVATION_MODIFIER", 50, 59], ["lung", "ANATOMY", 63, 67], ["tumors", "OBSERVATION", 68, 74], ["lung", "ANATOMY", 141, 145], ["cancer cells", "OBSERVATION", 146, 158], ["lung", "ANATOMY", 191, 195], ["tumor", "OBSERVATION", 196, 201], ["neurodegenerative diseases", "OBSERVATION", 314, 340], ["neurodegenerative", "OBSERVATION_MODIFIER", 382, 399], ["diseases", "OBSERVATION", 400, 408], ["neurodegenerative diseases", "OBSERVATION", 423, 449]]], ["PRDX1 has a protective role in counteracting A\u03b2 injury by increasing cell viability, preserving neurites, and decreasing cell death (Cimini et al., 2013).", [["cell", "ANATOMY", 69, 73], ["neurites", "ANATOMY", 96, 104], ["cell", "ANATOMY", 121, 125], ["PRDX1", "CHEMICAL", 0, 5], ["death", "DISEASE", 126, 131], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 45, 47], ["cell", "CELL", 69, 73], ["neurites", "CELLULAR_COMPONENT", 96, 104], ["cell", "CELL", 121, 125], ["PRDX1", "PROTEIN", 0, 5], ["A\u03b2 injury", "PROBLEM", 45, 54], ["increasing cell viability", "PROBLEM", 58, 83], ["decreasing cell death", "PROBLEM", 110, 131], ["increasing cell viability", "OBSERVATION", 58, 83]]], ["The neurodegenerative role of PRDX1 is also established in neuroblastoma cells (Lee et al., 2011).Neuroprotective or neurodegenerative effect of PRDX2 ::: Roles of PRDXs in the development of neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesThe neuroprotective role of PRDX2 is well established in AD and PD.", [["neuroblastoma cells", "ANATOMY", 59, 78], ["neuroblastoma", "DISEASE", 59, 72], ["neurodegenerative diseases", "DISEASE", 192, 218], ["neurodegenerative diseases", "DISEASE", 233, 259], ["AD", "DISEASE", 316, 318], ["PD", "DISEASE", 323, 325], ["PRDX1", "GENE_OR_GENE_PRODUCT", 30, 35], ["neuroblastoma cells", "CELL", 59, 78], ["PRDX2", "SIMPLE_CHEMICAL", 145, 150], ["PRDXs", "GENE_OR_GENE_PRODUCT", 164, 169], ["PRDX2", "GENE_OR_GENE_PRODUCT", 287, 292], ["PRDX1", "PROTEIN", 30, 35], ["neuroblastoma cells", "CELL_TYPE", 59, 78], ["PRDX2", "PROTEIN", 145, 150], ["PRDXs", "PROTEIN", 164, 169], ["PRDX2", "PROTEIN", 287, 292], ["The neurodegenerative role of PRDX1", "PROBLEM", 0, 35], ["neurodegenerative diseases", "PROBLEM", 192, 218], ["PRDXs", "PROBLEM", 223, 228], ["neurodegenerative diseases", "PROBLEM", 233, 259], ["PRDX2", "TREATMENT", 287, 292], ["neurodegenerative", "OBSERVATION_MODIFIER", 4, 21], ["neurodegenerative", "OBSERVATION_MODIFIER", 117, 134], ["neurodegenerative", "OBSERVATION_MODIFIER", 192, 209], ["diseases", "OBSERVATION", 210, 218], ["neurodegenerative diseases", "OBSERVATION", 233, 259]]], ["Among the antioxidant PRDX enzymes, PRDX2 is the most abundant in mammalian neurons, making it a prime candidate to defend against oxidative stress (Fang, Nakamura, Cho, Gu, & Lipton, 2007).", [["neurons", "ANATOMY", 76, 83], ["PRDX", "GENE_OR_GENE_PRODUCT", 22, 26], ["PRDX2", "GENE_OR_GENE_PRODUCT", 36, 41], ["mammalian neurons", "CELL", 66, 83], ["antioxidant PRDX enzymes", "PROTEIN", 10, 34], ["PRDX2", "PROTEIN", 36, 41], ["mammalian neurons", "CELL_TYPE", 66, 83], ["the antioxidant PRDX enzymes", "TEST", 6, 34], ["oxidative stress", "PROBLEM", 131, 147]]], ["PRDX2 is overexpressed in the brain of Alzheimer\u2019s disease (AD) indicating that PRDX2 protects the brain from A\u03b21-42 induced neurotoxicity (Yao et al., 2007).", [["brain", "ANATOMY", 30, 35], ["brain", "ANATOMY", 99, 104], ["Alzheimer\u2019s disease", "DISEASE", 39, 58], ["AD", "DISEASE", 60, 62], ["PRDX2", "CHEMICAL", 80, 85], ["A\u03b21-42", "CHEMICAL", 110, 116], ["neurotoxicity", "DISEASE", 125, 138], ["A\u03b21-42", "CHEMICAL", 110, 116], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["brain", "ORGAN", 30, 35], ["Alzheimer\u2019s disease", "CANCER", 39, 58], ["PRDX2", "GENE_OR_GENE_PRODUCT", 80, 85], ["brain", "ORGAN", 99, 104], ["A\u03b21-42", "GENE_OR_GENE_PRODUCT", 110, 116], ["PRDX2", "PROTEIN", 0, 5], ["PRDX2", "PROTEIN", 80, 85], ["Alzheimer\u2019s disease", "PROBLEM", 39, 58], ["PRDX2 protects the brain", "PROBLEM", 80, 104], ["neurotoxicity", "PROBLEM", 125, 138], ["brain", "ANATOMY", 30, 35], ["Alzheimer", "OBSERVATION", 39, 48], ["brain", "ANATOMY", 99, 104]]], ["Another study also suggested that PRDX2 exhibited anti apoptotic effects in DA neurons via suppression of ASK1 dependent activation of JNK and p38 pathways which are activated in PA neurons of PD brains (Hu et al., 2011).", [["DA neurons", "ANATOMY", 76, 86], ["PA neurons", "ANATOMY", 179, 189], ["brains", "ANATOMY", 196, 202], ["PRDX2", "CHEMICAL", 34, 39], ["DA", "CHEMICAL", 76, 78], ["PRDX2", "GENE_OR_GENE_PRODUCT", 34, 39], ["DA neurons", "CELL", 76, 86], ["ASK1", "GENE_OR_GENE_PRODUCT", 106, 110], ["JNK", "GENE_OR_GENE_PRODUCT", 135, 138], ["p38", "GENE_OR_GENE_PRODUCT", 143, 146], ["PA neurons", "CELL", 179, 189], ["PRDX2", "PROTEIN", 34, 39], ["DA neurons", "CELL_TYPE", 76, 86], ["ASK1", "PROTEIN", 106, 110], ["JNK", "PROTEIN", 135, 138], ["p38", "PROTEIN", 143, 146], ["Another study", "TEST", 0, 13], ["PRDX2", "TEST", 34, 39], ["anti apoptotic effects", "PROBLEM", 50, 72], ["p38 pathways", "TEST", 143, 155], ["anti apoptotic", "OBSERVATION_MODIFIER", 50, 64]]], ["The neurodegenerative role of PRDX2 is also established in AD and PD.", [["AD", "DISEASE", 59, 61], ["PD", "DISEASE", 66, 68], ["PRDX2", "GENE_OR_GENE_PRODUCT", 30, 35], ["PRDX2", "PROTEIN", 30, 35], ["neurodegenerative", "OBSERVATION_MODIFIER", 4, 21]]], ["The role of PRDX2 in PD is controversial.", [["PD", "DISEASE", 21, 23], ["PRDX2", "GENE_OR_GENE_PRODUCT", 12, 17], ["PRDX2", "PROTEIN", 12, 17], ["PRDX2 in PD", "TREATMENT", 12, 23]]], ["Garcia-Garcia et al suggested that the oxidative modification of PRDX2 is associated with drug induced apoptosis signaling in the model of Parkinson disease (Garcia-Garcia, Zavala-Flores, Rodriguez-Rocha, & Franco, 2012).", [["PRDX2", "CHEMICAL", 65, 70], ["Parkinson disease", "DISEASE", 139, 156], ["PRDX2", "GENE_OR_GENE_PRODUCT", 65, 70], ["PRDX2", "PROTEIN", 65, 70], ["the oxidative modification of PRDX2", "PROBLEM", 35, 70], ["drug induced apoptosis signaling", "PROBLEM", 90, 122], ["Parkinson disease", "PROBLEM", 139, 156], ["associated with", "UNCERTAINTY", 74, 89], ["Parkinson disease", "OBSERVATION", 139, 156]]], ["They suggested that the oxidative modification of PRDX2 is involved in the regulation of 6-OHDA-induced apoptotic signaling in DA induced neuronal cell death.", [["neuronal cell", "ANATOMY", 138, 151], ["PRDX2", "CHEMICAL", 50, 55], ["6-OHDA", "CHEMICAL", 89, 95], ["DA", "CHEMICAL", 127, 129], ["neuronal cell death", "DISEASE", 138, 157], ["6-OHDA", "CHEMICAL", 89, 95], ["PRDX2", "GENE_OR_GENE_PRODUCT", 50, 55], ["6-OHDA", "SIMPLE_CHEMICAL", 89, 95], ["DA", "SIMPLE_CHEMICAL", 127, 129], ["neuronal cell", "CELL", 138, 151], ["PRDX2", "PROTEIN", 50, 55], ["the oxidative modification of PRDX2", "TREATMENT", 20, 55], ["neuronal cell death", "PROBLEM", 138, 157], ["neuronal cell death", "OBSERVATION", 138, 157]]], ["Qu et al defined the role of PRDX2 in PD and suggested that phosphorylation of PRDX2 isoform is involved in PD (Qu et al., 2007).", [["PD", "DISEASE", 38, 40], ["PD", "DISEASE", 108, 110], ["PRDX2", "GENE_OR_GENE_PRODUCT", 29, 34], ["PRDX2", "GENE_OR_GENE_PRODUCT", 79, 84], ["PRDX2", "PROTEIN", 29, 34], ["PRDX2 isoform", "PROTEIN", 79, 92], ["PRDX2 in PD", "TREATMENT", 29, 40], ["phosphorylation of PRDX2 isoform", "TREATMENT", 60, 92]]], ["In a histochemical study of brains from AD patients, nitrated PRDX2 was identified.", [["brains", "ANATOMY", 28, 34], ["AD", "DISEASE", 40, 42], ["brains", "ORGANISM", 28, 34], ["patients", "ORGANISM", 43, 51], ["PRDX2", "GENE_OR_GENE_PRODUCT", 62, 67], ["nitrated PRDX2", "PROTEIN", 53, 67], ["patients", "SPECIES", 43, 51], ["a histochemical study", "TEST", 3, 24], ["nitrated PRDX2", "TREATMENT", 53, 67]]], ["Randall et al. investigated the functional consequences of PRDX2 tyrosine nitration, and demonstrated that nitration was on a non-catalytic residue that resulted in increases in peroxidase activity and resistance to over-oxidation (Randall et al., 2014).", [["tyrosine", "CHEMICAL", 65, 73], ["tyrosine", "CHEMICAL", 65, 73], ["PRDX2", "GENE_OR_GENE_PRODUCT", 59, 64], ["tyrosine", "AMINO_ACID", 65, 73], ["peroxidase", "GENE_OR_GENE_PRODUCT", 178, 188], ["PRDX2", "PROTEIN", 59, 64], ["peroxidase", "PROTEIN", 178, 188], ["PRDX2 tyrosine nitration", "TREATMENT", 59, 83], ["a non-catalytic residue", "PROBLEM", 124, 147], ["increases in peroxidase activity", "PROBLEM", 165, 197], ["increases", "OBSERVATION_MODIFIER", 165, 174], ["peroxidase activity", "OBSERVATION", 178, 197]]], ["Fang et al observed increased S-nitrosylation of PRDX2 in human Parkinson's disease (PD) brains, and S-nitrosylation of PRDX2 inhibited both its enzymatic activity and protective function from oxidative stress (Fang et al., 2007).", [["brains", "ANATOMY", 89, 95], ["Parkinson's disease", "DISEASE", 64, 83], ["PD", "DISEASE", 85, 87], ["PRDX2", "CHEMICAL", 120, 125], ["PRDX2", "GENE_OR_GENE_PRODUCT", 49, 54], ["human", "ORGANISM", 58, 63], ["Parkinson's disease", "ORGANISM", 64, 83], ["brains", "ORGAN", 89, 95], ["PRDX2", "GENE_OR_GENE_PRODUCT", 120, 125], ["PRDX2", "PROTEIN", 49, 54], ["PRDX2", "PROTEIN", 120, 125], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["increased S-nitrosylation of PRDX2", "TREATMENT", 20, 54], ["human Parkinson's disease (PD) brains", "PROBLEM", 58, 95], ["S-nitrosylation of PRDX2", "TREATMENT", 101, 125], ["oxidative stress", "PROBLEM", 193, 209], ["brains", "ANATOMY", 89, 95]]], ["Dopaminergic neurons, which are lost in PD, become particularly vulnerable, provided a direct link between nitrosative/oxidative stress and neurodegenerative disorders such as PD (Fang et al., 2007).", [["Dopaminergic neurons", "ANATOMY", 0, 20], ["PD", "DISEASE", 40, 42], ["neurodegenerative disorders", "DISEASE", 140, 167], ["PD", "DISEASE", 176, 178], ["Dopaminergic neurons", "CELL", 0, 20], ["Dopaminergic neurons", "CELL_TYPE", 0, 20], ["nitrosative/oxidative stress", "TREATMENT", 107, 135], ["neurodegenerative disorders", "PROBLEM", 140, 167], ["PD", "PROBLEM", 176, 178]]], ["These data suggest that not only is PRDX2 involved in neuroprotection via inhibition of A\u03b21-42 induced apoptosis and suppression of JNK and p38 pathways, but also involved in neurodegeneration via oxidative modification, phosphorylation and s-nitrosylation of PRDX2.Dual function of PRDX3 in neurodegenerative diseases ::: Roles of PRDXs in the development of neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesThe neuroprotective role of PRDX3 is well established.", [["A\u03b21-42", "CHEMICAL", 88, 94], ["neurodegeneration", "DISEASE", 175, 192], ["PRDX3", "CHEMICAL", 283, 288], ["neurodegenerative diseases", "DISEASE", 292, 318], ["neurodegenerative diseases", "DISEASE", 360, 386], ["neurodegenerative diseases", "DISEASE", 401, 427], ["PRDX2", "GENE_OR_GENE_PRODUCT", 36, 41], ["A\u03b21-42", "GENE_OR_GENE_PRODUCT", 88, 94], ["JNK", "GENE_OR_GENE_PRODUCT", 132, 135], ["p38", "GENE_OR_GENE_PRODUCT", 140, 143], ["PRDX2", "GENE_OR_GENE_PRODUCT", 260, 265], ["PRDX3", "GENE_OR_GENE_PRODUCT", 283, 288], ["PRDXs", "GENE_OR_GENE_PRODUCT", 332, 337], ["PRDX3", "GENE_OR_GENE_PRODUCT", 455, 460], ["PRDX2", "PROTEIN", 36, 41], ["JNK", "PROTEIN", 132, 135], ["p38", "PROTEIN", 140, 143], ["PRDX2", "PROTEIN", 260, 265], ["PRDX3", "PROTEIN", 283, 288], ["PRDXs", "PROTEIN", 332, 337], ["PRDX3", "PROTEIN", 455, 460], ["A\u03b21", "TREATMENT", 88, 91], ["apoptosis", "PROBLEM", 103, 112], ["JNK and p38 pathways", "TEST", 132, 152], ["neurodegeneration", "PROBLEM", 175, 192], ["oxidative modification", "TREATMENT", 197, 219], ["phosphorylation", "TREATMENT", 221, 236], ["s-nitrosylation of PRDX2", "TREATMENT", 241, 265], ["neurodegenerative diseases", "PROBLEM", 360, 386], ["PRDXs", "PROBLEM", 391, 396], ["neurodegenerative diseases", "PROBLEM", 401, 427], ["neurodegenerative diseases", "OBSERVATION", 292, 318], ["neurodegenerative", "OBSERVATION_MODIFIER", 360, 377], ["diseases", "OBSERVATION", 378, 386], ["neurodegenerative diseases", "OBSERVATION", 401, 427]]], ["PRDX3 is involved in the protection of hippocampal neurons from excitotoxic injury.", [["hippocampal neurons", "ANATOMY", 39, 58], ["excitotoxic injury", "DISEASE", 64, 82], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["hippocampal neurons", "CELL", 39, 58], ["PRDX3", "PROTEIN", 0, 5], ["hippocampal neurons", "CELL_TYPE", 39, 58], ["hippocampal neurons", "PROBLEM", 39, 58], ["excitotoxic injury", "PROBLEM", 64, 82], ["hippocampal neurons", "ANATOMY", 39, 58], ["excitotoxic injury", "OBSERVATION", 64, 82]]], ["Hattori et al showed that PRDX3 is up-regulated in the mitochondria of damaged nerve cells (Hattori, Murayama, Noshita, & Oikawa, 2003).", [["mitochondria", "ANATOMY", 55, 67], ["nerve cells", "ANATOMY", 79, 90], ["PRDX3", "GENE_OR_GENE_PRODUCT", 26, 31], ["mitochondria", "CELLULAR_COMPONENT", 55, 67], ["nerve cells", "CELL", 79, 90], ["PRDX3", "PROTEIN", 26, 31], ["damaged nerve cells", "CELL_TYPE", 71, 90], ["PRDX3", "TEST", 26, 31], ["damaged nerve cells", "OBSERVATION", 71, 90]]], ["Because mitochondria is involved in excitotoxic damage of nerve cells, mitochondrial PRDX3 seems to be neuroprotective against oxidative insults (Hattori et al., 2003).", [["mitochondria", "ANATOMY", 8, 20], ["nerve cells", "ANATOMY", 58, 69], ["mitochondrial", "ANATOMY", 71, 84], ["PRDX3", "CHEMICAL", 85, 90], ["mitochondria", "CELLULAR_COMPONENT", 8, 20], ["nerve cells", "CELL", 58, 69], ["mitochondrial", "CELLULAR_COMPONENT", 71, 84], ["PRDX3", "GENE_OR_GENE_PRODUCT", 85, 90], ["nerve cells", "CELL_TYPE", 58, 69], ["mitochondrial PRDX3", "PROTEIN", 71, 90], ["excitotoxic damage of nerve cells", "PROBLEM", 36, 69], ["mitochondrial PRDX3", "PROBLEM", 71, 90], ["oxidative insults", "PROBLEM", 127, 144], ["excitotoxic damage", "OBSERVATION", 36, 54], ["nerve cells", "OBSERVATION", 58, 69]]], ["Also, PRDX3 is decreased in the frontal cortex of patients with Down syndrome (P < 0.01) and Pick\u2019s disease (P < 0.001) (Krapfenbauer, Engidawork, Cairns, Fountoulakis, & Lubec, 2003).", [["frontal cortex", "ANATOMY", 32, 46], ["Down syndrome", "DISEASE", 64, 77], ["Pick\u2019s disease", "DISEASE", 93, 107], ["PRDX3", "GENE_OR_GENE_PRODUCT", 6, 11], ["frontal cortex", "MULTI-TISSUE_STRUCTURE", 32, 46], ["patients", "ORGANISM", 50, 58], ["PRDX3", "PROTEIN", 6, 11], ["patients", "SPECIES", 50, 58], ["PRDX3", "TEST", 6, 11], ["Down syndrome", "PROBLEM", 64, 77], ["Pick\u2019s disease", "PROBLEM", 93, 107], ["decreased", "OBSERVATION_MODIFIER", 15, 24], ["frontal cortex", "ANATOMY", 32, 46], ["Down syndrome", "OBSERVATION", 64, 77]]], ["The neurodegenerative role of PRDX3 is established in PD.", [["PD", "DISEASE", 54, 56], ["PRDX3", "GENE_OR_GENE_PRODUCT", 30, 35], ["PRDX3", "PROTEIN", 30, 35], ["PRDX3", "TREATMENT", 30, 35], ["neurodegenerative", "OBSERVATION_MODIFIER", 4, 21]]], ["A recent study also suggested that the autosomal dominant mutation of LRRK2 that is important for PD, increased the phosphorylation of PRDX3 and resulted in the oxidative stress induced neuronal death (Angeles et al., 2011).", [["neuronal", "ANATOMY", 186, 194], ["PD", "DISEASE", 98, 100], ["neuronal death", "DISEASE", 186, 200], ["LRRK2", "GENE_OR_GENE_PRODUCT", 70, 75], ["PRDX3", "GENE_OR_GENE_PRODUCT", 135, 140], ["neuronal", "CELL", 186, 194], ["LRRK2", "PROTEIN", 70, 75], ["PRDX3", "PROTEIN", 135, 140], ["A recent study", "TEST", 0, 14], ["the autosomal dominant mutation of LRRK2", "PROBLEM", 35, 75], ["PD", "TREATMENT", 98, 100], ["the phosphorylation of PRDX3", "TREATMENT", 112, 140], ["the oxidative stress induced neuronal death", "PROBLEM", 157, 200], ["neuronal death", "OBSERVATION", 186, 200]]], ["These data indicate that PRDX3 is involved in the neuroprotection against oxidative insults in the mitochondria, and involved in neurodegeneration through increased phosphorylation by LRRK2 mutation.Role of PRDX4 and PRDX5 in neurodegenerative diseases ::: Roles of PRDXs in the development of neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesThere are not many research reports in PRDX4 and PRDX5.", [["mitochondria", "ANATOMY", 99, 111], ["PRDX3", "CHEMICAL", 25, 30], ["neurodegeneration", "DISEASE", 129, 146], ["neurodegenerative diseases", "DISEASE", 226, 252], ["neurodegenerative diseases", "DISEASE", 294, 320], ["neurodegenerative diseases", "DISEASE", 335, 361], ["PRDX3", "GENE_OR_GENE_PRODUCT", 25, 30], ["mitochondria", "CELLULAR_COMPONENT", 99, 111], ["LRRK2", "GENE_OR_GENE_PRODUCT", 184, 189], ["PRDX4", "GENE_OR_GENE_PRODUCT", 207, 212], ["PRDX5", "GENE_OR_GENE_PRODUCT", 217, 222], ["PRDXs", "GENE_OR_GENE_PRODUCT", 266, 271], ["PRDX4", "GENE_OR_GENE_PRODUCT", 400, 405], ["PRDX5", "GENE_OR_GENE_PRODUCT", 410, 415], ["PRDX3", "PROTEIN", 25, 30], ["LRRK2", "PROTEIN", 184, 189], ["PRDX4", "PROTEIN", 207, 212], ["PRDX5", "PROTEIN", 217, 222], ["PRDXs", "PROTEIN", 266, 271], ["PRDX4", "PROTEIN", 400, 405], ["PRDX5", "PROTEIN", 410, 415], ["oxidative insults in the mitochondria", "PROBLEM", 74, 111], ["neurodegeneration", "PROBLEM", 129, 146], ["increased phosphorylation by LRRK2 mutation", "PROBLEM", 155, 198], ["neurodegenerative diseases", "PROBLEM", 294, 320], ["PRDXs", "PROBLEM", 325, 330], ["neurodegenerative diseases", "PROBLEM", 335, 361], ["PRDX4", "TREATMENT", 400, 405], ["PRDX5", "TREATMENT", 410, 415], ["LRRK2 mutation", "OBSERVATION", 184, 198], ["neurodegenerative diseases", "OBSERVATION", 226, 252], ["neurodegenerative", "OBSERVATION_MODIFIER", 294, 311], ["diseases", "OBSERVATION", 312, 320], ["neurodegenerative diseases", "OBSERVATION", 335, 361]]], ["PRDX4 is significantly increased only in Pick\u2019s disease frontal cortex (Krapfenbauer et al., 2003).", [["Pick\u2019s disease frontal cortex", "ANATOMY", 41, 70], ["Pick\u2019s disease frontal cortex", "DISEASE", 41, 70], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["frontal cortex", "CANCER", 56, 70], ["PRDX4", "PROTEIN", 0, 5], ["significantly", "OBSERVATION_MODIFIER", 9, 22], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["frontal cortex", "ANATOMY", 56, 70]]], ["PRDX5 is involved in PD through mitochondrial redox signaling with Ca2 + influx resulting in the development of PD (Davey & Bola\u00f1os, 2013).Role of PRDX6 in neuroprotection and neurodegeneration ::: Roles of PRDXs in the development of neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesThe neuroprotective role of PRDX6 is established in an experimental autoimmune encephalomyelitis (EAE) model.", [["mitochondrial", "ANATOMY", 32, 45], ["PD", "DISEASE", 21, 23], ["Ca2", "CHEMICAL", 67, 70], ["PD", "DISEASE", 112, 114], ["neurodegeneration", "DISEASE", 176, 193], ["neurodegenerative diseases", "DISEASE", 235, 261], ["neurodegenerative diseases", "DISEASE", 276, 302], ["PRDX6", "CHEMICAL", 330, 335], ["autoimmune encephalomyelitis", "DISEASE", 370, 398], ["EAE", "DISEASE", 400, 403], ["Ca2 +", "CHEMICAL", 67, 72], ["PRDX5", "GENE_OR_GENE_PRODUCT", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 32, 45], ["Ca2 +", "SIMPLE_CHEMICAL", 67, 72], ["PRDX6", "GENE_OR_GENE_PRODUCT", 147, 152], ["PRDXs", "GENE_OR_GENE_PRODUCT", 207, 212], ["PRDX6", "GENE_OR_GENE_PRODUCT", 330, 335], ["PRDX5", "PROTEIN", 0, 5], ["Ca2", "PROTEIN", 67, 70], ["PRDX6", "PROTEIN", 147, 152], ["PRDXs", "PROTEIN", 207, 212], ["PRDX6", "PROTEIN", 330, 335], ["influx", "PROBLEM", 73, 79], ["PD", "PROBLEM", 112, 114], ["neurodegeneration", "PROBLEM", 176, 193], ["neurodegenerative diseases", "PROBLEM", 235, 261], ["PRDXs", "PROBLEM", 266, 271], ["neurodegenerative diseases", "PROBLEM", 276, 302], ["an experimental autoimmune encephalomyelitis", "PROBLEM", 354, 398], ["neurodegenerative", "OBSERVATION_MODIFIER", 235, 252], ["diseases", "OBSERVATION", 253, 261], ["neurodegenerative diseases", "OBSERVATION", 276, 302], ["autoimmune encephalomyelitis", "OBSERVATION", 370, 398]]], ["In the recent study, we also showed that the expression of an PRDX6 is markedly increased in spinal cords of mice with EAE compared to other PRDXs.", [["spinal cords", "ANATOMY", 93, 105], ["EAE", "DISEASE", 119, 122], ["PRDX6", "GENE_OR_GENE_PRODUCT", 62, 67], ["spinal cords", "ORGAN", 93, 105], ["mice", "ORGANISM", 109, 113], ["PRDX6", "PROTEIN", 62, 67], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 109, 113], ["the recent study", "TEST", 3, 19], ["an PRDX6", "TEST", 59, 67], ["EAE", "PROBLEM", 119, 122], ["PRDX6", "OBSERVATION", 62, 67], ["markedly", "OBSERVATION_MODIFIER", 71, 79], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["spinal cords", "ANATOMY", 93, 105]]], ["PRDX6 transgenic mice displayed a significant decrease in clinical severity and attenuated demyelination in EAE compared to wild type mice, suggesting that PRDX6 expression may represent a therapeutic way to restrict inflammation in the central nervous system and potentiate oligodendrocyte survival, and suggest a new molecule for neuroprotective therapies in MS (Yun et al., 2015a, Yun et al., 2015b, Yun et al., 2015c).", [["central nervous system", "ANATOMY", 237, 259], ["oligodendrocyte", "ANATOMY", 275, 290], ["demyelination", "DISEASE", 91, 104], ["EAE", "DISEASE", 108, 111], ["inflammation", "DISEASE", 217, 229], ["MS", "DISEASE", 361, 363], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 17, 21], ["mice", "ORGANISM", 134, 138], ["PRDX6", "GENE_OR_GENE_PRODUCT", 156, 161], ["central nervous system", "ANATOMICAL_SYSTEM", 237, 259], ["oligodendrocyte", "CELL", 275, 290], ["PRDX6", "PROTEIN", 0, 5], ["PRDX6", "PROTEIN", 156, 161], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 17, 21], ["a significant decrease in clinical severity", "PROBLEM", 32, 75], ["attenuated demyelination in EAE", "PROBLEM", 80, 111], ["PRDX6 expression", "PROBLEM", 156, 172], ["inflammation in the central nervous system", "PROBLEM", 217, 259], ["neuroprotective therapies", "TREATMENT", 332, 357], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["decrease", "OBSERVATION_MODIFIER", 46, 54], ["attenuated", "OBSERVATION_MODIFIER", 80, 90], ["demyelination", "OBSERVATION", 91, 104], ["inflammation", "OBSERVATION", 217, 229], ["central", "ANATOMY_MODIFIER", 237, 244], ["nervous system", "ANATOMY", 245, 259], ["potentiate", "UNCERTAINTY", 264, 274], ["oligodendrocyte survival", "OBSERVATION", 275, 299]]], ["The neurodegenerative role of PRDX6 is established in AD and PD.", [["AD", "DISEASE", 54, 56], ["PD", "DISEASE", 61, 63], ["PRDX6", "GENE_OR_GENE_PRODUCT", 30, 35], ["PRDX6", "PROTEIN", 30, 35], ["neurodegenerative", "OBSERVATION_MODIFIER", 4, 21]]], ["Our recent study suggested that overexpression of PRDX6 could accelerate the development of AD through increased amyloidogenesis through independent PLA2 activation and Nrf2 transcription (Yun et al., 2013).", [["PRDX6", "CHEMICAL", 50, 55], ["AD", "DISEASE", 92, 94], ["PRDX6", "GENE_OR_GENE_PRODUCT", 50, 55], ["PLA2", "GENE_OR_GENE_PRODUCT", 149, 153], ["Nrf2", "GENE_OR_GENE_PRODUCT", 169, 173], ["PRDX6", "PROTEIN", 50, 55], ["PLA2", "PROTEIN", 149, 153], ["Nrf2", "PROTEIN", 169, 173], ["Our recent study", "TEST", 0, 16], ["overexpression of PRDX6", "PROBLEM", 32, 55], ["increased amyloidogenesis", "PROBLEM", 103, 128], ["independent PLA2 activation", "TREATMENT", 137, 164], ["Nrf2 transcription", "TREATMENT", 169, 187]]], ["In a mouse model after amyloid beta infusion, memory impairment in PRDX6 transgenic mice was worse than C57BL/6 mice.", [["memory impairment", "DISEASE", 46, 63], ["mouse", "ORGANISM", 5, 10], ["amyloid beta", "GENE_OR_GENE_PRODUCT", 23, 35], ["PRDX6", "GENE_OR_GENE_PRODUCT", 67, 72], ["mice", "ORGANISM", 84, 88], ["C57BL/6 mice", "ORGANISM", 104, 116], ["amyloid beta", "PROTEIN", 23, 35], ["PRDX6", "PROTEIN", 67, 72], ["mouse", "SPECIES", 5, 10], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 112, 116], ["mouse", "SPECIES", 5, 10], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 112, 116], ["amyloid beta infusion", "TREATMENT", 23, 44], ["memory impairment", "PROBLEM", 46, 63]]], ["In addition, the astrocytes and microglia cells of amyloid-infused PRDX6 transgenic mice were more activated, lipid peroxidation and protein carbonyl levels were increased and glutathione levels were lower, suggesting that PRDX6 is promoting rather than preventing oxidative stress (Yun et al., 2013).", [["astrocytes", "ANATOMY", 17, 27], ["microglia cells", "ANATOMY", 32, 47], ["carbonyl", "CHEMICAL", 141, 149], ["glutathione", "CHEMICAL", 176, 187], ["PRDX6", "CHEMICAL", 223, 228], ["carbonyl", "CHEMICAL", 141, 149], ["glutathione", "CHEMICAL", 176, 187], ["astrocytes", "CELL", 17, 27], ["microglia cells", "CELL", 32, 47], ["amyloid", "GENE_OR_GENE_PRODUCT", 51, 58], ["PRDX6", "GENE_OR_GENE_PRODUCT", 67, 72], ["mice", "ORGANISM", 84, 88], ["lipid", "SIMPLE_CHEMICAL", 110, 115], ["protein carbonyl", "SIMPLE_CHEMICAL", 133, 149], ["glutathione", "SIMPLE_CHEMICAL", 176, 187], ["PRDX6", "GENE_OR_GENE_PRODUCT", 223, 228], ["astrocytes", "CELL_TYPE", 17, 27], ["microglia cells", "CELL_TYPE", 32, 47], ["PRDX6", "PROTEIN", 67, 72], ["PRDX6", "PROTEIN", 223, 228], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["the astrocytes", "TEST", 13, 27], ["amyloid", "TEST", 51, 58], ["PRDX6 transgenic mice", "TREATMENT", 67, 88], ["lipid peroxidation", "TEST", 110, 128], ["protein carbonyl levels", "TEST", 133, 156], ["glutathione levels", "TEST", 176, 194], ["PRDX6", "PROBLEM", 223, 228], ["oxidative stress", "PROBLEM", 265, 281], ["astrocytes", "ANATOMY", 17, 27], ["microglia cells", "OBSERVATION", 32, 47]]], ["Our recent study also suggested that PRDX6 exacerbates dopaminergic neurodegeneration in a MPTP mouse model of PD (Yun et al., 2015a, Yun et al., 2015b, Yun et al., 2015c).", [["PRDX6", "CHEMICAL", 37, 42], ["neurodegeneration", "DISEASE", 68, 85], ["MPTP", "CHEMICAL", 91, 95], ["PD", "DISEASE", 111, 113], ["MPTP", "CHEMICAL", 91, 95], ["PRDX6", "GENE_OR_GENE_PRODUCT", 37, 42], ["mouse", "ORGANISM", 96, 101], ["PRDX6", "PROTEIN", 37, 42], ["mouse", "SPECIES", 96, 101], ["mouse", "SPECIES", 96, 101], ["Our recent study", "TEST", 0, 16], ["PRDX6", "PROBLEM", 37, 42], ["dopaminergic neurodegeneration", "PROBLEM", 55, 85], ["dopaminergic neurodegeneration", "OBSERVATION", 55, 85]]], ["These data indicate that PRDX6 induces neurodegeneration through iPLA2 and nrf2 activation in AD, and induction of MPTP-induced dopaminergic neurodegeneration of PD, but inhibits multiple sclerosis by suppressing inflammation and blood brain barrier disruption in EAE model.Signaling pathway of PRDXs in neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesThe Trx system protects against H2O2-induced apoptosis, and the Trx-PRDX system detoxifies peroxides by transferring reducing equivalents from NADPH to peroxides with cytoprotective and antioxidative effect (Soriano et al., 2008).", [["blood brain barrier", "ANATOMY", 230, 249], ["PRDX6", "CHEMICAL", 25, 30], ["neurodegeneration", "DISEASE", 39, 56], ["AD", "DISEASE", 94, 96], ["MPTP", "CHEMICAL", 115, 119], ["neurodegeneration", "DISEASE", 141, 158], ["PD", "DISEASE", 162, 164], ["multiple sclerosis", "DISEASE", 179, 197], ["inflammation", "DISEASE", 213, 225], ["EAE", "DISEASE", 264, 267], ["neurodegenerative diseases", "DISEASE", 304, 330], ["neurodegenerative diseases", "DISEASE", 345, 371], ["H2O2", "CHEMICAL", 403, 407], ["NADPH", "CHEMICAL", 514, 519], ["MPTP", "CHEMICAL", 115, 119], ["H2O2", "CHEMICAL", 403, 407], ["peroxides", "CHEMICAL", 462, 471], ["NADPH", "CHEMICAL", 514, 519], ["peroxides", "CHEMICAL", 523, 532], ["PRDX6", "GENE_OR_GENE_PRODUCT", 25, 30], ["iPLA2", "GENE_OR_GENE_PRODUCT", 65, 70], ["nrf2", "GENE_OR_GENE_PRODUCT", 75, 79], ["MPTP", "SIMPLE_CHEMICAL", 115, 119], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 230, 249], ["PRDXs", "GENE_OR_GENE_PRODUCT", 295, 300], ["Trx", "GENE_OR_GENE_PRODUCT", 375, 378], ["H2O2", "SIMPLE_CHEMICAL", 403, 407], ["Trx", "GENE_OR_GENE_PRODUCT", 435, 438], ["PRDX", "GENE_OR_GENE_PRODUCT", 439, 443], ["peroxides", "SIMPLE_CHEMICAL", 462, 471], ["NADPH", "SIMPLE_CHEMICAL", 514, 519], ["peroxides", "SIMPLE_CHEMICAL", 523, 532], ["PRDX6", "PROTEIN", 25, 30], ["iPLA2", "PROTEIN", 65, 70], ["nrf2", "PROTEIN", 75, 79], ["PRDXs", "PROTEIN", 295, 300], ["Trx", "PROTEIN", 375, 378], ["Trx", "PROTEIN", 435, 438], ["PRDX", "PROTEIN", 439, 443], ["These data", "TEST", 0, 10], ["PRDX6", "PROBLEM", 25, 30], ["neurodegeneration", "PROBLEM", 39, 56], ["iPLA2", "PROBLEM", 65, 70], ["nrf2 activation", "PROBLEM", 75, 90], ["AD", "PROBLEM", 94, 96], ["MPTP", "TREATMENT", 115, 119], ["dopaminergic neurodegeneration of PD", "PROBLEM", 128, 164], ["multiple sclerosis", "PROBLEM", 179, 197], ["suppressing inflammation", "PROBLEM", 201, 225], ["blood brain barrier disruption in EAE model", "PROBLEM", 230, 273], ["neurodegenerative diseases", "PROBLEM", 304, 330], ["PRDXs", "PROBLEM", 335, 340], ["neurodegenerative diseases", "PROBLEM", 345, 371], ["The Trx system", "TREATMENT", 371, 385], ["H2O2", "PROBLEM", 403, 407], ["apoptosis", "PROBLEM", 416, 425], ["the Trx-PRDX system detoxifies peroxides", "TREATMENT", 431, 471], ["NADPH to peroxides", "TREATMENT", 514, 532], ["cytoprotective and antioxidative effect", "TREATMENT", 538, 577], ["nrf2 activation", "OBSERVATION", 75, 90], ["dopaminergic neurodegeneration", "OBSERVATION", 128, 158], ["multiple", "OBSERVATION_MODIFIER", 179, 187], ["sclerosis", "OBSERVATION", 188, 197], ["inflammation", "OBSERVATION", 213, 225], ["blood brain", "OBSERVATION", 230, 241], ["barrier disruption", "OBSERVATION", 242, 260], ["neurodegenerative diseases", "OBSERVATION", 304, 330], ["neurodegenerative", "OBSERVATION_MODIFIER", 345, 362], ["diseases", "OBSERVATION", 363, 371]]], ["Several studies reported that PRDX1-4 are implicated in protecting neuronal cells from A\u03b2 toxicity (Yao et al., 2007), peroxide and 1-methyl-4-phenylpyridinium (MPP(+)) toxicity (Qu et al., 2007), oxygen-glucose deprivation and excitotoxicity (Hattori et al., 2003).", [["neuronal cells", "ANATOMY", 67, 81], ["toxicity", "DISEASE", 90, 98], ["peroxide", "CHEMICAL", 119, 127], ["1-methyl-4-phenylpyridinium", "CHEMICAL", 132, 159], ["MPP", "CHEMICAL", 161, 164], ["toxicity", "DISEASE", 169, 177], ["oxygen-glucose", "CHEMICAL", 197, 211], ["excitotoxicity", "DISEASE", 228, 242], ["peroxide", "CHEMICAL", 119, 127], ["1-methyl-4-phenylpyridinium", "CHEMICAL", 132, 159], ["MPP(+)", "CHEMICAL", 161, 167], ["oxygen", "CHEMICAL", 197, 203], ["glucose", "CHEMICAL", 204, 211], ["PRDX1-4", "GENE_OR_GENE_PRODUCT", 30, 37], ["neuronal cells", "CELL", 67, 81], ["A\u03b2", "SIMPLE_CHEMICAL", 87, 89], ["peroxide", "SIMPLE_CHEMICAL", 119, 127], ["1-methyl-4-phenylpyridinium", "SIMPLE_CHEMICAL", 132, 159], ["MPP(+)", "SIMPLE_CHEMICAL", 161, 167], ["oxygen-glucose", "SIMPLE_CHEMICAL", 197, 211], ["PRDX1-4", "PROTEIN", 30, 37], ["neuronal cells", "CELL_TYPE", 67, 81], ["Several studies", "TEST", 0, 15], ["PRDX1", "TEST", 30, 35], ["A\u03b2 toxicity", "PROBLEM", 87, 98], ["peroxide", "TREATMENT", 119, 127], ["methyl", "TREATMENT", 134, 140], ["toxicity", "PROBLEM", 169, 177], ["oxygen-glucose deprivation", "TREATMENT", 197, 223], ["excitotoxicity", "PROBLEM", 228, 242], ["neuronal cells", "OBSERVATION", 67, 81]]], ["Also, other PRDXs are also involved in neurodegenerative diseases.", [["neurodegenerative diseases", "DISEASE", 39, 65], ["PRDXs", "GENE_OR_GENE_PRODUCT", 12, 17], ["PRDXs", "PROTEIN", 12, 17], ["neurodegenerative diseases", "PROBLEM", 39, 65], ["neurodegenerative", "OBSERVATION_MODIFIER", 39, 56], ["diseases", "OBSERVATION", 57, 65]]], ["Fig. 5illustrates the roles of PRDXs in the signaling pathways for the neurodegenerative diseases.Signaling pathway of PRDXs in neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesOverexpression of PRDX1 protects against 6 hydroxydopamine toxicity, prevents p38 MAPK activation and subsequent activation of caspase-3 in MN9D cells, but apoptotic death signals were enhanced by RNA interference-targeted reduction of PRDX1 (Lee et al., 2008).", [["MN9D cells", "ANATOMY", 335, 345], ["neurodegenerative diseases", "DISEASE", 71, 97], ["neurodegenerative diseases", "DISEASE", 128, 154], ["neurodegenerative diseases", "DISEASE", 169, 195], ["PRDX1", "CHEMICAL", 213, 218], ["6 hydroxydopamine", "CHEMICAL", 236, 253], ["toxicity", "DISEASE", 254, 262], ["death", "DISEASE", 361, 366], ["6 hydroxydopamine", "CHEMICAL", 236, 253], ["PRDXs", "GENE_OR_GENE_PRODUCT", 31, 36], ["PRDXs", "GENE_OR_GENE_PRODUCT", 119, 124], ["PRDX1", "GENE_OR_GENE_PRODUCT", 213, 218], ["6 hydroxydopamine", "SIMPLE_CHEMICAL", 236, 253], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 273, 281], ["caspase-3", "GENE_OR_GENE_PRODUCT", 322, 331], ["MN9D cells", "CELL", 335, 345], ["PRDX1", "GENE_OR_GENE_PRODUCT", 431, 436], ["PRDXs", "PROTEIN", 31, 36], ["PRDXs", "PROTEIN", 119, 124], ["PRDX1", "PROTEIN", 213, 218], ["p38 MAPK", "PROTEIN", 273, 281], ["caspase-3", "PROTEIN", 322, 331], ["MN9D cells", "CELL_LINE", 335, 345], ["PRDX1", "PROTEIN", 431, 436], ["PRDXs", "TREATMENT", 31, 36], ["the neurodegenerative diseases", "PROBLEM", 67, 97], ["neurodegenerative diseases", "PROBLEM", 128, 154], ["PRDXs", "PROBLEM", 159, 164], ["neurodegenerative diseases", "PROBLEM", 169, 195], ["PRDX1", "TREATMENT", 213, 218], ["6 hydroxydopamine toxicity", "PROBLEM", 236, 262], ["p38 MAPK activation", "TREATMENT", 273, 292], ["caspase", "TEST", 322, 329], ["apoptotic death signals", "PROBLEM", 351, 374], ["neurodegenerative", "OBSERVATION_MODIFIER", 71, 88], ["diseases", "OBSERVATION", 89, 97], ["neurodegenerative diseases", "OBSERVATION", 128, 154], ["neurodegenerative", "OBSERVATION_MODIFIER", 169, 186], ["diseases", "OBSERVATION", 187, 195]]], ["PRDX2 is involved in neurodegeneration through phosphorylation by cdk2, a serine/threonine kinase, and contributes to PD.Signaling pathway of PRDXs in neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesIn a recent study, Qu et al. showed that cyclin-dependent kinase 5 (cdk5) inhibits PRDX2 activity, leading to increased levels of ROS in PD models (Qu et al., 2007).", [["neurodegeneration", "DISEASE", 21, 38], ["PD", "DISEASE", 118, 120], ["neurodegenerative diseases", "DISEASE", 151, 177], ["neurodegenerative diseases", "DISEASE", 192, 218], ["ROS", "CHEMICAL", 348, 351], ["serine", "CHEMICAL", 74, 80], ["threonine", "CHEMICAL", 81, 90], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["cdk2", "GENE_OR_GENE_PRODUCT", 66, 70], ["serine", "AMINO_ACID", 74, 80], ["threonine", "AMINO_ACID", 81, 90], ["PRDXs", "GENE_OR_GENE_PRODUCT", 142, 147], ["cyclin-dependent kinase 5", "GENE_OR_GENE_PRODUCT", 259, 284], ["cdk5", "GENE_OR_GENE_PRODUCT", 286, 290], ["PRDX2", "GENE_OR_GENE_PRODUCT", 301, 306], ["ROS", "SIMPLE_CHEMICAL", 348, 351], ["PRDX2", "PROTEIN", 0, 5], ["cdk2", "PROTEIN", 66, 70], ["serine/threonine kinase", "PROTEIN", 74, 97], ["PRDXs", "PROTEIN", 142, 147], ["cyclin-dependent kinase 5", "PROTEIN", 259, 284], ["cdk5", "PROTEIN", 286, 290], ["PRDX2", "PROTEIN", 301, 306], ["neurodegeneration", "PROBLEM", 21, 38], ["a serine/threonine kinase", "TREATMENT", 72, 97], ["PD", "PROBLEM", 118, 120], ["neurodegenerative diseases", "PROBLEM", 151, 177], ["PRDXs", "PROBLEM", 182, 187], ["neurodegenerative diseases", "PROBLEM", 192, 218], ["a recent study", "TEST", 221, 235], ["cyclin-dependent kinase", "TEST", 259, 282], ["PRDX2 activity", "PROBLEM", 301, 315], ["increased levels of ROS in PD models", "PROBLEM", 328, 364], ["neurodegenerative diseases", "OBSERVATION", 151, 177], ["neurodegenerative", "OBSERVATION_MODIFIER", 192, 209], ["diseases", "OBSERVATION", 210, 218], ["increased", "OBSERVATION_MODIFIER", 328, 337]]], ["They also demonstrated that PRDX2 is a bona fide substrate for the cdk5-p35 complex, which phosphorylated PRDX2 at the threonine residue at position 89.", [["threonine", "CHEMICAL", 119, 128], ["threonine", "CHEMICAL", 119, 128], ["PRDX2", "GENE_OR_GENE_PRODUCT", 28, 33], ["cdk5", "GENE_OR_GENE_PRODUCT", 67, 71], ["p35", "GENE_OR_GENE_PRODUCT", 72, 75], ["PRDX2", "GENE_OR_GENE_PRODUCT", 106, 111], ["threonine residue", "AMINO_ACID", 119, 136], ["position 89", "AMINO_ACID", 140, 151], ["PRDX2", "PROTEIN", 28, 33], ["cdk5", "PROTEIN", 67, 71], ["p35 complex", "PROTEIN", 72, 83], ["PRDX2", "PROTEIN", 106, 111], ["phosphorylated PRDX2", "TREATMENT", 91, 111]]], ["Cyclin-dependent kinase 5, a serine/threonine kinase, contributes to neurodegeneration in PD.", [["neurodegeneration", "DISEASE", 69, 86], ["PD", "DISEASE", 90, 92], ["serine", "CHEMICAL", 29, 35], ["threonine", "CHEMICAL", 36, 45], ["Cyclin-dependent kinase 5", "GENE_OR_GENE_PRODUCT", 0, 25], ["serine", "AMINO_ACID", 29, 35], ["threonine", "AMINO_ACID", 36, 45], ["Cyclin-dependent kinase 5", "PROTEIN", 0, 25], ["serine/threonine kinase", "PROTEIN", 29, 52], ["Cyclin-dependent kinase", "TREATMENT", 0, 23], ["a serine/threonine kinase", "TREATMENT", 27, 52], ["neurodegeneration", "PROBLEM", 69, 86], ["PD", "PROBLEM", 90, 92], ["neurodegeneration", "OBSERVATION", 69, 86]]], ["This kinase is shown to phosphorylate PRDX2, inactivating it, and thereby sensitizing neurons to the deleterious effects of parkinsonian toxins.", [["neurons", "ANATOMY", 86, 93], ["parkinsonian", "DISEASE", 124, 136], ["PRDX2", "GENE_OR_GENE_PRODUCT", 38, 43], ["neurons", "CELL", 86, 93], ["PRDX2", "PROTEIN", 38, 43], ["phosphorylate PRDX2", "TREATMENT", 24, 43], ["parkinsonian toxins", "PROBLEM", 124, 143], ["parkinsonian toxins", "OBSERVATION", 124, 143]]], ["Hu et al. explored the role of PRDX2 and showed it inhibited 6 hydroxydopamine-induced ASK1 activation by modulating the redox state of Trx1 preventing its dissociation from ASK1 (Hu et al., 2011).", [["6 hydroxydopamine", "CHEMICAL", 61, 78], ["6 hydroxydopamine", "CHEMICAL", 61, 78], ["PRDX2", "GENE_OR_GENE_PRODUCT", 31, 36], ["6 hydroxydopamine", "SIMPLE_CHEMICAL", 61, 78], ["ASK1", "GENE_OR_GENE_PRODUCT", 87, 91], ["Trx1", "GENE_OR_GENE_PRODUCT", 136, 140], ["ASK1", "GENE_OR_GENE_PRODUCT", 174, 178], ["PRDX2", "PROTEIN", 31, 36], ["ASK1", "PROTEIN", 87, 91], ["Trx1", "PROTEIN", 136, 140], ["ASK1", "PROTEIN", 174, 178], ["hydroxydopamine", "TREATMENT", 63, 78], ["ASK1 activation", "PROBLEM", 87, 102]]], ["They showed that Lentivirus-mediated PRDX2 overexpression conferred marked in vitro and in vivo neuroprotection against 6-OHDA toxicity in DA neurons, and preserved motor functions involving the dopamine system in mouse.", [["DA neurons", "ANATOMY", 139, 149], ["6-OHDA", "CHEMICAL", 120, 126], ["toxicity", "DISEASE", 127, 135], ["DA", "CHEMICAL", 139, 141], ["dopamine", "CHEMICAL", 195, 203], ["6-OHDA", "CHEMICAL", 120, 126], ["dopamine", "CHEMICAL", 195, 203], ["Lentivirus", "ORGANISM", 17, 27], ["PRDX2", "GENE_OR_GENE_PRODUCT", 37, 42], ["6-OHDA", "SIMPLE_CHEMICAL", 120, 126], ["DA neurons", "CELL", 139, 149], ["dopamine", "SIMPLE_CHEMICAL", 195, 203], ["mouse", "ORGANISM", 214, 219], ["PRDX2", "PROTEIN", 37, 42], ["DA neurons", "CELL_TYPE", 139, 149], ["mouse", "SPECIES", 214, 219], ["Lentivirus", "SPECIES", 17, 27], ["mouse", "SPECIES", 214, 219], ["Lentivirus-mediated PRDX2 overexpression", "TREATMENT", 17, 57], ["OHDA toxicity in DA neurons", "PROBLEM", 122, 149], ["the dopamine system", "TREATMENT", 191, 210], ["Lentivirus", "OBSERVATION", 17, 27], ["marked", "OBSERVATION_MODIFIER", 68, 74], ["motor functions", "OBSERVATION", 165, 180]]], ["In addition to its role as an antioxidant enzyme, PRDX2 exhibited anti-apoptotic effects in DA neurons via suppression of apoptosis signal-regulating kinase (ASK1)-dependent activation of the c-Jun N-terminal kinase/c-Jun and p38 pro-death pathways, which are also activated in DA neurons of postmortem PD brains.", [["DA neurons", "ANATOMY", 92, 102], ["DA neurons", "ANATOMY", 278, 288], ["brains", "ANATOMY", 306, 312], ["PRDX2", "CHEMICAL", 50, 55], ["DA", "CHEMICAL", 92, 94], ["DA", "CHEMICAL", 278, 280], ["N", "CHEMICAL", 198, 199], ["PRDX2", "GENE_OR_GENE_PRODUCT", 50, 55], ["DA neurons", "CELL", 92, 102], ["apoptosis signal-regulating kinase", "GENE_OR_GENE_PRODUCT", 122, 156], ["ASK1", "GENE_OR_GENE_PRODUCT", 158, 162], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 192, 215], ["c-Jun", "GENE_OR_GENE_PRODUCT", 216, 221], ["p38", "GENE_OR_GENE_PRODUCT", 226, 229], ["DA neurons", "CELL", 278, 288], ["brains", "ORGAN", 306, 312], ["PRDX2", "PROTEIN", 50, 55], ["DA neurons", "CELL_TYPE", 92, 102], ["apoptosis signal-regulating kinase", "PROTEIN", 122, 156], ["ASK1", "PROTEIN", 158, 162], ["Jun N-terminal kinase", "PROTEIN", 194, 215], ["Jun", "PROTEIN", 218, 221], ["p38 pro", "PROTEIN", 226, 233], ["DA neurons", "CELL_TYPE", 278, 288], ["an antioxidant enzyme", "TEST", 27, 48], ["anti-apoptotic effects in DA neurons", "PROBLEM", 66, 102], ["apoptosis signal", "TEST", 122, 138], ["dependent activation of the c-Jun N", "PROBLEM", 164, 199], ["terminal kinase", "TEST", 200, 215]]], ["PRDX2 inhibited 6-OHDA-induced ASK1 activation by modulating the redox status of the endogenous ASK1 inhibitor Trx.", [["PRDX2", "CHEMICAL", 0, 5], ["6-OHDA", "CHEMICAL", 16, 22], ["6-OHDA", "CHEMICAL", 16, 22], ["PRDX2", "SIMPLE_CHEMICAL", 0, 5], ["6-OHDA", "SIMPLE_CHEMICAL", 16, 22], ["ASK1", "GENE_OR_GENE_PRODUCT", 31, 35], ["ASK1", "GENE_OR_GENE_PRODUCT", 96, 100], ["Trx", "GENE_OR_GENE_PRODUCT", 111, 114], ["ASK1", "PROTEIN", 31, 35], ["ASK1", "PROTEIN", 96, 100], ["Trx", "PROTEIN", 111, 114], ["ASK1 activation", "PROBLEM", 31, 46], ["the endogenous ASK1 inhibitor Trx", "TREATMENT", 81, 114]]], ["PRDX2 overexpression maintained Trx in a reduced state by inhibiting the cysteine thiol-disulphide exchange, thereby preventing its dissociation from ASK1.Signaling pathway of PRDXs in neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesIn cells expressing the LRRK2 mutant gene that is responsible for up to 30\u201340% of PD cases in some ethnic populations, the phosphorylation of PRDX3 is increased but decreased peroxidase activity and increased death in neuronal cells (Angeles et al., 2011).Signaling pathway of PRDXs in neurodegenerative diseases ::: PRDXs and neurodegenerative diseasesKim et al suggested that apoptosis was inhibited after amyloid beta treatment in PC12 cells overexpressing wild-type PRDX6, but not in cells that overexpressed the C47S catalytic mutant.", [["cells", "ANATOMY", 255, 260], ["neuronal cells", "ANATOMY", 470, 484], ["PC12 cells", "ANATOMY", 686, 696], ["cells", "ANATOMY", 740, 745], ["thiol-disulphide", "CHEMICAL", 82, 98], ["neurodegenerative diseases", "DISEASE", 185, 211], ["neurodegenerative diseases", "DISEASE", 226, 252], ["PD", "DISEASE", 334, 336], ["death", "DISEASE", 461, 466], ["neurodegenerative diseases", "DISEASE", 538, 564], ["cysteine", "CHEMICAL", 73, 81], ["thiol", "CHEMICAL", 82, 87], ["disulphide", "CHEMICAL", 88, 98], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Trx", "GENE_OR_GENE_PRODUCT", 32, 35], ["cysteine", "AMINO_ACID", 73, 81], ["ASK1", "GENE_OR_GENE_PRODUCT", 150, 154], ["PRDXs", "GENE_OR_GENE_PRODUCT", 176, 181], ["cells", "CELL", 255, 260], ["LRRK2", "GENE_OR_GENE_PRODUCT", 276, 281], ["PRDX3", "GENE_OR_GENE_PRODUCT", 394, 399], ["peroxidase", "GENE_OR_GENE_PRODUCT", 427, 437], ["neuronal cells", "CELL", 470, 484], ["PRDXs", "GENE_OR_GENE_PRODUCT", 529, 534], ["amyloid beta", "GENE_OR_GENE_PRODUCT", 660, 672], ["PC12 cells", "CELL", 686, 696], ["PRDX6", "GENE_OR_GENE_PRODUCT", 722, 727], ["cells", "CELL", 740, 745], ["C47S", "GENE_OR_GENE_PRODUCT", 769, 773], ["PRDX2", "PROTEIN", 0, 5], ["Trx", "PROTEIN", 32, 35], ["ASK1", "PROTEIN", 150, 154], ["PRDXs", "PROTEIN", 176, 181], ["LRRK2 mutant gene", "DNA", 276, 293], ["PRDX3", "PROTEIN", 394, 399], ["peroxidase", "PROTEIN", 427, 437], ["neuronal cells", "CELL_TYPE", 470, 484], ["PRDXs", "PROTEIN", 529, 534], ["amyloid beta", "PROTEIN", 660, 672], ["PC12 cells", "CELL_LINE", 686, 696], ["PRDX6", "PROTEIN", 722, 727], ["C47S catalytic mutant", "PROTEIN", 769, 790], ["Trx", "PROBLEM", 32, 35], ["the cysteine thiol-disulphide exchange", "TREATMENT", 69, 107], ["its dissociation from ASK1", "PROBLEM", 128, 154], ["neurodegenerative diseases", "PROBLEM", 185, 211], ["PRDXs", "PROBLEM", 216, 221], ["neurodegenerative diseases", "PROBLEM", 226, 252], ["PD cases", "PROBLEM", 334, 342], ["some ethnic populations", "PROBLEM", 346, 369], ["the phosphorylation of PRDX3", "TREATMENT", 371, 399], ["decreased peroxidase activity", "PROBLEM", 417, 446], ["increased death in neuronal cells", "PROBLEM", 451, 484], ["Signaling pathway of PRDXs", "PROBLEM", 508, 534], ["neurodegenerative diseases", "PROBLEM", 538, 564], ["PRDXs", "PROBLEM", 569, 574], ["neurodegenerative diseasesKim et al", "PROBLEM", 579, 614], ["apoptosis", "PROBLEM", 630, 639], ["amyloid beta treatment", "TREATMENT", 660, 682], ["PC12 cells", "PROBLEM", 686, 696], ["type PRDX6", "PROBLEM", 717, 727], ["neurodegenerative diseases", "OBSERVATION", 185, 211], ["neurodegenerative", "OBSERVATION_MODIFIER", 226, 243], ["diseases", "OBSERVATION", 244, 252], ["increased", "OBSERVATION_MODIFIER", 403, 412], ["decreased", "OBSERVATION_MODIFIER", 417, 426], ["peroxidase activity", "OBSERVATION", 427, 446], ["increased", "OBSERVATION_MODIFIER", 451, 460], ["neuronal cells", "OBSERVATION", 470, 484], ["neurodegenerative diseases", "OBSERVATION", 538, 564]]], ["This indicates that the peroxidase activity of PRDX6 protects PC12 cells from amyloid-induced neurotoxicity (Kim et al., 2013a, b).", [["PC12 cells", "ANATOMY", 62, 72], ["PRDX6", "CHEMICAL", 47, 52], ["neurotoxicity", "DISEASE", 94, 107], ["peroxidase", "GENE_OR_GENE_PRODUCT", 24, 34], ["PRDX6", "GENE_OR_GENE_PRODUCT", 47, 52], ["PC12 cells", "CELL", 62, 72], ["amyloid", "SIMPLE_CHEMICAL", 78, 85], ["peroxidase", "PROTEIN", 24, 34], ["PRDX6", "PROTEIN", 47, 52], ["PC12 cells", "CELL_LINE", 62, 72], ["PC12 cells", "PROBLEM", 62, 72], ["amyloid-induced neurotoxicity", "PROBLEM", 78, 107], ["PC12 cells", "OBSERVATION", 62, 72]]], ["Our recent study also demonstrated that A\u03b21-42-induced memory impairment in PRDX6 transgenic mice was worse than C57BL/6 mice, and the expression of amyloid precursor protein cleavage, C99, \u03b2-site APP-cleaving enzyme 1, inducible nitric oxide synthase, and cyclooxygenase-2 was greatly increased (Yun et al., 2013).", [["A\u03b21-42", "CHEMICAL", 40, 46], ["memory impairment", "DISEASE", 55, 72], ["nitric oxide", "CHEMICAL", 230, 242], ["nitric oxide", "CHEMICAL", 230, 242], ["A\u03b21-42", "GENE_OR_GENE_PRODUCT", 40, 46], ["PRDX6", "GENE_OR_GENE_PRODUCT", 76, 81], ["mice", "ORGANISM", 93, 97], ["C57BL/6 mice", "ORGANISM", 113, 125], ["amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 149, 174], ["C99", "GENE_OR_GENE_PRODUCT", 185, 188], ["\u03b2-site APP-cleaving enzyme 1", "GENE_OR_GENE_PRODUCT", 190, 218], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 220, 251], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 257, 273], ["PRDX6", "PROTEIN", 76, 81], ["amyloid precursor protein", "PROTEIN", 149, 174], ["C99", "PROTEIN", 185, 188], ["\u03b2-site APP-cleaving enzyme 1", "PROTEIN", 190, 218], ["inducible nitric oxide synthase", "PROTEIN", 220, 251], ["cyclooxygenase", "PROTEIN", 257, 271], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 121, 125], ["Our recent study", "TEST", 0, 16], ["A\u03b21", "TEST", 40, 43], ["memory impairment", "PROBLEM", 55, 72], ["amyloid precursor protein cleavage", "PROBLEM", 149, 183], ["C99", "TEST", 185, 188], ["cleaving enzyme", "TREATMENT", 201, 216], ["inducible nitric oxide synthase", "TREATMENT", 220, 251], ["cyclooxygenase", "TEST", 257, 271], ["amyloid precursor", "OBSERVATION", 149, 166], ["protein cleavage", "OBSERVATION", 167, 183], ["nitric oxide synthase", "OBSERVATION", 230, 251], ["increased", "OBSERVATION_MODIFIER", 286, 295]]], ["In addition, the astrocytes and microglia cells of A\u03b2-infused PRDX6 transgenic mice were more activated, and A\u03b2 also significantly increased lipid peroxidation and protein carbonyl levels, but decreased glutathione levels.", [["astrocytes", "ANATOMY", 17, 27], ["microglia cells", "ANATOMY", 32, 47], ["A\u03b2", "CHEMICAL", 51, 53], ["A\u03b2", "CHEMICAL", 109, 111], ["glutathione", "CHEMICAL", 203, 214], ["carbonyl", "CHEMICAL", 172, 180], ["glutathione", "CHEMICAL", 203, 214], ["astrocytes", "CELL", 17, 27], ["microglia cells", "CELL", 32, 47], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 51, 53], ["PRDX6", "GENE_OR_GENE_PRODUCT", 62, 67], ["mice", "ORGANISM", 79, 83], ["A\u03b2", "SIMPLE_CHEMICAL", 109, 111], ["lipid", "SIMPLE_CHEMICAL", 141, 146], ["carbonyl", "SIMPLE_CHEMICAL", 172, 180], ["glutathione", "SIMPLE_CHEMICAL", 203, 214], ["astrocytes", "CELL_TYPE", 17, 27], ["microglia cells", "CELL_TYPE", 32, 47], ["PRDX6", "PROTEIN", 62, 67], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 79, 83], ["the astrocytes", "TEST", 13, 27], ["A\u03b2", "TEST", 51, 53], ["infused PRDX6 transgenic mice", "TREATMENT", 54, 83], ["significantly increased lipid peroxidation", "PROBLEM", 117, 159], ["protein carbonyl levels", "TEST", 164, 187], ["decreased glutathione levels", "PROBLEM", 193, 221], ["astrocytes", "ANATOMY", 17, 27], ["microglia cells", "OBSERVATION", 32, 47], ["significantly", "OBSERVATION_MODIFIER", 117, 130], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["lipid peroxidation", "OBSERVATION", 141, 159], ["carbonyl levels", "OBSERVATION", 172, 187], ["decreased", "OBSERVATION_MODIFIER", 193, 202], ["glutathione levels", "OBSERVATION", 203, 221]]], ["Furthermore, we found that translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) to the nucleus was increased in A\u03b2-infused PRDX6 transgenic mice.", [["nucleus", "ANATOMY", 102, 109], ["A\u03b2", "CHEMICAL", 127, 129], ["nuclear factor erythroid 2-related factor 2", "GENE_OR_GENE_PRODUCT", 44, 87], ["Nrf2", "GENE_OR_GENE_PRODUCT", 89, 93], ["nucleus", "CELLULAR_COMPONENT", 102, 109], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 127, 129], ["PRDX6", "GENE_OR_GENE_PRODUCT", 138, 143], ["mice", "ORGANISM", 155, 159], ["nuclear factor erythroid 2-related factor 2", "PROTEIN", 44, 87], ["Nrf2", "PROTEIN", 89, 93], ["A\u03b2", "PROTEIN", 127, 129], ["PRDX6", "PROTEIN", 138, 143], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 155, 159], ["nuclear factor erythroid", "TEST", 44, 68], ["nucleus", "ANATOMY", 102, 109], ["increased", "OBSERVATION_MODIFIER", 114, 123]]], ["These results suggest that the overexpression of PRDX6 could accelerate the development of AD through increased amyloidogenesis through independent PLA2 activation and Nrf2 transcription.", [["PRDX6", "CHEMICAL", 49, 54], ["AD", "DISEASE", 91, 93], ["PRDX6", "GENE_OR_GENE_PRODUCT", 49, 54], ["PLA2", "GENE_OR_GENE_PRODUCT", 148, 152], ["Nrf2", "GENE_OR_GENE_PRODUCT", 168, 172], ["PRDX6", "PROTEIN", 49, 54], ["PLA2", "PROTEIN", 148, 152], ["Nrf2", "PROTEIN", 168, 172], ["the overexpression of PRDX6", "PROBLEM", 27, 54], ["increased amyloidogenesis", "PROBLEM", 102, 127], ["independent PLA2 activation", "TREATMENT", 136, 163], ["Nrf2 transcription", "TREATMENT", 168, 186]]], ["We also recently investigated the effects of PRDX6 on MPTP-induced dopaminergic neurodegeneration using PRDX6 Tg mice (Yun et al., 2015a, Yun et al., 2015b, Yun et al., 2015c).", [["PRDX6", "CHEMICAL", 45, 50], ["MPTP", "CHEMICAL", 54, 58], ["neurodegeneration", "DISEASE", 80, 97], ["MPTP", "CHEMICAL", 54, 58], ["PRDX6", "SIMPLE_CHEMICAL", 45, 50], ["MPTP", "SIMPLE_CHEMICAL", 54, 58], ["dopaminergic", "CELL", 67, 79], ["PRDX6", "GENE_OR_GENE_PRODUCT", 104, 109], ["mice", "ORGANISM", 113, 117], ["PRDX6", "PROTEIN", 104, 109], ["mice", "SPECIES", 113, 117], ["PRDX6", "PROBLEM", 45, 50], ["MPTP", "TREATMENT", 54, 58], ["dopaminergic neurodegeneration", "PROBLEM", 67, 97], ["dopaminergic neurodegeneration", "OBSERVATION", 67, 97]]], ["PRDX6 Tg mice had a much higher loss of dopaminergic neurons by MPTP administration compared to non-Tg mice.", [["dopaminergic neurons", "ANATOMY", 40, 60], ["loss of dopaminergic neurons", "DISEASE", 32, 60], ["MPTP", "CHEMICAL", 64, 68], ["MPTP", "CHEMICAL", 64, 68], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 9, 13], ["dopaminergic neurons", "CELL", 40, 60], ["MPTP", "SIMPLE_CHEMICAL", 64, 68], ["non-Tg mice", "ORGANISM", 96, 107], ["PRDX6", "PROTEIN", 0, 5], ["dopaminergic neurons", "CELL_TYPE", 40, 60], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 103, 107], ["a much higher loss of dopaminergic neurons", "PROBLEM", 18, 60], ["MPTP administration", "TREATMENT", 64, 83]]], ["There was also a much higher behavioral impairment and astrocyte activation in PRDX6 Tg mice.", [["astrocyte", "ANATOMY", 55, 64], ["behavioral impairment", "DISEASE", 29, 50], ["astrocyte", "CELL", 55, 64], ["PRDX6 Tg mice", "ORGANISM", 79, 92], ["mice", "SPECIES", 88, 92], ["a much higher behavioral impairment", "PROBLEM", 15, 50], ["much", "OBSERVATION_MODIFIER", 17, 21], ["higher", "OBSERVATION_MODIFIER", 22, 28], ["behavioral", "OBSERVATION_MODIFIER", 29, 39], ["impairment", "OBSERVATION", 40, 50]]], ["MPTP-induced GPx activity was not different between PRDX6 Tg mice and non-Tg mice, which is accompanied by hyperoxidation of PRDX6.", [["MPTP", "CHEMICAL", 0, 4], ["MPTP", "CHEMICAL", 0, 4], ["MPTP", "SIMPLE_CHEMICAL", 0, 4], ["GPx", "GENE_OR_GENE_PRODUCT", 13, 16], ["PRDX6 Tg mice", "ORGANISM", 52, 65], ["non-Tg mice", "ORGANISM", 70, 81], ["PRDX6", "GENE_OR_GENE_PRODUCT", 125, 130], ["GPx", "PROTEIN", 13, 16], ["PRDX6", "PROTEIN", 52, 57], ["PRDX6", "PROTEIN", 125, 130], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["MPTP", "TEST", 0, 4], ["GPx activity", "PROBLEM", 13, 25], ["PRDX6", "PROBLEM", 125, 130]]], ["Intriguingly, the expression pattern of PRDX6 showed similar distribution and co-localization with astrocytes, but not neurons in the mouse and human brain.", [["astrocytes", "ANATOMY", 99, 109], ["neurons", "ANATOMY", 119, 126], ["brain", "ANATOMY", 150, 155], ["PRDX6", "GENE_OR_GENE_PRODUCT", 40, 45], ["astrocytes", "CELL", 99, 109], ["neurons", "CELL", 119, 126], ["mouse", "ORGANISM", 134, 139], ["human", "ORGANISM", 144, 149], ["brain", "ORGAN", 150, 155], ["PRDX6", "PROTEIN", 40, 45], ["astrocytes", "CELL_TYPE", 99, 109], ["mouse", "SPECIES", 134, 139], ["human", "SPECIES", 144, 149], ["mouse", "SPECIES", 134, 139], ["human", "SPECIES", 144, 149], ["PRDX6", "TEST", 40, 45], ["astrocytes", "PROBLEM", 99, 109], ["human brain", "ANATOMY", 144, 155]]], ["Furthermore, we demonstrated that iPLA2 activity of PRDX6 induced astrocytic activation followed by increased proinflammatory cytokines (TNF- \u03b1 and IL1-\u03b2), 4-HNE, and PRDX6 hyperoxidation in primary cultured astrocytes.", [["astrocytic", "ANATOMY", 66, 76], ["astrocytes", "ANATOMY", 208, 218], ["PRDX6", "CHEMICAL", 52, 57], ["4-HNE", "CHEMICAL", 156, 161], ["4-HNE", "CHEMICAL", 156, 161], ["iPLA2", "GENE_OR_GENE_PRODUCT", 34, 39], ["PRDX6", "GENE_OR_GENE_PRODUCT", 52, 57], ["TNF- \u03b1", "GENE_OR_GENE_PRODUCT", 137, 143], ["IL1-\u03b2", "GENE_OR_GENE_PRODUCT", 148, 153], ["4-HNE", "SIMPLE_CHEMICAL", 156, 161], ["PRDX6", "GENE_OR_GENE_PRODUCT", 167, 172], ["astrocytes", "CELL", 208, 218], ["iPLA2", "PROTEIN", 34, 39], ["PRDX6", "PROTEIN", 52, 57], ["proinflammatory cytokines", "PROTEIN", 110, 135], ["TNF", "PROTEIN", 137, 140], ["IL1", "PROTEIN", 148, 151], ["\u03b2", "PROTEIN", 152, 153], ["PRDX6", "PROTEIN", 167, 172], ["primary cultured astrocytes", "CELL_TYPE", 191, 218], ["PRDX6 induced astrocytic activation", "PROBLEM", 52, 87], ["increased proinflammatory cytokines", "PROBLEM", 100, 135], ["TNF", "TEST", 137, 140], ["IL1", "TEST", 148, 151], ["PRDX6 hyperoxidation in primary cultured astrocytes", "PROBLEM", 167, 218], ["astrocytic activation", "OBSERVATION", 66, 87], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["proinflammatory cytokines", "OBSERVATION", 110, 135]]], ["A recent study suggested the translational potential of blocking TLR4/PRDX6 signaling for the treatment of ischemic stroke (Kuang et al., 2014).", [["ischemic stroke", "DISEASE", 107, 122], ["TLR4", "GENE_OR_GENE_PRODUCT", 65, 69], ["PRDX6", "GENE_OR_GENE_PRODUCT", 70, 75], ["TLR4", "PROTEIN", 65, 69], ["PRDX6", "PROTEIN", 70, 75], ["A recent study", "TEST", 0, 14], ["blocking TLR4/PRDX6 signaling", "TREATMENT", 56, 85], ["ischemic stroke", "PROBLEM", 107, 122], ["ischemic", "OBSERVATION_MODIFIER", 107, 115], ["stroke", "OBSERVATION", 116, 122]]], ["They showed that ligustilide (LIG) exerted antineuroinflammatory and neuroprotective effects against an ischemic insult, and showed that TLR4/PRDX6 pathway is involved in the protective effect of LIG against postischemic neuroinflammation and brain injury induced by transient middle cerebral artery occlusion (MCAO) in rats.", [["brain", "ANATOMY", 243, 248], ["middle cerebral artery", "ANATOMY", 277, 299], ["ligustilide", "CHEMICAL", 17, 28], ["LIG", "CHEMICAL", 30, 33], ["ischemic insult", "DISEASE", 104, 119], ["LIG", "CHEMICAL", 196, 199], ["postischemic neuroinflammation", "DISEASE", 208, 238], ["brain injury", "DISEASE", 243, 255], ["middle cerebral artery occlusion", "DISEASE", 277, 309], ["ligustilide", "CHEMICAL", 17, 28], ["LIG", "CHEMICAL", 30, 33], ["ligustilide", "SIMPLE_CHEMICAL", 17, 28], ["LIG", "SIMPLE_CHEMICAL", 30, 33], ["TLR4", "GENE_OR_GENE_PRODUCT", 137, 141], ["PRDX6", "GENE_OR_GENE_PRODUCT", 142, 147], ["LIG", "SIMPLE_CHEMICAL", 196, 199], ["brain", "ORGAN", 243, 248], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 284, 299], ["rats", "ORGANISM", 320, 324], ["TLR4", "PROTEIN", 137, 141], ["PRDX6", "PROTEIN", 142, 147], ["rats", "SPECIES", 320, 324], ["ligustilide (LIG)", "TREATMENT", 17, 34], ["an ischemic insult", "PROBLEM", 101, 119], ["TLR4/PRDX6 pathway", "TREATMENT", 137, 155], ["LIG", "TREATMENT", 196, 199], ["postischemic neuroinflammation", "PROBLEM", 208, 238], ["brain injury", "PROBLEM", 243, 255], ["transient middle cerebral artery occlusion", "PROBLEM", 267, 309], ["ischemic", "OBSERVATION", 104, 112], ["neuroinflammation", "OBSERVATION", 221, 238], ["brain", "ANATOMY", 243, 248], ["injury", "OBSERVATION", 249, 255], ["transient", "OBSERVATION_MODIFIER", 267, 276], ["middle cerebral artery", "ANATOMY", 277, 299], ["occlusion", "OBSERVATION", 300, 309], ["MCAO", "OBSERVATION_MODIFIER", 311, 315]]], ["Also, LIG-induced neuroprotection was accompanied by the improvement of neuropathological alterations, including neuron loss, astrocyte and microglia/macrophage activation, neutrophil and T-lymphocyte invasion, and regulation of inflammatory mediator expression.", [["neuron", "ANATOMY", 113, 119], ["astrocyte", "ANATOMY", 126, 135], ["microglia", "ANATOMY", 140, 149], ["macrophage", "ANATOMY", 150, 160], ["neutrophil", "ANATOMY", 173, 183], ["T-lymphocyte", "ANATOMY", 188, 200], ["LIG", "CHEMICAL", 6, 9], ["LIG", "CHEMICAL", 6, 9], ["LIG", "SIMPLE_CHEMICAL", 6, 9], ["neuron", "CELL", 113, 119], ["astrocyte", "CELL", 126, 135], ["microglia", "CELL", 140, 149], ["macrophage", "CELL", 150, 160], ["neutrophil", "CELL", 173, 183], ["T-lymphocyte", "CELL", 188, 200], ["LIG-induced neuroprotection", "PROBLEM", 6, 33], ["neuropathological alterations", "PROBLEM", 72, 101], ["neuron loss", "PROBLEM", 113, 124], ["astrocyte and microglia/macrophage activation", "PROBLEM", 126, 171], ["neutrophil", "TEST", 173, 183], ["T-lymphocyte invasion", "PROBLEM", 188, 209], ["inflammatory mediator expression", "PROBLEM", 229, 261], ["LIG", "OBSERVATION_MODIFIER", 6, 9], ["-induced", "OBSERVATION_MODIFIER", 9, 17], ["neuroprotection", "OBSERVATION", 18, 33], ["improvement", "OBSERVATION_MODIFIER", 57, 68], ["neuropathological alterations", "OBSERVATION", 72, 101], ["neuron loss", "OBSERVATION", 113, 124], ["macrophage activation", "OBSERVATION", 150, 171], ["lymphocyte invasion", "OBSERVATION", 190, 209], ["inflammatory", "OBSERVATION_MODIFIER", 229, 241], ["mediator expression", "OBSERVATION", 242, 261]]], ["Moreover, LIG significantly inhibited the expression and extracellular release of PRDX6 and activation of TLR4 signaling, reflected by decreased TLR4 expression, extracellular signal-regulated kinase 1/2 phosphorylation, and transcriptional activity of NF-\u03baB and signal transducer and activator of transcription 3 in the ischemic brain.Dual function of PRDX1 in inflammatory diseases ::: Roles of PRDXs in the development of inflammatory disease ::: PRDXs and inflammatory diseaseThe beneficial role of PRDX1 in inflammatory diseases is well established.", [["extracellular", "ANATOMY", 57, 70], ["brain", "ANATOMY", 330, 335], ["LIG", "CHEMICAL", 10, 13], ["inflammatory diseases", "DISEASE", 362, 383], ["inflammatory disease", "DISEASE", 425, 445], ["inflammatory disease", "DISEASE", 460, 480], ["PRDX1", "CHEMICAL", 503, 508], ["inflammatory diseases", "DISEASE", 512, 533], ["LIG", "CHEMICAL", 10, 13], ["LIG", "SIMPLE_CHEMICAL", 10, 13], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 70], ["PRDX6", "GENE_OR_GENE_PRODUCT", 82, 87], ["TLR4", "GENE_OR_GENE_PRODUCT", 106, 110], ["TLR4", "GENE_OR_GENE_PRODUCT", 145, 149], ["extracellular signal-regulated kinase 1/2", "GENE_OR_GENE_PRODUCT", 162, 203], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 253, 258], ["signal transducer and activator of transcription 3", "GENE_OR_GENE_PRODUCT", 263, 313], ["brain", "ORGAN", 330, 335], ["PRDX1", "GENE_OR_GENE_PRODUCT", 353, 358], ["PRDXs", "GENE_OR_GENE_PRODUCT", 397, 402], ["PRDXs", "GENE_OR_GENE_PRODUCT", 450, 455], ["PRDX1", "GENE_OR_GENE_PRODUCT", 503, 508], ["PRDX6", "PROTEIN", 82, 87], ["TLR4", "PROTEIN", 106, 110], ["TLR4", "PROTEIN", 145, 149], ["extracellular signal-regulated kinase 1/2", "PROTEIN", 162, 203], ["NF-\u03baB", "PROTEIN", 253, 258], ["signal transducer and activator of transcription 3", "PROTEIN", 263, 313], ["PRDX1", "PROTEIN", 353, 358], ["PRDXs", "PROTEIN", 397, 402], ["PRDX1", "PROTEIN", 503, 508], ["extracellular release of PRDX6", "TREATMENT", 57, 87], ["TLR4 signaling", "PROBLEM", 106, 120], ["decreased TLR4 expression", "PROBLEM", 135, 160], ["extracellular signal", "TEST", 162, 182], ["phosphorylation", "TEST", 204, 219], ["NF", "TEST", 253, 255], ["the ischemic brain", "PROBLEM", 317, 335], ["inflammatory diseases", "PROBLEM", 362, 383], ["inflammatory disease", "PROBLEM", 425, 445], ["PRDXs", "PROBLEM", 450, 455], ["inflammatory disease", "PROBLEM", 460, 480], ["inflammatory diseases", "PROBLEM", 512, 533], ["TLR4 signaling", "OBSERVATION", 106, 120], ["decreased", "OBSERVATION_MODIFIER", 135, 144], ["TLR4 expression", "OBSERVATION", 145, 160], ["ischemic", "OBSERVATION", 321, 329], ["brain", "ANATOMY", 330, 335], ["inflammatory", "OBSERVATION_MODIFIER", 362, 374], ["inflammatory", "OBSERVATION_MODIFIER", 425, 437], ["inflammatory disease", "OBSERVATION", 460, 480], ["inflammatory", "OBSERVATION", 512, 524]]], ["In addition, PRDX1 deficiency enhanced the regulated secretion pathway in endothelial cells by the promotion of excessive release of several proinflammatory components.", [["endothelial cells", "ANATOMY", 74, 91], ["PRDX1", "GENE_OR_GENE_PRODUCT", 13, 18], ["endothelial cells", "CELL", 74, 91], ["PRDX1", "PROTEIN", 13, 18], ["endothelial cells", "CELL_TYPE", 74, 91], ["proinflammatory components", "PROTEIN", 141, 167], ["PRDX1 deficiency", "PROBLEM", 13, 29], ["several proinflammatory components", "PROBLEM", 133, 167], ["PRDX1 deficiency", "OBSERVATION", 13, 29], ["secretion pathway", "OBSERVATION", 53, 70], ["endothelial cells", "OBSERVATION", 74, 91], ["excessive", "OBSERVATION_MODIFIER", 112, 121], ["release", "OBSERVATION_MODIFIER", 122, 129], ["several", "OBSERVATION_MODIFIER", 133, 140], ["proinflammatory", "OBSERVATION_MODIFIER", 141, 156], ["components", "OBSERVATION_MODIFIER", 157, 167]]], ["Kisucka et al examined the role of PRDX1 in the apolipoprotein E-deficient (apoE-/-) murine spontaneous model of atherosclerosis (Kisucka et al., 2008).", [["atherosclerosis", "DISEASE", 113, 128], ["PRDX1", "GENE_OR_GENE_PRODUCT", 35, 40], ["apolipoprotein E", "GENE_OR_GENE_PRODUCT", 48, 64], ["apoE", "GENE_OR_GENE_PRODUCT", 76, 80], ["PRDX1", "PROTEIN", 35, 40], ["apolipoprotein E", "PROTEIN", 48, 64], ["apoE", "PROTEIN", 76, 80], ["murine", "SPECIES", 85, 91], ["PRDX1", "TEST", 35, 40], ["apoE", "TEST", 76, 80], ["atherosclerosis", "PROBLEM", 113, 128], ["atherosclerosis", "OBSERVATION", 113, 128]]], ["They showed that PRDX1-/-/apoE-/- mice fed normal chow developed larger, more macrophage-rich aortic sinus lesions than PRDX1+/+/apoE-/- mice, despite similar amounts and size distributions of cholesterol in their plasma lipoproteins, suggesting that PRDX1 protects against excessive endothelial activation and atherosclerosis.", [["macrophage", "ANATOMY", 78, 88], ["aortic sinus lesions", "ANATOMY", 94, 114], ["plasma", "ANATOMY", 214, 220], ["endothelial", "ANATOMY", 284, 295], ["cholesterol", "CHEMICAL", 193, 204], ["PRDX1", "CHEMICAL", 251, 256], ["atherosclerosis", "DISEASE", 311, 326], ["cholesterol", "CHEMICAL", 193, 204], ["PRDX1", "GENE_OR_GENE_PRODUCT", 17, 22], ["apoE", "GENE_OR_GENE_PRODUCT", 26, 30], ["macrophage", "CELL", 78, 88], ["aortic sinus lesions", "PATHOLOGICAL_FORMATION", 94, 114], ["PRDX1", "GENE_OR_GENE_PRODUCT", 120, 125], ["apoE", "GENE_OR_GENE_PRODUCT", 129, 133], ["cholesterol", "SIMPLE_CHEMICAL", 193, 204], ["plasma", "ORGANISM_SUBSTANCE", 214, 220], ["PRDX1", "GENE_OR_GENE_PRODUCT", 251, 256], ["endothelial", "CELL", 284, 295], ["PRDX1", "PROTEIN", 17, 22], ["apoE", "PROTEIN", 26, 30], ["PRDX1", "PROTEIN", 120, 125], ["apoE", "PROTEIN", 129, 133], ["plasma lipoproteins", "PROTEIN", 214, 233], ["PRDX1", "PROTEIN", 251, 256], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 34, 38], ["PRDX1", "TEST", 17, 22], ["apoE", "TEST", 26, 30], ["aortic sinus lesions", "PROBLEM", 94, 114], ["PRDX1", "TEST", 120, 125], ["PRDX1", "PROBLEM", 251, 256], ["excessive endothelial activation", "PROBLEM", 274, 306], ["atherosclerosis", "PROBLEM", 311, 326], ["larger", "OBSERVATION_MODIFIER", 65, 71], ["more macrophage", "OBSERVATION_MODIFIER", 73, 88], ["aortic sinus", "ANATOMY", 94, 106], ["lesions", "OBSERVATION", 107, 114], ["size", "OBSERVATION_MODIFIER", 171, 175], ["endothelial activation", "OBSERVATION", 284, 306], ["atherosclerosis", "OBSERVATION", 311, 326]]], ["The role of PRDX1 as non-beneficial in inflammatory diseases is also established.", [["inflammatory diseases", "DISEASE", 39, 60], ["PRDX1", "GENE_OR_GENE_PRODUCT", 12, 17], ["PRDX1", "PROTEIN", 12, 17], ["inflammatory diseases", "PROBLEM", 39, 60], ["inflammatory diseases", "OBSERVATION", 39, 60]]], ["PRDX1 is induced by exposing macrophages to oxidized LDL5 and by laminar shear stress in endothelial cells (Conway and Kinter, 2006, Mowbray et al., 2008).", [["macrophages", "ANATOMY", 29, 40], ["endothelial cells", "ANATOMY", 89, 106], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophages", "CELL", 29, 40], ["LDL5", "SIMPLE_CHEMICAL", 53, 57], ["endothelial cells", "CELL", 89, 106], ["PRDX1", "PROTEIN", 0, 5], ["macrophages", "CELL_TYPE", 29, 40], ["endothelial cells", "CELL_TYPE", 89, 106], ["PRDX1", "PROBLEM", 0, 5], ["laminar shear stress in endothelial cells", "PROBLEM", 65, 106], ["macrophages", "OBSERVATION", 29, 40], ["laminar shear", "OBSERVATION", 65, 78], ["endothelial cells", "ANATOMY", 89, 106]]], ["Also, transcription factor Nrf2, one of the erythroid transcription factor NFE2 subunit factors responsible for the induction of defense proteins including PRDX1, is activated in oxidized LDL-treated macrophage cells, thus these data suggested that PRDX1 is involved in macrophage activation (Kisucka et al., 2008).", [["macrophage cells", "ANATOMY", 200, 216], ["macrophage", "ANATOMY", 270, 280], ["Nrf2", "GENE_OR_GENE_PRODUCT", 27, 31], ["erythroid", "CELL", 44, 53], ["NFE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["PRDX1", "GENE_OR_GENE_PRODUCT", 156, 161], ["LDL", "SIMPLE_CHEMICAL", 188, 191], ["macrophage cells", "CELL", 200, 216], ["PRDX1", "GENE_OR_GENE_PRODUCT", 249, 254], ["macrophage", "CELL", 270, 280], ["transcription factor", "PROTEIN", 6, 26], ["Nrf2", "PROTEIN", 27, 31], ["erythroid transcription factor NFE2 subunit factors", "PROTEIN", 44, 95], ["defense proteins", "PROTEIN", 129, 145], ["PRDX1", "PROTEIN", 156, 161], ["oxidized LDL-treated macrophage cells", "CELL_LINE", 179, 216], ["PRDX1", "PROTEIN", 249, 254], ["the erythroid transcription", "TREATMENT", 40, 67], ["defense proteins", "PROBLEM", 129, 145], ["PRDX1", "TEST", 156, 161], ["macrophage cells", "PROBLEM", 200, 216], ["these data", "TEST", 223, 233], ["PRDX1", "PROBLEM", 249, 254], ["macrophage cells", "OBSERVATION", 200, 216]]], ["In the RA patient tissue, the PRDX1 is overexpressed by more than 3 fold compared with normal tissues (Li et al., 2013).", [["RA patient tissue", "ANATOMY", 7, 24], ["tissues", "ANATOMY", 94, 101], ["patient", "ORGANISM", 10, 17], ["tissue", "TISSUE", 18, 24], ["PRDX1", "GENE_OR_GENE_PRODUCT", 30, 35], ["normal tissues", "TISSUE", 87, 101], ["PRDX1", "PROTEIN", 30, 35], ["patient", "SPECIES", 10, 17], ["the PRDX1", "TEST", 26, 35], ["RA", "ANATOMY", 7, 9]]], ["Demasi et al suggested that PRDX1 induction could be considered a crucial part of the cellular adaptive response to the B-cell differentiation process to cope with the additional H2O2 associated with massive disulphide bond formation during immunoglobulin folding in the ER of plasma cells (Demasi et al., 2007).", [["cellular", "ANATOMY", 86, 94], ["B-cell", "ANATOMY", 120, 126], ["ER", "ANATOMY", 271, 273], ["plasma cells", "ANATOMY", 277, 289], ["H2O2", "CHEMICAL", 179, 183], ["H2O2", "CHEMICAL", 179, 183], ["disulphide", "CHEMICAL", 208, 218], ["PRDX1", "GENE_OR_GENE_PRODUCT", 28, 33], ["cellular", "CELL", 86, 94], ["B-cell", "CELL", 120, 126], ["H2O2", "SIMPLE_CHEMICAL", 179, 183], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 241, 255], ["ER", "GENE_OR_GENE_PRODUCT", 271, 273], ["plasma cells", "CELL", 277, 289], ["PRDX1", "PROTEIN", 28, 33], ["immunoglobulin", "PROTEIN", 241, 255], ["ER", "PROTEIN", 271, 273], ["plasma cells", "CELL_TYPE", 277, 289], ["PRDX1 induction", "TREATMENT", 28, 43], ["the B-cell differentiation process", "TREATMENT", 116, 150], ["the additional H2O2", "TREATMENT", 164, 183], ["massive disulphide bond formation", "PROBLEM", 200, 233], ["immunoglobulin folding", "PROBLEM", 241, 263], ["massive", "OBSERVATION_MODIFIER", 200, 207], ["disulphide bond formation", "OBSERVATION", 208, 233], ["plasma cells", "ANATOMY", 277, 289]]], ["These data indicate that PRDX1 inhibits inflammatory disease by protection of excessive endothelial activation and atherosclerosis, but induces inflammatory disease via activation of Nrf2.Dual function of PRDX2 in inflammatory diseases ::: Roles of PRDXs in the development of inflammatory disease ::: PRDXs and inflammatory diseaseThe beneficial role of PRDX2 in inflammatory diseases is well established.", [["endothelial", "ANATOMY", 88, 99], ["PRDX1", "CHEMICAL", 25, 30], ["inflammatory disease", "DISEASE", 40, 60], ["atherosclerosis", "DISEASE", 115, 130], ["inflammatory diseases", "DISEASE", 214, 235], ["inflammatory disease", "DISEASE", 277, 297], ["inflammatory disease", "DISEASE", 312, 332], ["PRDX2", "CHEMICAL", 355, 360], ["inflammatory diseases", "DISEASE", 364, 385], ["PRDX1", "GENE_OR_GENE_PRODUCT", 25, 30], ["endothelial", "CELL", 88, 99], ["Nrf2", "GENE_OR_GENE_PRODUCT", 183, 187], ["PRDX2", "GENE_OR_GENE_PRODUCT", 205, 210], ["PRDXs", "GENE_OR_GENE_PRODUCT", 249, 254], ["PRDXs", "GENE_OR_GENE_PRODUCT", 302, 307], ["PRDX2", "GENE_OR_GENE_PRODUCT", 355, 360], ["PRDX1", "PROTEIN", 25, 30], ["Nrf2", "PROTEIN", 183, 187], ["PRDX2", "PROTEIN", 205, 210], ["PRDXs", "PROTEIN", 249, 254], ["PRDX2", "PROTEIN", 355, 360], ["These data", "TEST", 0, 10], ["PRDX1", "PROBLEM", 25, 30], ["inflammatory disease", "PROBLEM", 40, 60], ["excessive endothelial activation", "PROBLEM", 78, 110], ["atherosclerosis", "PROBLEM", 115, 130], ["inflammatory disease", "PROBLEM", 144, 164], ["activation of Nrf2", "TREATMENT", 169, 187], ["inflammatory diseases", "PROBLEM", 214, 235], ["inflammatory disease", "PROBLEM", 277, 297], ["PRDXs", "PROBLEM", 302, 307], ["inflammatory disease", "PROBLEM", 312, 332], ["PRDX2", "TREATMENT", 355, 360], ["inflammatory diseases", "PROBLEM", 364, 385], ["inflammatory", "OBSERVATION_MODIFIER", 40, 52], ["excessive endothelial activation", "OBSERVATION", 78, 110], ["atherosclerosis", "OBSERVATION", 115, 130], ["inflammatory", "OBSERVATION_MODIFIER", 144, 156], ["inflammatory", "OBSERVATION_MODIFIER", 214, 226], ["inflammatory", "OBSERVATION_MODIFIER", 277, 289], ["inflammatory disease", "OBSERVATION", 312, 332], ["inflammatory", "OBSERVATION", 364, 376]]], ["PRDX2, a thiol-specific peroxidase, has been reported to regulate proinflammatory responses, vascular remodeling, and global oxidative stress (Park et al., 2011).", [["vascular", "ANATOMY", 93, 101], ["PRDX2", "CHEMICAL", 0, 5], ["thiol", "CHEMICAL", 9, 14], ["thiol", "CHEMICAL", 9, 14], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["thiol", "SIMPLE_CHEMICAL", 9, 14], ["peroxidase", "GENE_OR_GENE_PRODUCT", 24, 34], ["vascular", "MULTI-TISSUE_STRUCTURE", 93, 101], ["PRDX2", "PROTEIN", 0, 5], ["thiol-specific peroxidase", "PROTEIN", 9, 34], ["global oxidative stress", "PROBLEM", 118, 141], ["proinflammatory", "OBSERVATION_MODIFIER", 66, 81], ["vascular", "ANATOMY", 93, 101]]], ["PRDX2 removes transiently produced H2O2 in response to activation of various cell surface receptors.", [["cell surface", "ANATOMY", 77, 89], ["H2O2", "CHEMICAL", 35, 39], ["H2O2", "CHEMICAL", 35, 39], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["H2O2", "SIMPLE_CHEMICAL", 35, 39], ["cell", "CELL", 77, 81], ["PRDX2", "PROTEIN", 0, 5], ["cell surface receptors", "PROTEIN", 77, 99], ["H2O2", "TREATMENT", 35, 39], ["various cell surface receptors", "TREATMENT", 69, 99]]], ["PRDX2 regulates platelet-derived growth factor (PDGF) signaling, including enhanced activation of the PDGF receptor and phospholipase C\u03b31, and vascular remodeling, including PDGF-dependent neointimal thickening of vascular smooth muscle cells (Choi et al., 2005).", [["vascular", "ANATOMY", 143, 151], ["neointimal", "ANATOMY", 189, 199], ["vascular smooth muscle cells", "ANATOMY", 214, 242], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["platelet-derived growth factor", "GENE_OR_GENE_PRODUCT", 16, 46], ["PDGF", "GENE_OR_GENE_PRODUCT", 48, 52], ["PDGF receptor", "GENE_OR_GENE_PRODUCT", 102, 115], ["phospholipase C\u03b31", "GENE_OR_GENE_PRODUCT", 120, 137], ["vascular", "MULTI-TISSUE_STRUCTURE", 143, 151], ["PDGF", "GENE_OR_GENE_PRODUCT", 174, 178], ["neointimal", "TISSUE", 189, 199], ["vascular smooth muscle cells", "CELL", 214, 242], ["PRDX2", "PROTEIN", 0, 5], ["platelet-derived growth factor", "PROTEIN", 16, 46], ["PDGF", "PROTEIN", 48, 52], ["PDGF receptor", "PROTEIN", 102, 115], ["phospholipase C\u03b31", "PROTEIN", 120, 137], ["PDGF", "PROTEIN", 174, 178], ["vascular smooth muscle cells", "CELL_TYPE", 214, 242], ["platelet", "TEST", 16, 24], ["the PDGF receptor", "TEST", 98, 115], ["phospholipase C\u03b31", "TEST", 120, 137], ["vascular remodeling", "PROBLEM", 143, 162], ["PDGF-dependent neointimal thickening of vascular smooth muscle cells", "PROBLEM", 174, 242], ["growth", "OBSERVATION_MODIFIER", 33, 39], ["vascular", "ANATOMY", 143, 151], ["remodeling", "OBSERVATION", 152, 162], ["PDGF", "OBSERVATION_MODIFIER", 174, 178], ["dependent", "OBSERVATION_MODIFIER", 179, 188], ["neointimal", "OBSERVATION_MODIFIER", 189, 199], ["thickening", "OBSERVATION", 200, 210], ["vascular smooth", "ANATOMY", 214, 229], ["muscle cells", "OBSERVATION", 230, 242]]], ["Yang et al showed that PRDX2 inhibits general immune cell responsiveness by scavenging low levels of ROS, modulating LPS-induced proinflammatory responses, and protecting against endotoxin-induced lethal shock (Yang et al., 2007).", [["immune cell", "ANATOMY", 46, 57], ["PRDX2", "CHEMICAL", 23, 28], ["ROS", "CHEMICAL", 101, 104], ["LPS", "CHEMICAL", 117, 120], ["endotoxin", "CHEMICAL", 179, 188], ["shock", "DISEASE", 204, 209], ["PRDX2", "GENE_OR_GENE_PRODUCT", 23, 28], ["immune cell", "CELL", 46, 57], ["ROS", "SIMPLE_CHEMICAL", 101, 104], ["LPS", "SIMPLE_CHEMICAL", 117, 120], ["endotoxin", "SIMPLE_CHEMICAL", 179, 188], ["PRDX2", "PROTEIN", 23, 28], ["general immune cell responsiveness", "PROBLEM", 38, 72], ["scavenging low levels of ROS", "PROBLEM", 76, 104], ["endotoxin", "TREATMENT", 179, 188], ["lethal shock", "PROBLEM", 197, 209], ["immune cell", "OBSERVATION", 46, 57]]], ["A recent report showed that PRDX2 is more susceptible than PRDX1 to hyperoxidation in cells subjected to sustained global oxidative stress, which suggests that PRDX2 deficiency may lead to accelerated atherosclerosis due to failure to eliminate ROS (Woo et al., 2010).", [["cells", "ANATOMY", 86, 91], ["PRDX2", "CHEMICAL", 160, 165], ["atherosclerosis", "DISEASE", 201, 216], ["ROS", "CHEMICAL", 245, 248], ["PRDX2", "GENE_OR_GENE_PRODUCT", 28, 33], ["PRDX1", "GENE_OR_GENE_PRODUCT", 59, 64], ["cells", "CELL", 86, 91], ["PRDX2", "GENE_OR_GENE_PRODUCT", 160, 165], ["ROS", "SIMPLE_CHEMICAL", 245, 248], ["PRDX2", "PROTEIN", 28, 33], ["PRDX1", "PROTEIN", 59, 64], ["PRDX2", "PROTEIN", 160, 165], ["PRDX2", "PROBLEM", 28, 33], ["hyperoxidation in cells", "PROBLEM", 68, 91], ["sustained global oxidative stress", "PROBLEM", 105, 138], ["PRDX2 deficiency", "PROBLEM", 160, 176], ["accelerated atherosclerosis", "PROBLEM", 189, 216], ["failure", "PROBLEM", 224, 231], ["oxidative stress", "OBSERVATION", 122, 138], ["atherosclerosis", "OBSERVATION", 201, 216], ["failure", "OBSERVATION", 224, 231]]], ["It has recently been shown that PRDX2 suppresses the proliferation and migration of smooth muscle cells (SMCs) through the site-selective phosphorylation of the PDGF receptor and, furthermore, is involved in the neointimal thickening of SMCs in balloon-injured carotidartery (Kang et al., 2013).", [["smooth muscle cells", "ANATOMY", 84, 103], ["SMCs", "ANATOMY", 105, 109], ["neointimal", "ANATOMY", 212, 222], ["SMCs", "ANATOMY", 237, 241], ["PRDX2", "GENE_OR_GENE_PRODUCT", 32, 37], ["smooth muscle cells", "CELL", 84, 103], ["SMCs", "CELL", 105, 109], ["PDGF receptor", "GENE_OR_GENE_PRODUCT", 161, 174], ["neointimal", "TISSUE", 212, 222], ["SMCs", "CELL", 237, 241], ["PRDX2", "PROTEIN", 32, 37], ["smooth muscle cells", "CELL_TYPE", 84, 103], ["SMCs", "CELL_TYPE", 105, 109], ["PDGF receptor", "PROTEIN", 161, 174], ["SMCs", "CELL_TYPE", 237, 241], ["PRDX2", "TREATMENT", 32, 37], ["the proliferation", "PROBLEM", 49, 66], ["smooth muscle cells", "PROBLEM", 84, 103], ["the PDGF receptor", "TREATMENT", 157, 174], ["the neointimal thickening of SMCs", "PROBLEM", 208, 241], ["proliferation", "OBSERVATION_MODIFIER", 53, 66], ["migration", "OBSERVATION_MODIFIER", 71, 80], ["smooth muscle cells", "OBSERVATION", 84, 103], ["selective", "OBSERVATION_MODIFIER", 128, 137], ["neointimal", "OBSERVATION_MODIFIER", 212, 222], ["thickening", "OBSERVATION", 223, 233], ["SMCs", "ANATOMY", 237, 241], ["balloon", "OBSERVATION_MODIFIER", 245, 252], ["injured", "OBSERVATION_MODIFIER", 253, 260], ["carotidartery", "ANATOMY", 261, 274]]], ["The role of PRDX2 in inflammatory diseases as non-beneficial in inflammatory diseases is also established.", [["inflammatory diseases", "DISEASE", 21, 42], ["inflammatory diseases", "DISEASE", 64, 85], ["PRDX2", "GENE_OR_GENE_PRODUCT", 12, 17], ["PRDX2", "PROTEIN", 12, 17], ["PRDX2", "TREATMENT", 12, 17], ["inflammatory diseases", "PROBLEM", 21, 42], ["inflammatory diseases", "PROBLEM", 64, 85], ["inflammatory", "OBSERVATION_MODIFIER", 21, 33], ["diseases", "OBSERVATION", 34, 42], ["inflammatory", "OBSERVATION_MODIFIER", 64, 76]]], ["In a recent study by Bayer et al, PRDX2 is increased in the presence of the neutrophils and under acidotic conditions and also oxidation of erythrocyte PRDX2 is increased in a mouse model of endotoxemia (Bayer, Maghzal, Stocker, Hampton, & Winterbourn, 2013).", [["neutrophils", "ANATOMY", 76, 87], ["erythrocyte", "ANATOMY", 140, 151], ["endotoxemia", "DISEASE", 191, 202], ["PRDX2", "GENE_OR_GENE_PRODUCT", 34, 39], ["neutrophils", "CELL", 76, 87], ["erythrocyte", "CELL", 140, 151], ["PRDX2", "GENE_OR_GENE_PRODUCT", 152, 157], ["mouse", "ORGANISM", 176, 181], ["PRDX2", "PROTEIN", 34, 39], ["neutrophils", "CELL_TYPE", 76, 87], ["erythrocyte PRDX2", "PROTEIN", 140, 157], ["mouse", "SPECIES", 176, 181], ["mouse", "SPECIES", 176, 181], ["a recent study", "TEST", 3, 17], ["the neutrophils", "PROBLEM", 72, 87], ["acidotic conditions", "PROBLEM", 98, 117], ["erythrocyte PRDX2", "TEST", 140, 157], ["endotoxemia", "PROBLEM", 191, 202], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["neutrophils", "OBSERVATION", 76, 87], ["acidotic conditions", "OBSERVATION", 98, 117], ["erythrocyte PRDX2", "OBSERVATION", 140, 157], ["increased", "OBSERVATION_MODIFIER", 161, 170], ["mouse model", "OBSERVATION_MODIFIER", 176, 187], ["endotoxemia", "OBSERVATION", 191, 202]]], ["Another recent study also showed that the level of intracellular PRDX2 protein content of lymphocytes from RA patients was more than 2-fold higher compared with healthy lymphocytes suggesting that PRDX2 is involved in the persistence of pro-inflammatory cells in chronic inflammation (Szab\u00f3-Taylor et al., 2012).", [["intracellular", "ANATOMY", 51, 64], ["lymphocytes", "ANATOMY", 90, 101], ["lymphocytes", "ANATOMY", 169, 180], ["cells", "ANATOMY", 254, 259], ["inflammation", "DISEASE", 271, 283], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 64], ["PRDX2", "GENE_OR_GENE_PRODUCT", 65, 70], ["lymphocytes", "CELL", 90, 101], ["patients", "ORGANISM", 110, 118], ["lymphocytes", "CELL", 169, 180], ["PRDX2", "GENE_OR_GENE_PRODUCT", 197, 202], ["cells", "CELL", 254, 259], ["PRDX2", "PROTEIN", 65, 70], ["lymphocytes", "CELL_TYPE", 90, 101], ["healthy lymphocytes", "CELL_TYPE", 161, 180], ["PRDX2", "PROTEIN", 197, 202], ["pro-inflammatory cells", "CELL_TYPE", 237, 259], ["patients", "SPECIES", 110, 118], ["Another recent study", "TEST", 0, 20], ["intracellular PRDX2 protein content", "TEST", 51, 86], ["lymphocytes", "TEST", 90, 101], ["PRDX2", "PROBLEM", 197, 202], ["pro-inflammatory cells", "PROBLEM", 237, 259], ["chronic inflammation", "PROBLEM", 263, 283], ["lymphocytes", "ANATOMY", 90, 101], ["RA", "ANATOMY", 107, 109], ["healthy lymphocytes", "OBSERVATION_MODIFIER", 161, 180], ["pro-inflammatory cells", "OBSERVATION", 237, 259], ["chronic", "OBSERVATION_MODIFIER", 263, 270], ["inflammation", "OBSERVATION", 271, 283]]], ["Also, PRDX2 is readily detected in the blood of severe acute respiratory syndrome patients, whereas it is undetectable in normal control blood (Chen et al., 2004).", [["blood", "ANATOMY", 39, 44], ["blood", "ANATOMY", 137, 142], ["acute respiratory syndrome", "DISEASE", 55, 81], ["PRDX2", "GENE_OR_GENE_PRODUCT", 6, 11], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["patients", "ORGANISM", 82, 90], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["PRDX2", "PROTEIN", 6, 11], ["patients", "SPECIES", 82, 90], ["severe acute respiratory syndrome", "PROBLEM", 48, 81], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["respiratory syndrome", "OBSERVATION", 61, 81]]], ["Recombinant PRDX2 induces macrophages to produce TNF-\u03b1 in the absence of any other stimuli, demonstrating that the Trx peroxidase PRDX2 is appropriately classified as a danger signal, meaning a molecule that is released by cells undergoing stress and acts as an immune mediator (Salzano et al., 2014).", [["macrophages", "ANATOMY", 26, 37], ["cells", "ANATOMY", 223, 228], ["PRDX2", "CHEMICAL", 12, 17], ["PRDX2", "GENE_OR_GENE_PRODUCT", 12, 17], ["macrophages", "CELL", 26, 37], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 49, 54], ["Trx peroxidase", "GENE_OR_GENE_PRODUCT", 115, 129], ["PRDX2", "GENE_OR_GENE_PRODUCT", 130, 135], ["cells", "CELL", 223, 228], ["PRDX2", "PROTEIN", 12, 17], ["macrophages", "CELL_TYPE", 26, 37], ["TNF-\u03b1", "PROTEIN", 49, 54], ["Trx peroxidase", "PROTEIN", 115, 129], ["PRDX2", "PROTEIN", 130, 135], ["macrophages", "PROBLEM", 26, 37], ["TNF", "TEST", 49, 52], ["the Trx peroxidase PRDX2", "TREATMENT", 111, 135], ["macrophages", "OBSERVATION", 26, 37]]], ["These data suggest that PRDX2 suppresses inflammatory diseases through inhibition of PDGF signaling, inhibition of immune cell responsiveness and elimination of ROS, but induces inflammatory diseases through persistence of pro-inflammatory cells and mediation of TNF-\u03b1 production.Anti-inflammatory effect of PRDX3 ::: Roles of PRDXs in the development of inflammatory disease ::: PRDXs and inflammatory diseaseThe beneficial role of PRDX3 in inflammatory diseases is well established.", [["immune cell", "ANATOMY", 115, 126], ["cells", "ANATOMY", 240, 245], ["PRDX2", "CHEMICAL", 24, 29], ["inflammatory diseases", "DISEASE", 41, 62], ["ROS", "CHEMICAL", 161, 164], ["inflammatory disease", "DISEASE", 355, 375], ["inflammatory disease", "DISEASE", 390, 410], ["PRDX3", "CHEMICAL", 433, 438], ["inflammatory diseases", "DISEASE", 442, 463], ["PRDX2", "GENE_OR_GENE_PRODUCT", 24, 29], ["PDGF", "GENE_OR_GENE_PRODUCT", 85, 89], ["immune cell", "CELL", 115, 126], ["ROS", "SIMPLE_CHEMICAL", 161, 164], ["cells", "CELL", 240, 245], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 263, 268], ["PRDX3", "SIMPLE_CHEMICAL", 308, 313], ["PRDXs", "GENE_OR_GENE_PRODUCT", 327, 332], ["PRDXs", "GENE_OR_GENE_PRODUCT", 380, 385], ["PRDX3", "GENE_OR_GENE_PRODUCT", 433, 438], ["PRDX2", "PROTEIN", 24, 29], ["PDGF", "PROTEIN", 85, 89], ["pro-inflammatory cells", "CELL_TYPE", 223, 245], ["TNF", "PROTEIN", 263, 266], ["PRDX3", "PROTEIN", 308, 313], ["PRDXs", "PROTEIN", 327, 332], ["PRDX3", "PROTEIN", 433, 438], ["These data", "TEST", 0, 10], ["PRDX2 suppresses inflammatory diseases", "PROBLEM", 24, 62], ["PDGF signaling", "PROBLEM", 85, 99], ["immune cell responsiveness", "PROBLEM", 115, 141], ["ROS", "PROBLEM", 161, 164], ["inflammatory diseases", "PROBLEM", 178, 199], ["pro-inflammatory cells", "PROBLEM", 223, 245], ["TNF", "PROBLEM", 263, 266], ["inflammatory disease", "PROBLEM", 355, 375], ["PRDXs", "PROBLEM", 380, 385], ["inflammatory disease", "PROBLEM", 390, 410], ["PRDX3", "TREATMENT", 433, 438], ["inflammatory diseases", "PROBLEM", 442, 463], ["inflammatory", "OBSERVATION_MODIFIER", 41, 53], ["immune cell responsiveness", "OBSERVATION", 115, 141], ["inflammatory", "OBSERVATION_MODIFIER", 178, 190], ["pro-inflammatory cells", "OBSERVATION", 223, 245], ["inflammatory", "OBSERVATION_MODIFIER", 355, 367], ["inflammatory disease", "OBSERVATION", 390, 410], ["inflammatory", "OBSERVATION", 442, 454]]], ["PRDX3 deficiency increased abnormal lipid accumulation in adipose tissue, due to increased ROS (Huh et al., 2012).", [["adipose tissue", "ANATOMY", 58, 72], ["PRDX3", "CHEMICAL", 0, 5], ["ROS", "CHEMICAL", 91, 94], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["lipid", "SIMPLE_CHEMICAL", 36, 41], ["adipose tissue", "TISSUE", 58, 72], ["ROS", "SIMPLE_CHEMICAL", 91, 94], ["PRDX3", "PROTEIN", 0, 5], ["PRDX3 deficiency", "PROBLEM", 0, 16], ["increased abnormal lipid accumulation in adipose tissue", "PROBLEM", 17, 72], ["increased ROS", "PROBLEM", 81, 94], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["abnormal", "OBSERVATION_MODIFIER", 27, 35], ["lipid accumulation", "OBSERVATION", 36, 54], ["adipose tissue", "OBSERVATION", 58, 72], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["ROS", "OBSERVATION_MODIFIER", 91, 94]]], ["They suggested that endogenous PRDX3 may play an essential role in maintaining normal characteristics of adipocytes and that a defect in PRDX3 alters mitochondrial redox state and function, and adipokine expression in adipocytes leading to metabolic alteration (Huh et al., 2012).", [["adipocytes", "ANATOMY", 105, 115], ["mitochondrial", "ANATOMY", 150, 163], ["adipocytes", "ANATOMY", 218, 228], ["PRDX3", "CHEMICAL", 31, 36], ["PRDX3", "GENE_OR_GENE_PRODUCT", 31, 36], ["adipocytes", "CELL", 105, 115], ["PRDX3", "GENE_OR_GENE_PRODUCT", 137, 142], ["mitochondrial", "CELLULAR_COMPONENT", 150, 163], ["adipokine", "GENE_OR_GENE_PRODUCT", 194, 203], ["adipocytes", "CELL", 218, 228], ["PRDX3", "PROTEIN", 31, 36], ["adipocytes", "CELL_TYPE", 105, 115], ["PRDX3", "PROTEIN", 137, 142], ["adipocytes", "CELL_TYPE", 218, 228], ["endogenous PRDX3", "PROBLEM", 20, 36], ["adipocytes", "PROBLEM", 105, 115], ["a defect in PRDX3 alters mitochondrial redox state", "PROBLEM", 125, 175], ["adipokine expression in adipocytes", "PROBLEM", 194, 228], ["metabolic alteration", "PROBLEM", 240, 260], ["defect", "OBSERVATION", 127, 133]]], ["These data indicate that PRDX3 protects the inflammatory diseases through elimination of lipid accumulation.Beneficial or non-beneficial role of PRDX4 in inflammatory diseases ::: Roles of PRDXs in the development of inflammatory disease ::: PRDXs and inflammatory diseaseThe beneficial role of PRDX4 in inflammatory diseases is well established.", [["PRDX3", "CHEMICAL", 25, 30], ["inflammatory diseases", "DISEASE", 44, 65], ["PRDX4", "CHEMICAL", 145, 150], ["inflammatory diseases", "DISEASE", 154, 175], ["inflammatory disease", "DISEASE", 217, 237], ["inflammatory disease", "DISEASE", 252, 272], ["PRDX4", "CHEMICAL", 295, 300], ["inflammatory diseases", "DISEASE", 304, 325], ["PRDX3", "GENE_OR_GENE_PRODUCT", 25, 30], ["lipid", "SIMPLE_CHEMICAL", 89, 94], ["PRDX4", "GENE_OR_GENE_PRODUCT", 145, 150], ["PRDXs", "GENE_OR_GENE_PRODUCT", 189, 194], ["PRDXs", "GENE_OR_GENE_PRODUCT", 242, 247], ["PRDX4", "GENE_OR_GENE_PRODUCT", 295, 300], ["PRDX3", "PROTEIN", 25, 30], ["PRDX4", "PROTEIN", 145, 150], ["PRDXs", "PROTEIN", 189, 194], ["PRDX4", "PROTEIN", 295, 300], ["These data", "TEST", 0, 10], ["PRDX3", "PROBLEM", 25, 30], ["the inflammatory diseases", "PROBLEM", 40, 65], ["lipid accumulation", "PROBLEM", 89, 107], ["inflammatory disease", "PROBLEM", 217, 237], ["PRDXs", "PROBLEM", 242, 247], ["inflammatory disease", "PROBLEM", 252, 272], ["inflammatory diseases", "PROBLEM", 304, 325], ["inflammatory", "OBSERVATION_MODIFIER", 44, 56], ["lipid accumulation", "OBSERVATION", 89, 107], ["inflammatory", "OBSERVATION_MODIFIER", 154, 166], ["inflammatory", "OBSERVATION_MODIFIER", 217, 229], ["inflammatory disease", "OBSERVATION", 252, 272], ["inflammatory", "OBSERVATION", 304, 316]]], ["It was reported that HFD-induced hepatic steatosis and insulin resistance were prevented in PRDX4 transgenic mice by amelioration of oxidative stress (Nabeshima et al., 2013).", [["hepatic", "ANATOMY", 33, 40], ["steatosis", "DISEASE", 41, 50], ["HFD", "SIMPLE_CHEMICAL", 21, 24], ["hepatic", "ORGAN", 33, 40], ["insulin", "GENE_OR_GENE_PRODUCT", 55, 62], ["PRDX4 transgenic mice", "ORGANISM", 92, 113], ["PRDX4", "PROTEIN", 92, 97], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 109, 113], ["HFD", "TEST", 21, 24], ["hepatic steatosis", "PROBLEM", 33, 50], ["insulin resistance", "TREATMENT", 55, 73], ["oxidative stress", "PROBLEM", 133, 149], ["hepatic", "ANATOMY", 33, 40], ["steatosis", "OBSERVATION", 41, 50], ["insulin resistance", "OBSERVATION", 55, 73]]], ["It has been suggested that streptozotocin-treated Tg mice, which overexpress PRDX4 in pancreatic islets, can protect pancreatic beta-cells against streptozotocin-induced injury (insulitis) by suppressing increased oxidative stress and inflammatory signaling activation (Ding et al., 2010).", [["pancreatic islets", "ANATOMY", 86, 103], ["pancreatic beta-cells", "ANATOMY", 117, 138], ["streptozotocin", "CHEMICAL", 27, 41], ["streptozotocin", "CHEMICAL", 147, 161], ["insulitis", "DISEASE", 178, 187], ["streptozotocin", "CHEMICAL", 27, 41], ["streptozotocin", "CHEMICAL", 147, 161], ["streptozotocin", "SIMPLE_CHEMICAL", 27, 41], ["Tg mice", "ORGANISM", 50, 57], ["PRDX4", "GENE_OR_GENE_PRODUCT", 77, 82], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 86, 103], ["pancreatic beta-cells", "CELL", 117, 138], ["streptozotocin", "SIMPLE_CHEMICAL", 147, 161], ["PRDX4", "PROTEIN", 77, 82], ["pancreatic islets", "CELL_TYPE", 86, 103], ["pancreatic beta-cells", "CELL_TYPE", 117, 138], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["streptozotocin", "TREATMENT", 27, 41], ["Tg mice", "TREATMENT", 50, 57], ["pancreatic islets", "PROBLEM", 86, 103], ["streptozotocin", "PROBLEM", 147, 161], ["induced injury", "PROBLEM", 162, 176], ["insulitis", "PROBLEM", 178, 187], ["suppressing increased oxidative stress", "PROBLEM", 192, 230], ["inflammatory signaling activation", "PROBLEM", 235, 268], ["pancreatic", "ANATOMY", 86, 96], ["pancreatic", "ANATOMY", 117, 127], ["oxidative stress", "OBSERVATION", 214, 230], ["inflammatory", "OBSERVATION_MODIFIER", 235, 247]]], ["The role of PRDX4 in inflammatory diseases as non-beneficial is also established.", [["PRDX4", "CHEMICAL", 12, 17], ["inflammatory diseases", "DISEASE", 21, 42], ["PRDX4", "GENE_OR_GENE_PRODUCT", 12, 17], ["PRDX4", "PROTEIN", 12, 17], ["inflammatory diseases", "PROBLEM", 21, 42], ["inflammatory", "OBSERVATION_MODIFIER", 21, 33], ["diseases", "OBSERVATION", 34, 42]]], ["Chang et al demonstrated that the expression of PRDX4 is increased in synovial tissues of RA patients (Chang et al., 2009).", [["synovial tissues", "ANATOMY", 70, 86], ["RA", "DISEASE", 90, 92], ["PRDX4", "GENE_OR_GENE_PRODUCT", 48, 53], ["synovial tissues", "TISSUE", 70, 86], ["patients", "ORGANISM", 93, 101], ["PRDX4", "PROTEIN", 48, 53], ["patients", "SPECIES", 93, 101], ["PRDX4", "PROBLEM", 48, 53], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["synovial tissues", "ANATOMY", 70, 86], ["RA", "ANATOMY", 90, 92]]], ["These data indicate that PRDX4 inhibits inflammatory diseases by suppressing oxidative stress and inflammatory signaling.Pro-or anti-inflammatory effect of PRDX6 in inflammatory diseases ::: Roles of PRDXs in the development of inflammatory disease ::: PRDXs and inflammatory diseaseThe beneficial role of PRDX6 in inflammatory diseases is well established.", [["PRDX4", "CHEMICAL", 25, 30], ["inflammatory diseases", "DISEASE", 40, 61], ["PRDX6", "CHEMICAL", 156, 161], ["inflammatory diseases", "DISEASE", 165, 186], ["inflammatory disease", "DISEASE", 228, 248], ["inflammatory disease", "DISEASE", 263, 283], ["PRDX6", "CHEMICAL", 306, 311], ["inflammatory diseases", "DISEASE", 315, 336], ["PRDX4", "GENE_OR_GENE_PRODUCT", 25, 30], ["PRDX6", "SIMPLE_CHEMICAL", 156, 161], ["PRDXs", "GENE_OR_GENE_PRODUCT", 200, 205], ["PRDXs", "GENE_OR_GENE_PRODUCT", 253, 258], ["PRDX6", "GENE_OR_GENE_PRODUCT", 306, 311], ["PRDX4", "PROTEIN", 25, 30], ["PRDX6", "PROTEIN", 156, 161], ["PRDXs", "PROTEIN", 200, 205], ["PRDX6", "PROTEIN", 306, 311], ["These data", "TEST", 0, 10], ["PRDX4", "PROBLEM", 25, 30], ["inflammatory diseases", "PROBLEM", 40, 61], ["suppressing oxidative stress", "PROBLEM", 65, 93], ["inflammatory signaling", "PROBLEM", 98, 120], ["inflammatory diseases", "PROBLEM", 165, 186], ["inflammatory disease", "PROBLEM", 228, 248], ["PRDXs", "PROBLEM", 253, 258], ["inflammatory disease", "PROBLEM", 263, 283], ["inflammatory diseases", "PROBLEM", 315, 336], ["inflammatory", "OBSERVATION_MODIFIER", 40, 52], ["oxidative stress", "OBSERVATION", 77, 93], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110], ["inflammatory", "OBSERVATION_MODIFIER", 165, 177], ["inflammatory", "OBSERVATION_MODIFIER", 228, 240], ["inflammatory disease", "OBSERVATION", 263, 283], ["inflammatory", "OBSERVATION_MODIFIER", 315, 327]]], ["Wang et al showed that PRDX6-/- macrophages oxidized LDL significantly more than it did in controls and plasma lipid hydroperoxide levels were higher in atherogenic diet-fed PRDX6-/- mice than in controls (Wang et al., 2004).", [["macrophages", "ANATOMY", 32, 43], ["plasma", "ANATOMY", 104, 110], ["hydroperoxide", "CHEMICAL", 117, 130], ["hydroperoxide", "CHEMICAL", 117, 130], ["PRDX6", "GENE_OR_GENE_PRODUCT", 23, 28], ["macrophages", "CELL", 32, 43], ["LDL", "SIMPLE_CHEMICAL", 53, 56], ["plasma", "ORGANISM_SUBSTANCE", 104, 110], ["lipid", "SIMPLE_CHEMICAL", 111, 116], ["hydroperoxide", "SIMPLE_CHEMICAL", 117, 130], ["PRDX6", "GENE_OR_GENE_PRODUCT", 174, 179], ["mice", "ORGANISM", 183, 187], ["PRDX6", "PROTEIN", 23, 28], ["macrophages", "CELL_TYPE", 32, 43], ["LDL", "PROTEIN", 53, 56], ["PRDX6", "PROTEIN", 174, 179], ["mice", "SPECIES", 183, 187], ["oxidized LDL", "TEST", 44, 56], ["plasma lipid hydroperoxide levels", "TEST", 104, 137], ["macrophages oxidized", "OBSERVATION", 32, 52], ["LDL", "OBSERVATION_MODIFIER", 53, 56]]], ["A recent study showed that increased PRDX6 expression suppresses liver injury induced by free radical-mediated damage via inflammation (Khoontawad et al., 2010).", [["liver", "ANATOMY", 65, 70], ["liver injury", "DISEASE", 65, 77], ["inflammation", "DISEASE", 122, 134], ["PRDX6", "GENE_OR_GENE_PRODUCT", 37, 42], ["liver", "ORGAN", 65, 70], ["free radical", "SIMPLE_CHEMICAL", 89, 101], ["PRDX6", "PROTEIN", 37, 42], ["A recent study", "TEST", 0, 14], ["increased PRDX6 expression suppresses liver injury", "PROBLEM", 27, 77], ["free radical-mediated damage via inflammation", "PROBLEM", 89, 134], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["PRDX6", "OBSERVATION", 37, 42], ["liver", "ANATOMY", 65, 70], ["injury", "OBSERVATION", 71, 77], ["free", "OBSERVATION_MODIFIER", 89, 93], ["radical", "OBSERVATION_MODIFIER", 94, 101], ["damage", "OBSERVATION", 111, 117], ["inflammation", "OBSERVATION", 122, 134]]], ["Likewise, an increased liver injury in PRDX6-knockout mice occurred via increased mitochondrial generation of H2O2 (Eismann et al., 2009).", [["liver", "ANATOMY", 23, 28], ["mitochondrial", "ANATOMY", 82, 95], ["liver injury", "DISEASE", 23, 35], ["H2O2", "CHEMICAL", 110, 114], ["H2O2", "CHEMICAL", 110, 114], ["liver", "ORGAN", 23, 28], ["PRDX6", "GENE_OR_GENE_PRODUCT", 39, 44], ["mice", "ORGANISM", 54, 58], ["mitochondrial", "CELLULAR_COMPONENT", 82, 95], ["H2O2", "SIMPLE_CHEMICAL", 110, 114], ["PRDX6", "PROTEIN", 39, 44], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["an increased liver injury", "PROBLEM", 10, 35], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["liver", "ANATOMY", 23, 28], ["injury", "OBSERVATION", 29, 35], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["mitochondrial generation", "OBSERVATION", 82, 106]]], ["The role of PRDX6 in inflammatory diseases as non-beneficial is also established.", [["PRDX6", "CHEMICAL", 12, 17], ["inflammatory diseases", "DISEASE", 21, 42], ["PRDX6", "GENE_OR_GENE_PRODUCT", 12, 17], ["PRDX6", "PROTEIN", 12, 17], ["inflammatory diseases", "PROBLEM", 21, 42], ["inflammatory", "OBSERVATION_MODIFIER", 21, 33], ["diseases", "OBSERVATION", 34, 42]]], ["PRDX6 is also involved in the several inflammation related diseases.", [["inflammation", "DISEASE", 38, 50], ["PRDX6", "GENE_OR_GENE_PRODUCT", 0, 5], ["PRDX6", "PROTEIN", 0, 5], ["PRDX6", "PROBLEM", 0, 5], ["the several inflammation related diseases", "PROBLEM", 26, 67], ["several", "OBSERVATION_MODIFIER", 30, 37], ["inflammation", "OBSERVATION", 38, 50]]], ["Our recent study suggested that overexpression of PRDX6 promotes development of RA through activation of coupling NF-\u03baB/AP-1 with the JNK pathway or NF-\u03baB/AP-1 coupled with the JNK pathway in the CAIA and AIA-induced arthritis development model (Kim et al., 2015).", [["PRDX6", "CHEMICAL", 50, 55], ["RA", "DISEASE", 80, 82], ["CAIA", "CHEMICAL", 196, 200], ["AIA", "CHEMICAL", 205, 208], ["arthritis", "DISEASE", 217, 226], ["PRDX6", "GENE_OR_GENE_PRODUCT", 50, 55], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 114, 119], ["AP-1", "GENE_OR_GENE_PRODUCT", 120, 124], ["JNK", "GENE_OR_GENE_PRODUCT", 134, 137], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 149, 154], ["AP-1", "GENE_OR_GENE_PRODUCT", 155, 159], ["JNK", "GENE_OR_GENE_PRODUCT", 177, 180], ["CAIA", "SIMPLE_CHEMICAL", 196, 200], ["AIA", "SIMPLE_CHEMICAL", 205, 208], ["PRDX6", "PROTEIN", 50, 55], ["NF-\u03baB", "PROTEIN", 114, 119], ["AP-1", "PROTEIN", 120, 124], ["JNK", "PROTEIN", 134, 137], ["NF-\u03baB", "PROTEIN", 149, 154], ["AP-1", "PROTEIN", 155, 159], ["JNK", "PROTEIN", 177, 180], ["Our recent study", "TEST", 0, 16], ["overexpression of PRDX6", "PROBLEM", 32, 55], ["coupling NF", "TEST", 105, 116], ["the JNK pathway", "TEST", 130, 145], ["NF", "TEST", 149, 151], ["\u03baB/AP", "TEST", 152, 157], ["the JNK pathway", "TEST", 173, 188], ["the CAIA", "PROBLEM", 192, 200], ["AIA", "PROBLEM", 205, 208], ["arthritis", "PROBLEM", 217, 226], ["RA", "ANATOMY", 80, 82], ["CAIA", "ANATOMY", 196, 200], ["AIA", "ANATOMY", 205, 208], ["arthritis", "OBSERVATION", 217, 226]]], ["Our data and other data suggest that PRDX6 inhibits inflammatory diseases by suppression of free radical-induced damage and mitochondrial generation of H2O2, and induces inflammatory diseases through activation of NF-\u03baB/AP-1 coupled with the JNK pathway.Signaling pathway of PRDXs in the development of inflammatory diseases ::: PRDXs and inflammatory diseasePRDXs secreted from cells under mild oxidative stress binds TLR4 and PRDXs induces Nrf2 or NF-\u03baB activation that is important for the expression of inflammatory proteins, suggesting that PRDXs are involved in inflammation related disease (Madrigal-Matute et al., 2012, Westermann et al., 1996).", [["mitochondrial", "ANATOMY", 124, 137], ["cells", "ANATOMY", 379, 384], ["PRDX6", "CHEMICAL", 37, 42], ["inflammatory diseases", "DISEASE", 52, 73], ["H2O2", "CHEMICAL", 152, 156], ["inflammatory diseases", "DISEASE", 303, 324], ["inflammation", "DISEASE", 568, 580], ["H2O2", "CHEMICAL", 152, 156], ["PRDX6", "GENE_OR_GENE_PRODUCT", 37, 42], ["free radical", "SIMPLE_CHEMICAL", 92, 104], ["mitochondrial", "CELLULAR_COMPONENT", 124, 137], ["H2O2", "SIMPLE_CHEMICAL", 152, 156], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 214, 219], ["AP-1", "GENE_OR_GENE_PRODUCT", 220, 224], ["JNK", "GENE_OR_GENE_PRODUCT", 242, 245], ["PRDXs", "GENE_OR_GENE_PRODUCT", 275, 280], ["PRDXs", "GENE_OR_GENE_PRODUCT", 329, 334], ["cells", "CELL", 379, 384], ["TLR4", "GENE_OR_GENE_PRODUCT", 419, 423], ["PRDXs", "GENE_OR_GENE_PRODUCT", 428, 433], ["Nrf2", "GENE_OR_GENE_PRODUCT", 442, 446], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 450, 455], ["PRDXs", "GENE_OR_GENE_PRODUCT", 546, 551], ["NF-\u03baB", "PROTEIN", 214, 219], ["AP-1", "PROTEIN", 220, 224], ["JNK", "PROTEIN", 242, 245], ["PRDXs", "PROTEIN", 275, 280], ["inflammatory diseasePRDXs", "PROTEIN", 339, 364], ["TLR4", "PROTEIN", 419, 423], ["PRDXs", "PROTEIN", 428, 433], ["Nrf2", "PROTEIN", 442, 446], ["NF-\u03baB", "PROTEIN", 450, 455], ["inflammatory proteins", "PROTEIN", 507, 528], ["PRDXs", "PROTEIN", 546, 551], ["Our data", "TEST", 0, 8], ["other data", "TEST", 13, 23], ["PRDX6", "PROBLEM", 37, 42], ["inflammatory diseases", "PROBLEM", 52, 73], ["free radical", "TREATMENT", 92, 104], ["induced damage", "PROBLEM", 105, 119], ["mitochondrial generation of H2O2", "TREATMENT", 124, 156], ["inflammatory diseases", "PROBLEM", 170, 191], ["NF", "TEST", 214, 216], ["the JNK pathway", "TEST", 238, 253], ["Signaling pathway of PRDXs", "PROBLEM", 254, 280], ["inflammatory diseases", "PROBLEM", 303, 324], ["PRDXs", "PROBLEM", 329, 334], ["inflammatory diseasePRDXs", "PROBLEM", 339, 364], ["mild oxidative stress binds", "PROBLEM", 391, 418], ["Nrf2", "PROBLEM", 442, 446], ["NF", "PROBLEM", 450, 452], ["inflammatory proteins", "PROBLEM", 507, 528], ["inflammation related disease", "PROBLEM", 568, 596], ["inflammatory", "OBSERVATION_MODIFIER", 52, 64], ["free radical", "OBSERVATION", 92, 104], ["mitochondrial generation", "OBSERVATION", 124, 148], ["inflammatory", "OBSERVATION_MODIFIER", 170, 182], ["inflammatory", "OBSERVATION_MODIFIER", 303, 315], ["inflammatory", "OBSERVATION_MODIFIER", 339, 351], ["mild", "OBSERVATION_MODIFIER", 391, 395], ["oxidative stress", "OBSERVATION", 396, 412], ["binds TLR4", "OBSERVATION", 413, 423], ["inflammatory", "OBSERVATION", 507, 519]]], ["Fig. 6illustrates the roles of PRDXs in the signaling pathways for the development of inflammatory diseases.Signaling pathway of PRDXs in the development of inflammatory diseases ::: PRDXs and inflammatory diseaseRiddell et al. found that extracellular PRDX1 can induce activation of NF-\u03baB through TLR4 (Riddell et al., 2012).", [["extracellular", "ANATOMY", 239, 252], ["inflammatory diseases", "DISEASE", 86, 107], ["inflammatory diseases", "DISEASE", 157, 178], ["PRDX1", "CHEMICAL", 253, 258], ["PRDXs", "GENE_OR_GENE_PRODUCT", 31, 36], ["PRDXs", "GENE_OR_GENE_PRODUCT", 129, 134], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 239, 252], ["PRDX1", "GENE_OR_GENE_PRODUCT", 253, 258], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 284, 289], ["TLR4", "GENE_OR_GENE_PRODUCT", 298, 302], ["PRDXs", "PROTEIN", 31, 36], ["PRDXs", "PROTEIN", 129, 134], ["extracellular PRDX1", "PROTEIN", 239, 258], ["NF-\u03baB", "PROTEIN", 284, 289], ["TLR4", "PROTEIN", 298, 302], ["Fig", "TREATMENT", 0, 3], ["PRDXs", "TREATMENT", 31, 36], ["inflammatory diseases", "PROBLEM", 86, 107], ["Signaling pathway of PRDXs", "PROBLEM", 108, 134], ["inflammatory diseases", "PROBLEM", 157, 178], ["PRDXs", "PROBLEM", 183, 188], ["inflammatory diseaseRiddell et al", "PROBLEM", 193, 226], ["extracellular PRDX1", "PROBLEM", 239, 258], ["activation of NF", "PROBLEM", 270, 286], ["inflammatory", "OBSERVATION", 86, 98], ["inflammatory", "OBSERVATION_MODIFIER", 157, 169], ["inflammatory", "OBSERVATION_MODIFIER", 193, 205], ["PRDX1", "OBSERVATION", 253, 258]]], ["They showed that incubation of mouse vascular endothelial cells with recombinant PRDX1 caused an increase of VEGF expression that was dependent upon TLR4 and required hypoxia inducible factor-1 (HIF-1) interaction with the VEGF promoter.", [["vascular endothelial cells", "ANATOMY", 37, 63], ["PRDX1", "CHEMICAL", 81, 86], ["mouse", "ORGANISM", 31, 36], ["vascular endothelial cells", "CELL", 37, 63], ["PRDX1", "GENE_OR_GENE_PRODUCT", 81, 86], ["VEGF", "GENE_OR_GENE_PRODUCT", 109, 113], ["TLR4", "GENE_OR_GENE_PRODUCT", 149, 153], ["hypoxia inducible factor-1", "GENE_OR_GENE_PRODUCT", 167, 193], ["HIF-1", "GENE_OR_GENE_PRODUCT", 195, 200], ["VEGF", "GENE_OR_GENE_PRODUCT", 223, 227], ["mouse vascular endothelial cells", "CELL_LINE", 31, 63], ["recombinant PRDX1", "PROTEIN", 69, 86], ["VEGF", "PROTEIN", 109, 113], ["TLR4", "PROTEIN", 149, 153], ["HIF", "PROTEIN", 195, 198], ["VEGF promoter", "DNA", 223, 236], ["mouse", "SPECIES", 31, 36], ["mouse", "SPECIES", 31, 36], ["mouse vascular endothelial cells", "PROBLEM", 31, 63], ["recombinant PRDX1", "PROBLEM", 69, 86], ["an increase of VEGF expression", "PROBLEM", 94, 124], ["dependent upon TLR4", "PROBLEM", 134, 153], ["hypoxia inducible factor", "PROBLEM", 167, 191], ["the VEGF promoter", "TREATMENT", 219, 236], ["vascular endothelial cells", "OBSERVATION", 37, 63], ["increase", "OBSERVATION_MODIFIER", 97, 105], ["VEGF expression", "OBSERVATION", 109, 124]]], ["The induction of VEGF was also dependent upon NF-\u03baB; however, NF-\u03baB interaction with the VEGF promoter was not required for PRDX1 induction of VEGF suggesting that NF-\u03baB was acting indirectly to induce VEGF expression.", [["VEGF", "GENE_OR_GENE_PRODUCT", 17, 21], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 46, 51], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 62, 67], ["VEGF", "GENE_OR_GENE_PRODUCT", 89, 93], ["PRDX1", "GENE_OR_GENE_PRODUCT", 124, 129], ["VEGF", "GENE_OR_GENE_PRODUCT", 143, 147], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 164, 169], ["VEGF", "GENE_OR_GENE_PRODUCT", 202, 206], ["VEGF", "PROTEIN", 17, 21], ["NF-\u03baB", "PROTEIN", 46, 51], ["NF-\u03baB", "PROTEIN", 62, 67], ["VEGF promoter", "DNA", 89, 102], ["PRDX1", "PROTEIN", 124, 129], ["VEGF", "PROTEIN", 143, 147], ["NF-\u03baB", "PROTEIN", 164, 169], ["VEGF", "PROTEIN", 202, 206], ["the VEGF promoter", "TREATMENT", 85, 102], ["PRDX1 induction", "TREATMENT", 124, 139], ["VEGF", "PROBLEM", 143, 147]]], ["Riddell et al. also showed that recombinant PRDX1 supplemented to the culture medium induced secretion of TNF-\u03b1 and IL-6 from mouse thioglycolate-elicited peritoneal macrophages (Riddell et al., 2010).", [["peritoneal macrophages", "ANATOMY", 155, 177], ["PRDX1", "CHEMICAL", 44, 49], ["thioglycolate", "CHEMICAL", 132, 145], ["PRDX1", "GENE_OR_GENE_PRODUCT", 44, 49], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 106, 111], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["mouse", "ORGANISM", 126, 131], ["thioglycolate", "SIMPLE_CHEMICAL", 132, 145], ["peritoneal macrophages", "CELL", 155, 177], ["recombinant PRDX1", "PROTEIN", 32, 49], ["TNF", "PROTEIN", 106, 109], ["IL-6", "PROTEIN", 116, 120], ["peritoneal macrophages", "CELL_TYPE", 155, 177], ["mouse", "SPECIES", 126, 131], ["mouse", "SPECIES", 126, 131], ["recombinant PRDX1", "PROBLEM", 32, 49], ["the culture", "TEST", 66, 77], ["TNF", "TEST", 106, 109], ["IL", "TEST", 116, 118], ["mouse thioglycolate", "TREATMENT", 126, 145], ["peritoneal macrophages", "PROBLEM", 155, 177], ["peritoneal", "ANATOMY", 155, 165], ["macrophages", "OBSERVATION", 166, 177]]], ["They showed that secretion of cytokines in response to PRDX1 was dependent upon serum and required CD14 and MD2.", [["serum", "ANATOMY", 80, 85], ["PRDX1", "GENE_OR_GENE_PRODUCT", 55, 60], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["CD14", "GENE_OR_GENE_PRODUCT", 99, 103], ["MD2", "GENE_OR_GENE_PRODUCT", 108, 111], ["cytokines", "PROTEIN", 30, 39], ["PRDX1", "PROTEIN", 55, 60], ["CD14", "PROTEIN", 99, 103], ["MD2", "PROTEIN", 108, 111], ["secretion of cytokines", "PROBLEM", 17, 39], ["PRDX1", "TEST", 55, 60], ["serum", "TEST", 80, 85], ["CD14", "TEST", 99, 103]]], ["Binding of PRDX1 to TG-macrophages occurred within minutes and resulted in TLR4 endocytosis.", [["TG-macrophages", "ANATOMY", 20, 34], ["PRDX1", "GENE_OR_GENE_PRODUCT", 11, 16], ["TG-macrophages", "CELL", 20, 34], ["TLR4", "GENE_OR_GENE_PRODUCT", 75, 79], ["PRDX1", "PROTEIN", 11, 16], ["TG", "PROTEIN", 20, 22], ["macrophages", "CELL_TYPE", 23, 34], ["TLR4", "PROTEIN", 75, 79], ["TG", "TEST", 20, 22], ["TLR4 endocytosis", "PROBLEM", 75, 91], ["TLR4 endocytosis", "OBSERVATION", 75, 91]]], ["PRDX1 interaction with TLR4 was independent of its peroxidase activity and appeared to be dependent upon its chaperone activity and ability to form decamers.", [["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["TLR4", "GENE_OR_GENE_PRODUCT", 23, 27], ["peroxidase", "GENE_OR_GENE_PRODUCT", 51, 61], ["PRDX1", "PROTEIN", 0, 5], ["TLR4", "PROTEIN", 23, 27], ["peroxidase", "PROTEIN", 51, 61]]], ["Cytokine expression occurred via the TLR-MyD88 signaling pathway, which resulted in nuclear translocation and activation of NF-\u03baB.", [["nuclear", "ANATOMY", 84, 91], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["TLR", "GENE_OR_GENE_PRODUCT", 37, 40], ["MyD88", "GENE_OR_GENE_PRODUCT", 41, 46], ["nuclear", "CELLULAR_COMPONENT", 84, 91], ["NF-\u03baB.", "GENE_OR_GENE_PRODUCT", 124, 130], ["Cytokine", "PROTEIN", 0, 8], ["TLR", "PROTEIN", 37, 40], ["MyD88", "PROTEIN", 41, 46], ["NF-\u03baB.", "PROTEIN", 124, 130], ["Cytokine expression", "PROBLEM", 0, 19], ["nuclear translocation", "PROBLEM", 84, 105], ["nuclear translocation", "OBSERVATION", 84, 105]]], ["These findings suggest that PRDX1 may act as a danger signal similar to other TLR4 binding chaperone molecules such as HSP72.", [["PRDX1", "CHEMICAL", 28, 33], ["PRDX1", "GENE_OR_GENE_PRODUCT", 28, 33], ["TLR4", "GENE_OR_GENE_PRODUCT", 78, 82], ["HSP72", "GENE_OR_GENE_PRODUCT", 119, 124], ["PRDX1", "PROTEIN", 28, 33], ["TLR4 binding chaperone molecules", "PROTEIN", 78, 110], ["HSP72", "PROTEIN", 119, 124], ["PRDX1", "PROBLEM", 28, 33], ["a danger signal", "PROBLEM", 45, 60], ["HSP72", "TEST", 119, 124]]], ["Shichita et al. showed that PRDX1 to 6 all bind to TLR4 and induce IL-23 (Shichita et al., 2012a, Shichita et al., 2012b).", [["PRDX1", "GENE_OR_GENE_PRODUCT", 28, 33], ["TLR4", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL-23", "GENE_OR_GENE_PRODUCT", 67, 72], ["PRDX1 to 6", "PROTEIN", 28, 38], ["TLR4", "PROTEIN", 51, 55], ["PRDX1", "TEST", 28, 33], ["IL", "TEST", 67, 69]]], ["The authors identified PRDXs as key initiators of post-ischemic inflammation in the brain.", [["brain", "ANATOMY", 84, 89], ["inflammation", "DISEASE", 64, 76], ["PRDXs", "GENE_OR_GENE_PRODUCT", 23, 28], ["brain", "ORGAN", 84, 89], ["post-ischemic inflammation in the brain", "PROBLEM", 50, 89], ["post-ischemic", "OBSERVATION_MODIFIER", 50, 63], ["inflammation", "OBSERVATION", 64, 76], ["brain", "ANATOMY", 84, 89]]], ["They showed that IL-23 production from infiltrated macrophages induces IL-17-producing T cells, which play a role in the promotion of delayed ischemic brain damages.", [["macrophages", "ANATOMY", 51, 62], ["IL-17-producing T cells", "ANATOMY", 71, 94], ["brain", "ANATOMY", 151, 156], ["ischemic brain damages", "DISEASE", 142, 164], ["IL-23", "GENE_OR_GENE_PRODUCT", 17, 22], ["macrophages", "CELL", 51, 62], ["IL-17", "GENE_OR_GENE_PRODUCT", 71, 76], ["T cells", "CELL", 87, 94], ["brain", "ORGAN", 151, 156], ["IL-23", "PROTEIN", 17, 22], ["infiltrated macrophages", "CELL_TYPE", 39, 62], ["IL-17", "PROTEIN", 71, 76], ["T cells", "CELL_TYPE", 87, 94], ["IL", "TEST", 17, 19], ["infiltrated macrophages", "PROBLEM", 39, 62], ["IL", "TEST", 71, 73], ["T cells", "PROBLEM", 87, 94], ["delayed ischemic brain damages", "PROBLEM", 134, 164], ["brain", "ANATOMY", 151, 156]]], ["It was speculated that PRDXs released from necrotic cells induce NF-\u03baB activation and the production of IL-23 (Salzano et al., 2014).", [["necrotic cells", "ANATOMY", 43, 57], ["PRDXs", "CHEMICAL", 23, 28], ["necrotic", "DISEASE", 43, 51], ["PRDXs", "SIMPLE_CHEMICAL", 23, 28], ["necrotic cells", "CELL", 43, 57], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 65, 70], ["IL-23", "GENE_OR_GENE_PRODUCT", 104, 109], ["PRDXs", "PROTEIN", 23, 28], ["necrotic cells", "CELL_TYPE", 43, 57], ["NF-\u03baB", "PROTEIN", 65, 70], ["PRDXs", "PROBLEM", 23, 28], ["necrotic cells", "PROBLEM", 43, 57], ["NF", "TEST", 65, 67], ["necrotic cells", "OBSERVATION", 43, 57]]], ["The authors identified a domain on PRDXs required for the TLR4-mediated cytokine production.", [["PRDXs", "GENE_OR_GENE_PRODUCT", 35, 40], ["TLR4", "GENE_OR_GENE_PRODUCT", 58, 62], ["PRDXs", "PROTEIN", 35, 40], ["TLR4", "PROTEIN", 58, 62], ["cytokine", "PROTEIN", 72, 80], ["a domain on PRDXs", "PROBLEM", 23, 40], ["the TLR4-mediated cytokine production", "TREATMENT", 54, 91]]], ["This domain is amino acid residues between 70 and 90 of PRDX5 and homologous regions in other PRDXs that commonly contain \u03b24 sheet and \u03b13 helix regions.", [["amino acid", "CHEMICAL", 15, 25], ["amino acid", "CHEMICAL", 15, 25], ["amino acid", "AMINO_ACID", 15, 25], ["PRDX5", "GENE_OR_GENE_PRODUCT", 56, 61], ["PRDXs", "GENE_OR_GENE_PRODUCT", 94, 99], ["\u03b24", "GENE_OR_GENE_PRODUCT", 122, 124], ["PRDX5", "PROTEIN", 56, 61], ["PRDXs", "PROTEIN", 94, 99], ["\u03b24 sheet", "PROTEIN", 122, 130], ["\u03b13 helix regions", "PROTEIN", 135, 151], ["amino acid residues", "TEST", 15, 34], ["homologous regions in other PRDXs", "PROBLEM", 66, 99], ["amino acid", "OBSERVATION", 15, 25], ["helix", "ANATOMY_MODIFIER", 138, 143]]], ["It is noted, however, that the activity of domain containing GST-PRDX fusion proteins induced the IL-23 mRNA to a much lesser extent compared to whole PRDXs.", [["GST", "GENE_OR_GENE_PRODUCT", 61, 64], ["PRDX", "GENE_OR_GENE_PRODUCT", 65, 69], ["IL-23", "GENE_OR_GENE_PRODUCT", 98, 103], ["GST", "PROTEIN", 61, 64], ["PRDX fusion proteins", "PROTEIN", 65, 85], ["IL-23 mRNA", "RNA", 98, 108], ["GST", "TEST", 61, 64], ["PRDX fusion proteins", "TREATMENT", 65, 85], ["the IL", "TREATMENT", 94, 100], ["lesser extent", "OBSERVATION_MODIFIER", 119, 132]]], ["The interaction of PRDXs with TLR4 should be strictly regulated by a manner different from that of LPS.", [["LPS", "CHEMICAL", 99, 102], ["PRDXs", "GENE_OR_GENE_PRODUCT", 19, 24], ["TLR4", "GENE_OR_GENE_PRODUCT", 30, 34], ["LPS", "SIMPLE_CHEMICAL", 99, 102], ["PRDXs", "PROTEIN", 19, 24], ["TLR4", "PROTEIN", 30, 34], ["TLR4", "TREATMENT", 30, 34]]], ["Kisucka et al examined the role of PRDX1 in the apoE-/- murine spontaneous model of atherosclerosis (Kisucka et al., 2008).", [["atherosclerosis", "DISEASE", 84, 99], ["PRDX1", "GENE_OR_GENE_PRODUCT", 35, 40], ["apoE", "GENE_OR_GENE_PRODUCT", 48, 52], ["murine", "ORGANISM", 56, 62], ["PRDX1", "PROTEIN", 35, 40], ["apoE", "PROTEIN", 48, 52], ["murine", "SPECIES", 56, 62], ["atherosclerosis", "PROBLEM", 84, 99], ["atherosclerosis", "OBSERVATION", 84, 99]]], ["They showed that PRDX1-/-/apoE-/- mice fed normal chow developed larger, more macrophage-rich aortic sinus lesions than PRDX1+/+/apoE-/- mice, despite similar amounts and size distributions of cholesterol in their plasma lipoproteins, suggesting that PRDX1 protects against excessive endothelial activation and atherosclerosis.", [["macrophage", "ANATOMY", 78, 88], ["aortic sinus lesions", "ANATOMY", 94, 114], ["plasma", "ANATOMY", 214, 220], ["endothelial", "ANATOMY", 284, 295], ["cholesterol", "CHEMICAL", 193, 204], ["PRDX1", "CHEMICAL", 251, 256], ["atherosclerosis", "DISEASE", 311, 326], ["cholesterol", "CHEMICAL", 193, 204], ["PRDX1", "GENE_OR_GENE_PRODUCT", 17, 22], ["apoE", "GENE_OR_GENE_PRODUCT", 26, 30], ["macrophage", "CELL", 78, 88], ["aortic sinus lesions", "PATHOLOGICAL_FORMATION", 94, 114], ["PRDX1", "GENE_OR_GENE_PRODUCT", 120, 125], ["apoE", "GENE_OR_GENE_PRODUCT", 129, 133], ["cholesterol", "SIMPLE_CHEMICAL", 193, 204], ["plasma", "ORGANISM_SUBSTANCE", 214, 220], ["PRDX1", "GENE_OR_GENE_PRODUCT", 251, 256], ["endothelial", "CELL", 284, 295], ["PRDX1", "PROTEIN", 17, 22], ["apoE", "PROTEIN", 26, 30], ["PRDX1", "PROTEIN", 120, 125], ["apoE", "PROTEIN", 129, 133], ["plasma lipoproteins", "PROTEIN", 214, 233], ["PRDX1", "PROTEIN", 251, 256], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 34, 38], ["PRDX1", "TEST", 17, 22], ["apoE", "TEST", 26, 30], ["aortic sinus lesions", "PROBLEM", 94, 114], ["PRDX1", "TEST", 120, 125], ["PRDX1", "PROBLEM", 251, 256], ["excessive endothelial activation", "PROBLEM", 274, 306], ["atherosclerosis", "PROBLEM", 311, 326], ["larger", "OBSERVATION_MODIFIER", 65, 71], ["more macrophage", "OBSERVATION_MODIFIER", 73, 88], ["aortic sinus", "ANATOMY", 94, 106], ["lesions", "OBSERVATION", 107, 114], ["size", "OBSERVATION_MODIFIER", 171, 175], ["endothelial activation", "OBSERVATION", 284, 306], ["atherosclerosis", "OBSERVATION", 311, 326]]], ["PRDX1 deficiency enhanced the regulated secretion pathway in endothelial cells by promotion of excessive release of several proinflammatory components of Weibel-Palade bodies, such as P-selectin and von Willebrand factor (Kisucka et al., 2008).", [["endothelial cells", "ANATOMY", 61, 78], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["endothelial cells", "CELL", 61, 78], ["P-selectin", "GENE_OR_GENE_PRODUCT", 184, 194], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 199, 220], ["PRDX1", "PROTEIN", 0, 5], ["endothelial cells", "CELL_TYPE", 61, 78], ["proinflammatory components", "PROTEIN", 124, 150], ["Weibel", "PROTEIN", 154, 160], ["P-selectin", "PROTEIN", 184, 194], ["von Willebrand factor", "PROTEIN", 199, 220], ["PRDX1 deficiency", "PROBLEM", 0, 16], ["the regulated secretion pathway in endothelial cells", "PROBLEM", 26, 78], ["excessive release", "PROBLEM", 95, 112], ["several proinflammatory components", "PROBLEM", 116, 150], ["Weibel-Palade bodies", "PROBLEM", 154, 174], ["secretion pathway", "OBSERVATION", 40, 57], ["endothelial cells", "OBSERVATION", 61, 78], ["excessive", "OBSERVATION_MODIFIER", 95, 104], ["several", "OBSERVATION_MODIFIER", 116, 123], ["proinflammatory", "OBSERVATION_MODIFIER", 124, 139], ["Palade", "ANATOMY", 161, 167], ["bodies", "ANATOMY_MODIFIER", 168, 174]]], ["However, PRDX1 deficiency did not affect transcriptional regulation of receptors such as intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule-1 (VCAM-1).Signaling pathway of PRDXs in the development of inflammatory diseases ::: PRDXs and inflammatory diseaseOne study showed that PRDX2 is highly expressed in endothelial and immune cells in atherosclerotic lesions and blocked the increase of endogenous H2O2 by atherogenic stimulation (Park et al., 2011).", [["endothelial", "ANATOMY", 333, 344], ["immune cells", "ANATOMY", 349, 361], ["atherosclerotic lesions", "ANATOMY", 365, 388], ["inflammatory diseases", "DISEASE", 226, 247], ["inflammatory disease", "DISEASE", 262, 282], ["atherosclerotic", "DISEASE", 365, 380], ["H2O2", "CHEMICAL", 428, 432], ["H2O2", "CHEMICAL", 428, 432], ["PRDX1", "GENE_OR_GENE_PRODUCT", 9, 14], ["intercellular adhesion molecule (ICAM)-1", "GENE_OR_GENE_PRODUCT", 89, 129], ["vascular cell adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 134, 167], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 169, 175], ["PRDXs", "GENE_OR_GENE_PRODUCT", 198, 203], ["PRDXs", "GENE_OR_GENE_PRODUCT", 252, 257], ["PRDX2", "GENE_OR_GENE_PRODUCT", 304, 309], ["endothelial", "CELL", 333, 344], ["immune cells", "CELL", 349, 361], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 365, 388], ["H2O2", "SIMPLE_CHEMICAL", 428, 432], ["PRDX1", "PROTEIN", 9, 14], ["intercellular adhesion molecule (ICAM)-1", "PROTEIN", 89, 129], ["vascular cell adhesion molecule-1", "PROTEIN", 134, 167], ["VCAM", "PROTEIN", 169, 173], ["PRDXs", "PROTEIN", 198, 203], ["PRDX2", "PROTEIN", 304, 309], ["endothelial and immune cells", "CELL_TYPE", 333, 361], ["PRDX1 deficiency", "PROBLEM", 9, 25], ["intercellular adhesion molecule", "TEST", 89, 120], ["ICAM)", "TEST", 122, 127], ["vascular cell adhesion molecule", "TEST", 134, 165], ["VCAM", "TEST", 169, 173], ["Signaling pathway of PRDXs", "PROBLEM", 177, 203], ["inflammatory diseases", "PROBLEM", 226, 247], ["PRDXs", "PROBLEM", 252, 257], ["inflammatory disease", "PROBLEM", 262, 282], ["One study", "TEST", 282, 291], ["PRDX2", "PROBLEM", 304, 309], ["atherosclerotic lesions", "PROBLEM", 365, 388], ["endogenous H2O2", "TREATMENT", 417, 432], ["PRDX1 deficiency", "OBSERVATION", 9, 25], ["vascular", "ANATOMY", 134, 142], ["cell adhesion", "OBSERVATION", 143, 156], ["inflammatory", "OBSERVATION_MODIFIER", 226, 238], ["diseases", "OBSERVATION", 239, 247], ["inflammatory", "OBSERVATION_MODIFIER", 262, 274], ["disease", "OBSERVATION", 275, 282], ["endothelial", "ANATOMY", 333, 344], ["immune cells", "OBSERVATION", 349, 361], ["atherosclerotic", "OBSERVATION_MODIFIER", 365, 380], ["lesions", "OBSERVATION", 381, 388], ["increase", "OBSERVATION_MODIFIER", 405, 413], ["endogenous H2O2", "OBSERVATION", 417, 432]]], ["Deficiency of PRDX2 in apoE-/- mice accelerated plaque formation with enhanced activation of p65, c-Jun, JNKs, and p38 mitogen-activated protein kinase; and these proatherogenic effects of PRDX2 deficiency were rescued by the administration of the antioxidant ebselen.", [["plaque", "ANATOMY", 48, 54], ["plaque", "DISEASE", 48, 54], ["PRDX2", "CHEMICAL", 189, 194], ["ebselen", "CHEMICAL", 260, 267], ["ebselen", "CHEMICAL", 260, 267], ["PRDX2", "GENE_OR_GENE_PRODUCT", 14, 19], ["apoE", "GENE_OR_GENE_PRODUCT", 23, 27], ["plaque", "PATHOLOGICAL_FORMATION", 48, 54], ["p65", "GENE_OR_GENE_PRODUCT", 93, 96], ["c-Jun", "GENE_OR_GENE_PRODUCT", 98, 103], ["JNKs", "GENE_OR_GENE_PRODUCT", 105, 109], ["p38 mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 115, 151], ["PRDX2", "GENE_OR_GENE_PRODUCT", 189, 194], ["ebselen", "SIMPLE_CHEMICAL", 260, 267], ["PRDX2", "PROTEIN", 14, 19], ["apoE", "PROTEIN", 23, 27], ["p65", "PROTEIN", 93, 96], ["Jun", "PROTEIN", 100, 103], ["JNKs", "PROTEIN", 105, 109], ["p38 mitogen-activated protein kinase", "PROTEIN", 115, 151], ["PRDX2", "PROTEIN", 189, 194], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["Deficiency of PRDX2", "PROBLEM", 0, 19], ["accelerated plaque formation", "PROBLEM", 36, 64], ["enhanced activation of p65", "PROBLEM", 70, 96], ["JNKs", "TEST", 105, 109], ["p38 mitogen", "TEST", 115, 126], ["activated protein kinase", "TEST", 127, 151], ["PRDX2 deficiency", "PROBLEM", 189, 205], ["the antioxidant ebselen", "TREATMENT", 244, 267], ["plaque", "OBSERVATION", 48, 54], ["proatherogenic", "OBSERVATION_MODIFIER", 163, 177]]], ["Also, they showed that PRDX2 deficiency resulted in increased expression of vascular adhesion molecule-1, intercellular adhesion molecule-1, and monocyte chemotactic protein-1, which led to increased immune cell adhesion and infiltration into the aortic intima.", [["immune cell", "ANATOMY", 200, 211], ["aortic intima", "ANATOMY", 247, 260], ["PRDX2", "GENE_OR_GENE_PRODUCT", 23, 28], ["vascular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 76, 104], ["intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 106, 139], ["monocyte chemotactic protein-1", "GENE_OR_GENE_PRODUCT", 145, 175], ["immune cell", "CELL", 200, 211], ["aortic intima", "TISSUE", 247, 260], ["PRDX2", "PROTEIN", 23, 28], ["vascular adhesion molecule-1", "PROTEIN", 76, 104], ["intercellular adhesion molecule-1", "PROTEIN", 106, 139], ["monocyte chemotactic protein-1", "PROTEIN", 145, 175], ["PRDX2 deficiency", "PROBLEM", 23, 39], ["vascular adhesion molecule", "TEST", 76, 102], ["intercellular adhesion molecule", "TEST", 106, 137], ["monocyte chemotactic protein", "TEST", 145, 173], ["increased immune cell adhesion", "PROBLEM", 190, 220], ["infiltration into the aortic intima", "PROBLEM", 225, 260], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["vascular adhesion", "ANATOMY", 76, 93], ["increased", "OBSERVATION_MODIFIER", 190, 199], ["immune cell adhesion", "OBSERVATION", 200, 220], ["infiltration", "OBSERVATION", 225, 237], ["aortic", "ANATOMY", 247, 253], ["intima", "ANATOMY_MODIFIER", 254, 260]]], ["Moreover, compared with deficiency of glutathione peroxidase 1 or catalase, PRDX2 deficiency showed a severe predisposition to develop atherosclerosis.", [["glutathione", "CHEMICAL", 38, 49], ["atherosclerosis", "DISEASE", 135, 150], ["glutathione", "CHEMICAL", 38, 49], ["glutathione peroxidase 1", "GENE_OR_GENE_PRODUCT", 38, 62], ["catalase", "GENE_OR_GENE_PRODUCT", 66, 74], ["PRDX2", "GENE_OR_GENE_PRODUCT", 76, 81], ["glutathione peroxidase 1", "PROTEIN", 38, 62], ["catalase", "PROTEIN", 66, 74], ["PRDX2", "PROTEIN", 76, 81], ["glutathione peroxidase", "TEST", 38, 60], ["catalase", "TEST", 66, 74], ["PRDX2 deficiency", "PROBLEM", 76, 92], ["a severe predisposition", "PROBLEM", 100, 123], ["atherosclerosis", "PROBLEM", 135, 150], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["atherosclerosis", "OBSERVATION", 135, 150]]], ["Chen et al showed that inflammatory stimuli induce the release of oxidized PRDX2, a ubiquitous redox-active intracellular enzyme (Chen et al., 2004).", [["intracellular", "ANATOMY", 108, 121], ["PRDX2", "GENE_OR_GENE_PRODUCT", 75, 80], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 121], ["PRDX2", "PROTEIN", 75, 80], ["inflammatory stimuli", "PROBLEM", 23, 43], ["a ubiquitous redox", "TEST", 82, 100], ["inflammatory stimuli", "OBSERVATION", 23, 43]]], ["Once released, the extracellular PRDX2 acts as a redox-dependent inflammatory mediator, triggering macrophages to produce and release TNF-\u03b1.", [["extracellular", "ANATOMY", 19, 32], ["macrophages", "ANATOMY", 99, 110], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 32], ["PRDX2", "GENE_OR_GENE_PRODUCT", 33, 38], ["macrophages", "CELL", 99, 110], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 134, 140], ["extracellular PRDX2", "PROTEIN", 19, 38], ["macrophages", "CELL_TYPE", 99, 110], ["TNF", "PROTEIN", 134, 137], ["dependent inflammatory mediator", "PROBLEM", 55, 86], ["TNF", "TEST", 134, 137], ["inflammatory", "OBSERVATION", 65, 77]]], ["The oxidative coupling of glutathione (GSH) to PRDX2 cysteine residues occurs before or during PRDX2 release, a process central to the regulation of immunity (Salzano et al., 2014).", [["glutathione", "CHEMICAL", 26, 37], ["GSH", "CHEMICAL", 39, 42], ["PRDX2 cysteine", "CHEMICAL", 47, 61], ["glutathione", "CHEMICAL", 26, 37], ["GSH", "CHEMICAL", 39, 42], ["cysteine", "CHEMICAL", 53, 61], ["glutathione", "SIMPLE_CHEMICAL", 26, 37], ["GSH", "SIMPLE_CHEMICAL", 39, 42], ["PRDX2", "SIMPLE_CHEMICAL", 47, 52], ["cysteine", "AMINO_ACID", 53, 61], ["PRDX2", "GENE_OR_GENE_PRODUCT", 95, 100], ["PRDX2", "PROTEIN", 95, 100], ["The oxidative coupling of glutathione (GSH)", "TREATMENT", 0, 43], ["PRDX2 cysteine residues", "TREATMENT", 47, 70]]], ["Salzano et al identified PRDX2 among the glutathionylated proteins released in vitro by LPS-stimulated macrophages using mass spectrometry proteomic methods.", [["macrophages", "ANATOMY", 103, 114], ["LPS", "CHEMICAL", 88, 91], ["PRDX2", "GENE_OR_GENE_PRODUCT", 25, 30], ["LPS", "SIMPLE_CHEMICAL", 88, 91], ["macrophages", "CELL", 103, 114], ["PRDX2", "PROTEIN", 25, 30], ["glutathionylated proteins", "PROTEIN", 41, 66], ["stimulated macrophages", "CELL_TYPE", 92, 114], ["Salzano et al identified PRDX2", "TREATMENT", 0, 30], ["the glutathionylated proteins", "TREATMENT", 37, 66], ["mass spectrometry proteomic methods", "PROBLEM", 121, 156]]], ["Consistent with being part of an inflammatory cascade, it was found that PRDX2 then induces TNF-\u03b1 release (Salzano et al., 2014).", [["PRDX2", "GENE_OR_GENE_PRODUCT", 73, 78], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 92, 97], ["PRDX2", "PROTEIN", 73, 78], ["TNF", "PROTEIN", 92, 95], ["an inflammatory cascade", "PROBLEM", 30, 53], ["inflammatory", "OBSERVATION", 33, 45]]], ["Importantly, the PRDX2 substrate TRX is also released along with PRDX2, enabling an oxidative cascade that can alter the \u2013SH status of surface proteins and thereby facilitate activation via cytokine and Toll-like receptors (Salzano et al., 2014).Signaling pathway of PRDXs in the development of inflammatory diseases ::: PRDXs and inflammatory diseasePRDX3 deficiency increased abnormal lipid accumulation in adipose tissue, due to increased ROS.", [["surface", "ANATOMY", 135, 142], ["adipose tissue", "ANATOMY", 409, 423], ["inflammatory diseases", "DISEASE", 295, 316], ["ROS", "CHEMICAL", 442, 445], ["PRDX2", "GENE_OR_GENE_PRODUCT", 17, 22], ["TRX", "GENE_OR_GENE_PRODUCT", 33, 36], ["PRDX2", "GENE_OR_GENE_PRODUCT", 65, 70], ["\u2013SH", "GENE_OR_GENE_PRODUCT", 121, 124], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 203, 222], ["PRDXs", "GENE_OR_GENE_PRODUCT", 267, 272], ["PRDXs", "GENE_OR_GENE_PRODUCT", 321, 326], ["diseasePRDX3", "GENE_OR_GENE_PRODUCT", 344, 356], ["lipid", "SIMPLE_CHEMICAL", 387, 392], ["adipose tissue", "TISSUE", 409, 423], ["ROS", "SIMPLE_CHEMICAL", 442, 445], ["PRDX2 substrate", "PROTEIN", 17, 32], ["TRX", "PROTEIN", 33, 36], ["PRDX2", "PROTEIN", 65, 70], ["\u2013SH", "PROTEIN", 121, 124], ["surface proteins", "PROTEIN", 135, 151], ["cytokine", "PROTEIN", 190, 198], ["Toll-like receptors", "PROTEIN", 203, 222], ["PRDXs", "PROTEIN", 267, 272], ["inflammatory diseasePRDX3", "PROTEIN", 331, 356], ["the PRDX2 substrate TRX", "TREATMENT", 13, 36], ["PRDX2", "TREATMENT", 65, 70], ["an oxidative cascade", "PROBLEM", 81, 101], ["surface proteins", "PROBLEM", 135, 151], ["Signaling pathway of PRDXs", "PROBLEM", 246, 272], ["inflammatory diseases", "PROBLEM", 295, 316], ["PRDXs", "PROBLEM", 321, 326], ["inflammatory diseasePRDX3 deficiency", "PROBLEM", 331, 367], ["increased abnormal lipid accumulation in adipose tissue", "PROBLEM", 368, 423], ["increased ROS", "PROBLEM", 432, 445], ["oxidative cascade", "OBSERVATION", 84, 101], ["inflammatory", "OBSERVATION_MODIFIER", 295, 307], ["inflammatory", "OBSERVATION_MODIFIER", 331, 343], ["diseasePRDX3 deficiency", "OBSERVATION", 344, 367], ["increased", "OBSERVATION_MODIFIER", 368, 377], ["abnormal", "OBSERVATION_MODIFIER", 378, 386], ["lipid accumulation", "OBSERVATION", 387, 405], ["adipose tissue", "OBSERVATION", 409, 423], ["increased", "OBSERVATION_MODIFIER", 432, 441], ["ROS", "OBSERVATION", 442, 445]]], ["PRDX4 is a secretory antioxidant protein which can be detected in plasma.", [["plasma", "ANATOMY", 66, 72], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["plasma", "ORGANISM_SUBSTANCE", 66, 72], ["PRDX4", "PROTEIN", 0, 5], ["secretory antioxidant protein", "PROTEIN", 11, 40], ["a secretory antioxidant protein", "PROBLEM", 9, 40]]], ["By virtue of its antioxidant activity, the extracellular PRDX4 can protect the vascular tissue against ROS and hence, it has ability to inhibit the oxidative stress induced inflammation in various tissues and it can also reduce the chances of oxidative stress induced diabetes mellitus in animal models (Ding et al., 2010).", [["extracellular", "ANATOMY", 43, 56], ["vascular tissue", "ANATOMY", 79, 94], ["tissues", "ANATOMY", 197, 204], ["PRDX4", "CHEMICAL", 57, 62], ["ROS", "CHEMICAL", 103, 106], ["inflammation", "DISEASE", 173, 185], ["diabetes mellitus", "DISEASE", 268, 285], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 56], ["PRDX4", "SIMPLE_CHEMICAL", 57, 62], ["vascular tissue", "TISSUE", 79, 94], ["ROS", "SIMPLE_CHEMICAL", 103, 106], ["tissues", "TISSUE", 197, 204], ["extracellular PRDX4", "PROTEIN", 43, 62], ["the extracellular PRDX4", "TREATMENT", 39, 62], ["the oxidative stress induced inflammation in various tissues", "PROBLEM", 144, 204], ["oxidative stress induced diabetes mellitus", "PROBLEM", 243, 285], ["vascular tissue", "ANATOMY", 79, 94], ["inflammation", "OBSERVATION", 173, 185], ["various tissues", "ANATOMY", 189, 204], ["oxidative stress induced", "OBSERVATION", 243, 267], ["diabetes mellitus", "OBSERVATION", 268, 285]]], ["Yamada et al demonstrated that streptozotocin-treated Tg mice, which overexpress hPRDX4 in pancreatic islets, can protect pancreatic beta-cells against streptozotocin-induced injury (insulitis) by suppressing increased oxidative stress and inflammatory signaling activation (Yamada, Ding, & Sasaguri, 2012).", [["pancreatic islets", "ANATOMY", 91, 108], ["pancreatic beta-cells", "ANATOMY", 122, 143], ["streptozotocin", "CHEMICAL", 31, 45], ["streptozotocin", "CHEMICAL", 152, 166], ["insulitis", "DISEASE", 183, 192], ["streptozotocin", "CHEMICAL", 31, 45], ["streptozotocin", "CHEMICAL", 152, 166], ["streptozotocin", "SIMPLE_CHEMICAL", 31, 45], ["Tg mice", "ORGANISM", 54, 61], ["hPRDX4", "GENE_OR_GENE_PRODUCT", 81, 87], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 91, 108], ["pancreatic beta-cells", "CELL", 122, 143], ["streptozotocin", "SIMPLE_CHEMICAL", 152, 166], ["hPRDX4", "PROTEIN", 81, 87], ["pancreatic islets", "CELL_TYPE", 91, 108], ["pancreatic beta-cells", "CELL_TYPE", 122, 143], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["streptozotocin", "TREATMENT", 31, 45], ["pancreatic islets", "PROBLEM", 91, 108], ["pancreatic beta-cells", "TEST", 122, 143], ["streptozotocin", "PROBLEM", 152, 166], ["induced injury (insulitis)", "PROBLEM", 167, 193], ["suppressing increased oxidative stress", "PROBLEM", 197, 235], ["inflammatory signaling activation", "PROBLEM", 240, 273], ["pancreatic islets", "ANATOMY", 91, 108], ["pancreatic", "ANATOMY", 122, 132], ["oxidative stress", "OBSERVATION", 219, 235], ["inflammatory", "OBSERVATION_MODIFIER", 240, 252]]], ["These observations indicate that Tg mice could become a useful animal model to study the relevance of oxidative stress to inflammation, and that a specific accelerator of PRDX4 might prove to be a potential therapeutic agent for ameliorating various chronic inflammatory diseases.", [["inflammation", "DISEASE", 122, 134], ["PRDX4", "CHEMICAL", 171, 176], ["Tg mice", "ORGANISM", 33, 40], ["PRDX4", "GENE_OR_GENE_PRODUCT", 171, 176], ["PRDX4", "PROTEIN", 171, 176], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["oxidative stress to inflammation", "PROBLEM", 102, 134], ["PRDX4", "TREATMENT", 171, 176], ["therapeutic agent", "TREATMENT", 207, 224], ["ameliorating various chronic inflammatory diseases", "PROBLEM", 229, 279], ["inflammation", "OBSERVATION", 122, 134], ["chronic", "OBSERVATION_MODIFIER", 250, 257], ["inflammatory", "OBSERVATION", 258, 270]]], ["It was also reported that HFD-induced hepatic steatosis and insulin resistance were prevented in PRDX4 transgenic mice by amelioration of oxidative stress (Ding et al., 2010).", [["hepatic", "ANATOMY", 38, 45], ["steatosis", "DISEASE", 46, 55], ["HFD", "SIMPLE_CHEMICAL", 26, 29], ["hepatic", "ORGAN", 38, 45], ["insulin", "GENE_OR_GENE_PRODUCT", 60, 67], ["PRDX4 transgenic mice", "ORGANISM", 97, 118], ["PRDX4", "PROTEIN", 97, 102], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 114, 118], ["HFD", "TEST", 26, 29], ["hepatic steatosis", "PROBLEM", 38, 55], ["insulin resistance", "TREATMENT", 60, 78], ["oxidative stress", "PROBLEM", 138, 154], ["hepatic", "ANATOMY", 38, 45], ["steatosis", "OBSERVATION", 46, 55], ["insulin resistance", "OBSERVATION", 60, 78]]], ["They showed that PRDX4 protects against the progression of nonalcoholic steatohepatitis and insulin resistance, particularly in the liver, in a nongenetic mouse model of nonalcoholic fatty liver disease /or type 2 diabetes mellitus.", [["liver", "ANATOMY", 132, 137], ["nonalcoholic fatty liver", "ANATOMY", 170, 194], ["PRDX4", "CHEMICAL", 17, 22], ["nonalcoholic steatohepatitis", "DISEASE", 59, 87], ["nonalcoholic fatty liver disease", "DISEASE", 170, 202], ["type 2 diabetes mellitus", "DISEASE", 207, 231], ["PRDX4", "GENE_OR_GENE_PRODUCT", 17, 22], ["insulin", "GENE_OR_GENE_PRODUCT", 92, 99], ["liver", "ORGAN", 132, 137], ["mouse", "ORGANISM", 155, 160], ["liver", "ORGAN", 189, 194], ["PRDX4", "PROTEIN", 17, 22], ["mouse", "SPECIES", 155, 160], ["mouse", "SPECIES", 155, 160], ["PRDX4", "TREATMENT", 17, 22], ["nonalcoholic steatohepatitis", "PROBLEM", 59, 87], ["insulin resistance", "PROBLEM", 92, 110], ["nonalcoholic fatty liver disease", "PROBLEM", 170, 202], ["type 2 diabetes mellitus", "PROBLEM", 207, 231], ["progression", "OBSERVATION_MODIFIER", 44, 55], ["nonalcoholic", "OBSERVATION_MODIFIER", 59, 71], ["steatohepatitis", "OBSERVATION", 72, 87], ["insulin resistance", "OBSERVATION", 92, 110], ["liver", "ANATOMY", 132, 137], ["nongenetic mouse model", "OBSERVATION_MODIFIER", 144, 166], ["nonalcoholic", "OBSERVATION_MODIFIER", 170, 182], ["fatty liver disease", "OBSERVATION", 183, 202], ["diabetes mellitus", "OBSERVATION", 214, 231]]], ["These effects of PRDX4 were achieved by reducing oxidative stress and ameliorating hepatic steatosis, inflammatory reaction, apoptotic activity, and fibrogenesis at systemic as well as local levels.Signaling pathway of PRDXs in the development of inflammatory diseases ::: PRDXs and inflammatory diseasePRDX6 is also involved in the several inflammatory related diseases.", [["hepatic", "ANATOMY", 83, 90], ["PRDX4", "CHEMICAL", 17, 22], ["steatosis", "DISEASE", 91, 100], ["fibrogenesis", "DISEASE", 149, 161], ["inflammatory diseases", "DISEASE", 247, 268], ["PRDX4", "GENE_OR_GENE_PRODUCT", 17, 22], ["hepatic", "ORGAN", 83, 90], ["PRDXs", "GENE_OR_GENE_PRODUCT", 219, 224], ["PRDXs", "GENE_OR_GENE_PRODUCT", 273, 278], ["PRDX4", "PROTEIN", 17, 22], ["PRDXs", "PROTEIN", 219, 224], ["inflammatory diseasePRDX6", "PROTEIN", 283, 308], ["PRDX4", "TREATMENT", 17, 22], ["reducing oxidative stress", "PROBLEM", 40, 65], ["ameliorating hepatic steatosis", "PROBLEM", 70, 100], ["inflammatory reaction", "PROBLEM", 102, 123], ["apoptotic activity", "PROBLEM", 125, 143], ["fibrogenesis", "PROBLEM", 149, 161], ["local levels", "TEST", 185, 197], ["Signaling pathway of PRDXs", "PROBLEM", 198, 224], ["inflammatory diseases", "PROBLEM", 247, 268], ["PRDXs", "PROBLEM", 273, 278], ["inflammatory diseasePRDX6", "PROBLEM", 283, 308], ["the several inflammatory related diseases", "PROBLEM", 329, 370], ["oxidative stress", "OBSERVATION", 49, 65], ["ameliorating", "OBSERVATION_MODIFIER", 70, 82], ["hepatic", "ANATOMY", 83, 90], ["steatosis", "OBSERVATION", 91, 100], ["inflammatory", "OBSERVATION_MODIFIER", 102, 114], ["apoptotic activity", "OBSERVATION", 125, 143], ["fibrogenesis", "OBSERVATION", 149, 161], ["inflammatory", "OBSERVATION_MODIFIER", 247, 259], ["diseases", "OBSERVATION", 260, 268], ["inflammatory", "OBSERVATION_MODIFIER", 283, 295], ["several", "OBSERVATION_MODIFIER", 333, 340], ["inflammatory", "OBSERVATION", 341, 353]]], ["Wang et al showed that PRDX6-/- macrophages oxidized LDL significantly more than did controls and plasma lipid hydroperoxide levels were higher in atherogenic diet-fed PRDX6-/- mice than in controls (Wang et al., 2004).", [["PRDX6-/- macrophages", "ANATOMY", 23, 43], ["plasma", "ANATOMY", 98, 104], ["hydroperoxide", "CHEMICAL", 111, 124], ["hydroperoxide", "CHEMICAL", 111, 124], ["PRDX6", "GENE_OR_GENE_PRODUCT", 23, 28], ["LDL", "SIMPLE_CHEMICAL", 53, 56], ["plasma", "ORGANISM_SUBSTANCE", 98, 104], ["lipid", "SIMPLE_CHEMICAL", 105, 110], ["hydroperoxide", "SIMPLE_CHEMICAL", 111, 124], ["PRDX6", "GENE_OR_GENE_PRODUCT", 168, 173], ["mice", "ORGANISM", 177, 181], ["PRDX6", "PROTEIN", 23, 28], ["/- macrophages", "CELL_TYPE", 29, 43], ["LDL", "PROTEIN", 53, 56], ["PRDX6", "PROTEIN", 168, 173], ["mice", "SPECIES", 177, 181], ["PRDX6", "TEST", 23, 28], ["LDL", "TEST", 53, 56], ["plasma lipid hydroperoxide levels", "TEST", 98, 131]]], ["Recent study showed that increased PRDX6 expression suppresses liver injury induced by free radical-mediated damage via inflammation (Khoontawad et al., 2010).", [["liver", "ANATOMY", 63, 68], ["liver injury", "DISEASE", 63, 75], ["inflammation", "DISEASE", 120, 132], ["PRDX6", "GENE_OR_GENE_PRODUCT", 35, 40], ["liver", "ORGAN", 63, 68], ["free radical", "SIMPLE_CHEMICAL", 87, 99], ["PRDX6", "PROTEIN", 35, 40], ["Recent study", "TEST", 0, 12], ["increased PRDX6 expression", "PROBLEM", 25, 51], ["liver injury", "PROBLEM", 63, 75], ["free radical-mediated damage via inflammation", "PROBLEM", 87, 132], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["PRDX6", "OBSERVATION", 35, 40], ["liver", "ANATOMY", 63, 68], ["injury", "OBSERVATION", 69, 75], ["free", "OBSERVATION_MODIFIER", 87, 91], ["radical", "OBSERVATION_MODIFIER", 92, 99], ["damage", "OBSERVATION", 109, 115], ["inflammation", "OBSERVATION", 120, 132]]], ["Likewise, an increased liver injury in PRDX6-knockout mice occurred via increased mitochondrial generation of H2O2 (Eismann et al., 2009).", [["liver", "ANATOMY", 23, 28], ["mitochondrial", "ANATOMY", 82, 95], ["liver injury", "DISEASE", 23, 35], ["H2O2", "CHEMICAL", 110, 114], ["H2O2", "CHEMICAL", 110, 114], ["liver", "ORGAN", 23, 28], ["PRDX6", "GENE_OR_GENE_PRODUCT", 39, 44], ["mice", "ORGANISM", 54, 58], ["mitochondrial", "CELLULAR_COMPONENT", 82, 95], ["H2O2", "SIMPLE_CHEMICAL", 110, 114], ["PRDX6", "PROTEIN", 39, 44], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["an increased liver injury", "PROBLEM", 10, 35], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["liver", "ANATOMY", 23, 28], ["injury", "OBSERVATION", 29, 35], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["mitochondrial generation", "OBSERVATION", 82, 106]]], ["Our recent study suggested that overexpression of PRDX6 promotes development of RA through activation of NF-\u03baB/AP-1 coupled JNK pathway in the CAIA and AIA-induced arthritis development model (Kim et al., 2015).Therapeutic approaches of PRDXs for treatment of diseasePRDXs involved in the several disease related signal pathways.", [["PRDX6", "CHEMICAL", 50, 55], ["RA", "DISEASE", 80, 82], ["CAIA", "CHEMICAL", 143, 147], ["AIA", "CHEMICAL", 152, 155], ["arthritis", "DISEASE", 164, 173], ["PRDXs", "CHEMICAL", 237, 242], ["PRDXs", "DISEASE", 267, 272], ["PRDX6", "GENE_OR_GENE_PRODUCT", 50, 55], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 105, 110], ["AP-1", "GENE_OR_GENE_PRODUCT", 111, 115], ["JNK", "GENE_OR_GENE_PRODUCT", 124, 127], ["CAIA", "SIMPLE_CHEMICAL", 143, 147], ["AIA", "SIMPLE_CHEMICAL", 152, 155], ["PRDXs", "SIMPLE_CHEMICAL", 237, 242], ["PRDXs", "GENE_OR_GENE_PRODUCT", 267, 272], ["PRDX6", "PROTEIN", 50, 55], ["NF-\u03baB", "PROTEIN", 105, 110], ["AP-1", "PROTEIN", 111, 115], ["JNK", "PROTEIN", 124, 127], ["Our recent study", "TEST", 0, 16], ["overexpression of PRDX6", "PROBLEM", 32, 55], ["NF", "TEST", 105, 107], ["AP", "TEST", 111, 113], ["JNK pathway", "TEST", 124, 135], ["the CAIA", "PROBLEM", 139, 147], ["AIA", "PROBLEM", 152, 155], ["arthritis", "PROBLEM", 164, 173], ["PRDXs", "TREATMENT", 237, 242], ["treatment", "TREATMENT", 247, 256], ["diseasePRDXs", "PROBLEM", 260, 272], ["the several disease related signal pathways", "PROBLEM", 285, 328], ["RA", "ANATOMY", 80, 82], ["CAIA", "ANATOMY", 143, 147], ["AIA", "ANATOMY", 152, 155], ["arthritis", "OBSERVATION", 164, 173], ["disease", "OBSERVATION", 260, 267]]], ["Also, PRDXs are involved in inhibiting the cancer development or promoting growth of cancers.", [["cancer", "ANATOMY", 43, 49], ["cancers", "ANATOMY", 85, 92], ["cancer", "DISEASE", 43, 49], ["cancers", "DISEASE", 85, 92], ["PRDXs", "GENE_OR_GENE_PRODUCT", 6, 11], ["cancer", "CANCER", 43, 49], ["cancers", "CANCER", 85, 92], ["PRDXs", "PROTEIN", 6, 11], ["the cancer development", "PROBLEM", 39, 61], ["promoting growth of cancers", "PROBLEM", 65, 92], ["cancer", "OBSERVATION", 43, 49], ["growth", "OBSERVATION_MODIFIER", 75, 81], ["cancers", "OBSERVATION", 85, 92]]], ["So, they can be a potential therapeutic target through targeting these signal pathways.Therapeutic approaches of PRDXs for treatment of diseasePRDX1 has breast tumor suppressive role mediated via c-Myc or PTEN pathways.", [["breast tumor", "ANATOMY", 153, 165], ["PRDXs", "CHEMICAL", 113, 118], ["diseasePRDX1", "CHEMICAL", 136, 148], ["breast tumor", "DISEASE", 153, 165], ["PRDXs", "SIMPLE_CHEMICAL", 113, 118], ["diseasePRDX1", "GENE_OR_GENE_PRODUCT", 136, 148], ["breast tumor", "CANCER", 153, 165], ["c-Myc", "GENE_OR_GENE_PRODUCT", 196, 201], ["PTEN", "GENE_OR_GENE_PRODUCT", 205, 209], ["Myc", "PROTEIN", 198, 201], ["PTEN", "PROTEIN", 205, 209], ["PRDXs", "TREATMENT", 113, 118], ["treatment", "TREATMENT", 123, 132], ["diseasePRDX1", "PROBLEM", 136, 148], ["breast tumor", "PROBLEM", 153, 165], ["breast", "ANATOMY", 153, 159], ["tumor", "OBSERVATION", 160, 165]]], ["This study provides that tumour suppressive function of PRDX1 and PTEN through understanding the mechanistic details of PRDX1 peroxidase activity and PTEN oxidation.", [["tumour", "ANATOMY", 25, 31], ["tumour", "DISEASE", 25, 31], ["tumour", "CANCER", 25, 31], ["PRDX1", "GENE_OR_GENE_PRODUCT", 56, 61], ["PTEN", "GENE_OR_GENE_PRODUCT", 66, 70], ["PRDX1", "GENE_OR_GENE_PRODUCT", 120, 125], ["peroxidase", "GENE_OR_GENE_PRODUCT", 126, 136], ["PTEN", "GENE_OR_GENE_PRODUCT", 150, 154], ["PRDX1", "PROTEIN", 56, 61], ["PTEN", "PROTEIN", 66, 70], ["PRDX1 peroxidase", "PROTEIN", 120, 136], ["PTEN", "PROTEIN", 150, 154], ["This study", "TEST", 0, 10], ["PRDX1 peroxidase activity", "TREATMENT", 120, 145], ["PTEN oxidation", "TREATMENT", 150, 164]]], ["On the other hand, PRDX1 has a tumor promoting effect through NF-kB pathway in Breast cancer, oral cancer and bladder cancer.", [["tumor", "ANATOMY", 31, 36], ["Breast cancer", "ANATOMY", 79, 92], ["oral cancer", "ANATOMY", 94, 105], ["bladder cancer", "ANATOMY", 110, 124], ["PRDX1", "CHEMICAL", 19, 24], ["tumor", "DISEASE", 31, 36], ["Breast cancer", "DISEASE", 79, 92], ["oral cancer", "DISEASE", 94, 105], ["bladder cancer", "DISEASE", 110, 124], ["PRDX1", "GENE_OR_GENE_PRODUCT", 19, 24], ["tumor", "CANCER", 31, 36], ["NF-kB", "GENE_OR_GENE_PRODUCT", 62, 67], ["Breast cancer", "CANCER", 79, 92], ["oral cancer", "CANCER", 94, 105], ["bladder cancer", "CANCER", 110, 124], ["PRDX1", "PROTEIN", 19, 24], ["NF-kB", "PROTEIN", 62, 67], ["a tumor", "PROBLEM", 29, 36], ["Breast cancer", "PROBLEM", 79, 92], ["oral cancer", "PROBLEM", 94, 105], ["bladder cancer", "PROBLEM", 110, 124], ["tumor", "OBSERVATION", 31, 36], ["Breast", "ANATOMY", 79, 85], ["cancer", "OBSERVATION", 86, 92], ["oral", "ANATOMY", 94, 98], ["cancer", "OBSERVATION", 99, 105], ["bladder", "ANATOMY", 110, 117], ["cancer", "OBSERVATION", 118, 124]]], ["PRDX1 suppressed FOXO1 induced apoptosis in lung cancer, activates mTOR/p70S6K pathway in esophageal squamous cell carcinoma and upregulates pancreatic cancer invasion by modulating p38 MAPK signaling.", [["lung cancer", "ANATOMY", 44, 55], ["esophageal squamous cell carcinoma", "ANATOMY", 90, 124], ["pancreatic cancer", "ANATOMY", 141, 158], ["PRDX1", "CHEMICAL", 0, 5], ["lung cancer", "DISEASE", 44, 55], ["esophageal squamous cell carcinoma", "DISEASE", 90, 124], ["pancreatic cancer", "DISEASE", 141, 158], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["FOXO1", "GENE_OR_GENE_PRODUCT", 17, 22], ["lung cancer", "CANCER", 44, 55], ["mTOR", "GENE_OR_GENE_PRODUCT", 67, 71], ["p70S6K", "GENE_OR_GENE_PRODUCT", 72, 78], ["esophageal squamous cell carcinoma", "CANCER", 90, 124], ["pancreatic cancer", "CANCER", 141, 158], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 182, 190], ["PRDX1", "PROTEIN", 0, 5], ["FOXO1", "PROTEIN", 17, 22], ["mTOR", "PROTEIN", 67, 71], ["70S6K", "PROTEIN", 73, 78], ["p38 MAPK", "PROTEIN", 182, 190], ["PRDX1", "PROBLEM", 0, 5], ["FOXO1 induced apoptosis in lung cancer", "PROBLEM", 17, 55], ["esophageal squamous cell carcinoma", "PROBLEM", 90, 124], ["pancreatic cancer invasion", "PROBLEM", 141, 167], ["apoptosis", "OBSERVATION_MODIFIER", 31, 40], ["lung", "ANATOMY", 44, 48], ["cancer", "OBSERVATION", 49, 55], ["esophageal", "ANATOMY", 90, 100], ["squamous cell carcinoma", "OBSERVATION", 101, 124], ["pancreatic", "ANATOMY", 141, 151], ["cancer", "OBSERVATION", 152, 158]]], ["So, enhanced expression of PRDX1 through cancer related pathways serves as a useful marker for the prognosis of patients with this disease and PRDX1 may be a promising molecular target for the therapeutic intervention of these cancer types.Therapeutic approaches of PRDXs for treatment of diseasePRDX2 promotes colon cancer through upregulation of Wnt/\u03b2-catenin pathway, promotes prostate cancer through upregulation of AR activity.", [["cancer", "ANATOMY", 41, 47], ["cancer", "ANATOMY", 227, 233], ["colon cancer", "ANATOMY", 311, 323], ["prostate cancer", "ANATOMY", 380, 395], ["cancer", "DISEASE", 41, 47], ["cancer", "DISEASE", 227, 233], ["PRDXs", "CHEMICAL", 266, 271], ["diseasePRDX2", "CHEMICAL", 289, 301], ["colon cancer", "DISEASE", 311, 323], ["prostate cancer", "DISEASE", 380, 395], ["PRDX1", "GENE_OR_GENE_PRODUCT", 27, 32], ["cancer", "CANCER", 41, 47], ["patients", "ORGANISM", 112, 120], ["PRDX1", "GENE_OR_GENE_PRODUCT", 143, 148], ["cancer", "CANCER", 227, 233], ["PRDXs", "SIMPLE_CHEMICAL", 266, 271], ["diseasePRDX2", "GENE_OR_GENE_PRODUCT", 289, 301], ["colon cancer", "CANCER", 311, 323], ["Wnt", "GENE_OR_GENE_PRODUCT", 348, 351], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 352, 361], ["prostate cancer", "CANCER", 380, 395], ["AR", "GENE_OR_GENE_PRODUCT", 420, 422], ["PRDX1", "PROTEIN", 27, 32], ["PRDX1", "PROTEIN", 143, 148], ["diseasePRDX2", "PROTEIN", 289, 301], ["\u03b2-catenin", "PROTEIN", 352, 361], ["AR", "PROTEIN", 420, 422], ["patients", "SPECIES", 112, 120], ["PRDX1 through cancer", "PROBLEM", 27, 47], ["this disease", "PROBLEM", 126, 138], ["PRDX1", "PROBLEM", 143, 148], ["the therapeutic intervention", "TREATMENT", 189, 217], ["these cancer types", "PROBLEM", 221, 239], ["PRDXs", "TREATMENT", 266, 271], ["treatment", "TREATMENT", 276, 285], ["diseasePRDX2", "PROBLEM", 289, 301], ["colon cancer", "PROBLEM", 311, 323], ["Wnt/\u03b2-catenin pathway", "TREATMENT", 348, 369], ["prostate cancer", "PROBLEM", 380, 395], ["AR activity", "PROBLEM", 420, 431], ["cancer", "OBSERVATION", 41, 47], ["cancer", "OBSERVATION", 227, 233], ["colon", "ANATOMY", 311, 316], ["cancer", "OBSERVATION", 317, 323], ["prostate", "ANATOMY", 380, 388], ["cancer", "OBSERVATION", 389, 395], ["activity", "OBSERVATION_MODIFIER", 423, 431]]], ["So, designing therapeutics targeting PRDX2 may offer a novel strategy for developing treatment for cancer.Therapeutic approaches of PRDXs for treatment of diseaseMoreover, several studies demonstrated that overexpression of PRDX1 and PRDX2 has an important role in several drug resistances, and several therapeutic agents targeting PRDX1 and PRDX2 are studied for treatment of cancer.", [["cancer", "ANATOMY", 99, 105], ["cancer", "ANATOMY", 377, 383], ["PRDX2", "CHEMICAL", 37, 42], ["cancer", "DISEASE", 99, 105], ["PRDXs", "CHEMICAL", 132, 137], ["PRDX2", "CHEMICAL", 234, 239], ["cancer", "DISEASE", 377, 383], ["PRDX2", "GENE_OR_GENE_PRODUCT", 37, 42], ["cancer", "CANCER", 99, 105], ["PRDXs", "SIMPLE_CHEMICAL", 132, 137], ["PRDX1", "GENE_OR_GENE_PRODUCT", 224, 229], ["PRDX2", "GENE_OR_GENE_PRODUCT", 234, 239], ["PRDX1", "GENE_OR_GENE_PRODUCT", 332, 337], ["PRDX2", "GENE_OR_GENE_PRODUCT", 342, 347], ["cancer", "CANCER", 377, 383], ["PRDX2", "PROTEIN", 37, 42], ["PRDX1", "PROTEIN", 224, 229], ["PRDX2", "PROTEIN", 234, 239], ["PRDX1", "PROTEIN", 332, 337], ["PRDX2", "PROTEIN", 342, 347], ["therapeutics targeting PRDX2", "TREATMENT", 14, 42], ["a novel strategy", "TREATMENT", 53, 69], ["developing treatment", "TREATMENT", 74, 94], ["cancer", "PROBLEM", 99, 105], ["PRDXs", "TREATMENT", 132, 137], ["treatment", "TREATMENT", 142, 151], ["diseaseMoreover", "PROBLEM", 155, 170], ["several studies", "TEST", 172, 187], ["overexpression of PRDX1", "PROBLEM", 206, 229], ["PRDX2", "TREATMENT", 234, 239], ["several drug resistances", "TREATMENT", 265, 289], ["several therapeutic agents", "TREATMENT", 295, 321], ["PRDX2", "TREATMENT", 342, 347], ["cancer", "PROBLEM", 377, 383], ["cancer", "OBSERVATION", 99, 105], ["cancer", "OBSERVATION", 377, 383]]], ["He et al showed that PRDX1 knockdown enhances sensitization to \u03b2-lap that is an anticancer agent through modulating ROS accumulation and MAPK activation (He et al., 2013).", [["anticancer", "ANATOMY", 80, 90], ["PRDX1", "CHEMICAL", 21, 26], ["\u03b2-lap", "CHEMICAL", 63, 68], ["\u03b2-lap", "CHEMICAL", 63, 68], ["PRDX1", "GENE_OR_GENE_PRODUCT", 21, 26], ["\u03b2-lap", "SIMPLE_CHEMICAL", 63, 68], ["anticancer", "CANCER", 80, 90], ["ROS", "SIMPLE_CHEMICAL", 116, 119], ["MAPK", "GENE_OR_GENE_PRODUCT", 137, 141], ["PRDX1", "PROTEIN", 21, 26], ["MAPK", "PROTEIN", 137, 141], ["an anticancer agent", "TREATMENT", 77, 96], ["modulating ROS accumulation", "PROBLEM", 105, 132], ["MAPK activation", "TEST", 137, 152], ["anticancer", "OBSERVATION", 80, 90], ["ROS accumulation", "OBSERVATION", 116, 132]]], ["Also, downregulation of PRDX1 by a novel fully human phage display recombinant antibody induces apoptosis and enhances radiation sensitization in lung carcinoma cells (Guo et al., 2011), indicating that PRDX1 could be targets competing against cancer.", [["lung carcinoma cells", "ANATOMY", 146, 166], ["cancer", "ANATOMY", 244, 250], ["lung carcinoma", "DISEASE", 146, 160], ["PRDX1", "CHEMICAL", 203, 208], ["cancer", "DISEASE", 244, 250], ["PRDX1", "GENE_OR_GENE_PRODUCT", 24, 29], ["human", "ORGANISM", 47, 52], ["lung carcinoma cells", "CELL", 146, 166], ["PRDX1", "GENE_OR_GENE_PRODUCT", 203, 208], ["cancer", "CANCER", 244, 250], ["PRDX1", "PROTEIN", 24, 29], ["human phage display recombinant antibody", "PROTEIN", 47, 87], ["lung carcinoma cells", "CELL_TYPE", 146, 166], ["PRDX1", "PROTEIN", 203, 208], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["downregulation of PRDX1", "TREATMENT", 6, 29], ["a novel fully human phage", "TREATMENT", 33, 58], ["recombinant antibody", "PROBLEM", 67, 87], ["apoptosis", "PROBLEM", 96, 105], ["enhances radiation sensitization", "TREATMENT", 110, 142], ["lung carcinoma cells", "PROBLEM", 146, 166], ["PRDX1", "PROBLEM", 203, 208], ["cancer", "PROBLEM", 244, 250], ["radiation sensitization", "OBSERVATION", 119, 142], ["lung", "ANATOMY", 146, 150], ["carcinoma", "OBSERVATION", 151, 160]]], ["The therapeutic agents targeting PRDX1 are studied for treatment of cancer.", [["cancer", "ANATOMY", 68, 74], ["cancer", "DISEASE", 68, 74], ["PRDX1", "GENE_OR_GENE_PRODUCT", 33, 38], ["cancer", "CANCER", 68, 74], ["PRDX1", "PROTEIN", 33, 38], ["The therapeutic agents", "TREATMENT", 0, 22], ["cancer", "PROBLEM", 68, 74], ["cancer", "OBSERVATION", 68, 74]]], ["A recent study demonstrated that theonellasterone, a steroidal metabolite isolated from a Theonellasponge targets the PRDX1 and protects its cysteine over-oxidation induced by H2O2 both in vitro and in vivo.", [["theonellasterone", "CHEMICAL", 33, 49], ["PRDX1", "CHEMICAL", 118, 123], ["H2O2", "CHEMICAL", 176, 180], ["theonellasterone", "CHEMICAL", 33, 49], ["cysteine", "CHEMICAL", 141, 149], ["H2O2", "CHEMICAL", 176, 180], ["theonellasterone", "SIMPLE_CHEMICAL", 33, 49], ["PRDX1", "GENE_OR_GENE_PRODUCT", 118, 123], ["cysteine", "AMINO_ACID", 141, 149], ["H2O2", "SIMPLE_CHEMICAL", 176, 180], ["A recent study", "TEST", 0, 14], ["theonellasterone", "TREATMENT", 33, 49], ["a steroidal metabolite", "PROBLEM", 51, 73], ["a Theonellasponge", "TREATMENT", 88, 105], ["the PRDX1", "TREATMENT", 114, 123], ["its cysteine", "TREATMENT", 137, 149], ["H2O2", "TREATMENT", 176, 180]]], ["This suggested that THS can be used as an anticancer agent for several cancers (Margarucci et al., 2015).", [["anticancer", "ANATOMY", 42, 52], ["cancers", "ANATOMY", 71, 78], ["THS", "CHEMICAL", 20, 23], ["cancers", "DISEASE", 71, 78], ["THS", "CHEMICAL", 20, 23], ["THS", "SIMPLE_CHEMICAL", 20, 23], ["anticancer", "CANCER", 42, 52], ["cancers", "CANCER", 71, 78], ["an anticancer agent", "TREATMENT", 39, 58], ["several cancers", "PROBLEM", 63, 78]]], ["Liu et al also demonstrated that adenanthin, a diterpenoid isolated from the leaves of Rabdosia adenantha inhibits the tumor growth in the mouse acute promyelocytic leukemia mouse model by directly targeting the conserved resolving cysteines of PRDX1 as well as PRDX2 and inhibits their peroxidase activities (Liu et al., 2012).", [["leaves", "ANATOMY", 77, 83], ["tumor", "ANATOMY", 119, 124], ["acute promyelocytic leukemia", "ANATOMY", 145, 173], ["adenanthin", "CHEMICAL", 33, 43], ["Rabdosia adenantha", "CHEMICAL", 87, 105], ["tumor", "DISEASE", 119, 124], ["acute promyelocytic leukemia", "DISEASE", 145, 173], ["adenanthin", "CHEMICAL", 33, 43], ["diterpenoid", "CHEMICAL", 47, 58], ["cysteines", "CHEMICAL", 232, 241], ["adenanthin", "SIMPLE_CHEMICAL", 33, 43], ["leaves", "ORGANISM_SUBDIVISION", 77, 83], ["Rabdosia adenantha", "ORGANISM", 87, 105], ["tumor", "CANCER", 119, 124], ["mouse", "ORGANISM", 139, 144], ["acute promyelocytic leukemia", "CANCER", 145, 173], ["mouse", "ORGANISM", 174, 179], ["PRDX1", "GENE_OR_GENE_PRODUCT", 245, 250], ["PRDX2", "GENE_OR_GENE_PRODUCT", 262, 267], ["peroxidase", "GENE_OR_GENE_PRODUCT", 287, 297], ["PRDX1", "PROTEIN", 245, 250], ["PRDX2", "PROTEIN", 262, 267], ["peroxidase", "PROTEIN", 287, 297], ["Rabdosia adenantha", "SPECIES", 87, 105], ["mouse", "SPECIES", 139, 144], ["mouse", "SPECIES", 174, 179], ["Rabdosia adenantha", "SPECIES", 87, 105], ["mouse acute promyelocytic leukemia mouse", "SPECIES", 139, 179], ["a diterpenoid", "PROBLEM", 45, 58], ["Rabdosia adenantha", "PROBLEM", 87, 105], ["the tumor growth", "PROBLEM", 115, 131], ["the mouse acute promyelocytic leukemia mouse model", "PROBLEM", 135, 185], ["cysteines of PRDX1", "TREATMENT", 232, 250], ["tumor", "OBSERVATION", 119, 124], ["growth", "OBSERVATION_MODIFIER", 125, 131], ["mouse", "OBSERVATION_MODIFIER", 139, 144], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["promyelocytic leukemia mouse model", "OBSERVATION", 151, 185]]], ["Hou et al also investigated the effect of adenanthin on HCC cells, and found that the natural agent can kill malignant liver cells in vitro and xenografts through targeting PRDX1 and PRDX2, thus increasing ROS level (Hou et al., 2014).Therapeutic approaches of PRDXs for treatment of diseaseOverexpression of PRDX3 has an important role in several drug resistances.", [["HCC cells", "ANATOMY", 56, 65], ["malignant liver cells", "ANATOMY", 109, 130], ["xenografts", "ANATOMY", 144, 154], ["adenanthin", "CHEMICAL", 42, 52], ["HCC", "DISEASE", 56, 59], ["PRDXs", "CHEMICAL", 261, 266], ["PRDX3", "CHEMICAL", 309, 314], ["adenanthin", "CHEMICAL", 42, 52], ["adenanthin", "SIMPLE_CHEMICAL", 42, 52], ["HCC cells", "CELL", 56, 65], ["malignant liver cells", "CELL", 109, 130], ["xenografts", "CANCER", 144, 154], ["PRDX1", "GENE_OR_GENE_PRODUCT", 173, 178], ["PRDX2", "GENE_OR_GENE_PRODUCT", 183, 188], ["ROS", "SIMPLE_CHEMICAL", 206, 209], ["PRDXs", "SIMPLE_CHEMICAL", 261, 266], ["PRDX3", "GENE_OR_GENE_PRODUCT", 309, 314], ["HCC cells", "CELL_TYPE", 56, 65], ["malignant liver cells", "CELL_TYPE", 109, 130], ["PRDX1", "PROTEIN", 173, 178], ["PRDX2", "PROTEIN", 183, 188], ["PRDX3", "PROTEIN", 309, 314], ["adenanthin on HCC cells", "PROBLEM", 42, 65], ["malignant liver cells", "PROBLEM", 109, 130], ["vitro and xenografts", "TREATMENT", 134, 154], ["PRDX1", "TEST", 173, 178], ["PRDX2", "TREATMENT", 183, 188], ["increasing ROS level", "PROBLEM", 195, 215], ["PRDXs", "TREATMENT", 261, 266], ["treatment", "TREATMENT", 271, 280], ["disease", "PROBLEM", 284, 291], ["disease", "OBSERVATION", 284, 291]]], ["The silencing of PRDX3 triggered cisplatin\u2011mediated apoptosis in ovarian cancer cells through suppression of the NF\u2011\u03baB signaling pathway (Duan et al., 2013), suggesting that PRDX3 is involved in drug resistance.", [["ovarian cancer cells", "ANATOMY", 65, 85], ["PRDX3", "CHEMICAL", 17, 22], ["ovarian cancer", "DISEASE", 65, 79], ["PRDX3", "CHEMICAL", 174, 179], ["PRDX3", "GENE_OR_GENE_PRODUCT", 17, 22], ["ovarian cancer cells", "CELL", 65, 85], ["NF\u2011\u03baB", "GENE_OR_GENE_PRODUCT", 113, 118], ["PRDX3", "GENE_OR_GENE_PRODUCT", 174, 179], ["PRDX3", "PROTEIN", 17, 22], ["ovarian cancer cells", "CELL_TYPE", 65, 85], ["NF\u2011\u03baB", "PROTEIN", 113, 118], ["PRDX3", "PROTEIN", 174, 179], ["PRDX3", "PROBLEM", 17, 22], ["cisplatin\u2011mediated apoptosis", "PROBLEM", 33, 61], ["ovarian cancer cells", "PROBLEM", 65, 85], ["ovarian", "ANATOMY", 65, 72], ["cancer", "OBSERVATION", 73, 79], ["drug resistance", "OBSERVATION", 195, 210]]], ["PRDX3 also promotes breast cancer through upregulation of cell cycle and cell proliferation, enhances the risk of prostate cancer, thymoma and hepatocellular carcinoma through increased resistance to oxidative stress.", [["breast cancer", "ANATOMY", 20, 33], ["cell", "ANATOMY", 58, 62], ["cell", "ANATOMY", 73, 77], ["prostate cancer", "ANATOMY", 114, 129], ["thymoma", "ANATOMY", 131, 138], ["hepatocellular carcinoma", "ANATOMY", 143, 167], ["PRDX3", "CHEMICAL", 0, 5], ["breast cancer", "DISEASE", 20, 33], ["prostate cancer", "DISEASE", 114, 129], ["thymoma", "DISEASE", 131, 138], ["hepatocellular carcinoma", "DISEASE", 143, 167], ["PRDX3", "GENE_OR_GENE_PRODUCT", 0, 5], ["breast cancer", "CANCER", 20, 33], ["cell", "CELL", 58, 62], ["cell", "CELL", 73, 77], ["prostate cancer", "CANCER", 114, 129], ["thymoma", "CANCER", 131, 138], ["hepatocellular carcinoma", "CANCER", 143, 167], ["PRDX3", "PROTEIN", 0, 5], ["breast cancer", "PROBLEM", 20, 33], ["cell cycle", "TREATMENT", 58, 68], ["cell proliferation", "PROBLEM", 73, 91], ["prostate cancer", "PROBLEM", 114, 129], ["thymoma", "PROBLEM", 131, 138], ["hepatocellular carcinoma", "PROBLEM", 143, 167], ["increased resistance to oxidative stress", "PROBLEM", 176, 216], ["breast", "ANATOMY", 20, 26], ["cancer", "OBSERVATION", 27, 33], ["cell cycle", "OBSERVATION", 58, 68], ["cell proliferation", "OBSERVATION", 73, 91], ["prostate", "ANATOMY", 114, 122], ["cancer", "OBSERVATION", 123, 129], ["thymoma", "OBSERVATION", 131, 138], ["hepatocellular", "ANATOMY", 143, 157], ["carcinoma", "OBSERVATION", 158, 167], ["increased", "OBSERVATION_MODIFIER", 176, 185], ["resistance", "OBSERVATION_MODIFIER", 186, 196], ["oxidative stress", "OBSERVATION", 200, 216]]], ["Prolonged drug exposure may result in cumulative toxicity.", [["toxicity", "DISEASE", 49, 57], ["Prolonged drug exposure", "PROBLEM", 0, 23], ["cumulative toxicity", "PROBLEM", 38, 57], ["cumulative toxicity", "OBSERVATION", 38, 57]]], ["The clinical efficacy of chemotherapy must be enhanced, its attendant toxicity reduced, and resistance overcome.", [["toxicity", "DISEASE", 70, 78], ["chemotherapy", "TREATMENT", 25, 37], ["its attendant toxicity", "PROBLEM", 56, 78]]], ["To overcome multidrug resistance in cancer cells, recent chemotherapeutics could be used in combination with other molecules.", [["cancer cells", "ANATOMY", 36, 48], ["cancer", "DISEASE", 36, 42], ["cancer cells", "CELL", 36, 48], ["cancer cells", "CELL_TYPE", 36, 48], ["multidrug resistance in cancer cells", "PROBLEM", 12, 48], ["recent chemotherapeutics", "TREATMENT", 50, 74], ["multidrug resistance", "OBSERVATION", 12, 32], ["cancer cells", "OBSERVATION", 36, 48]]], ["So, PRDX3 may be a therapeutic target for the combination treatment of several drug resistant cancers.Therapeutic approaches of PRDXs for treatment of diseasePRDX4 promotes lung cancer, leukemia, glioblastoma, oral squamous cell carcinoma, cardiovascular disease, hepatic diseases and colorectal carcinoma.", [["cancers", "ANATOMY", 94, 101], ["lung cancer", "ANATOMY", 173, 184], ["leukemia", "ANATOMY", 186, 194], ["glioblastoma", "ANATOMY", 196, 208], ["oral squamous cell carcinoma", "ANATOMY", 210, 238], ["cardiovascular", "ANATOMY", 240, 254], ["hepatic", "ANATOMY", 264, 271], ["colorectal carcinoma", "ANATOMY", 285, 305], ["PRDX3", "CHEMICAL", 4, 9], ["cancers", "DISEASE", 94, 101], ["PRDXs", "CHEMICAL", 128, 133], ["diseasePRDX4", "CHEMICAL", 151, 163], ["lung cancer", "DISEASE", 173, 184], ["leukemia", "DISEASE", 186, 194], ["glioblastoma", "DISEASE", 196, 208], ["oral squamous cell carcinoma", "DISEASE", 210, 238], ["cardiovascular disease", "DISEASE", 240, 262], ["hepatic diseases", "DISEASE", 264, 280], ["colorectal carcinoma", "DISEASE", 285, 305], ["PRDX3", "GENE_OR_GENE_PRODUCT", 4, 9], ["cancers", "CANCER", 94, 101], ["PRDXs", "SIMPLE_CHEMICAL", 128, 133], ["lung cancer", "CANCER", 173, 184], ["leukemia", "CANCER", 186, 194], ["glioblastoma", "CANCER", 196, 208], ["oral squamous cell carcinoma", "CANCER", 210, 238], ["cardiovascular", "ANATOMICAL_SYSTEM", 240, 254], ["hepatic", "ORGAN", 264, 271], ["colorectal carcinoma", "CANCER", 285, 305], ["PRDX3", "PROTEIN", 4, 9], ["PRDX3", "TREATMENT", 4, 9], ["the combination treatment", "TREATMENT", 42, 67], ["several drug resistant cancers", "PROBLEM", 71, 101], ["PRDXs", "TREATMENT", 128, 133], ["treatment", "TREATMENT", 138, 147], ["diseasePRDX4", "PROBLEM", 151, 163], ["lung cancer", "PROBLEM", 173, 184], ["leukemia", "PROBLEM", 186, 194], ["glioblastoma", "PROBLEM", 196, 208], ["oral squamous cell carcinoma", "PROBLEM", 210, 238], ["cardiovascular disease", "PROBLEM", 240, 262], ["hepatic diseases", "PROBLEM", 264, 280], ["colorectal carcinoma", "PROBLEM", 285, 305], ["several", "OBSERVATION_MODIFIER", 71, 78], ["drug resistant cancers", "OBSERVATION", 79, 101], ["lung", "ANATOMY", 173, 177], ["cancer", "OBSERVATION", 178, 184], ["leukemia", "OBSERVATION", 186, 194], ["glioblastoma", "OBSERVATION", 196, 208], ["squamous cell carcinoma", "OBSERVATION", 215, 238], ["hepatic", "ANATOMY", 264, 271], ["diseases", "OBSERVATION", 272, 280], ["colorectal", "ANATOMY", 285, 295], ["carcinoma", "OBSERVATION", 296, 305]]], ["PRDX4 is involved in the tumor promoting effect through formation of Srx-PRDX4 via AP-1/MMP-9 and MAPK signaling, and remove cellular ROS which provides a favorable microenvironment for cell proliferation.", [["tumor", "ANATOMY", 25, 30], ["cellular", "ANATOMY", 125, 133], ["cell", "ANATOMY", 186, 190], ["tumor", "DISEASE", 25, 30], ["ROS", "CHEMICAL", 134, 137], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor", "CANCER", 25, 30], ["Srx-PRDX4", "GENE_OR_GENE_PRODUCT", 69, 78], ["AP-1", "GENE_OR_GENE_PRODUCT", 83, 87], ["MMP-9", "GENE_OR_GENE_PRODUCT", 88, 93], ["MAPK", "GENE_OR_GENE_PRODUCT", 98, 102], ["cellular", "CELL", 125, 133], ["ROS", "SIMPLE_CHEMICAL", 134, 137], ["cell", "CELL", 186, 190], ["PRDX4", "PROTEIN", 0, 5], ["Srx-PRDX4", "PROTEIN", 69, 78], ["MMP", "PROTEIN", 88, 91], ["MAPK", "PROTEIN", 98, 102], ["Srx-", "TEST", 69, 73], ["AP", "TEST", 83, 85], ["MMP", "TEST", 88, 91], ["MAPK signaling", "TEST", 98, 112], ["cellular ROS", "TEST", 125, 137], ["cell proliferation", "PROBLEM", 186, 204], ["tumor", "OBSERVATION", 25, 30], ["cell proliferation", "OBSERVATION", 186, 204]]], ["Prx-4 can be used as an important therapeutic target in this disorder.Therapeutic approaches of PRDXs for treatment of diseasePRDX6 promotes lung tumor development via JAK2/STAT3 pathway, its GPx and iPLA2 activities, and is involved in drug resistance of several cancer types, suggesting that PRDX6 can be a therapeutic target for cancer treatment.", [["lung tumor", "ANATOMY", 141, 151], ["cancer", "ANATOMY", 264, 270], ["cancer", "ANATOMY", 332, 338], ["PRDXs", "CHEMICAL", 96, 101], ["diseasePRDX6", "CHEMICAL", 119, 131], ["tumor", "DISEASE", 146, 151], ["cancer", "DISEASE", 264, 270], ["PRDX6", "CHEMICAL", 294, 299], ["cancer", "DISEASE", 332, 338], ["Prx-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["PRDXs", "SIMPLE_CHEMICAL", 96, 101], ["diseasePRDX6", "GENE_OR_GENE_PRODUCT", 119, 131], ["lung tumor", "CANCER", 141, 151], ["JAK2", "GENE_OR_GENE_PRODUCT", 168, 172], ["STAT3", "GENE_OR_GENE_PRODUCT", 173, 178], ["GPx", "GENE_OR_GENE_PRODUCT", 192, 195], ["iPLA2", "GENE_OR_GENE_PRODUCT", 200, 205], ["cancer", "CANCER", 264, 270], ["PRDX6", "GENE_OR_GENE_PRODUCT", 294, 299], ["cancer", "CANCER", 332, 338], ["Prx-4", "PROTEIN", 0, 5], ["diseasePRDX6", "PROTEIN", 119, 131], ["JAK2", "PROTEIN", 168, 172], ["STAT3", "PROTEIN", 173, 178], ["GPx", "PROTEIN", 192, 195], ["iPLA2", "PROTEIN", 200, 205], ["PRDX6", "PROTEIN", 294, 299], ["Prx", "TEST", 0, 3], ["this disorder", "PROBLEM", 56, 69], ["PRDXs", "TREATMENT", 96, 101], ["treatment", "TREATMENT", 106, 115], ["diseasePRDX6", "PROBLEM", 119, 131], ["lung tumor", "PROBLEM", 141, 151], ["JAK2/STAT3 pathway", "TREATMENT", 168, 186], ["several cancer types", "PROBLEM", 256, 276], ["PRDX6", "PROBLEM", 294, 299], ["cancer treatment", "TREATMENT", 332, 348], ["lung", "ANATOMY", 141, 145], ["tumor", "OBSERVATION", 146, 151], ["several", "OBSERVATION_MODIFIER", 256, 263], ["cancer", "OBSERVATION", 264, 270]]], ["Our recent study suggested that thiacremonone inhibits tumor growth via inhibition of glutathione peroxidase activity of PRDX6 through interaction, suggesting that thiacremonone may have potential beneficial effects in lung cancer (Jo et al., 2014).", [["tumor", "ANATOMY", 55, 60], ["lung cancer", "ANATOMY", 219, 230], ["thiacremonone", "CHEMICAL", 32, 45], ["tumor", "DISEASE", 55, 60], ["glutathione", "CHEMICAL", 86, 97], ["thiacremonone", "CHEMICAL", 164, 177], ["lung cancer", "DISEASE", 219, 230], ["thiacremonone", "CHEMICAL", 32, 45], ["glutathione", "CHEMICAL", 86, 97], ["thiacremonone", "CHEMICAL", 164, 177], ["thiacremonone", "SIMPLE_CHEMICAL", 32, 45], ["tumor", "CANCER", 55, 60], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 86, 108], ["PRDX6", "GENE_OR_GENE_PRODUCT", 121, 126], ["thiacremonone", "SIMPLE_CHEMICAL", 164, 177], ["lung cancer", "CANCER", 219, 230], ["glutathione peroxidase", "PROTEIN", 86, 108], ["PRDX6", "PROTEIN", 121, 126], ["Our recent study", "TEST", 0, 16], ["thiacremonone inhibits tumor growth", "PROBLEM", 32, 67], ["glutathione peroxidase activity", "TREATMENT", 86, 117], ["lung cancer", "PROBLEM", 219, 230], ["tumor", "OBSERVATION", 55, 60], ["lung", "ANATOMY", 219, 223], ["cancer", "OBSERVATION", 224, 230]]], ["These data indicate that PRDX6 could be targets of several cancers and the therapeutic agents for targeting PRDX6 may have potentially beneficial effects in cancer treatment.Therapeutic approaches of PRDXs for treatment of diseasePRDXs could be targets for the treatment of neurodegenerative diseases.", [["cancers", "ANATOMY", 59, 66], ["cancer", "ANATOMY", 157, 163], ["PRDX6", "CHEMICAL", 25, 30], ["cancers", "DISEASE", 59, 66], ["PRDX6", "CHEMICAL", 108, 113], ["cancer", "DISEASE", 157, 163], ["PRDXs", "CHEMICAL", 200, 205], ["PRDXs", "DISEASE", 230, 235], ["neurodegenerative diseases", "DISEASE", 274, 300], ["PRDX6", "GENE_OR_GENE_PRODUCT", 25, 30], ["cancers", "CANCER", 59, 66], ["PRDX6", "GENE_OR_GENE_PRODUCT", 108, 113], ["cancer", "CANCER", 157, 163], ["PRDXs", "SIMPLE_CHEMICAL", 200, 205], ["PRDXs", "GENE_OR_GENE_PRODUCT", 230, 235], ["PRDX6", "PROTEIN", 25, 30], ["PRDX6", "PROTEIN", 108, 113], ["PRDX6", "PROBLEM", 25, 30], ["several cancers", "PROBLEM", 51, 66], ["the therapeutic agents", "TREATMENT", 71, 93], ["targeting PRDX6", "TREATMENT", 98, 113], ["cancer treatment", "TREATMENT", 157, 173], ["PRDXs", "TREATMENT", 200, 205], ["treatment", "TREATMENT", 210, 219], ["diseasePRDXs", "PROBLEM", 223, 235], ["neurodegenerative diseases", "PROBLEM", 274, 300], ["several", "OBSERVATION_MODIFIER", 51, 58], ["cancers", "OBSERVATION", 59, 66], ["cancer", "OBSERVATION", 157, 163], ["disease", "OBSERVATION", 223, 230], ["neurodegenerative", "OBSERVATION_MODIFIER", 274, 291], ["diseases", "OBSERVATION", 292, 300]]], ["PRDX1 has a protective role in counteracting A\u03b2 injury by increasing cell viability, preserving neurites, and decreasing cell death (Cimini et al., 2013).", [["cell", "ANATOMY", 69, 73], ["neurites", "ANATOMY", 96, 104], ["cell", "ANATOMY", 121, 125], ["PRDX1", "CHEMICAL", 0, 5], ["death", "DISEASE", 126, 131], ["PRDX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 45, 47], ["cell", "CELL", 69, 73], ["neurites", "CELLULAR_COMPONENT", 96, 104], ["cell", "CELL", 121, 125], ["PRDX1", "PROTEIN", 0, 5], ["A\u03b2 injury", "PROBLEM", 45, 54], ["increasing cell viability", "PROBLEM", 58, 83], ["decreasing cell death", "PROBLEM", 110, 131], ["increasing cell viability", "OBSERVATION", 58, 83]]], ["These researches provide the neuroprotective function of PRDX1 and understanding the mechanistic details of PRDX1 peroxidase activity in the neurodegenerative diseases.Therapeutic approaches of PRDXs for treatment of diseasePRDX2 is involved in neuroprotection via inhibition of A\u03b21-42 induced apoptosis and suppression of JNK and p38 pathways, providing the neuroprotective function of PRDX2 and understanding the mechanistic details of PRDX1 peroxidase activity in the neurodegenerative diseases.", [["neurodegenerative diseases", "DISEASE", 141, 167], ["PRDXs", "CHEMICAL", 194, 199], ["A\u03b21-42", "CHEMICAL", 279, 285], ["neurodegenerative diseases", "DISEASE", 471, 497], ["PRDX1", "GENE_OR_GENE_PRODUCT", 57, 62], ["PRDX1", "GENE_OR_GENE_PRODUCT", 108, 113], ["peroxidase", "GENE_OR_GENE_PRODUCT", 114, 124], ["PRDXs", "SIMPLE_CHEMICAL", 194, 199], ["PRDX2", "GENE_OR_GENE_PRODUCT", 224, 229], ["A\u03b21-42", "GENE_OR_GENE_PRODUCT", 279, 285], ["JNK", "GENE_OR_GENE_PRODUCT", 323, 326], ["p38", "GENE_OR_GENE_PRODUCT", 331, 334], ["PRDX2", "GENE_OR_GENE_PRODUCT", 387, 392], ["PRDX1", "GENE_OR_GENE_PRODUCT", 438, 443], ["peroxidase", "GENE_OR_GENE_PRODUCT", 444, 454], ["PRDX1", "PROTEIN", 57, 62], ["PRDX1 peroxidase", "PROTEIN", 108, 124], ["PRDX2", "PROTEIN", 224, 229], ["JNK", "PROTEIN", 323, 326], ["p38", "PROTEIN", 331, 334], ["PRDX2", "PROTEIN", 387, 392], ["PRDX1 peroxidase", "PROTEIN", 438, 454], ["PRDX1 peroxidase activity", "PROBLEM", 108, 133], ["the neurodegenerative diseases", "PROBLEM", 137, 167], ["PRDXs", "TREATMENT", 194, 199], ["treatment", "TREATMENT", 204, 213], ["diseasePRDX2", "PROBLEM", 217, 229], ["A\u03b21", "TREATMENT", 279, 282], ["apoptosis", "PROBLEM", 294, 303], ["JNK", "TEST", 323, 326], ["p38 pathways", "TEST", 331, 343], ["PRDX2", "TREATMENT", 387, 392], ["PRDX1 peroxidase activity", "PROBLEM", 438, 463], ["the neurodegenerative diseases", "PROBLEM", 467, 497], ["neurodegenerative diseases", "OBSERVATION", 141, 167], ["disease", "OBSERVATION", 217, 224], ["neurodegenerative diseases", "OBSERVATION", 471, 497]]], ["Also, because cdk5 that inhibits PRDX2 activity leads to increased levels of ROS in PD, cdk5 is used as therapeutic target for treatment of PD.", [["ROS", "CHEMICAL", 77, 80], ["PD", "DISEASE", 84, 86], ["PD", "DISEASE", 140, 142], ["cdk5", "GENE_OR_GENE_PRODUCT", 14, 18], ["PRDX2", "GENE_OR_GENE_PRODUCT", 33, 38], ["ROS", "SIMPLE_CHEMICAL", 77, 80], ["cdk5", "GENE_OR_GENE_PRODUCT", 88, 92], ["cdk5", "PROTEIN", 14, 18], ["PRDX2", "PROTEIN", 33, 38], ["cdk5", "PROTEIN", 88, 92], ["cdk5", "PROBLEM", 14, 18], ["increased levels of ROS", "PROBLEM", 57, 80], ["cdk5", "PROBLEM", 88, 92], ["PD", "PROBLEM", 140, 142]]], ["Using novel Cdk5 modulators, Sun et al further showed the mechanism by which Cdk5 can induce oxidative stress in the disease's early stage and cell death in the late stage (Sun et al., 2008).", [["cell", "ANATOMY", 143, 147], ["death", "DISEASE", 148, 153], ["Cdk5", "GENE_OR_GENE_PRODUCT", 12, 16], ["Cdk5", "GENE_OR_GENE_PRODUCT", 77, 81], ["cell", "CELL", 143, 147], ["Cdk5", "PROTEIN", 12, 16], ["Cdk5", "PROTEIN", 77, 81], ["novel Cdk5 modulators", "TREATMENT", 6, 27], ["oxidative stress", "PROBLEM", 93, 109], ["the disease", "PROBLEM", 113, 124], ["cell death", "PROBLEM", 143, 153], ["cell death", "OBSERVATION", 143, 153], ["late stage", "OBSERVATION_MODIFIER", 161, 171]]], ["Cdk5 inhibition rescues mitochondrial damage upon neurotoxic insults, thereby revealing Cdk5 as an upstream regulator of mitochondrial dysfunction.", [["mitochondrial", "ANATOMY", 24, 37], ["mitochondrial", "ANATOMY", 121, 134], ["mitochondrial damage", "DISEASE", 24, 44], ["neurotoxic", "DISEASE", 50, 60], ["mitochondrial dysfunction", "DISEASE", 121, 146], ["Cdk5", "GENE_OR_GENE_PRODUCT", 0, 4], ["mitochondrial", "CELLULAR_COMPONENT", 24, 37], ["Cdk5", "GENE_OR_GENE_PRODUCT", 88, 92], ["mitochondrial", "CELLULAR_COMPONENT", 121, 134], ["Cdk5", "PROTEIN", 0, 4], ["Cdk5", "PROTEIN", 88, 92], ["Cdk5 inhibition rescues mitochondrial damage", "PROBLEM", 0, 44], ["neurotoxic insults", "PROBLEM", 50, 68], ["Cdk5", "PROBLEM", 88, 92], ["mitochondrial dysfunction", "PROBLEM", 121, 146], ["mitochondrial damage", "OBSERVATION", 24, 44], ["mitochondrial dysfunction", "OBSERVATION", 121, 146]]], ["As oxidative stress and mitochondrial dysfunction play pivotal roles in promoting neurodegeneration, Cdk5 could be a viable therapeutic target for AD.", [["mitochondrial", "ANATOMY", 24, 37], ["mitochondrial dysfunction", "DISEASE", 24, 49], ["neurodegeneration", "DISEASE", 82, 99], ["AD", "DISEASE", 147, 149], ["mitochondrial", "CELLULAR_COMPONENT", 24, 37], ["Cdk5", "GENE_OR_GENE_PRODUCT", 101, 105], ["Cdk5", "PROTEIN", 101, 105], ["oxidative stress", "PROBLEM", 3, 19], ["mitochondrial dysfunction", "PROBLEM", 24, 49], ["neurodegeneration", "PROBLEM", 82, 99], ["Cdk5", "PROBLEM", 101, 105], ["AD", "PROBLEM", 147, 149], ["mitochondrial dysfunction", "OBSERVATION", 24, 49]]], ["Zhang et al found that neurotoxin, MPP(+) induces CdK5/p25-dependent phosphorylation of PRDX2, resulting in inhibition of its peroxireductase activity and accumulation of ROS (Zhang et al., 2012a, b).", [["MPP", "CHEMICAL", 35, 38], ["ROS", "CHEMICAL", 171, 174], ["MPP(+)", "CHEMICAL", 35, 41], ["MPP", "SIMPLE_CHEMICAL", 35, 38], ["CdK5", "GENE_OR_GENE_PRODUCT", 50, 54], ["p25", "GENE_OR_GENE_PRODUCT", 55, 58], ["PRDX2", "GENE_OR_GENE_PRODUCT", 88, 93], ["peroxireductase", "GENE_OR_GENE_PRODUCT", 126, 141], ["ROS", "SIMPLE_CHEMICAL", 171, 174], ["CdK5", "PROTEIN", 50, 54], ["p25", "PROTEIN", 55, 58], ["PRDX2", "PROTEIN", 88, 93], ["peroxireductase", "PROTEIN", 126, 141], ["MPP", "TEST", 35, 38], ["CdK5/p25", "TEST", 50, 58], ["dependent phosphorylation of PRDX2", "PROBLEM", 59, 93], ["accumulation of ROS", "PROBLEM", 155, 174]]], ["On the other hand, PRDX2 is also involved in neurodegeneration through phosphorylation by cdk2, a serine/threonine kinase, and contributes to PD, providing that PRDX2 can be used for therapeutic target for treatment of PD through targeting this pathway.Therapeutic approaches of PRDXs for treatment of diseasePRDX3 is involved in the neuroprotection against oxidative insults in the mitochondria, suggesting that PRDX3 up-regulation might be a useful novel approach for the management of neurodegenerative diseases.", [["mitochondria", "ANATOMY", 383, 395], ["neurodegeneration", "DISEASE", 45, 62], ["PD", "DISEASE", 142, 144], ["PD", "DISEASE", 219, 221], ["PRDXs", "CHEMICAL", 279, 284], ["diseasePRDX3", "CHEMICAL", 302, 314], ["neurodegenerative diseases", "DISEASE", 488, 514], ["serine", "CHEMICAL", 98, 104], ["threonine", "CHEMICAL", 105, 114], ["PRDX2", "GENE_OR_GENE_PRODUCT", 19, 24], ["cdk2", "GENE_OR_GENE_PRODUCT", 90, 94], ["serine", "AMINO_ACID", 98, 104], ["threonine", "AMINO_ACID", 105, 114], ["PRDX2", "GENE_OR_GENE_PRODUCT", 161, 166], ["PRDXs", "SIMPLE_CHEMICAL", 279, 284], ["diseasePRDX3", "GENE_OR_GENE_PRODUCT", 302, 314], ["mitochondria", "CELLULAR_COMPONENT", 383, 395], ["PRDX3", "GENE_OR_GENE_PRODUCT", 413, 418], ["PRDX2", "PROTEIN", 19, 24], ["cdk2", "PROTEIN", 90, 94], ["serine/threonine kinase", "PROTEIN", 98, 121], ["PRDX2", "PROTEIN", 161, 166], ["PRDX3", "PROTEIN", 413, 418], ["neurodegeneration", "PROBLEM", 45, 62], ["a serine/threonine kinase", "TEST", 96, 121], ["PD", "PROBLEM", 142, 144], ["PRDX2", "TREATMENT", 161, 166], ["treatment", "TREATMENT", 206, 215], ["PD", "TREATMENT", 219, 221], ["this pathway", "TREATMENT", 240, 252], ["PRDXs", "TREATMENT", 279, 284], ["treatment", "TREATMENT", 289, 298], ["diseasePRDX3", "PROBLEM", 302, 314], ["oxidative insults in the mitochondria", "PROBLEM", 358, 395], ["PRDX3", "TEST", 413, 418], ["neurodegenerative diseases", "PROBLEM", 488, 514], ["neurodegenerative", "OBSERVATION_MODIFIER", 488, 505], ["diseases", "OBSERVATION", 506, 514]]], ["On the other hand, PRDX3 is involved in neurodegeneration through increased phosphorylation by LRRK2 mutation, providing therapeutic target in PD patients carrying LRRK2 mutations.", [["neurodegeneration", "DISEASE", 40, 57], ["PD", "DISEASE", 143, 145], ["PRDX3", "GENE_OR_GENE_PRODUCT", 19, 24], ["LRRK2", "GENE_OR_GENE_PRODUCT", 95, 100], ["patients", "ORGANISM", 146, 154], ["LRRK2", "GENE_OR_GENE_PRODUCT", 164, 169], ["PRDX3", "PROTEIN", 19, 24], ["LRRK2", "PROTEIN", 95, 100], ["LRRK2", "PROTEIN", 164, 169], ["patients", "SPECIES", 146, 154], ["neurodegeneration", "PROBLEM", 40, 57], ["increased phosphorylation", "TREATMENT", 66, 91], ["LRRK2 mutation", "PROBLEM", 95, 109], ["LRRK2 mutations", "PROBLEM", 164, 179], ["LRRK2 mutations", "OBSERVATION", 164, 179]]], ["PRDX5 is involved in PD through mitochondrial redox signaling with Ca2 + influx resulting in the development of PD (Davey & Bola\u00f1os, 2013), also can be used for therapeutic target.Therapeutic approaches of PRDXs for treatment of diseasePRDX6 induces neurodegeneration through aiPLA2 and nrf2 activation in AD, and induces neurodegeneration through induction of MPTP-induced dopaminergic neurodegeneration of PD, providing that PRDX6 might be used a useful novel approach for the management of neurodegenerative diseases.", [["mitochondrial", "ANATOMY", 32, 45], ["PD", "DISEASE", 21, 23], ["Ca2", "CHEMICAL", 67, 70], ["PD", "DISEASE", 112, 114], ["PRDXs", "CHEMICAL", 206, 211], ["diseasePRDX6", "CHEMICAL", 229, 241], ["neurodegeneration", "DISEASE", 250, 267], ["AD", "DISEASE", 306, 308], ["neurodegeneration", "DISEASE", 322, 339], ["MPTP", "CHEMICAL", 361, 365], ["neurodegeneration", "DISEASE", 387, 404], ["PD", "DISEASE", 408, 410], ["PRDX6", "CHEMICAL", 427, 432], ["neurodegenerative diseases", "DISEASE", 493, 519], ["Ca2 +", "CHEMICAL", 67, 72], ["MPTP", "CHEMICAL", 361, 365], ["PRDX5", "GENE_OR_GENE_PRODUCT", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 32, 45], ["Ca2 +", "SIMPLE_CHEMICAL", 67, 72], ["PRDXs", "SIMPLE_CHEMICAL", 206, 211], ["diseasePRDX6", "GENE_OR_GENE_PRODUCT", 229, 241], ["aiPLA2", "GENE_OR_GENE_PRODUCT", 276, 282], ["nrf2", "GENE_OR_GENE_PRODUCT", 287, 291], ["MPTP", "SIMPLE_CHEMICAL", 361, 365], ["dopaminergic", "CELL", 374, 386], ["PRDX6", "GENE_OR_GENE_PRODUCT", 427, 432], ["PRDX5", "PROTEIN", 0, 5], ["Ca2", "PROTEIN", 67, 70], ["diseasePRDX6", "PROTEIN", 229, 241], ["aiPLA2", "PROTEIN", 276, 282], ["nrf2", "PROTEIN", 287, 291], ["PRDX6", "PROTEIN", 427, 432], ["influx", "PROBLEM", 73, 79], ["PD", "PROBLEM", 112, 114], ["PRDXs", "TREATMENT", 206, 211], ["treatment", "TREATMENT", 216, 225], ["diseasePRDX6", "PROBLEM", 229, 241], ["neurodegeneration", "PROBLEM", 250, 267], ["aiPLA2", "PROBLEM", 276, 282], ["nrf2 activation", "PROBLEM", 287, 302], ["AD", "PROBLEM", 306, 308], ["neurodegeneration", "PROBLEM", 322, 339], ["MPTP", "TREATMENT", 361, 365], ["dopaminergic neurodegeneration of PD", "PROBLEM", 374, 410], ["a useful novel approach", "TREATMENT", 447, 470], ["the management", "TREATMENT", 475, 489], ["neurodegenerative diseases", "PROBLEM", 493, 519], ["nrf2 activation", "OBSERVATION", 287, 302], ["neurodegenerative", "OBSERVATION_MODIFIER", 493, 510], ["diseases", "OBSERVATION", 511, 519]]], ["On the other hand, PRDX6 inhibits multiple sclerosis by suppressing inflammation and blood brain barrier disruption in EAE model, suggesting a new molecule for neuroprotective therapies in multiple sclerosis.Therapeutic approaches of PRDXs for treatment of diseasePRDXs could be targets for the treatment of inflammatory diseases.", [["blood brain barrier", "ANATOMY", 85, 104], ["PRDX6", "CHEMICAL", 19, 24], ["multiple sclerosis", "DISEASE", 34, 52], ["inflammation", "DISEASE", 68, 80], ["EAE", "DISEASE", 119, 122], ["multiple sclerosis", "DISEASE", 189, 207], ["PRDXs", "CHEMICAL", 234, 239], ["PRDXs", "DISEASE", 264, 269], ["inflammatory diseases", "DISEASE", 308, 329], ["PRDX6", "CHEMICAL", 19, 24], ["PRDX6", "GENE_OR_GENE_PRODUCT", 19, 24], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 85, 104], ["PRDXs", "SIMPLE_CHEMICAL", 234, 239], ["PRDXs", "GENE_OR_GENE_PRODUCT", 264, 269], ["PRDX6", "PROTEIN", 19, 24], ["multiple sclerosis", "PROBLEM", 34, 52], ["suppressing inflammation", "PROBLEM", 56, 80], ["blood brain barrier disruption in EAE model", "PROBLEM", 85, 128], ["a new molecule", "PROBLEM", 141, 155], ["neuroprotective therapies", "TREATMENT", 160, 185], ["multiple sclerosis", "PROBLEM", 189, 207], ["PRDXs", "TREATMENT", 234, 239], ["treatment", "TREATMENT", 244, 253], ["diseasePRDXs", "PROBLEM", 257, 269], ["inflammatory diseases", "PROBLEM", 308, 329], ["multiple", "OBSERVATION_MODIFIER", 34, 42], ["sclerosis", "OBSERVATION", 43, 52], ["inflammation", "OBSERVATION", 68, 80], ["blood brain", "OBSERVATION", 85, 96], ["barrier disruption", "OBSERVATION", 97, 115], ["new", "OBSERVATION_MODIFIER", 143, 146], ["multiple", "OBSERVATION_MODIFIER", 189, 197], ["sclerosis", "OBSERVATION", 198, 207], ["disease", "OBSERVATION", 257, 264], ["inflammatory", "OBSERVATION", 308, 320]]], ["PRDX2 suppresses atherosclerosis through the site-selective phosphorylation of the PDGF receptor pathways, suggesting upregulation of PRDX2 can be used for treatment of atherosclerosis.", [["PRDX2", "CHEMICAL", 0, 5], ["atherosclerosis", "DISEASE", 17, 32], ["PRDX2", "CHEMICAL", 134, 139], ["atherosclerosis", "DISEASE", 169, 184], ["PRDX2", "GENE_OR_GENE_PRODUCT", 0, 5], ["PDGF receptor", "GENE_OR_GENE_PRODUCT", 83, 96], ["PRDX2", "GENE_OR_GENE_PRODUCT", 134, 139], ["PRDX2", "PROTEIN", 0, 5], ["PDGF receptor", "PROTEIN", 83, 96], ["PRDX2", "PROTEIN", 134, 139], ["atherosclerosis", "PROBLEM", 17, 32], ["the PDGF receptor pathways", "TEST", 79, 105], ["upregulation of PRDX2", "TREATMENT", 118, 139], ["atherosclerosis", "PROBLEM", 169, 184], ["atherosclerosis", "OBSERVATION", 17, 32], ["atherosclerosis", "OBSERVATION", 169, 184]]], ["Du et al examined the expressions of PRDX2 and Foxo3a that were down-regulated in ischemic brain compared with the normal-control group (Du et al., 2012).", [["brain", "ANATOMY", 91, 96], ["PRDX2", "GENE_OR_GENE_PRODUCT", 37, 42], ["Foxo3a", "GENE_OR_GENE_PRODUCT", 47, 53], ["brain", "ORGAN", 91, 96], ["PRDX2", "PROTEIN", 37, 42], ["Foxo3a", "PROTEIN", 47, 53], ["ischemic brain", "PROBLEM", 82, 96], ["ischemic", "OBSERVATION_MODIFIER", 82, 90], ["brain", "ANATOMY", 91, 96]]], ["They showed that the combined treatment of probucol or atorvastatin dramatically reduced the brain water content and the infarct volume, along with the decrease of PRDX2, Foxo3a and Nrf2 was significantly alleviated in combined treatment group.", [["brain", "ANATOMY", 93, 98], ["infarct", "ANATOMY", 121, 128], ["probucol", "CHEMICAL", 43, 51], ["atorvastatin", "CHEMICAL", 55, 67], ["infarct", "DISEASE", 121, 128], ["probucol", "CHEMICAL", 43, 51], ["atorvastatin", "CHEMICAL", 55, 67], ["probucol", "SIMPLE_CHEMICAL", 43, 51], ["atorvastatin", "SIMPLE_CHEMICAL", 55, 67], ["brain", "ORGAN", 93, 98], ["PRDX2", "GENE_OR_GENE_PRODUCT", 164, 169], ["Foxo3a", "GENE_OR_GENE_PRODUCT", 171, 177], ["Nrf2", "GENE_OR_GENE_PRODUCT", 182, 186], ["PRDX2", "PROTEIN", 164, 169], ["Foxo3a", "PROTEIN", 171, 177], ["Nrf2", "PROTEIN", 182, 186], ["probucol", "TREATMENT", 43, 51], ["atorvastatin", "TREATMENT", 55, 67], ["the brain water content", "PROBLEM", 89, 112], ["the infarct volume", "PROBLEM", 117, 135], ["the decrease of PRDX2", "TREATMENT", 148, 169], ["Foxo3a", "TREATMENT", 171, 177], ["Nrf2", "TREATMENT", 182, 186], ["brain", "ANATOMY", 93, 98], ["water content", "OBSERVATION", 99, 112], ["infarct volume", "OBSERVATION", 121, 135]]], ["They suggested that probucol combined with atorvastatin effect in the neuroprotection from the damage caused by MCAO through up-regulation of PRDX2, Foxo3a and Nrf2.", [["probucol", "CHEMICAL", 20, 28], ["atorvastatin", "CHEMICAL", 43, 55], ["probucol", "CHEMICAL", 20, 28], ["atorvastatin", "CHEMICAL", 43, 55], ["probucol", "SIMPLE_CHEMICAL", 20, 28], ["atorvastatin", "SIMPLE_CHEMICAL", 43, 55], ["PRDX2", "GENE_OR_GENE_PRODUCT", 142, 147], ["Foxo3a", "GENE_OR_GENE_PRODUCT", 149, 155], ["Nrf2", "GENE_OR_GENE_PRODUCT", 160, 164], ["PRDX2", "PROTEIN", 142, 147], ["Foxo3a", "PROTEIN", 149, 155], ["Nrf2", "PROTEIN", 160, 164], ["probucol", "TREATMENT", 20, 28], ["atorvastatin effect", "TREATMENT", 43, 62], ["the neuroprotection", "TREATMENT", 66, 85], ["the damage", "PROBLEM", 91, 101], ["PRDX2", "TREATMENT", 142, 147], ["Foxo3a", "TREATMENT", 149, 155], ["Nrf2", "TREATMENT", 160, 164]]], ["On the other hand, PRDX2 enhances the risk of RA because PRDX2 is involved in the persistence of pro-inflammatory cells in chronic inflammation, providing PRDX2 can be used as therapeutic target of RA.Therapeutic approaches of PRDXs for treatment of diseasePRDX3 inhibits the risk of obesity through decreased abnormal lipid accumulation in adipose tissue, due to increased ROS, suggesting PRDX3 can be used for the treatment of obesity.", [["cells", "ANATOMY", 114, 119], ["adipose tissue", "ANATOMY", 341, 355], ["RA", "DISEASE", 46, 48], ["inflammation", "DISEASE", 131, 143], ["RA", "DISEASE", 198, 200], ["PRDXs", "CHEMICAL", 227, 232], ["PRDX3", "CHEMICAL", 257, 262], ["obesity", "DISEASE", 284, 291], ["ROS", "CHEMICAL", 374, 377], ["PRDX3", "CHEMICAL", 390, 395], ["obesity", "DISEASE", 429, 436], ["PRDX2", "GENE_OR_GENE_PRODUCT", 19, 24], ["PRDX2", "GENE_OR_GENE_PRODUCT", 57, 62], ["cells", "CELL", 114, 119], ["PRDX2", "GENE_OR_GENE_PRODUCT", 155, 160], ["PRDXs", "SIMPLE_CHEMICAL", 227, 232], ["PRDX3", "GENE_OR_GENE_PRODUCT", 257, 262], ["lipid", "SIMPLE_CHEMICAL", 319, 324], ["adipose tissue", "TISSUE", 341, 355], ["ROS", "SIMPLE_CHEMICAL", 374, 377], ["PRDX3", "SIMPLE_CHEMICAL", 390, 395], ["PRDX2", "PROTEIN", 19, 24], ["PRDX2", "PROTEIN", 57, 62], ["pro-inflammatory cells", "CELL_TYPE", 97, 119], ["PRDX2", "PROTEIN", 155, 160], ["PRDX3", "PROTEIN", 390, 395], ["PRDX2", "PROBLEM", 57, 62], ["pro-inflammatory cells", "PROBLEM", 97, 119], ["chronic inflammation", "PROBLEM", 123, 143], ["PRDX2", "TREATMENT", 155, 160], ["therapeutic target of RA", "TREATMENT", 176, 200], ["PRDXs", "TREATMENT", 227, 232], ["treatment", "TREATMENT", 237, 246], ["diseasePRDX3", "PROBLEM", 250, 262], ["obesity", "PROBLEM", 284, 291], ["decreased abnormal lipid accumulation in adipose tissue", "PROBLEM", 300, 355], ["increased ROS", "PROBLEM", 364, 377], ["PRDX3", "TREATMENT", 390, 395], ["obesity", "PROBLEM", 429, 436], ["RA", "ANATOMY", 46, 48], ["pro-inflammatory cells", "OBSERVATION", 97, 119], ["chronic", "OBSERVATION_MODIFIER", 123, 130], ["inflammation", "OBSERVATION", 131, 143], ["RA", "ANATOMY", 198, 200], ["disease", "OBSERVATION", 250, 257], ["obesity", "OBSERVATION", 284, 291], ["decreased", "OBSERVATION_MODIFIER", 300, 309], ["abnormal", "OBSERVATION_MODIFIER", 310, 318], ["lipid accumulation", "OBSERVATION", 319, 337], ["adipose tissue", "OBSERVATION", 341, 355], ["obesity", "OBSERVATION", 429, 436]]], ["PRDX4 protects against atherosclerosis and obesity through inhibiting the oxidative stress induced inflammation in various tissues, suggesting up-regulation might be a useful novel approach for the management of atherosclerosis and obesity.", [["tissues", "ANATOMY", 123, 130], ["PRDX4", "CHEMICAL", 0, 5], ["atherosclerosis", "DISEASE", 23, 38], ["obesity", "DISEASE", 43, 50], ["inflammation", "DISEASE", 99, 111], ["atherosclerosis", "DISEASE", 212, 227], ["obesity", "DISEASE", 232, 239], ["PRDX4", "GENE_OR_GENE_PRODUCT", 0, 5], ["tissues", "TISSUE", 123, 130], ["PRDX4", "PROTEIN", 0, 5], ["PRDX4", "TREATMENT", 0, 5], ["atherosclerosis", "PROBLEM", 23, 38], ["obesity", "PROBLEM", 43, 50], ["the oxidative stress induced inflammation in various tissues", "PROBLEM", 70, 130], ["the management", "TREATMENT", 194, 208], ["atherosclerosis", "PROBLEM", 212, 227], ["obesity", "PROBLEM", 232, 239], ["atherosclerosis", "OBSERVATION", 23, 38], ["obesity", "OBSERVATION", 43, 50], ["oxidative stress induced", "OBSERVATION_MODIFIER", 74, 98], ["inflammation", "OBSERVATION", 99, 111], ["various tissues", "ANATOMY", 115, 130], ["atherosclerosis", "OBSERVATION", 212, 227], ["obesity", "OBSERVATION", 232, 239]]], ["But PRDX4 enhances the risk of RA, providing therapeutic target for treatment of RA.Therapeutic approaches of PRDXs for treatment of diseasePRDX6 enhances the risk of RA through activation of NF-\u03baB/AP-1 coupled JNK pathway in the CAIA and AIA-induced arthritis development model, suggesting PRDX6 can be used as therapeutic target for treatment of RA.", [["PRDX4", "CHEMICAL", 4, 9], ["RA", "DISEASE", 31, 33], ["RA", "DISEASE", 81, 83], ["PRDXs", "CHEMICAL", 110, 115], ["diseasePRDX6", "CHEMICAL", 133, 145], ["RA", "DISEASE", 167, 169], ["AIA", "CHEMICAL", 239, 242], ["arthritis", "DISEASE", 251, 260], ["PRDX6", "CHEMICAL", 291, 296], ["RA", "DISEASE", 348, 350], ["PRDX4", "GENE_OR_GENE_PRODUCT", 4, 9], ["PRDXs", "SIMPLE_CHEMICAL", 110, 115], ["diseasePRDX6", "GENE_OR_GENE_PRODUCT", 133, 145], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 192, 197], ["AP-1", "GENE_OR_GENE_PRODUCT", 198, 202], ["JNK", "GENE_OR_GENE_PRODUCT", 211, 214], ["CAIA", "CANCER", 230, 234], ["AIA", "SIMPLE_CHEMICAL", 239, 242], ["PRDX6", "GENE_OR_GENE_PRODUCT", 291, 296], ["PRDX4", "PROTEIN", 4, 9], ["NF-\u03baB", "PROTEIN", 192, 197], ["AP-1", "PROTEIN", 198, 202], ["JNK", "PROTEIN", 211, 214], ["PRDX6", "PROTEIN", 291, 296], ["treatment of RA", "TREATMENT", 68, 83], ["PRDXs", "TREATMENT", 110, 115], ["treatment", "TREATMENT", 120, 129], ["diseasePRDX6", "PROBLEM", 133, 145], ["NF", "TEST", 192, 194], ["AP", "TEST", 198, 200], ["JNK pathway", "TEST", 211, 222], ["the CAIA", "PROBLEM", 226, 234], ["AIA", "PROBLEM", 239, 242], ["arthritis development model", "PROBLEM", 251, 278], ["PRDX6", "PROBLEM", 291, 296], ["treatment of RA", "TREATMENT", 335, 350], ["RA", "ANATOMY", 31, 33], ["RA", "ANATOMY", 81, 83], ["RA", "ANATOMY", 167, 169], ["CAIA", "ANATOMY", 230, 234], ["AIA", "ANATOMY", 239, 242], ["arthritis", "OBSERVATION", 251, 260], ["RA", "ANATOMY", 348, 350]]], ["Moreover, several therapeutic agents targeting PRDX6 are studied for treatment of inflammatory diseases.", [["PRDX6", "CHEMICAL", 47, 52], ["inflammatory diseases", "DISEASE", 82, 103], ["PRDX6", "GENE_OR_GENE_PRODUCT", 47, 52], ["PRDX6", "PROTEIN", 47, 52], ["several therapeutic agents", "TREATMENT", 10, 36], ["inflammatory diseases", "PROBLEM", 82, 103], ["inflammatory", "OBSERVATION", 82, 94]]], ["Among them, Epigallocatechin-3-gallate modulates the levels of the antioxidant enzymes PRDX6, catalase and superoxide dismutase (SOD), as well as PCNA, in NOD (Ohno et al., 2012).", [["Epigallocatechin-3-gallate", "CHEMICAL", 12, 38], ["superoxide", "CHEMICAL", 107, 117], ["Epigallocatechin-3-gallate", "CHEMICAL", 12, 38], ["superoxide", "CHEMICAL", 107, 117], ["Epigallocatechin-3-gallate", "SIMPLE_CHEMICAL", 12, 38], ["PRDX6", "GENE_OR_GENE_PRODUCT", 87, 92], ["catalase", "GENE_OR_GENE_PRODUCT", 94, 102], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 107, 127], ["SOD", "GENE_OR_GENE_PRODUCT", 129, 132], ["PCNA", "GENE_OR_GENE_PRODUCT", 146, 150], ["antioxidant enzymes", "PROTEIN", 67, 86], ["PRDX6", "PROTEIN", 87, 92], ["catalase", "PROTEIN", 94, 102], ["superoxide dismutase", "PROTEIN", 107, 127], ["SOD", "PROTEIN", 129, 132], ["PCNA", "PROTEIN", 146, 150], ["Epigallocatechin", "TEST", 12, 28], ["the antioxidant enzymes PRDX6", "TEST", 63, 92], ["catalase", "TEST", 94, 102], ["superoxide dismutase (SOD)", "PROBLEM", 107, 133], ["PCNA", "PROBLEM", 146, 150]]], ["They showed that the early PCNA elevation was followed by a decline of PRDX6 protein, in contrast EGCG-fed mice exhibited normal levels of PCNA and PRDX6, comparable to healthy untreated BALB/c mice.Therapeutic approaches of PRDXs for treatment of diseaseIn conclusion, we discussed the roles and mechanisms of PRDXs on cellular homeostasis, diseases development and drug resistance, and propose potential therapeutic approaches for targeting PRDXs.", [["cellular", "ANATOMY", 320, 328], ["EGCG", "CHEMICAL", 98, 102], ["PRDXs", "CHEMICAL", 225, 230], ["EGCG", "CHEMICAL", 98, 102], ["PCNA", "GENE_OR_GENE_PRODUCT", 27, 31], ["PRDX6", "GENE_OR_GENE_PRODUCT", 71, 76], ["EGCG", "SIMPLE_CHEMICAL", 98, 102], ["mice", "ORGANISM", 107, 111], ["PCNA", "GENE_OR_GENE_PRODUCT", 139, 143], ["PRDX6", "GENE_OR_GENE_PRODUCT", 148, 153], ["BALB/c mice", "ORGANISM", 187, 198], ["PRDXs", "SIMPLE_CHEMICAL", 225, 230], ["PRDXs", "GENE_OR_GENE_PRODUCT", 311, 316], ["cellular", "CELL", 320, 328], ["PRDXs", "GENE_OR_GENE_PRODUCT", 443, 448], ["PCNA", "PROTEIN", 27, 31], ["PRDX6 protein", "PROTEIN", 71, 84], ["PCNA", "PROTEIN", 139, 143], ["PRDX6", "PROTEIN", 148, 153], ["PRDXs", "PROTEIN", 311, 316], ["PRDXs", "PROTEIN", 443, 448], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 194, 198], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 194, 198], ["the early PCNA elevation", "PROBLEM", 17, 41], ["PRDX6 protein", "TEST", 71, 84], ["contrast EGCG", "TEST", 89, 102], ["PRDXs", "TREATMENT", 225, 230], ["treatment", "TREATMENT", 235, 244], ["disease", "PROBLEM", 248, 255], ["cellular homeostasis", "TREATMENT", 320, 340], ["drug resistance", "TREATMENT", 367, 382], ["targeting PRDXs", "PROBLEM", 433, 448], ["PCNA elevation", "OBSERVATION", 27, 41], ["disease", "OBSERVATION", 248, 255]]], ["We hope this review provides a foundation for further studies to design novel therapeutic approaches targeting PRDXs.Conflicts of interestThe authors declare that there are no conflicts of interest.", [["PRDXs", "GENE_OR_GENE_PRODUCT", 111, 116], ["PRDXs", "PROTEIN", 111, 116], ["further studies", "TEST", 46, 61], ["no", "UNCERTAINTY", 173, 175]]]]}